data_3bdo_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 3bdo _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 N-CA-C 112.456 -0.258 . . . . 0.0 112.456 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.578 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 36.6 t60 -175.9 77.66 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.767 0.318 . . . . 0.0 110.888 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.566 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 0.1 OUTLIER -84.26 178.9 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 120.914 0.388 . . . . 0.0 111.08 179.868 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.528 ' CG2' HG11 ' A' ' 153' ' ' VAL . 25.2 t -130.42 37.98 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.903 179.686 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.505 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 10.9 ptt-85 -34.07 119.01 0.39 Allowed 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.906 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.477 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 3.7 t -34.86 104.46 0.25 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.984 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -47.2 -22.35 2.3 Favored 'Trans proline' 0 N--CA 1.465 -0.192 0 C-N-CA 122.678 2.252 . . . . 0.0 112.093 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.452 ' SD ' ' HB3' ' A' ' 120' ' ' ALA . 0.0 OUTLIER -151.41 -168.93 3.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.545 179.805 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.458 ' O ' HG11 ' A' ' 88' ' ' VAL . 67.5 t -77.76 56.91 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.04 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.407 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -103.55 -153.33 23.62 Favored Glycine 0 C--N 1.332 0.319 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.438 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.572 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 17.8 m -130.68 145.17 51.86 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.901 0.382 . . . . 0.0 111.221 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.656 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 36.0 t80 -91.91 145.86 24.21 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.249 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.591 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 10.2 m-85 -146.65 154.29 41.29 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.003 0.43 . . . . 0.0 111.286 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.437 ' O ' ' HA ' ' A' ' 101' ' ' ALA . 6.7 ptt85 -144.65 25.14 1.5 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.609 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.457 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 0.9 OUTLIER -151.17 100.04 3.03 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.905 179.909 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -68.95 -32.46 22.02 Favored 'Trans proline' 0 C--O 1.231 0.133 0 C-N-CA 122.76 2.307 . . . . 0.0 112.213 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.462 ' CB ' ' HB1' ' A' ' 99' ' ' ALA . 0.4 OUTLIER -123.1 141.18 35.16 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.822 179.86 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -52.51 106.61 0.15 Allowed 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.732 2.288 . . . . 0.0 112.401 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 43.5 t0 71.24 34.7 1.72 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.043 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.462 ' HB1' ' CB ' ' A' ' 96' ' ' SER . . . -86.93 -154.94 0.25 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.976 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . 0.413 ' HA ' ' HD2' ' A' ' 100' ' ' LYS . 16.5 mmmt -94.83 23.52 5.43 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.832 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.457 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 56.86 167.08 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.019 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.531 ' O ' ' CD1' ' A' ' 103' ' ' ILE . 0.1 OUTLIER -81.44 -51.68 8.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.677 179.868 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.531 ' CD1' ' O ' ' A' ' 102' ' ' PHE . 0.4 OUTLIER -152.59 148.25 14.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.023 179.759 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -143.39 149.17 37.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.838 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.412 ' N ' HG13 ' A' ' 135' ' ' VAL . 16.7 t -44.59 123.37 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.053 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 123.98 -33.59 3.83 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.367 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.411 ' HA ' ' OE1' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -74.87 142.41 44.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.829 0.347 . . . . 0.0 110.748 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -103.58 101.61 11.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.067 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.535 ' CG2' ' N ' ' A' ' 110' ' ' ASN . 2.3 p -66.23 164.39 2.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.775 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.535 ' N ' ' CG2' ' A' ' 109' ' ' VAL . 3.2 m120 -155.99 133.31 10.8 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-O 120.882 0.372 . . . . 0.0 110.376 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.47 ' C ' ' O ' ' A' ' 110' ' ' ASN . 2.4 t -26.16 123.41 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.518 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 85.92 21.5 52.69 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.216 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.464 ' HB2' ' O ' ' A' ' 110' ' ' ASN . 26.8 t0 -119.49 102.78 8.9 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.823 0.344 . . . . 0.0 110.832 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.463 HG22 ' HB2' ' A' ' 126' ' ' GLN . 1.4 m -41.28 132.16 2.64 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.912 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.524 ' O ' ' CG1' ' A' ' 103' ' ' ILE . 56.4 mt -96.5 -86.25 0.32 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.829 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -131.94 -175.59 3.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.04 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.515 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.1 OUTLIER -104.11 127.02 58.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.95 179.942 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.523 ' O ' ' N ' ' A' ' 120' ' ' ALA . 58.8 t -108.31 60.25 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.942 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.472 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.3 OUTLIER -43.05 88.56 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.247 -179.888 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.545 ' O ' ' CB ' ' A' ' 121' ' ' MET . . . -92.65 109.55 20.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.718 179.735 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.557 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.8 OUTLIER 90.18 -29.59 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.763 -179.683 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.557 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 150.04 -15.95 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.88 179.622 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.472 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.4 OUTLIER -101.08 134.54 43.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.049 -179.662 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.515 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -55.25 145.34 21.89 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.125 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.469 ' HB2' ' O ' ' A' ' 118' ' ' VAL . 1.0 OUTLIER -134.4 65.95 1.55 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.571 179.797 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.463 ' HB2' HG22 ' A' ' 114' ' ' THR . 4.8 pm0 -38.85 145.1 0.1 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.049 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.47 ' O ' ' N ' ' A' ' 115' ' ' LEU . 29.2 mm -117.18 130.62 71.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.986 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -105.56 128.11 53.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.079 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.521 ' HB1' ' CG2' ' A' ' 109' ' ' VAL . . . -44.32 147.24 0.57 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.922 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -114.06 -15.41 12.28 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.453 ' HG2' ' O ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -163.22 36.86 0.1 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.086 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.468 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.6 t 55.92 -174.9 0.05 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.582 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.513 ' N ' HG11 ' A' ' 109' ' ' VAL . . . 149.71 -178.88 26.92 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.604 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.535 ' HB ' ' CG ' ' A' ' 156' ' ' GLU . 26.7 m -136.27 117.38 14.4 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.611 0.243 . . . . 0.0 111.17 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.515 HG11 ' N ' ' A' ' 136' ' ' LYS . 97.7 t -49.92 140.45 3.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.476 179.452 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.515 ' N ' HG11 ' A' ' 135' ' ' VAL . 27.7 mmmt -125.02 -19.65 5.14 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.576 -0.284 . . . . 0.0 111.376 -179.461 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.447 ' O ' HG21 ' A' ' 154' ' ' VAL . . . 168.51 159.96 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.888 0.375 . . . . 0.0 111.584 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.656 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -110.72 83.62 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.815 179.83 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.53 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 4.7 mt -44.27 -34.87 2.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.081 0.467 . . . . 0.0 110.336 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.537 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 52.1 t -96.54 160.86 2.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.626 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.51 ' HB2' ' CG ' ' A' ' 144' ' ' GLN . 3.0 mm-40 -58.75 -149.54 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.492 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -103.43 -63.61 1.16 Allowed 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.695 179.393 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.591 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -124.88 97.37 0.53 Allowed Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.632 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.51 ' CG ' ' HB2' ' A' ' 141' ' ' GLU . 0.0 OUTLIER -166.53 156.3 10.41 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.954 0.407 . . . . 0.0 110.998 179.839 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.468 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 35.4 Cg_exo -59.86 160.15 22.66 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.827 2.351 . . . . 0.0 112.277 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.496 HG13 ' CG ' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -152.66 176.19 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.06 179.878 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.48 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 3.8 tt0 -126.71 145.11 50.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.996 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.541 ' CE2' ' OD1' ' A' ' 149' ' ' ASP . 16.9 t80 -34.96 139.4 0.09 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.91 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.541 ' OD1' ' CE2' ' A' ' 148' ' ' PHE . 1.6 m-20 68.6 27.45 6.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.788 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.496 ' CG ' HG13 ' A' ' 146' ' ' VAL . 7.0 tp10 -105.38 74.63 0.28 Allowed Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.897 179.864 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.505 ' CD ' ' HB3' ' A' ' 84' ' ' ARG . 64.3 Cg_exo -35.84 131.99 0.3 Allowed 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 122.924 2.416 . . . . 0.0 112.086 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.537 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -123.61 -58.91 1.57 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.355 -179.345 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.528 HG11 ' CG2' ' A' ' 83' ' ' VAL . 1.6 p -108.75 111.82 37.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.066 -179.581 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.53 ' CG2' ' HG ' ' A' ' 139' ' ' LEU . 2.5 t -88.27 136.88 22.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.23 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.528 HG22 ' N ' ' A' ' 134' ' ' THR . 9.0 mt -134.56 138.42 49.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.019 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.535 ' CG ' ' HB ' ' A' ' 134' ' ' THR . 0.9 OUTLIER . . . . . 0 C--O 1.249 1.044 0 CA-C-O 118.172 -0.918 . . . . 0.0 110.904 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.441 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.45 -0.379 0 N-CA-C 112.568 -0.213 . . . . 0.0 112.568 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.463 ' ND1' ' HD3' ' A' ' 131' ' ' LYS . 18.2 t60 174.38 82.29 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.78 0.324 . . . . 0.0 110.877 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.467 HG12 ' CG1' ' A' ' 154' ' ' VAL . 4.6 mt -115.58 151.7 17.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.117 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.591 ' CG1' ' CG1' ' A' ' 153' ' ' VAL . 3.6 p -109.85 44.24 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.026 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.471 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -33.51 131.48 0.23 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.092 -179.943 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.502 ' N ' HD13 ' A' ' 152' ' ' LEU . 4.4 p -35.83 97.51 0.13 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.873 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 14.2 Cg_endo -57.41 -14.95 17.66 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.608 2.205 . . . . 0.0 111.87 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -151.31 164.96 35.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.47 179.718 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.41 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 1.7 p -71.01 77.9 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.975 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -127.65 -128.58 3.13 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.545 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.523 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 8.3 m -147.44 134.49 20.36 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.773 0.32 . . . . 0.0 110.924 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.639 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 1.7 t80 -95.69 144.76 25.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.781 179.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.586 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 12.8 m-85 -141.04 160.07 40.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.061 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.508 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 0.8 OUTLIER -142.22 24.8 1.94 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.689 179.885 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.4 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 82.5 p -132.29 101.98 14.5 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.799 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.546 ' HB3' ' CE1' ' A' ' 102' ' ' PHE . 41.1 Cg_endo -67.37 -43.44 5.98 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.828 2.352 . . . . 0.0 112.403 -179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -129.95 160.45 65.09 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.06 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.449 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 55.9 Cg_endo -70.73 106.98 1.94 Allowed 'Trans proline' 0 N--CA 1.464 -0.208 0 C-N-CA 122.72 2.28 . . . . 0.0 112.319 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.449 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 18.7 t70 80.24 43.58 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.918 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -109.04 -160.39 0.72 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.029 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 1.1 mtpp -93.65 23.02 4.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.844 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 64.34 176.83 0.18 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.013 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.569 ' CE2' HG13 ' A' ' 117' ' ' ILE . 0.2 OUTLIER -85.69 -42.14 14.53 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.714 179.942 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.532 ' CD1' HG23 ' A' ' 153' ' ' VAL . 1.1 pp -172.68 145.78 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.959 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.42 ' O ' ' HB2' ' A' ' 107' ' ' GLN . 5.9 pt-20 -149.99 167.69 26.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.906 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.52 ' N ' HG13 ' A' ' 135' ' ' VAL . 89.9 t -45.56 128.02 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.104 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 100.42 -13.74 59.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.508 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.42 ' HB2' ' O ' ' A' ' 104' ' ' GLU . 0.0 OUTLIER -72.93 114.98 11.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.853 0.358 . . . . 0.0 110.935 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.445 ' O ' ' ND2' ' A' ' 110' ' ' ASN . 17.6 mttt -81.95 83.57 7.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.925 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.462 HG21 ' O ' ' A' ' 133' ' ' GLY . 3.0 m -68.04 165.09 2.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.038 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.464 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 2.6 m-80 -157.74 130.39 7.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.101 0.477 . . . . 0.0 110.789 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.459 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 0.0 OUTLIER -33.87 112.37 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.536 -0.757 . . . . 0.0 111.174 -179.984 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 110.39 13.0 15.87 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.844 -0.694 . . . . 0.0 112.385 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.476 ' O ' ' N ' ' A' ' 115' ' ' LEU . 17.3 t0 -122.58 103.04 8.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.753 0.311 . . . . 0.0 110.724 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.432 ' C ' ' O ' ' A' ' 113' ' ' ASP . 2.0 m -34.13 93.29 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.113 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.476 ' N ' ' O ' ' A' ' 113' ' ' ASP . 8.3 mt -50.05 -76.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.699 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.439 ' HA ' ' CG ' ' A' ' 102' ' ' PHE . 14.1 p -146.9 -155.66 0.64 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.653 179.76 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.569 HG13 ' CE2' ' A' ' 102' ' ' PHE . 2.3 mt -136.71 152.86 29.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.691 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.513 ' O ' ' N ' ' A' ' 120' ' ' ALA . 92.3 t -139.59 88.5 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.205 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.576 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -51.16 85.8 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.916 179.99 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 118' ' ' VAL . . . -104.4 140.2 38.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.517 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 50.64 22.13 1.03 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.577 -179.726 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.535 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 86.17 36.41 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.859 -179.803 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.468 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 32.4 mmm -151.33 129.27 11.72 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.076 179.752 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.522 ' CG ' HG23 ' A' ' 117' ' ' ILE . 33.0 mtt -67.13 93.39 0.29 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.945 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -70.7 76.86 0.6 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.889 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.479 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 17.3 pt20 -55.39 108.67 0.45 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.859 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 12.8 mm -74.53 151.41 6.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.053 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -123.51 123.23 40.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.91 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.459 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -41.0 124.95 2.29 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.89 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -113.26 15.0 19.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.917 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.463 ' HD3' ' ND1' ' A' ' 81' ' ' HIS . 2.0 tmtt? 176.35 105.32 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.864 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.464 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 2.4 t -37.06 114.59 0.33 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.622 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.462 ' O ' HG21 ' A' ' 109' ' ' VAL . . . -147.31 -173.49 18.5 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.732 -179.758 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.419 ' O ' ' C ' ' A' ' 135' ' ' VAL . 19.7 m -128.73 108.55 10.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.662 0.268 . . . . 0.0 111.251 -179.685 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.52 HG13 ' N ' ' A' ' 105' ' ' VAL . 69.9 t -39.29 144.81 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 179.224 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.505 ' O ' ' CB ' ' A' ' 137' ' ' ALA . 38.4 mtpt -121.45 -20.58 6.56 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.666 0.269 . . . . 0.0 111.117 -179.583 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.505 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 160.81 165.29 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.382 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.639 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -107.93 81.8 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.624 179.595 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.528 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 2.4 mt -41.55 -29.07 0.15 Allowed 'General case' 0 CA--C 1.52 -0.211 0 CA-C-O 121.064 0.459 . . . . 0.0 110.467 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.526 HG22 ' CD2' ' A' ' 152' ' ' LEU . 54.8 t -102.85 137.36 31.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.771 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.434 ' O ' ' C ' ' A' ' 142' ' ' SER . 5.9 mt-10 -66.73 94.11 0.29 Allowed 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.349 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.508 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 77.4 p -34.95 137.44 0.13 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.816 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.586 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 84.02 35.82 14.6 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.529 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.443 ' HB2' ' HD2' ' A' ' 145' ' ' PRO . 0.6 OUTLIER -155.33 159.36 31.78 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.983 0.42 . . . . 0.0 111.125 -179.881 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.463 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 45.5 Cg_endo -68.65 178.37 3.95 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.79 2.327 . . . . 0.0 112.47 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.51 HG12 ' CD2' ' A' ' 152' ' ' LEU . 0.0 OUTLIER -157.86 -173.82 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.066 -179.944 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.47 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 1.8 tt0 -140.59 148.43 40.93 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.982 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.43 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 66.7 t80 -37.66 122.62 0.97 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.868 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.43 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 7.1 t70 79.81 35.54 0.15 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.894 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.47 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 1.8 mt-10 -112.64 74.48 1.64 Allowed Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.845 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 84' ' ' ARG . 52.6 Cg_exo -32.95 120.45 0.1 Allowed 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 122.926 2.417 . . . . 0.0 111.834 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.562 ' CB ' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -109.62 -60.69 1.74 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.979 -179.102 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.591 ' CG1' ' CG1' ' A' ' 83' ' ' VAL . 2.3 p -111.96 110.35 31.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.066 0.46 . . . . 0.0 111.531 -179.275 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.528 ' CG2' ' HG ' ' A' ' 139' ' ' LEU . 4.9 t -92.2 145.49 7.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.354 179.811 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.514 ' CG1' ' HA ' ' A' ' 135' ' ' VAL . 35.8 mt -142.7 138.4 28.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.063 179.909 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.491 ' N ' HG21 ' A' ' 155' ' ' ILE . 2.2 tm-20 . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.217 -0.897 . . . . 0.0 110.914 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.466 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.365 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.525 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 22.2 t60 167.69 86.34 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.784 0.326 . . . . 0.0 110.672 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.523 ' CD1' HG12 ' A' ' 154' ' ' VAL . 0.3 OUTLIER -85.07 164.23 2.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 121.05 0.453 . . . . 0.0 111.101 179.962 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.461 ' O ' HD11 ' A' ' 152' ' ' LEU . 4.3 t -120.01 49.35 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.295 -179.828 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.506 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 5.2 ptt180 -48.41 136.04 13.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.892 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.518 ' N ' HD13 ' A' ' 152' ' ' LEU . 24.1 p -45.19 111.91 1.43 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.798 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.407 ' HG2' ' SD ' ' A' ' 87' ' ' MET . 24.7 Cg_endo -61.51 -10.21 15.66 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.652 2.235 . . . . 0.0 112.139 179.751 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.407 ' SD ' ' HG2' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -160.3 -170.46 2.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.687 179.902 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 60.2 t -86.62 84.18 2.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.071 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.408 ' O ' ' HA ' ' A' ' 145' ' ' PRO . . . -135.27 -138.97 3.96 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.699 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.581 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 62.0 m -141.33 141.2 33.88 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.85 0.357 . . . . 0.0 111.036 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.602 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 18.2 t80 -86.64 144.73 27.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.749 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.581 ' CZ ' HG23 ' A' ' 90' ' ' THR . 16.0 m-85 -146.49 159.09 43.86 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.856 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.482 ' O ' ' CB ' ' A' ' 101' ' ' ALA . 1.6 ptt85 -149.3 21.28 0.95 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.85 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.443 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 33.5 p -149.75 107.69 3.28 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.839 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.43 ' HG2' ' CB ' ' A' ' 99' ' ' ALA . 58.9 Cg_endo -72.07 -15.73 28.97 Favored 'Trans proline' 0 N--CA 1.465 -0.199 0 C-N-CA 122.776 2.318 . . . . 0.0 112.369 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.36 149.13 6.28 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.999 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_exo -51.32 -25.82 19.13 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.802 2.335 . . . . 0.0 112.282 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -125.68 51.2 1.75 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.789 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.43 ' CB ' ' HG2' ' A' ' 95' ' ' PRO . . . -114.34 -162.39 0.81 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.28 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . 0.46 ' O ' ' O ' ' A' ' 101' ' ' ALA . 2.0 ptmt -115.16 24.2 11.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.881 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.482 ' CB ' ' O ' ' A' ' 93' ' ' ARG . . . 50.13 172.35 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.14 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.586 ' CE2' HG12 ' A' ' 117' ' ' ILE . 11.6 m-30 -98.56 -45.42 6.09 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.84 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.47 HG12 ' O ' ' A' ' 115' ' ' LEU . 2.5 pp -160.14 141.74 4.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.176 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.437 ' HG2' ' HB2' ' A' ' 107' ' ' GLN . 15.2 pt-20 -132.18 171.64 13.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.919 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.45 HG12 ' O ' ' A' ' 105' ' ' VAL . 9.5 p -56.29 114.89 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.207 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 92.52 0.62 69.6 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.614 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.437 ' HB2' ' HG2' ' A' ' 104' ' ' GLU . 4.4 tp-100 -74.57 115.17 13.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.82 0.343 . . . . 0.0 110.845 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.09 129.1 37.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.97 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.421 ' O ' ' CG ' ' A' ' 110' ' ' ASN . 28.5 m -112.19 172.99 2.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.275 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.432 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 4.0 m120 -162.36 130.95 4.13 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-O 121.12 0.486 . . . . 0.0 110.657 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.485 HG13 ' N ' ' A' ' 131' ' ' LYS . 27.3 m -41.46 126.87 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.137 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 113.16 -1.95 25.41 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.534 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -112.21 -148.32 0.43 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.685 0.278 . . . . 0.0 110.616 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.8 134.01 44.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.936 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.47 ' O ' HG12 ' A' ' 103' ' ' ILE . 61.5 mt -87.35 -72.64 0.51 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.809 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -155.74 -174.91 5.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.856 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.586 HG12 ' CE2' ' A' ' 102' ' ' PHE . 0.0 OUTLIER -110.31 115.8 50.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.179 -179.879 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.469 ' HA ' ' O ' ' A' ' 90' ' ' THR . 1.7 t -99.27 56.69 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.677 179.671 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.467 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.4 OUTLIER -33.85 93.98 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.224 -179.606 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.482 ' O ' ' HG3' ' A' ' 121' ' ' MET . . . -110.76 138.76 46.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.897 179.751 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.511 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 62.71 13.17 6.18 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.796 -179.95 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.511 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.1 OUTLIER 85.44 53.42 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.866 -179.881 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.467 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.2 OUTLIER -171.11 132.79 0.84 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.988 179.884 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -49.46 125.28 10.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.977 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.446 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 1.7 t-20 -107.92 60.4 0.61 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.719 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.403 ' C ' ' O ' ' A' ' 125' ' ' ASN . 13.6 pt20 -36.58 131.1 0.7 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.877 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 37.2 mm -111.05 118.1 56.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.173 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 14.8 mm-40 -88.32 124.86 34.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.95 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.47 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -44.96 116.08 1.02 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.081 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -101.41 12.72 36.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.797 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.485 ' N ' HG13 ' A' ' 111' ' ' VAL . 0.3 OUTLIER 179.51 122.91 0.06 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.758 -179.954 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.432 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.4 t -56.41 126.75 27.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.71 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.43 ' HA3' ' CG2' ' A' ' 155' ' ' ILE . . . -157.17 -173.38 25.52 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.587 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.529 ' N ' HG22 ' A' ' 155' ' ' ILE . 61.6 m -135.51 108.79 7.79 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.765 0.317 . . . . 0.0 111.066 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.493 ' HA ' ' HA ' ' A' ' 155' ' ' ILE . 94.7 t -46.65 143.89 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.612 179.602 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.532 ' CD ' ' HB ' ' A' ' 154' ' ' VAL . 0.0 OUTLIER -115.03 -35.56 4.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 121.317 0.579 . . . . 0.0 109.729 -179.934 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.5 ' N ' ' HG2' ' A' ' 136' ' ' LYS . . . 177.64 142.41 0.09 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.164 -0.925 . . . . 0.0 111.36 -179.667 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.602 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -88.93 86.88 2.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.249 179.421 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.431 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 75.9 mt -41.62 -28.45 0.14 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.438 -179.653 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.542 HG22 ' CB ' ' A' ' 152' ' ' LEU . 54.5 t -102.07 158.42 4.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.102 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.468 ' O ' ' O ' ' A' ' 140' ' ' VAL . 1.1 mm-40 -59.56 -146.84 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 178.784 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.489 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -101.73 -59.6 1.67 Allowed 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.623 -0.431 . . . . 0.0 110.913 179.404 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.543 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -125.48 102.34 0.66 Allowed Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.64 -179.78 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.494 ' C ' ' CG2' ' A' ' 90' ' ' THR . 0.5 OUTLIER -167.99 136.64 1.96 Allowed Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 120.959 0.409 . . . . 0.0 111.259 179.766 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.467 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 50.5 Cg_exo -53.28 154.06 15.42 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.849 2.366 . . . . 0.0 112.405 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.463 HG11 ' O ' ' A' ' 145' ' ' PRO . 4.5 m -144.87 -156.48 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.999 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.527 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 24.5 mt-10 -149.28 150.86 33.22 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.969 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.446 ' HA ' ' O ' ' A' ' 85' ' ' SER . 37.5 t80 -42.75 141.4 1.08 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.805 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 66.13 29.47 9.85 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.772 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 0.8 OUTLIER -110.06 74.66 0.81 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.897 179.886 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.506 ' HA ' ' HA ' ' A' ' 84' ' ' ARG . 58.4 Cg_exo -32.89 135.56 0.08 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.579 0 C-N-CA 122.898 2.399 . . . . 0.0 111.999 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.542 ' CB ' HG22 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -134.32 -37.69 0.86 Allowed 'General case' 0 N--CA 1.453 -0.282 0 CA-C-O 121.024 0.44 . . . . 0.0 110.657 -179.511 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.571 HG21 ' CE2' ' A' ' 91' ' ' PHE . 2.3 t -128.34 115.64 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.595 -178.743 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.532 ' HB ' ' CD ' ' A' ' 136' ' ' LYS . 1.2 t -97.18 127.07 49.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.017 179.505 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.529 HG22 ' N ' ' A' ' 134' ' ' THR . 7.9 mt -121.88 149.05 25.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.272 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.508 ' N ' HG21 ' A' ' 155' ' ' ILE . 25.4 tt0 . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.217 -0.897 . . . . 0.0 110.947 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.379 0 N-CA-C 112.27 -0.332 . . . . 0.0 112.27 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.52 ' N ' ' O ' ' A' ' 155' ' ' ILE . 27.6 t60 -176.49 77.98 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.808 0.337 . . . . 0.0 111.009 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.526 HG12 ' CG1' ' A' ' 154' ' ' VAL . 18.5 mt -96.36 140.84 16.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.002 0.43 . . . . 0.0 111.07 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.561 ' CG2' ' CG1' ' A' ' 153' ' ' VAL . 1.8 t -91.69 48.7 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.104 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.462 ' O ' ' N ' ' A' ' 86' ' ' PRO . 7.1 ptt-85 -35.49 130.63 0.51 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.843 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.465 ' CB ' HG22 ' A' ' 146' ' ' VAL . 28.4 t -35.45 94.36 0.07 OUTLIER Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.038 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.462 ' N ' ' O ' ' A' ' 84' ' ' ARG . 51.3 Cg_exo -53.98 -24.98 34.25 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.662 2.242 . . . . 0.0 112.04 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.496 ' SD ' ' CB ' ' A' ' 120' ' ' ALA . 14.5 ptp -157.0 176.37 12.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.712 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 69.2 t -71.97 85.88 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.171 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.48 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -137.72 -150.87 5.77 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.572 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.622 ' CG2' ' CZ ' ' A' ' 92' ' ' TYR . 3.0 m -129.09 130.87 47.05 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.913 0.387 . . . . 0.0 111.043 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.659 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 53.2 t80 -76.52 146.87 38.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.562 179.765 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.622 ' CZ ' ' CG2' ' A' ' 90' ' ' THR . 14.7 m-85 -150.45 154.76 38.27 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.921 0.391 . . . . 0.0 110.872 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.465 ' HD3' ' OG ' ' A' ' 142' ' ' SER . 4.1 ptm180 -142.28 34.53 1.5 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.866 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.455 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 18.3 p -149.44 110.6 3.41 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.882 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -67.83 -24.85 39.86 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.697 2.265 . . . . 0.0 112.196 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -141.42 143.84 31.59 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.876 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -50.18 -19.77 4.71 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.701 2.267 . . . . 0.0 112.37 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -143.72 74.19 1.42 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -140.07 -155.57 0.6 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.137 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.68 36.94 2.26 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.812 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.455 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 66.56 -174.05 0.19 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.049 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.518 ' O ' ' CG2' ' A' ' 103' ' ' ILE . 0.1 OUTLIER -104.22 -46.14 4.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.94 179.942 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.518 ' CG2' ' O ' ' A' ' 102' ' ' PHE . 1.9 pp -164.68 131.39 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.123 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 18.0 pt-20 -132.29 170.08 15.56 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.883 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.476 ' HA ' ' CG1' ' A' ' 135' ' ' VAL . 3.6 t -53.13 128.2 12.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.029 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.52 -14.93 50.27 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.357 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -80.35 102.27 9.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.817 0.341 . . . . 0.0 110.901 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' A' ' 133' ' ' GLY . 0.0 OUTLIER -73.37 75.7 1.38 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.974 -179.88 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.449 HG21 ' O ' ' A' ' 133' ' ' GLY . 32.6 m -48.81 174.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.001 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.441 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 18.1 m-80 -162.36 130.31 3.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.008 0.433 . . . . 0.0 110.717 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.457 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 34.0 m -37.94 145.93 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.126 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 92.73 -6.04 76.92 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.421 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -105.63 -146.25 0.39 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.672 0.272 . . . . 0.0 110.573 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.5 HG23 ' CZ ' ' A' ' 102' ' ' PHE . 6.5 m -145.16 116.61 8.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.814 0.34 . . . . 0.0 111.023 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.455 ' O ' HG12 ' A' ' 103' ' ' ILE . 94.8 mt -69.23 -86.53 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.753 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.436 ' SG ' ' CG1' ' A' ' 153' ' ' VAL . 0.6 OUTLIER -135.17 -171.26 2.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.812 179.913 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.523 ' CG2' ' HB3' ' A' ' 124' ' ' MET . 0.1 OUTLIER -110.82 123.26 66.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.073 -180.0 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.426 HG22 HD13 ' A' ' 127' ' ' ILE . 87.3 t -105.99 58.32 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.753 179.662 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.465 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.5 OUTLIER -33.71 101.57 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.307 -179.658 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.518 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -122.99 149.37 44.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.745 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.518 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 5.4 ptm 50.71 21.72 0.97 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.944 0.402 . . . . 0.0 110.611 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.455 ' O ' ' HE3' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 77.56 60.12 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.246 -179.983 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.467 ' HG2' ' O ' ' A' ' 120' ' ' ALA . 2.9 ptt? -175.33 128.68 0.27 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.069 0.461 . . . . 0.0 111.151 179.497 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.523 ' HB3' ' CG2' ' A' ' 117' ' ' ILE . 1.7 mtp -53.29 95.03 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.979 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -82.08 70.93 9.11 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.83 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 84.9 mt-30 -51.89 120.9 5.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.947 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.426 HD13 HG22 ' A' ' 118' ' ' VAL . 41.4 mm -88.39 109.8 20.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.184 -179.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 129' ' ' ALA . 1.4 pt-20 -74.4 124.64 26.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.84 179.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.457 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -36.19 112.29 0.17 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.113 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.0 14.26 32.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.759 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.421 ' N ' HG11 ' A' ' 111' ' ' VAL . 0.3 OUTLIER 169.19 118.85 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.938 -179.979 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.441 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 25.3 p -49.5 129.58 19.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.857 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.449 ' O ' HG21 ' A' ' 109' ' ' VAL . . . -158.28 -178.1 31.99 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.642 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.579 ' N ' ' CG2' ' A' ' 155' ' ' ILE . 23.4 m -129.81 108.7 10.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.58 0.229 . . . . 0.0 111.152 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.476 ' CG1' ' HA ' ' A' ' 105' ' ' VAL . 69.9 t -42.25 142.44 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 110.295 -0.261 . . . . 0.0 110.295 179.504 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.486 ' O ' ' CB ' ' A' ' 137' ' ' ALA . 5.8 mmmt -124.88 -18.66 5.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.677 0.275 . . . . 0.0 111.342 -179.426 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.486 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 165.17 154.22 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.841 0.353 . . . . 0.0 111.448 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.659 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -106.0 78.7 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.79 179.922 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.531 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 22.0 mt -42.14 -29.49 0.24 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.149 0.5 . . . . 0.0 110.385 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.528 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 55.4 t -100.7 161.89 3.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.694 179.73 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.519 ' N ' ' CG1' ' A' ' 140' ' ' VAL . 1.8 mm-40 -58.49 -149.13 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.345 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.481 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 35.8 m -107.67 -63.94 1.26 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.826 0.346 . . . . 0.0 110.893 179.605 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.613 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -123.44 90.47 0.42 Allowed Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.851 -179.783 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.457 ' O ' HG21 ' A' ' 90' ' ' THR . 36.3 mm-40 -156.57 156.34 29.88 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-O 120.908 0.385 . . . . 0.0 110.969 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.458 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 48.6 Cg_endo -69.26 120.98 7.77 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.681 2.254 . . . . 0.0 112.132 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.508 HG13 ' CD2' ' A' ' 152' ' ' LEU . 18.3 m -105.92 -173.83 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.123 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.491 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 6.2 mm-40 -140.7 144.41 35.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.031 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.432 ' HA ' ' O ' ' A' ' 85' ' ' SER . 63.9 t80 -35.7 137.94 0.18 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.051 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 7.9 t70 69.67 27.78 4.63 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.891 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.491 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 1.2 tp10 -108.87 73.79 0.53 Allowed Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.833 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.471 ' O ' HG21 ' A' ' 140' ' ' VAL . 61.4 Cg_exo -34.18 123.2 0.16 Allowed 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.804 2.336 . . . . 0.0 112.042 179.674 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.528 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -120.64 -70.86 0.76 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.699 -179.254 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.561 ' CG1' ' CG2' ' A' ' 83' ' ' VAL . 1.3 p -97.04 106.24 18.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.559 -179.146 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.531 ' CG2' ' HG ' ' A' ' 139' ' ' LEU . 23.4 t -89.33 133.41 31.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.865 179.349 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.579 ' CG2' ' N ' ' A' ' 134' ' ' THR . 82.9 mt -134.38 135.37 54.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.191 -179.799 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.465 ' HB2' ' CD ' ' A' ' 136' ' ' LYS . 0.7 OUTLIER . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.228 -0.891 . . . . 0.0 110.939 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.452 -0.283 0 N-CA-C 112.462 -0.255 . . . . 0.0 112.462 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.565 ' CG ' HG23 ' A' ' 155' ' ' ILE . 11.9 t-80 173.11 83.07 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.827 0.346 . . . . 0.0 110.823 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.533 HG12 ' CG1' ' A' ' 154' ' ' VAL . 1.6 mt -118.17 151.05 20.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.071 0.462 . . . . 0.0 111.31 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.527 ' HB ' ' CG1' ' A' ' 153' ' ' VAL . 20.4 t -95.19 37.69 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.168 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.482 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 20.1 ptt85 -37.2 127.77 0.98 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.711 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.479 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 0.2 OUTLIER -45.33 109.38 0.92 Allowed Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.726 179.96 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -61.61 -13.22 28.59 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.72 2.28 . . . . 0.0 112.126 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.423 ' SD ' ' HB3' ' A' ' 120' ' ' ALA . 1.9 ptp -150.08 -159.58 1.05 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.821 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.44 ' O ' HG21 ' A' ' 88' ' ' VAL . 5.2 m -92.25 87.27 2.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.103 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.476 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -141.99 -163.5 9.65 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.468 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.575 HG23 ' CE1' ' A' ' 92' ' ' TYR . 25.8 m -119.98 145.41 46.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.843 0.354 . . . . 0.0 110.881 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.643 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 1.0 OUTLIER -102.08 147.71 26.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.031 -179.839 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.578 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 23.3 m-85 -142.73 167.59 21.72 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.865 179.843 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.465 ' HD3' ' HB3' ' A' ' 142' ' ' SER . 32.1 ptt85 -152.96 21.23 0.58 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.689 179.866 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.477 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 6.5 p -155.24 113.67 2.29 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.753 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.42 ' HG2' ' HB2' ' A' ' 99' ' ' ALA . 49.2 Cg_endo -68.59 -39.15 9.64 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.702 2.268 . . . . 0.0 112.342 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.516 ' CB ' ' HD2' ' A' ' 97' ' ' PRO . 0.2 OUTLIER -135.23 172.49 7.13 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.914 -179.947 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.516 ' HD2' ' CB ' ' A' ' 96' ' ' SER . 51.9 Cg_endo -69.22 -27.61 28.83 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.725 2.283 . . . . 0.0 112.284 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -135.46 39.63 2.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.874 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.506 ' HB1' ' CB ' ' A' ' 96' ' ' SER . . . -95.28 -156.07 0.5 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.108 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . 0.414 ' O ' ' CG ' ' A' ' 100' ' ' LYS . 0.0 OUTLIER -102.81 34.79 2.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.91 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.477 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 45.01 -158.87 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.179 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.565 ' CD2' HG12 ' A' ' 117' ' ' ILE . 0.1 OUTLIER -139.27 40.28 2.09 Favored 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.059 179.816 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.536 ' CB ' ' O ' ' A' ' 102' ' ' PHE . 2.6 mt 87.07 122.04 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.113 -179.806 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.416 ' O ' ' HB ' ' A' ' 135' ' ' VAL . 1.7 pt-20 -131.17 -175.75 3.79 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.905 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.459 HG12 ' O ' ' A' ' 136' ' ' LYS . 46.7 t -53.31 134.06 15.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.079 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 93.22 -26.91 12.9 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.399 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.7 tp60 -72.35 131.63 42.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.803 0.335 . . . . 0.0 110.832 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.42 118.91 33.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.963 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.498 ' CG2' HD12 ' A' ' 155' ' ' ILE . 4.4 m -89.97 178.35 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.06 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.432 ' CG ' ' O ' ' A' ' 109' ' ' VAL . 18.4 m120 -164.71 131.27 2.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.068 0.461 . . . . 0.0 110.641 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.463 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 34.7 m -38.65 159.51 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.123 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 79.63 -6.04 59.31 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.499 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -108.88 -147.49 0.41 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.708 0.289 . . . . 0.0 110.651 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 14.4 m -135.93 150.12 49.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.847 0.356 . . . . 0.0 110.854 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.448 ' O ' ' O ' ' A' ' 102' ' ' PHE . 49.4 mt -96.95 -75.58 0.54 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.881 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.461 ' HB3' ' O ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -148.4 -168.31 3.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.803 -179.916 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.565 HG12 ' CD2' ' A' ' 102' ' ' PHE . 0.1 OUTLIER -108.63 120.29 59.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.178 179.926 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.517 ' O ' ' CB ' ' A' ' 125' ' ' ASN . 11.1 t -118.43 73.38 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.03 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.545 ' HG2' ' CE2' ' A' ' 92' ' ' TYR . 0.9 OUTLIER -59.32 119.55 7.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.832 -179.953 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.423 ' HB3' ' SD ' ' A' ' 87' ' ' MET . . . -94.0 -70.26 0.71 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.28 0.562 . . . . 0.0 111.365 -179.834 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.532 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 1.9 ptp -92.53 36.21 1.01 Allowed 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.447 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.538 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 0.4 OUTLIER 88.54 -7.74 0.5 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.87 -179.814 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.474 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 6.2 mtt -107.72 128.07 54.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.956 0.407 . . . . 0.0 110.896 179.68 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.517 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 1.0 OUTLIER -43.83 149.67 0.3 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.148 -179.867 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.517 ' CB ' ' O ' ' A' ' 118' ' ' VAL . 30.1 t-20 -129.58 74.25 1.57 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.572 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 9.9 pt20 -47.06 112.85 0.57 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.051 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.444 HD12 ' O ' ' A' ' 125' ' ' ASN . 23.2 mm -92.8 105.92 17.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.103 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -70.21 143.2 52.28 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.932 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -66.04 119.22 11.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.123 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -97.8 -10.63 24.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.911 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.421 ' O ' ' C ' ' A' ' 132' ' ' SER . 10.0 tttt -161.61 109.47 1.45 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.918 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 131' ' ' LYS . 4.8 p -36.04 141.18 0.1 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.958 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.494 ' O ' ' N ' ' A' ' 109' ' ' VAL . . . -169.45 -165.12 26.31 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.521 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.511 ' N ' HG12 ' A' ' 155' ' ' ILE . 55.9 m -150.97 110.08 3.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.672 0.272 . . . . 0.0 110.938 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.502 ' N ' HG13 ' A' ' 155' ' ' ILE . 61.8 t -41.86 141.34 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.843 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.542 ' CD ' HG13 ' A' ' 154' ' ' VAL . 0.0 OUTLIER -114.51 -35.88 4.77 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 121.456 0.646 . . . . 0.0 109.462 179.934 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.515 ' N ' ' HG2' ' A' ' 136' ' ' LYS . . . -175.44 155.01 1.75 Allowed 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.775 -179.579 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.643 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -103.06 84.35 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.406 179.648 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.525 ' CD1' HG23 ' A' ' 154' ' ' VAL . 0.2 OUTLIER -41.59 -28.81 0.15 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.106 0.479 . . . . 0.0 110.278 -179.872 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.53 HG22 ' CD2' ' A' ' 152' ' ' LEU . 79.7 t -103.38 134.45 44.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.826 179.753 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.449 ' O ' ' C ' ' A' ' 142' ' ' SER . 13.6 mt-10 -67.5 100.77 0.9 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.161 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.465 ' HB3' ' HD3' ' A' ' 93' ' ' ARG . 6.9 p -34.41 134.96 0.18 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.783 -179.524 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.578 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 80.72 39.31 14.31 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.583 -0.817 . . . . 0.0 112.255 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.461 ' O ' HG21 ' A' ' 90' ' ' THR . 0.6 OUTLIER -148.78 139.55 13.6 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 120.977 0.417 . . . . 0.0 111.076 -179.947 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.513 ' N ' HG22 ' A' ' 90' ' ' THR . 31.3 Cg_exo -59.03 158.75 24.14 Favored 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 122.845 2.363 . . . . 0.0 112.389 -179.725 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.477 ' CG1' HG12 ' A' ' 140' ' ' VAL . 19.7 m -147.22 -173.5 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.981 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.455 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.3 OUTLIER -138.06 174.44 10.56 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.933 179.956 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.494 ' CD1' ' HB2' ' A' ' 149' ' ' ASP . 1.3 p90 -55.2 140.31 39.21 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.834 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.494 ' HB2' ' CD1' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 59.41 34.4 22.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.867 0.365 . . . . 0.0 110.902 179.994 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.517 ' OE2' ' CG2' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -109.46 74.68 0.69 Allowed Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.88 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.482 ' HA ' ' HA ' ' A' ' 84' ' ' ARG . 57.2 Cg_exo -33.43 133.93 0.11 Allowed 'Trans proline' 0 N--CA 1.459 -0.553 0 C-N-CA 122.926 2.417 . . . . 0.0 112.104 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.579 ' HB2' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -128.29 -50.7 1.3 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.739 -179.194 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.527 ' CG1' ' HB ' ' A' ' 83' ' ' VAL . 2.3 p -117.93 112.23 37.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.899 0.381 . . . . 0.0 111.541 -179.1 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.542 HG13 ' CD ' ' A' ' 136' ' ' LYS . 0.7 OUTLIER -96.0 129.81 45.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.888 179.523 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.565 HG23 ' CG ' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -113.28 157.58 13.92 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.778 -179.934 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.448 ' N ' ' O ' ' A' ' 134' ' ' THR . 29.1 tt0 . . . . . 0 C--O 1.25 1.101 0 CA-C-O 118.211 -0.9 . . . . 0.0 110.976 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.438 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.45 -0.372 0 N-CA-C 112.609 -0.196 . . . . 0.0 112.609 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.524 ' CD2' ' HD2' ' A' ' 131' ' ' LYS . 14.9 t-80 172.78 83.36 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.773 0.32 . . . . 0.0 110.721 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.58 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -97.73 176.46 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.145 179.977 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.589 ' CG1' ' CG1' ' A' ' 153' ' ' VAL . 2.3 p -132.45 28.18 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.811 179.557 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.526 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 6.2 ptt180 -25.97 120.42 0.07 Allowed 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.542 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.468 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 0.2 OUTLIER -38.58 116.25 0.93 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.835 -179.855 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.08 -9.31 25.7 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.634 2.222 . . . . 0.0 111.919 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 13.6 ptm -151.24 -168.96 3.25 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.626 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.431 ' CG2' ' O ' ' A' ' 88' ' ' VAL . 32.3 m -88.81 83.01 2.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.132 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.423 ' C ' HG23 ' A' ' 146' ' ' VAL . . . -126.17 -140.56 5.32 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.612 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.604 ' CG2' ' CZ ' ' A' ' 92' ' ' TYR . 4.9 m -146.73 128.06 14.88 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.008 0.432 . . . . 0.0 111.274 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.669 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 30.2 t80 -75.5 139.1 41.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.125 179.36 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.604 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 12.7 m-85 -142.67 156.35 45.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.927 0.394 . . . . 0.0 111.213 -179.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 23.8 ptt85 -142.62 40.85 1.57 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.805 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -146.57 95.23 4.63 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.858 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.425 ' HD3' ' N ' ' A' ' 102' ' ' PHE . 49.7 Cg_endo -69.15 -38.84 8.53 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.817 2.345 . . . . 0.0 112.407 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.512 ' HB2' ' CB ' ' A' ' 99' ' ' ALA . 70.4 m -129.53 160.85 62.41 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.963 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.4 101.06 0.06 OUTLIER 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.717 2.278 . . . . 0.0 112.285 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 63.54 36.39 11.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.861 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.512 ' CB ' ' HB2' ' A' ' 96' ' ' SER . . . -76.56 -158.02 0.09 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.157 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . 0.416 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 0.6 OUTLIER -89.35 23.34 2.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.99 179.972 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.416 ' HB1' ' O ' ' A' ' 100' ' ' LYS . . . 67.85 159.65 0.16 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.185 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.571 ' CZ ' HG23 ' A' ' 114' ' ' THR . 0.0 OUTLIER -84.65 -46.01 11.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.81 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.465 ' HA ' ' HG3' ' A' ' 107' ' ' GLN . 1.1 pp -163.63 112.03 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.039 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.454 ' O ' ' HB2' ' A' ' 107' ' ' GLN . 10.2 pt-20 -123.72 172.35 8.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.909 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.3 t -51.97 119.06 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.179 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 107.44 -4.86 35.15 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.522 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.465 ' HG3' ' HA ' ' A' ' 103' ' ' ILE . 1.6 mm-40 -73.8 129.64 38.33 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.771 0.319 . . . . 0.0 110.987 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.423 ' O ' ' ND2' ' A' ' 110' ' ' ASN . 6.0 mttt -98.8 72.11 1.94 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.885 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.522 HG13 ' CD2' ' A' ' 115' ' ' LEU . 6.0 m -48.86 167.03 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.023 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.487 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 9.6 m-80 -159.87 129.87 5.45 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.083 0.468 . . . . 0.0 110.82 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.495 ' O ' ' CG2' ' A' ' 111' ' ' VAL . 5.0 m -34.99 115.37 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.056 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 99.96 12.69 39.23 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.344 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.423 ' O ' ' C ' ' A' ' 114' ' ' THR . 1.8 t70 -123.7 103.1 8.19 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.824 0.345 . . . . 0.0 110.811 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.571 HG23 ' CZ ' ' A' ' 102' ' ' PHE . 3.2 m -35.06 132.91 0.33 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.066 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.522 ' CD2' HG13 ' A' ' 109' ' ' VAL . 67.1 mt -93.68 -81.63 0.36 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.843 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -133.16 -172.89 3.05 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.701 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.512 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.2 OUTLIER -110.79 123.71 66.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.136 179.975 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.523 ' O ' ' N ' ' A' ' 120' ' ' ALA . 23.6 t -103.42 55.81 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.725 179.773 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.462 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.1 OUTLIER -31.38 89.0 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.721 -179.689 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 118' ' ' VAL . . . -88.82 134.24 34.0 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.141 179.25 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.554 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 2.8 ptt? 50.37 22.89 1.09 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.242 -179.337 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.554 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 96.21 -10.18 0.09 Allowed 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.544 179.698 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.515 ' O ' ' N ' ' A' ' 120' ' ' ALA . 12.5 ptm -99.18 131.69 45.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.157 0.503 . . . . 0.0 111.35 -179.766 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.512 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 1.4 ptt? -55.16 130.5 42.27 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.914 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.468 ' HB2' ' O ' ' A' ' 118' ' ' VAL . 0.7 OUTLIER -121.92 65.34 0.91 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.955 -179.967 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.524 ' HB2' ' CG2' ' A' ' 114' ' ' THR . 2.6 pm0 -39.2 144.36 0.14 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.918 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.44 HG12 HG22 ' A' ' 118' ' ' VAL . 31.8 mm -113.1 123.03 68.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.079 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 129' ' ' ALA . 5.5 mt-10 -85.23 118.39 24.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.843 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.428 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.94 127.81 0.7 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.002 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -100.57 -10.81 20.63 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.974 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.524 ' HD2' ' CD2' ' A' ' 81' ' ' HIS . 2.0 tmtt? -168.86 123.22 0.86 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.004 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.0 OUTLIER -51.26 112.39 0.73 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.396 179.729 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.527 ' HA3' ' CG2' ' A' ' 155' ' ' ILE . . . -145.28 -179.83 21.86 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.713 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.498 ' N ' HG21 ' A' ' 155' ' ' ILE . 29.9 m -122.4 112.32 17.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.693 0.282 . . . . 0.0 111.396 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.515 HG11 ' N ' ' A' ' 136' ' ' LYS . 85.7 t -46.56 144.34 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.524 179.293 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.537 ' CD ' ' HB ' ' A' ' 154' ' ' VAL . 0.0 OUTLIER -114.52 -35.75 4.81 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-O 121.496 0.665 . . . . 0.0 109.682 -179.809 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.505 ' N ' ' HG2' ' A' ' 136' ' ' LYS . . . 179.62 172.71 0.94 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.951 -179.672 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.669 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.6 OUTLIER -119.09 82.9 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.059 179.843 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 3.8 mt -41.09 -29.53 0.12 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.2 0.524 . . . . 0.0 110.073 179.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.54 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 54.5 t -100.08 158.9 3.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.555 179.538 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.477 ' N ' ' CG1' ' A' ' 140' ' ' VAL . 2.8 mt-10 -58.81 -150.43 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.067 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.487 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -102.49 -60.75 1.49 Allowed 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 120.81 -0.356 . . . . 0.0 110.822 179.623 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.604 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -127.07 89.09 0.34 Allowed Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.793 -179.779 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.453 ' O ' HG21 ' A' ' 90' ' ' THR . 25.2 mm-40 -153.09 155.61 32.08 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 120.997 0.427 . . . . 0.0 110.979 179.77 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.475 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 39.6 Cg_exo -56.81 153.29 37.77 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.855 2.37 . . . . 0.0 112.391 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.45 HG22 ' OG ' ' A' ' 85' ' ' SER . 31.1 m -141.45 -173.08 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.967 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.471 ' O ' ' HG2' ' A' ' 150' ' ' GLU . 1.0 OUTLIER -146.82 144.58 29.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.896 0.379 . . . . 0.0 111.16 -179.94 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.468 ' HA ' ' O ' ' A' ' 85' ' ' SER . 5.5 p90 -35.62 124.35 0.67 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.953 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.442 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 79.46 33.22 0.22 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.824 -179.945 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.471 ' HG2' ' O ' ' A' ' 147' ' ' GLU . 13.0 mm-40 -109.26 75.23 0.69 Allowed Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.867 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.526 ' CD ' ' HB3' ' A' ' 84' ' ' ARG . 75.1 Cg_exo -37.38 129.15 0.68 Allowed 'Trans proline' 0 N--CA 1.461 -0.413 0 C-N-CA 122.774 2.316 . . . . 0.0 111.925 179.594 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.54 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -123.27 -61.1 1.44 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.635 -179.3 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.589 ' CG1' ' CG1' ' A' ' 83' ' ' VAL . 2.1 p -108.26 120.91 60.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 121.172 0.511 . . . . 0.0 111.292 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.537 ' HB ' ' CD ' ' A' ' 136' ' ' LYS . 0.2 OUTLIER -100.55 137.92 26.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.219 -179.98 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.527 ' CG2' ' HA3' ' A' ' 133' ' ' GLY . 45.6 mt -123.43 147.16 27.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.229 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.516 ' N ' HG21 ' A' ' 155' ' ' ILE . 2.1 tt0 . . . . . 0 C--O 1.248 1.018 0 CA-C-O 118.323 -0.846 . . . . 0.0 110.922 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.34 0 N-CA-C 112.647 -0.181 . . . . 0.0 112.647 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.504 ' O ' ' ND1' ' A' ' 81' ' ' HIS . 23.7 t-80 -170.03 76.15 0.08 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.847 0.355 . . . . 0.0 110.802 179.838 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.479 HG12 ' HA ' ' A' ' 154' ' ' VAL . 5.1 mt -101.86 155.07 4.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.066 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.52 ' CG2' HG11 ' A' ' 153' ' ' VAL . 4.0 t -102.42 51.2 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.969 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.533 ' CD ' ' O ' ' A' ' 84' ' ' ARG . 0.5 OUTLIER -35.48 133.19 0.38 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.875 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.491 ' N ' HD13 ' A' ' 152' ' ' LEU . 11.2 p -39.41 98.6 0.17 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.757 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.415 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 12.2 Cg_endo -56.3 -15.44 14.84 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.506 2.137 . . . . 0.0 111.91 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.457 ' SD ' ' HB3' ' A' ' 120' ' ' ALA . 5.2 ptp -160.29 172.38 17.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.534 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 27.2 m -67.32 68.33 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.037 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 87' ' ' MET . . . -119.04 -155.68 9.88 Favored Glycine 0 C--N 1.331 0.289 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.648 -179.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.579 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 20.2 m -131.5 124.85 31.0 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.908 0.385 . . . . 0.0 111.07 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.639 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 72.4 t80 -62.61 141.95 58.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.52 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.579 ' CZ ' HG23 ' A' ' 90' ' ' THR . 5.6 m-30 -148.37 127.73 13.06 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.964 0.412 . . . . 0.0 110.919 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.461 ' HA ' ' HB2' ' A' ' 102' ' ' PHE . 0.1 OUTLIER -124.27 25.52 7.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.825 179.857 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 2.7 p -149.21 108.16 3.4 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.882 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.34 -44.1 1.85 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.82 2.346 . . . . 0.0 112.309 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.461 ' OG ' ' HD2' ' A' ' 97' ' ' PRO . 0.1 OUTLIER -110.64 166.93 9.83 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.928 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.461 ' HD2' ' OG ' ' A' ' 96' ' ' SER . 51.1 Cg_endo -69.42 -25.56 30.05 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.737 2.291 . . . . 0.0 112.224 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -136.17 26.86 3.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.817 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -71.49 -163.92 0.1 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.121 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -103.83 20.75 17.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.921 179.854 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 71.47 162.9 0.26 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.274 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.54 ' CE2' HG13 ' A' ' 117' ' ' ILE . 0.1 OUTLIER -84.93 -37.42 20.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.765 179.922 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.457 HG22 ' O ' ' A' ' 102' ' ' PHE . 1.2 pp -161.29 158.56 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.019 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.417 ' O ' ' HB3' ' A' ' 107' ' ' GLN . 0.2 OUTLIER -140.42 151.23 44.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.906 -179.989 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.528 ' HA ' ' CG1' ' A' ' 135' ' ' VAL . 4.8 p -54.08 127.94 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.199 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 93.83 -9.77 72.9 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.521 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.516 ' O ' ' N ' ' A' ' 109' ' ' VAL . 2.7 tp-100 -68.93 99.83 1.11 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.855 0.36 . . . . 0.0 110.801 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.423 ' HA ' ' HA ' ' A' ' 134' ' ' THR . 0.0 OUTLIER -59.26 75.62 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.952 -179.839 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.516 ' N ' ' O ' ' A' ' 107' ' ' GLN . 6.6 m -53.28 172.0 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.008 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.471 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 3.9 p-10 -163.06 133.03 4.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.058 0.456 . . . . 0.0 110.947 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.454 ' O ' HG21 ' A' ' 111' ' ' VAL . 29.3 m -38.25 130.18 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.131 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 101.95 2.01 52.02 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.417 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.434 ' O ' ' N ' ' A' ' 115' ' ' LEU . 4.2 t70 -117.93 99.22 6.77 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.777 0.322 . . . . 0.0 110.859 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.453 ' HA ' ' HA ' ' A' ' 128' ' ' GLU . 6.5 m -35.41 96.11 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.004 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.464 ' N ' ' O ' ' A' ' 127' ' ' ILE . 7.1 mt -46.4 -89.98 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.75 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.467 ' O ' ' N ' ' A' ' 127' ' ' ILE . 0.5 OUTLIER -136.86 -168.91 2.36 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.687 -179.992 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.54 HG13 ' CE2' ' A' ' 102' ' ' PHE . 2.2 mt -125.83 153.83 34.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.885 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.462 ' HA ' ' O ' ' A' ' 90' ' ' THR . 27.5 t -142.61 101.64 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.872 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.544 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.5 OUTLIER -62.7 89.66 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.201 -179.799 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.457 ' HB3' ' SD ' ' A' ' 87' ' ' MET . . . -69.28 -136.07 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.649 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.466 ' O ' ' HB2' ' A' ' 122' ' ' LYS . 0.0 OUTLIER -34.14 -39.84 0.08 Allowed 'General case' 0 CA--C 1.519 -0.224 0 CA-C-O 121.444 0.64 . . . . 0.0 110.173 179.608 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.519 ' CG ' ' O ' ' A' ' 122' ' ' LYS . 0.1 OUTLIER 169.27 38.21 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.873 179.482 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 36.8 mmm -146.93 131.87 18.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.045 -179.422 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.531 ' HB2' ' CD1' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -64.47 101.44 0.45 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.836 179.994 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.436 ' HB2' ' O ' ' A' ' 118' ' ' VAL . 0.9 OUTLIER -77.07 83.28 3.58 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.877 179.946 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.521 ' CA ' HG12 ' A' ' 117' ' ' ILE . 7.8 pt20 -64.29 103.92 0.69 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.959 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.467 ' N ' ' O ' ' A' ' 116' ' ' CYS . 17.3 mm -75.38 139.09 19.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.04 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.453 ' HA ' ' HA ' ' A' ' 114' ' ' THR . 2.2 mt-10 -110.4 122.05 46.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.923 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.436 ' HB2' ' HA ' ' A' ' 111' ' ' VAL . . . -36.78 114.89 0.33 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.064 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -107.82 17.19 22.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 1.9 ttmt 177.32 113.5 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.9 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 15.6 p -43.51 121.31 2.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.758 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.455 ' O ' HG21 ' A' ' 109' ' ' VAL . . . -152.2 -171.52 19.92 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.599 -179.802 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.506 ' N ' HG22 ' A' ' 155' ' ' ILE . 21.8 m -140.14 107.81 5.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.582 0.229 . . . . 0.0 111.239 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.528 ' CG1' ' HA ' ' A' ' 105' ' ' VAL . 92.5 t -41.79 142.71 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.437 179.459 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.511 ' N ' HG11 ' A' ' 135' ' ' VAL . 30.5 mtpt -124.91 -18.93 5.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.455 -179.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.433 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 169.15 155.38 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.935 0.398 . . . . 0.0 111.622 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.639 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -111.11 77.44 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.61 179.792 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.433 HD13 HG23 ' A' ' 154' ' ' VAL . 9.7 mt -46.25 -24.92 0.53 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.965 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.531 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 45.3 t -104.13 144.18 14.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.239 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.47 ' HB2' ' HG2' ' A' ' 144' ' ' GLN . 4.7 mt-10 -62.35 137.62 58.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.069 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.494 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -31.58 -62.33 0.2 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.621 -179.331 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.561 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -125.58 104.21 0.75 Allowed Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.483 -0.865 . . . . 0.0 112.995 -179.483 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.47 ' HG2' ' HB2' ' A' ' 141' ' ' GLU . 0.6 OUTLIER -167.62 156.16 8.72 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-O 120.93 0.395 . . . . 0.0 111.137 179.553 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.465 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 37.8 Cg_endo -66.31 138.38 50.8 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.807 2.338 . . . . 0.0 112.329 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.419 HG21 ' HA ' ' A' ' 90' ' ' THR . 1.5 m -132.14 -174.77 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.089 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.431 ' O ' ' C ' ' A' ' 148' ' ' PHE . 18.5 mt-10 -145.7 144.03 30.13 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.929 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.48 ' HA ' ' O ' ' A' ' 85' ' ' SER . 39.6 t80 -34.5 135.02 0.18 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.947 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 76.3 23.96 1.15 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.709 -179.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.435 ' O ' ' HG3' ' A' ' 150' ' ' GLU . 4.5 tp10 -109.93 74.26 0.76 Allowed Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.788 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.462 ' HB3' HG23 ' A' ' 82' ' ' ILE . 63.3 Cg_exo -33.27 130.57 0.13 Allowed 'Trans proline' 0 N--CA 1.457 -0.635 0 C-N-CA 122.888 2.392 . . . . 0.0 112.116 179.652 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.531 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -121.86 -72.2 0.7 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.555 -179.231 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.52 HG11 ' CG2' ' A' ' 83' ' ' VAL . 1.2 p -96.61 102.92 14.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.226 0.536 . . . . 0.0 111.37 -179.38 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.479 ' HA ' HG12 ' A' ' 82' ' ' ILE . 6.3 t -83.38 138.64 18.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.017 179.675 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.506 HG22 ' N ' ' A' ' 134' ' ' THR . 17.9 mt -136.72 143.2 35.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.352 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.496 ' CB ' ' HD2' ' A' ' 136' ' ' LYS . 29.5 tt0 . . . . . 0 C--O 1.25 1.094 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.881 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 N-CA-C 112.475 -0.25 . . . . 0.0 112.475 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.524 ' N ' ' O ' ' A' ' 155' ' ' ILE . 19.7 t-80 175.85 82.21 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.789 0.328 . . . . 0.0 110.849 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.535 HG12 ' CG1' ' A' ' 154' ' ' VAL . 7.1 mt -98.93 157.27 3.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.087 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.52 ' HB ' ' CG1' ' A' ' 153' ' ' VAL . 1.9 t -113.67 53.91 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.148 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.474 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -41.08 134.6 2.0 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.855 179.938 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.468 ' N ' HD13 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -35.86 109.23 0.4 Allowed Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.855 -179.916 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.426 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 35.4 Cg_endo -64.74 -8.56 18.01 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.744 2.296 . . . . 0.0 112.109 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.502 ' HE1' ' CB ' ' A' ' 120' ' ' ALA . 0.9 OUTLIER -167.85 176.17 6.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.757 179.911 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.504 ' CG2' ' O ' ' A' ' 88' ' ' VAL . 32.6 m -71.42 82.83 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.129 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -142.78 -159.06 7.78 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.581 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.566 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 23.2 m -116.62 142.98 46.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.785 0.326 . . . . 0.0 110.803 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.637 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 2.6 t80 -100.23 140.16 34.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.586 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 19.9 m-85 -138.66 145.9 40.99 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.987 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.535 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 0.0 OUTLIER -125.49 28.24 6.31 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.852 179.846 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.452 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 12.1 p -146.96 115.5 4.36 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.847 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.422 ' HG2' ' CB ' ' A' ' 99' ' ' ALA . 55.5 Cg_endo -69.93 -39.44 6.17 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.685 2.257 . . . . 0.0 112.376 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.522 ' CB ' ' HB1' ' A' ' 99' ' ' ALA . 0.3 OUTLIER -129.16 160.57 63.19 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.952 179.998 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -52.58 -37.14 73.7 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.72 2.28 . . . . 0.0 112.332 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.411 ' CG ' ' O ' ' A' ' 98' ' ' ASP . 34.9 t0 -131.45 32.39 4.2 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.885 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.522 ' HB1' ' CB ' ' A' ' 96' ' ' SER . . . -76.24 -158.27 0.09 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.061 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 6.1 ptmt -104.72 23.6 13.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.917 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.452 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 68.65 166.31 0.26 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.187 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.569 ' CE2' HG13 ' A' ' 117' ' ' ILE . 0.2 OUTLIER -93.78 -34.02 13.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.818 179.915 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.515 ' CG2' ' O ' ' A' ' 102' ' ' PHE . 1.0 OUTLIER -164.84 150.37 2.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.134 179.913 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -155.17 146.89 23.25 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.961 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.518 ' N ' HG13 ' A' ' 135' ' ' VAL . 3.0 t -54.11 116.45 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.148 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 129.5 -36.31 2.4 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.546 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.452 ' OE1' ' HA ' ' A' ' 103' ' ' ILE . 12.7 pt20 -76.38 130.08 37.53 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.842 0.354 . . . . 0.0 110.895 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 134' ' ' THR . 2.6 mtpt -90.23 91.4 8.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.949 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.521 HG13 ' CD2' ' A' ' 115' ' ' LEU . 15.4 m -51.5 173.44 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.074 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.435 ' CG ' ' O ' ' A' ' 109' ' ' VAL . 75.1 m-80 -163.6 130.54 3.34 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.691 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.47 ' HA ' ' CB ' ' A' ' 129' ' ' ALA . 3.2 t -37.45 135.43 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.073 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 89.59 7.9 68.52 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.519 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 114' ' ' THR . 91.1 m-20 -121.08 101.98 8.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.933 0.397 . . . . 0.0 110.783 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.425 ' C ' ' O ' ' A' ' 113' ' ' ASP . 1.7 m -35.25 101.66 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.104 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.521 ' CD2' HG13 ' A' ' 109' ' ' VAL . 7.7 mt -56.77 -83.66 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.63 179.785 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.457 ' HB3' HG12 ' A' ' 103' ' ' ILE . 0.8 OUTLIER -144.34 178.21 8.08 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.764 179.804 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.569 HG13 ' CE2' ' A' ' 102' ' ' PHE . 4.2 mt -111.01 152.47 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.013 0.435 . . . . 0.0 110.803 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.52 ' O ' ' N ' ' A' ' 120' ' ' ALA . 94.5 t -140.72 94.93 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.898 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.569 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.8 OUTLIER -50.51 84.83 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.103 -179.834 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.531 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -103.76 114.39 28.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.833 179.84 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.548 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 81.97 19.85 0.34 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.774 -179.746 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.548 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 91.13 -1.07 0.19 Allowed 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.141 179.896 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 5.7 mmt -123.0 134.87 54.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.915 0.388 . . . . 0.0 111.171 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.539 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 1.3 ptp -63.31 123.14 17.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.042 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -103.79 80.99 1.83 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.803 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.491 ' CA ' HG12 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -57.59 115.59 2.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.933 -179.989 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 3.6 mm -81.2 148.71 5.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.043 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.423 ' O ' ' C ' ' A' ' 129' ' ' ALA . 22.3 tt0 -112.26 124.78 53.2 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.851 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.47 ' CB ' ' HA ' ' A' ' 111' ' ' VAL . . . -35.46 107.19 0.05 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.17 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -95.28 3.98 53.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.142 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 10.1 tttt 175.82 121.19 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.908 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 86.8 p -47.32 135.03 10.94 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.793 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -164.84 -171.12 30.7 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.578 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.536 ' N ' ' CG2' ' A' ' 155' ' ' ILE . 24.3 m -136.09 107.41 6.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.614 0.245 . . . . 0.0 111.073 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.518 HG13 ' N ' ' A' ' 105' ' ' VAL . 75.4 t -39.83 139.77 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 121.04 -0.264 . . . . 0.0 110.501 179.594 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.527 ' O ' ' CB ' ' A' ' 137' ' ' ALA . 0.1 OUTLIER -122.84 -19.93 6.02 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.583 -0.28 . . . . 0.0 111.119 -179.47 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.527 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 161.13 154.04 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.385 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.637 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -100.75 86.54 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.605 179.752 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.532 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 2.0 mt -43.24 -28.08 0.28 Allowed 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.192 0.52 . . . . 0.0 110.342 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.485 HG22 ' CD2' ' A' ' 152' ' ' LEU . 75.3 t -104.63 135.62 41.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.823 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.503 ' N ' ' OE1' ' A' ' 144' ' ' GLN . 10.0 mt-10 -66.49 97.06 0.4 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.395 179.656 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.535 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 73.1 p -35.92 138.99 0.16 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.677 -179.642 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.586 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 81.21 35.8 22.75 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.457 -0.878 . . . . 0.0 112.346 -179.799 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.503 ' OE1' ' N ' ' A' ' 141' ' ' GLU . 1.2 pt20 -148.97 159.39 37.54 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 120.89 0.376 . . . . 0.0 111.144 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.517 ' O ' ' CG1' ' A' ' 146' ' ' VAL . 45.1 Cg_endo -68.27 178.76 3.39 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.748 2.298 . . . . 0.0 112.195 179.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.517 ' CG1' ' O ' ' A' ' 145' ' ' PRO . 1.2 m -170.47 -175.67 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.283 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.523 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -142.74 155.47 44.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.869 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . . . . . . . . . 64.7 t80 -42.32 140.99 1.04 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.924 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.416 ' HA ' ' HD2' ' A' ' 84' ' ' ARG . 7.8 t0 66.4 28.94 9.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.841 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.523 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 2.4 tp10 -109.13 73.68 0.56 Allowed Pre-proline 0 C--N 1.327 -0.375 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.848 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.474 ' HA ' ' HA ' ' A' ' 84' ' ' ARG . 51.3 Cg_exo -32.56 120.94 0.1 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.598 0 C-N-CA 123.001 2.468 . . . . 0.0 112.232 179.706 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.486 ' O ' ' HA ' ' A' ' 138' ' ' ILE . 0.0 OUTLIER -116.41 -64.38 1.32 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.6 -179.254 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.52 ' CG1' ' HB ' ' A' ' 83' ' ' VAL . 1.5 p -99.43 103.99 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.178 0.514 . . . . 0.0 111.584 -179.11 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.535 ' CG1' HG12 ' A' ' 82' ' ' ILE . 4.7 t -87.85 135.11 26.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.033 179.571 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.536 ' CG2' ' N ' ' A' ' 134' ' ' THR . 96.6 mt -138.0 135.33 45.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.205 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.472 ' HB2' ' HD3' ' A' ' 136' ' ' LYS . 0.4 OUTLIER . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.249 -0.882 . . . . 0.0 110.902 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.406 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.333 0 N-CA-C 112.644 -0.182 . . . . 0.0 112.644 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.524 ' O ' ' ND1' ' A' ' 81' ' ' HIS . 17.9 t-80 174.45 83.22 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.835 0.35 . . . . 0.0 110.928 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.495 HG12 ' CG1' ' A' ' 154' ' ' VAL . 23.4 mt -98.66 127.99 50.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.994 0.426 . . . . 0.0 110.819 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.511 ' HB ' ' CG1' ' A' ' 153' ' ' VAL . 3.5 t -83.52 56.9 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.408 -179.543 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.471 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 1.9 ptt85 -42.96 134.55 3.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.67 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.504 ' N ' HD12 ' A' ' 152' ' ' LEU . 9.6 t -35.98 96.86 0.11 Allowed Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.896 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.412 ' N ' ' O ' ' A' ' 84' ' ' ARG . 87.9 Cg_exo -46.07 -27.05 4.03 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.742 2.295 . . . . 0.0 112.186 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.52 ' SD ' ' CB ' ' A' ' 120' ' ' ALA . 10.0 ptp -147.75 168.5 21.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.705 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.461 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 1.5 p -69.39 91.08 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.051 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -146.46 -133.3 2.46 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.397 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.571 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 1.2 m -136.29 153.74 51.08 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.782 0.325 . . . . 0.0 110.954 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.645 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 1.1 t80 -118.38 140.15 50.29 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.968 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.586 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 22.0 m-85 -140.15 163.41 32.81 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.061 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.535 ' HD2' ' CB ' ' A' ' 142' ' ' SER . 0.0 OUTLIER -130.08 13.09 5.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.914 179.729 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.46 HG21 ' HA ' ' A' ' 101' ' ' ALA . 0.7 OUTLIER -151.36 109.27 2.98 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.897 -179.973 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -74.72 -5.04 16.31 Favored 'Trans proline' 0 C--O 1.232 0.201 0 C-N-CA 122.812 2.341 . . . . 0.0 112.454 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.59 167.88 12.24 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.05 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -74.55 106.43 2.25 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.747 2.298 . . . . 0.0 112.247 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 74.21 31.74 1.07 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.835 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -76.78 -166.8 0.73 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.003 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.01 33.38 0.87 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.885 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.46 ' HA ' HG21 ' A' ' 94' ' ' THR . . . 51.58 175.75 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.182 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.567 ' CE1' HG23 ' A' ' 114' ' ' THR . 0.0 OUTLIER -111.68 -34.59 6.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.967 179.998 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.53 ' CD1' HG22 ' A' ' 153' ' ' VAL . 1.0 OUTLIER -170.08 129.08 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.186 179.933 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.5 ' O ' ' N ' ' A' ' 106' ' ' GLY . 3.2 mt-10 -136.72 148.87 47.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.835 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.517 ' N ' HG13 ' A' ' 135' ' ' VAL . 52.6 t -35.78 92.55 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.064 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . 0.5 ' N ' ' O ' ' A' ' 104' ' ' GLU . . . 133.39 -0.31 4.26 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.536 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.463 ' O ' ' HA ' ' A' ' 134' ' ' THR . 0.0 OUTLIER -71.24 112.58 7.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.82 0.343 . . . . 0.0 110.83 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 31.6 mttt -82.37 79.76 8.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.046 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.565 ' CG2' ' N ' ' A' ' 110' ' ' ASN . 1.4 p -78.03 164.08 3.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.974 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.565 ' N ' ' CG2' ' A' ' 109' ' ' VAL . 7.8 m120 -153.83 130.04 10.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.49 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.432 ' C ' ' O ' ' A' ' 110' ' ' ASN . 2.6 m -31.74 114.76 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.461 -179.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 111.87 9.24 21.08 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.488 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.421 ' O ' ' HA ' ' A' ' 128' ' ' GLU . 6.4 t0 -113.74 -148.86 0.44 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.794 0.33 . . . . 0.0 110.684 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.567 HG23 ' CE1' ' A' ' 102' ' ' PHE . 1.9 m -131.0 147.89 52.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.788 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.461 ' O ' HG22 ' A' ' 103' ' ' ILE . 80.9 mt -116.46 -81.1 0.61 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.131 -179.749 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.472 ' HB2' ' O ' ' A' ' 92' ' ' TYR . 8.0 p -136.57 -176.13 4.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.282 -179.619 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.523 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.3 OUTLIER -102.52 117.89 48.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.18 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.527 HG11 ' CB ' ' A' ' 125' ' ' ASN . 12.1 p -97.12 50.98 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.923 179.837 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.476 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.1 OUTLIER -35.91 96.43 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.96 -179.885 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.522 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -116.92 115.64 25.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.023 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.522 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 0.1 OUTLIER 84.06 18.18 0.2 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.821 -179.95 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.528 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 0.3 OUTLIER 85.43 26.14 0.07 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.963 179.998 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.476 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.9 OUTLIER -141.96 128.36 20.03 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.107 179.832 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.523 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 1.0 OUTLIER -66.68 131.55 46.21 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.906 179.884 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.527 ' CB ' HG11 ' A' ' 118' ' ' VAL . 0.5 OUTLIER -125.99 88.39 2.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.825 -179.985 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 -50.61 112.04 0.63 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.875 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 31.5 mm -72.53 137.78 22.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.083 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.421 ' HA ' ' O ' ' A' ' 113' ' ' ASP . 50.2 mt-10 -97.01 126.44 42.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.93 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.463 ' HB1' ' CG2' ' A' ' 109' ' ' VAL . . . -38.49 124.84 1.33 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.153 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -101.67 -13.59 17.73 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.846 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 9.8 tttp -168.05 120.02 0.85 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.807 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 90.3 p -42.74 121.59 2.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.714 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.414 ' O ' HG11 ' A' ' 109' ' ' VAL . . . -157.56 -176.5 29.69 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.67 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.588 ' N ' ' CG2' ' A' ' 155' ' ' ILE . 24.2 m -131.86 110.78 11.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.582 0.229 . . . . 0.0 111.137 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.517 HG13 ' N ' ' A' ' 105' ' ' VAL . 73.4 t -40.03 141.76 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 110.353 -0.24 . . . . 0.0 110.353 179.531 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.516 ' N ' HG11 ' A' ' 135' ' ' VAL . 5.7 mmmt -126.19 -19.89 4.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.633 -179.459 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.407 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 169.49 161.18 0.06 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.834 0.349 . . . . 0.0 111.514 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.645 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -108.49 80.2 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.915 179.917 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.541 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 2.8 mt -41.33 -30.33 0.18 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.104 0.478 . . . . 0.0 109.919 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.523 HG22 ' CD2' ' A' ' 152' ' ' LEU . 71.7 t -98.64 139.19 21.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.827 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.486 ' O ' ' CG ' ' A' ' 144' ' ' GLN . 6.7 mt-10 -70.59 98.14 1.44 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.351 179.654 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.535 ' CB ' ' HD2' ' A' ' 93' ' ' ARG . 35.5 p -35.83 154.36 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.703 -179.65 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.582 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 62.69 38.12 95.93 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.33 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.486 ' CG ' ' O ' ' A' ' 141' ' ' GLU . 12.3 mm-40 -150.48 145.27 18.29 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 120.931 0.396 . . . . 0.0 111.042 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.526 ' HA ' ' CG2' ' A' ' 90' ' ' THR . 52.4 Cg_exo -54.81 173.04 0.29 Allowed 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.755 2.303 . . . . 0.0 112.17 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.522 HG13 ' CD2' ' A' ' 152' ' ' LEU . 0.4 OUTLIER -165.76 175.86 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.042 179.939 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.509 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 0.8 OUTLIER -135.26 162.17 33.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.991 -179.935 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.453 ' HA ' ' O ' ' A' ' 85' ' ' SER . 6.8 t80 -48.65 141.49 7.08 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.789 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 65.42 29.78 11.19 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.775 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.509 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 1.2 tp10 -108.16 73.36 0.44 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.762 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 84' ' ' ARG . 55.7 Cg_exo -32.2 119.35 0.09 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 123.013 2.475 . . . . 0.0 112.145 179.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.523 ' CD2' HG22 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -116.82 -71.32 0.74 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.545 -179.298 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.53 HG22 ' CD1' ' A' ' 103' ' ' ILE . 1.6 p -93.69 105.32 16.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 121.159 0.504 . . . . 0.0 111.732 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.541 ' CG2' ' HG ' ' A' ' 139' ' ' LEU . 41.5 t -84.16 135.38 24.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.861 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.588 ' CG2' ' N ' ' A' ' 134' ' ' THR . 95.6 mt -133.64 135.63 55.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.362 -179.707 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.448 ' HB2' ' HD3' ' A' ' 136' ' ' LYS . 1.7 tt0 . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.18 -0.914 . . . . 0.0 110.871 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.453 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.774 -0.13 . . . . 0.0 112.774 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.523 ' O ' ' ND1' ' A' ' 81' ' ' HIS . 13.4 t-80 171.9 83.85 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.754 0.311 . . . . 0.0 110.582 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.545 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -103.08 -178.42 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.97 0.414 . . . . 0.0 111.184 -179.995 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.54 ' CG2' ' CG1' ' A' ' 153' ' ' VAL . 11.3 t -130.41 32.45 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.763 179.696 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.535 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 4.7 ptt180 -30.41 119.92 0.18 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.283 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.52 ' N ' HD13 ' A' ' 152' ' ' LEU . 0.7 OUTLIER -36.48 103.14 0.24 Allowed Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.94 -179.771 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -51.54 -22.58 12.89 Favored 'Trans proline' 0 N--CA 1.464 -0.226 0 C-N-CA 122.653 2.235 . . . . 0.0 112.052 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.0 ptm -141.56 -176.79 4.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.789 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.45 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 15.1 t -82.29 93.5 2.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.046 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -146.22 -141.42 3.61 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.587 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.575 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 42.4 m -136.57 141.84 43.35 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.792 0.329 . . . . 0.0 111.023 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.65 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 0.8 OUTLIER -100.74 146.24 27.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.961 -179.981 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.581 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 16.5 m-85 -143.16 162.61 35.11 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.904 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.532 ' CD ' ' HB3' ' A' ' 142' ' ' SER . 9.5 ptm180 -139.75 31.53 2.04 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.874 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.467 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 68.7 p -145.74 122.15 5.92 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.491 ' HG2' ' CB ' ' A' ' 99' ' ' ALA . 55.7 Cg_endo -70.36 -21.48 30.65 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.701 2.268 . . . . 0.0 112.358 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 15.2 m -162.8 152.97 13.67 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.081 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_exo -49.63 -20.76 4.65 Favored 'Trans proline' 0 C--O 1.232 0.215 0 C-N-CA 122.8 2.333 . . . . 0.0 112.284 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -138.31 72.7 1.41 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.815 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.491 ' CB ' ' HG2' ' A' ' 95' ' ' PRO . . . -137.1 -154.87 0.57 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.197 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -113.15 36.51 3.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.846 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.467 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 62.06 -178.44 0.13 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.115 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.576 ' CE2' HG13 ' A' ' 117' ' ' ILE . 0.2 OUTLIER -104.17 -37.13 7.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.866 -179.964 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.524 ' CD1' HG22 ' A' ' 153' ' ' VAL . 0.3 OUTLIER -178.18 146.62 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.11 179.992 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.424 ' C ' HG13 ' A' ' 135' ' ' VAL . 5.7 pt-20 -146.75 162.72 37.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.854 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.511 ' CG2' ' HA ' ' A' ' 137' ' ' ALA . 14.4 t -45.07 134.87 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.193 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 94.43 -11.95 69.55 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.543 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.426 ' O ' ' N ' ' A' ' 109' ' ' VAL . 3.6 tp60 -77.2 95.67 4.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.838 0.351 . . . . 0.0 110.892 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.9 mtmt -64.39 74.24 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.963 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.451 HG21 ' O ' ' A' ' 133' ' ' GLY . 17.7 m -54.6 167.87 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.014 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.471 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 3.4 p-10 -157.31 131.26 8.2 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 121.174 0.512 . . . . 0.0 110.83 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.454 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 26.1 t -34.69 136.04 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.092 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 86.87 11.83 69.76 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.337 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.418 ' O ' ' C ' ' A' ' 114' ' ' THR . 26.4 t70 -124.69 102.53 7.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.783 0.325 . . . . 0.0 110.867 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.418 ' C ' ' O ' ' A' ' 113' ' ' ASP . 1.6 m -35.52 113.02 0.18 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.154 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.458 ' O ' HG12 ' A' ' 103' ' ' ILE . 19.2 mt -69.77 -87.53 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.648 179.734 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.504 ' HA ' ' CG ' ' A' ' 102' ' ' PHE . 9.1 p -135.32 -166.52 1.85 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.681 179.729 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.576 HG13 ' CE2' ' A' ' 102' ' ' PHE . 1.7 mt -126.48 153.77 35.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.595 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.53 ' CG1' ' O ' ' A' ' 90' ' ' THR . 46.7 t -141.04 103.12 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.965 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.514 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.5 OUTLIER -62.04 69.96 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.118 -179.773 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.518 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -92.81 145.31 24.5 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.904 179.833 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.518 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 9.1 ptp 51.96 21.03 1.37 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.737 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.511 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 1.6 tmtt? 80.28 52.03 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.877 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.467 ' HG3' ' O ' ' A' ' 120' ' ' ALA . 0.2 OUTLIER -172.0 133.13 0.7 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.091 179.804 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.529 ' CG ' HG23 ' A' ' 117' ' ' ILE . 45.2 mtt -67.54 97.16 0.57 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.951 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -79.43 82.08 5.61 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.779 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.52 ' CA ' HG12 ' A' ' 117' ' ' ILE . 4.3 pt20 -58.28 107.71 0.52 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.863 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.467 ' N ' ' O ' ' A' ' 116' ' ' CYS . 7.3 mm -74.99 162.51 4.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.164 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -130.04 141.1 50.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.852 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.454 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -46.24 113.65 0.66 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.995 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.402 ' OD1' ' N ' ' A' ' 130' ' ' ASP . 0.4 OUTLIER -101.09 11.09 40.18 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.936 -179.952 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 14.7 tttt 169.99 117.39 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.836 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 34.8 p -44.25 111.15 0.27 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.781 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.451 ' O ' HG21 ' A' ' 109' ' ' VAL . . . -145.96 -175.46 19.02 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.554 -179.766 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.464 ' N ' ' CG2' ' A' ' 155' ' ' ILE . 20.7 m -129.54 109.38 10.98 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.645 0.26 . . . . 0.0 111.215 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.507 HG11 ' N ' ' A' ' 136' ' ' LYS . 95.5 t -43.29 143.64 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.626 -0.261 . . . . 0.0 110.364 179.474 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.514 ' O ' ' CB ' ' A' ' 137' ' ' ALA . 1.3 mmmp? -123.72 -18.69 5.99 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.233 -179.55 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.514 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 162.79 164.31 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.888 0.375 . . . . 0.0 111.582 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.65 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -107.11 87.58 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.693 179.787 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.538 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 1.8 mt -43.0 -27.77 0.22 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.112 0.482 . . . . 0.0 110.437 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.523 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 55.6 t -106.64 140.4 24.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.924 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.522 ' O ' ' CG ' ' A' ' 144' ' ' GLN . 6.6 mt-10 -69.38 98.15 1.05 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.252 179.492 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.532 ' HB3' ' CD ' ' A' ' 93' ' ' ARG . 55.5 p -34.0 150.6 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.732 -179.469 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.581 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 67.33 35.86 88.4 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.383 -0.913 . . . . 0.0 112.149 -179.775 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.522 ' CG ' ' O ' ' A' ' 141' ' ' GLU . 29.2 mm-40 -147.91 154.06 43.04 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 120.86 0.362 . . . . 0.0 111.103 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.486 ' O ' ' CG1' ' A' ' 146' ' ' VAL . 59.8 Cg_endo -72.29 173.67 12.69 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.823 2.349 . . . . 0.0 112.344 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.512 HG22 ' CB ' ' A' ' 85' ' ' SER . 10.5 m -163.65 -173.74 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.071 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.528 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 6.3 pt-20 -140.16 174.08 10.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.966 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.468 ' HA ' ' O ' ' A' ' 85' ' ' SER . 17.1 t80 -50.19 147.59 4.07 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.881 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 53.94 33.36 17.16 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.918 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 19.7 tp10 -109.45 74.74 0.7 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.741 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.535 ' CD ' ' HB3' ' A' ' 84' ' ' ARG . 69.7 Cg_exo -36.34 128.98 0.43 Allowed 'Trans proline' 0 N--CA 1.46 -0.487 0 C-N-CA 122.705 2.27 . . . . 0.0 111.794 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.583 ' HB2' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -122.22 -48.91 2.07 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 111.866 0.321 . . . . 0.0 111.866 -179.059 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.54 ' CG1' ' CG2' ' A' ' 83' ' ' VAL . 1.6 p -116.94 113.45 42.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 121.026 0.441 . . . . 0.0 111.423 -179.375 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.538 ' CG2' ' HG ' ' A' ' 139' ' ' LEU . 1.6 t -93.84 144.6 9.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.073 179.77 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.477 HG21 ' N ' ' A' ' 156' ' ' GLU . 60.3 mt -144.18 141.86 24.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.146 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.512 ' HB2' ' CE ' ' A' ' 136' ' ' LYS . 15.7 tt0 . . . . . 0 C--O 1.251 1.16 0 CA-C-O 118.224 -0.893 . . . . 0.0 110.823 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.427 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.452 -0.251 0 N-CA-C 112.623 -0.191 . . . . 0.0 112.623 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.57 ' CD2' HG23 ' A' ' 155' ' ' ILE . 21.2 t60 170.38 86.12 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.799 0.333 . . . . 0.0 110.817 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.481 HG23 ' HB3' ' A' ' 151' ' ' PRO . 0.3 OUTLIER -101.76 159.22 4.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 121.03 0.443 . . . . 0.0 111.176 -179.941 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.531 ' CG1' ' HB ' ' A' ' 153' ' ' VAL . 4.4 p -109.43 46.64 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.132 -179.855 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.468 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 7.4 ptt180 -31.0 136.64 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.247 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.526 ' HB2' ' CG2' ' A' ' 146' ' ' VAL . 0.3 OUTLIER -43.34 106.42 0.49 Allowed Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.055 -179.734 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -56.71 -20.97 37.22 Favored 'Trans proline' 0 C--O 1.231 0.14 0 C-N-CA 122.736 2.29 . . . . 0.0 111.98 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -155.99 -175.7 5.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.855 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 3.5 m -82.78 76.32 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.168 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -129.96 -146.24 5.97 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.539 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.514 ' CG2' ' HA ' ' A' ' 145' ' ' PRO . 1.5 m -131.55 154.39 48.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.707 0.289 . . . . 0.0 110.904 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.615 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 0.3 OUTLIER -115.39 146.61 41.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.948 0.404 . . . . 0.0 111.25 -179.859 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.577 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 24.0 m-85 -144.04 164.96 29.11 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.862 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.527 ' CD ' ' HB3' ' A' ' 142' ' ' SER . 16.6 ptt180 -149.73 21.92 0.9 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.713 179.8 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.44 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 72.6 p -147.14 86.11 6.63 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.866 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -67.95 -20.89 44.39 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.746 2.297 . . . . 0.0 112.39 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.523 ' OG ' ' CB ' ' A' ' 99' ' ' ALA . 0.0 OUTLIER -120.39 145.04 39.61 Favored Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.958 179.934 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_exo -50.7 -41.48 53.9 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.752 2.301 . . . . 0.0 112.344 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -134.16 60.42 1.7 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.523 ' CB ' ' OG ' ' A' ' 96' ' ' SER . . . -111.14 -169.9 1.54 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.096 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . 0.427 ' N ' ' CD ' ' A' ' 100' ' ' LYS . 0.4 OUTLIER -93.71 24.64 3.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.833 179.984 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.527 ' CB ' ' O ' ' A' ' 93' ' ' ARG . . . 67.13 -178.37 0.21 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.061 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.547 ' CE2' HG12 ' A' ' 117' ' ' ILE . 0.1 OUTLIER -89.09 -59.27 2.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.591 179.79 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.559 ' CG2' ' CG2' ' A' ' 135' ' ' VAL . 24.6 mm -154.15 94.74 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.908 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -94.66 165.72 12.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.961 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.487 ' CG2' ' O ' ' A' ' 136' ' ' LYS . 2.1 p -53.58 101.62 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.066 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 141.11 -29.86 2.28 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.523 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.423 ' HA ' ' OE1' ' A' ' 107' ' ' GLN . 1.9 mp0 -72.04 121.17 18.73 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.782 0.325 . . . . 0.0 110.861 179.903 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 1.8 mttt -86.36 97.31 10.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.959 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.517 HG23 ' CD1' ' A' ' 155' ' ' ILE . 15.3 m -61.48 176.74 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.123 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.501 ' HA ' ' CB ' ' A' ' 132' ' ' SER . 66.0 m-20 -168.89 133.81 1.57 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.672 179.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.428 ' C ' ' O ' ' A' ' 110' ' ' ASN . 0.2 OUTLIER -35.14 123.79 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.128 179.89 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 91.65 21.12 35.08 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.444 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.43 ' O ' ' C ' ' A' ' 114' ' ' THR . 20.1 t0 -132.37 107.21 8.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.707 0.289 . . . . 0.0 110.87 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.529 ' CG2' ' HB2' ' A' ' 126' ' ' GLN . 2.4 m -34.16 132.9 0.24 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.025 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.51 ' O ' ' CG1' ' A' ' 103' ' ' ILE . 18.0 mt -89.07 -83.0 0.24 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.992 -179.858 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . . . . . . . . . 19.0 p -135.91 -166.2 1.83 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.039 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.547 HG12 ' CE2' ' A' ' 102' ' ' PHE . 0.3 OUTLIER -113.58 114.49 46.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.21 -179.883 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.529 HG11 ' CB ' ' A' ' 125' ' ' ASN . 9.1 p -103.49 58.26 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.831 179.746 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.473 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.5 OUTLIER -34.72 91.32 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.115 -179.778 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' A' ' 118' ' ' VAL . . . -108.4 145.77 34.05 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.009 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.476 ' HG2' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 46.85 24.86 0.39 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.574 -179.868 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.497 ' O ' ' CG ' ' A' ' 123' ' ' MET . 0.0 OUTLIER 79.33 50.21 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.886 -179.917 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.497 ' CG ' ' O ' ' A' ' 122' ' ' LYS . 40.5 mtp -162.28 125.56 2.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.081 179.798 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.531 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -60.28 77.96 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.994 179.947 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.529 ' CB ' HG11 ' A' ' 118' ' ' VAL . 1.0 OUTLIER -70.54 73.65 0.53 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.754 179.919 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.529 ' HB2' ' CG2' ' A' ' 114' ' ' THR . 0.0 OUTLIER -50.22 131.59 23.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.015 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.462 ' O ' ' HA ' ' A' ' 114' ' ' THR . 35.3 mm -94.03 161.64 2.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.08 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 5.8 mt-10 -127.99 142.24 51.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.978 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -62.38 136.81 58.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.085 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -115.87 -8.02 11.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.035 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.486 ' HE2' ' ND1' ' A' ' 81' ' ' HIS . 0.3 OUTLIER -159.94 35.3 0.18 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.839 179.96 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.501 ' CB ' ' HA ' ' A' ' 110' ' ' ASN . 96.1 p 43.64 -171.7 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.767 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.466 ' N ' HG21 ' A' ' 109' ' ' VAL . . . 148.22 -156.84 27.09 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.54 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.521 ' N ' HG12 ' A' ' 155' ' ' ILE . 85.7 m -162.81 110.01 1.24 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.721 0.296 . . . . 0.0 110.91 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.559 ' CG2' ' CG2' ' A' ' 103' ' ' ILE . 70.1 t -47.21 144.13 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.893 0.378 . . . . 0.0 111.015 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.522 ' CD ' ' CG1' ' A' ' 154' ' ' VAL . 0.0 OUTLIER -114.83 -35.82 4.68 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 121.494 0.664 . . . . 0.0 109.451 -179.95 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.516 ' N ' ' HG2' ' A' ' 136' ' ' LYS . . . 179.65 136.65 0.11 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 114.97 -1.014 . . . . 0.0 111.052 -179.724 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.615 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -88.92 85.38 2.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.927 0.394 . . . . 0.0 110.555 179.695 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.422 ' C ' ' O ' ' A' ' 138' ' ' ILE . 10.8 mt -37.16 -31.26 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.485 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.556 ' CG2' ' HB3' ' A' ' 152' ' ' LEU . 42.9 t -94.32 143.31 11.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.177 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.455 ' O ' ' C ' ' A' ' 142' ' ' SER . 27.3 mt-10 -77.59 105.36 8.69 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.917 179.235 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.527 ' HB3' ' CD ' ' A' ' 93' ' ' ARG . 24.4 p -34.45 135.82 0.16 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.765 -179.342 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.577 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 83.64 34.79 18.32 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.41 -0.9 . . . . 0.0 111.93 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.457 ' HG3' ' N ' ' A' ' 145' ' ' PRO . 1.0 OUTLIER -143.42 145.28 31.23 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 120.88 0.372 . . . . 0.0 110.976 -179.658 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.514 ' HA ' ' CG2' ' A' ' 90' ' ' THR . 57.2 Cg_endo -71.2 171.97 14.94 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.789 2.326 . . . . 0.0 112.204 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.526 ' CG2' ' HB2' ' A' ' 85' ' ' SER . 6.0 m -153.44 -165.12 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.192 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.517 ' O ' ' CG ' ' A' ' 150' ' ' GLU . 3.3 mt-10 -146.03 157.88 43.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.043 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.457 ' HA ' ' O ' ' A' ' 85' ' ' SER . 3.4 t80 -47.39 135.05 11.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.912 179.949 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.416 ' N ' ' CD1' ' A' ' 148' ' ' PHE . 58.1 t0 67.4 34.8 4.57 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.939 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.527 ' O ' ' CD2' ' A' ' 152' ' ' LEU . 14.6 mm-40 -115.29 75.43 4.48 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.857 179.769 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.481 ' HB3' HG23 ' A' ' 82' ' ' ILE . 71.2 Cg_exo -36.61 125.53 0.41 Allowed 'Trans proline' 0 N--CA 1.459 -0.528 0 C-N-CA 122.75 2.3 . . . . 0.0 111.637 179.51 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.58 HD11 ' CD2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -129.29 -36.24 1.72 Allowed 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 120.962 0.411 . . . . 0.0 110.98 -179.005 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.531 ' HB ' ' CG1' ' A' ' 83' ' ' VAL . 1.3 t -115.99 109.46 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.347 -178.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.522 ' CG1' ' CD ' ' A' ' 136' ' ' LYS . 1.4 t -98.46 119.04 45.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.612 179.429 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.57 HG23 ' CD2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -110.1 154.66 11.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.863 -179.772 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.467 ' N ' ' O ' ' A' ' 134' ' ' THR . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.241 -0.885 . . . . 0.0 110.939 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.469 -0.252 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.49 ' N ' ' O ' ' A' ' 155' ' ' ILE . 24.5 t60 -178.87 79.79 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.802 0.334 . . . . 0.0 110.874 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.53 HD11 ' CG1' ' A' ' 154' ' ' VAL . 0.2 OUTLIER -92.04 -176.14 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.031 179.845 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.53 ' HB ' ' CG1' ' A' ' 153' ' ' VAL . 2.1 t -142.02 41.56 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.859 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.515 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -33.84 132.81 0.22 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.088 -179.845 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.485 ' N ' HD13 ' A' ' 152' ' ' LEU . 1.5 m -44.44 103.91 0.36 Allowed Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.903 -179.909 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_exo -50.98 -20.04 6.56 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.586 2.191 . . . . 0.0 112.064 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 14.9 ptm -150.34 166.73 29.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.681 179.793 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.456 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 1.5 p -68.14 95.9 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.004 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -147.56 -133.0 2.31 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.579 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.546 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 24.3 m -140.43 151.19 44.7 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.831 0.348 . . . . 0.0 110.884 -179.889 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.641 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 0.4 OUTLIER -118.22 151.47 37.56 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.828 179.953 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.58 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 23.4 m-85 -147.24 168.76 20.91 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.789 -0.642 . . . . 0.0 111.0 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.468 ' O ' ' N ' ' A' ' 102' ' ' PHE . 0.0 OUTLIER -135.66 18.07 3.32 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.688 179.742 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.45 ' O ' HD13 ' A' ' 117' ' ' ILE . 2.1 p -132.6 108.73 13.24 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.815 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.577 ' HG3' ' CD1' ' A' ' 102' ' ' PHE . 51.8 Cg_exo -53.72 -18.06 11.43 Favored 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.743 2.296 . . . . 0.0 112.3 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -178.96 167.95 0.88 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.902 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.515 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 59.2 Cg_endo -72.29 113.77 3.8 Favored 'Trans proline' 0 N--CA 1.464 -0.215 0 C-N-CA 122.735 2.29 . . . . 0.0 112.361 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.515 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 0.6 OUTLIER 85.15 49.96 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.914 179.934 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -125.88 -163.58 1.23 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.093 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 1.2 mtpp -101.15 38.05 1.64 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.9 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 54.15 175.76 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.084 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.577 ' CD1' ' HG3' ' A' ' 95' ' ' PRO . 0.0 OUTLIER -100.75 -34.56 9.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.945 179.952 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.523 ' CG2' ' O ' ' A' ' 102' ' ' PHE . 0.3 OUTLIER -179.05 144.04 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.035 179.922 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.46 ' O ' HG12 ' A' ' 135' ' ' VAL . 2.3 mt-10 -146.33 148.33 32.27 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.948 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.463 ' CA ' HG12 ' A' ' 135' ' ' VAL . 3.9 t -35.36 123.82 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.109 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 111.48 -24.97 14.36 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.323 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 22.4 tp60 -82.25 117.24 22.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.784 0.326 . . . . 0.0 110.814 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 134' ' ' THR . 0.0 OUTLIER -81.69 100.0 9.23 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.037 -179.885 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.513 ' N ' ' O ' ' A' ' 133' ' ' GLY . 7.7 m -59.27 176.09 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.019 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.432 ' CG ' ' O ' ' A' ' 109' ' ' VAL . 21.3 m120 -163.15 131.31 3.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.036 0.446 . . . . 0.0 110.766 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.51 ' CG1' ' HA ' ' A' ' 131' ' ' LYS . 33.2 m -35.42 138.4 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.011 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 80.74 16.42 75.39 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.333 -179.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -124.41 102.62 7.75 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.865 0.364 . . . . 0.0 110.848 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.566 HG23 ' CZ ' ' A' ' 102' ' ' PHE . 9.0 m -40.54 110.77 0.16 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.022 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.427 ' CD2' HG13 ' A' ' 109' ' ' VAL . 20.6 mt -65.96 -87.42 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.802 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.422 ' SG ' HG13 ' A' ' 153' ' ' VAL . 0.8 OUTLIER -124.7 -171.28 2.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.768 179.904 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.516 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.3 OUTLIER -106.01 113.57 43.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.203 -179.932 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.52 ' O ' ' N ' ' A' ' 120' ' ' ALA . 75.7 t -97.3 59.22 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.036 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.46 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.4 OUTLIER -39.1 90.76 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.039 -179.798 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.52 ' N ' ' O ' ' A' ' 118' ' ' VAL . . . -110.55 144.6 39.15 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.958 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.5 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.1 OUTLIER 56.2 17.03 2.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.892 -179.917 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.5 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.6 OUTLIER 83.41 53.4 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.925 -179.995 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.472 ' HG2' ' O ' ' A' ' 120' ' ' ALA . 3.1 ptt? -173.07 133.45 0.53 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.991 179.769 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.516 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -53.04 96.14 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.019 179.945 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.425 ' O ' ' C ' ' A' ' 126' ' ' GLN . 4.2 t30 -88.18 65.18 8.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.847 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.443 ' HB2' HG21 ' A' ' 114' ' ' THR . 0.0 OUTLIER -35.12 154.46 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.065 -179.857 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.461 ' O ' ' HA ' ' A' ' 114' ' ' THR . 47.0 mm -121.97 120.3 61.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.22 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 58.4 mm-40 -83.11 119.77 24.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.777 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.455 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -41.61 114.39 0.51 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.164 -179.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -74.76 -27.0 60.16 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.721 179.878 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.51 ' HA ' ' CG1' ' A' ' 111' ' ' VAL . 0.0 OUTLIER -165.05 136.13 4.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.812 179.954 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.414 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.2 t -45.84 132.75 8.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.79 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.513 ' O ' ' N ' ' A' ' 109' ' ' VAL . . . -159.03 176.44 35.85 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.604 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.582 ' N ' ' CG2' ' A' ' 155' ' ' ILE . 13.8 m -122.88 108.21 12.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.663 0.268 . . . . 0.0 111.263 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.467 ' HA ' ' HA ' ' A' ' 155' ' ' ILE . 2.8 p -49.16 144.68 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.517 -0.311 . . . . 0.0 110.566 179.515 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.512 ' CG ' ' HB2' ' A' ' 156' ' ' GLU . 1.1 mmmp? -124.14 -19.24 5.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.632 0.253 . . . . 0.0 111.234 -179.553 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.47 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 166.3 163.23 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.843 0.354 . . . . 0.0 111.433 -179.779 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.641 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.1 OUTLIER -105.23 85.46 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.74 179.626 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.523 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 12.4 mt -42.49 -28.03 0.19 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.969 0.414 . . . . 0.0 110.231 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.514 HG22 ' CD2' ' A' ' 152' ' ' LEU . 52.2 t -104.59 141.81 19.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.78 179.593 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 142' ' ' SER . 6.5 mt-10 -69.75 97.12 1.04 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.58 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.444 ' HB2' ' HD2' ' A' ' 93' ' ' ARG . 0.3 OUTLIER -36.93 135.22 0.46 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.627 -179.957 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.58 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 85.81 38.09 8.96 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.534 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.459 ' HB2' ' HD2' ' A' ' 145' ' ' PRO . 4.1 pt20 -155.64 163.61 24.08 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.884 0.373 . . . . 0.0 111.155 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.525 ' O ' ' CG1' ' A' ' 146' ' ' VAL . 55.4 Cg_endo -70.47 -168.78 0.32 Allowed 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.762 2.308 . . . . 0.0 112.646 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.525 ' CG1' ' O ' ' A' ' 145' ' ' PRO . 0.2 OUTLIER -175.72 -174.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.965 -179.982 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.456 ' HA ' ' HA ' ' A' ' 88' ' ' VAL . 4.0 mt-10 -145.6 157.37 43.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.933 0.396 . . . . 0.0 111.089 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.446 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 1.2 t80 -42.94 125.13 3.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.946 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.446 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 2.4 t0 79.61 31.95 0.24 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.951 0.405 . . . . 0.0 110.606 -179.804 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.468 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 44.1 tp10 -111.03 74.99 1.05 Allowed Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.879 179.861 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.515 ' CD ' ' HB3' ' A' ' 84' ' ' ARG . 63.3 Cg_exo -35.93 122.75 0.27 Allowed 'Trans proline' 0 N--CA 1.459 -0.508 0 C-N-CA 122.812 2.341 . . . . 0.0 112.084 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.542 ' HB2' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -116.66 -54.09 2.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.619 -179.208 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.53 ' CG1' ' HB ' ' A' ' 83' ' ' VAL . 1.3 p -108.07 108.72 25.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.121 0.486 . . . . 0.0 111.339 -179.262 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.53 ' CG1' HD11 ' A' ' 82' ' ' ILE . 6.0 t -91.14 138.96 18.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.976 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.582 ' CG2' ' N ' ' A' ' 134' ' ' THR . 37.3 mt -141.3 141.1 31.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.18 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.512 ' HB2' ' CG ' ' A' ' 136' ' ' LYS . 10.6 tt0 . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.248 -0.882 . . . . 0.0 110.877 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.305 0 N-CA-C 112.422 -0.271 . . . . 0.0 112.422 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.526 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 30.6 t60 -172.52 77.62 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.806 0.336 . . . . 0.0 110.925 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.537 HG12 ' CG1' ' A' ' 154' ' ' VAL . 10.2 mt -99.22 150.92 4.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.955 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.541 ' CG2' ' CG1' ' A' ' 153' ' ' VAL . 4.5 t -96.91 59.93 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.15 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.492 ' O ' ' N ' ' A' ' 86' ' ' PRO . 4.2 mmt85 -28.88 103.3 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.025 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.523 ' HB2' ' CD2' ' A' ' 152' ' ' LEU . 0.4 OUTLIER -32.12 91.95 0.05 OUTLIER Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.251 -179.789 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.492 ' N ' ' O ' ' A' ' 84' ' ' ARG . 77.5 Cg_exo -50.22 140.21 34.01 Favored 'Trans proline' 0 N--CA 1.464 -0.25 0 C-N-CA 122.755 2.303 . . . . 0.0 112.058 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.458 ' O ' ' O ' ' A' ' 86' ' ' PRO . 7.6 ptm 41.22 -167.09 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.465 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.435 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 72.5 t -90.32 114.49 28.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.783 0.325 . . . . 0.0 111.208 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -165.02 -164.11 19.69 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.537 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.533 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 1.9 m -115.48 151.56 34.58 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.853 0.359 . . . . 0.0 110.901 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.647 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 2.9 t80 -110.78 141.96 43.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.954 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.579 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 21.0 m-85 -142.41 157.49 44.72 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.808 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.485 ' CG ' ' HB3' ' A' ' 142' ' ' SER . 1.7 ptm180 -134.39 20.88 3.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.398 179.568 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.445 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 69.2 p -123.05 121.84 27.09 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.694 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.07 -59.76 0.93 Allowed 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.685 2.257 . . . . 0.0 112.336 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.581 ' CB ' ' CD ' ' A' ' 97' ' ' PRO . 0.9 OUTLIER 170.99 -66.04 0.0 OUTLIER Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 121.191 0.519 . . . . 0.0 111.106 179.869 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.581 ' CD ' ' CB ' ' A' ' 96' ' ' SER . 46.5 Cg_endo -68.94 53.6 0.81 Allowed 'Trans proline' 0 C--N 1.333 -0.268 0 C-N-CA 123.37 2.713 . . . . 0.0 112.496 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.432 ' C ' ' O ' ' A' ' 97' ' ' PRO . 4.5 p30 35.18 45.2 0.18 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.033 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -71.68 -160.13 0.05 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.087 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . 0.459 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 0.4 OUTLIER -90.77 27.48 1.77 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.842 179.921 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.459 ' HB1' ' O ' ' A' ' 100' ' ' LYS . . . 75.68 155.85 0.17 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.071 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.48 ' O ' ' CG2' ' A' ' 103' ' ' ILE . 0.2 OUTLIER -69.11 -37.51 78.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.49 179.885 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.505 ' CD1' HG22 ' A' ' 153' ' ' VAL . 1.9 pp -163.34 157.67 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.934 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -154.79 147.57 24.41 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.056 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.505 ' N ' HG13 ' A' ' 135' ' ' VAL . 2.0 p -44.2 109.4 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.05 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 126.38 -18.07 6.5 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.397 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -85.48 106.37 16.77 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.842 0.353 . . . . 0.0 110.867 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' A' ' 109' ' ' VAL . 2.4 mttp -67.03 79.53 0.12 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.908 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.515 HG21 ' N ' ' A' ' 133' ' ' GLY . 22.1 m -45.8 175.55 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.109 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.42 ' O ' ' C ' ' A' ' 111' ' ' VAL . 1.7 p-10 -165.27 135.02 3.58 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 121.026 0.441 . . . . 0.0 110.742 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.428 ' HA ' ' HB2' ' A' ' 129' ' ' ALA . 20.2 t -34.82 137.24 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 115.711 -0.677 . . . . 0.0 111.077 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 81.31 16.22 74.61 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.414 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 114' ' ' THR . 9.0 t0 -122.54 101.71 7.64 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.814 0.34 . . . . 0.0 110.952 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.438 ' HA ' ' O ' ' A' ' 127' ' ' ILE . 1.5 m -35.4 108.7 0.07 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.898 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.51 ' N ' ' O ' ' A' ' 127' ' ' ILE . 14.7 mt -62.24 -67.04 0.45 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.791 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.498 ' SG ' ' N ' ' A' ' 117' ' ' ILE . 2.5 p -162.46 -154.47 0.31 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.942 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.532 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.1 OUTLIER -122.23 119.37 58.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.282 -179.85 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.51 ' CG2' ' CG1' ' A' ' 127' ' ' ILE . 2.4 t -109.21 58.46 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.801 179.644 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.472 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.4 OUTLIER -34.74 104.11 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.165 -179.703 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.524 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -121.81 108.91 14.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.995 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.532 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 86.16 17.8 0.11 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.676 -179.802 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.541 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 5.0 tmtm? 87.61 26.58 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.861 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.472 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 1.1 mmm -139.85 124.81 18.56 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.927 0.394 . . . . 0.0 111.157 179.768 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.532 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -55.55 102.97 0.08 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.875 179.762 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.427 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 9.8 t30 -84.78 65.21 9.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.813 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.426 ' HA ' ' O ' ' A' ' 116' ' ' CYS . 6.7 pt20 -45.79 118.99 2.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.96 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.51 ' O ' ' N ' ' A' ' 115' ' ' LEU . 3.7 mm -94.2 151.66 3.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.005 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -126.65 130.45 50.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.922 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.428 ' HB2' ' HA ' ' A' ' 111' ' ' VAL . . . -42.44 134.07 3.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.111 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . 0.446 ' OD1' ' O ' ' A' ' 130' ' ' ASP . 10.5 t70 -118.44 -0.24 11.47 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.076 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.458 ' O ' ' O ' ' A' ' 132' ' ' SER . 1.3 ptmt -170.73 29.61 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.941 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.458 ' O ' ' O ' ' A' ' 131' ' ' LYS . 0.9 OUTLIER 47.38 -179.52 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.743 -179.815 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.515 ' N ' HG21 ' A' ' 109' ' ' VAL . . . 152.01 174.19 22.42 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.625 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.536 ' N ' ' CG2' ' A' ' 155' ' ' ILE . 27.5 m -120.94 110.68 16.58 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.553 0.216 . . . . 0.0 111.235 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.541 HG11 ' N ' ' A' ' 136' ' ' LYS . 61.3 t -49.77 145.66 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.63 -0.259 . . . . 0.0 110.32 179.461 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.541 ' N ' HG11 ' A' ' 135' ' ' VAL . 50.9 mmtt -125.38 -18.04 5.44 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 121.049 -0.26 . . . . 0.0 111.643 -179.417 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.507 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 164.66 153.46 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.927 0.394 . . . . 0.0 111.857 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.647 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -95.7 77.9 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.419 179.499 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.471 HD13 ' CG2' ' A' ' 154' ' ' VAL . 3.9 mt -38.44 -30.86 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.118 0.485 . . . . 0.0 110.223 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.518 HG22 ' CD2' ' A' ' 152' ' ' LEU . 55.3 t -102.93 138.32 27.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.818 179.725 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.518 ' O ' ' CG ' ' A' ' 144' ' ' GLN . 1.7 mt-10 -68.92 106.5 2.75 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.385 179.801 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.485 ' HB3' ' CG ' ' A' ' 93' ' ' ARG . 6.3 p -36.41 152.07 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.697 -179.554 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.579 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 56.99 43.86 92.97 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.395 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.518 ' CG ' ' O ' ' A' ' 141' ' ' GLU . 61.6 mm-40 -147.39 137.95 12.71 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.895 0.378 . . . . 0.0 111.245 -179.769 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.516 ' N ' HG22 ' A' ' 90' ' ' THR . 57.1 Cg_endo -70.64 156.18 61.55 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.691 2.261 . . . . 0.0 112.266 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.523 HG22 ' CB ' ' A' ' 85' ' ' SER . 4.1 m -152.24 -156.51 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.208 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.455 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -147.57 174.31 11.87 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.95 -179.943 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.435 ' HA ' ' O ' ' A' ' 85' ' ' SER . 25.4 t80 -53.84 150.81 7.12 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.87 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 60.2 23.6 12.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.928 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.462 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 4.6 tt0 -107.17 74.51 0.4 Allowed Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.815 179.738 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.49 ' HB3' HG22 ' A' ' 82' ' ' ILE . 62.9 Cg_exo -35.51 127.92 0.3 Allowed 'Trans proline' 0 N--CA 1.459 -0.542 0 C-N-CA 122.996 2.464 . . . . 0.0 112.5 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.572 ' HB2' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -120.89 -59.97 1.69 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.273 -179.729 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.541 ' CG1' ' CG2' ' A' ' 83' ' ' VAL . 1.4 p -102.93 101.88 12.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.202 -179.663 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.537 ' CG1' HG12 ' A' ' 82' ' ' ILE . 17.0 t -87.11 136.0 23.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.811 -0.632 . . . . 0.0 111.292 179.844 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.536 ' CG2' ' N ' ' A' ' 134' ' ' THR . 22.8 mt -140.34 139.85 35.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.049 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.525 ' HB3' ' CE ' ' A' ' 136' ' ' LYS . 6.0 tp10 . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.243 -0.884 . . . . 0.0 110.841 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.424 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.33 0 N-CA-C 112.517 -0.233 . . . . 0.0 112.517 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.536 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 26.8 t60 171.89 83.94 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.896 0.379 . . . . 0.0 110.964 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.486 HG12 ' HA ' ' A' ' 154' ' ' VAL . 6.8 mt -100.67 147.05 8.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.017 0.436 . . . . 0.0 110.999 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.542 ' CG2' ' CG1' ' A' ' 153' ' ' VAL . 3.5 t -93.36 45.31 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.993 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.436 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -34.61 127.39 0.48 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.8 -179.978 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.467 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 5.3 t -34.83 107.68 0.32 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.956 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -63.74 -20.95 69.64 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.791 2.327 . . . . 0.0 111.945 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.457 ' HG3' ' HB3' ' A' ' 120' ' ' ALA . 9.9 ptp -154.37 172.59 17.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.781 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.445 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 30.7 m -66.7 87.71 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.057 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.455 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -147.82 -161.16 9.33 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.635 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.654 ' CG2' ' CE1' ' A' ' 92' ' ' TYR . 5.3 m -117.48 140.6 49.39 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.893 0.378 . . . . 0.0 111.124 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.641 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 14.4 t80 -89.3 143.02 27.15 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.269 179.453 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.654 ' CE1' ' CG2' ' A' ' 90' ' ' THR . 18.5 m-85 -139.91 148.81 42.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.888 0.375 . . . . 0.0 111.22 -179.521 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.466 ' O ' ' N ' ' A' ' 102' ' ' PHE . 0.7 OUTLIER -135.11 13.18 3.58 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.809 179.818 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.443 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 52.5 p -141.49 110.3 6.28 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.954 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.1 -39.45 5.85 Favored 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 122.725 2.283 . . . . 0.0 112.414 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.452 ' CB ' ' HB1' ' A' ' 99' ' ' ALA . 0.0 OUTLIER -129.72 148.98 71.66 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.92 -179.944 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.33 -34.74 71.96 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.693 2.262 . . . . 0.0 112.294 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -118.63 42.46 2.75 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.856 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.452 ' HB1' ' CB ' ' A' ' 96' ' ' SER . . . -100.26 -154.86 0.49 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.094 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.19 36.78 4.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.863 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.443 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 56.67 165.67 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.117 179.846 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.527 ' O ' ' CG2' ' A' ' 103' ' ' ILE . 0.1 OUTLIER -89.22 -34.63 16.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.964 179.994 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.527 ' CG2' ' O ' ' A' ' 102' ' ' PHE . 0.2 OUTLIER 176.49 127.34 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.104 -179.912 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.84 165.6 17.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.807 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.463 ' HB ' ' HA ' ' A' ' 137' ' ' ALA . 1.9 p -44.28 119.59 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.927 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 114.25 -14.05 21.12 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.374 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.4 mm-40 -74.26 126.02 29.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.827 0.346 . . . . 0.0 110.887 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.0 74.03 5.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.855 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.453 HG21 ' O ' ' A' ' 133' ' ' GLY . 22.1 m -47.14 172.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.984 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.458 ' O ' ' HB2' ' A' ' 113' ' ' ASP . 27.2 m120 -163.95 131.13 3.31 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.022 0.439 . . . . 0.0 110.72 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.462 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 33.8 m -35.54 118.72 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.022 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 100.91 15.51 28.47 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.317 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.458 ' HB2' ' O ' ' A' ' 110' ' ' ASN . 0.3 OUTLIER -125.2 103.92 8.23 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.854 0.359 . . . . 0.0 110.669 179.993 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.529 ' CG2' ' HB3' ' A' ' 126' ' ' GLN . 2.3 m -33.92 122.14 0.46 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.149 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.466 ' O ' HG12 ' A' ' 103' ' ' ILE . 15.1 mt -78.24 -86.08 0.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.929 179.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -135.04 -174.33 3.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.101 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.593 ' CG2' ' CB ' ' A' ' 124' ' ' MET . 0.1 OUTLIER -104.86 129.45 57.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.016 -179.954 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 124' ' ' MET . 6.0 t -123.06 100.89 8.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.591 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.578 ' HG2' ' CE2' ' A' ' 92' ' ' TYR . 1.0 OUTLIER -100.16 117.71 34.98 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.522 179.571 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.523 ' O ' ' CB ' ' A' ' 121' ' ' MET . . . -112.55 47.27 1.1 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.468 -179.512 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.523 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 6.1 ptm 155.13 -39.42 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.267 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.487 ' HB3' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 172.48 -28.44 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.042 -179.971 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.516 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.8 OUTLIER -97.61 127.27 43.43 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.945 179.498 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.593 ' CB ' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -93.94 153.62 18.12 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.366 -179.249 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.508 ' O ' ' N ' ' A' ' 127' ' ' ILE . 59.5 t-20 -114.04 101.92 9.68 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.192 179.617 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.529 ' HB3' ' CG2' ' A' ' 114' ' ' THR . 0.7 OUTLIER -62.65 69.23 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.786 -179.721 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.508 ' N ' ' O ' ' A' ' 125' ' ' ASN . 26.1 mm -37.06 147.28 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.132 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.41 ' O ' ' C ' ' A' ' 129' ' ' ALA . 10.2 pt-20 -116.03 128.73 55.95 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.755 179.858 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.462 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -35.48 116.15 0.35 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.238 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -87.3 -12.61 46.01 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.739 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.461 ' HG3' ' O ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -174.28 126.52 0.34 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.764 179.96 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 8.0 t -41.83 124.87 2.71 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.779 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.453 ' O ' HG21 ' A' ' 109' ' ' VAL . . . -152.21 176.01 30.66 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.548 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.492 ' N ' ' CG2' ' A' ' 155' ' ' ILE . 13.1 m -125.15 108.26 11.6 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.701 0.286 . . . . 0.0 111.288 -179.828 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.504 ' HA ' ' CG1' ' A' ' 155' ' ' ILE . 19.0 t -44.2 144.97 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.624 179.435 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.527 ' HD2' ' CA ' ' A' ' 156' ' ' GLU . 21.3 mtpt -123.7 -18.49 6.07 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.225 -179.567 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.497 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 163.11 161.56 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.976 0.417 . . . . 0.0 111.631 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.641 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.6 OUTLIER -111.93 85.0 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.894 179.753 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.532 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 8.5 mt -49.12 -38.35 24.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.99 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.526 HG22 ' CD2' ' A' ' 152' ' ' LEU . 49.2 t -83.6 143.7 11.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.146 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.485 ' O ' ' C ' ' A' ' 142' ' ' SER . 17.2 mt-10 -74.5 78.15 1.94 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.06 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.491 ' HA ' ' CE2' ' A' ' 91' ' ' PHE . 11.6 p 21.77 -114.56 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 115.285 -0.871 . . . . 0.0 111.815 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.563 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -62.81 80.84 0.03 OUTLIER Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.839 -0.696 . . . . 0.0 113.043 -179.794 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.467 ' O ' HG22 ' A' ' 90' ' ' THR . 0.5 OUTLIER -157.56 144.15 13.12 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-O 121.078 0.466 . . . . 0.0 111.435 179.593 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.474 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 27.6 Cg_endo -62.4 151.57 81.98 Favored 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.974 2.449 . . . . 0.0 112.546 -179.792 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.514 HG13 ' CD2' ' A' ' 152' ' ' LEU . 18.3 m -143.93 -173.16 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.883 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.437 ' O ' ' C ' ' A' ' 148' ' ' PHE . 0.1 OUTLIER -150.26 149.64 30.43 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.899 179.992 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.499 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 2.0 t80 -34.33 124.15 0.5 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.822 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.499 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 17.4 t0 83.94 27.14 0.09 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.593 -179.607 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 44.0 tp10 -110.33 73.73 0.79 Allowed Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.908 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.479 ' HB3' HG23 ' A' ' 82' ' ' ILE . 68.6 Cg_exo -34.18 127.59 0.18 Allowed 'Trans proline' 0 N--CA 1.459 -0.559 0 C-N-CA 122.825 2.35 . . . . 0.0 112.044 179.681 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.526 ' CD2' ' HB2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -122.46 -64.98 1.14 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.525 -179.425 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.542 ' CG1' ' CG2' ' A' ' 83' ' ' VAL . 1.6 p -103.92 102.89 14.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.254 -179.469 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.532 ' CG2' ' HG ' ' A' ' 139' ' ' LEU . 10.3 t -83.47 142.67 13.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 115.76 -0.654 . . . . 0.0 111.275 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.512 HG21 ' N ' ' A' ' 156' ' ' GLU . 27.5 mt -144.48 141.47 23.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.994 179.858 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.527 ' CA ' ' HD2' ' A' ' 136' ' ' LYS . 3.0 tt0 . . . . . 0 C--O 1.249 1.036 0 CA-C-O 118.283 -0.865 . . . . 0.0 110.919 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.441 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.328 0 N-CA-C 112.442 -0.263 . . . . 0.0 112.442 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.566 ' CD2' ' HE3' ' A' ' 131' ' ' LYS . 17.1 t-80 172.53 84.19 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.788 0.328 . . . . 0.0 110.983 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.521 HG12 ' CG1' ' A' ' 154' ' ' VAL . 29.8 mt -92.26 116.62 33.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.07 0.462 . . . . 0.0 110.836 179.727 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.517 HG23 ' CD1' ' A' ' 115' ' ' LEU . 2.0 t -69.85 59.79 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.244 -179.701 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.477 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -47.53 135.08 11.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.725 179.823 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.528 ' CB ' HG22 ' A' ' 146' ' ' VAL . 1.3 p -39.3 104.63 0.32 Allowed Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.996 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.18 -7.18 16.51 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.656 2.237 . . . . 0.0 112.018 179.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.449 ' HG3' ' CB ' ' A' ' 120' ' ' ALA . 2.0 ptm -155.72 168.3 27.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.641 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 7.1 m -71.87 60.16 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.124 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.515 ' O ' ' CG2' ' A' ' 146' ' ' VAL . . . -116.96 -165.69 13.93 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.454 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.523 ' N ' ' O ' ' A' ' 119' ' ' GLU . 24.4 m -108.99 156.92 19.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.987 0.422 . . . . 0.0 111.024 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.649 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 11.9 t80 -106.77 140.68 39.22 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.263 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.578 ' CD2' ' OE1' ' A' ' 119' ' ' GLU . 17.6 m-85 -143.13 151.09 40.32 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.971 0.415 . . . . 0.0 111.063 179.607 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.475 ' O ' ' CB ' ' A' ' 101' ' ' ALA . 18.2 ptt180 -132.11 23.92 4.54 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.663 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.452 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 63.5 p -150.57 107.11 3.1 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.868 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.21 -16.11 31.68 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.651 2.234 . . . . 0.0 112.221 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -142.93 159.64 55.77 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.918 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -53.32 -63.33 0.24 Allowed 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.806 2.337 . . . . 0.0 112.341 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -110.99 79.79 1.24 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.876 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -135.2 -166.91 1.91 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.102 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.09 38.09 1.27 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.928 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.475 ' CB ' ' O ' ' A' ' 93' ' ' ARG . . . 49.39 -177.18 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.239 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.577 ' CZ ' HG23 ' A' ' 114' ' ' THR . 0.1 OUTLIER -90.11 -61.44 1.68 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.126 179.55 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.538 ' CG1' ' O ' ' A' ' 115' ' ' LEU . 2.2 mm -153.52 145.03 14.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.7 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -147.45 162.84 38.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.738 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.458 HG11 ' HA ' ' A' ' 136' ' ' LYS . 6.0 t -47.32 119.68 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.995 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 120.15 -27.04 6.86 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.249 -179.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.83 112.49 18.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.759 0.314 . . . . 0.0 110.807 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.465 ' O ' ' O ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -79.49 81.83 5.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.843 179.998 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.524 ' CG2' ' O ' ' A' ' 133' ' ' GLY . 14.7 m -45.28 176.11 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.003 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 109' ' ' VAL . 35.0 m120 -163.19 131.1 3.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.615 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.465 ' HA ' ' CB ' ' A' ' 129' ' ' ALA . 2.3 p -37.58 155.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.968 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . 0.423 ' N ' ' CG2' ' A' ' 111' ' ' VAL . . . 75.78 -0.08 62.6 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.339 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.457 ' O ' ' HA ' ' A' ' 128' ' ' GLU . 2.5 t0 -107.17 -149.53 0.43 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.691 0.282 . . . . 0.0 110.689 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.577 HG23 ' CZ ' ' A' ' 102' ' ' PHE . 6.1 m -135.73 150.4 49.51 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.89 0.376 . . . . 0.0 111.012 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.538 ' O ' ' CG1' ' A' ' 103' ' ' ILE . 83.0 mt -106.81 -79.74 0.57 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.892 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . . . . . . . . . 14.9 p -134.51 -166.1 1.76 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.97 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.549 ' CG2' ' OE2' ' A' ' 119' ' ' GLU . 0.3 OUTLIER -115.01 125.22 72.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.297 -179.725 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.505 HG22 ' CG1' ' A' ' 127' ' ' ILE . 54.7 t -108.58 95.0 3.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.449 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.578 ' OE1' ' CD2' ' A' ' 92' ' ' TYR . 0.5 OUTLIER -102.76 105.0 15.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.877 -179.083 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.557 ' O ' ' CB ' ' A' ' 121' ' ' MET . . . -126.57 48.01 2.22 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.709 -179.684 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.557 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 152.55 51.88 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.25 179.907 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.48 ' HD3' ' O ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 56.14 18.2 3.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.343 -179.313 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.475 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 1.7 mtt -141.24 122.8 15.1 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.821 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.529 ' CA ' ' HG3' ' A' ' 119' ' ' GLU . 0.0 OUTLIER -75.15 171.82 13.47 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.428 -0.806 . . . . 0.0 111.44 -179.839 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.435 ' HB2' ' HB ' ' A' ' 118' ' ' VAL . 3.5 m120 -151.49 83.79 1.3 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.473 179.73 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -50.23 113.41 0.86 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.06 -179.67 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.505 ' CG1' HG22 ' A' ' 118' ' ' VAL . 18.8 mm -81.42 95.65 2.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.919 179.802 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.458 ' HA ' ' HA ' ' A' ' 114' ' ' THR . 1.4 mt-10 -72.05 144.08 48.87 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.115 -179.773 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.465 ' CB ' ' HA ' ' A' ' 111' ' ' VAL . . . -68.67 142.46 55.05 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.831 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 55.7 p30 -126.74 1.87 6.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.341 -0.391 . . . . 0.0 111.08 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.566 ' HE3' ' CD2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -158.83 22.21 0.21 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.092 -179.927 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.504 ' O ' ' NZ ' ' A' ' 131' ' ' LYS . 1.1 p 49.94 173.56 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.783 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.524 ' O ' ' CG2' ' A' ' 109' ' ' VAL . . . 156.56 176.02 28.18 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.571 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.55 ' N ' ' CG2' ' A' ' 155' ' ' ILE . 25.9 m -127.78 119.56 25.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.582 0.229 . . . . 0.0 111.307 -179.765 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.444 HG11 ' N ' ' A' ' 136' ' ' LYS . 73.3 t -52.36 144.7 3.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 179.172 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.53 ' HD3' ' CG ' ' A' ' 156' ' ' GLU . 22.4 mmmt -125.17 -18.77 5.32 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.685 0.279 . . . . 0.0 111.422 -179.431 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.45 ' HA ' ' CG2' ' A' ' 105' ' ' VAL . . . 167.05 156.78 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.178 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.649 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -109.88 84.58 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.032 179.821 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.519 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 3.6 mt -47.13 -25.86 0.98 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.415 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.531 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 78.3 t -104.8 149.47 8.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.735 179.71 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.513 ' HB2' ' CG ' ' A' ' 144' ' ' GLN . 4.1 mm-40 -52.55 -170.99 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.376 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.522 ' O ' ' O ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -84.87 -55.41 4.1 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 120.837 -0.345 . . . . 0.0 111.509 -179.789 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.536 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -128.16 103.14 0.61 Allowed Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.857 -179.342 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.513 ' CG ' ' HB2' ' A' ' 141' ' ' GLU . 0.0 OUTLIER -174.05 144.17 0.98 Allowed Pre-proline 0 C--N 1.326 -0.413 0 CA-C-O 121.034 0.445 . . . . 0.0 111.18 179.669 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 144' ' ' GLN . 43.7 Cg_exo -56.58 142.97 90.06 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.83 2.353 . . . . 0.0 112.036 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.528 HG22 ' CB ' ' A' ' 85' ' ' SER . 4.8 m -128.86 179.52 3.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.157 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.458 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 1.3 mt-10 -129.82 141.4 50.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.73 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.449 ' HA ' ' O ' ' A' ' 85' ' ' SER . 34.5 t80 -35.45 137.52 0.18 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.903 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.461 ' HA ' ' HD2' ' A' ' 84' ' ' ARG . 0.6 OUTLIER 72.32 26.13 2.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.756 -179.799 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.461 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 6.7 tp10 -106.81 73.96 0.35 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.869 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.477 ' HB3' HG22 ' A' ' 82' ' ' ILE . 61.0 Cg_exo -34.19 122.19 0.15 Allowed 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.869 2.379 . . . . 0.0 111.96 179.581 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.531 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -118.57 -66.61 1.06 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.563 -179.215 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.513 ' CG1' ' HB ' ' A' ' 83' ' ' VAL . 0.8 OUTLIER -96.7 106.22 18.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.289 -179.393 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.521 ' CG1' HG12 ' A' ' 82' ' ' ILE . 34.5 t -87.51 134.45 27.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.291 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.55 ' CG2' ' N ' ' A' ' 134' ' ' THR . 72.0 mt -135.73 140.02 45.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.987 179.785 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.538 ' CG ' ' HB ' ' A' ' 134' ' ' THR . 10.0 pt-20 . . . . . 0 C--O 1.249 1.027 0 CA-C-O 118.26 -0.876 . . . . 0.0 110.88 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.467 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.45 -0.386 0 N-CA-C 112.533 -0.227 . . . . 0.0 112.533 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.577 ' CD2' ' HB ' ' A' ' 155' ' ' ILE . 16.1 t60 173.74 83.7 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.763 0.316 . . . . 0.0 110.901 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.557 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -97.74 -179.2 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.56 179.617 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.514 ' CG2' ' CG1' ' A' ' 153' ' ' VAL . 48.7 t -117.62 2.87 7.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.365 179.728 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.498 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.9 OUTLIER 23.97 98.22 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.486 179.858 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.513 ' OG ' ' CG2' ' A' ' 146' ' ' VAL . 4.1 t -34.37 95.81 0.09 OUTLIER Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.795 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.519 ' O ' ' CD1' ' A' ' 148' ' ' PHE . 18.8 Cg_endo -58.91 -74.45 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.638 2.225 . . . . 0.0 111.9 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.513 ' CE ' ' HB1' ' A' ' 120' ' ' ALA . 6.0 mtm -70.77 156.51 39.43 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.783 179.645 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.515 ' CG2' ' O ' ' A' ' 88' ' ' VAL . 2.6 p -79.43 57.74 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.048 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.453 ' O ' HG21 ' A' ' 146' ' ' VAL . . . -114.34 -148.2 9.69 Favored Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.38 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.583 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 16.9 m -122.91 144.22 49.37 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-O 121.087 0.47 . . . . 0.0 111.24 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.656 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 29.5 t80 -83.34 142.62 30.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.615 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.583 ' CZ ' HG23 ' A' ' 90' ' ' THR . 12.1 m-85 -144.88 153.68 41.84 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -139.73 32.83 2.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.845 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -148.5 109.5 3.61 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.881 179.902 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.22 -38.9 19.5 Favored 'Trans proline' 0 C--O 1.231 0.137 0 C-N-CA 122.752 2.301 . . . . 0.0 112.272 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.426 ' OG ' ' HD2' ' A' ' 97' ' ' PRO . 0.2 OUTLIER -129.02 168.78 14.86 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.9 179.995 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.426 ' HD2' ' OG ' ' A' ' 96' ' ' SER . 52.9 Cg_exo -52.29 -53.98 5.99 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.787 2.325 . . . . 0.0 112.221 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -124.5 71.79 1.17 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.874 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -119.09 -166.9 1.31 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.128 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -92.85 29.05 1.89 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.768 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.465 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 60.81 170.84 0.1 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.001 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.529 ' O ' ' CG2' ' A' ' 103' ' ' ILE . 0.0 OUTLIER -87.15 -43.26 12.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.849 -179.996 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.529 ' CG2' ' O ' ' A' ' 102' ' ' PHE . 1.1 pp -169.79 134.0 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.04 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.463 ' O ' ' CG1' ' A' ' 135' ' ' VAL . 5.7 mt-10 -137.5 157.8 45.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.966 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.458 ' HA ' HG23 ' A' ' 135' ' ' VAL . 3.0 t -38.55 125.36 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.078 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 109.45 -28.05 11.47 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.466 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.461 ' O ' HG11 ' A' ' 135' ' ' VAL . 5.6 tp60 -71.61 109.74 5.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.807 0.337 . . . . 0.0 110.867 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.454 ' O ' ' OD1' ' A' ' 110' ' ' ASN . 4.0 mttt -74.47 91.43 2.26 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.014 -179.862 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.581 ' CG1' ' CD2' ' A' ' 115' ' ' LEU . 0.0 OUTLIER -50.37 174.88 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.911 179.889 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.484 ' O ' ' CB ' ' A' ' 113' ' ' ASP . 6.9 m120 -162.53 131.33 4.15 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.09 0.472 . . . . 0.0 110.719 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.468 ' CG1' ' HA ' ' A' ' 131' ' ' LYS . 34.5 m -34.79 137.38 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.071 179.8 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 65.56 30.26 77.04 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.497 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.484 ' CB ' ' O ' ' A' ' 110' ' ' ASN . 11.1 t70 -125.52 104.86 8.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.743 0.306 . . . . 0.0 110.735 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.465 HG21 ' HB2' ' A' ' 126' ' ' GLN . 1.6 m -34.34 128.48 0.42 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.045 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.581 ' CD2' ' CG1' ' A' ' 109' ' ' VAL . 11.1 mt -95.15 -83.31 0.36 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.789 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.519 ' CB ' ' O ' ' A' ' 92' ' ' TYR . 0.5 OUTLIER -132.36 -169.26 2.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.673 179.927 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.519 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.2 OUTLIER -111.65 123.81 67.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.211 179.895 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.423 ' HB ' ' HB3' ' A' ' 125' ' ' ASN . 96.5 t -113.73 74.64 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.218 179.4 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.556 ' CG ' ' HB ' ' A' ' 90' ' ' THR . 2.4 pt-20 -58.31 89.96 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.286 -179.333 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.554 ' O ' ' CB ' ' A' ' 121' ' ' MET . . . -94.17 116.9 29.36 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.449 179.515 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.571 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.3 OUTLIER 90.25 -33.1 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.648 -179.344 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.571 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 150.34 -13.46 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.02 179.903 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.497 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 2.5 ptt? -106.57 134.32 49.9 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.91 0.386 . . . . 0.0 111.164 -179.623 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.519 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 2.4 ptm -55.51 133.31 50.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.135 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.447 ' OD1' ' CE ' ' A' ' 87' ' ' MET . 2.0 t-20 -120.27 68.6 0.85 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.669 179.823 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.465 ' HB2' HG21 ' A' ' 114' ' ' THR . 0.2 OUTLIER -43.01 131.86 4.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.844 -179.836 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.45 ' O ' ' HA ' ' A' ' 114' ' ' THR . 57.7 mt -95.18 149.59 4.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.245 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . 0.4 ' N ' HG21 ' A' ' 127' ' ' ILE . 4.5 mp0 -108.55 131.58 54.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.888 179.899 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.456 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -45.28 110.03 0.21 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.161 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -68.51 -20.4 64.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.796 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.468 ' HA ' ' CG1' ' A' ' 111' ' ' VAL . 0.0 OUTLIER -179.0 137.04 0.14 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.776 179.945 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.4 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 24.6 t -41.31 127.3 2.88 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.805 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.493 ' O ' ' N ' ' A' ' 109' ' ' VAL . . . -161.67 -178.94 36.02 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.613 -0.804 . . . . 0.0 112.63 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.547 ' N ' ' CG2' ' A' ' 155' ' ' ILE . 16.5 m -129.43 108.62 10.42 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.645 0.259 . . . . 0.0 111.419 -179.755 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.493 HG21 ' N ' ' A' ' 136' ' ' LYS . 2.2 p -49.13 144.12 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 179.284 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.529 ' CE ' ' HB2' ' A' ' 156' ' ' GLU . 4.5 mmtt -122.25 -20.28 6.23 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 121.05 -0.26 . . . . 0.0 111.456 -179.232 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.42 ' O ' HD11 ' A' ' 138' ' ' ILE . . . 175.35 175.32 0.23 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.054 0.454 . . . . 0.0 111.798 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.656 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 1.2 mm -125.82 85.09 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.861 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.525 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 5.9 mt -50.79 -21.73 1.8 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.768 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.535 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 69.9 t -108.11 151.44 10.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.254 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.446 ' O ' ' C ' ' A' ' 142' ' ' SER . 39.6 mt-10 -64.17 135.75 56.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.942 179.19 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.493 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -32.17 -61.35 0.25 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.595 -179.272 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.534 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -125.11 103.34 0.72 Allowed Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.505 -0.855 . . . . 0.0 112.895 -179.619 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.462 ' O ' HG21 ' A' ' 90' ' ' THR . 6.4 pt20 -170.94 153.81 4.02 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-O 120.938 0.399 . . . . 0.0 111.215 179.718 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.45 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 37.0 Cg_endo -65.92 140.03 59.07 Favored 'Trans proline' 0 C--O 1.232 0.209 0 C-N-CA 122.843 2.362 . . . . 0.0 112.534 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.513 ' CG2' ' OG ' ' A' ' 85' ' ' SER . 26.7 m -130.32 -171.68 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.893 179.864 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.422 ' O ' ' C ' ' A' ' 148' ' ' PHE . 2.5 tm-20 -130.11 137.92 50.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.971 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.521 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 1.5 t80 -35.72 120.01 0.57 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.744 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.521 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 5.4 t70 86.19 31.38 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.887 0.375 . . . . 0.0 110.524 -179.553 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.474 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 5.8 tp10 -107.18 75.1 0.42 Allowed Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.66 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.498 ' HA ' ' HA ' ' A' ' 84' ' ' ARG . 48.5 Cg_exo -30.58 109.71 0.04 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.723 0 C-N-CA 123.159 2.573 . . . . 0.0 112.377 179.69 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.566 ' HB2' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -104.68 -56.1 2.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.315 -179.412 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.514 ' CG1' ' CG2' ' A' ' 83' ' ' VAL . 0.9 OUTLIER -103.43 111.8 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.402 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.45 -179.185 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.525 ' CG2' ' HG ' ' A' ' 139' ' ' LEU . 3.1 t -91.77 145.1 7.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.863 179.763 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.577 ' HB ' ' CD2' ' A' ' 81' ' ' HIS . 4.4 mt -138.53 147.68 25.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.433 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.529 ' HB2' ' CE ' ' A' ' 136' ' ' LYS . 6.8 tp10 . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.271 -0.871 . . . . 0.0 110.844 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.265 0 N-CA-C 112.489 -0.244 . . . . 0.0 112.489 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.549 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 31.8 t60 -177.98 79.39 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.776 0.322 . . . . 0.0 110.871 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.525 HG12 ' CG1' ' A' ' 154' ' ' VAL . 16.7 mt -95.54 143.05 12.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.157 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.52 ' HB ' ' CG1' ' A' ' 153' ' ' VAL . 2.2 t -103.34 54.32 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.21 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.456 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 2.1 ptt180 -38.21 141.97 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.803 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.475 ' N ' HD13 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -35.52 95.6 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.94 -179.974 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.441 ' N ' ' O ' ' A' ' 84' ' ' ARG . 66.7 Cg_exo -50.63 -20.2 6.1 Favored 'Trans proline' 0 N--CA 1.466 -0.143 0 C-N-CA 122.648 2.232 . . . . 0.0 112.157 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.485 ' SD ' ' CB ' ' A' ' 120' ' ' ALA . 2.2 ptm -162.76 177.52 9.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.723 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 93.3 t -70.77 97.66 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.145 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.522 ' O ' ' CG2' ' A' ' 146' ' ' VAL . . . -162.04 -166.86 21.58 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.37 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.543 ' HB ' ' CG ' ' A' ' 119' ' ' GLU . 3.6 m -109.52 126.96 54.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.789 0.328 . . . . 0.0 110.883 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.633 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 2.7 t80 -82.15 140.1 33.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.796 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.585 ' CE2' ' HG2' ' A' ' 119' ' ' GLU . 18.7 m-85 -137.92 152.9 49.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.934 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.526 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 0.7 OUTLIER -134.27 18.57 3.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.818 179.808 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.439 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 5.4 p -145.44 106.43 4.38 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.803 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.585 ' HG3' ' CG ' ' A' ' 102' ' ' PHE . 27.9 Cg_exo -61.98 -9.63 15.08 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.776 2.317 . . . . 0.0 112.429 -179.837 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 1.5 t -172.23 153.84 3.13 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.912 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_exo -55.84 -50.88 11.06 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.722 2.281 . . . . 0.0 112.269 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -106.29 56.52 0.66 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -121.08 -160.78 0.86 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.123 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 2.0 mmmt -103.99 24.26 11.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.002 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.439 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 57.81 162.64 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.073 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.585 ' CG ' ' HG3' ' A' ' 95' ' ' PRO . 0.1 OUTLIER -88.42 -41.38 12.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.981 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.522 ' CG2' ' O ' ' A' ' 102' ' ' PHE . 0.8 OUTLIER -175.53 150.29 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-O 120.939 0.4 . . . . 0.0 111.271 179.668 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.43 ' C ' HG13 ' A' ' 135' ' ' VAL . 5.0 pt-20 -152.06 158.62 43.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.683 179.775 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.483 HG21 ' HA ' ' A' ' 136' ' ' LYS . 6.8 p -48.24 105.26 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.166 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 123.9 -0.03 9.1 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.369 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.4 mm-40 -77.99 144.02 37.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.751 0.31 . . . . 0.0 110.98 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -98.94 90.73 4.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.907 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.466 HG21 ' O ' ' A' ' 133' ' ' GLY . 15.6 m -87.89 159.63 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.105 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.452 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 31.9 m-80 -162.35 130.39 3.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.067 0.46 . . . . 0.0 110.776 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 24.6 m -35.84 123.49 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.224 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 108.44 3.06 33.07 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.559 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -113.42 -149.39 0.45 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.766 0.317 . . . . 0.0 110.685 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.47 ' CG2' ' OE1' ' A' ' 126' ' ' GLN . 5.5 m -136.23 132.23 35.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.924 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.474 ' O ' HG22 ' A' ' 103' ' ' ILE . 75.4 mt -92.43 -84.71 0.27 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.916 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.505 ' HA ' ' CG ' ' A' ' 102' ' ' PHE . 2.3 p -143.78 -167.13 2.51 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.037 -179.894 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.583 HG13 ' CE2' ' A' ' 102' ' ' PHE . 2.8 mt -131.59 150.44 34.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.812 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.446 ' O ' ' N ' ' A' ' 120' ' ' ALA . 53.6 t -143.93 103.22 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.856 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.585 ' HG2' ' CE2' ' A' ' 92' ' ' TYR . 6.8 pt-20 -58.6 82.28 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.146 -179.681 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.54 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -95.67 99.92 11.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.663 179.627 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.54 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 88.43 30.96 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.563 -179.53 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.49 ' HB3' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 75.8 30.49 0.76 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.217 -179.996 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.485 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 18.6 mmt -149.39 124.77 10.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.967 0.413 . . . . 0.0 110.906 179.558 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.491 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -59.75 103.18 0.19 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.148 -179.824 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 31.4 t30 -83.31 80.68 9.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.547 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.47 ' OE1' ' CG2' ' A' ' 114' ' ' THR . 17.3 tt0 -56.81 124.03 17.07 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.94 -179.837 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 15.3 mm -91.17 120.35 39.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.136 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -90.93 143.16 27.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.882 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -57.05 116.73 3.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.047 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -117.42 14.35 14.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.811 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.462 ' HB3' ' CE1' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -179.39 102.99 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.69 -180.0 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.452 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 0.9 OUTLIER -42.77 122.59 2.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.616 179.897 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.466 ' O ' HG21 ' A' ' 109' ' ' VAL . . . -156.25 -167.32 17.42 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.615 -179.846 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.524 ' N ' HG22 ' A' ' 155' ' ' ILE . 21.3 m -140.16 112.42 7.75 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.511 0.196 . . . . 0.0 111.169 -179.791 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.459 ' HA ' ' HA ' ' A' ' 155' ' ' ILE . 38.3 t -44.85 140.14 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.243 179.365 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.531 ' HD3' ' CB ' ' A' ' 156' ' ' GLU . 1.0 OUTLIER -122.42 -17.01 7.17 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.755 0.312 . . . . 0.0 111.152 -179.263 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.52 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 162.41 148.17 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.486 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.633 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -94.92 86.18 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.498 179.649 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.537 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 0.6 OUTLIER -40.81 -29.41 0.1 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.094 0.473 . . . . 0.0 110.207 -179.87 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.525 HG22 ' CD2' ' A' ' 152' ' ' LEU . 56.1 t -106.99 137.98 35.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.863 179.843 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.458 ' O ' ' CG ' ' A' ' 144' ' ' GLN . 3.4 mt-10 -67.65 98.11 0.67 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.219 179.513 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.526 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 24.2 p -34.15 135.87 0.14 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.899 -179.588 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.578 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 84.24 34.34 17.63 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.323 -179.663 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.468 ' O ' HG21 ' A' ' 90' ' ' THR . 37.8 mm-40 -146.2 144.8 22.27 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 120.898 0.38 . . . . 0.0 111.144 -179.736 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.524 ' N ' HG22 ' A' ' 90' ' ' THR . 52.5 Cg_exo -55.32 177.26 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.862 2.375 . . . . 0.0 112.325 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.522 ' CG2' ' O ' ' A' ' 89' ' ' GLY . 0.2 OUTLIER -173.31 -174.42 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.193 -179.997 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.524 ' O ' ' CG ' ' A' ' 150' ' ' GLU . 8.8 tt0 -155.71 158.5 38.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.903 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.463 ' HA ' ' O ' ' A' ' 85' ' ' SER . 42.5 t80 -42.42 138.84 1.65 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.967 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 74.67 24.1 1.73 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.524 ' CG ' ' O ' ' A' ' 147' ' ' GLU . 67.4 mm-40 -115.12 73.3 3.37 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.841 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.456 ' HA ' ' HA ' ' A' ' 84' ' ' ARG . 62.7 Cg_exo -33.75 129.04 0.16 Allowed 'Trans proline' 0 N--CA 1.458 -0.567 0 C-N-CA 122.974 2.449 . . . . 0.0 112.165 179.648 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.525 ' CD2' HG22 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -125.49 -71.67 0.69 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.727 -179.349 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.52 ' CG1' ' HB ' ' A' ' 83' ' ' VAL . 1.7 p -93.77 104.0 15.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.873 -179.085 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.537 ' CG2' ' HG ' ' A' ' 139' ' ' LEU . 21.4 t -89.13 133.1 32.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.814 179.333 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.524 HG22 ' N ' ' A' ' 134' ' ' THR . 97.1 mt -135.43 134.16 52.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.146 -179.727 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.531 ' CB ' ' HD3' ' A' ' 136' ' ' LYS . 1.2 tm-20 . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.259 -0.877 . . . . 0.0 110.898 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.532 ' CA ' ' HB2' ' A' ' 156' ' ' GLU . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.558 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 34.2 t60 -169.49 75.65 0.09 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.811 0.338 . . . . 0.0 110.812 179.814 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.529 HG12 ' CG1' ' A' ' 154' ' ' VAL . 6.2 mt -93.25 150.44 3.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.105 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.532 ' HB ' ' CG1' ' A' ' 153' ' ' VAL . 3.1 t -102.43 46.55 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.037 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.516 ' CD ' ' O ' ' A' ' 84' ' ' ARG . 0.0 OUTLIER -35.48 131.92 0.45 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.859 179.965 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.519 ' N ' HD13 ' A' ' 152' ' ' LEU . 95.2 p -36.56 99.16 0.17 Allowed Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.968 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -60.97 -11.98 20.57 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.619 2.213 . . . . 0.0 111.97 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.443 ' SD ' ' HB3' ' A' ' 120' ' ' ALA . 1.0 OUTLIER -160.58 167.76 26.42 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.607 179.856 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.481 ' CG2' ' O ' ' A' ' 88' ' ' VAL . 26.4 m -66.49 69.66 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.007 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.424 ' O ' HG21 ' A' ' 146' ' ' VAL . . . -121.67 -150.83 8.36 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.639 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.584 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 97.9 m -131.95 128.45 38.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.961 0.41 . . . . 0.0 111.028 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.633 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 69.8 t80 -68.75 143.49 54.65 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.526 179.724 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.584 ' CZ ' HG23 ' A' ' 90' ' ' THR . 7.8 m-30 -149.06 125.77 11.11 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.897 0.379 . . . . 0.0 110.85 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.494 ' O ' ' N ' ' A' ' 102' ' ' PHE . 39.8 ptt85 -117.54 22.52 12.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.883 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.52 112.24 5.03 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.962 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.52 -38.86 3.05 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.689 2.259 . . . . 0.0 112.333 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -130.38 161.64 59.31 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.849 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.457 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 38.4 Cg_endo -66.83 102.92 0.66 Allowed 'Trans proline' 0 C--O 1.231 0.13 0 C-N-CA 122.722 2.282 . . . . 0.0 112.362 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.457 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 9.3 t70 80.16 35.29 0.14 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.884 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -88.74 -155.31 0.33 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.012 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.93 27.97 3.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.801 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 54.48 174.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.054 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.576 ' CE2' HG13 ' A' ' 117' ' ' ILE . 0.1 OUTLIER -99.51 -35.2 9.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.874 179.972 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.521 ' CG2' ' O ' ' A' ' 102' ' ' PHE . 1.2 pp -179.03 123.53 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.987 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.421 ' C ' HG13 ' A' ' 135' ' ' VAL . 1.7 mt-10 -141.34 164.7 29.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.949 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.408 ' N ' HG13 ' A' ' 135' ' ' VAL . 38.7 t -37.09 135.38 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.118 -179.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 87.78 -24.5 10.47 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.557 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.419 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 0.0 OUTLIER -71.66 94.62 1.36 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.84 0.352 . . . . 0.0 110.842 -179.967 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 10.5 mttm -75.53 105.16 6.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.906 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 5.5 m -80.04 173.44 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.177 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.466 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 4.5 p-10 -152.62 129.87 11.25 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.756 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.516 HG21 ' N ' ' A' ' 112' ' ' GLY . 7.5 p -43.26 143.17 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.582 -0.735 . . . . 0.0 111.081 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . 0.516 ' N ' HG21 ' A' ' 111' ' ' VAL . . . 90.12 -2.13 81.07 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.412 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -105.98 -146.81 0.39 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.571 0.224 . . . . 0.0 110.63 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 3.9 m -130.13 120.36 24.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.789 0.328 . . . . 0.0 111.016 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.414 ' N ' ' O ' ' A' ' 127' ' ' ILE . 15.8 mt -77.06 -85.35 0.06 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.793 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.439 ' O ' ' N ' ' A' ' 127' ' ' ILE . 5.0 p -148.14 171.09 16.46 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.795 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.576 HG13 ' CE2' ' A' ' 102' ' ' PHE . 3.7 mt -105.24 152.58 7.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.834 -179.874 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 90' ' ' THR . 55.6 t -144.04 103.23 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.052 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.498 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 1.9 mt-10 -65.54 100.78 0.53 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.151 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.443 ' HB3' ' SD ' ' A' ' 87' ' ' MET . . . -83.26 -77.09 0.26 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.377 0.608 . . . . 0.0 111.071 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.531 ' O ' ' CG ' ' A' ' 122' ' ' LYS . 7.6 ptm -91.37 32.71 1.03 Allowed 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.367 179.695 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.531 ' CG ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 90.47 2.73 0.16 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.817 -179.63 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.468 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 4.9 ptm -116.78 133.58 55.84 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.841 179.785 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.545 ' HB3' ' CD1' ' A' ' 117' ' ' ILE . 3.3 mpp? -55.85 120.09 6.82 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.872 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.415 ' CB ' ' O ' ' A' ' 118' ' ' VAL . 35.8 t30 -102.3 73.44 1.35 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.947 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.52 ' CA ' HG12 ' A' ' 117' ' ' ILE . 15.4 pt20 -51.75 130.9 29.77 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.039 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.439 ' N ' ' O ' ' A' ' 116' ' ' CYS . 31.2 mm -103.59 136.79 34.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.094 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -95.41 145.32 25.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.883 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.438 ' CB ' ' HA ' ' A' ' 111' ' ' VAL . . . -64.78 121.63 15.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.062 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -94.88 -8.86 36.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.988 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -173.99 134.12 0.45 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.829 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.466 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 88.7 p -49.81 119.14 3.29 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.646 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -141.83 -176.77 16.34 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.628 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.529 ' N ' HG22 ' A' ' 155' ' ' ILE . 23.4 m -136.17 109.34 7.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.631 0.253 . . . . 0.0 111.139 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.505 HG11 ' N ' ' A' ' 136' ' ' LYS . 67.1 t -48.27 142.49 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.289 179.4 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.536 ' CD ' ' HB3' ' A' ' 156' ' ' GLU . 55.1 mtpt -126.93 -19.8 4.35 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 121.042 -0.263 . . . . 0.0 111.705 -179.258 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 173.62 162.52 0.16 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.025 0.44 . . . . 0.0 111.773 -179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.633 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.6 OUTLIER -116.59 80.08 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.752 179.656 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.408 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 13.3 mt -47.99 -23.28 0.75 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.856 -179.822 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.53 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 53.5 t -108.16 143.34 18.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.235 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.472 ' HB2' ' HG2' ' A' ' 144' ' ' GLN . 4.9 mt-10 -59.61 136.06 57.87 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.922 179.31 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.472 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -30.61 -63.5 0.14 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.817 -179.259 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.576 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -124.06 103.54 0.77 Allowed Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.528 -0.844 . . . . 0.0 113.028 -179.393 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.486 ' C ' ' CG2' ' A' ' 90' ' ' THR . 0.0 OUTLIER -169.98 145.93 2.53 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-O 120.904 0.383 . . . . 0.0 111.149 179.616 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.466 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 39.0 Cg_exo -56.94 144.59 88.49 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.751 2.301 . . . . 0.0 112.066 179.803 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.526 HG12 ' CD2' ' A' ' 152' ' ' LEU . 0.2 OUTLIER -136.23 -174.21 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.201 -179.926 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -143.75 142.59 30.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.929 179.915 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.49 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 4.4 t80 -34.68 129.71 0.41 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.072 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.49 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.7 t70 83.01 23.6 0.15 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.918 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.458 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 25.7 mm-40 -109.54 74.28 0.68 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.835 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 84' ' ' ARG . 53.6 Cg_exo -33.71 126.38 0.15 Allowed 'Trans proline' 0 N--CA 1.458 -0.605 0 C-N-CA 122.866 2.377 . . . . 0.0 112.14 179.607 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.597 ' CB ' ' CD1' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -117.89 -68.42 0.92 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.607 -179.175 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.532 ' CG1' ' HB ' ' A' ' 83' ' ' VAL . 1.3 p -102.45 106.22 19.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.418 -179.217 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.529 ' CG1' HG12 ' A' ' 82' ' ' ILE . 4.2 t -87.89 130.2 37.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.05 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.529 HG22 ' N ' ' A' ' 134' ' ' THR . 91.3 mt -132.99 131.87 58.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.215 -179.788 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.536 ' HB3' ' CD ' ' A' ' 136' ' ' LYS . 14.9 tt0 . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.259 -0.877 . . . . 0.0 110.96 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.416 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.45 -0.371 0 N-CA-C 112.336 -0.306 . . . . 0.0 112.336 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.52 ' N ' ' O ' ' A' ' 155' ' ' ILE . 23.7 t60 175.56 82.42 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.759 0.314 . . . . 0.0 110.943 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.533 HG12 ' CG1' ' A' ' 154' ' ' VAL . 10.8 mt -98.73 123.14 51.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.074 0.464 . . . . 0.0 110.976 179.79 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.51 ' HB ' ' CG1' ' A' ' 153' ' ' VAL . 2.0 t -76.29 57.55 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.762 -0.653 . . . . 0.0 111.312 -179.693 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.463 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -35.39 119.42 0.51 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.723 -179.977 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.531 ' N ' HD13 ' A' ' 152' ' ' LEU . 0.3 OUTLIER -35.26 104.84 0.26 Allowed Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.177 -179.755 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.458 ' O ' ' O ' ' A' ' 87' ' ' MET . 32.6 Cg_endo -64.14 138.57 62.37 Favored 'Trans proline' 0 C--O 1.231 0.145 0 C-N-CA 122.62 2.213 . . . . 0.0 111.654 179.508 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.458 ' O ' ' O ' ' A' ' 86' ' ' PRO . 3.9 ptp 42.3 -167.81 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.354 -179.613 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.412 HG23 ' HG2' ' A' ' 147' ' ' GLU . 52.4 t -88.36 106.96 17.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.847 0.356 . . . . 0.0 111.203 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.424 ' O ' HG21 ' A' ' 146' ' ' VAL . . . -157.54 -158.05 8.74 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.582 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.581 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 4.4 m -123.89 148.74 46.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.909 0.385 . . . . 0.0 111.088 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.654 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 46.8 t80 -90.99 140.6 29.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.042 -0.527 . . . . 0.0 109.927 179.307 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.582 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 11.3 m-85 -146.19 123.05 11.3 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.975 0.417 . . . . 0.0 111.169 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.463 ' HA ' ' HB2' ' A' ' 102' ' ' PHE . 41.3 ptt85 -116.04 39.35 3.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.673 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' THR . . . . . 0.454 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 31.2 p -150.86 115.6 3.23 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.022 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -71.85 -29.58 15.2 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.738 2.292 . . . . 0.0 112.204 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -143.35 158.88 56.94 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.875 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_exo -52.44 -38.74 74.58 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.69 2.26 . . . . 0.0 112.263 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 -129.05 60.34 1.55 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.922 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -116.14 -168.95 1.51 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.14 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . 0.475 ' NZ ' ' HB2' ' A' ' 100' ' ' LYS . 0.8 OUTLIER -91.4 27.04 2.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.978 179.951 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . 0.454 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 65.42 178.59 0.2 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.192 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.581 ' CE2' HG13 ' A' ' 117' ' ' ILE . 0.1 OUTLIER -95.22 -31.88 13.29 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.709 179.9 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.532 ' CG2' ' O ' ' A' ' 102' ' ' PHE . 0.1 OUTLIER 169.42 138.49 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.21 179.621 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.523 ' O ' ' CG1' ' A' ' 135' ' ' VAL . 5.3 pt-20 -140.78 160.0 40.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.0 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.445 ' HA ' HG23 ' A' ' 135' ' ' VAL . 7.7 p -43.57 123.14 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.217 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 111.07 -19.98 24.42 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.446 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.456 ' O ' HG11 ' A' ' 135' ' ' VAL . 0.2 OUTLIER -87.47 113.6 23.33 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.801 0.334 . . . . 0.0 110.859 179.975 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 1.1 pttt -75.84 117.1 17.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.896 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.501 ' CG1' HD22 ' A' ' 115' ' ' LEU . 35.2 m -86.78 168.41 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.087 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.47 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 2.5 p-10 -160.11 132.14 6.21 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 121.129 0.49 . . . . 0.0 110.696 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.498 ' HA ' ' CB ' ' A' ' 129' ' ' ALA . 4.1 t -36.86 139.87 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.963 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 88.99 7.38 70.54 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.27 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.461 ' O ' ' N ' ' A' ' 115' ' ' LEU . 6.8 m-20 -123.63 103.2 8.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.857 0.36 . . . . 0.0 110.835 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.414 ' C ' ' O ' ' A' ' 113' ' ' ASP . 4.3 m -37.23 94.72 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.925 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.501 HD22 ' CG1' ' A' ' 109' ' ' VAL . 9.9 mt -47.87 -91.0 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.703 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.453 ' O ' HG12 ' A' ' 127' ' ' ILE . 2.0 p -138.33 155.95 48.09 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.851 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.581 HG13 ' CE2' ' A' ' 102' ' ' PHE . 3.7 mt -89.79 153.21 3.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.025 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.475 ' HA ' ' O ' ' A' ' 90' ' ' THR . 86.3 t -145.23 101.08 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.852 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.516 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 2.4 mm-40 -55.27 84.49 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.243 -179.779 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.469 ' C ' ' CG ' ' A' ' 121' ' ' MET . . . -103.04 145.68 29.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.722 179.7 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.469 ' CG ' ' C ' ' A' ' 120' ' ' ALA . 2.2 ptm 45.53 26.82 0.34 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.035 0.445 . . . . 0.0 110.252 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.525 ' O ' ' CE ' ' A' ' 122' ' ' LYS . 0.1 OUTLIER 77.89 45.1 0.08 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.746 -179.698 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.51 ' N ' ' OE1' ' A' ' 119' ' ' GLU . 11.1 mtt -162.21 127.84 3.47 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.992 179.713 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.515 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.9 OUTLIER -57.68 87.18 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.56 179.61 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 12.6 t-20 -65.59 79.9 0.07 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.945 -179.799 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . 0.46 ' HG2' ' O ' ' A' ' 126' ' ' GLN . 0.0 OUTLIER -57.16 118.87 5.48 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.87 179.99 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.475 ' O ' ' N ' ' A' ' 115' ' ' LEU . 34.7 mm -84.77 134.26 27.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.042 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -108.08 116.55 32.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.957 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.498 ' CB ' ' HA ' ' A' ' 111' ' ' VAL . . . -37.8 113.49 0.28 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.131 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 42.9 p-10 -93.96 -14.36 26.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.935 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 15.6 ptmt -162.37 126.07 3.05 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.783 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.47 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 5.3 p -46.39 120.01 2.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.993 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.472 ' O ' HG21 ' A' ' 109' ' ' VAL . . . -143.59 -168.59 12.26 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.433 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.502 ' N ' HG22 ' A' ' 155' ' ' ILE . 17.4 m -143.81 107.31 4.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.684 0.278 . . . . 0.0 111.25 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.523 ' CG1' ' O ' ' A' ' 104' ' ' GLU . 7.1 p -45.73 141.15 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.301 179.43 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.494 ' O ' ' CB ' ' A' ' 137' ' ' ALA . 20.6 mtpt -120.82 -18.65 7.58 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.711 0.291 . . . . 0.0 111.111 -179.522 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.494 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 163.71 153.31 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.983 0.42 . . . . 0.0 111.765 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.654 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.1 OUTLIER -108.31 79.35 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.545 179.684 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 8.2 mt -44.93 -25.96 0.37 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.722 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.534 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 62.3 t -102.85 146.71 10.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.009 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.556 ' O ' ' CD2' ' A' ' 91' ' ' PHE . 15.4 mt-10 -51.25 -174.84 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.172 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.487 ' O ' ' O ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -82.18 -55.4 4.57 Favored 'General case' 0 C--N 1.324 -0.529 0 C-N-CA 120.881 -0.327 . . . . 0.0 110.921 179.935 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.569 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -126.5 103.1 0.66 Allowed Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.577 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.501 ' NE2' ' O ' ' A' ' 145' ' ' PRO . 0.0 OUTLIER -165.03 151.56 9.21 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-O 120.948 0.404 . . . . 0.0 111.352 179.92 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.501 ' O ' ' NE2' ' A' ' 144' ' ' GLN . 30.7 Cg_endo -63.72 131.17 30.29 Favored 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.97 2.447 . . . . 0.0 112.48 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.466 HG22 HD23 ' A' ' 152' ' ' LEU . 0.2 OUTLIER -133.05 176.81 8.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.896 179.886 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.54 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 2.3 mt-10 -133.41 156.86 46.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.969 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.473 ' HA ' ' O ' ' A' ' 85' ' ' SER . 8.3 t80 -40.57 153.6 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.895 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.453 ' OD1' ' O ' ' A' ' 149' ' ' ASP . 1.0 OUTLIER 54.8 28.04 9.73 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.529 179.806 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.54 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 11.0 tp10 -107.23 74.35 0.4 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.702 179.492 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.472 ' HB3' HG23 ' A' ' 82' ' ' ILE . 48.8 Cg_exo -31.35 129.13 0.08 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 123.138 2.559 . . . . 0.0 112.362 179.758 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.534 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -130.16 -68.91 0.69 Allowed 'General case' 0 C--O 1.232 0.181 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.694 -179.484 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.51 ' CG1' ' HB ' ' A' ' 83' ' ' VAL . 1.5 p -99.65 101.78 12.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.606 -178.941 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.533 ' CG1' HG12 ' A' ' 82' ' ' ILE . 23.8 t -81.86 138.49 19.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.0 179.602 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.52 ' O ' ' N ' ' A' ' 81' ' ' HIS . 83.6 mt -139.05 136.62 42.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.285 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.446 ' CA ' ' HD2' ' A' ' 136' ' ' LYS . 0.5 OUTLIER . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.282 -0.866 . . . . 0.0 110.927 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . 0.469 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.452 -0.299 0 N-CA-C 112.592 -0.203 . . . . 0.0 112.592 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' HIS . . . . . 0.509 ' N ' ' O ' ' A' ' 155' ' ' ILE . 24.7 t60 171.21 83.98 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.778 0.323 . . . . 0.0 110.797 -179.864 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . 0.58 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 0.2 OUTLIER -88.02 -177.52 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.992 0.425 . . . . 0.0 111.001 179.909 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.523 ' CG2' ' CG1' ' A' ' 153' ' ' VAL . 1.7 t -140.92 39.17 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.705 179.603 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' ARG . . . . . 0.528 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 1.7 ptt-85 -34.07 127.42 0.42 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.979 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' SER . . . . . 0.405 ' HA ' ' HD2' ' A' ' 86' ' ' PRO . 0.9 OUTLIER -38.37 112.02 0.64 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.883 179.986 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' PRO . . . . . 0.405 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 25.9 Cg_endo -61.96 -11.27 20.65 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.669 2.246 . . . . 0.0 111.945 179.853 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' MET . . . . . 0.507 ' SD ' ' CB ' ' A' ' 120' ' ' ALA . 5.6 ptm -156.59 177.09 11.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.598 179.844 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' VAL . . . . . 0.404 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 1.7 p -80.43 94.18 2.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.082 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -143.64 -123.42 1.74 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.613 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' THR . . . . . 0.545 ' CG2' ' CZ ' ' A' ' 92' ' ' TYR . 38.5 m -150.9 150.78 31.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.861 0.362 . . . . 0.0 110.996 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' PHE . . . . . 0.652 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 0.8 OUTLIER -116.89 143.27 45.89 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.931 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' TYR . . . . . 0.581 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 22.5 m-85 -142.9 163.17 33.52 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.029 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' ARG . . . . . 0.46 ' HG2' ' CB ' ' A' ' 142' ' ' SER . 29.0 ptt180 -143.83 24.69 1.67 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.752 179.695 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -156.51 91.99 2.52 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.767 179.833 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -68.47 -25.32 35.46 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.785 2.323 . . . . 0.0 112.565 -179.811 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' SER . . . . . 0.458 ' O ' ' HB1' ' A' ' 99' ' ' ALA . 0.9 OUTLIER -135.57 133.13 20.06 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 120.966 0.413 . . . . 0.0 111.057 -179.896 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.483 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 52.1 Cg_exo -54.55 109.98 0.46 Allowed 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.803 2.335 . . . . 0.0 112.23 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' ASP . . . . . 0.483 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 10.4 t70 81.6 46.67 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.823 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' ALA . . . . . 0.458 ' HB1' ' O ' ' A' ' 96' ' ' SER . . . -107.2 -166.47 1.16 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.081 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -90.41 23.51 2.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.795 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 56.88 159.7 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.146 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' PHE . . . . . 0.55 ' CD2' HG12 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -87.63 -37.79 16.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.82 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' ILE . . . . . 0.485 ' CG2' ' O ' ' A' ' 102' ' ' PHE . 0.6 OUTLIER -170.19 110.03 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.134 -179.999 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' GLU . . . . . 0.504 ' N ' ' OE1' ' A' ' 104' ' ' GLU . 12.5 pm0 -121.73 162.3 21.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.852 179.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.509 ' N ' HG13 ' A' ' 135' ' ' VAL . 4.4 t -45.36 97.74 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.091 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.02 -8.97 6.03 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.513 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 29.7 tp60 -70.64 99.59 1.69 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.793 0.33 . . . . 0.0 110.881 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' LYS . . . . . 0.444 ' O ' ' O ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -67.67 61.06 0.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.962 -179.984 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . 0.517 HG21 ' N ' ' A' ' 133' ' ' GLY . 16.9 m -42.09 168.15 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.047 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' ASN . . . . . 0.49 ' ND2' ' HB2' ' A' ' 132' ' ' SER . 23.0 m120 -167.18 132.99 2.13 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.579 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.461 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 18.1 m -34.05 136.34 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.172 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 81.33 14.97 77.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.303 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' ASP . . . . . 0.422 ' O ' ' C ' ' A' ' 114' ' ' THR . 0.8 OUTLIER -128.51 105.88 8.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.854 0.359 . . . . 0.0 110.824 179.957 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' THR . . . . . 0.476 HG23 ' CZ ' ' A' ' 102' ' ' PHE . 1.3 m -35.18 127.93 0.54 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.033 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' LEU . . . . . 0.448 ' O ' HG22 ' A' ' 103' ' ' ILE . 14.7 mt -87.63 -83.95 0.2 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.908 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' CYS . . . . . 0.467 ' HB2' ' O ' ' A' ' 92' ' ' TYR . 21.4 p -135.2 -165.51 1.69 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.917 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' ILE . . . . . 0.566 ' CG2' ' CB ' ' A' ' 124' ' ' MET . 0.2 OUTLIER -113.7 113.92 45.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.212 -179.988 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.464 ' HB ' ' HB3' ' A' ' 125' ' ' ASN . 25.8 t -103.47 55.1 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.82 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' GLU . . . . . 0.465 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.2 OUTLIER -35.44 98.8 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.093 -179.842 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' ALA . . . . . 0.533 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -118.16 110.27 17.39 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.923 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' MET . . . . . 0.544 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.3 OUTLIER 87.07 21.42 0.06 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.855 -179.908 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.544 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 89.69 0.81 0.26 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.252 179.907 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.465 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.4 OUTLIER -119.86 133.58 55.53 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.854 0.359 . . . . 0.0 111.138 179.942 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.566 ' CB ' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -64.22 112.63 3.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.051 179.87 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.464 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 0.8 OUTLIER -86.7 74.93 9.74 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.656 179.715 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -48.88 112.27 0.59 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.005 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' ILE . . . . . 0.433 ' CG1' HG22 ' A' ' 118' ' ' VAL . 3.9 mm -90.94 145.5 7.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.044 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -122.61 123.65 41.67 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.985 -179.873 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -38.95 142.58 0.21 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.119 179.874 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -121.49 -7.56 9.18 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.042 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.485 ' NZ ' ' O ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -160.13 23.88 0.17 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.769 179.991 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' SER . . . . . 0.49 ' HB2' ' ND2' ' A' ' 110' ' ' ASN . 1.3 p 53.66 -176.57 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.632 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' GLY . . . . . 0.517 ' N ' HG21 ' A' ' 109' ' ' VAL . . . 150.13 167.09 14.0 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.575 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' THR . . . . . 0.543 ' N ' ' CG2' ' A' ' 155' ' ' ILE . 18.8 m -116.57 110.74 18.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.658 0.266 . . . . 0.0 111.18 -179.902 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.509 HG13 ' N ' ' A' ' 105' ' ' VAL . 95.0 t -47.22 142.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.472 179.51 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.509 ' N ' HG11 ' A' ' 135' ' ' VAL . 0.2 OUTLIER -124.83 -19.18 5.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.424 -179.399 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . 0.454 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 167.23 155.97 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.835 0.35 . . . . 0.0 111.351 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' ILE . . . . . 0.652 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -106.94 82.92 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.948 179.835 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' LEU . . . . . 0.547 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 6.6 mt -41.2 -34.96 0.53 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 121.168 0.508 . . . . 0.0 109.97 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' VAL . . . . . 0.525 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 59.0 t -92.18 136.86 23.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.701 179.648 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . 0.463 ' O ' ' HG2' ' A' ' 144' ' ' GLN . 4.5 mt-10 -70.22 100.19 1.64 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.443 179.817 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.46 ' CB ' ' HG2' ' A' ' 93' ' ' ARG . 5.9 p -36.13 147.66 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.682 -179.698 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' GLY . . . . . 0.581 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 71.97 35.29 61.44 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.451 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' GLN . . . . . 0.463 ' HG2' ' O ' ' A' ' 141' ' ' GLU . 0.7 OUTLIER -149.03 153.48 38.27 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.883 0.373 . . . . 0.0 111.115 -179.913 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' PRO . . . . . 0.461 ' O ' HG11 ' A' ' 146' ' ' VAL . 57.3 Cg_endo -70.64 164.13 36.49 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.939 2.426 . . . . 0.0 112.268 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' VAL . . . . . 0.595 ' CG1' ' CD2' ' A' ' 152' ' ' LEU . 29.3 m -143.99 -179.38 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.195 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.43 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.5 OUTLIER -137.49 160.54 38.85 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.068 -179.853 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' PHE . . . . . 0.421 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 1.2 t80 -44.52 121.88 2.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.843 179.95 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' ASP . . . . . 0.421 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 4.9 t0 78.24 34.92 0.27 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.74 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' GLU . . . . . 0.443 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 3.9 tp10 -107.36 74.15 0.4 Allowed Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.94 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' PRO . . . . . 0.528 ' CD ' ' HB3' ' A' ' 84' ' ' ARG . 61.6 Cg_exo -34.7 119.65 0.14 Allowed 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 122.79 2.327 . . . . 0.0 111.915 179.577 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' LEU . . . . . 0.595 ' CD2' ' CG1' ' A' ' 146' ' ' VAL . 0.0 OUTLIER -116.06 -70.69 0.78 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.746 -179.163 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' VAL . . . . . 0.523 ' CG1' ' CG2' ' A' ' 83' ' ' VAL . 1.4 p -93.06 109.95 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.252 0 CA-C-O 121.152 0.501 . . . . 0.0 111.836 -179.13 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' VAL . . . . . 0.547 ' CG2' ' HG ' ' A' ' 139' ' ' LEU . 4.1 t -92.3 132.79 35.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.638 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.543 ' CG2' ' N ' ' A' ' 134' ' ' THR . 39.5 mt -132.73 140.0 48.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.229 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.493 ' HB2' ' CD ' ' A' ' 136' ' ' LYS . 31.7 tt0 . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.22 -0.895 . . . . 0.0 110.943 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.742 0.306 . . . . 0.0 111.014 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -114.09 74.48 0.87 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.045 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.475 ' O ' HG21 ' A' ' 78' ' ' ILE . 0.6 OUTLIER -168.41 -173.9 2.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.916 179.976 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.475 HG21 ' O ' ' A' ' 77' ' ' GLU . 0.1 OUTLIER 70.07 11.42 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 121.136 0.493 . . . . 0.0 111.036 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 3.4 m -53.43 121.61 8.01 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.841 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -51.62 -79.06 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.456 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.578 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 36.6 t60 -175.9 77.66 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.767 0.318 . . . . 0.0 110.888 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.566 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 0.1 OUTLIER -84.26 178.9 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 120.914 0.388 . . . . 0.0 111.08 179.868 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.528 ' CG2' HG11 ' A' ' 153' ' ' VAL . 25.2 t -130.42 37.98 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.903 179.686 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.505 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 10.9 ptt-85 -34.07 119.01 0.39 Allowed 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.906 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.477 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 3.7 t -34.86 104.46 0.25 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.984 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -47.2 -22.35 2.3 Favored 'Trans proline' 0 N--CA 1.465 -0.192 0 C-N-CA 122.678 2.252 . . . . 0.0 112.093 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.452 ' SD ' ' HB3' ' A' ' 120' ' ' ALA . 0.0 OUTLIER -151.41 -168.93 3.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.545 179.805 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.458 ' O ' HG11 ' A' ' 88' ' ' VAL . 67.5 t -77.76 56.91 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.04 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.407 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -103.55 -153.33 23.62 Favored Glycine 0 C--N 1.332 0.319 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.438 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.572 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 17.8 m -130.68 145.17 51.86 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.901 0.382 . . . . 0.0 111.221 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.656 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 36.0 t80 -91.91 145.86 24.21 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.249 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.591 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 10.2 m-85 -146.65 154.29 41.29 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.003 0.43 . . . . 0.0 111.286 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.437 ' O ' ' HA ' ' A' ' 101' ' ' ALA . 6.7 ptt85 -144.65 25.14 1.5 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.609 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.457 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 0.9 OUTLIER -151.17 100.04 3.03 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.905 179.909 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -68.95 -32.46 22.02 Favored 'Trans proline' 0 C--O 1.231 0.133 0 C-N-CA 122.76 2.307 . . . . 0.0 112.213 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.462 ' CB ' ' HB1' ' A' ' 99' ' ' ALA . 0.4 OUTLIER -123.1 141.18 35.16 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.822 179.86 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -52.51 106.61 0.15 Allowed 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.732 2.288 . . . . 0.0 112.401 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 43.5 t0 71.24 34.7 1.72 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.043 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.462 ' HB1' ' CB ' ' A' ' 96' ' ' SER . . . -86.93 -154.94 0.25 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.976 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . 0.413 ' HA ' ' HD2' ' A' ' 100' ' ' LYS . 16.5 mmmt -94.83 23.52 5.43 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.832 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.457 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 56.86 167.08 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.019 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.531 ' O ' ' CD1' ' A' ' 103' ' ' ILE . 0.1 OUTLIER -81.44 -51.68 8.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.677 179.868 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.531 ' CD1' ' O ' ' A' ' 102' ' ' PHE . 0.4 OUTLIER -152.59 148.25 14.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.023 179.759 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -143.39 149.17 37.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.838 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.412 ' N ' HG13 ' A' ' 135' ' ' VAL . 16.7 t -44.59 123.37 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.053 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 123.98 -33.59 3.83 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.367 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.411 ' HA ' ' OE1' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -74.87 142.41 44.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.829 0.347 . . . . 0.0 110.748 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -103.58 101.61 11.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.067 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.535 ' CG2' ' N ' ' A' ' 110' ' ' ASN . 2.3 p -66.23 164.39 2.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.775 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.535 ' N ' ' CG2' ' A' ' 109' ' ' VAL . 3.2 m120 -155.99 133.31 10.8 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-O 120.882 0.372 . . . . 0.0 110.376 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.47 ' C ' ' O ' ' A' ' 110' ' ' ASN . 2.4 t -26.16 123.41 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.518 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 85.92 21.5 52.69 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.216 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.464 ' HB2' ' O ' ' A' ' 110' ' ' ASN . 26.8 t0 -119.49 102.78 8.9 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.823 0.344 . . . . 0.0 110.832 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.463 HG22 ' HB2' ' A' ' 126' ' ' GLN . 1.4 m -41.28 132.16 2.64 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.912 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.524 ' O ' ' CG1' ' A' ' 103' ' ' ILE . 56.4 mt -96.5 -86.25 0.32 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.829 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -131.94 -175.59 3.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.04 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.515 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.1 OUTLIER -104.11 127.02 58.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.95 179.942 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.523 ' O ' ' N ' ' A' ' 120' ' ' ALA . 58.8 t -108.31 60.25 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.942 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.472 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.3 OUTLIER -43.05 88.56 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.247 -179.888 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.545 ' O ' ' CB ' ' A' ' 121' ' ' MET . . . -92.65 109.55 20.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.718 179.735 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.557 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.8 OUTLIER 90.18 -29.59 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.763 -179.683 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.557 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 150.04 -15.95 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.88 179.622 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.472 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.4 OUTLIER -101.08 134.54 43.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.049 -179.662 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.515 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -55.25 145.34 21.89 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.125 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.469 ' HB2' ' O ' ' A' ' 118' ' ' VAL . 1.0 OUTLIER -134.4 65.95 1.55 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.571 179.797 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.463 ' HB2' HG22 ' A' ' 114' ' ' THR . 4.8 pm0 -38.85 145.1 0.1 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.049 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.47 ' O ' ' N ' ' A' ' 115' ' ' LEU . 29.2 mm -117.18 130.62 71.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.986 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -105.56 128.11 53.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.079 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.521 ' HB1' ' CG2' ' A' ' 109' ' ' VAL . . . -44.32 147.24 0.57 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.922 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -114.06 -15.41 12.28 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.453 ' HG2' ' O ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -163.22 36.86 0.1 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.086 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.468 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.6 t 55.92 -174.9 0.05 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.582 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.513 ' N ' HG11 ' A' ' 109' ' ' VAL . . . 149.71 -178.88 26.92 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.604 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.535 ' HB ' ' CG ' ' A' ' 156' ' ' GLU . 26.7 m -136.27 117.38 14.4 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.611 0.243 . . . . 0.0 111.17 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.515 HG11 ' N ' ' A' ' 136' ' ' LYS . 97.7 t -49.92 140.45 3.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.476 179.452 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.515 ' N ' HG11 ' A' ' 135' ' ' VAL . 27.7 mmmt -125.02 -19.65 5.14 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.576 -0.284 . . . . 0.0 111.376 -179.461 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.447 ' O ' HG21 ' A' ' 154' ' ' VAL . . . 168.51 159.96 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.888 0.375 . . . . 0.0 111.584 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.656 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -110.72 83.62 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.815 179.83 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.53 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 4.7 mt -44.27 -34.87 2.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.081 0.467 . . . . 0.0 110.336 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.537 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 52.1 t -96.54 160.86 2.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.626 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.51 ' HB2' ' CG ' ' A' ' 144' ' ' GLN . 3.0 mm-40 -58.75 -149.54 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.492 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -103.43 -63.61 1.16 Allowed 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.695 179.393 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.591 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -124.88 97.37 0.53 Allowed Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.632 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.51 ' CG ' ' HB2' ' A' ' 141' ' ' GLU . 0.0 OUTLIER -166.53 156.3 10.41 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.954 0.407 . . . . 0.0 110.998 179.839 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.468 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 35.4 Cg_exo -59.86 160.15 22.66 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.827 2.351 . . . . 0.0 112.277 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.496 HG13 ' CG ' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -152.66 176.19 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.06 179.878 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.48 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 3.8 tt0 -126.71 145.11 50.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.996 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.541 ' CE2' ' OD1' ' A' ' 149' ' ' ASP . 16.9 t80 -34.96 139.4 0.09 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.91 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.541 ' OD1' ' CE2' ' A' ' 148' ' ' PHE . 1.6 m-20 68.6 27.45 6.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.788 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.496 ' CG ' HG13 ' A' ' 146' ' ' VAL . 7.0 tp10 -105.38 74.63 0.28 Allowed Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.897 179.864 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.505 ' CD ' ' HB3' ' A' ' 84' ' ' ARG . 64.3 Cg_exo -35.84 131.99 0.3 Allowed 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 122.924 2.416 . . . . 0.0 112.086 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.537 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -123.61 -58.91 1.57 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.355 -179.345 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.528 HG11 ' CG2' ' A' ' 83' ' ' VAL . 1.6 p -108.75 111.82 37.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.066 -179.581 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.53 ' CG2' ' HG ' ' A' ' 139' ' ' LEU . 2.5 t -88.27 136.88 22.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.23 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.528 HG22 ' N ' ' A' ' 134' ' ' THR . 9.0 mt -134.56 138.42 49.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.019 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.535 ' CG ' ' HB ' ' A' ' 134' ' ' THR . 0.9 OUTLIER . . . . . 0 C--O 1.249 1.044 0 CA-C-O 118.172 -0.918 . . . . 0.0 110.904 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.442 ' O ' ' O ' ' A' ' 76' ' ' ALA . . . . . . . . 0 N--CA 1.457 -0.116 0 CA-C-O 120.828 0.347 . . . . 0.0 111.106 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.442 ' O ' ' O ' ' A' ' 75' ' ' ALA . . . 57.63 149.83 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.027 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -63.6 116.07 5.31 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.86 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.471 ' O ' ' HB3' ' A' ' 79' ' ' SER . 0.1 OUTLIER -103.53 -11.94 9.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.141 -179.991 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.471 ' HB3' ' O ' ' A' ' 78' ' ' ILE . 1.6 p 173.9 -152.07 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.474 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.441 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -164.77 -140.95 2.99 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.568 179.77 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.463 ' ND1' ' HD3' ' A' ' 131' ' ' LYS . 18.2 t60 174.38 82.29 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.78 0.324 . . . . 0.0 110.877 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.467 HG12 ' CG1' ' A' ' 154' ' ' VAL . 4.6 mt -115.58 151.7 17.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.117 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.591 ' CG1' ' CG1' ' A' ' 153' ' ' VAL . 3.6 p -109.85 44.24 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.026 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.471 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -33.51 131.48 0.23 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.092 -179.943 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.502 ' N ' HD13 ' A' ' 152' ' ' LEU . 4.4 p -35.83 97.51 0.13 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.873 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 14.2 Cg_endo -57.41 -14.95 17.66 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.608 2.205 . . . . 0.0 111.87 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -151.31 164.96 35.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.47 179.718 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.41 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 1.7 p -71.01 77.9 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.975 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -127.65 -128.58 3.13 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.545 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.523 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 8.3 m -147.44 134.49 20.36 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.773 0.32 . . . . 0.0 110.924 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.639 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 1.7 t80 -95.69 144.76 25.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.781 179.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.586 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 12.8 m-85 -141.04 160.07 40.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.061 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.508 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 0.8 OUTLIER -142.22 24.8 1.94 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.689 179.885 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.4 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 82.5 p -132.29 101.98 14.5 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.799 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.546 ' HB3' ' CE1' ' A' ' 102' ' ' PHE . 41.1 Cg_endo -67.37 -43.44 5.98 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.828 2.352 . . . . 0.0 112.403 -179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -129.95 160.45 65.09 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.06 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.449 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 55.9 Cg_endo -70.73 106.98 1.94 Allowed 'Trans proline' 0 N--CA 1.464 -0.208 0 C-N-CA 122.72 2.28 . . . . 0.0 112.319 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.449 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 18.7 t70 80.24 43.58 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.918 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -109.04 -160.39 0.72 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.029 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 1.1 mtpp -93.65 23.02 4.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.844 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 64.34 176.83 0.18 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.013 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.569 ' CE2' HG13 ' A' ' 117' ' ' ILE . 0.2 OUTLIER -85.69 -42.14 14.53 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.714 179.942 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.532 ' CD1' HG23 ' A' ' 153' ' ' VAL . 1.1 pp -172.68 145.78 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.959 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.42 ' O ' ' HB2' ' A' ' 107' ' ' GLN . 5.9 pt-20 -149.99 167.69 26.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.906 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.52 ' N ' HG13 ' A' ' 135' ' ' VAL . 89.9 t -45.56 128.02 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.104 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 100.42 -13.74 59.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.508 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.42 ' HB2' ' O ' ' A' ' 104' ' ' GLU . 0.0 OUTLIER -72.93 114.98 11.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.853 0.358 . . . . 0.0 110.935 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.445 ' O ' ' ND2' ' A' ' 110' ' ' ASN . 17.6 mttt -81.95 83.57 7.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.925 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.462 HG21 ' O ' ' A' ' 133' ' ' GLY . 3.0 m -68.04 165.09 2.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.038 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.464 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 2.6 m-80 -157.74 130.39 7.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.101 0.477 . . . . 0.0 110.789 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.459 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 0.0 OUTLIER -33.87 112.37 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.536 -0.757 . . . . 0.0 111.174 -179.984 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 110.39 13.0 15.87 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.844 -0.694 . . . . 0.0 112.385 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.476 ' O ' ' N ' ' A' ' 115' ' ' LEU . 17.3 t0 -122.58 103.04 8.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.753 0.311 . . . . 0.0 110.724 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.432 ' C ' ' O ' ' A' ' 113' ' ' ASP . 2.0 m -34.13 93.29 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.113 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.476 ' N ' ' O ' ' A' ' 113' ' ' ASP . 8.3 mt -50.05 -76.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.699 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.439 ' HA ' ' CG ' ' A' ' 102' ' ' PHE . 14.1 p -146.9 -155.66 0.64 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.653 179.76 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.569 HG13 ' CE2' ' A' ' 102' ' ' PHE . 2.3 mt -136.71 152.86 29.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.691 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.513 ' O ' ' N ' ' A' ' 120' ' ' ALA . 92.3 t -139.59 88.5 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.205 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.576 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -51.16 85.8 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.916 179.99 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 118' ' ' VAL . . . -104.4 140.2 38.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.517 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 50.64 22.13 1.03 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.577 -179.726 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.535 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 86.17 36.41 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.859 -179.803 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.468 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 32.4 mmm -151.33 129.27 11.72 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.076 179.752 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.522 ' CG ' HG23 ' A' ' 117' ' ' ILE . 33.0 mtt -67.13 93.39 0.29 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.945 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -70.7 76.86 0.6 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.889 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.479 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 17.3 pt20 -55.39 108.67 0.45 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.859 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 12.8 mm -74.53 151.41 6.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.053 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -123.51 123.23 40.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.91 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.459 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -41.0 124.95 2.29 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.89 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -113.26 15.0 19.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.917 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.463 ' HD3' ' ND1' ' A' ' 81' ' ' HIS . 2.0 tmtt? 176.35 105.32 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.864 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.464 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 2.4 t -37.06 114.59 0.33 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.622 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.462 ' O ' HG21 ' A' ' 109' ' ' VAL . . . -147.31 -173.49 18.5 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.732 -179.758 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.419 ' O ' ' C ' ' A' ' 135' ' ' VAL . 19.7 m -128.73 108.55 10.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.662 0.268 . . . . 0.0 111.251 -179.685 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.52 HG13 ' N ' ' A' ' 105' ' ' VAL . 69.9 t -39.29 144.81 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 179.224 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.505 ' O ' ' CB ' ' A' ' 137' ' ' ALA . 38.4 mtpt -121.45 -20.58 6.56 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.666 0.269 . . . . 0.0 111.117 -179.583 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.505 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 160.81 165.29 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.382 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.639 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -107.93 81.8 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.624 179.595 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.528 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 2.4 mt -41.55 -29.07 0.15 Allowed 'General case' 0 CA--C 1.52 -0.211 0 CA-C-O 121.064 0.459 . . . . 0.0 110.467 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.526 HG22 ' CD2' ' A' ' 152' ' ' LEU . 54.8 t -102.85 137.36 31.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.771 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.434 ' O ' ' C ' ' A' ' 142' ' ' SER . 5.9 mt-10 -66.73 94.11 0.29 Allowed 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.349 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.508 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 77.4 p -34.95 137.44 0.13 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.816 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.586 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 84.02 35.82 14.6 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.529 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.443 ' HB2' ' HD2' ' A' ' 145' ' ' PRO . 0.6 OUTLIER -155.33 159.36 31.78 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.983 0.42 . . . . 0.0 111.125 -179.881 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.463 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 45.5 Cg_endo -68.65 178.37 3.95 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.79 2.327 . . . . 0.0 112.47 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.51 HG12 ' CD2' ' A' ' 152' ' ' LEU . 0.0 OUTLIER -157.86 -173.82 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.066 -179.944 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.47 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 1.8 tt0 -140.59 148.43 40.93 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.982 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.43 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 66.7 t80 -37.66 122.62 0.97 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.868 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.43 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 7.1 t70 79.81 35.54 0.15 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.894 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.47 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 1.8 mt-10 -112.64 74.48 1.64 Allowed Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.845 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 84' ' ' ARG . 52.6 Cg_exo -32.95 120.45 0.1 Allowed 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 122.926 2.417 . . . . 0.0 111.834 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.562 ' CB ' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -109.62 -60.69 1.74 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.979 -179.102 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.591 ' CG1' ' CG1' ' A' ' 83' ' ' VAL . 2.3 p -111.96 110.35 31.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.066 0.46 . . . . 0.0 111.531 -179.275 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.528 ' CG2' ' HG ' ' A' ' 139' ' ' LEU . 4.9 t -92.2 145.49 7.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.354 179.811 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.514 ' CG1' ' HA ' ' A' ' 135' ' ' VAL . 35.8 mt -142.7 138.4 28.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.063 179.909 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.491 ' N ' HG21 ' A' ' 155' ' ' ILE . 2.2 tm-20 . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.217 -0.897 . . . . 0.0 110.914 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.069 0 CA-C-O 120.823 0.344 . . . . 0.0 111.026 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . 70.55 127.14 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.133 179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 46.34 61.46 2.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.984 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 2.9 tp -81.63 -0.78 4.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.306 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -42.28 133.79 3.07 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.961 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.466 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -75.52 -142.0 0.98 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.487 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.525 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 22.2 t60 167.69 86.34 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.784 0.326 . . . . 0.0 110.672 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.523 ' CD1' HG12 ' A' ' 154' ' ' VAL . 0.3 OUTLIER -85.07 164.23 2.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 121.05 0.453 . . . . 0.0 111.101 179.962 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.461 ' O ' HD11 ' A' ' 152' ' ' LEU . 4.3 t -120.01 49.35 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.295 -179.828 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.506 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 5.2 ptt180 -48.41 136.04 13.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.892 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.518 ' N ' HD13 ' A' ' 152' ' ' LEU . 24.1 p -45.19 111.91 1.43 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.798 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.407 ' HG2' ' SD ' ' A' ' 87' ' ' MET . 24.7 Cg_endo -61.51 -10.21 15.66 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.652 2.235 . . . . 0.0 112.139 179.751 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.407 ' SD ' ' HG2' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -160.3 -170.46 2.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.687 179.902 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 60.2 t -86.62 84.18 2.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.071 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.408 ' O ' ' HA ' ' A' ' 145' ' ' PRO . . . -135.27 -138.97 3.96 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.699 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.581 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 62.0 m -141.33 141.2 33.88 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.85 0.357 . . . . 0.0 111.036 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.602 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 18.2 t80 -86.64 144.73 27.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.749 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.581 ' CZ ' HG23 ' A' ' 90' ' ' THR . 16.0 m-85 -146.49 159.09 43.86 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.856 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.482 ' O ' ' CB ' ' A' ' 101' ' ' ALA . 1.6 ptt85 -149.3 21.28 0.95 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.85 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.443 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 33.5 p -149.75 107.69 3.28 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.839 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.43 ' HG2' ' CB ' ' A' ' 99' ' ' ALA . 58.9 Cg_endo -72.07 -15.73 28.97 Favored 'Trans proline' 0 N--CA 1.465 -0.199 0 C-N-CA 122.776 2.318 . . . . 0.0 112.369 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.36 149.13 6.28 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.999 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_exo -51.32 -25.82 19.13 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.802 2.335 . . . . 0.0 112.282 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -125.68 51.2 1.75 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.789 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.43 ' CB ' ' HG2' ' A' ' 95' ' ' PRO . . . -114.34 -162.39 0.81 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.28 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . 0.46 ' O ' ' O ' ' A' ' 101' ' ' ALA . 2.0 ptmt -115.16 24.2 11.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.881 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.482 ' CB ' ' O ' ' A' ' 93' ' ' ARG . . . 50.13 172.35 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.14 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.586 ' CE2' HG12 ' A' ' 117' ' ' ILE . 11.6 m-30 -98.56 -45.42 6.09 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.84 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.47 HG12 ' O ' ' A' ' 115' ' ' LEU . 2.5 pp -160.14 141.74 4.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.176 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.437 ' HG2' ' HB2' ' A' ' 107' ' ' GLN . 15.2 pt-20 -132.18 171.64 13.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.919 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.45 HG12 ' O ' ' A' ' 105' ' ' VAL . 9.5 p -56.29 114.89 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.207 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 92.52 0.62 69.6 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.614 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.437 ' HB2' ' HG2' ' A' ' 104' ' ' GLU . 4.4 tp-100 -74.57 115.17 13.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.82 0.343 . . . . 0.0 110.845 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.09 129.1 37.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.97 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.421 ' O ' ' CG ' ' A' ' 110' ' ' ASN . 28.5 m -112.19 172.99 2.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.275 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.432 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 4.0 m120 -162.36 130.95 4.13 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-O 121.12 0.486 . . . . 0.0 110.657 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.485 HG13 ' N ' ' A' ' 131' ' ' LYS . 27.3 m -41.46 126.87 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.137 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 113.16 -1.95 25.41 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.534 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -112.21 -148.32 0.43 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.685 0.278 . . . . 0.0 110.616 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.8 134.01 44.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.936 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.47 ' O ' HG12 ' A' ' 103' ' ' ILE . 61.5 mt -87.35 -72.64 0.51 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.809 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -155.74 -174.91 5.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.856 179.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.586 HG12 ' CE2' ' A' ' 102' ' ' PHE . 0.0 OUTLIER -110.31 115.8 50.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.179 -179.879 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.469 ' HA ' ' O ' ' A' ' 90' ' ' THR . 1.7 t -99.27 56.69 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.677 179.671 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.467 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.4 OUTLIER -33.85 93.98 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.224 -179.606 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.482 ' O ' ' HG3' ' A' ' 121' ' ' MET . . . -110.76 138.76 46.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.897 179.751 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.511 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 62.71 13.17 6.18 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.796 -179.95 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.511 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.1 OUTLIER 85.44 53.42 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.866 -179.881 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.467 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.2 OUTLIER -171.11 132.79 0.84 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.988 179.884 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -49.46 125.28 10.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.977 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.446 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 1.7 t-20 -107.92 60.4 0.61 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.719 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.403 ' C ' ' O ' ' A' ' 125' ' ' ASN . 13.6 pt20 -36.58 131.1 0.7 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.877 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 37.2 mm -111.05 118.1 56.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.173 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 14.8 mm-40 -88.32 124.86 34.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.95 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.47 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -44.96 116.08 1.02 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.081 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -101.41 12.72 36.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.797 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.485 ' N ' HG13 ' A' ' 111' ' ' VAL . 0.3 OUTLIER 179.51 122.91 0.06 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.758 -179.954 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.432 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.4 t -56.41 126.75 27.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.71 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.43 ' HA3' ' CG2' ' A' ' 155' ' ' ILE . . . -157.17 -173.38 25.52 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.587 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.529 ' N ' HG22 ' A' ' 155' ' ' ILE . 61.6 m -135.51 108.79 7.79 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.765 0.317 . . . . 0.0 111.066 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.493 ' HA ' ' HA ' ' A' ' 155' ' ' ILE . 94.7 t -46.65 143.89 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.612 179.602 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.532 ' CD ' ' HB ' ' A' ' 154' ' ' VAL . 0.0 OUTLIER -115.03 -35.56 4.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 121.317 0.579 . . . . 0.0 109.729 -179.934 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.5 ' N ' ' HG2' ' A' ' 136' ' ' LYS . . . 177.64 142.41 0.09 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.164 -0.925 . . . . 0.0 111.36 -179.667 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.602 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -88.93 86.88 2.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.249 179.421 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.431 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 75.9 mt -41.62 -28.45 0.14 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.438 -179.653 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.542 HG22 ' CB ' ' A' ' 152' ' ' LEU . 54.5 t -102.07 158.42 4.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.102 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.468 ' O ' ' O ' ' A' ' 140' ' ' VAL . 1.1 mm-40 -59.56 -146.84 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 178.784 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.489 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -101.73 -59.6 1.67 Allowed 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.623 -0.431 . . . . 0.0 110.913 179.404 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.543 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -125.48 102.34 0.66 Allowed Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.64 -179.78 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.494 ' C ' ' CG2' ' A' ' 90' ' ' THR . 0.5 OUTLIER -167.99 136.64 1.96 Allowed Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 120.959 0.409 . . . . 0.0 111.259 179.766 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.467 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 50.5 Cg_exo -53.28 154.06 15.42 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.849 2.366 . . . . 0.0 112.405 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.463 HG11 ' O ' ' A' ' 145' ' ' PRO . 4.5 m -144.87 -156.48 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.999 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.527 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 24.5 mt-10 -149.28 150.86 33.22 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.969 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.446 ' HA ' ' O ' ' A' ' 85' ' ' SER . 37.5 t80 -42.75 141.4 1.08 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.805 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 66.13 29.47 9.85 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.772 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 0.8 OUTLIER -110.06 74.66 0.81 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.897 179.886 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.506 ' HA ' ' HA ' ' A' ' 84' ' ' ARG . 58.4 Cg_exo -32.89 135.56 0.08 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.579 0 C-N-CA 122.898 2.399 . . . . 0.0 111.999 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.542 ' CB ' HG22 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -134.32 -37.69 0.86 Allowed 'General case' 0 N--CA 1.453 -0.282 0 CA-C-O 121.024 0.44 . . . . 0.0 110.657 -179.511 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.571 HG21 ' CE2' ' A' ' 91' ' ' PHE . 2.3 t -128.34 115.64 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.595 -178.743 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.532 ' HB ' ' CD ' ' A' ' 136' ' ' LYS . 1.2 t -97.18 127.07 49.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.017 179.505 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.529 HG22 ' N ' ' A' ' 134' ' ' THR . 7.9 mt -121.88 149.05 25.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.272 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.508 ' N ' HG21 ' A' ' 155' ' ' ILE . 25.4 tt0 . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.217 -0.897 . . . . 0.0 110.947 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.824 0.345 . . . . 0.0 111.116 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -66.82 98.23 0.53 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.186 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.491 ' O ' HG21 ' A' ' 78' ' ' ILE . 52.5 mt-10 -103.52 99.25 9.06 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.83 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.526 ' O ' ' N ' ' A' ' 80' ' ' GLY . 0.3 OUTLIER 67.72 14.23 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.98 -179.96 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.435 ' C ' ' O ' ' A' ' 78' ' ' ILE . 53.1 m -32.22 90.43 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.351 -0.841 . . . . 0.0 111.033 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.526 ' N ' ' O ' ' A' ' 78' ' ' ILE . . . 172.44 -153.29 18.69 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.27 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.52 ' N ' ' O ' ' A' ' 155' ' ' ILE . 27.6 t60 -176.49 77.98 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.808 0.337 . . . . 0.0 111.009 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.526 HG12 ' CG1' ' A' ' 154' ' ' VAL . 18.5 mt -96.36 140.84 16.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.002 0.43 . . . . 0.0 111.07 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.561 ' CG2' ' CG1' ' A' ' 153' ' ' VAL . 1.8 t -91.69 48.7 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.104 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.462 ' O ' ' N ' ' A' ' 86' ' ' PRO . 7.1 ptt-85 -35.49 130.63 0.51 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.843 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.465 ' CB ' HG22 ' A' ' 146' ' ' VAL . 28.4 t -35.45 94.36 0.07 OUTLIER Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.038 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.462 ' N ' ' O ' ' A' ' 84' ' ' ARG . 51.3 Cg_exo -53.98 -24.98 34.25 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.662 2.242 . . . . 0.0 112.04 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.496 ' SD ' ' CB ' ' A' ' 120' ' ' ALA . 14.5 ptp -157.0 176.37 12.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.712 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 69.2 t -71.97 85.88 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.171 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.48 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -137.72 -150.87 5.77 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.572 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.622 ' CG2' ' CZ ' ' A' ' 92' ' ' TYR . 3.0 m -129.09 130.87 47.05 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.913 0.387 . . . . 0.0 111.043 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.659 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 53.2 t80 -76.52 146.87 38.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.562 179.765 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.622 ' CZ ' ' CG2' ' A' ' 90' ' ' THR . 14.7 m-85 -150.45 154.76 38.27 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.921 0.391 . . . . 0.0 110.872 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.465 ' HD3' ' OG ' ' A' ' 142' ' ' SER . 4.1 ptm180 -142.28 34.53 1.5 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.866 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.455 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 18.3 p -149.44 110.6 3.41 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.882 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -67.83 -24.85 39.86 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.697 2.265 . . . . 0.0 112.196 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -141.42 143.84 31.59 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.876 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -50.18 -19.77 4.71 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.701 2.267 . . . . 0.0 112.37 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -143.72 74.19 1.42 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -140.07 -155.57 0.6 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.137 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.68 36.94 2.26 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.812 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.455 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 66.56 -174.05 0.19 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.049 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.518 ' O ' ' CG2' ' A' ' 103' ' ' ILE . 0.1 OUTLIER -104.22 -46.14 4.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.94 179.942 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.518 ' CG2' ' O ' ' A' ' 102' ' ' PHE . 1.9 pp -164.68 131.39 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.123 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 18.0 pt-20 -132.29 170.08 15.56 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.883 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.476 ' HA ' ' CG1' ' A' ' 135' ' ' VAL . 3.6 t -53.13 128.2 12.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.029 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.52 -14.93 50.27 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.357 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -80.35 102.27 9.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.817 0.341 . . . . 0.0 110.901 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.407 ' HA ' ' O ' ' A' ' 133' ' ' GLY . 0.0 OUTLIER -73.37 75.7 1.38 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.974 -179.88 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.449 HG21 ' O ' ' A' ' 133' ' ' GLY . 32.6 m -48.81 174.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.001 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.441 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 18.1 m-80 -162.36 130.31 3.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.008 0.433 . . . . 0.0 110.717 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.457 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 34.0 m -37.94 145.93 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.126 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 92.73 -6.04 76.92 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.421 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -105.63 -146.25 0.39 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.672 0.272 . . . . 0.0 110.573 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.5 HG23 ' CZ ' ' A' ' 102' ' ' PHE . 6.5 m -145.16 116.61 8.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.814 0.34 . . . . 0.0 111.023 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.455 ' O ' HG12 ' A' ' 103' ' ' ILE . 94.8 mt -69.23 -86.53 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.753 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.436 ' SG ' ' CG1' ' A' ' 153' ' ' VAL . 0.6 OUTLIER -135.17 -171.26 2.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.812 179.913 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.523 ' CG2' ' HB3' ' A' ' 124' ' ' MET . 0.1 OUTLIER -110.82 123.26 66.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.073 -180.0 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.426 HG22 HD13 ' A' ' 127' ' ' ILE . 87.3 t -105.99 58.32 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.753 179.662 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.465 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.5 OUTLIER -33.71 101.57 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.307 -179.658 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.518 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -122.99 149.37 44.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.745 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.518 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 5.4 ptm 50.71 21.72 0.97 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.944 0.402 . . . . 0.0 110.611 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.455 ' O ' ' HE3' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 77.56 60.12 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.246 -179.983 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.467 ' HG2' ' O ' ' A' ' 120' ' ' ALA . 2.9 ptt? -175.33 128.68 0.27 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.069 0.461 . . . . 0.0 111.151 179.497 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.523 ' HB3' ' CG2' ' A' ' 117' ' ' ILE . 1.7 mtp -53.29 95.03 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.979 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -82.08 70.93 9.11 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.83 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 84.9 mt-30 -51.89 120.9 5.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.947 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.426 HD13 HG22 ' A' ' 118' ' ' VAL . 41.4 mm -88.39 109.8 20.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.184 -179.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 129' ' ' ALA . 1.4 pt-20 -74.4 124.64 26.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.84 179.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.457 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -36.19 112.29 0.17 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.113 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.0 14.26 32.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.759 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.421 ' N ' HG11 ' A' ' 111' ' ' VAL . 0.3 OUTLIER 169.19 118.85 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.938 -179.979 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.441 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 25.3 p -49.5 129.58 19.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.857 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.449 ' O ' HG21 ' A' ' 109' ' ' VAL . . . -158.28 -178.1 31.99 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.642 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.579 ' N ' ' CG2' ' A' ' 155' ' ' ILE . 23.4 m -129.81 108.7 10.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.58 0.229 . . . . 0.0 111.152 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.476 ' CG1' ' HA ' ' A' ' 105' ' ' VAL . 69.9 t -42.25 142.44 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 110.295 -0.261 . . . . 0.0 110.295 179.504 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.486 ' O ' ' CB ' ' A' ' 137' ' ' ALA . 5.8 mmmt -124.88 -18.66 5.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.677 0.275 . . . . 0.0 111.342 -179.426 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.486 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 165.17 154.22 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.841 0.353 . . . . 0.0 111.448 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.659 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -106.0 78.7 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.79 179.922 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.531 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 22.0 mt -42.14 -29.49 0.24 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.149 0.5 . . . . 0.0 110.385 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.528 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 55.4 t -100.7 161.89 3.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.694 179.73 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.519 ' N ' ' CG1' ' A' ' 140' ' ' VAL . 1.8 mm-40 -58.49 -149.13 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.345 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.481 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 35.8 m -107.67 -63.94 1.26 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.826 0.346 . . . . 0.0 110.893 179.605 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.613 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -123.44 90.47 0.42 Allowed Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.851 -179.783 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.457 ' O ' HG21 ' A' ' 90' ' ' THR . 36.3 mm-40 -156.57 156.34 29.88 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-O 120.908 0.385 . . . . 0.0 110.969 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.458 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 48.6 Cg_endo -69.26 120.98 7.77 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.681 2.254 . . . . 0.0 112.132 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.508 HG13 ' CD2' ' A' ' 152' ' ' LEU . 18.3 m -105.92 -173.83 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.123 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.491 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 6.2 mm-40 -140.7 144.41 35.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.031 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.432 ' HA ' ' O ' ' A' ' 85' ' ' SER . 63.9 t80 -35.7 137.94 0.18 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.051 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 7.9 t70 69.67 27.78 4.63 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.891 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.491 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 1.2 tp10 -108.87 73.79 0.53 Allowed Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.833 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.471 ' O ' HG21 ' A' ' 140' ' ' VAL . 61.4 Cg_exo -34.18 123.2 0.16 Allowed 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.804 2.336 . . . . 0.0 112.042 179.674 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.528 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -120.64 -70.86 0.76 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.699 -179.254 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.561 ' CG1' ' CG2' ' A' ' 83' ' ' VAL . 1.3 p -97.04 106.24 18.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.559 -179.146 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.531 ' CG2' ' HG ' ' A' ' 139' ' ' LEU . 23.4 t -89.33 133.41 31.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.865 179.349 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.579 ' CG2' ' N ' ' A' ' 134' ' ' THR . 82.9 mt -134.38 135.37 54.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.191 -179.799 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.465 ' HB2' ' CD ' ' A' ' 136' ' ' LYS . 0.7 OUTLIER . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.228 -0.891 . . . . 0.0 110.939 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.814 0.34 . . . . 0.0 111.136 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -106.54 -176.79 3.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.062 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -41.25 150.11 0.09 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.897 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.427 ' O ' ' C ' ' A' ' 79' ' ' SER . 0.8 OUTLIER -114.31 21.69 6.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.084 -179.939 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.427 ' C ' ' O ' ' A' ' 78' ' ' ILE . 0.3 OUTLIER 35.69 43.5 0.17 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.96 179.952 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -139.07 -162.35 9.09 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.462 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.565 ' CG ' HG23 ' A' ' 155' ' ' ILE . 11.9 t-80 173.11 83.07 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.827 0.346 . . . . 0.0 110.823 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.533 HG12 ' CG1' ' A' ' 154' ' ' VAL . 1.6 mt -118.17 151.05 20.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.071 0.462 . . . . 0.0 111.31 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.527 ' HB ' ' CG1' ' A' ' 153' ' ' VAL . 20.4 t -95.19 37.69 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.168 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.482 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 20.1 ptt85 -37.2 127.77 0.98 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.711 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.479 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 0.2 OUTLIER -45.33 109.38 0.92 Allowed Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.726 179.96 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -61.61 -13.22 28.59 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.72 2.28 . . . . 0.0 112.126 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.423 ' SD ' ' HB3' ' A' ' 120' ' ' ALA . 1.9 ptp -150.08 -159.58 1.05 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.821 -179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.44 ' O ' HG21 ' A' ' 88' ' ' VAL . 5.2 m -92.25 87.27 2.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.103 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.476 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -141.99 -163.5 9.65 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.468 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.575 HG23 ' CE1' ' A' ' 92' ' ' TYR . 25.8 m -119.98 145.41 46.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.843 0.354 . . . . 0.0 110.881 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.643 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 1.0 OUTLIER -102.08 147.71 26.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.031 -179.839 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.578 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 23.3 m-85 -142.73 167.59 21.72 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.865 179.843 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.465 ' HD3' ' HB3' ' A' ' 142' ' ' SER . 32.1 ptt85 -152.96 21.23 0.58 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.689 179.866 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.477 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 6.5 p -155.24 113.67 2.29 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.753 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.42 ' HG2' ' HB2' ' A' ' 99' ' ' ALA . 49.2 Cg_endo -68.59 -39.15 9.64 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.702 2.268 . . . . 0.0 112.342 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.516 ' CB ' ' HD2' ' A' ' 97' ' ' PRO . 0.2 OUTLIER -135.23 172.49 7.13 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.914 -179.947 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.516 ' HD2' ' CB ' ' A' ' 96' ' ' SER . 51.9 Cg_endo -69.22 -27.61 28.83 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.725 2.283 . . . . 0.0 112.284 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -135.46 39.63 2.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.874 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.506 ' HB1' ' CB ' ' A' ' 96' ' ' SER . . . -95.28 -156.07 0.5 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.108 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . 0.414 ' O ' ' CG ' ' A' ' 100' ' ' LYS . 0.0 OUTLIER -102.81 34.79 2.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.91 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.477 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 45.01 -158.87 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.179 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.565 ' CD2' HG12 ' A' ' 117' ' ' ILE . 0.1 OUTLIER -139.27 40.28 2.09 Favored 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.059 179.816 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.536 ' CB ' ' O ' ' A' ' 102' ' ' PHE . 2.6 mt 87.07 122.04 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.113 -179.806 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.416 ' O ' ' HB ' ' A' ' 135' ' ' VAL . 1.7 pt-20 -131.17 -175.75 3.79 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.905 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.459 HG12 ' O ' ' A' ' 136' ' ' LYS . 46.7 t -53.31 134.06 15.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.079 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 93.22 -26.91 12.9 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.399 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 6.7 tp60 -72.35 131.63 42.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.803 0.335 . . . . 0.0 110.832 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.42 118.91 33.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.963 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.498 ' CG2' HD12 ' A' ' 155' ' ' ILE . 4.4 m -89.97 178.35 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.06 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.432 ' CG ' ' O ' ' A' ' 109' ' ' VAL . 18.4 m120 -164.71 131.27 2.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.068 0.461 . . . . 0.0 110.641 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.463 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 34.7 m -38.65 159.51 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.123 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 79.63 -6.04 59.31 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.499 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -108.88 -147.49 0.41 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.708 0.289 . . . . 0.0 110.651 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 14.4 m -135.93 150.12 49.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.847 0.356 . . . . 0.0 110.854 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.448 ' O ' ' O ' ' A' ' 102' ' ' PHE . 49.4 mt -96.95 -75.58 0.54 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.881 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.461 ' HB3' ' O ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -148.4 -168.31 3.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.803 -179.916 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.565 HG12 ' CD2' ' A' ' 102' ' ' PHE . 0.1 OUTLIER -108.63 120.29 59.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.178 179.926 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.517 ' O ' ' CB ' ' A' ' 125' ' ' ASN . 11.1 t -118.43 73.38 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.03 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.545 ' HG2' ' CE2' ' A' ' 92' ' ' TYR . 0.9 OUTLIER -59.32 119.55 7.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.832 -179.953 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.423 ' HB3' ' SD ' ' A' ' 87' ' ' MET . . . -94.0 -70.26 0.71 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.28 0.562 . . . . 0.0 111.365 -179.834 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.532 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 1.9 ptp -92.53 36.21 1.01 Allowed 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.447 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.538 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 0.4 OUTLIER 88.54 -7.74 0.5 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.87 -179.814 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.474 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 6.2 mtt -107.72 128.07 54.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.956 0.407 . . . . 0.0 110.896 179.68 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.517 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 1.0 OUTLIER -43.83 149.67 0.3 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.148 -179.867 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.517 ' CB ' ' O ' ' A' ' 118' ' ' VAL . 30.1 t-20 -129.58 74.25 1.57 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.572 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 9.9 pt20 -47.06 112.85 0.57 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.051 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.444 HD12 ' O ' ' A' ' 125' ' ' ASN . 23.2 mm -92.8 105.92 17.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.103 179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -70.21 143.2 52.28 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.932 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -66.04 119.22 11.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.123 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -97.8 -10.63 24.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.911 179.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.421 ' O ' ' C ' ' A' ' 132' ' ' SER . 10.0 tttt -161.61 109.47 1.45 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.918 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 131' ' ' LYS . 4.8 p -36.04 141.18 0.1 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.958 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.494 ' O ' ' N ' ' A' ' 109' ' ' VAL . . . -169.45 -165.12 26.31 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.521 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.511 ' N ' HG12 ' A' ' 155' ' ' ILE . 55.9 m -150.97 110.08 3.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.672 0.272 . . . . 0.0 110.938 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.502 ' N ' HG13 ' A' ' 155' ' ' ILE . 61.8 t -41.86 141.34 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.843 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.542 ' CD ' HG13 ' A' ' 154' ' ' VAL . 0.0 OUTLIER -114.51 -35.88 4.77 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 121.456 0.646 . . . . 0.0 109.462 179.934 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.515 ' N ' ' HG2' ' A' ' 136' ' ' LYS . . . -175.44 155.01 1.75 Allowed 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.775 -179.579 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.643 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -103.06 84.35 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.406 179.648 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.525 ' CD1' HG23 ' A' ' 154' ' ' VAL . 0.2 OUTLIER -41.59 -28.81 0.15 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.106 0.479 . . . . 0.0 110.278 -179.872 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.53 HG22 ' CD2' ' A' ' 152' ' ' LEU . 79.7 t -103.38 134.45 44.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.826 179.753 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.449 ' O ' ' C ' ' A' ' 142' ' ' SER . 13.6 mt-10 -67.5 100.77 0.9 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.161 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.465 ' HB3' ' HD3' ' A' ' 93' ' ' ARG . 6.9 p -34.41 134.96 0.18 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.783 -179.524 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.578 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 80.72 39.31 14.31 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.583 -0.817 . . . . 0.0 112.255 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.461 ' O ' HG21 ' A' ' 90' ' ' THR . 0.6 OUTLIER -148.78 139.55 13.6 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 120.977 0.417 . . . . 0.0 111.076 -179.947 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.513 ' N ' HG22 ' A' ' 90' ' ' THR . 31.3 Cg_exo -59.03 158.75 24.14 Favored 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 122.845 2.363 . . . . 0.0 112.389 -179.725 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.477 ' CG1' HG12 ' A' ' 140' ' ' VAL . 19.7 m -147.22 -173.5 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.981 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.455 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.3 OUTLIER -138.06 174.44 10.56 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.933 179.956 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.494 ' CD1' ' HB2' ' A' ' 149' ' ' ASP . 1.3 p90 -55.2 140.31 39.21 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.834 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.494 ' HB2' ' CD1' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 59.41 34.4 22.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.867 0.365 . . . . 0.0 110.902 179.994 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.517 ' OE2' ' CG2' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -109.46 74.68 0.69 Allowed Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.88 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.482 ' HA ' ' HA ' ' A' ' 84' ' ' ARG . 57.2 Cg_exo -33.43 133.93 0.11 Allowed 'Trans proline' 0 N--CA 1.459 -0.553 0 C-N-CA 122.926 2.417 . . . . 0.0 112.104 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.579 ' HB2' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -128.29 -50.7 1.3 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.739 -179.194 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.527 ' CG1' ' HB ' ' A' ' 83' ' ' VAL . 2.3 p -117.93 112.23 37.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.899 0.381 . . . . 0.0 111.541 -179.1 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.542 HG13 ' CD ' ' A' ' 136' ' ' LYS . 0.7 OUTLIER -96.0 129.81 45.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.888 179.523 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.565 HG23 ' CG ' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -113.28 157.58 13.92 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.778 -179.934 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.448 ' N ' ' O ' ' A' ' 134' ' ' THR . 29.1 tt0 . . . . . 0 C--O 1.25 1.101 0 CA-C-O 118.211 -0.9 . . . . 0.0 110.976 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.82 0.343 . . . . 0.0 111.023 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . 40.21 51.64 2.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.11 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -143.74 111.81 6.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.002 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -80.49 -3.14 6.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 121.06 0.457 . . . . 0.0 111.389 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.61 83.94 5.53 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.877 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.438 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . 166.64 -178.34 41.08 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.609 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.524 ' CD2' ' HD2' ' A' ' 131' ' ' LYS . 14.9 t-80 172.78 83.36 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.773 0.32 . . . . 0.0 110.721 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.58 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -97.73 176.46 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.145 179.977 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.589 ' CG1' ' CG1' ' A' ' 153' ' ' VAL . 2.3 p -132.45 28.18 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.811 179.557 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.526 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 6.2 ptt180 -25.97 120.42 0.07 Allowed 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.542 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.468 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 0.2 OUTLIER -38.58 116.25 0.93 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.835 -179.855 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.08 -9.31 25.7 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.634 2.222 . . . . 0.0 111.919 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 13.6 ptm -151.24 -168.96 3.25 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.626 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.431 ' CG2' ' O ' ' A' ' 88' ' ' VAL . 32.3 m -88.81 83.01 2.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.132 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.423 ' C ' HG23 ' A' ' 146' ' ' VAL . . . -126.17 -140.56 5.32 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.612 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.604 ' CG2' ' CZ ' ' A' ' 92' ' ' TYR . 4.9 m -146.73 128.06 14.88 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.008 0.432 . . . . 0.0 111.274 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.669 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 30.2 t80 -75.5 139.1 41.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.125 179.36 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.604 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 12.7 m-85 -142.67 156.35 45.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.927 0.394 . . . . 0.0 111.213 -179.908 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 23.8 ptt85 -142.62 40.85 1.57 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.805 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -146.57 95.23 4.63 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.858 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.425 ' HD3' ' N ' ' A' ' 102' ' ' PHE . 49.7 Cg_endo -69.15 -38.84 8.53 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.817 2.345 . . . . 0.0 112.407 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.512 ' HB2' ' CB ' ' A' ' 99' ' ' ALA . 70.4 m -129.53 160.85 62.41 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.963 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.4 101.06 0.06 OUTLIER 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.717 2.278 . . . . 0.0 112.285 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 63.54 36.39 11.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.861 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.512 ' CB ' ' HB2' ' A' ' 96' ' ' SER . . . -76.56 -158.02 0.09 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.157 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . 0.416 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 0.6 OUTLIER -89.35 23.34 2.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.99 179.972 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.416 ' HB1' ' O ' ' A' ' 100' ' ' LYS . . . 67.85 159.65 0.16 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.185 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.571 ' CZ ' HG23 ' A' ' 114' ' ' THR . 0.0 OUTLIER -84.65 -46.01 11.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.81 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.465 ' HA ' ' HG3' ' A' ' 107' ' ' GLN . 1.1 pp -163.63 112.03 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.039 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.454 ' O ' ' HB2' ' A' ' 107' ' ' GLN . 10.2 pt-20 -123.72 172.35 8.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.909 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 21.3 t -51.97 119.06 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.179 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 107.44 -4.86 35.15 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.522 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.465 ' HG3' ' HA ' ' A' ' 103' ' ' ILE . 1.6 mm-40 -73.8 129.64 38.33 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.771 0.319 . . . . 0.0 110.987 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.423 ' O ' ' ND2' ' A' ' 110' ' ' ASN . 6.0 mttt -98.8 72.11 1.94 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.885 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.522 HG13 ' CD2' ' A' ' 115' ' ' LEU . 6.0 m -48.86 167.03 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.023 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.487 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 9.6 m-80 -159.87 129.87 5.45 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.083 0.468 . . . . 0.0 110.82 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.495 ' O ' ' CG2' ' A' ' 111' ' ' VAL . 5.0 m -34.99 115.37 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.056 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 99.96 12.69 39.23 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.344 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.423 ' O ' ' C ' ' A' ' 114' ' ' THR . 1.8 t70 -123.7 103.1 8.19 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.824 0.345 . . . . 0.0 110.811 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.571 HG23 ' CZ ' ' A' ' 102' ' ' PHE . 3.2 m -35.06 132.91 0.33 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.066 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.522 ' CD2' HG13 ' A' ' 109' ' ' VAL . 67.1 mt -93.68 -81.63 0.36 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.843 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -133.16 -172.89 3.05 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.701 179.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.512 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.2 OUTLIER -110.79 123.71 66.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.136 179.975 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.523 ' O ' ' N ' ' A' ' 120' ' ' ALA . 23.6 t -103.42 55.81 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.725 179.773 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.462 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.1 OUTLIER -31.38 89.0 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.721 -179.689 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 118' ' ' VAL . . . -88.82 134.24 34.0 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.141 179.25 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.554 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 2.8 ptt? 50.37 22.89 1.09 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.242 -179.337 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.554 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 96.21 -10.18 0.09 Allowed 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.544 179.698 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.515 ' O ' ' N ' ' A' ' 120' ' ' ALA . 12.5 ptm -99.18 131.69 45.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.157 0.503 . . . . 0.0 111.35 -179.766 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.512 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 1.4 ptt? -55.16 130.5 42.27 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.914 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.468 ' HB2' ' O ' ' A' ' 118' ' ' VAL . 0.7 OUTLIER -121.92 65.34 0.91 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.955 -179.967 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.524 ' HB2' ' CG2' ' A' ' 114' ' ' THR . 2.6 pm0 -39.2 144.36 0.14 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.918 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.44 HG12 HG22 ' A' ' 118' ' ' VAL . 31.8 mm -113.1 123.03 68.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.079 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 129' ' ' ALA . 5.5 mt-10 -85.23 118.39 24.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.843 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.428 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.94 127.81 0.7 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.002 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -100.57 -10.81 20.63 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.974 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.524 ' HD2' ' CD2' ' A' ' 81' ' ' HIS . 2.0 tmtt? -168.86 123.22 0.86 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.004 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.487 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.0 OUTLIER -51.26 112.39 0.73 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.396 179.729 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.527 ' HA3' ' CG2' ' A' ' 155' ' ' ILE . . . -145.28 -179.83 21.86 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.713 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.498 ' N ' HG21 ' A' ' 155' ' ' ILE . 29.9 m -122.4 112.32 17.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.693 0.282 . . . . 0.0 111.396 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.515 HG11 ' N ' ' A' ' 136' ' ' LYS . 85.7 t -46.56 144.34 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.524 179.293 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.537 ' CD ' ' HB ' ' A' ' 154' ' ' VAL . 0.0 OUTLIER -114.52 -35.75 4.81 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-O 121.496 0.665 . . . . 0.0 109.682 -179.809 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.505 ' N ' ' HG2' ' A' ' 136' ' ' LYS . . . 179.62 172.71 0.94 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.951 -179.672 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.669 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.6 OUTLIER -119.09 82.9 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.059 179.843 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 3.8 mt -41.09 -29.53 0.12 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.2 0.524 . . . . 0.0 110.073 179.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.54 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 54.5 t -100.08 158.9 3.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.555 179.538 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.477 ' N ' ' CG1' ' A' ' 140' ' ' VAL . 2.8 mt-10 -58.81 -150.43 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.067 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.487 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -102.49 -60.75 1.49 Allowed 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 120.81 -0.356 . . . . 0.0 110.822 179.623 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.604 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -127.07 89.09 0.34 Allowed Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.793 -179.779 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.453 ' O ' HG21 ' A' ' 90' ' ' THR . 25.2 mm-40 -153.09 155.61 32.08 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 120.997 0.427 . . . . 0.0 110.979 179.77 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.475 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 39.6 Cg_exo -56.81 153.29 37.77 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.855 2.37 . . . . 0.0 112.391 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.45 HG22 ' OG ' ' A' ' 85' ' ' SER . 31.1 m -141.45 -173.08 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.967 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.471 ' O ' ' HG2' ' A' ' 150' ' ' GLU . 1.0 OUTLIER -146.82 144.58 29.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.896 0.379 . . . . 0.0 111.16 -179.94 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.468 ' HA ' ' O ' ' A' ' 85' ' ' SER . 5.5 p90 -35.62 124.35 0.67 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.953 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.442 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 79.46 33.22 0.22 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.824 -179.945 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.471 ' HG2' ' O ' ' A' ' 147' ' ' GLU . 13.0 mm-40 -109.26 75.23 0.69 Allowed Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.867 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.526 ' CD ' ' HB3' ' A' ' 84' ' ' ARG . 75.1 Cg_exo -37.38 129.15 0.68 Allowed 'Trans proline' 0 N--CA 1.461 -0.413 0 C-N-CA 122.774 2.316 . . . . 0.0 111.925 179.594 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.54 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -123.27 -61.1 1.44 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.635 -179.3 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.589 ' CG1' ' CG1' ' A' ' 83' ' ' VAL . 2.1 p -108.26 120.91 60.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 121.172 0.511 . . . . 0.0 111.292 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.537 ' HB ' ' CD ' ' A' ' 136' ' ' LYS . 0.2 OUTLIER -100.55 137.92 26.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.219 -179.98 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.527 ' CG2' ' HA3' ' A' ' 133' ' ' GLY . 45.6 mt -123.43 147.16 27.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.229 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.516 ' N ' HG21 ' A' ' 155' ' ' ILE . 2.1 tt0 . . . . . 0 C--O 1.248 1.018 0 CA-C-O 118.323 -0.846 . . . . 0.0 110.922 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.826 0.346 . . . . 0.0 111.154 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . 67.8 129.16 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.038 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -62.84 158.95 17.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.926 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.429 ' O ' ' C ' ' A' ' 79' ' ' SER . 2.0 mt -112.85 21.05 6.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.143 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.429 ' C ' ' O ' ' A' ' 78' ' ' ILE . 3.2 p 35.72 71.18 0.13 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.918 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -127.68 150.45 18.26 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.647 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.504 ' O ' ' ND1' ' A' ' 81' ' ' HIS . 23.7 t-80 -170.03 76.15 0.08 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.847 0.355 . . . . 0.0 110.802 179.838 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.479 HG12 ' HA ' ' A' ' 154' ' ' VAL . 5.1 mt -101.86 155.07 4.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.066 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.52 ' CG2' HG11 ' A' ' 153' ' ' VAL . 4.0 t -102.42 51.2 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.969 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.533 ' CD ' ' O ' ' A' ' 84' ' ' ARG . 0.5 OUTLIER -35.48 133.19 0.38 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.875 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.491 ' N ' HD13 ' A' ' 152' ' ' LEU . 11.2 p -39.41 98.6 0.17 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.757 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.415 ' HD3' ' O ' ' A' ' 84' ' ' ARG . 12.2 Cg_endo -56.3 -15.44 14.84 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.506 2.137 . . . . 0.0 111.91 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.457 ' SD ' ' HB3' ' A' ' 120' ' ' ALA . 5.2 ptp -160.29 172.38 17.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.534 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 27.2 m -67.32 68.33 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.037 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 87' ' ' MET . . . -119.04 -155.68 9.88 Favored Glycine 0 C--N 1.331 0.289 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.648 -179.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.579 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 20.2 m -131.5 124.85 31.0 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.908 0.385 . . . . 0.0 111.07 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.639 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 72.4 t80 -62.61 141.95 58.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.52 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.579 ' CZ ' HG23 ' A' ' 90' ' ' THR . 5.6 m-30 -148.37 127.73 13.06 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.964 0.412 . . . . 0.0 110.919 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.461 ' HA ' ' HB2' ' A' ' 102' ' ' PHE . 0.1 OUTLIER -124.27 25.52 7.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.825 179.857 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 2.7 p -149.21 108.16 3.4 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.882 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.34 -44.1 1.85 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.82 2.346 . . . . 0.0 112.309 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.461 ' OG ' ' HD2' ' A' ' 97' ' ' PRO . 0.1 OUTLIER -110.64 166.93 9.83 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.928 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.461 ' HD2' ' OG ' ' A' ' 96' ' ' SER . 51.1 Cg_endo -69.42 -25.56 30.05 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.737 2.291 . . . . 0.0 112.224 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -136.17 26.86 3.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.817 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -71.49 -163.92 0.1 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.121 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -103.83 20.75 17.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.921 179.854 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 71.47 162.9 0.26 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.274 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.54 ' CE2' HG13 ' A' ' 117' ' ' ILE . 0.1 OUTLIER -84.93 -37.42 20.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.765 179.922 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.457 HG22 ' O ' ' A' ' 102' ' ' PHE . 1.2 pp -161.29 158.56 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.019 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.417 ' O ' ' HB3' ' A' ' 107' ' ' GLN . 0.2 OUTLIER -140.42 151.23 44.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.906 -179.989 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.528 ' HA ' ' CG1' ' A' ' 135' ' ' VAL . 4.8 p -54.08 127.94 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.199 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 93.83 -9.77 72.9 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.521 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.516 ' O ' ' N ' ' A' ' 109' ' ' VAL . 2.7 tp-100 -68.93 99.83 1.11 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.855 0.36 . . . . 0.0 110.801 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.423 ' HA ' ' HA ' ' A' ' 134' ' ' THR . 0.0 OUTLIER -59.26 75.62 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.952 -179.839 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.516 ' N ' ' O ' ' A' ' 107' ' ' GLN . 6.6 m -53.28 172.0 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.008 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.471 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 3.9 p-10 -163.06 133.03 4.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.058 0.456 . . . . 0.0 110.947 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.454 ' O ' HG21 ' A' ' 111' ' ' VAL . 29.3 m -38.25 130.18 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.131 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 101.95 2.01 52.02 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.417 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.434 ' O ' ' N ' ' A' ' 115' ' ' LEU . 4.2 t70 -117.93 99.22 6.77 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.777 0.322 . . . . 0.0 110.859 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.453 ' HA ' ' HA ' ' A' ' 128' ' ' GLU . 6.5 m -35.41 96.11 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.004 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.464 ' N ' ' O ' ' A' ' 127' ' ' ILE . 7.1 mt -46.4 -89.98 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.75 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.467 ' O ' ' N ' ' A' ' 127' ' ' ILE . 0.5 OUTLIER -136.86 -168.91 2.36 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.687 -179.992 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.54 HG13 ' CE2' ' A' ' 102' ' ' PHE . 2.2 mt -125.83 153.83 34.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.885 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.462 ' HA ' ' O ' ' A' ' 90' ' ' THR . 27.5 t -142.61 101.64 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.872 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.544 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.5 OUTLIER -62.7 89.66 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.201 -179.799 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.457 ' HB3' ' SD ' ' A' ' 87' ' ' MET . . . -69.28 -136.07 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.649 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.466 ' O ' ' HB2' ' A' ' 122' ' ' LYS . 0.0 OUTLIER -34.14 -39.84 0.08 Allowed 'General case' 0 CA--C 1.519 -0.224 0 CA-C-O 121.444 0.64 . . . . 0.0 110.173 179.608 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.519 ' CG ' ' O ' ' A' ' 122' ' ' LYS . 0.1 OUTLIER 169.27 38.21 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.873 179.482 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 36.8 mmm -146.93 131.87 18.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.045 -179.422 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.531 ' HB2' ' CD1' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -64.47 101.44 0.45 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.836 179.994 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.436 ' HB2' ' O ' ' A' ' 118' ' ' VAL . 0.9 OUTLIER -77.07 83.28 3.58 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.877 179.946 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.521 ' CA ' HG12 ' A' ' 117' ' ' ILE . 7.8 pt20 -64.29 103.92 0.69 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.959 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.467 ' N ' ' O ' ' A' ' 116' ' ' CYS . 17.3 mm -75.38 139.09 19.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.04 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.453 ' HA ' ' HA ' ' A' ' 114' ' ' THR . 2.2 mt-10 -110.4 122.05 46.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.923 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.436 ' HB2' ' HA ' ' A' ' 111' ' ' VAL . . . -36.78 114.89 0.33 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.064 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -107.82 17.19 22.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 1.9 ttmt 177.32 113.5 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.9 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 15.6 p -43.51 121.31 2.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.758 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.455 ' O ' HG21 ' A' ' 109' ' ' VAL . . . -152.2 -171.52 19.92 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.599 -179.802 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.506 ' N ' HG22 ' A' ' 155' ' ' ILE . 21.8 m -140.14 107.81 5.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.582 0.229 . . . . 0.0 111.239 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.528 ' CG1' ' HA ' ' A' ' 105' ' ' VAL . 92.5 t -41.79 142.71 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.437 179.459 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.511 ' N ' HG11 ' A' ' 135' ' ' VAL . 30.5 mtpt -124.91 -18.93 5.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.455 -179.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.433 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 169.15 155.38 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.935 0.398 . . . . 0.0 111.622 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.639 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -111.11 77.44 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.61 179.792 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.433 HD13 HG23 ' A' ' 154' ' ' VAL . 9.7 mt -46.25 -24.92 0.53 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.965 -179.734 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.531 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 45.3 t -104.13 144.18 14.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.239 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.47 ' HB2' ' HG2' ' A' ' 144' ' ' GLN . 4.7 mt-10 -62.35 137.62 58.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.069 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.494 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -31.58 -62.33 0.2 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.621 -179.331 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.561 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -125.58 104.21 0.75 Allowed Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.483 -0.865 . . . . 0.0 112.995 -179.483 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.47 ' HG2' ' HB2' ' A' ' 141' ' ' GLU . 0.6 OUTLIER -167.62 156.16 8.72 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-O 120.93 0.395 . . . . 0.0 111.137 179.553 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.465 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 37.8 Cg_endo -66.31 138.38 50.8 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.807 2.338 . . . . 0.0 112.329 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.419 HG21 ' HA ' ' A' ' 90' ' ' THR . 1.5 m -132.14 -174.77 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.089 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.431 ' O ' ' C ' ' A' ' 148' ' ' PHE . 18.5 mt-10 -145.7 144.03 30.13 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.929 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.48 ' HA ' ' O ' ' A' ' 85' ' ' SER . 39.6 t80 -34.5 135.02 0.18 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.947 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 76.3 23.96 1.15 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.709 -179.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.435 ' O ' ' HG3' ' A' ' 150' ' ' GLU . 4.5 tp10 -109.93 74.26 0.76 Allowed Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.788 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.462 ' HB3' HG23 ' A' ' 82' ' ' ILE . 63.3 Cg_exo -33.27 130.57 0.13 Allowed 'Trans proline' 0 N--CA 1.457 -0.635 0 C-N-CA 122.888 2.392 . . . . 0.0 112.116 179.652 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.531 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -121.86 -72.2 0.7 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.555 -179.231 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.52 HG11 ' CG2' ' A' ' 83' ' ' VAL . 1.2 p -96.61 102.92 14.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.226 0.536 . . . . 0.0 111.37 -179.38 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.479 ' HA ' HG12 ' A' ' 82' ' ' ILE . 6.3 t -83.38 138.64 18.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.017 179.675 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.506 HG22 ' N ' ' A' ' 134' ' ' THR . 17.9 mt -136.72 143.2 35.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.352 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.496 ' CB ' ' HD2' ' A' ' 136' ' ' LYS . 29.5 tt0 . . . . . 0 C--O 1.25 1.094 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.881 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.073 0 CA-C-O 120.799 0.333 . . . . 0.0 111.147 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -81.11 151.12 28.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.135 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -132.6 82.35 2.0 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.92 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.465 ' O ' HD12 ' A' ' 78' ' ' ILE . 0.0 OUTLIER -99.71 3.43 10.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.087 0.47 . . . . 0.0 111.292 179.967 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -78.63 84.26 4.75 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.901 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -70.84 -67.13 1.97 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.475 -179.957 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.524 ' N ' ' O ' ' A' ' 155' ' ' ILE . 19.7 t-80 175.85 82.21 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.789 0.328 . . . . 0.0 110.849 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.535 HG12 ' CG1' ' A' ' 154' ' ' VAL . 7.1 mt -98.93 157.27 3.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.087 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.52 ' HB ' ' CG1' ' A' ' 153' ' ' VAL . 1.9 t -113.67 53.91 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.148 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.474 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -41.08 134.6 2.0 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.855 179.938 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.468 ' N ' HD13 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -35.86 109.23 0.4 Allowed Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.855 -179.916 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.426 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 35.4 Cg_endo -64.74 -8.56 18.01 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.744 2.296 . . . . 0.0 112.109 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.502 ' HE1' ' CB ' ' A' ' 120' ' ' ALA . 0.9 OUTLIER -167.85 176.17 6.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.757 179.911 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.504 ' CG2' ' O ' ' A' ' 88' ' ' VAL . 32.6 m -71.42 82.83 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.129 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -142.78 -159.06 7.78 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.581 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.566 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 23.2 m -116.62 142.98 46.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.785 0.326 . . . . 0.0 110.803 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.637 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 2.6 t80 -100.23 140.16 34.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.586 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 19.9 m-85 -138.66 145.9 40.99 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.987 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.535 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 0.0 OUTLIER -125.49 28.24 6.31 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.852 179.846 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.452 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 12.1 p -146.96 115.5 4.36 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.847 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.422 ' HG2' ' CB ' ' A' ' 99' ' ' ALA . 55.5 Cg_endo -69.93 -39.44 6.17 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.685 2.257 . . . . 0.0 112.376 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.522 ' CB ' ' HB1' ' A' ' 99' ' ' ALA . 0.3 OUTLIER -129.16 160.57 63.19 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.952 179.998 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -52.58 -37.14 73.7 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.72 2.28 . . . . 0.0 112.332 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.411 ' CG ' ' O ' ' A' ' 98' ' ' ASP . 34.9 t0 -131.45 32.39 4.2 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.885 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.522 ' HB1' ' CB ' ' A' ' 96' ' ' SER . . . -76.24 -158.27 0.09 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.061 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 6.1 ptmt -104.72 23.6 13.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.917 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.452 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 68.65 166.31 0.26 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.187 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.569 ' CE2' HG13 ' A' ' 117' ' ' ILE . 0.2 OUTLIER -93.78 -34.02 13.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.818 179.915 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.515 ' CG2' ' O ' ' A' ' 102' ' ' PHE . 1.0 OUTLIER -164.84 150.37 2.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.134 179.913 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -155.17 146.89 23.25 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.961 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.518 ' N ' HG13 ' A' ' 135' ' ' VAL . 3.0 t -54.11 116.45 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.148 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 129.5 -36.31 2.4 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.546 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.452 ' OE1' ' HA ' ' A' ' 103' ' ' ILE . 12.7 pt20 -76.38 130.08 37.53 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.842 0.354 . . . . 0.0 110.895 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.422 ' HA ' ' HA ' ' A' ' 134' ' ' THR . 2.6 mtpt -90.23 91.4 8.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.949 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.521 HG13 ' CD2' ' A' ' 115' ' ' LEU . 15.4 m -51.5 173.44 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.074 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.435 ' CG ' ' O ' ' A' ' 109' ' ' VAL . 75.1 m-80 -163.6 130.54 3.34 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.691 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.47 ' HA ' ' CB ' ' A' ' 129' ' ' ALA . 3.2 t -37.45 135.43 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.073 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 89.59 7.9 68.52 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.519 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 114' ' ' THR . 91.1 m-20 -121.08 101.98 8.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.933 0.397 . . . . 0.0 110.783 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.425 ' C ' ' O ' ' A' ' 113' ' ' ASP . 1.7 m -35.25 101.66 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.104 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.521 ' CD2' HG13 ' A' ' 109' ' ' VAL . 7.7 mt -56.77 -83.66 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.63 179.785 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.457 ' HB3' HG12 ' A' ' 103' ' ' ILE . 0.8 OUTLIER -144.34 178.21 8.08 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.764 179.804 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.569 HG13 ' CE2' ' A' ' 102' ' ' PHE . 4.2 mt -111.01 152.47 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.013 0.435 . . . . 0.0 110.803 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.52 ' O ' ' N ' ' A' ' 120' ' ' ALA . 94.5 t -140.72 94.93 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.898 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.569 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.8 OUTLIER -50.51 84.83 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.103 -179.834 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.531 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -103.76 114.39 28.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.833 179.84 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.548 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 81.97 19.85 0.34 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.774 -179.746 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.548 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 91.13 -1.07 0.19 Allowed 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.141 179.896 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 5.7 mmt -123.0 134.87 54.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.915 0.388 . . . . 0.0 111.171 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.539 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 1.3 ptp -63.31 123.14 17.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.042 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -103.79 80.99 1.83 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.803 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.491 ' CA ' HG12 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -57.59 115.59 2.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.933 -179.989 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 3.6 mm -81.2 148.71 5.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.043 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.423 ' O ' ' C ' ' A' ' 129' ' ' ALA . 22.3 tt0 -112.26 124.78 53.2 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.851 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.47 ' CB ' ' HA ' ' A' ' 111' ' ' VAL . . . -35.46 107.19 0.05 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.17 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -95.28 3.98 53.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.142 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 10.1 tttt 175.82 121.19 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.908 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 86.8 p -47.32 135.03 10.94 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.793 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -164.84 -171.12 30.7 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.578 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.536 ' N ' ' CG2' ' A' ' 155' ' ' ILE . 24.3 m -136.09 107.41 6.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.614 0.245 . . . . 0.0 111.073 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.518 HG13 ' N ' ' A' ' 105' ' ' VAL . 75.4 t -39.83 139.77 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 121.04 -0.264 . . . . 0.0 110.501 179.594 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.527 ' O ' ' CB ' ' A' ' 137' ' ' ALA . 0.1 OUTLIER -122.84 -19.93 6.02 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.583 -0.28 . . . . 0.0 111.119 -179.47 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.527 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 161.13 154.04 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.385 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.637 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -100.75 86.54 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.605 179.752 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.532 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 2.0 mt -43.24 -28.08 0.28 Allowed 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.192 0.52 . . . . 0.0 110.342 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.485 HG22 ' CD2' ' A' ' 152' ' ' LEU . 75.3 t -104.63 135.62 41.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.823 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.503 ' N ' ' OE1' ' A' ' 144' ' ' GLN . 10.0 mt-10 -66.49 97.06 0.4 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.395 179.656 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.535 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 73.1 p -35.92 138.99 0.16 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.677 -179.642 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.586 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 81.21 35.8 22.75 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.457 -0.878 . . . . 0.0 112.346 -179.799 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.503 ' OE1' ' N ' ' A' ' 141' ' ' GLU . 1.2 pt20 -148.97 159.39 37.54 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 120.89 0.376 . . . . 0.0 111.144 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.517 ' O ' ' CG1' ' A' ' 146' ' ' VAL . 45.1 Cg_endo -68.27 178.76 3.39 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.748 2.298 . . . . 0.0 112.195 179.897 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.517 ' CG1' ' O ' ' A' ' 145' ' ' PRO . 1.2 m -170.47 -175.67 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.283 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.523 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -142.74 155.47 44.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.869 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . . . . . . . . . 64.7 t80 -42.32 140.99 1.04 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.924 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.416 ' HA ' ' HD2' ' A' ' 84' ' ' ARG . 7.8 t0 66.4 28.94 9.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.841 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.523 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 2.4 tp10 -109.13 73.68 0.56 Allowed Pre-proline 0 C--N 1.327 -0.375 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.848 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.474 ' HA ' ' HA ' ' A' ' 84' ' ' ARG . 51.3 Cg_exo -32.56 120.94 0.1 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.598 0 C-N-CA 123.001 2.468 . . . . 0.0 112.232 179.706 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.486 ' O ' ' HA ' ' A' ' 138' ' ' ILE . 0.0 OUTLIER -116.41 -64.38 1.32 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.6 -179.254 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.52 ' CG1' ' HB ' ' A' ' 83' ' ' VAL . 1.5 p -99.43 103.99 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.178 0.514 . . . . 0.0 111.584 -179.11 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.535 ' CG1' HG12 ' A' ' 82' ' ' ILE . 4.7 t -87.85 135.11 26.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.033 179.571 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.536 ' CG2' ' N ' ' A' ' 134' ' ' THR . 96.6 mt -138.0 135.33 45.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.205 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.472 ' HB2' ' HD3' ' A' ' 136' ' ' LYS . 0.4 OUTLIER . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.249 -0.882 . . . . 0.0 110.902 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.83 0.348 . . . . 0.0 111.192 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -164.58 107.95 0.9 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.141 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 176.14 114.68 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.822 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.425 ' O ' ' C ' ' A' ' 79' ' ' SER . 3.7 tt -79.4 -5.29 7.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.506 -179.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.425 ' C ' ' O ' ' A' ' 78' ' ' ILE . 35.4 p 33.67 75.13 0.05 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.006 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.406 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -110.45 170.84 14.27 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.644 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.524 ' O ' ' ND1' ' A' ' 81' ' ' HIS . 17.9 t-80 174.45 83.22 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.835 0.35 . . . . 0.0 110.928 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.495 HG12 ' CG1' ' A' ' 154' ' ' VAL . 23.4 mt -98.66 127.99 50.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.994 0.426 . . . . 0.0 110.819 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.511 ' HB ' ' CG1' ' A' ' 153' ' ' VAL . 3.5 t -83.52 56.9 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.408 -179.543 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.471 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 1.9 ptt85 -42.96 134.55 3.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.67 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.504 ' N ' HD12 ' A' ' 152' ' ' LEU . 9.6 t -35.98 96.86 0.11 Allowed Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.896 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.412 ' N ' ' O ' ' A' ' 84' ' ' ARG . 87.9 Cg_exo -46.07 -27.05 4.03 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.742 2.295 . . . . 0.0 112.186 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.52 ' SD ' ' CB ' ' A' ' 120' ' ' ALA . 10.0 ptp -147.75 168.5 21.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.705 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.461 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 1.5 p -69.39 91.08 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.051 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -146.46 -133.3 2.46 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.397 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.571 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 1.2 m -136.29 153.74 51.08 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.782 0.325 . . . . 0.0 110.954 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.645 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 1.1 t80 -118.38 140.15 50.29 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.968 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.586 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 22.0 m-85 -140.15 163.41 32.81 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.061 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.535 ' HD2' ' CB ' ' A' ' 142' ' ' SER . 0.0 OUTLIER -130.08 13.09 5.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.914 179.729 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.46 HG21 ' HA ' ' A' ' 101' ' ' ALA . 0.7 OUTLIER -151.36 109.27 2.98 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.897 -179.973 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -74.72 -5.04 16.31 Favored 'Trans proline' 0 C--O 1.232 0.201 0 C-N-CA 122.812 2.341 . . . . 0.0 112.454 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.59 167.88 12.24 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.05 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -74.55 106.43 2.25 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.747 2.298 . . . . 0.0 112.247 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 74.21 31.74 1.07 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.835 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -76.78 -166.8 0.73 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.003 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.01 33.38 0.87 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.885 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.46 ' HA ' HG21 ' A' ' 94' ' ' THR . . . 51.58 175.75 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.182 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.567 ' CE1' HG23 ' A' ' 114' ' ' THR . 0.0 OUTLIER -111.68 -34.59 6.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.967 179.998 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.53 ' CD1' HG22 ' A' ' 153' ' ' VAL . 1.0 OUTLIER -170.08 129.08 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.186 179.933 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.5 ' O ' ' N ' ' A' ' 106' ' ' GLY . 3.2 mt-10 -136.72 148.87 47.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.835 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.517 ' N ' HG13 ' A' ' 135' ' ' VAL . 52.6 t -35.78 92.55 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.064 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . 0.5 ' N ' ' O ' ' A' ' 104' ' ' GLU . . . 133.39 -0.31 4.26 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.536 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.463 ' O ' ' HA ' ' A' ' 134' ' ' THR . 0.0 OUTLIER -71.24 112.58 7.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.82 0.343 . . . . 0.0 110.83 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 31.6 mttt -82.37 79.76 8.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.046 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.565 ' CG2' ' N ' ' A' ' 110' ' ' ASN . 1.4 p -78.03 164.08 3.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.974 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.565 ' N ' ' CG2' ' A' ' 109' ' ' VAL . 7.8 m120 -153.83 130.04 10.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.49 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.432 ' C ' ' O ' ' A' ' 110' ' ' ASN . 2.6 m -31.74 114.76 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.461 -179.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 111.87 9.24 21.08 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.488 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.421 ' O ' ' HA ' ' A' ' 128' ' ' GLU . 6.4 t0 -113.74 -148.86 0.44 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.794 0.33 . . . . 0.0 110.684 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.567 HG23 ' CE1' ' A' ' 102' ' ' PHE . 1.9 m -131.0 147.89 52.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.788 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.461 ' O ' HG22 ' A' ' 103' ' ' ILE . 80.9 mt -116.46 -81.1 0.61 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.131 -179.749 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.472 ' HB2' ' O ' ' A' ' 92' ' ' TYR . 8.0 p -136.57 -176.13 4.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.282 -179.619 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.523 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.3 OUTLIER -102.52 117.89 48.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.18 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.527 HG11 ' CB ' ' A' ' 125' ' ' ASN . 12.1 p -97.12 50.98 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.923 179.837 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.476 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.1 OUTLIER -35.91 96.43 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.96 -179.885 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.522 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -116.92 115.64 25.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.023 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.522 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 0.1 OUTLIER 84.06 18.18 0.2 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.821 -179.95 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.528 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 0.3 OUTLIER 85.43 26.14 0.07 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.963 179.998 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.476 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.9 OUTLIER -141.96 128.36 20.03 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.107 179.832 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.523 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 1.0 OUTLIER -66.68 131.55 46.21 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.906 179.884 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.527 ' CB ' HG11 ' A' ' 118' ' ' VAL . 0.5 OUTLIER -125.99 88.39 2.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.825 -179.985 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 -50.61 112.04 0.63 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.875 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 31.5 mm -72.53 137.78 22.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.083 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.421 ' HA ' ' O ' ' A' ' 113' ' ' ASP . 50.2 mt-10 -97.01 126.44 42.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.93 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.463 ' HB1' ' CG2' ' A' ' 109' ' ' VAL . . . -38.49 124.84 1.33 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.153 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -101.67 -13.59 17.73 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.846 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 9.8 tttp -168.05 120.02 0.85 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.807 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 90.3 p -42.74 121.59 2.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.714 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.414 ' O ' HG11 ' A' ' 109' ' ' VAL . . . -157.56 -176.5 29.69 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.67 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.588 ' N ' ' CG2' ' A' ' 155' ' ' ILE . 24.2 m -131.86 110.78 11.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.582 0.229 . . . . 0.0 111.137 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.517 HG13 ' N ' ' A' ' 105' ' ' VAL . 73.4 t -40.03 141.76 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 110.353 -0.24 . . . . 0.0 110.353 179.531 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.516 ' N ' HG11 ' A' ' 135' ' ' VAL . 5.7 mmmt -126.19 -19.89 4.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.633 -179.459 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.407 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 169.49 161.18 0.06 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.834 0.349 . . . . 0.0 111.514 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.645 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -108.49 80.2 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.915 179.917 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.541 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 2.8 mt -41.33 -30.33 0.18 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.104 0.478 . . . . 0.0 109.919 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.523 HG22 ' CD2' ' A' ' 152' ' ' LEU . 71.7 t -98.64 139.19 21.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.827 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.486 ' O ' ' CG ' ' A' ' 144' ' ' GLN . 6.7 mt-10 -70.59 98.14 1.44 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.351 179.654 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.535 ' CB ' ' HD2' ' A' ' 93' ' ' ARG . 35.5 p -35.83 154.36 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.703 -179.65 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.582 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 62.69 38.12 95.93 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.33 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.486 ' CG ' ' O ' ' A' ' 141' ' ' GLU . 12.3 mm-40 -150.48 145.27 18.29 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 120.931 0.396 . . . . 0.0 111.042 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.526 ' HA ' ' CG2' ' A' ' 90' ' ' THR . 52.4 Cg_exo -54.81 173.04 0.29 Allowed 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.755 2.303 . . . . 0.0 112.17 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.522 HG13 ' CD2' ' A' ' 152' ' ' LEU . 0.4 OUTLIER -165.76 175.86 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.042 179.939 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.509 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 0.8 OUTLIER -135.26 162.17 33.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.991 -179.935 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.453 ' HA ' ' O ' ' A' ' 85' ' ' SER . 6.8 t80 -48.65 141.49 7.08 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.789 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 65.42 29.78 11.19 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.775 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.509 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 1.2 tp10 -108.16 73.36 0.44 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.762 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.471 ' HA ' ' HA ' ' A' ' 84' ' ' ARG . 55.7 Cg_exo -32.2 119.35 0.09 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 123.013 2.475 . . . . 0.0 112.145 179.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.523 ' CD2' HG22 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -116.82 -71.32 0.74 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.545 -179.298 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.53 HG22 ' CD1' ' A' ' 103' ' ' ILE . 1.6 p -93.69 105.32 16.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 121.159 0.504 . . . . 0.0 111.732 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.541 ' CG2' ' HG ' ' A' ' 139' ' ' LEU . 41.5 t -84.16 135.38 24.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.861 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.588 ' CG2' ' N ' ' A' ' 134' ' ' THR . 95.6 mt -133.64 135.63 55.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.362 -179.707 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.448 ' HB2' ' HD3' ' A' ' 136' ' ' LYS . 1.7 tt0 . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.18 -0.914 . . . . 0.0 110.871 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.517 ' O ' ' CB ' ' A' ' 76' ' ' ALA . . . . . . . . 0 N--CA 1.457 -0.123 0 CA-C-O 120.839 0.352 . . . . 0.0 111.101 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.517 ' CB ' ' O ' ' A' ' 75' ' ' ALA . . . 84.77 -11.95 0.76 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER 45.2 40.3 4.86 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.972 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.532 ' O ' ' CG2' ' A' ' 78' ' ' ILE . 2.6 mm -121.2 -0.27 7.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.404 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.466 ' C ' ' O ' ' A' ' 78' ' ' ILE . 5.7 t 30.12 42.58 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.235 179.832 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.453 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -83.09 159.22 37.25 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.774 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.523 ' O ' ' ND1' ' A' ' 81' ' ' HIS . 13.4 t-80 171.9 83.85 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.754 0.311 . . . . 0.0 110.582 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.545 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -103.08 -178.42 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.97 0.414 . . . . 0.0 111.184 -179.995 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.54 ' CG2' ' CG1' ' A' ' 153' ' ' VAL . 11.3 t -130.41 32.45 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.763 179.696 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.535 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 4.7 ptt180 -30.41 119.92 0.18 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.283 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.52 ' N ' HD13 ' A' ' 152' ' ' LEU . 0.7 OUTLIER -36.48 103.14 0.24 Allowed Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.94 -179.771 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -51.54 -22.58 12.89 Favored 'Trans proline' 0 N--CA 1.464 -0.226 0 C-N-CA 122.653 2.235 . . . . 0.0 112.052 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.0 ptm -141.56 -176.79 4.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.789 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.45 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 15.1 t -82.29 93.5 2.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.046 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -146.22 -141.42 3.61 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.587 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.575 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 42.4 m -136.57 141.84 43.35 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.792 0.329 . . . . 0.0 111.023 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.65 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 0.8 OUTLIER -100.74 146.24 27.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.961 -179.981 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.581 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 16.5 m-85 -143.16 162.61 35.11 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.904 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.532 ' CD ' ' HB3' ' A' ' 142' ' ' SER . 9.5 ptm180 -139.75 31.53 2.04 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.874 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.467 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 68.7 p -145.74 122.15 5.92 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.491 ' HG2' ' CB ' ' A' ' 99' ' ' ALA . 55.7 Cg_endo -70.36 -21.48 30.65 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.701 2.268 . . . . 0.0 112.358 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 15.2 m -162.8 152.97 13.67 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.081 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_exo -49.63 -20.76 4.65 Favored 'Trans proline' 0 C--O 1.232 0.215 0 C-N-CA 122.8 2.333 . . . . 0.0 112.284 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -138.31 72.7 1.41 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.815 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.491 ' CB ' ' HG2' ' A' ' 95' ' ' PRO . . . -137.1 -154.87 0.57 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.197 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -113.15 36.51 3.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.846 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.467 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 62.06 -178.44 0.13 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.115 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.576 ' CE2' HG13 ' A' ' 117' ' ' ILE . 0.2 OUTLIER -104.17 -37.13 7.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.866 -179.964 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.524 ' CD1' HG22 ' A' ' 153' ' ' VAL . 0.3 OUTLIER -178.18 146.62 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.11 179.992 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.424 ' C ' HG13 ' A' ' 135' ' ' VAL . 5.7 pt-20 -146.75 162.72 37.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.854 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.511 ' CG2' ' HA ' ' A' ' 137' ' ' ALA . 14.4 t -45.07 134.87 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.193 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 94.43 -11.95 69.55 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.543 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.426 ' O ' ' N ' ' A' ' 109' ' ' VAL . 3.6 tp60 -77.2 95.67 4.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.838 0.351 . . . . 0.0 110.892 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.9 mtmt -64.39 74.24 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.963 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.451 HG21 ' O ' ' A' ' 133' ' ' GLY . 17.7 m -54.6 167.87 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.014 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.471 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 3.4 p-10 -157.31 131.26 8.2 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 121.174 0.512 . . . . 0.0 110.83 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.454 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 26.1 t -34.69 136.04 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.092 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 86.87 11.83 69.76 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.337 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.418 ' O ' ' C ' ' A' ' 114' ' ' THR . 26.4 t70 -124.69 102.53 7.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.783 0.325 . . . . 0.0 110.867 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.418 ' C ' ' O ' ' A' ' 113' ' ' ASP . 1.6 m -35.52 113.02 0.18 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.154 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.458 ' O ' HG12 ' A' ' 103' ' ' ILE . 19.2 mt -69.77 -87.53 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.648 179.734 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.504 ' HA ' ' CG ' ' A' ' 102' ' ' PHE . 9.1 p -135.32 -166.52 1.85 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.681 179.729 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.576 HG13 ' CE2' ' A' ' 102' ' ' PHE . 1.7 mt -126.48 153.77 35.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.595 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.53 ' CG1' ' O ' ' A' ' 90' ' ' THR . 46.7 t -141.04 103.12 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.965 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.514 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.5 OUTLIER -62.04 69.96 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.118 -179.773 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.518 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -92.81 145.31 24.5 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.904 179.833 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.518 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 9.1 ptp 51.96 21.03 1.37 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.737 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.511 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 1.6 tmtt? 80.28 52.03 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.877 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.467 ' HG3' ' O ' ' A' ' 120' ' ' ALA . 0.2 OUTLIER -172.0 133.13 0.7 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.091 179.804 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.529 ' CG ' HG23 ' A' ' 117' ' ' ILE . 45.2 mtt -67.54 97.16 0.57 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.951 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -79.43 82.08 5.61 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.779 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.52 ' CA ' HG12 ' A' ' 117' ' ' ILE . 4.3 pt20 -58.28 107.71 0.52 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.863 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.467 ' N ' ' O ' ' A' ' 116' ' ' CYS . 7.3 mm -74.99 162.51 4.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.164 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -130.04 141.1 50.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.852 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.454 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -46.24 113.65 0.66 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.995 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.402 ' OD1' ' N ' ' A' ' 130' ' ' ASP . 0.4 OUTLIER -101.09 11.09 40.18 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.936 -179.952 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 14.7 tttt 169.99 117.39 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.836 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.471 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 34.8 p -44.25 111.15 0.27 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.781 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.451 ' O ' HG21 ' A' ' 109' ' ' VAL . . . -145.96 -175.46 19.02 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.554 -179.766 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.464 ' N ' ' CG2' ' A' ' 155' ' ' ILE . 20.7 m -129.54 109.38 10.98 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.645 0.26 . . . . 0.0 111.215 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.507 HG11 ' N ' ' A' ' 136' ' ' LYS . 95.5 t -43.29 143.64 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.626 -0.261 . . . . 0.0 110.364 179.474 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.514 ' O ' ' CB ' ' A' ' 137' ' ' ALA . 1.3 mmmp? -123.72 -18.69 5.99 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.233 -179.55 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.514 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 162.79 164.31 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.888 0.375 . . . . 0.0 111.582 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.65 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -107.11 87.58 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.693 179.787 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.538 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 1.8 mt -43.0 -27.77 0.22 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.112 0.482 . . . . 0.0 110.437 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.523 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 55.6 t -106.64 140.4 24.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.924 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.522 ' O ' ' CG ' ' A' ' 144' ' ' GLN . 6.6 mt-10 -69.38 98.15 1.05 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.252 179.492 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.532 ' HB3' ' CD ' ' A' ' 93' ' ' ARG . 55.5 p -34.0 150.6 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.732 -179.469 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.581 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 67.33 35.86 88.4 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.383 -0.913 . . . . 0.0 112.149 -179.775 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.522 ' CG ' ' O ' ' A' ' 141' ' ' GLU . 29.2 mm-40 -147.91 154.06 43.04 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 120.86 0.362 . . . . 0.0 111.103 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.486 ' O ' ' CG1' ' A' ' 146' ' ' VAL . 59.8 Cg_endo -72.29 173.67 12.69 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.823 2.349 . . . . 0.0 112.344 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.512 HG22 ' CB ' ' A' ' 85' ' ' SER . 10.5 m -163.65 -173.74 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.071 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.528 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 6.3 pt-20 -140.16 174.08 10.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.966 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.468 ' HA ' ' O ' ' A' ' 85' ' ' SER . 17.1 t80 -50.19 147.59 4.07 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.881 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 53.94 33.36 17.16 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.918 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 19.7 tp10 -109.45 74.74 0.7 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.741 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.535 ' CD ' ' HB3' ' A' ' 84' ' ' ARG . 69.7 Cg_exo -36.34 128.98 0.43 Allowed 'Trans proline' 0 N--CA 1.46 -0.487 0 C-N-CA 122.705 2.27 . . . . 0.0 111.794 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.583 ' HB2' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -122.22 -48.91 2.07 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 111.866 0.321 . . . . 0.0 111.866 -179.059 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.54 ' CG1' ' CG2' ' A' ' 83' ' ' VAL . 1.6 p -116.94 113.45 42.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 121.026 0.441 . . . . 0.0 111.423 -179.375 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.538 ' CG2' ' HG ' ' A' ' 139' ' ' LEU . 1.6 t -93.84 144.6 9.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.073 179.77 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.477 HG21 ' N ' ' A' ' 156' ' ' GLU . 60.3 mt -144.18 141.86 24.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.146 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.512 ' HB2' ' CE ' ' A' ' 136' ' ' LYS . 15.7 tt0 . . . . . 0 C--O 1.251 1.16 0 CA-C-O 118.224 -0.893 . . . . 0.0 110.823 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.803 0.335 . . . . 0.0 111.078 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . 65.1 -175.7 0.18 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.157 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 15.5 mm-40 -120.54 144.06 48.26 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.87 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.6 mp -137.7 24.27 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.13 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.7 m 48.81 47.63 21.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.012 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.427 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . 73.54 -133.82 18.28 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.623 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.57 ' CD2' HG23 ' A' ' 155' ' ' ILE . 21.2 t60 170.38 86.12 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.799 0.333 . . . . 0.0 110.817 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.481 HG23 ' HB3' ' A' ' 151' ' ' PRO . 0.3 OUTLIER -101.76 159.22 4.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 121.03 0.443 . . . . 0.0 111.176 -179.941 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.531 ' CG1' ' HB ' ' A' ' 153' ' ' VAL . 4.4 p -109.43 46.64 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.132 -179.855 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.468 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 7.4 ptt180 -31.0 136.64 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.247 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.526 ' HB2' ' CG2' ' A' ' 146' ' ' VAL . 0.3 OUTLIER -43.34 106.42 0.49 Allowed Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.055 -179.734 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -56.71 -20.97 37.22 Favored 'Trans proline' 0 C--O 1.231 0.14 0 C-N-CA 122.736 2.29 . . . . 0.0 111.98 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -155.99 -175.7 5.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.855 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 3.5 m -82.78 76.32 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.168 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -129.96 -146.24 5.97 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.539 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.514 ' CG2' ' HA ' ' A' ' 145' ' ' PRO . 1.5 m -131.55 154.39 48.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.707 0.289 . . . . 0.0 110.904 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.615 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 0.3 OUTLIER -115.39 146.61 41.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.948 0.404 . . . . 0.0 111.25 -179.859 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.577 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 24.0 m-85 -144.04 164.96 29.11 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.862 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.527 ' CD ' ' HB3' ' A' ' 142' ' ' SER . 16.6 ptt180 -149.73 21.92 0.9 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.713 179.8 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.44 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 72.6 p -147.14 86.11 6.63 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.866 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -67.95 -20.89 44.39 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.746 2.297 . . . . 0.0 112.39 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.523 ' OG ' ' CB ' ' A' ' 99' ' ' ALA . 0.0 OUTLIER -120.39 145.04 39.61 Favored Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.958 179.934 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_exo -50.7 -41.48 53.9 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.752 2.301 . . . . 0.0 112.344 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -134.16 60.42 1.7 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.523 ' CB ' ' OG ' ' A' ' 96' ' ' SER . . . -111.14 -169.9 1.54 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.096 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . 0.427 ' N ' ' CD ' ' A' ' 100' ' ' LYS . 0.4 OUTLIER -93.71 24.64 3.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.833 179.984 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.527 ' CB ' ' O ' ' A' ' 93' ' ' ARG . . . 67.13 -178.37 0.21 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.061 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.547 ' CE2' HG12 ' A' ' 117' ' ' ILE . 0.1 OUTLIER -89.09 -59.27 2.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.591 179.79 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.559 ' CG2' ' CG2' ' A' ' 135' ' ' VAL . 24.6 mm -154.15 94.74 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.908 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -94.66 165.72 12.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.961 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.487 ' CG2' ' O ' ' A' ' 136' ' ' LYS . 2.1 p -53.58 101.62 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.066 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 141.11 -29.86 2.28 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.523 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.423 ' HA ' ' OE1' ' A' ' 107' ' ' GLN . 1.9 mp0 -72.04 121.17 18.73 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.782 0.325 . . . . 0.0 110.861 179.903 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 1.8 mttt -86.36 97.31 10.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.959 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.517 HG23 ' CD1' ' A' ' 155' ' ' ILE . 15.3 m -61.48 176.74 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.123 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.501 ' HA ' ' CB ' ' A' ' 132' ' ' SER . 66.0 m-20 -168.89 133.81 1.57 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.672 179.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.428 ' C ' ' O ' ' A' ' 110' ' ' ASN . 0.2 OUTLIER -35.14 123.79 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.128 179.89 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 91.65 21.12 35.08 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.444 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.43 ' O ' ' C ' ' A' ' 114' ' ' THR . 20.1 t0 -132.37 107.21 8.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.707 0.289 . . . . 0.0 110.87 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.529 ' CG2' ' HB2' ' A' ' 126' ' ' GLN . 2.4 m -34.16 132.9 0.24 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.025 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.51 ' O ' ' CG1' ' A' ' 103' ' ' ILE . 18.0 mt -89.07 -83.0 0.24 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.992 -179.858 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . . . . . . . . . 19.0 p -135.91 -166.2 1.83 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.039 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.547 HG12 ' CE2' ' A' ' 102' ' ' PHE . 0.3 OUTLIER -113.58 114.49 46.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.21 -179.883 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.529 HG11 ' CB ' ' A' ' 125' ' ' ASN . 9.1 p -103.49 58.26 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.831 179.746 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.473 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.5 OUTLIER -34.72 91.32 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.115 -179.778 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' A' ' 118' ' ' VAL . . . -108.4 145.77 34.05 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.009 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.476 ' HG2' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 46.85 24.86 0.39 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.574 -179.868 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.497 ' O ' ' CG ' ' A' ' 123' ' ' MET . 0.0 OUTLIER 79.33 50.21 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.886 -179.917 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.497 ' CG ' ' O ' ' A' ' 122' ' ' LYS . 40.5 mtp -162.28 125.56 2.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.081 179.798 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.531 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -60.28 77.96 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.994 179.947 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.529 ' CB ' HG11 ' A' ' 118' ' ' VAL . 1.0 OUTLIER -70.54 73.65 0.53 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.754 179.919 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.529 ' HB2' ' CG2' ' A' ' 114' ' ' THR . 0.0 OUTLIER -50.22 131.59 23.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.015 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.462 ' O ' ' HA ' ' A' ' 114' ' ' THR . 35.3 mm -94.03 161.64 2.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.08 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 5.8 mt-10 -127.99 142.24 51.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.978 -179.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -62.38 136.81 58.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.085 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -115.87 -8.02 11.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.035 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.486 ' HE2' ' ND1' ' A' ' 81' ' ' HIS . 0.3 OUTLIER -159.94 35.3 0.18 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.839 179.96 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.501 ' CB ' ' HA ' ' A' ' 110' ' ' ASN . 96.1 p 43.64 -171.7 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.767 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.466 ' N ' HG21 ' A' ' 109' ' ' VAL . . . 148.22 -156.84 27.09 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.54 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.521 ' N ' HG12 ' A' ' 155' ' ' ILE . 85.7 m -162.81 110.01 1.24 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.721 0.296 . . . . 0.0 110.91 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.559 ' CG2' ' CG2' ' A' ' 103' ' ' ILE . 70.1 t -47.21 144.13 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.893 0.378 . . . . 0.0 111.015 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.522 ' CD ' ' CG1' ' A' ' 154' ' ' VAL . 0.0 OUTLIER -114.83 -35.82 4.68 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 121.494 0.664 . . . . 0.0 109.451 -179.95 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.516 ' N ' ' HG2' ' A' ' 136' ' ' LYS . . . 179.65 136.65 0.11 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 114.97 -1.014 . . . . 0.0 111.052 -179.724 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.615 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -88.92 85.38 2.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.927 0.394 . . . . 0.0 110.555 179.695 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.422 ' C ' ' O ' ' A' ' 138' ' ' ILE . 10.8 mt -37.16 -31.26 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.485 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.556 ' CG2' ' HB3' ' A' ' 152' ' ' LEU . 42.9 t -94.32 143.31 11.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.177 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.455 ' O ' ' C ' ' A' ' 142' ' ' SER . 27.3 mt-10 -77.59 105.36 8.69 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.917 179.235 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.527 ' HB3' ' CD ' ' A' ' 93' ' ' ARG . 24.4 p -34.45 135.82 0.16 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.765 -179.342 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.577 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 83.64 34.79 18.32 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.41 -0.9 . . . . 0.0 111.93 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.457 ' HG3' ' N ' ' A' ' 145' ' ' PRO . 1.0 OUTLIER -143.42 145.28 31.23 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 120.88 0.372 . . . . 0.0 110.976 -179.658 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.514 ' HA ' ' CG2' ' A' ' 90' ' ' THR . 57.2 Cg_endo -71.2 171.97 14.94 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.789 2.326 . . . . 0.0 112.204 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.526 ' CG2' ' HB2' ' A' ' 85' ' ' SER . 6.0 m -153.44 -165.12 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.192 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.517 ' O ' ' CG ' ' A' ' 150' ' ' GLU . 3.3 mt-10 -146.03 157.88 43.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.043 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.457 ' HA ' ' O ' ' A' ' 85' ' ' SER . 3.4 t80 -47.39 135.05 11.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.912 179.949 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.416 ' N ' ' CD1' ' A' ' 148' ' ' PHE . 58.1 t0 67.4 34.8 4.57 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.939 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.527 ' O ' ' CD2' ' A' ' 152' ' ' LEU . 14.6 mm-40 -115.29 75.43 4.48 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.857 179.769 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.481 ' HB3' HG23 ' A' ' 82' ' ' ILE . 71.2 Cg_exo -36.61 125.53 0.41 Allowed 'Trans proline' 0 N--CA 1.459 -0.528 0 C-N-CA 122.75 2.3 . . . . 0.0 111.637 179.51 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.58 HD11 ' CD2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -129.29 -36.24 1.72 Allowed 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 120.962 0.411 . . . . 0.0 110.98 -179.005 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.531 ' HB ' ' CG1' ' A' ' 83' ' ' VAL . 1.3 t -115.99 109.46 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.347 -178.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.522 ' CG1' ' CD ' ' A' ' 136' ' ' LYS . 1.4 t -98.46 119.04 45.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.612 179.429 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.57 HG23 ' CD2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -110.1 154.66 11.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.863 -179.772 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.467 ' N ' ' O ' ' A' ' 134' ' ' THR . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.241 -0.885 . . . . 0.0 110.939 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' A' ' 76' ' ' ALA . . . . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.83 0.347 . . . . 0.0 111.132 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' A' ' 75' ' ' ALA . . . 37.3 -158.02 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.071 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -128.73 27.26 5.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.816 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.418 ' O ' ' C ' ' A' ' 79' ' ' SER . 3.4 mp -142.78 21.35 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.083 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 78' ' ' ILE . 35.4 t 35.93 46.57 0.36 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.951 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 63.46 -139.7 44.02 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.469 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.49 ' N ' ' O ' ' A' ' 155' ' ' ILE . 24.5 t60 -178.87 79.79 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.802 0.334 . . . . 0.0 110.874 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.53 HD11 ' CG1' ' A' ' 154' ' ' VAL . 0.2 OUTLIER -92.04 -176.14 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.031 179.845 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.53 ' HB ' ' CG1' ' A' ' 153' ' ' VAL . 2.1 t -142.02 41.56 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.859 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.515 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -33.84 132.81 0.22 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.088 -179.845 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.485 ' N ' HD13 ' A' ' 152' ' ' LEU . 1.5 m -44.44 103.91 0.36 Allowed Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.903 -179.909 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_exo -50.98 -20.04 6.56 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.586 2.191 . . . . 0.0 112.064 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 14.9 ptm -150.34 166.73 29.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.681 179.793 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.456 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 1.5 p -68.14 95.9 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.004 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -147.56 -133.0 2.31 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.579 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.546 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 24.3 m -140.43 151.19 44.7 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.831 0.348 . . . . 0.0 110.884 -179.889 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.641 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 0.4 OUTLIER -118.22 151.47 37.56 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.828 179.953 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.58 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 23.4 m-85 -147.24 168.76 20.91 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.789 -0.642 . . . . 0.0 111.0 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.468 ' O ' ' N ' ' A' ' 102' ' ' PHE . 0.0 OUTLIER -135.66 18.07 3.32 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.688 179.742 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.45 ' O ' HD13 ' A' ' 117' ' ' ILE . 2.1 p -132.6 108.73 13.24 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.815 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.577 ' HG3' ' CD1' ' A' ' 102' ' ' PHE . 51.8 Cg_exo -53.72 -18.06 11.43 Favored 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.743 2.296 . . . . 0.0 112.3 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -178.96 167.95 0.88 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.902 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.515 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 59.2 Cg_endo -72.29 113.77 3.8 Favored 'Trans proline' 0 N--CA 1.464 -0.215 0 C-N-CA 122.735 2.29 . . . . 0.0 112.361 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.515 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 0.6 OUTLIER 85.15 49.96 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.914 179.934 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -125.88 -163.58 1.23 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.093 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 1.2 mtpp -101.15 38.05 1.64 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.9 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 54.15 175.76 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.084 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.577 ' CD1' ' HG3' ' A' ' 95' ' ' PRO . 0.0 OUTLIER -100.75 -34.56 9.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.945 179.952 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.523 ' CG2' ' O ' ' A' ' 102' ' ' PHE . 0.3 OUTLIER -179.05 144.04 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.035 179.922 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.46 ' O ' HG12 ' A' ' 135' ' ' VAL . 2.3 mt-10 -146.33 148.33 32.27 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.948 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.463 ' CA ' HG12 ' A' ' 135' ' ' VAL . 3.9 t -35.36 123.82 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.109 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 111.48 -24.97 14.36 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.323 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 22.4 tp60 -82.25 117.24 22.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.784 0.326 . . . . 0.0 110.814 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.46 ' HA ' ' HA ' ' A' ' 134' ' ' THR . 0.0 OUTLIER -81.69 100.0 9.23 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.037 -179.885 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.513 ' N ' ' O ' ' A' ' 133' ' ' GLY . 7.7 m -59.27 176.09 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.019 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.432 ' CG ' ' O ' ' A' ' 109' ' ' VAL . 21.3 m120 -163.15 131.31 3.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.036 0.446 . . . . 0.0 110.766 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.51 ' CG1' ' HA ' ' A' ' 131' ' ' LYS . 33.2 m -35.42 138.4 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.011 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 80.74 16.42 75.39 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.333 -179.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -124.41 102.62 7.75 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.865 0.364 . . . . 0.0 110.848 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.566 HG23 ' CZ ' ' A' ' 102' ' ' PHE . 9.0 m -40.54 110.77 0.16 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.022 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.427 ' CD2' HG13 ' A' ' 109' ' ' VAL . 20.6 mt -65.96 -87.42 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.802 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.422 ' SG ' HG13 ' A' ' 153' ' ' VAL . 0.8 OUTLIER -124.7 -171.28 2.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.768 179.904 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.516 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.3 OUTLIER -106.01 113.57 43.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.203 -179.932 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.52 ' O ' ' N ' ' A' ' 120' ' ' ALA . 75.7 t -97.3 59.22 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.036 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.46 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.4 OUTLIER -39.1 90.76 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.039 -179.798 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.52 ' N ' ' O ' ' A' ' 118' ' ' VAL . . . -110.55 144.6 39.15 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.958 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.5 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.1 OUTLIER 56.2 17.03 2.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.892 -179.917 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.5 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.6 OUTLIER 83.41 53.4 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.925 -179.995 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.472 ' HG2' ' O ' ' A' ' 120' ' ' ALA . 3.1 ptt? -173.07 133.45 0.53 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.991 179.769 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.516 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -53.04 96.14 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.019 179.945 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.425 ' O ' ' C ' ' A' ' 126' ' ' GLN . 4.2 t30 -88.18 65.18 8.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.847 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.443 ' HB2' HG21 ' A' ' 114' ' ' THR . 0.0 OUTLIER -35.12 154.46 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.065 -179.857 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.461 ' O ' ' HA ' ' A' ' 114' ' ' THR . 47.0 mm -121.97 120.3 61.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.22 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 58.4 mm-40 -83.11 119.77 24.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.777 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.455 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -41.61 114.39 0.51 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.164 -179.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -74.76 -27.0 60.16 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.721 179.878 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.51 ' HA ' ' CG1' ' A' ' 111' ' ' VAL . 0.0 OUTLIER -165.05 136.13 4.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.812 179.954 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.414 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.2 t -45.84 132.75 8.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.79 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.513 ' O ' ' N ' ' A' ' 109' ' ' VAL . . . -159.03 176.44 35.85 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.604 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.582 ' N ' ' CG2' ' A' ' 155' ' ' ILE . 13.8 m -122.88 108.21 12.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.663 0.268 . . . . 0.0 111.263 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.467 ' HA ' ' HA ' ' A' ' 155' ' ' ILE . 2.8 p -49.16 144.68 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.517 -0.311 . . . . 0.0 110.566 179.515 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.512 ' CG ' ' HB2' ' A' ' 156' ' ' GLU . 1.1 mmmp? -124.14 -19.24 5.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.632 0.253 . . . . 0.0 111.234 -179.553 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.47 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 166.3 163.23 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.843 0.354 . . . . 0.0 111.433 -179.779 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.641 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.1 OUTLIER -105.23 85.46 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.74 179.626 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.523 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 12.4 mt -42.49 -28.03 0.19 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.969 0.414 . . . . 0.0 110.231 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.514 HG22 ' CD2' ' A' ' 152' ' ' LEU . 52.2 t -104.59 141.81 19.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.78 179.593 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 142' ' ' SER . 6.5 mt-10 -69.75 97.12 1.04 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.58 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.444 ' HB2' ' HD2' ' A' ' 93' ' ' ARG . 0.3 OUTLIER -36.93 135.22 0.46 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.627 -179.957 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.58 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 85.81 38.09 8.96 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.534 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.459 ' HB2' ' HD2' ' A' ' 145' ' ' PRO . 4.1 pt20 -155.64 163.61 24.08 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.884 0.373 . . . . 0.0 111.155 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.525 ' O ' ' CG1' ' A' ' 146' ' ' VAL . 55.4 Cg_endo -70.47 -168.78 0.32 Allowed 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.762 2.308 . . . . 0.0 112.646 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.525 ' CG1' ' O ' ' A' ' 145' ' ' PRO . 0.2 OUTLIER -175.72 -174.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.965 -179.982 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.456 ' HA ' ' HA ' ' A' ' 88' ' ' VAL . 4.0 mt-10 -145.6 157.37 43.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.933 0.396 . . . . 0.0 111.089 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.446 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 1.2 t80 -42.94 125.13 3.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.946 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.446 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 2.4 t0 79.61 31.95 0.24 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.951 0.405 . . . . 0.0 110.606 -179.804 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.468 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 44.1 tp10 -111.03 74.99 1.05 Allowed Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.879 179.861 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.515 ' CD ' ' HB3' ' A' ' 84' ' ' ARG . 63.3 Cg_exo -35.93 122.75 0.27 Allowed 'Trans proline' 0 N--CA 1.459 -0.508 0 C-N-CA 122.812 2.341 . . . . 0.0 112.084 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.542 ' HB2' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -116.66 -54.09 2.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.619 -179.208 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.53 ' CG1' ' HB ' ' A' ' 83' ' ' VAL . 1.3 p -108.07 108.72 25.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.121 0.486 . . . . 0.0 111.339 -179.262 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.53 ' CG1' HD11 ' A' ' 82' ' ' ILE . 6.0 t -91.14 138.96 18.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.976 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.582 ' CG2' ' N ' ' A' ' 134' ' ' THR . 37.3 mt -141.3 141.1 31.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.18 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.512 ' HB2' ' CG ' ' A' ' 136' ' ' LYS . 10.6 tt0 . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.248 -0.882 . . . . 0.0 110.877 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.791 0.329 . . . . 0.0 111.094 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -68.87 173.07 5.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.044 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 71.22 152.34 0.11 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.819 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 2.2 tp -79.92 -1.23 4.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.116 0.484 . . . . 0.0 111.41 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.444 ' O ' ' OE2' ' A' ' 156' ' ' GLU . 0.1 OUTLIER 47.26 35.77 4.09 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.966 179.905 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -160.1 -147.06 4.78 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.422 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.526 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 30.6 t60 -172.52 77.62 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.806 0.336 . . . . 0.0 110.925 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.537 HG12 ' CG1' ' A' ' 154' ' ' VAL . 10.2 mt -99.22 150.92 4.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.955 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.541 ' CG2' ' CG1' ' A' ' 153' ' ' VAL . 4.5 t -96.91 59.93 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.15 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.492 ' O ' ' N ' ' A' ' 86' ' ' PRO . 4.2 mmt85 -28.88 103.3 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.025 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.523 ' HB2' ' CD2' ' A' ' 152' ' ' LEU . 0.4 OUTLIER -32.12 91.95 0.05 OUTLIER Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.251 -179.789 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.492 ' N ' ' O ' ' A' ' 84' ' ' ARG . 77.5 Cg_exo -50.22 140.21 34.01 Favored 'Trans proline' 0 N--CA 1.464 -0.25 0 C-N-CA 122.755 2.303 . . . . 0.0 112.058 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.458 ' O ' ' O ' ' A' ' 86' ' ' PRO . 7.6 ptm 41.22 -167.09 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.465 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.435 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 72.5 t -90.32 114.49 28.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.783 0.325 . . . . 0.0 111.208 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -165.02 -164.11 19.69 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.537 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.533 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 1.9 m -115.48 151.56 34.58 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.853 0.359 . . . . 0.0 110.901 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.647 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 2.9 t80 -110.78 141.96 43.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.954 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.579 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 21.0 m-85 -142.41 157.49 44.72 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.808 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.485 ' CG ' ' HB3' ' A' ' 142' ' ' SER . 1.7 ptm180 -134.39 20.88 3.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.398 179.568 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.445 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 69.2 p -123.05 121.84 27.09 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.694 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -53.07 -59.76 0.93 Allowed 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.685 2.257 . . . . 0.0 112.336 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.581 ' CB ' ' CD ' ' A' ' 97' ' ' PRO . 0.9 OUTLIER 170.99 -66.04 0.0 OUTLIER Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 121.191 0.519 . . . . 0.0 111.106 179.869 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.581 ' CD ' ' CB ' ' A' ' 96' ' ' SER . 46.5 Cg_endo -68.94 53.6 0.81 Allowed 'Trans proline' 0 C--N 1.333 -0.268 0 C-N-CA 123.37 2.713 . . . . 0.0 112.496 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.432 ' C ' ' O ' ' A' ' 97' ' ' PRO . 4.5 p30 35.18 45.2 0.18 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.033 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -71.68 -160.13 0.05 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.087 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . 0.459 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 0.4 OUTLIER -90.77 27.48 1.77 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.842 179.921 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.459 ' HB1' ' O ' ' A' ' 100' ' ' LYS . . . 75.68 155.85 0.17 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.071 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.48 ' O ' ' CG2' ' A' ' 103' ' ' ILE . 0.2 OUTLIER -69.11 -37.51 78.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.49 179.885 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.505 ' CD1' HG22 ' A' ' 153' ' ' VAL . 1.9 pp -163.34 157.67 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.934 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -154.79 147.57 24.41 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.056 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.505 ' N ' HG13 ' A' ' 135' ' ' VAL . 2.0 p -44.2 109.4 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.05 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 126.38 -18.07 6.5 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.397 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -85.48 106.37 16.77 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.842 0.353 . . . . 0.0 110.867 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' A' ' 109' ' ' VAL . 2.4 mttp -67.03 79.53 0.12 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.908 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.515 HG21 ' N ' ' A' ' 133' ' ' GLY . 22.1 m -45.8 175.55 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.109 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.42 ' O ' ' C ' ' A' ' 111' ' ' VAL . 1.7 p-10 -165.27 135.02 3.58 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 121.026 0.441 . . . . 0.0 110.742 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.428 ' HA ' ' HB2' ' A' ' 129' ' ' ALA . 20.2 t -34.82 137.24 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 115.711 -0.677 . . . . 0.0 111.077 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 81.31 16.22 74.61 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.414 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 114' ' ' THR . 9.0 t0 -122.54 101.71 7.64 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.814 0.34 . . . . 0.0 110.952 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.438 ' HA ' ' O ' ' A' ' 127' ' ' ILE . 1.5 m -35.4 108.7 0.07 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.898 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.51 ' N ' ' O ' ' A' ' 127' ' ' ILE . 14.7 mt -62.24 -67.04 0.45 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.791 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.498 ' SG ' ' N ' ' A' ' 117' ' ' ILE . 2.5 p -162.46 -154.47 0.31 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.942 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.532 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.1 OUTLIER -122.23 119.37 58.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.282 -179.85 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.51 ' CG2' ' CG1' ' A' ' 127' ' ' ILE . 2.4 t -109.21 58.46 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.801 179.644 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.472 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.4 OUTLIER -34.74 104.11 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.165 -179.703 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.524 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -121.81 108.91 14.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.995 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.532 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 86.16 17.8 0.11 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.676 -179.802 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.541 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 5.0 tmtm? 87.61 26.58 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.861 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.472 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 1.1 mmm -139.85 124.81 18.56 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.927 0.394 . . . . 0.0 111.157 179.768 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.532 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -55.55 102.97 0.08 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.875 179.762 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.427 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 9.8 t30 -84.78 65.21 9.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.813 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.426 ' HA ' ' O ' ' A' ' 116' ' ' CYS . 6.7 pt20 -45.79 118.99 2.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.96 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.51 ' O ' ' N ' ' A' ' 115' ' ' LEU . 3.7 mm -94.2 151.66 3.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.005 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -126.65 130.45 50.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.922 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.428 ' HB2' ' HA ' ' A' ' 111' ' ' VAL . . . -42.44 134.07 3.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.111 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . 0.446 ' OD1' ' O ' ' A' ' 130' ' ' ASP . 10.5 t70 -118.44 -0.24 11.47 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.076 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.458 ' O ' ' O ' ' A' ' 132' ' ' SER . 1.3 ptmt -170.73 29.61 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.941 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.458 ' O ' ' O ' ' A' ' 131' ' ' LYS . 0.9 OUTLIER 47.38 -179.52 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.743 -179.815 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.515 ' N ' HG21 ' A' ' 109' ' ' VAL . . . 152.01 174.19 22.42 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.625 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.536 ' N ' ' CG2' ' A' ' 155' ' ' ILE . 27.5 m -120.94 110.68 16.58 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.553 0.216 . . . . 0.0 111.235 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.541 HG11 ' N ' ' A' ' 136' ' ' LYS . 61.3 t -49.77 145.66 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.63 -0.259 . . . . 0.0 110.32 179.461 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.541 ' N ' HG11 ' A' ' 135' ' ' VAL . 50.9 mmtt -125.38 -18.04 5.44 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 121.049 -0.26 . . . . 0.0 111.643 -179.417 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.507 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 164.66 153.46 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.927 0.394 . . . . 0.0 111.857 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.647 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -95.7 77.9 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.419 179.499 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.471 HD13 ' CG2' ' A' ' 154' ' ' VAL . 3.9 mt -38.44 -30.86 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.118 0.485 . . . . 0.0 110.223 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.518 HG22 ' CD2' ' A' ' 152' ' ' LEU . 55.3 t -102.93 138.32 27.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.818 179.725 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.518 ' O ' ' CG ' ' A' ' 144' ' ' GLN . 1.7 mt-10 -68.92 106.5 2.75 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.385 179.801 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.485 ' HB3' ' CG ' ' A' ' 93' ' ' ARG . 6.3 p -36.41 152.07 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.697 -179.554 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.579 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 56.99 43.86 92.97 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.395 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.518 ' CG ' ' O ' ' A' ' 141' ' ' GLU . 61.6 mm-40 -147.39 137.95 12.71 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.895 0.378 . . . . 0.0 111.245 -179.769 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.516 ' N ' HG22 ' A' ' 90' ' ' THR . 57.1 Cg_endo -70.64 156.18 61.55 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.691 2.261 . . . . 0.0 112.266 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.523 HG22 ' CB ' ' A' ' 85' ' ' SER . 4.1 m -152.24 -156.51 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.208 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.455 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -147.57 174.31 11.87 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.95 -179.943 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.435 ' HA ' ' O ' ' A' ' 85' ' ' SER . 25.4 t80 -53.84 150.81 7.12 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.87 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 84.1 m-20 60.2 23.6 12.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.928 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.462 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 4.6 tt0 -107.17 74.51 0.4 Allowed Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.815 179.738 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.49 ' HB3' HG22 ' A' ' 82' ' ' ILE . 62.9 Cg_exo -35.51 127.92 0.3 Allowed 'Trans proline' 0 N--CA 1.459 -0.542 0 C-N-CA 122.996 2.464 . . . . 0.0 112.5 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.572 ' HB2' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -120.89 -59.97 1.69 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.273 -179.729 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.541 ' CG1' ' CG2' ' A' ' 83' ' ' VAL . 1.4 p -102.93 101.88 12.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.202 -179.663 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.537 ' CG1' HG12 ' A' ' 82' ' ' ILE . 17.0 t -87.11 136.0 23.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.811 -0.632 . . . . 0.0 111.292 179.844 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.536 ' CG2' ' N ' ' A' ' 134' ' ' THR . 22.8 mt -140.34 139.85 35.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.049 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.525 ' HB3' ' CE ' ' A' ' 136' ' ' LYS . 6.0 tp10 . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.243 -0.884 . . . . 0.0 110.841 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.782 0.325 . . . . 0.0 111.125 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . 61.2 121.18 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.092 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER 66.01 -175.29 0.18 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.943 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.3 mp -131.05 23.76 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.071 -179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 68.15 93.87 0.07 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.002 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.424 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -124.0 -142.93 6.11 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.517 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.536 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 26.8 t60 171.89 83.94 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.896 0.379 . . . . 0.0 110.964 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.486 HG12 ' HA ' ' A' ' 154' ' ' VAL . 6.8 mt -100.67 147.05 8.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.017 0.436 . . . . 0.0 110.999 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.542 ' CG2' ' CG1' ' A' ' 153' ' ' VAL . 3.5 t -93.36 45.31 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.993 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.436 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -34.61 127.39 0.48 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.8 -179.978 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.467 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 5.3 t -34.83 107.68 0.32 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.956 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -63.74 -20.95 69.64 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.791 2.327 . . . . 0.0 111.945 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.457 ' HG3' ' HB3' ' A' ' 120' ' ' ALA . 9.9 ptp -154.37 172.59 17.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.781 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.445 ' O ' ' CG2' ' A' ' 88' ' ' VAL . 30.7 m -66.7 87.71 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.057 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.455 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -147.82 -161.16 9.33 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.635 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.654 ' CG2' ' CE1' ' A' ' 92' ' ' TYR . 5.3 m -117.48 140.6 49.39 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.893 0.378 . . . . 0.0 111.124 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.641 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 14.4 t80 -89.3 143.02 27.15 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.269 179.453 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.654 ' CE1' ' CG2' ' A' ' 90' ' ' THR . 18.5 m-85 -139.91 148.81 42.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.888 0.375 . . . . 0.0 111.22 -179.521 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.466 ' O ' ' N ' ' A' ' 102' ' ' PHE . 0.7 OUTLIER -135.11 13.18 3.58 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.809 179.818 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.443 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 52.5 p -141.49 110.3 6.28 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.954 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.1 -39.45 5.85 Favored 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 122.725 2.283 . . . . 0.0 112.414 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.452 ' CB ' ' HB1' ' A' ' 99' ' ' ALA . 0.0 OUTLIER -129.72 148.98 71.66 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.92 -179.944 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.33 -34.74 71.96 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.693 2.262 . . . . 0.0 112.294 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -118.63 42.46 2.75 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.856 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.452 ' HB1' ' CB ' ' A' ' 96' ' ' SER . . . -100.26 -154.86 0.49 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.094 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.19 36.78 4.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.863 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.443 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 56.67 165.67 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.117 179.846 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.527 ' O ' ' CG2' ' A' ' 103' ' ' ILE . 0.1 OUTLIER -89.22 -34.63 16.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.964 179.994 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.527 ' CG2' ' O ' ' A' ' 102' ' ' PHE . 0.2 OUTLIER 176.49 127.34 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.104 -179.912 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.84 165.6 17.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.807 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.463 ' HB ' ' HA ' ' A' ' 137' ' ' ALA . 1.9 p -44.28 119.59 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.927 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 114.25 -14.05 21.12 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.374 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.4 mm-40 -74.26 126.02 29.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.827 0.346 . . . . 0.0 110.887 179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.0 74.03 5.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.855 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.453 HG21 ' O ' ' A' ' 133' ' ' GLY . 22.1 m -47.14 172.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.984 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.458 ' O ' ' HB2' ' A' ' 113' ' ' ASP . 27.2 m120 -163.95 131.13 3.31 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.022 0.439 . . . . 0.0 110.72 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.462 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 33.8 m -35.54 118.72 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.022 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 100.91 15.51 28.47 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.317 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.458 ' HB2' ' O ' ' A' ' 110' ' ' ASN . 0.3 OUTLIER -125.2 103.92 8.23 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.854 0.359 . . . . 0.0 110.669 179.993 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.529 ' CG2' ' HB3' ' A' ' 126' ' ' GLN . 2.3 m -33.92 122.14 0.46 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.149 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.466 ' O ' HG12 ' A' ' 103' ' ' ILE . 15.1 mt -78.24 -86.08 0.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.929 179.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -135.04 -174.33 3.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.101 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.593 ' CG2' ' CB ' ' A' ' 124' ' ' MET . 0.1 OUTLIER -104.86 129.45 57.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.016 -179.954 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 124' ' ' MET . 6.0 t -123.06 100.89 8.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.591 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.578 ' HG2' ' CE2' ' A' ' 92' ' ' TYR . 1.0 OUTLIER -100.16 117.71 34.98 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.522 179.571 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.523 ' O ' ' CB ' ' A' ' 121' ' ' MET . . . -112.55 47.27 1.1 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.468 -179.512 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.523 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 6.1 ptm 155.13 -39.42 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.267 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.487 ' HB3' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 172.48 -28.44 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.042 -179.971 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.516 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.8 OUTLIER -97.61 127.27 43.43 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.945 179.498 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.593 ' CB ' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -93.94 153.62 18.12 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.366 -179.249 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.508 ' O ' ' N ' ' A' ' 127' ' ' ILE . 59.5 t-20 -114.04 101.92 9.68 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.192 179.617 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.529 ' HB3' ' CG2' ' A' ' 114' ' ' THR . 0.7 OUTLIER -62.65 69.23 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.786 -179.721 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.508 ' N ' ' O ' ' A' ' 125' ' ' ASN . 26.1 mm -37.06 147.28 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.132 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.41 ' O ' ' C ' ' A' ' 129' ' ' ALA . 10.2 pt-20 -116.03 128.73 55.95 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.755 179.858 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.462 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -35.48 116.15 0.35 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.238 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -87.3 -12.61 46.01 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.739 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.461 ' HG3' ' O ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -174.28 126.52 0.34 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.764 179.96 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.457 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 8.0 t -41.83 124.87 2.71 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.779 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.453 ' O ' HG21 ' A' ' 109' ' ' VAL . . . -152.21 176.01 30.66 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.548 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.492 ' N ' ' CG2' ' A' ' 155' ' ' ILE . 13.1 m -125.15 108.26 11.6 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.701 0.286 . . . . 0.0 111.288 -179.828 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.504 ' HA ' ' CG1' ' A' ' 155' ' ' ILE . 19.0 t -44.2 144.97 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.624 179.435 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.527 ' HD2' ' CA ' ' A' ' 156' ' ' GLU . 21.3 mtpt -123.7 -18.49 6.07 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.225 -179.567 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.497 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 163.11 161.56 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.976 0.417 . . . . 0.0 111.631 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.641 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.6 OUTLIER -111.93 85.0 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.894 179.753 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.532 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 8.5 mt -49.12 -38.35 24.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.99 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.526 HG22 ' CD2' ' A' ' 152' ' ' LEU . 49.2 t -83.6 143.7 11.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.146 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.485 ' O ' ' C ' ' A' ' 142' ' ' SER . 17.2 mt-10 -74.5 78.15 1.94 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.06 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.491 ' HA ' ' CE2' ' A' ' 91' ' ' PHE . 11.6 p 21.77 -114.56 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 115.285 -0.871 . . . . 0.0 111.815 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.563 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -62.81 80.84 0.03 OUTLIER Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.839 -0.696 . . . . 0.0 113.043 -179.794 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.467 ' O ' HG22 ' A' ' 90' ' ' THR . 0.5 OUTLIER -157.56 144.15 13.12 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-O 121.078 0.466 . . . . 0.0 111.435 179.593 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.474 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 27.6 Cg_endo -62.4 151.57 81.98 Favored 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.974 2.449 . . . . 0.0 112.546 -179.792 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.514 HG13 ' CD2' ' A' ' 152' ' ' LEU . 18.3 m -143.93 -173.16 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.883 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.437 ' O ' ' C ' ' A' ' 148' ' ' PHE . 0.1 OUTLIER -150.26 149.64 30.43 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.899 179.992 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.499 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 2.0 t80 -34.33 124.15 0.5 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.822 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.499 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 17.4 t0 83.94 27.14 0.09 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.593 -179.607 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . . . . . . . . . 44.0 tp10 -110.33 73.73 0.79 Allowed Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.908 -179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.479 ' HB3' HG23 ' A' ' 82' ' ' ILE . 68.6 Cg_exo -34.18 127.59 0.18 Allowed 'Trans proline' 0 N--CA 1.459 -0.559 0 C-N-CA 122.825 2.35 . . . . 0.0 112.044 179.681 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.526 ' CD2' ' HB2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -122.46 -64.98 1.14 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.525 -179.425 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.542 ' CG1' ' CG2' ' A' ' 83' ' ' VAL . 1.6 p -103.92 102.89 14.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.254 -179.469 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.532 ' CG2' ' HG ' ' A' ' 139' ' ' LEU . 10.3 t -83.47 142.67 13.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 115.76 -0.654 . . . . 0.0 111.275 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.512 HG21 ' N ' ' A' ' 156' ' ' GLU . 27.5 mt -144.48 141.47 23.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.994 179.858 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.527 ' CA ' ' HD2' ' A' ' 136' ' ' LYS . 3.0 tt0 . . . . . 0 C--O 1.249 1.036 0 CA-C-O 118.283 -0.865 . . . . 0.0 110.919 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.753 0.311 . . . . 0.0 111.148 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -173.9 73.9 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.108 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -118.52 116.09 25.94 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.901 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.449 ' O ' ' O ' ' A' ' 79' ' ' SER . 0.9 OUTLIER -80.55 -11.85 12.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.277 -179.975 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.449 ' O ' ' O ' ' A' ' 78' ' ' ILE . 0.3 OUTLIER 33.87 -154.46 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.107 179.934 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.441 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -135.02 -123.27 2.32 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.442 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.566 ' CD2' ' HE3' ' A' ' 131' ' ' LYS . 17.1 t-80 172.53 84.19 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.788 0.328 . . . . 0.0 110.983 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.521 HG12 ' CG1' ' A' ' 154' ' ' VAL . 29.8 mt -92.26 116.62 33.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.07 0.462 . . . . 0.0 110.836 179.727 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.517 HG23 ' CD1' ' A' ' 115' ' ' LEU . 2.0 t -69.85 59.79 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.244 -179.701 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.477 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -47.53 135.08 11.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.725 179.823 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.528 ' CB ' HG22 ' A' ' 146' ' ' VAL . 1.3 p -39.3 104.63 0.32 Allowed Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.996 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.18 -7.18 16.51 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.656 2.237 . . . . 0.0 112.018 179.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.449 ' HG3' ' CB ' ' A' ' 120' ' ' ALA . 2.0 ptm -155.72 168.3 27.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.641 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 7.1 m -71.87 60.16 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.124 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.515 ' O ' ' CG2' ' A' ' 146' ' ' VAL . . . -116.96 -165.69 13.93 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.454 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.523 ' N ' ' O ' ' A' ' 119' ' ' GLU . 24.4 m -108.99 156.92 19.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.987 0.422 . . . . 0.0 111.024 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.649 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 11.9 t80 -106.77 140.68 39.22 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.263 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.578 ' CD2' ' OE1' ' A' ' 119' ' ' GLU . 17.6 m-85 -143.13 151.09 40.32 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.971 0.415 . . . . 0.0 111.063 179.607 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.475 ' O ' ' CB ' ' A' ' 101' ' ' ALA . 18.2 ptt180 -132.11 23.92 4.54 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.663 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.452 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 63.5 p -150.57 107.11 3.1 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.868 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.21 -16.11 31.68 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.651 2.234 . . . . 0.0 112.221 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -142.93 159.64 55.77 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.918 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -53.32 -63.33 0.24 Allowed 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.806 2.337 . . . . 0.0 112.341 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -110.99 79.79 1.24 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.876 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -135.2 -166.91 1.91 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.102 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.09 38.09 1.27 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.928 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.475 ' CB ' ' O ' ' A' ' 93' ' ' ARG . . . 49.39 -177.18 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.239 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.577 ' CZ ' HG23 ' A' ' 114' ' ' THR . 0.1 OUTLIER -90.11 -61.44 1.68 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.126 179.55 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.538 ' CG1' ' O ' ' A' ' 115' ' ' LEU . 2.2 mm -153.52 145.03 14.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.7 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -147.45 162.84 38.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.738 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.458 HG11 ' HA ' ' A' ' 136' ' ' LYS . 6.0 t -47.32 119.68 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.995 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 120.15 -27.04 6.86 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.249 -179.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.83 112.49 18.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.759 0.314 . . . . 0.0 110.807 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.465 ' O ' ' O ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -79.49 81.83 5.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.843 179.998 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.524 ' CG2' ' O ' ' A' ' 133' ' ' GLY . 14.7 m -45.28 176.11 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.003 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 109' ' ' VAL . 35.0 m120 -163.19 131.1 3.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.615 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.465 ' HA ' ' CB ' ' A' ' 129' ' ' ALA . 2.3 p -37.58 155.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.968 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.423 ' N ' ' CG2' ' A' ' 111' ' ' VAL . . . 75.78 -0.08 62.6 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.339 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.457 ' O ' ' HA ' ' A' ' 128' ' ' GLU . 2.5 t0 -107.17 -149.53 0.43 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.691 0.282 . . . . 0.0 110.689 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.577 HG23 ' CZ ' ' A' ' 102' ' ' PHE . 6.1 m -135.73 150.4 49.51 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.89 0.376 . . . . 0.0 111.012 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.538 ' O ' ' CG1' ' A' ' 103' ' ' ILE . 83.0 mt -106.81 -79.74 0.57 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.892 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . . . . . . . . . 14.9 p -134.51 -166.1 1.76 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.97 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.549 ' CG2' ' OE2' ' A' ' 119' ' ' GLU . 0.3 OUTLIER -115.01 125.22 72.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.297 -179.725 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.505 HG22 ' CG1' ' A' ' 127' ' ' ILE . 54.7 t -108.58 95.0 3.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.449 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.578 ' OE1' ' CD2' ' A' ' 92' ' ' TYR . 0.5 OUTLIER -102.76 105.0 15.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.877 -179.083 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.557 ' O ' ' CB ' ' A' ' 121' ' ' MET . . . -126.57 48.01 2.22 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.709 -179.684 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.557 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 152.55 51.88 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.25 179.907 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.48 ' HD3' ' O ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 56.14 18.2 3.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.343 -179.313 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.475 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 1.7 mtt -141.24 122.8 15.1 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.821 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.529 ' CA ' ' HG3' ' A' ' 119' ' ' GLU . 0.0 OUTLIER -75.15 171.82 13.47 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.428 -0.806 . . . . 0.0 111.44 -179.839 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.435 ' HB2' ' HB ' ' A' ' 118' ' ' VAL . 3.5 m120 -151.49 83.79 1.3 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.473 179.73 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -50.23 113.41 0.86 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.06 -179.67 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.505 ' CG1' HG22 ' A' ' 118' ' ' VAL . 18.8 mm -81.42 95.65 2.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.919 179.802 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.458 ' HA ' ' HA ' ' A' ' 114' ' ' THR . 1.4 mt-10 -72.05 144.08 48.87 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.115 -179.773 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.465 ' CB ' ' HA ' ' A' ' 111' ' ' VAL . . . -68.67 142.46 55.05 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.831 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 55.7 p30 -126.74 1.87 6.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.341 -0.391 . . . . 0.0 111.08 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.566 ' HE3' ' CD2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -158.83 22.21 0.21 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.092 -179.927 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.504 ' O ' ' NZ ' ' A' ' 131' ' ' LYS . 1.1 p 49.94 173.56 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.783 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.524 ' O ' ' CG2' ' A' ' 109' ' ' VAL . . . 156.56 176.02 28.18 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.571 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.55 ' N ' ' CG2' ' A' ' 155' ' ' ILE . 25.9 m -127.78 119.56 25.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.582 0.229 . . . . 0.0 111.307 -179.765 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.444 HG11 ' N ' ' A' ' 136' ' ' LYS . 73.3 t -52.36 144.7 3.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 179.172 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.53 ' HD3' ' CG ' ' A' ' 156' ' ' GLU . 22.4 mmmt -125.17 -18.77 5.32 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.685 0.279 . . . . 0.0 111.422 -179.431 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.45 ' HA ' ' CG2' ' A' ' 105' ' ' VAL . . . 167.05 156.78 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.178 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.649 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -109.88 84.58 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.032 179.821 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.519 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 3.6 mt -47.13 -25.86 0.98 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.415 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.531 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 78.3 t -104.8 149.47 8.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.735 179.71 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.513 ' HB2' ' CG ' ' A' ' 144' ' ' GLN . 4.1 mm-40 -52.55 -170.99 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.376 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.522 ' O ' ' O ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -84.87 -55.41 4.1 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 120.837 -0.345 . . . . 0.0 111.509 -179.789 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.536 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -128.16 103.14 0.61 Allowed Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.857 -179.342 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.513 ' CG ' ' HB2' ' A' ' 141' ' ' GLU . 0.0 OUTLIER -174.05 144.17 0.98 Allowed Pre-proline 0 C--N 1.326 -0.413 0 CA-C-O 121.034 0.445 . . . . 0.0 111.18 179.669 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 144' ' ' GLN . 43.7 Cg_exo -56.58 142.97 90.06 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.83 2.353 . . . . 0.0 112.036 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.528 HG22 ' CB ' ' A' ' 85' ' ' SER . 4.8 m -128.86 179.52 3.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.157 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.458 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 1.3 mt-10 -129.82 141.4 50.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.73 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.449 ' HA ' ' O ' ' A' ' 85' ' ' SER . 34.5 t80 -35.45 137.52 0.18 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.903 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.461 ' HA ' ' HD2' ' A' ' 84' ' ' ARG . 0.6 OUTLIER 72.32 26.13 2.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.756 -179.799 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.461 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 6.7 tp10 -106.81 73.96 0.35 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.869 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.477 ' HB3' HG22 ' A' ' 82' ' ' ILE . 61.0 Cg_exo -34.19 122.19 0.15 Allowed 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.869 2.379 . . . . 0.0 111.96 179.581 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.531 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -118.57 -66.61 1.06 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.563 -179.215 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.513 ' CG1' ' HB ' ' A' ' 83' ' ' VAL . 0.8 OUTLIER -96.7 106.22 18.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.289 -179.393 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.521 ' CG1' HG12 ' A' ' 82' ' ' ILE . 34.5 t -87.51 134.45 27.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.291 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.55 ' CG2' ' N ' ' A' ' 134' ' ' THR . 72.0 mt -135.73 140.02 45.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.987 179.785 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.538 ' CG ' ' HB ' ' A' ' 134' ' ' THR . 10.0 pt-20 . . . . . 0 C--O 1.249 1.027 0 CA-C-O 118.26 -0.876 . . . . 0.0 110.88 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . 0.405 ' O ' ' HB1' ' A' ' 76' ' ' ALA . . . . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.809 0.338 . . . . 0.0 111.042 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.405 ' HB1' ' O ' ' A' ' 75' ' ' ALA . . . 69.97 34.14 2.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.109 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -167.01 141.16 3.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.919 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.445 ' O ' HG21 ' A' ' 78' ' ' ILE . 8.5 mt -121.02 24.11 4.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.139 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 49.44 60.62 3.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.982 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.467 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -130.29 -176.89 14.6 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.533 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.577 ' CD2' ' HB ' ' A' ' 155' ' ' ILE . 16.1 t60 173.74 83.7 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.763 0.316 . . . . 0.0 110.901 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.557 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 0.0 OUTLIER -97.74 -179.2 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.56 179.617 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.514 ' CG2' ' CG1' ' A' ' 153' ' ' VAL . 48.7 t -117.62 2.87 7.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.365 179.728 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.498 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.9 OUTLIER 23.97 98.22 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.486 179.858 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.513 ' OG ' ' CG2' ' A' ' 146' ' ' VAL . 4.1 t -34.37 95.81 0.09 OUTLIER Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.795 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.519 ' O ' ' CD1' ' A' ' 148' ' ' PHE . 18.8 Cg_endo -58.91 -74.45 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.638 2.225 . . . . 0.0 111.9 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.513 ' CE ' ' HB1' ' A' ' 120' ' ' ALA . 6.0 mtm -70.77 156.51 39.43 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.783 179.645 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.515 ' CG2' ' O ' ' A' ' 88' ' ' VAL . 2.6 p -79.43 57.74 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.048 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.453 ' O ' HG21 ' A' ' 146' ' ' VAL . . . -114.34 -148.2 9.69 Favored Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.38 179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.583 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 16.9 m -122.91 144.22 49.37 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-O 121.087 0.47 . . . . 0.0 111.24 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.656 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 29.5 t80 -83.34 142.62 30.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.615 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.583 ' CZ ' HG23 ' A' ' 90' ' ' THR . 12.1 m-85 -144.88 153.68 41.84 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -139.73 32.83 2.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.845 179.845 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.465 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -148.5 109.5 3.61 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.881 179.902 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.22 -38.9 19.5 Favored 'Trans proline' 0 C--O 1.231 0.137 0 C-N-CA 122.752 2.301 . . . . 0.0 112.272 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.426 ' OG ' ' HD2' ' A' ' 97' ' ' PRO . 0.2 OUTLIER -129.02 168.78 14.86 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.9 179.995 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.426 ' HD2' ' OG ' ' A' ' 96' ' ' SER . 52.9 Cg_exo -52.29 -53.98 5.99 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.787 2.325 . . . . 0.0 112.221 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -124.5 71.79 1.17 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.874 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -119.09 -166.9 1.31 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.128 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -92.85 29.05 1.89 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.768 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.465 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 60.81 170.84 0.1 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.001 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.529 ' O ' ' CG2' ' A' ' 103' ' ' ILE . 0.0 OUTLIER -87.15 -43.26 12.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.849 -179.996 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.529 ' CG2' ' O ' ' A' ' 102' ' ' PHE . 1.1 pp -169.79 134.0 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.04 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.463 ' O ' ' CG1' ' A' ' 135' ' ' VAL . 5.7 mt-10 -137.5 157.8 45.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.966 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.458 ' HA ' HG23 ' A' ' 135' ' ' VAL . 3.0 t -38.55 125.36 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.078 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 109.45 -28.05 11.47 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.466 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.461 ' O ' HG11 ' A' ' 135' ' ' VAL . 5.6 tp60 -71.61 109.74 5.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.807 0.337 . . . . 0.0 110.867 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.454 ' O ' ' OD1' ' A' ' 110' ' ' ASN . 4.0 mttt -74.47 91.43 2.26 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.014 -179.862 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.581 ' CG1' ' CD2' ' A' ' 115' ' ' LEU . 0.0 OUTLIER -50.37 174.88 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.911 179.889 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.484 ' O ' ' CB ' ' A' ' 113' ' ' ASP . 6.9 m120 -162.53 131.33 4.15 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.09 0.472 . . . . 0.0 110.719 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.468 ' CG1' ' HA ' ' A' ' 131' ' ' LYS . 34.5 m -34.79 137.38 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.071 179.8 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 65.56 30.26 77.04 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.497 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.484 ' CB ' ' O ' ' A' ' 110' ' ' ASN . 11.1 t70 -125.52 104.86 8.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.743 0.306 . . . . 0.0 110.735 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.465 HG21 ' HB2' ' A' ' 126' ' ' GLN . 1.6 m -34.34 128.48 0.42 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.045 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.581 ' CD2' ' CG1' ' A' ' 109' ' ' VAL . 11.1 mt -95.15 -83.31 0.36 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.789 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.519 ' CB ' ' O ' ' A' ' 92' ' ' TYR . 0.5 OUTLIER -132.36 -169.26 2.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.673 179.927 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.519 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.2 OUTLIER -111.65 123.81 67.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.211 179.895 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.423 ' HB ' ' HB3' ' A' ' 125' ' ' ASN . 96.5 t -113.73 74.64 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.218 179.4 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.556 ' CG ' ' HB ' ' A' ' 90' ' ' THR . 2.4 pt-20 -58.31 89.96 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.286 -179.333 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.554 ' O ' ' CB ' ' A' ' 121' ' ' MET . . . -94.17 116.9 29.36 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.449 179.515 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.571 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.3 OUTLIER 90.25 -33.1 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.648 -179.344 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.571 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 150.34 -13.46 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.02 179.903 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.497 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 2.5 ptt? -106.57 134.32 49.9 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.91 0.386 . . . . 0.0 111.164 -179.623 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.519 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 2.4 ptm -55.51 133.31 50.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.135 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.447 ' OD1' ' CE ' ' A' ' 87' ' ' MET . 2.0 t-20 -120.27 68.6 0.85 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.669 179.823 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.465 ' HB2' HG21 ' A' ' 114' ' ' THR . 0.2 OUTLIER -43.01 131.86 4.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.844 -179.836 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.45 ' O ' ' HA ' ' A' ' 114' ' ' THR . 57.7 mt -95.18 149.59 4.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.245 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . 0.4 ' N ' HG21 ' A' ' 127' ' ' ILE . 4.5 mp0 -108.55 131.58 54.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.888 179.899 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.456 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -45.28 110.03 0.21 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.161 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -68.51 -20.4 64.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.796 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.468 ' HA ' ' CG1' ' A' ' 111' ' ' VAL . 0.0 OUTLIER -179.0 137.04 0.14 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.776 179.945 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.4 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 24.6 t -41.31 127.3 2.88 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.805 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.493 ' O ' ' N ' ' A' ' 109' ' ' VAL . . . -161.67 -178.94 36.02 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.613 -0.804 . . . . 0.0 112.63 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.547 ' N ' ' CG2' ' A' ' 155' ' ' ILE . 16.5 m -129.43 108.62 10.42 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.645 0.259 . . . . 0.0 111.419 -179.755 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.493 HG21 ' N ' ' A' ' 136' ' ' LYS . 2.2 p -49.13 144.12 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 179.284 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.529 ' CE ' ' HB2' ' A' ' 156' ' ' GLU . 4.5 mmtt -122.25 -20.28 6.23 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 121.05 -0.26 . . . . 0.0 111.456 -179.232 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.42 ' O ' HD11 ' A' ' 138' ' ' ILE . . . 175.35 175.32 0.23 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.054 0.454 . . . . 0.0 111.798 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.656 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 1.2 mm -125.82 85.09 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.861 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.525 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 5.9 mt -50.79 -21.73 1.8 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.768 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.535 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 69.9 t -108.11 151.44 10.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.254 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.446 ' O ' ' C ' ' A' ' 142' ' ' SER . 39.6 mt-10 -64.17 135.75 56.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.942 179.19 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.493 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -32.17 -61.35 0.25 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.595 -179.272 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.534 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -125.11 103.34 0.72 Allowed Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.505 -0.855 . . . . 0.0 112.895 -179.619 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.462 ' O ' HG21 ' A' ' 90' ' ' THR . 6.4 pt20 -170.94 153.81 4.02 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-O 120.938 0.399 . . . . 0.0 111.215 179.718 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.45 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 37.0 Cg_endo -65.92 140.03 59.07 Favored 'Trans proline' 0 C--O 1.232 0.209 0 C-N-CA 122.843 2.362 . . . . 0.0 112.534 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.513 ' CG2' ' OG ' ' A' ' 85' ' ' SER . 26.7 m -130.32 -171.68 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.893 179.864 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.422 ' O ' ' C ' ' A' ' 148' ' ' PHE . 2.5 tm-20 -130.11 137.92 50.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.971 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.521 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 1.5 t80 -35.72 120.01 0.57 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.744 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.521 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 5.4 t70 86.19 31.38 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.887 0.375 . . . . 0.0 110.524 -179.553 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.474 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 5.8 tp10 -107.18 75.1 0.42 Allowed Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.66 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.498 ' HA ' ' HA ' ' A' ' 84' ' ' ARG . 48.5 Cg_exo -30.58 109.71 0.04 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.723 0 C-N-CA 123.159 2.573 . . . . 0.0 112.377 179.69 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.566 ' HB2' ' CD2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -104.68 -56.1 2.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.315 -179.412 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.514 ' CG1' ' CG2' ' A' ' 83' ' ' VAL . 0.9 OUTLIER -103.43 111.8 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.402 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.45 -179.185 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.525 ' CG2' ' HG ' ' A' ' 139' ' ' LEU . 3.1 t -91.77 145.1 7.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.863 179.763 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.577 ' HB ' ' CD2' ' A' ' 81' ' ' HIS . 4.4 mt -138.53 147.68 25.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.433 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.529 ' HB2' ' CE ' ' A' ' 136' ' ' LYS . 6.8 tp10 . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.271 -0.871 . . . . 0.0 110.844 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.88 0.371 . . . . 0.0 111.108 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -129.42 170.59 13.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.106 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -131.75 65.99 1.56 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.9 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 5.7 tt -105.02 2.08 10.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.08 0.467 . . . . 0.0 111.397 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 43.32 34.09 0.68 Allowed 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.878 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -79.59 -158.66 15.34 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.489 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.549 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 31.8 t60 -177.98 79.39 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.776 0.322 . . . . 0.0 110.871 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.525 HG12 ' CG1' ' A' ' 154' ' ' VAL . 16.7 mt -95.54 143.05 12.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.157 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.52 ' HB ' ' CG1' ' A' ' 153' ' ' VAL . 2.2 t -103.34 54.32 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.21 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.456 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 2.1 ptt180 -38.21 141.97 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.803 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.475 ' N ' HD13 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -35.52 95.6 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.94 -179.974 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.441 ' N ' ' O ' ' A' ' 84' ' ' ARG . 66.7 Cg_exo -50.63 -20.2 6.1 Favored 'Trans proline' 0 N--CA 1.466 -0.143 0 C-N-CA 122.648 2.232 . . . . 0.0 112.157 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.485 ' SD ' ' CB ' ' A' ' 120' ' ' ALA . 2.2 ptm -162.76 177.52 9.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.723 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 93.3 t -70.77 97.66 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.145 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.522 ' O ' ' CG2' ' A' ' 146' ' ' VAL . . . -162.04 -166.86 21.58 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.37 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.543 ' HB ' ' CG ' ' A' ' 119' ' ' GLU . 3.6 m -109.52 126.96 54.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.789 0.328 . . . . 0.0 110.883 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.633 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 2.7 t80 -82.15 140.1 33.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.796 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.585 ' CE2' ' HG2' ' A' ' 119' ' ' GLU . 18.7 m-85 -137.92 152.9 49.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.934 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.526 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 0.7 OUTLIER -134.27 18.57 3.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.818 179.808 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.439 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 5.4 p -145.44 106.43 4.38 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.803 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.585 ' HG3' ' CG ' ' A' ' 102' ' ' PHE . 27.9 Cg_exo -61.98 -9.63 15.08 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.776 2.317 . . . . 0.0 112.429 -179.837 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 1.5 t -172.23 153.84 3.13 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.912 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_exo -55.84 -50.88 11.06 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.722 2.281 . . . . 0.0 112.269 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -106.29 56.52 0.66 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -121.08 -160.78 0.86 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.123 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 2.0 mmmt -103.99 24.26 11.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.002 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.439 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 57.81 162.64 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.073 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.585 ' CG ' ' HG3' ' A' ' 95' ' ' PRO . 0.1 OUTLIER -88.42 -41.38 12.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.981 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.522 ' CG2' ' O ' ' A' ' 102' ' ' PHE . 0.8 OUTLIER -175.53 150.29 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-O 120.939 0.4 . . . . 0.0 111.271 179.668 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.43 ' C ' HG13 ' A' ' 135' ' ' VAL . 5.0 pt-20 -152.06 158.62 43.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.683 179.775 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.483 HG21 ' HA ' ' A' ' 136' ' ' LYS . 6.8 p -48.24 105.26 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.166 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 123.9 -0.03 9.1 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.369 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.4 mm-40 -77.99 144.02 37.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.751 0.31 . . . . 0.0 110.98 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -98.94 90.73 4.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.907 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.466 HG21 ' O ' ' A' ' 133' ' ' GLY . 15.6 m -87.89 159.63 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.105 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.452 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 31.9 m-80 -162.35 130.39 3.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.067 0.46 . . . . 0.0 110.776 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 24.6 m -35.84 123.49 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.224 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 108.44 3.06 33.07 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.559 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -113.42 -149.39 0.45 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.766 0.317 . . . . 0.0 110.685 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.47 ' CG2' ' OE1' ' A' ' 126' ' ' GLN . 5.5 m -136.23 132.23 35.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.924 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.474 ' O ' HG22 ' A' ' 103' ' ' ILE . 75.4 mt -92.43 -84.71 0.27 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.916 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.505 ' HA ' ' CG ' ' A' ' 102' ' ' PHE . 2.3 p -143.78 -167.13 2.51 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.037 -179.894 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.583 HG13 ' CE2' ' A' ' 102' ' ' PHE . 2.8 mt -131.59 150.44 34.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.812 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.446 ' O ' ' N ' ' A' ' 120' ' ' ALA . 53.6 t -143.93 103.22 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.856 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.585 ' HG2' ' CE2' ' A' ' 92' ' ' TYR . 6.8 pt-20 -58.6 82.28 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.146 -179.681 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.54 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -95.67 99.92 11.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.663 179.627 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.54 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 88.43 30.96 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.563 -179.53 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.49 ' HB3' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 75.8 30.49 0.76 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.217 -179.996 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.485 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 18.6 mmt -149.39 124.77 10.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.967 0.413 . . . . 0.0 110.906 179.558 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.491 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -59.75 103.18 0.19 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.148 -179.824 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 31.4 t30 -83.31 80.68 9.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.547 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.47 ' OE1' ' CG2' ' A' ' 114' ' ' THR . 17.3 tt0 -56.81 124.03 17.07 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.94 -179.837 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 15.3 mm -91.17 120.35 39.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.136 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -90.93 143.16 27.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.882 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -57.05 116.73 3.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.047 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -117.42 14.35 14.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.811 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.462 ' HB3' ' CE1' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -179.39 102.99 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.69 -180.0 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.452 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 0.9 OUTLIER -42.77 122.59 2.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.616 179.897 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.466 ' O ' HG21 ' A' ' 109' ' ' VAL . . . -156.25 -167.32 17.42 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.615 -179.846 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.524 ' N ' HG22 ' A' ' 155' ' ' ILE . 21.3 m -140.16 112.42 7.75 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.511 0.196 . . . . 0.0 111.169 -179.791 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.459 ' HA ' ' HA ' ' A' ' 155' ' ' ILE . 38.3 t -44.85 140.14 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.243 179.365 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.531 ' HD3' ' CB ' ' A' ' 156' ' ' GLU . 1.0 OUTLIER -122.42 -17.01 7.17 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.755 0.312 . . . . 0.0 111.152 -179.263 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.52 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 162.41 148.17 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.486 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.633 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -94.92 86.18 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.498 179.649 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.537 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 0.6 OUTLIER -40.81 -29.41 0.1 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.094 0.473 . . . . 0.0 110.207 -179.87 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.525 HG22 ' CD2' ' A' ' 152' ' ' LEU . 56.1 t -106.99 137.98 35.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.863 179.843 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.458 ' O ' ' CG ' ' A' ' 144' ' ' GLN . 3.4 mt-10 -67.65 98.11 0.67 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.219 179.513 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.526 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 24.2 p -34.15 135.87 0.14 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.899 -179.588 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.578 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 84.24 34.34 17.63 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.323 -179.663 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.468 ' O ' HG21 ' A' ' 90' ' ' THR . 37.8 mm-40 -146.2 144.8 22.27 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 120.898 0.38 . . . . 0.0 111.144 -179.736 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.524 ' N ' HG22 ' A' ' 90' ' ' THR . 52.5 Cg_exo -55.32 177.26 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.862 2.375 . . . . 0.0 112.325 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.522 ' CG2' ' O ' ' A' ' 89' ' ' GLY . 0.2 OUTLIER -173.31 -174.42 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.193 -179.997 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.524 ' O ' ' CG ' ' A' ' 150' ' ' GLU . 8.8 tt0 -155.71 158.5 38.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.903 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.463 ' HA ' ' O ' ' A' ' 85' ' ' SER . 42.5 t80 -42.42 138.84 1.65 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.967 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 74.67 24.1 1.73 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.524 ' CG ' ' O ' ' A' ' 147' ' ' GLU . 67.4 mm-40 -115.12 73.3 3.37 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.841 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.456 ' HA ' ' HA ' ' A' ' 84' ' ' ARG . 62.7 Cg_exo -33.75 129.04 0.16 Allowed 'Trans proline' 0 N--CA 1.458 -0.567 0 C-N-CA 122.974 2.449 . . . . 0.0 112.165 179.648 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.525 ' CD2' HG22 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -125.49 -71.67 0.69 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.727 -179.349 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.52 ' CG1' ' HB ' ' A' ' 83' ' ' VAL . 1.7 p -93.77 104.0 15.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.873 -179.085 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.537 ' CG2' ' HG ' ' A' ' 139' ' ' LEU . 21.4 t -89.13 133.1 32.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.814 179.333 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.524 HG22 ' N ' ' A' ' 134' ' ' THR . 97.1 mt -135.43 134.16 52.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.146 -179.727 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.531 ' CB ' ' HD3' ' A' ' 136' ' ' LYS . 1.2 tm-20 . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.259 -0.877 . . . . 0.0 110.898 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.853 0.358 . . . . 0.0 111.173 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -166.74 40.94 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.062 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 50.0 tt0 -171.46 29.61 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.994 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 2.9 tp -81.58 -1.94 5.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.515 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' SER . . . . . 0.411 ' O ' ' C ' ' A' ' 80' ' ' GLY . 4.6 t -96.08 27.37 3.67 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.866 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.532 ' CA ' ' HB2' ' A' ' 156' ' ' GLU . . . 36.6 -114.62 0.22 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.487 -179.895 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.558 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 34.2 t60 -169.49 75.65 0.09 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.811 0.338 . . . . 0.0 110.812 179.814 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.529 HG12 ' CG1' ' A' ' 154' ' ' VAL . 6.2 mt -93.25 150.44 3.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.105 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.532 ' HB ' ' CG1' ' A' ' 153' ' ' VAL . 3.1 t -102.43 46.55 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.037 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.516 ' CD ' ' O ' ' A' ' 84' ' ' ARG . 0.0 OUTLIER -35.48 131.92 0.45 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.859 179.965 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.519 ' N ' HD13 ' A' ' 152' ' ' LEU . 95.2 p -36.56 99.16 0.17 Allowed Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.968 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -60.97 -11.98 20.57 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.619 2.213 . . . . 0.0 111.97 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.443 ' SD ' ' HB3' ' A' ' 120' ' ' ALA . 1.0 OUTLIER -160.58 167.76 26.42 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.607 179.856 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.481 ' CG2' ' O ' ' A' ' 88' ' ' VAL . 26.4 m -66.49 69.66 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.007 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.424 ' O ' HG21 ' A' ' 146' ' ' VAL . . . -121.67 -150.83 8.36 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.639 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.584 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 97.9 m -131.95 128.45 38.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.961 0.41 . . . . 0.0 111.028 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.633 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 69.8 t80 -68.75 143.49 54.65 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.526 179.724 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.584 ' CZ ' HG23 ' A' ' 90' ' ' THR . 7.8 m-30 -149.06 125.77 11.11 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.897 0.379 . . . . 0.0 110.85 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.494 ' O ' ' N ' ' A' ' 102' ' ' PHE . 39.8 ptt85 -117.54 22.52 12.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.883 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.52 112.24 5.03 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.962 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.52 -38.86 3.05 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.689 2.259 . . . . 0.0 112.333 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -130.38 161.64 59.31 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.849 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.457 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 38.4 Cg_endo -66.83 102.92 0.66 Allowed 'Trans proline' 0 C--O 1.231 0.13 0 C-N-CA 122.722 2.282 . . . . 0.0 112.362 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.457 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 9.3 t70 80.16 35.29 0.14 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.884 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -88.74 -155.31 0.33 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.012 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.93 27.97 3.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.801 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 54.48 174.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.054 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.576 ' CE2' HG13 ' A' ' 117' ' ' ILE . 0.1 OUTLIER -99.51 -35.2 9.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.874 179.972 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.521 ' CG2' ' O ' ' A' ' 102' ' ' PHE . 1.2 pp -179.03 123.53 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.987 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.421 ' C ' HG13 ' A' ' 135' ' ' VAL . 1.7 mt-10 -141.34 164.7 29.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.949 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.408 ' N ' HG13 ' A' ' 135' ' ' VAL . 38.7 t -37.09 135.38 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.118 -179.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 87.78 -24.5 10.47 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.557 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.419 ' HB3' ' O ' ' A' ' 104' ' ' GLU . 0.0 OUTLIER -71.66 94.62 1.36 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.84 0.352 . . . . 0.0 110.842 -179.967 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 10.5 mttm -75.53 105.16 6.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.906 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 5.5 m -80.04 173.44 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.177 -179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.466 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 4.5 p-10 -152.62 129.87 11.25 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.756 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.516 HG21 ' N ' ' A' ' 112' ' ' GLY . 7.5 p -43.26 143.17 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.582 -0.735 . . . . 0.0 111.081 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.516 ' N ' HG21 ' A' ' 111' ' ' VAL . . . 90.12 -2.13 81.07 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.412 -179.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -105.98 -146.81 0.39 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.571 0.224 . . . . 0.0 110.63 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 3.9 m -130.13 120.36 24.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.789 0.328 . . . . 0.0 111.016 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.414 ' N ' ' O ' ' A' ' 127' ' ' ILE . 15.8 mt -77.06 -85.35 0.06 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.793 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.439 ' O ' ' N ' ' A' ' 127' ' ' ILE . 5.0 p -148.14 171.09 16.46 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.795 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.576 HG13 ' CE2' ' A' ' 102' ' ' PHE . 3.7 mt -105.24 152.58 7.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.834 -179.874 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 90' ' ' THR . 55.6 t -144.04 103.23 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.052 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.498 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 1.9 mt-10 -65.54 100.78 0.53 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.151 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.443 ' HB3' ' SD ' ' A' ' 87' ' ' MET . . . -83.26 -77.09 0.26 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.377 0.608 . . . . 0.0 111.071 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.531 ' O ' ' CG ' ' A' ' 122' ' ' LYS . 7.6 ptm -91.37 32.71 1.03 Allowed 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.367 179.695 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.531 ' CG ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 90.47 2.73 0.16 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.817 -179.63 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.468 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 4.9 ptm -116.78 133.58 55.84 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.841 179.785 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.545 ' HB3' ' CD1' ' A' ' 117' ' ' ILE . 3.3 mpp? -55.85 120.09 6.82 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.872 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.415 ' CB ' ' O ' ' A' ' 118' ' ' VAL . 35.8 t30 -102.3 73.44 1.35 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.947 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.52 ' CA ' HG12 ' A' ' 117' ' ' ILE . 15.4 pt20 -51.75 130.9 29.77 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.039 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.439 ' N ' ' O ' ' A' ' 116' ' ' CYS . 31.2 mm -103.59 136.79 34.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.094 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -95.41 145.32 25.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.883 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.438 ' CB ' ' HA ' ' A' ' 111' ' ' VAL . . . -64.78 121.63 15.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.062 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -94.88 -8.86 36.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.988 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -173.99 134.12 0.45 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.829 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.466 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 88.7 p -49.81 119.14 3.29 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.646 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -141.83 -176.77 16.34 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.628 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.529 ' N ' HG22 ' A' ' 155' ' ' ILE . 23.4 m -136.17 109.34 7.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.631 0.253 . . . . 0.0 111.139 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.505 HG11 ' N ' ' A' ' 136' ' ' LYS . 67.1 t -48.27 142.49 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.289 179.4 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.536 ' CD ' ' HB3' ' A' ' 156' ' ' GLU . 55.1 mtpt -126.93 -19.8 4.35 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 121.042 -0.263 . . . . 0.0 111.705 -179.258 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 173.62 162.52 0.16 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.025 0.44 . . . . 0.0 111.773 -179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.633 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.6 OUTLIER -116.59 80.08 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.752 179.656 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.408 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 13.3 mt -47.99 -23.28 0.75 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.856 -179.822 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.53 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 53.5 t -108.16 143.34 18.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.235 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.472 ' HB2' ' HG2' ' A' ' 144' ' ' GLN . 4.9 mt-10 -59.61 136.06 57.87 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.922 179.31 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.472 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -30.61 -63.5 0.14 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.817 -179.259 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.576 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -124.06 103.54 0.77 Allowed Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.528 -0.844 . . . . 0.0 113.028 -179.393 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.486 ' C ' ' CG2' ' A' ' 90' ' ' THR . 0.0 OUTLIER -169.98 145.93 2.53 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-O 120.904 0.383 . . . . 0.0 111.149 179.616 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.466 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 39.0 Cg_exo -56.94 144.59 88.49 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.751 2.301 . . . . 0.0 112.066 179.803 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.526 HG12 ' CD2' ' A' ' 152' ' ' LEU . 0.2 OUTLIER -136.23 -174.21 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.201 -179.926 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -143.75 142.59 30.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.929 179.915 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.49 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 4.4 t80 -34.68 129.71 0.41 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.072 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.49 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.7 t70 83.01 23.6 0.15 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.918 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.458 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 25.7 mm-40 -109.54 74.28 0.68 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.835 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 84' ' ' ARG . 53.6 Cg_exo -33.71 126.38 0.15 Allowed 'Trans proline' 0 N--CA 1.458 -0.605 0 C-N-CA 122.866 2.377 . . . . 0.0 112.14 179.607 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.597 ' CB ' ' CD1' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -117.89 -68.42 0.92 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.607 -179.175 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.532 ' CG1' ' HB ' ' A' ' 83' ' ' VAL . 1.3 p -102.45 106.22 19.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.418 -179.217 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.529 ' CG1' HG12 ' A' ' 82' ' ' ILE . 4.2 t -87.89 130.2 37.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.05 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.529 HG22 ' N ' ' A' ' 134' ' ' THR . 91.3 mt -132.99 131.87 58.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.215 -179.788 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.536 ' HB3' ' CD ' ' A' ' 136' ' ' LYS . 14.9 tt0 . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.259 -0.877 . . . . 0.0 110.96 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.845 0.355 . . . . 0.0 111.051 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -152.95 -161.39 1.28 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.064 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -179.79 136.22 0.12 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.861 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -119.48 23.02 5.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.042 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 23.8 t 48.88 97.71 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.91 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.416 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -117.74 -174.56 16.72 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.336 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.52 ' N ' ' O ' ' A' ' 155' ' ' ILE . 23.7 t60 175.56 82.42 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.759 0.314 . . . . 0.0 110.943 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.533 HG12 ' CG1' ' A' ' 154' ' ' VAL . 10.8 mt -98.73 123.14 51.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.074 0.464 . . . . 0.0 110.976 179.79 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.51 ' HB ' ' CG1' ' A' ' 153' ' ' VAL . 2.0 t -76.29 57.55 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.762 -0.653 . . . . 0.0 111.312 -179.693 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.463 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -35.39 119.42 0.51 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.723 -179.977 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.531 ' N ' HD13 ' A' ' 152' ' ' LEU . 0.3 OUTLIER -35.26 104.84 0.26 Allowed Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.177 -179.755 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.458 ' O ' ' O ' ' A' ' 87' ' ' MET . 32.6 Cg_endo -64.14 138.57 62.37 Favored 'Trans proline' 0 C--O 1.231 0.145 0 C-N-CA 122.62 2.213 . . . . 0.0 111.654 179.508 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.458 ' O ' ' O ' ' A' ' 86' ' ' PRO . 3.9 ptp 42.3 -167.81 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.354 -179.613 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.412 HG23 ' HG2' ' A' ' 147' ' ' GLU . 52.4 t -88.36 106.96 17.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.847 0.356 . . . . 0.0 111.203 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.424 ' O ' HG21 ' A' ' 146' ' ' VAL . . . -157.54 -158.05 8.74 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.582 179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.581 HG23 ' CZ ' ' A' ' 92' ' ' TYR . 4.4 m -123.89 148.74 46.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.909 0.385 . . . . 0.0 111.088 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.654 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 46.8 t80 -90.99 140.6 29.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.042 -0.527 . . . . 0.0 109.927 179.307 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.582 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 11.3 m-85 -146.19 123.05 11.3 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.975 0.417 . . . . 0.0 111.169 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.463 ' HA ' ' HB2' ' A' ' 102' ' ' PHE . 41.3 ptt85 -116.04 39.35 3.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.673 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' THR . . . . . 0.454 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 31.2 p -150.86 115.6 3.23 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.022 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -71.85 -29.58 15.2 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.738 2.292 . . . . 0.0 112.204 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -143.35 158.88 56.94 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.875 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_exo -52.44 -38.74 74.58 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.69 2.26 . . . . 0.0 112.263 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 -129.05 60.34 1.55 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.922 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -116.14 -168.95 1.51 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.14 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . 0.475 ' NZ ' ' HB2' ' A' ' 100' ' ' LYS . 0.8 OUTLIER -91.4 27.04 2.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.978 179.951 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . 0.454 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 65.42 178.59 0.2 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.192 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.581 ' CE2' HG13 ' A' ' 117' ' ' ILE . 0.1 OUTLIER -95.22 -31.88 13.29 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.709 179.9 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.532 ' CG2' ' O ' ' A' ' 102' ' ' PHE . 0.1 OUTLIER 169.42 138.49 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.21 179.621 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.523 ' O ' ' CG1' ' A' ' 135' ' ' VAL . 5.3 pt-20 -140.78 160.0 40.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.0 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.445 ' HA ' HG23 ' A' ' 135' ' ' VAL . 7.7 p -43.57 123.14 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.217 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 111.07 -19.98 24.42 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.446 -179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.456 ' O ' HG11 ' A' ' 135' ' ' VAL . 0.2 OUTLIER -87.47 113.6 23.33 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.801 0.334 . . . . 0.0 110.859 179.975 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 1.1 pttt -75.84 117.1 17.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.896 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.501 ' CG1' HD22 ' A' ' 115' ' ' LEU . 35.2 m -86.78 168.41 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.087 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.47 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 2.5 p-10 -160.11 132.14 6.21 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 121.129 0.49 . . . . 0.0 110.696 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.498 ' HA ' ' CB ' ' A' ' 129' ' ' ALA . 4.1 t -36.86 139.87 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.963 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 88.99 7.38 70.54 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.27 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.461 ' O ' ' N ' ' A' ' 115' ' ' LEU . 6.8 m-20 -123.63 103.2 8.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.857 0.36 . . . . 0.0 110.835 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.414 ' C ' ' O ' ' A' ' 113' ' ' ASP . 4.3 m -37.23 94.72 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.925 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.501 HD22 ' CG1' ' A' ' 109' ' ' VAL . 9.9 mt -47.87 -91.0 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.703 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.453 ' O ' HG12 ' A' ' 127' ' ' ILE . 2.0 p -138.33 155.95 48.09 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.851 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.581 HG13 ' CE2' ' A' ' 102' ' ' PHE . 3.7 mt -89.79 153.21 3.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.025 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.475 ' HA ' ' O ' ' A' ' 90' ' ' THR . 86.3 t -145.23 101.08 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.852 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.516 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 2.4 mm-40 -55.27 84.49 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.243 -179.779 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.469 ' C ' ' CG ' ' A' ' 121' ' ' MET . . . -103.04 145.68 29.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.722 179.7 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.469 ' CG ' ' C ' ' A' ' 120' ' ' ALA . 2.2 ptm 45.53 26.82 0.34 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.035 0.445 . . . . 0.0 110.252 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.525 ' O ' ' CE ' ' A' ' 122' ' ' LYS . 0.1 OUTLIER 77.89 45.1 0.08 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.746 -179.698 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.51 ' N ' ' OE1' ' A' ' 119' ' ' GLU . 11.1 mtt -162.21 127.84 3.47 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.992 179.713 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.515 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.9 OUTLIER -57.68 87.18 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.56 179.61 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 12.6 t-20 -65.59 79.9 0.07 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.945 -179.799 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . 0.46 ' HG2' ' O ' ' A' ' 126' ' ' GLN . 0.0 OUTLIER -57.16 118.87 5.48 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.87 179.99 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.475 ' O ' ' N ' ' A' ' 115' ' ' LEU . 34.7 mm -84.77 134.26 27.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.042 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -108.08 116.55 32.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.957 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.498 ' CB ' ' HA ' ' A' ' 111' ' ' VAL . . . -37.8 113.49 0.28 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.131 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 42.9 p-10 -93.96 -14.36 26.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.935 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 15.6 ptmt -162.37 126.07 3.05 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.783 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.47 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 5.3 p -46.39 120.01 2.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.993 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.472 ' O ' HG21 ' A' ' 109' ' ' VAL . . . -143.59 -168.59 12.26 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.433 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.502 ' N ' HG22 ' A' ' 155' ' ' ILE . 17.4 m -143.81 107.31 4.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.684 0.278 . . . . 0.0 111.25 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.523 ' CG1' ' O ' ' A' ' 104' ' ' GLU . 7.1 p -45.73 141.15 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.301 179.43 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.494 ' O ' ' CB ' ' A' ' 137' ' ' ALA . 20.6 mtpt -120.82 -18.65 7.58 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.711 0.291 . . . . 0.0 111.111 -179.522 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.494 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 163.71 153.31 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.983 0.42 . . . . 0.0 111.765 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.654 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.1 OUTLIER -108.31 79.35 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.545 179.684 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 8.2 mt -44.93 -25.96 0.37 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.722 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.534 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 62.3 t -102.85 146.71 10.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.009 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.556 ' O ' ' CD2' ' A' ' 91' ' ' PHE . 15.4 mt-10 -51.25 -174.84 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.172 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.487 ' O ' ' O ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -82.18 -55.4 4.57 Favored 'General case' 0 C--N 1.324 -0.529 0 C-N-CA 120.881 -0.327 . . . . 0.0 110.921 179.935 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.569 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -126.5 103.1 0.66 Allowed Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.577 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.501 ' NE2' ' O ' ' A' ' 145' ' ' PRO . 0.0 OUTLIER -165.03 151.56 9.21 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-O 120.948 0.404 . . . . 0.0 111.352 179.92 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.501 ' O ' ' NE2' ' A' ' 144' ' ' GLN . 30.7 Cg_endo -63.72 131.17 30.29 Favored 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.97 2.447 . . . . 0.0 112.48 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.466 HG22 HD23 ' A' ' 152' ' ' LEU . 0.2 OUTLIER -133.05 176.81 8.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.896 179.886 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.54 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 2.3 mt-10 -133.41 156.86 46.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.969 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.473 ' HA ' ' O ' ' A' ' 85' ' ' SER . 8.3 t80 -40.57 153.6 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.895 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.453 ' OD1' ' O ' ' A' ' 149' ' ' ASP . 1.0 OUTLIER 54.8 28.04 9.73 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.529 179.806 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.54 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 11.0 tp10 -107.23 74.35 0.4 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.702 179.492 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.472 ' HB3' HG23 ' A' ' 82' ' ' ILE . 48.8 Cg_exo -31.35 129.13 0.08 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 123.138 2.559 . . . . 0.0 112.362 179.758 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.534 ' HA ' ' CG2' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -130.16 -68.91 0.69 Allowed 'General case' 0 C--O 1.232 0.181 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.694 -179.484 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.51 ' CG1' ' HB ' ' A' ' 83' ' ' VAL . 1.5 p -99.65 101.78 12.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.606 -178.941 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.533 ' CG1' HG12 ' A' ' 82' ' ' ILE . 23.8 t -81.86 138.49 19.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.0 179.602 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.52 ' O ' ' N ' ' A' ' 81' ' ' HIS . 83.6 mt -139.05 136.62 42.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.285 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.446 ' CA ' ' HD2' ' A' ' 136' ' ' LYS . 0.5 OUTLIER . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.282 -0.866 . . . . 0.0 110.927 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.114 0 CA-C-O 120.791 0.329 . . . . 0.0 111.003 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . 64.11 -81.12 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.062 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -91.58 131.48 36.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.903 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 7.0 mt -139.26 24.01 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.16 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 64.19 22.4 12.84 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.996 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . 0.469 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . 67.54 -150.1 51.26 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.592 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' HIS . . . . . 0.509 ' N ' ' O ' ' A' ' 155' ' ' ILE . 24.7 t60 171.21 83.98 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.778 0.323 . . . . 0.0 110.797 -179.864 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . 0.58 ' CD1' ' N ' ' A' ' 82' ' ' ILE . 0.2 OUTLIER -88.02 -177.52 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.992 0.425 . . . . 0.0 111.001 179.909 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.523 ' CG2' ' CG1' ' A' ' 153' ' ' VAL . 1.7 t -140.92 39.17 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.705 179.603 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' ARG . . . . . 0.528 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 1.7 ptt-85 -34.07 127.42 0.42 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.979 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' SER . . . . . 0.405 ' HA ' ' HD2' ' A' ' 86' ' ' PRO . 0.9 OUTLIER -38.37 112.02 0.64 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.883 179.986 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . 0.405 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 25.9 Cg_endo -61.96 -11.27 20.65 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.669 2.246 . . . . 0.0 111.945 179.853 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' MET . . . . . 0.507 ' SD ' ' CB ' ' A' ' 120' ' ' ALA . 5.6 ptm -156.59 177.09 11.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.598 179.844 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' VAL . . . . . 0.404 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 1.7 p -80.43 94.18 2.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.082 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -143.64 -123.42 1.74 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.613 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.545 ' CG2' ' CZ ' ' A' ' 92' ' ' TYR . 38.5 m -150.9 150.78 31.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.861 0.362 . . . . 0.0 110.996 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' PHE . . . . . 0.652 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 0.8 OUTLIER -116.89 143.27 45.89 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.931 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' TYR . . . . . 0.581 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 22.5 m-85 -142.9 163.17 33.52 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.029 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' ARG . . . . . 0.46 ' HG2' ' CB ' ' A' ' 142' ' ' SER . 29.0 ptt180 -143.83 24.69 1.67 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.752 179.695 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -156.51 91.99 2.52 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.767 179.833 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -68.47 -25.32 35.46 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.785 2.323 . . . . 0.0 112.565 -179.811 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.458 ' O ' ' HB1' ' A' ' 99' ' ' ALA . 0.9 OUTLIER -135.57 133.13 20.06 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 120.966 0.413 . . . . 0.0 111.057 -179.896 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.483 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 52.1 Cg_exo -54.55 109.98 0.46 Allowed 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.803 2.335 . . . . 0.0 112.23 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' ASP . . . . . 0.483 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 10.4 t70 81.6 46.67 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.823 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' ALA . . . . . 0.458 ' HB1' ' O ' ' A' ' 96' ' ' SER . . . -107.2 -166.47 1.16 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.081 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -90.41 23.51 2.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.795 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 56.88 159.7 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.146 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' PHE . . . . . 0.55 ' CD2' HG12 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -87.63 -37.79 16.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.82 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' ILE . . . . . 0.485 ' CG2' ' O ' ' A' ' 102' ' ' PHE . 0.6 OUTLIER -170.19 110.03 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.134 -179.999 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' GLU . . . . . 0.504 ' N ' ' OE1' ' A' ' 104' ' ' GLU . 12.5 pm0 -121.73 162.3 21.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.852 179.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.509 ' N ' HG13 ' A' ' 135' ' ' VAL . 4.4 t -45.36 97.74 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.091 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.02 -8.97 6.03 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.513 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 29.7 tp60 -70.64 99.59 1.69 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.793 0.33 . . . . 0.0 110.881 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.444 ' O ' ' O ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -67.67 61.06 0.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.962 -179.984 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . 0.517 HG21 ' N ' ' A' ' 133' ' ' GLY . 16.9 m -42.09 168.15 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.047 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' ASN . . . . . 0.49 ' ND2' ' HB2' ' A' ' 132' ' ' SER . 23.0 m120 -167.18 132.99 2.13 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.579 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.461 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 18.1 m -34.05 136.34 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.172 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 81.33 14.97 77.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.303 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' ASP . . . . . 0.422 ' O ' ' C ' ' A' ' 114' ' ' THR . 0.8 OUTLIER -128.51 105.88 8.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.854 0.359 . . . . 0.0 110.824 179.957 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' THR . . . . . 0.476 HG23 ' CZ ' ' A' ' 102' ' ' PHE . 1.3 m -35.18 127.93 0.54 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.033 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' LEU . . . . . 0.448 ' O ' HG22 ' A' ' 103' ' ' ILE . 14.7 mt -87.63 -83.95 0.2 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.908 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' CYS . . . . . 0.467 ' HB2' ' O ' ' A' ' 92' ' ' TYR . 21.4 p -135.2 -165.51 1.69 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.917 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' ILE . . . . . 0.566 ' CG2' ' CB ' ' A' ' 124' ' ' MET . 0.2 OUTLIER -113.7 113.92 45.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.212 -179.988 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.464 ' HB ' ' HB3' ' A' ' 125' ' ' ASN . 25.8 t -103.47 55.1 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.82 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' GLU . . . . . 0.465 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.2 OUTLIER -35.44 98.8 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.093 -179.842 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' ALA . . . . . 0.533 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -118.16 110.27 17.39 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.923 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' MET . . . . . 0.544 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.3 OUTLIER 87.07 21.42 0.06 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.855 -179.908 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.544 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 89.69 0.81 0.26 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.252 179.907 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.465 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.4 OUTLIER -119.86 133.58 55.53 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.854 0.359 . . . . 0.0 111.138 179.942 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.566 ' CB ' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -64.22 112.63 3.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.051 179.87 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.464 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 0.8 OUTLIER -86.7 74.93 9.74 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.656 179.715 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -48.88 112.27 0.59 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.005 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' ILE . . . . . 0.433 ' CG1' HG22 ' A' ' 118' ' ' VAL . 3.9 mm -90.94 145.5 7.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.044 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -122.61 123.65 41.67 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.985 -179.873 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -38.95 142.58 0.21 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.119 179.874 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -121.49 -7.56 9.18 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.042 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.485 ' NZ ' ' O ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -160.13 23.88 0.17 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.769 179.991 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' SER . . . . . 0.49 ' HB2' ' ND2' ' A' ' 110' ' ' ASN . 1.3 p 53.66 -176.57 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.632 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' GLY . . . . . 0.517 ' N ' HG21 ' A' ' 109' ' ' VAL . . . 150.13 167.09 14.0 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.575 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' THR . . . . . 0.543 ' N ' ' CG2' ' A' ' 155' ' ' ILE . 18.8 m -116.57 110.74 18.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.658 0.266 . . . . 0.0 111.18 -179.902 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.509 HG13 ' N ' ' A' ' 105' ' ' VAL . 95.0 t -47.22 142.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.472 179.51 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.509 ' N ' HG11 ' A' ' 135' ' ' VAL . 0.2 OUTLIER -124.83 -19.18 5.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.424 -179.399 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . 0.454 ' CB ' ' O ' ' A' ' 136' ' ' LYS . . . 167.23 155.97 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.835 0.35 . . . . 0.0 111.351 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' ILE . . . . . 0.652 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -106.94 82.92 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.948 179.835 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' LEU . . . . . 0.547 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 6.6 mt -41.2 -34.96 0.53 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 121.168 0.508 . . . . 0.0 109.97 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' VAL . . . . . 0.525 ' CG2' ' HA ' ' A' ' 152' ' ' LEU . 59.0 t -92.18 136.86 23.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.701 179.648 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . 0.463 ' O ' ' HG2' ' A' ' 144' ' ' GLN . 4.5 mt-10 -70.22 100.19 1.64 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.443 179.817 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.46 ' CB ' ' HG2' ' A' ' 93' ' ' ARG . 5.9 p -36.13 147.66 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.682 -179.698 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' GLY . . . . . 0.581 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 71.97 35.29 61.44 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.451 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' GLN . . . . . 0.463 ' HG2' ' O ' ' A' ' 141' ' ' GLU . 0.7 OUTLIER -149.03 153.48 38.27 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.883 0.373 . . . . 0.0 111.115 -179.913 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' PRO . . . . . 0.461 ' O ' HG11 ' A' ' 146' ' ' VAL . 57.3 Cg_endo -70.64 164.13 36.49 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.939 2.426 . . . . 0.0 112.268 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' VAL . . . . . 0.595 ' CG1' ' CD2' ' A' ' 152' ' ' LEU . 29.3 m -143.99 -179.38 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.195 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.43 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.5 OUTLIER -137.49 160.54 38.85 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.068 -179.853 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' PHE . . . . . 0.421 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 1.2 t80 -44.52 121.88 2.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.843 179.95 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' ASP . . . . . 0.421 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 4.9 t0 78.24 34.92 0.27 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.74 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' GLU . . . . . 0.443 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 3.9 tp10 -107.36 74.15 0.4 Allowed Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.94 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' PRO . . . . . 0.528 ' CD ' ' HB3' ' A' ' 84' ' ' ARG . 61.6 Cg_exo -34.7 119.65 0.14 Allowed 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 122.79 2.327 . . . . 0.0 111.915 179.577 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' LEU . . . . . 0.595 ' CD2' ' CG1' ' A' ' 146' ' ' VAL . 0.0 OUTLIER -116.06 -70.69 0.78 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.746 -179.163 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' VAL . . . . . 0.523 ' CG1' ' CG2' ' A' ' 83' ' ' VAL . 1.4 p -93.06 109.95 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.252 0 CA-C-O 121.152 0.501 . . . . 0.0 111.836 -179.13 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' VAL . . . . . 0.547 ' CG2' ' HG ' ' A' ' 139' ' ' LEU . 4.1 t -92.3 132.79 35.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.638 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.543 ' CG2' ' N ' ' A' ' 134' ' ' THR . 39.5 mt -132.73 140.0 48.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.229 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.493 ' HB2' ' CD ' ' A' ' 136' ' ' LYS . 31.7 tt0 . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.22 -0.895 . . . . 0.0 110.943 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 N-CA-C 112.456 -0.258 . . . . 0.0 112.456 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.514 ' N ' ' O ' ' A' ' 155' ' ' ILE . 25.6 t-80 -175.9 77.66 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.767 0.318 . . . . 0.0 110.888 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.998 HD12 HG13 ' A' ' 154' ' ' VAL . 0.1 OUTLIER -84.26 178.9 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 120.914 0.388 . . . . 0.0 111.08 179.868 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.737 ' CG2' HG13 ' A' ' 153' ' ' VAL . 25.2 t -130.42 37.98 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.903 179.686 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.526 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 10.9 ptt-85 -34.07 119.01 0.39 Allowed 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.906 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.489 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 3.7 t -34.86 104.46 0.25 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.984 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -47.2 -22.35 2.3 Favored 'Trans proline' 0 N--CA 1.465 -0.192 0 C-N-CA 122.678 2.252 . . . . 0.0 112.093 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -151.41 -168.93 3.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.545 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.632 HG12 ' O ' ' A' ' 88' ' ' VAL . 67.5 t -77.76 56.91 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.04 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.462 ' O ' HG23 ' A' ' 146' ' ' VAL . . . -103.55 -153.33 23.62 Favored Glycine 0 C--N 1.332 0.319 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.438 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.733 HG23 ' O ' ' A' ' 144' ' ' GLN . 17.8 m -130.68 145.17 51.86 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.901 0.382 . . . . 0.0 111.221 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.995 ' HB2' HD22 ' A' ' 152' ' ' LEU . 36.0 t80 -91.91 145.86 24.21 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.249 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.619 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 10.2 m-85 -146.65 154.29 41.29 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.003 0.43 . . . . 0.0 111.286 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.445 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 6.7 ptt85 -144.65 25.14 1.5 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.609 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.479 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 0.9 OUTLIER -151.17 100.04 3.03 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.905 179.909 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 94' ' ' THR . 47.5 Cg_endo -68.95 -32.46 22.02 Favored 'Trans proline' 0 C--O 1.231 0.133 0 C-N-CA 122.76 2.307 . . . . 0.0 112.213 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.534 ' CB ' ' HB2' ' A' ' 99' ' ' ALA . 0.4 OUTLIER -123.1 141.18 35.16 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.822 179.86 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -52.51 106.61 0.15 Allowed 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.732 2.288 . . . . 0.0 112.401 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 43.5 t0 71.24 34.7 1.72 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.043 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.534 ' HB2' ' CB ' ' A' ' 96' ' ' SER . . . -86.93 -154.94 0.25 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.976 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' LYS . . . . . 0.401 ' HA ' ' HD2' ' A' ' 100' ' ' LYS . 16.5 mmmt -94.83 23.52 5.43 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.832 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.479 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 56.86 167.08 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.019 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.958 ' O ' HD13 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -81.44 -51.68 8.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.677 179.868 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.958 HD13 ' O ' ' A' ' 102' ' ' PHE . 0.4 OUTLIER -152.59 148.25 14.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.023 179.759 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -143.39 149.17 37.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.838 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.428 HG13 ' HA ' ' A' ' 136' ' ' LYS . 16.7 t -44.59 123.37 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.053 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 123.98 -33.59 3.83 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.367 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.41 ' HA ' ' OE1' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -74.87 142.41 44.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.829 0.347 . . . . 0.0 110.748 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -103.58 101.61 11.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.067 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.782 ' CG2' ' HB2' ' A' ' 129' ' ' ALA . 2.3 p -66.23 164.39 2.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.775 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.587 ' N ' HG22 ' A' ' 109' ' ' VAL . 3.2 m120 -155.99 133.31 10.8 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-O 120.882 0.372 . . . . 0.0 110.376 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.47 ' C ' ' O ' ' A' ' 110' ' ' ASN . 2.4 t -26.16 123.41 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.518 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 85.92 21.5 52.69 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.216 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.487 ' HB2' ' O ' ' A' ' 110' ' ' ASN . 26.8 t0 -119.49 102.78 8.9 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.823 0.344 . . . . 0.0 110.832 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.467 HG23 ' HB2' ' A' ' 126' ' ' GLN . 1.4 m -41.28 132.16 2.64 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.912 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.524 ' O ' ' CG1' ' A' ' 103' ' ' ILE . 56.4 mt -96.5 -86.25 0.32 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.829 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.643 ' SG ' HG11 ' A' ' 153' ' ' VAL . 0.6 OUTLIER -131.94 -175.59 3.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.04 -179.945 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.537 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.1 OUTLIER -104.11 127.02 58.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.95 179.942 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.588 ' O ' HG12 ' A' ' 118' ' ' VAL . 58.8 t -108.31 60.25 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.942 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.484 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.3 OUTLIER -43.05 88.56 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.247 -179.888 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.545 ' O ' ' CB ' ' A' ' 121' ' ' MET . . . -92.65 109.55 20.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.718 179.735 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.557 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.8 OUTLIER 90.18 -29.59 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.763 -179.683 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.557 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 150.04 -15.95 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.88 179.622 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.484 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.4 OUTLIER -101.08 134.54 43.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.049 -179.662 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.537 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -55.25 145.34 21.89 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.125 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.493 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 1.0 OUTLIER -134.4 65.95 1.55 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.571 179.797 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.467 ' HB2' HG23 ' A' ' 114' ' ' THR . 4.8 pm0 -38.85 145.1 0.1 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.049 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.47 ' O ' ' N ' ' A' ' 115' ' ' LEU . 29.2 mm -117.18 130.62 71.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.986 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -105.56 128.11 53.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.079 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.782 ' HB2' ' CG2' ' A' ' 109' ' ' VAL . . . -44.32 147.24 0.57 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.922 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -114.06 -15.41 12.28 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.51 ' HD3' ' CD2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -163.22 36.86 0.1 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.086 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.6 t 55.92 -174.9 0.05 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.582 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.492 ' N ' HG13 ' A' ' 109' ' ' VAL . . . 149.71 -178.88 26.92 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.604 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.621 ' N ' HG23 ' A' ' 155' ' ' ILE . 26.7 m -136.27 117.38 14.4 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.611 0.243 . . . . 0.0 111.17 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.468 ' HA ' HG12 ' A' ' 155' ' ' ILE . 97.7 t -49.92 140.45 3.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.476 179.452 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.64 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 27.7 mmmt -125.02 -19.65 5.14 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.576 -0.284 . . . . 0.0 111.376 -179.461 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.64 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 168.51 159.96 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.888 0.375 . . . . 0.0 111.584 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.656 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -110.72 83.62 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.815 179.83 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.656 HD21 HG21 ' A' ' 154' ' ' VAL . 4.7 mt -44.27 -34.87 2.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.081 0.467 . . . . 0.0 110.336 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.979 HG21 HD23 ' A' ' 152' ' ' LEU . 52.1 t -96.54 160.86 2.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.626 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.529 ' N ' HG12 ' A' ' 140' ' ' VAL . 3.0 mm-40 -58.75 -149.54 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.506 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -103.43 -63.61 1.16 Allowed 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.695 179.393 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.619 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -124.88 97.37 0.53 Allowed Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.632 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.733 ' O ' HG23 ' A' ' 90' ' ' THR . 0.0 OUTLIER -166.53 156.3 10.41 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.954 0.407 . . . . 0.0 110.998 179.839 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.443 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 35.4 Cg_exo -59.86 160.15 22.66 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.827 2.351 . . . . 0.0 112.277 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.804 HG12 ' HG2' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -152.66 176.19 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.06 179.878 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.488 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 3.8 tt0 -126.71 145.11 50.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.996 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.541 ' CE2' ' OD1' ' A' ' 149' ' ' ASP . 16.9 t80 -34.96 139.4 0.09 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.91 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.541 ' OD1' ' CE2' ' A' ' 148' ' ' PHE . 1.6 m-20 68.6 27.45 6.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.788 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.804 ' HG2' HG12 ' A' ' 146' ' ' VAL . 7.0 tp10 -105.38 74.63 0.28 Allowed Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.897 179.864 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.912 ' O ' HG23 ' A' ' 140' ' ' VAL . 64.3 Cg_exo -35.84 131.99 0.3 Allowed 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 122.924 2.416 . . . . 0.0 112.086 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.995 HD22 ' HB2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -123.61 -58.91 1.57 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.355 -179.345 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.737 HG13 ' CG2' ' A' ' 83' ' ' VAL . 1.6 p -108.75 111.82 37.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.066 -179.581 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.998 HG13 HD12 ' A' ' 82' ' ' ILE . 2.5 t -88.27 136.88 22.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.23 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.621 HG23 ' N ' ' A' ' 134' ' ' THR . 9.0 mt -134.56 138.42 49.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.019 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.528 ' CG ' ' HB ' ' A' ' 134' ' ' THR . 0.9 OUTLIER . . . . . 0 C--O 1.249 1.044 0 CA-C-O 118.172 -0.918 . . . . 0.0 110.904 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.45 -0.379 0 N-CA-C 112.568 -0.213 . . . . 0.0 112.568 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.694 ' CD2' ' HD3' ' A' ' 131' ' ' LYS . 36.0 t-80 174.38 82.29 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.78 0.324 . . . . 0.0 110.877 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.859 HG12 HG13 ' A' ' 154' ' ' VAL . 4.6 mt -115.58 151.7 17.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.117 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.92 HG12 ' CG1' ' A' ' 153' ' ' VAL . 3.6 p -109.85 44.24 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.026 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.519 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -33.51 131.48 0.23 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.092 -179.943 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.584 ' HB3' HD21 ' A' ' 152' ' ' LEU . 4.4 p -35.83 97.51 0.13 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.873 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 14.2 Cg_endo -57.41 -14.95 17.66 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.608 2.205 . . . . 0.0 111.87 179.846 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.51 ' SD ' ' HB1' ' A' ' 120' ' ' ALA . 0.3 OUTLIER -151.31 164.96 35.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.47 179.718 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.655 HG22 ' O ' ' A' ' 88' ' ' VAL . 1.7 p -71.01 77.9 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.975 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -127.65 -128.58 3.13 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.545 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.525 ' HA ' ' HA ' ' A' ' 145' ' ' PRO . 8.3 m -147.44 134.49 20.36 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.773 0.32 . . . . 0.0 110.924 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.911 ' CB ' HD22 ' A' ' 152' ' ' LEU . 1.7 t80 -95.69 144.76 25.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.781 179.846 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.59 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 12.8 m-85 -141.04 160.07 40.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.061 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.523 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 0.8 OUTLIER -142.22 24.8 1.94 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.689 179.885 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.424 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 82.5 p -132.29 101.98 14.5 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.799 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.552 ' HB3' ' CE1' ' A' ' 102' ' ' PHE . 41.1 Cg_endo -67.37 -43.44 5.98 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.828 2.352 . . . . 0.0 112.403 -179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -129.95 160.45 65.09 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.06 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.449 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 55.9 Cg_endo -70.73 106.98 1.94 Allowed 'Trans proline' 0 N--CA 1.464 -0.208 0 C-N-CA 122.72 2.28 . . . . 0.0 112.319 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.449 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 18.7 t70 80.24 43.58 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.918 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -109.04 -160.39 0.72 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.029 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 1.1 mtpp -93.65 23.02 4.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.844 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.44 ' HB1' ' O ' ' A' ' 93' ' ' ARG . . . 64.34 176.83 0.18 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.013 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.895 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -85.69 -42.14 14.53 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.714 179.942 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.895 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.1 pp -172.68 145.78 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.959 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.44 ' O ' ' HB2' ' A' ' 107' ' ' GLN . 5.9 pt-20 -149.99 167.69 26.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.906 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.592 HG22 ' C ' ' A' ' 136' ' ' LYS . 89.9 t -45.56 128.02 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.104 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 100.42 -13.74 59.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.508 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.44 ' HB2' ' O ' ' A' ' 104' ' ' GLU . 0.0 OUTLIER -72.93 114.98 11.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.853 0.358 . . . . 0.0 110.935 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.445 ' O ' ' ND2' ' A' ' 110' ' ' ASN . 17.6 mttt -81.95 83.57 7.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.925 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.893 HG11 HD23 ' A' ' 115' ' ' LEU . 3.0 m -68.04 165.09 2.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.038 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.479 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 2.6 m-80 -157.74 130.39 7.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.101 0.477 . . . . 0.0 110.789 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.486 HG13 ' N ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -33.87 112.37 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.536 -0.757 . . . . 0.0 111.174 -179.984 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 110.39 13.0 15.87 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.844 -0.694 . . . . 0.0 112.385 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.476 ' O ' ' N ' ' A' ' 115' ' ' LEU . 17.3 t0 -122.58 103.04 8.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.753 0.311 . . . . 0.0 110.724 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.432 ' C ' ' O ' ' A' ' 113' ' ' ASP . 2.0 m -34.13 93.29 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.113 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.893 HD23 HG11 ' A' ' 109' ' ' VAL . 8.3 mt -50.05 -76.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.699 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.45 ' HA ' ' CG ' ' A' ' 102' ' ' PHE . 14.1 p -146.9 -155.66 0.64 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.653 179.76 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.979 HD13 ' HB3' ' A' ' 124' ' ' MET . 2.3 mt -136.71 152.86 29.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.691 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.513 ' O ' ' N ' ' A' ' 120' ' ' ALA . 92.3 t -139.59 88.5 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.205 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.579 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -51.16 85.8 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.916 179.99 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 118' ' ' VAL . . . -104.4 140.2 38.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.517 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 50.64 22.13 1.03 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.577 -179.726 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.535 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 86.17 36.41 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.859 -179.803 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.481 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 32.4 mmm -151.33 129.27 11.72 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.076 179.752 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.979 ' HB3' HD13 ' A' ' 117' ' ' ILE . 33.0 mtt -67.13 93.39 0.29 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.945 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -70.7 76.86 0.6 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.889 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.49 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 17.3 pt20 -55.39 108.67 0.45 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.859 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.504 HG21 HG21 ' A' ' 83' ' ' VAL . 12.8 mm -74.53 151.41 6.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.053 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -123.51 123.23 40.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.91 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -41.0 124.95 2.29 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.89 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -113.26 15.0 19.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.917 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.694 ' HD3' ' CD2' ' A' ' 81' ' ' HIS . 2.0 tmtt? 176.35 105.32 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.864 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.479 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 2.4 t -37.06 114.59 0.33 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.622 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.496 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -147.31 -173.49 18.5 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.732 -179.758 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.621 ' N ' HG23 ' A' ' 155' ' ' ILE . 19.7 m -128.73 108.55 10.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.662 0.268 . . . . 0.0 111.251 -179.685 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.534 ' HA ' ' CG1' ' A' ' 155' ' ' ILE . 69.9 t -39.29 144.81 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 179.224 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.72 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 38.4 mtpt -121.45 -20.58 6.56 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.666 0.269 . . . . 0.0 111.117 -179.583 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.72 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 160.81 165.29 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.382 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.639 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -107.93 81.8 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.624 179.595 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.747 HD12 ' HB2' ' A' ' 151' ' ' PRO . 2.4 mt -41.55 -29.07 0.15 Allowed 'General case' 0 CA--C 1.52 -0.211 0 CA-C-O 121.064 0.459 . . . . 0.0 110.467 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.981 HG21 HD23 ' A' ' 152' ' ' LEU . 54.8 t -102.85 137.36 31.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.771 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.434 ' O ' ' C ' ' A' ' 142' ' ' SER . 5.9 mt-10 -66.73 94.11 0.29 Allowed 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.349 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.523 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 77.4 p -34.95 137.44 0.13 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.816 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.59 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 84.02 35.82 14.6 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.529 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.506 ' O ' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -155.33 159.36 31.78 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.983 0.42 . . . . 0.0 111.125 -179.881 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.525 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 45.5 Cg_endo -68.65 178.37 3.95 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.79 2.327 . . . . 0.0 112.47 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.94 HG11 ' CD2' ' A' ' 152' ' ' LEU . 0.0 OUTLIER -157.86 -173.82 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.066 -179.944 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.461 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 1.8 tt0 -140.59 148.43 40.93 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.982 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.43 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 66.7 t80 -37.66 122.62 0.97 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.868 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.43 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 7.1 t70 79.81 35.54 0.15 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.894 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.461 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 1.8 mt-10 -112.64 74.48 1.64 Allowed Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.845 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.747 ' HB2' HD12 ' A' ' 139' ' ' LEU . 52.6 Cg_exo -32.95 120.45 0.1 Allowed 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 122.926 2.417 . . . . 0.0 111.834 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.981 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -109.62 -60.69 1.74 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.979 -179.102 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.92 ' CG1' HG12 ' A' ' 83' ' ' VAL . 2.3 p -111.96 110.35 31.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.066 0.46 . . . . 0.0 111.531 -179.275 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.859 HG13 HG12 ' A' ' 82' ' ' ILE . 4.9 t -92.2 145.49 7.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.354 179.811 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.621 HG23 ' N ' ' A' ' 134' ' ' THR . 35.8 mt -142.7 138.4 28.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.063 179.909 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.461 ' CA ' ' HD2' ' A' ' 136' ' ' LYS . 2.2 tm-20 . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.217 -0.897 . . . . 0.0 110.914 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.486 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.365 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.511 ' N ' ' O ' ' A' ' 155' ' ' ILE . 16.1 t-80 167.69 86.34 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.784 0.326 . . . . 0.0 110.672 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.565 HG21 ' HB3' ' A' ' 151' ' ' PRO . 0.3 OUTLIER -85.07 164.23 2.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 121.05 0.453 . . . . 0.0 111.101 179.962 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.6 ' O ' HD12 ' A' ' 152' ' ' LEU . 4.3 t -120.01 49.35 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.295 -179.828 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.56 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 5.2 ptt180 -48.41 136.04 13.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.892 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.798 ' HB3' HG21 ' A' ' 146' ' ' VAL . 24.1 p -45.19 111.91 1.43 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.798 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.654 ' HD2' HG11 ' A' ' 118' ' ' VAL . 24.7 Cg_endo -61.51 -10.21 15.66 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.652 2.235 . . . . 0.0 112.139 179.751 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.411 ' SD ' ' HG2' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -160.3 -170.46 2.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.687 179.902 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 60.2 t -86.62 84.18 2.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.071 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.46 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -135.27 -138.97 3.96 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.699 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' THR . . . . . 1.017 HG23 ' C ' ' A' ' 144' ' ' GLN . 62.0 m -141.33 141.2 33.88 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.85 0.357 . . . . 0.0 111.036 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.825 ' CZ ' HG21 ' A' ' 138' ' ' ILE . 18.2 t80 -86.64 144.73 27.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.749 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.579 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 16.0 m-85 -146.49 159.09 43.86 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.856 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.582 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 1.6 ptt85 -149.3 21.28 0.95 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.85 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.453 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 33.5 p -149.75 107.69 3.28 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.839 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.442 ' HG2' ' CB ' ' A' ' 99' ' ' ALA . 58.9 Cg_endo -72.07 -15.73 28.97 Favored 'Trans proline' 0 N--CA 1.465 -0.199 0 C-N-CA 122.776 2.318 . . . . 0.0 112.369 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.36 149.13 6.28 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.999 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_exo -51.32 -25.82 19.13 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.802 2.335 . . . . 0.0 112.282 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -125.68 51.2 1.75 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.789 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.442 ' CB ' ' HG2' ' A' ' 95' ' ' PRO . . . -114.34 -162.39 0.81 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.28 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' LYS . . . . . 0.46 ' O ' ' O ' ' A' ' 101' ' ' ALA . 2.0 ptmt -115.16 24.2 11.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.881 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.582 ' HB1' ' O ' ' A' ' 93' ' ' ARG . . . 50.13 172.35 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.14 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.577 ' CE2' HG12 ' A' ' 117' ' ' ILE . 11.6 m-30 -98.56 -45.42 6.09 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.84 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.838 HD11 HG21 ' A' ' 153' ' ' VAL . 2.5 pp -160.14 141.74 4.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.176 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.469 ' HG2' ' HB2' ' A' ' 107' ' ' GLN . 15.2 pt-20 -132.18 171.64 13.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.919 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.632 HG13 ' O ' ' A' ' 105' ' ' VAL . 9.5 p -56.29 114.89 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.207 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 92.52 0.62 69.6 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.614 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.469 ' HB2' ' HG2' ' A' ' 104' ' ' GLU . 4.4 tp-100 -74.57 115.17 13.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.82 0.343 . . . . 0.0 110.845 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.09 129.1 37.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.97 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.421 ' O ' ' CG ' ' A' ' 110' ' ' ASN . 28.5 m -112.19 172.99 2.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.275 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.451 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 4.0 m120 -162.36 130.95 4.13 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-O 121.12 0.486 . . . . 0.0 110.657 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.707 HG12 ' N ' ' A' ' 131' ' ' LYS . 27.3 m -41.46 126.87 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.137 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 113.16 -1.95 25.41 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.534 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -112.21 -148.32 0.43 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.685 0.278 . . . . 0.0 110.616 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.8 134.01 44.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.936 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.609 HD12 HG22 ' A' ' 127' ' ' ILE . 61.5 mt -87.35 -72.64 0.51 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.809 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.404 ' HB2' ' O ' ' A' ' 92' ' ' TYR . 0.8 OUTLIER -155.74 -174.91 5.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.856 179.941 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.577 HG12 ' CE2' ' A' ' 102' ' ' PHE . 0.0 OUTLIER -110.31 115.8 50.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.179 -179.879 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.654 HG11 ' HD2' ' A' ' 86' ' ' PRO . 1.7 t -99.27 56.69 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.677 179.671 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.482 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.4 OUTLIER -33.85 93.98 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.224 -179.606 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.495 ' O ' ' HG3' ' A' ' 121' ' ' MET . . . -110.76 138.76 46.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.897 179.751 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.511 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 62.71 13.17 6.18 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.796 -179.95 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.511 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.1 OUTLIER 85.44 53.42 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.866 -179.881 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.482 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.2 OUTLIER -171.11 132.79 0.84 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.988 179.884 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -49.46 125.28 10.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.977 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.463 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 1.7 t-20 -107.92 60.4 0.61 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.719 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.403 ' C ' ' O ' ' A' ' 125' ' ' ASN . 13.6 pt20 -36.58 131.1 0.7 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.877 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.609 HG22 HD12 ' A' ' 115' ' ' LEU . 37.2 mm -111.05 118.1 56.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.173 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 14.8 mm-40 -88.32 124.86 34.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.95 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -44.96 116.08 1.02 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.081 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -101.41 12.72 36.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.797 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.707 ' N ' HG12 ' A' ' 111' ' ' VAL . 0.3 OUTLIER 179.51 122.91 0.06 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.758 -179.954 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.451 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.4 t -56.41 126.75 27.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.71 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.431 ' HA3' ' CG2' ' A' ' 155' ' ' ILE . . . -157.17 -173.38 25.52 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.587 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.626 ' N ' HG23 ' A' ' 155' ' ' ILE . 61.6 m -135.51 108.79 7.79 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.765 0.317 . . . . 0.0 111.066 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.514 ' HA ' ' HA ' ' A' ' 155' ' ' ILE . 94.7 t -46.65 143.89 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.612 179.602 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.554 ' HD2' ' CG1' ' A' ' 154' ' ' VAL . 0.0 OUTLIER -115.03 -35.56 4.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 121.317 0.579 . . . . 0.0 109.729 -179.934 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.638 ' O ' HG23 ' A' ' 154' ' ' VAL . . . 177.64 142.41 0.09 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.164 -0.925 . . . . 0.0 111.36 -179.667 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.863 HG23 HG22 ' A' ' 153' ' ' VAL . 0.0 OUTLIER -88.93 86.88 2.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.249 179.421 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.431 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 75.9 mt -41.62 -28.45 0.14 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.438 -179.653 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.931 HG21 HD23 ' A' ' 152' ' ' LEU . 54.5 t -102.07 158.42 4.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.102 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.506 ' N ' HG12 ' A' ' 140' ' ' VAL . 1.1 mm-40 -59.56 -146.84 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 178.784 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.501 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -101.73 -59.6 1.67 Allowed 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.623 -0.431 . . . . 0.0 110.913 179.404 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.569 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -125.48 102.34 0.66 Allowed Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.64 -179.78 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 1.017 ' C ' HG23 ' A' ' 90' ' ' THR . 0.0 OUTLIER -167.99 136.64 1.96 Allowed Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 120.959 0.409 . . . . 0.0 111.259 179.766 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.502 ' N ' HG23 ' A' ' 90' ' ' THR . 50.5 Cg_exo -53.28 154.06 15.42 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.849 2.366 . . . . 0.0 112.405 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.798 HG21 ' HB3' ' A' ' 85' ' ' SER . 4.5 m -144.87 -156.48 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.999 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.573 ' N ' HG23 ' A' ' 146' ' ' VAL . 24.5 mt-10 -149.28 150.86 33.22 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.969 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.458 ' HA ' ' O ' ' A' ' 85' ' ' SER . 37.5 t80 -42.75 141.4 1.08 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.805 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 66.13 29.47 9.85 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.772 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 0.8 OUTLIER -110.06 74.66 0.81 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.897 179.886 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.565 ' HB3' HG21 ' A' ' 82' ' ' ILE . 58.4 Cg_exo -32.89 135.56 0.08 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.579 0 C-N-CA 122.898 2.399 . . . . 0.0 111.999 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.931 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -134.32 -37.69 0.86 Allowed 'General case' 0 N--CA 1.453 -0.282 0 CA-C-O 121.024 0.44 . . . . 0.0 110.657 -179.511 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.863 HG22 HG23 ' A' ' 138' ' ' ILE . 2.3 t -128.34 115.64 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.595 -178.743 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.638 HG23 ' O ' ' A' ' 137' ' ' ALA . 1.2 t -97.18 127.07 49.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.017 179.505 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.626 HG23 ' N ' ' A' ' 134' ' ' THR . 7.9 mt -121.88 149.05 25.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.272 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.217 -0.897 . . . . 0.0 110.947 -179.901 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.379 0 N-CA-C 112.27 -0.332 . . . . 0.0 112.27 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.52 ' N ' ' O ' ' A' ' 155' ' ' ILE . 39.0 t-80 -176.49 77.98 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.808 0.337 . . . . 0.0 111.009 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.881 HG12 HG13 ' A' ' 154' ' ' VAL . 18.5 mt -96.36 140.84 16.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.002 0.43 . . . . 0.0 111.07 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.865 HG23 HG13 ' A' ' 153' ' ' VAL . 1.8 t -91.69 48.7 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.104 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.485 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 7.1 ptt-85 -35.49 130.63 0.51 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.843 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.46 ' OG ' ' O ' ' A' ' 87' ' ' MET . 28.4 t -35.45 94.36 0.07 OUTLIER Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.038 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.462 ' N ' ' O ' ' A' ' 84' ' ' ARG . 51.3 Cg_exo -53.98 -24.98 34.25 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.662 2.242 . . . . 0.0 112.04 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.496 ' SD ' ' CB ' ' A' ' 120' ' ' ALA . 14.5 ptp -157.0 176.37 12.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.712 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 69.2 t -71.97 85.88 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.171 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.48 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -137.72 -150.87 5.77 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.572 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.622 ' CG2' ' CZ ' ' A' ' 92' ' ' TYR . 3.0 m -129.09 130.87 47.05 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.913 0.387 . . . . 0.0 111.043 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.779 ' HB2' HD22 ' A' ' 152' ' ' LEU . 53.2 t80 -76.52 146.87 38.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.562 179.765 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.644 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 14.7 m-85 -150.45 154.76 38.27 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.921 0.391 . . . . 0.0 110.872 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.507 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 4.1 ptm180 -142.28 34.53 1.5 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.866 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.482 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 18.3 p -149.44 110.6 3.41 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.882 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -67.83 -24.85 39.86 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.697 2.265 . . . . 0.0 112.196 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -141.42 143.84 31.59 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.876 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -50.18 -19.77 4.71 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.701 2.267 . . . . 0.0 112.37 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -143.72 74.19 1.42 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -140.07 -155.57 0.6 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.137 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' LYS . . . . . 0.412 ' O ' ' HB3' ' A' ' 101' ' ' ALA . 0.0 OUTLIER -104.68 36.94 2.26 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.812 -179.961 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.507 ' HB1' ' O ' ' A' ' 93' ' ' ARG . . . 66.56 -174.05 0.19 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.049 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.717 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -104.22 -46.14 4.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.94 179.942 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.717 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.9 pp -164.68 131.39 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.123 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 18.0 pt-20 -132.29 170.08 15.56 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.883 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.629 ' HA ' HG12 ' A' ' 135' ' ' VAL . 3.6 t -53.13 128.2 12.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.029 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.52 -14.93 50.27 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.357 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -80.35 102.27 9.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.817 0.341 . . . . 0.0 110.901 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.419 ' HA ' ' O ' ' A' ' 133' ' ' GLY . 0.0 OUTLIER -73.37 75.7 1.38 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.974 -179.88 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.674 HG11 ' CD2' ' A' ' 115' ' ' LEU . 32.6 m -48.81 174.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.001 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.454 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 18.1 m-80 -162.36 130.31 3.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.008 0.433 . . . . 0.0 110.717 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.566 HG12 ' N ' ' A' ' 131' ' ' LYS . 34.0 m -37.94 145.93 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.126 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 92.73 -6.04 76.92 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.421 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -105.63 -146.25 0.39 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.672 0.272 . . . . 0.0 110.573 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 6.5 m -145.16 116.61 8.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.814 0.34 . . . . 0.0 111.023 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.674 ' CD2' HG11 ' A' ' 109' ' ' VAL . 94.8 mt -69.23 -86.53 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.753 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.805 ' SG ' HG11 ' A' ' 153' ' ' VAL . 0.6 OUTLIER -135.17 -171.26 2.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.812 179.913 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.751 HG21 ' HG2' ' A' ' 124' ' ' MET . 0.1 OUTLIER -110.82 123.26 66.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.073 -180.0 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.657 ' O ' HG12 ' A' ' 118' ' ' VAL . 87.3 t -105.99 58.32 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.753 179.662 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.479 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.5 OUTLIER -33.71 101.57 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.307 -179.658 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.518 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -122.99 149.37 44.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.745 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.518 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 5.4 ptm 50.71 21.72 0.97 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.944 0.402 . . . . 0.0 110.611 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.442 ' O ' ' HE3' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 77.56 60.12 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.246 -179.983 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.481 ' HG2' ' O ' ' A' ' 120' ' ' ALA . 2.9 ptt? -175.33 128.68 0.27 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.069 0.461 . . . . 0.0 111.151 179.497 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.751 ' HG2' HG21 ' A' ' 117' ' ' ILE . 1.7 mtp -53.29 95.03 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.979 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -82.08 70.93 9.11 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.83 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 84.9 mt-30 -51.89 120.9 5.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.947 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.476 HG12 HG23 ' A' ' 118' ' ' VAL . 41.4 mm -88.39 109.8 20.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.184 -179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 129' ' ' ALA . 1.4 pt-20 -74.4 124.64 26.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.84 179.899 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.452 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -36.19 112.29 0.17 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.113 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.0 14.26 32.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.759 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.566 ' N ' HG12 ' A' ' 111' ' ' VAL . 0.3 OUTLIER 169.19 118.85 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.938 -179.979 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.454 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 25.3 p -49.5 129.58 19.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.857 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.419 ' O ' ' HA ' ' A' ' 108' ' ' LYS . . . -158.28 -178.1 31.99 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.642 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.63 ' N ' HG23 ' A' ' 155' ' ' ILE . 23.4 m -129.81 108.7 10.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.58 0.229 . . . . 0.0 111.152 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.629 HG12 ' HA ' ' A' ' 105' ' ' VAL . 69.9 t -42.25 142.44 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 110.295 -0.261 . . . . 0.0 110.295 179.504 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.68 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 5.8 mmmt -124.88 -18.66 5.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.677 0.275 . . . . 0.0 111.342 -179.426 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.68 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 165.17 154.22 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.841 0.353 . . . . 0.0 111.448 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.659 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -106.0 78.7 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.79 179.922 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.533 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 22.0 mt -42.14 -29.49 0.24 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.149 0.5 . . . . 0.0 110.385 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 1.085 HG21 HD23 ' A' ' 152' ' ' LEU . 55.4 t -100.7 161.89 3.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.694 179.73 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.554 ' N ' HG12 ' A' ' 140' ' ' VAL . 1.8 mm-40 -58.49 -149.13 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.345 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.49 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 35.8 m -107.67 -63.94 1.26 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.826 0.346 . . . . 0.0 110.893 179.605 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.644 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -123.44 90.47 0.42 Allowed Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.851 -179.783 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.474 ' C ' HG23 ' A' ' 90' ' ' THR . 36.3 mm-40 -156.57 156.34 29.88 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-O 120.908 0.385 . . . . 0.0 110.969 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.432 ' HD2' ' HB3' ' A' ' 144' ' ' GLN . 48.6 Cg_endo -69.26 120.98 7.77 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.681 2.254 . . . . 0.0 112.132 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.912 HG11 ' CD2' ' A' ' 152' ' ' LEU . 18.3 m -105.92 -173.83 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.123 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.491 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 6.2 mm-40 -140.7 144.41 35.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.031 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.446 ' HA ' ' O ' ' A' ' 85' ' ' SER . 63.9 t80 -35.7 137.94 0.18 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.051 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 7.9 t70 69.67 27.78 4.63 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.891 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.491 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 1.2 tp10 -108.87 73.79 0.53 Allowed Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.833 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.894 ' O ' HG23 ' A' ' 140' ' ' VAL . 61.4 Cg_exo -34.18 123.2 0.16 Allowed 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.804 2.336 . . . . 0.0 112.042 179.674 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 1.085 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -120.64 -70.86 0.76 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.699 -179.254 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.865 HG13 HG23 ' A' ' 83' ' ' VAL . 1.3 p -97.04 106.24 18.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.559 -179.146 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.881 HG13 HG12 ' A' ' 82' ' ' ILE . 23.4 t -89.33 133.41 31.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.865 179.349 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.63 HG23 ' N ' ' A' ' 134' ' ' THR . 82.9 mt -134.38 135.37 54.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.191 -179.799 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.486 ' HB2' ' CD ' ' A' ' 136' ' ' LYS . 0.7 OUTLIER . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.228 -0.891 . . . . 0.0 110.939 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.479 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.452 -0.283 0 N-CA-C 112.462 -0.255 . . . . 0.0 112.462 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.512 ' O ' ' ND1' ' A' ' 81' ' ' HIS . 11.9 t-80 173.11 83.07 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.827 0.346 . . . . 0.0 110.823 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 1.014 HG12 HG13 ' A' ' 154' ' ' VAL . 1.6 mt -118.17 151.05 20.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.071 0.462 . . . . 0.0 111.31 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.788 ' CG2' HD13 ' A' ' 115' ' ' LEU . 20.4 t -95.19 37.69 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.168 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.55 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 20.1 ptt85 -37.2 127.77 0.98 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.711 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.49 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 0.2 OUTLIER -45.33 109.38 0.92 Allowed Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.726 179.96 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -61.61 -13.22 28.59 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.72 2.28 . . . . 0.0 112.126 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 1.9 ptp -150.08 -159.58 1.05 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.821 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.449 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 5.2 m -92.25 87.27 2.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.103 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.476 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -141.99 -163.5 9.65 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.468 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.796 HG23 ' C ' ' A' ' 144' ' ' GLN . 25.8 m -119.98 145.41 46.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.843 0.354 . . . . 0.0 110.881 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.861 ' CB ' HD22 ' A' ' 152' ' ' LEU . 1.0 OUTLIER -102.08 147.71 26.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.031 -179.839 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.578 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 23.3 m-85 -142.73 167.59 21.72 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.865 179.843 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.453 ' HD3' ' HB3' ' A' ' 142' ' ' SER . 32.1 ptt85 -152.96 21.23 0.58 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.689 179.866 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.503 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 6.5 p -155.24 113.67 2.29 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.753 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.403 ' HG2' ' CB ' ' A' ' 99' ' ' ALA . 49.2 Cg_endo -68.59 -39.15 9.64 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.702 2.268 . . . . 0.0 112.342 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.521 ' CB ' ' HD2' ' A' ' 97' ' ' PRO . 0.2 OUTLIER -135.23 172.49 7.13 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.914 -179.947 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.521 ' HD2' ' CB ' ' A' ' 96' ' ' SER . 51.9 Cg_endo -69.22 -27.61 28.83 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.725 2.283 . . . . 0.0 112.284 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -135.46 39.63 2.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.874 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.403 ' CB ' ' HG2' ' A' ' 95' ' ' PRO . . . -95.28 -156.07 0.5 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.108 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' LYS . . . . . 0.414 ' O ' ' CG ' ' A' ' 100' ' ' LYS . 0.0 OUTLIER -102.81 34.79 2.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.91 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.503 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 45.01 -158.87 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.179 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.572 ' CD2' HG12 ' A' ' 117' ' ' ILE . 0.1 OUTLIER -139.27 40.28 2.09 Favored 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.059 179.816 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.784 HD13 HG12 ' A' ' 109' ' ' VAL . 2.6 mt 87.07 122.04 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.113 -179.806 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.425 ' O ' ' HB ' ' A' ' 135' ' ' VAL . 1.7 pt-20 -131.17 -175.75 3.79 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.905 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.548 HG22 ' HA ' ' A' ' 137' ' ' ALA . 46.7 t -53.31 134.06 15.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.079 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 93.22 -26.91 12.9 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.399 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.485 ' O ' HG23 ' A' ' 134' ' ' THR . 6.7 tp60 -72.35 131.63 42.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.803 0.335 . . . . 0.0 110.832 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.42 118.91 33.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.963 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.784 HG12 HD13 ' A' ' 103' ' ' ILE . 4.4 m -89.97 178.35 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.06 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.432 ' CG ' ' O ' ' A' ' 109' ' ' VAL . 18.4 m120 -164.71 131.27 2.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.068 0.461 . . . . 0.0 110.641 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.473 ' HA ' ' HB3' ' A' ' 129' ' ' ALA . 34.7 m -38.65 159.51 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.123 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 79.63 -6.04 59.31 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.499 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -108.88 -147.49 0.41 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.708 0.289 . . . . 0.0 110.651 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 14.4 m -135.93 150.12 49.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.847 0.356 . . . . 0.0 110.854 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.788 HD13 ' CG2' ' A' ' 83' ' ' VAL . 49.4 mt -96.95 -75.58 0.54 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.881 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.488 ' SG ' HG11 ' A' ' 153' ' ' VAL . 0.0 OUTLIER -148.4 -168.31 3.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.803 -179.916 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.572 HG12 ' CD2' ' A' ' 102' ' ' PHE . 0.1 OUTLIER -108.63 120.29 59.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.178 179.926 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.517 ' O ' ' CB ' ' A' ' 125' ' ' ASN . 11.1 t -118.43 73.38 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.03 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.543 ' HG2' ' CE2' ' A' ' 92' ' ' TYR . 0.9 OUTLIER -59.32 119.55 7.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.832 -179.953 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -94.0 -70.26 0.71 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.28 0.562 . . . . 0.0 111.365 -179.834 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.532 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 1.9 ptp -92.53 36.21 1.01 Allowed 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.447 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.538 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 0.4 OUTLIER 88.54 -7.74 0.5 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.87 -179.814 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.485 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 6.2 mtt -107.72 128.07 54.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.956 0.407 . . . . 0.0 110.896 179.68 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.539 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 1.0 OUTLIER -43.83 149.67 0.3 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.148 -179.867 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.517 ' CB ' ' O ' ' A' ' 118' ' ' VAL . 30.1 t-20 -129.58 74.25 1.57 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.572 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 9.9 pt20 -47.06 112.85 0.57 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.051 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 23.2 mm -92.8 105.92 17.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.103 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -70.21 143.2 52.28 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.932 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.473 ' HB3' ' HA ' ' A' ' 111' ' ' VAL . . . -66.04 119.22 11.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.123 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.421 ' C ' HG12 ' A' ' 111' ' ' VAL . 0.4 OUTLIER -97.8 -10.63 24.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.911 179.919 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.421 ' O ' ' C ' ' A' ' 132' ' ' SER . 10.0 tttt -161.61 109.47 1.45 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.918 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 131' ' ' LYS . 4.8 p -36.04 141.18 0.1 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.958 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.494 ' O ' ' N ' ' A' ' 109' ' ' VAL . . . -169.45 -165.12 26.31 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.521 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.53 ' N ' HG12 ' A' ' 155' ' ' ILE . 55.9 m -150.97 110.08 3.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.672 0.272 . . . . 0.0 110.938 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.58 HG21 HG22 ' A' ' 103' ' ' ILE . 61.8 t -41.86 141.34 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.843 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.519 ' HG2' ' N ' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -114.51 -35.88 4.77 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 121.456 0.646 . . . . 0.0 109.462 179.934 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.594 ' C ' HD13 ' A' ' 138' ' ' ILE . . . -175.44 155.01 1.75 Allowed 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.775 -179.579 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.787 ' N ' HD13 ' A' ' 138' ' ' ILE . 0.0 OUTLIER -103.06 84.35 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.406 179.648 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 1.013 HD11 HG22 ' A' ' 154' ' ' VAL . 0.2 OUTLIER -41.59 -28.81 0.15 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.106 0.479 . . . . 0.0 110.278 -179.872 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.988 HG21 HD23 ' A' ' 152' ' ' LEU . 79.7 t -103.38 134.45 44.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.826 179.753 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.449 ' O ' ' C ' ' A' ' 142' ' ' SER . 13.6 mt-10 -67.5 100.77 0.9 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.161 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.453 ' HB3' ' HD3' ' A' ' 93' ' ' ARG . 6.9 p -34.41 134.96 0.18 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.783 -179.524 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.578 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 80.72 39.31 14.31 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.583 -0.817 . . . . 0.0 112.255 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.796 ' C ' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -148.78 139.55 13.6 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 120.977 0.417 . . . . 0.0 111.076 -179.947 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.672 ' N ' HG23 ' A' ' 90' ' ' THR . 31.3 Cg_exo -59.03 158.75 24.14 Favored 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 122.845 2.363 . . . . 0.0 112.389 -179.725 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.926 HG11 ' CD2' ' A' ' 152' ' ' LEU . 19.7 m -147.22 -173.5 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.981 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.478 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.3 OUTLIER -138.06 174.44 10.56 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.933 179.956 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.501 ' CD1' ' HB2' ' A' ' 149' ' ' ASP . 1.3 p90 -55.2 140.31 39.21 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.834 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.501 ' HB2' ' CD1' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 59.41 34.4 22.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.867 0.365 . . . . 0.0 110.902 179.994 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.541 ' OE2' HG22 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -109.46 74.68 0.69 Allowed Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.88 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.601 ' O ' HG23 ' A' ' 140' ' ' VAL . 57.2 Cg_exo -33.43 133.93 0.11 Allowed 'Trans proline' 0 N--CA 1.459 -0.553 0 C-N-CA 122.926 2.417 . . . . 0.0 112.104 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.988 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -128.29 -50.7 1.3 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.739 -179.194 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.66 HG13 HG23 ' A' ' 83' ' ' VAL . 2.3 p -117.93 112.23 37.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.899 0.381 . . . . 0.0 111.541 -179.1 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 1.014 HG13 HG12 ' A' ' 82' ' ' ILE . 0.7 OUTLIER -96.0 129.81 45.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.888 179.523 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.571 HD11 HG11 ' A' ' 109' ' ' VAL . 0.0 OUTLIER -113.28 157.58 13.92 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.778 -179.934 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.448 ' N ' ' O ' ' A' ' 134' ' ' THR . 29.1 tt0 . . . . . 0 C--O 1.25 1.101 0 CA-C-O 118.211 -0.9 . . . . 0.0 110.976 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.458 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.45 -0.372 0 N-CA-C 112.609 -0.196 . . . . 0.0 112.609 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.587 ' ND1' HD12 ' A' ' 155' ' ' ILE . 14.9 t-80 172.78 83.36 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.773 0.32 . . . . 0.0 110.721 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.979 HD12 HG13 ' A' ' 154' ' ' VAL . 0.0 OUTLIER -97.73 176.46 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.145 179.977 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.723 HG12 ' CG1' ' A' ' 153' ' ' VAL . 2.3 p -132.45 28.18 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.811 179.557 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.545 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 6.2 ptt180 -25.97 120.42 0.07 Allowed 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.542 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.483 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 0.2 OUTLIER -38.58 116.25 0.93 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.835 -179.855 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.08 -9.31 25.7 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.634 2.222 . . . . 0.0 111.919 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 13.6 ptm -151.24 -168.96 3.25 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.626 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.676 ' O ' HG23 ' A' ' 88' ' ' VAL . 32.3 m -88.81 83.01 2.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.132 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.445 ' C ' HG22 ' A' ' 146' ' ' VAL . . . -126.17 -140.56 5.32 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.612 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.672 HG21 ' CZ ' ' A' ' 92' ' ' TYR . 4.9 m -146.73 128.06 14.88 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.008 0.432 . . . . 0.0 111.274 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 1.021 ' HB2' HD22 ' A' ' 152' ' ' LEU . 30.2 t80 -75.5 139.1 41.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.125 179.36 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.672 ' CZ ' HG21 ' A' ' 90' ' ' THR . 12.7 m-85 -142.67 156.35 45.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.927 0.394 . . . . 0.0 111.213 -179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 23.8 ptt85 -142.62 40.85 1.57 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.805 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -146.57 95.23 4.63 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.858 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.452 ' HD3' ' N ' ' A' ' 102' ' ' PHE . 49.7 Cg_endo -69.15 -38.84 8.53 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.817 2.345 . . . . 0.0 112.407 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.93 ' HB2' ' HB2' ' A' ' 99' ' ' ALA . 70.4 m -129.53 160.85 62.41 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.963 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.4 101.06 0.06 OUTLIER 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.717 2.278 . . . . 0.0 112.285 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 63.54 36.39 11.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.861 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.93 ' HB2' ' HB2' ' A' ' 96' ' ' SER . . . -76.56 -158.02 0.09 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.157 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' LYS . . . . . 0.419 ' O ' ' HB3' ' A' ' 101' ' ' ALA . 0.6 OUTLIER -89.35 23.34 2.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.99 179.972 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 100' ' ' LYS . . . 67.85 159.65 0.16 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.185 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.686 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -84.65 -46.01 11.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.81 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.686 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.1 pp -163.63 112.03 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.039 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.459 ' O ' ' HB2' ' A' ' 107' ' ' GLN . 10.2 pt-20 -123.72 172.35 8.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.909 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.814 HG22 ' HA ' ' A' ' 137' ' ' ALA . 21.3 t -51.97 119.06 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.179 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 107.44 -4.86 35.15 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.522 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.476 ' HG3' ' HA ' ' A' ' 103' ' ' ILE . 1.6 mm-40 -73.8 129.64 38.33 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.771 0.319 . . . . 0.0 110.987 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.423 ' O ' ' ND2' ' A' ' 110' ' ' ASN . 6.0 mttt -98.8 72.11 1.94 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.885 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.675 HG11 HD22 ' A' ' 115' ' ' LEU . 6.0 m -48.86 167.03 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.023 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.509 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 9.6 m-80 -159.87 129.87 5.45 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.083 0.468 . . . . 0.0 110.82 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.629 HG23 ' O ' ' A' ' 111' ' ' VAL . 5.0 m -34.99 115.37 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.056 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 99.96 12.69 39.23 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.344 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.423 ' O ' ' C ' ' A' ' 114' ' ' THR . 1.8 t70 -123.7 103.1 8.19 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.824 0.345 . . . . 0.0 110.811 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.525 ' CG2' ' HB2' ' A' ' 126' ' ' GLN . 3.2 m -35.06 132.91 0.33 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.066 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.675 HD22 HG11 ' A' ' 109' ' ' VAL . 67.1 mt -93.68 -81.63 0.36 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.843 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.412 ' SG ' HD11 ' A' ' 103' ' ' ILE . 0.5 OUTLIER -133.16 -172.89 3.05 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.701 179.894 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.532 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.2 OUTLIER -110.79 123.71 66.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.136 179.975 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.523 ' O ' ' N ' ' A' ' 120' ' ' ALA . 23.6 t -103.42 55.81 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.725 179.773 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.474 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.1 OUTLIER -31.38 89.0 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.721 -179.689 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 118' ' ' VAL . . . -88.82 134.24 34.0 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.141 179.25 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.554 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 2.8 ptt? 50.37 22.89 1.09 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.242 -179.337 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.554 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 96.21 -10.18 0.09 Allowed 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.544 179.698 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.515 ' O ' ' N ' ' A' ' 120' ' ' ALA . 12.5 ptm -99.18 131.69 45.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.157 0.503 . . . . 0.0 111.35 -179.766 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.532 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 1.4 ptt? -55.16 130.5 42.27 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.914 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.488 ' HB2' ' O ' ' A' ' 118' ' ' VAL . 0.7 OUTLIER -121.92 65.34 0.91 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.955 -179.967 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.525 ' HB2' ' CG2' ' A' ' 114' ' ' THR . 2.6 pm0 -39.2 144.36 0.14 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.918 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.55 HG21 HG21 ' A' ' 83' ' ' VAL . 31.8 mm -113.1 123.03 68.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.079 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 129' ' ' ALA . 5.5 mt-10 -85.23 118.39 24.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.843 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.428 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.94 127.81 0.7 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.002 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -100.57 -10.81 20.63 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.974 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.54 ' HD2' ' CD2' ' A' ' 81' ' ' HIS . 2.0 tmtt? -168.86 123.22 0.86 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.004 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.509 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.0 OUTLIER -51.26 112.39 0.73 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.396 179.729 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.58 ' HA3' HG21 ' A' ' 155' ' ' ILE . . . -145.28 -179.83 21.86 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.713 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.679 ' N ' HG23 ' A' ' 155' ' ' ILE . 29.9 m -122.4 112.32 17.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.693 0.282 . . . . 0.0 111.396 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.506 ' HA ' ' HA ' ' A' ' 155' ' ' ILE . 85.7 t -46.56 144.34 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.524 179.293 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.543 ' CD ' ' HB ' ' A' ' 154' ' ' VAL . 0.0 OUTLIER -114.52 -35.75 4.81 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-O 121.496 0.665 . . . . 0.0 109.682 -179.809 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.814 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 179.62 172.71 0.94 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.951 -179.672 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.754 HD13 ' C ' ' A' ' 137' ' ' ALA . 0.6 OUTLIER -119.09 82.9 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.059 179.843 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.562 ' N ' HD23 ' A' ' 139' ' ' LEU . 3.8 mt -41.09 -29.53 0.12 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.2 0.524 . . . . 0.0 110.073 179.724 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 1.056 HG21 HD23 ' A' ' 152' ' ' LEU . 54.5 t -100.08 158.9 3.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.555 179.538 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.498 ' N ' HG12 ' A' ' 140' ' ' VAL . 2.8 mt-10 -58.81 -150.43 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.067 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.499 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -102.49 -60.75 1.49 Allowed 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 120.81 -0.356 . . . . 0.0 110.822 179.623 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.635 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -127.07 89.09 0.34 Allowed Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.793 -179.779 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.462 ' C ' HG23 ' A' ' 90' ' ' THR . 25.2 mm-40 -153.09 155.61 32.08 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 120.997 0.427 . . . . 0.0 110.979 179.77 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.456 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 39.6 Cg_exo -56.81 153.29 37.77 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.855 2.37 . . . . 0.0 112.391 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.816 HG11 ' CD2' ' A' ' 152' ' ' LEU . 31.1 m -141.45 -173.08 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.967 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.48 ' O ' ' HG2' ' A' ' 150' ' ' GLU . 1.0 OUTLIER -146.82 144.58 29.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.896 0.379 . . . . 0.0 111.16 -179.94 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.483 ' HA ' ' O ' ' A' ' 85' ' ' SER . 5.5 p90 -35.62 124.35 0.67 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.953 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.442 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 79.46 33.22 0.22 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.824 -179.945 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.48 ' HG2' ' O ' ' A' ' 147' ' ' GLU . 13.0 mm-40 -109.26 75.23 0.69 Allowed Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.867 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.687 ' O ' HG23 ' A' ' 140' ' ' VAL . 75.1 Cg_exo -37.38 129.15 0.68 Allowed 'Trans proline' 0 N--CA 1.461 -0.413 0 C-N-CA 122.774 2.316 . . . . 0.0 111.925 179.594 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 1.056 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -123.27 -61.1 1.44 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.635 -179.3 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.723 ' CG1' HG12 ' A' ' 83' ' ' VAL . 2.1 p -108.26 120.91 60.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 121.172 0.511 . . . . 0.0 111.292 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.979 HG13 HD12 ' A' ' 82' ' ' ILE . 0.2 OUTLIER -100.55 137.92 26.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.219 -179.98 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.679 HG23 ' N ' ' A' ' 134' ' ' THR . 45.6 mt -123.43 147.16 27.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.229 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.402 ' O ' ' HG2' ' A' ' 156' ' ' GLU . 2.1 tt0 . . . . . 0 C--O 1.248 1.018 0 CA-C-O 118.323 -0.846 . . . . 0.0 110.922 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.34 0 N-CA-C 112.647 -0.181 . . . . 0.0 112.647 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.504 ' O ' ' ND1' ' A' ' 81' ' ' HIS . 23.7 t-80 -170.03 76.15 0.08 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.847 0.355 . . . . 0.0 110.802 179.838 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.836 HG12 HG13 ' A' ' 154' ' ' VAL . 5.1 mt -101.86 155.07 4.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.066 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.77 HG23 HG13 ' A' ' 153' ' ' VAL . 4.0 t -102.42 51.2 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.969 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.533 ' CD ' ' O ' ' A' ' 84' ' ' ARG . 0.5 OUTLIER -35.48 133.19 0.38 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.875 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.492 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 11.2 p -39.41 98.6 0.17 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.757 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.422 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 12.2 Cg_endo -56.3 -15.44 14.84 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.506 2.137 . . . . 0.0 111.91 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.411 ' O ' ' N ' ' A' ' 89' ' ' GLY . 5.2 ptp -160.29 172.38 17.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.534 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.595 ' O ' HG23 ' A' ' 88' ' ' VAL . 27.2 m -67.32 68.33 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.037 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 87' ' ' MET . . . -119.04 -155.68 9.88 Favored Glycine 0 C--N 1.331 0.289 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.648 -179.793 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.896 HG23 ' O ' ' A' ' 144' ' ' GLN . 20.2 m -131.5 124.85 31.0 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.908 0.385 . . . . 0.0 111.07 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.933 ' HB2' HD22 ' A' ' 152' ' ' LEU . 72.4 t80 -62.61 141.95 58.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.52 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.589 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 5.6 m-30 -148.37 127.73 13.06 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.964 0.412 . . . . 0.0 110.919 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.488 ' HA ' ' HB2' ' A' ' 102' ' ' PHE . 0.1 OUTLIER -124.27 25.52 7.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.825 179.857 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 2.7 p -149.21 108.16 3.4 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.882 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.34 -44.1 1.85 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.82 2.346 . . . . 0.0 112.309 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.747 ' HB2' ' HB2' ' A' ' 99' ' ' ALA . 0.1 OUTLIER -110.64 166.93 9.83 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.928 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.485 ' HD2' ' OG ' ' A' ' 96' ' ' SER . 51.1 Cg_endo -69.42 -25.56 30.05 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.737 2.291 . . . . 0.0 112.224 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -136.17 26.86 3.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.817 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.747 ' HB2' ' HB2' ' A' ' 96' ' ' SER . . . -71.49 -163.92 0.1 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.121 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' LYS . . . . . 0.486 ' O ' ' HB3' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -103.83 20.75 17.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.921 179.854 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.486 ' HB3' ' O ' ' A' ' 100' ' ' LYS . . . 71.47 162.9 0.26 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.274 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.616 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -84.93 -37.42 20.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.765 179.922 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.616 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.2 pp -161.29 158.56 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.019 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.437 ' O ' ' HB3' ' A' ' 107' ' ' GLN . 0.2 OUTLIER -140.42 151.23 44.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.906 -179.989 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.802 HG23 ' C ' ' A' ' 136' ' ' LYS . 4.8 p -54.08 127.94 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.199 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 93.83 -9.77 72.9 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.521 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.516 ' O ' ' N ' ' A' ' 109' ' ' VAL . 2.7 tp-100 -68.93 99.83 1.11 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.855 0.36 . . . . 0.0 110.801 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.43 ' HA ' ' HA ' ' A' ' 134' ' ' THR . 0.0 OUTLIER -59.26 75.62 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.952 -179.839 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.516 ' N ' ' O ' ' A' ' 107' ' ' GLN . 6.6 m -53.28 172.0 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.008 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.489 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 3.9 p-10 -163.06 133.03 4.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.058 0.456 . . . . 0.0 110.947 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.48 HG12 ' N ' ' A' ' 131' ' ' LYS . 29.3 m -38.25 130.18 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.131 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 101.95 2.01 52.02 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.417 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.434 ' O ' ' N ' ' A' ' 115' ' ' LEU . 4.2 t70 -117.93 99.22 6.77 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.777 0.322 . . . . 0.0 110.859 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.469 ' HA ' ' HA ' ' A' ' 128' ' ' GLU . 6.5 m -35.41 96.11 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.004 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.464 ' N ' ' O ' ' A' ' 127' ' ' ILE . 7.1 mt -46.4 -89.98 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.75 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.467 ' O ' ' N ' ' A' ' 127' ' ' ILE . 0.5 OUTLIER -136.86 -168.91 2.36 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.687 -179.992 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.998 HD13 ' HB2' ' A' ' 124' ' ' MET . 2.2 mt -125.83 153.83 34.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.885 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.457 ' HA ' ' O ' ' A' ' 90' ' ' THR . 27.5 t -142.61 101.64 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.872 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.544 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.5 OUTLIER -62.7 89.66 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.201 -179.799 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.449 ' O ' ' C ' ' A' ' 121' ' ' MET . . . -69.28 -136.07 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.649 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.482 ' O ' ' HB2' ' A' ' 122' ' ' LYS . 0.0 OUTLIER -34.14 -39.84 0.08 Allowed 'General case' 0 CA--C 1.519 -0.224 0 CA-C-O 121.444 0.64 . . . . 0.0 110.173 179.608 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.519 ' CG ' ' O ' ' A' ' 122' ' ' LYS . 0.1 OUTLIER 169.27 38.21 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.873 179.482 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.407 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 36.8 mmm -146.93 131.87 18.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.045 -179.422 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.998 ' HB2' HD13 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -64.47 101.44 0.45 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.836 179.994 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.457 ' HB2' ' O ' ' A' ' 118' ' ' VAL . 0.9 OUTLIER -77.07 83.28 3.58 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.877 179.946 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.546 ' CA ' HG12 ' A' ' 117' ' ' ILE . 7.8 pt20 -64.29 103.92 0.69 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.959 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.467 ' N ' ' O ' ' A' ' 116' ' ' CYS . 17.3 mm -75.38 139.09 19.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.04 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.469 ' HA ' ' HA ' ' A' ' 114' ' ' THR . 2.2 mt-10 -110.4 122.05 46.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.923 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.409 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -36.78 114.89 0.33 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.064 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -107.82 17.19 22.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.48 ' N ' HG12 ' A' ' 111' ' ' VAL . 1.9 ttmt 177.32 113.5 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.9 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.489 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 15.6 p -43.51 121.31 2.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.758 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.414 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -152.2 -171.52 19.92 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.599 -179.802 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.582 ' N ' HG23 ' A' ' 155' ' ' ILE . 21.8 m -140.14 107.81 5.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.582 0.229 . . . . 0.0 111.239 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.672 HG12 ' HA ' ' A' ' 105' ' ' VAL . 92.5 t -41.79 142.71 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.437 179.459 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.802 ' C ' HG23 ' A' ' 105' ' ' VAL . 30.5 mtpt -124.91 -18.93 5.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.455 -179.478 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.631 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 169.15 155.38 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.935 0.398 . . . . 0.0 111.622 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.639 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -111.11 77.44 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.61 179.792 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 9.7 mt -46.25 -24.92 0.53 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.965 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.994 HG21 HD23 ' A' ' 152' ' ' LEU . 45.3 t -104.13 144.18 14.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.239 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.494 ' HB2' ' HG2' ' A' ' 144' ' ' GLN . 4.7 mt-10 -62.35 137.62 58.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.069 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.504 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -31.58 -62.33 0.2 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.621 -179.331 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.589 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -125.58 104.21 0.75 Allowed Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.483 -0.865 . . . . 0.0 112.995 -179.483 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.896 ' O ' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -167.62 156.16 8.72 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-O 120.93 0.395 . . . . 0.0 111.137 179.553 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.435 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 37.8 Cg_endo -66.31 138.38 50.8 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.807 2.338 . . . . 0.0 112.329 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.613 HG11 ' CD2' ' A' ' 152' ' ' LEU . 1.5 m -132.14 -174.77 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.089 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.431 ' O ' ' C ' ' A' ' 148' ' ' PHE . 18.5 mt-10 -145.7 144.03 30.13 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.929 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.492 ' HA ' ' O ' ' A' ' 85' ' ' SER . 39.6 t80 -34.5 135.02 0.18 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.947 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 76.3 23.96 1.15 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.709 -179.829 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.476 ' HG2' HG12 ' A' ' 146' ' ' VAL . 4.5 tp10 -109.93 74.26 0.76 Allowed Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.788 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.752 ' O ' HG23 ' A' ' 140' ' ' VAL . 63.3 Cg_exo -33.27 130.57 0.13 Allowed 'Trans proline' 0 N--CA 1.457 -0.635 0 C-N-CA 122.888 2.392 . . . . 0.0 112.116 179.652 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.994 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -121.86 -72.2 0.7 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.555 -179.231 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.77 HG13 HG23 ' A' ' 83' ' ' VAL . 1.2 p -96.61 102.92 14.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.226 0.536 . . . . 0.0 111.37 -179.38 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.836 HG13 HG12 ' A' ' 82' ' ' ILE . 6.3 t -83.38 138.64 18.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.017 179.675 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.582 HG23 ' N ' ' A' ' 134' ' ' THR . 17.9 mt -136.72 143.2 35.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.352 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.503 ' CB ' ' HD2' ' A' ' 136' ' ' LYS . 29.5 tt0 . . . . . 0 C--O 1.25 1.094 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.881 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.417 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.36 0 N-CA-C 112.475 -0.25 . . . . 0.0 112.475 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.524 ' N ' ' O ' ' A' ' 155' ' ' ILE . 19.7 t-80 175.85 82.21 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.789 0.328 . . . . 0.0 110.849 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.887 HG12 HG13 ' A' ' 154' ' ' VAL . 7.1 mt -98.93 157.27 3.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.087 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.834 HG23 HG13 ' A' ' 153' ' ' VAL . 1.9 t -113.67 53.91 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.148 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.532 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -41.08 134.6 2.0 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.855 179.938 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.463 ' N ' HD11 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -35.86 109.23 0.4 Allowed Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.855 -179.916 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.453 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 35.4 Cg_endo -64.74 -8.56 18.01 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.744 2.296 . . . . 0.0 112.109 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -167.85 176.17 6.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.757 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.761 ' O ' HG23 ' A' ' 88' ' ' VAL . 32.6 m -71.42 82.83 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.129 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.431 ' O ' HG23 ' A' ' 146' ' ' VAL . . . -142.78 -159.06 7.78 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.581 -179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.709 HG23 ' C ' ' A' ' 144' ' ' GLN . 23.2 m -116.62 142.98 46.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.785 0.326 . . . . 0.0 110.803 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.738 ' HB2' HD22 ' A' ' 152' ' ' LEU . 2.6 t80 -100.23 140.16 34.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.588 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 19.9 m-85 -138.66 145.9 40.99 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.987 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.544 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 0.0 OUTLIER -125.49 28.24 6.31 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.852 179.846 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.477 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 12.1 p -146.96 115.5 4.36 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.847 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.434 ' HG2' ' CB ' ' A' ' 99' ' ' ALA . 55.5 Cg_endo -69.93 -39.44 6.17 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.685 2.257 . . . . 0.0 112.376 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.718 ' CB ' ' HB2' ' A' ' 99' ' ' ALA . 0.3 OUTLIER -129.16 160.57 63.19 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.952 179.998 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.407 ' HD2' ' OG ' ' A' ' 96' ' ' SER . 51.6 Cg_exo -52.58 -37.14 73.7 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.72 2.28 . . . . 0.0 112.332 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.411 ' CG ' ' O ' ' A' ' 98' ' ' ASP . 34.9 t0 -131.45 32.39 4.2 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.885 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.718 ' HB2' ' CB ' ' A' ' 96' ' ' SER . . . -76.24 -158.27 0.09 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.061 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' LYS . . . . . 0.436 ' O ' ' HB3' ' A' ' 101' ' ' ALA . 6.1 ptmt -104.72 23.6 13.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.917 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.477 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 68.65 166.31 0.26 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.187 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.724 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -93.78 -34.02 13.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.818 179.915 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.846 HD13 HG23 ' A' ' 153' ' ' VAL . 1.0 OUTLIER -164.84 150.37 2.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.134 179.913 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -155.17 146.89 23.25 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.961 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.558 HG13 ' HA ' ' A' ' 136' ' ' LYS . 3.0 t -54.11 116.45 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.148 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 129.5 -36.31 2.4 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.546 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.452 ' OE1' ' HA ' ' A' ' 103' ' ' ILE . 12.7 pt20 -76.38 130.08 37.53 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.842 0.354 . . . . 0.0 110.895 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.434 ' HA ' ' HA ' ' A' ' 134' ' ' THR . 2.6 mtpt -90.23 91.4 8.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.949 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.897 HG11 ' CD2' ' A' ' 115' ' ' LEU . 15.4 m -51.5 173.44 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.074 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.435 ' CG ' ' O ' ' A' ' 109' ' ' VAL . 75.1 m-80 -163.6 130.54 3.34 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.691 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.489 ' HA ' ' CB ' ' A' ' 129' ' ' ALA . 3.2 t -37.45 135.43 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.073 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 89.59 7.9 68.52 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.519 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 114' ' ' THR . 91.1 m-20 -121.08 101.98 8.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.933 0.397 . . . . 0.0 110.783 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.435 ' CG2' ' HB2' ' A' ' 126' ' ' GLN . 1.7 m -35.25 101.66 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.104 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.897 ' CD2' HG11 ' A' ' 109' ' ' VAL . 7.7 mt -56.77 -83.66 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.63 179.785 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.465 ' HB3' HG12 ' A' ' 103' ' ' ILE . 0.8 OUTLIER -144.34 178.21 8.08 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.764 179.804 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.741 HD13 ' HB2' ' A' ' 124' ' ' MET . 4.2 mt -111.01 152.47 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.013 0.435 . . . . 0.0 110.803 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.627 HG13 ' O ' ' A' ' 90' ' ' THR . 94.5 t -140.72 94.93 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.898 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.566 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.8 OUTLIER -50.51 84.83 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.103 -179.834 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.531 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -103.76 114.39 28.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.833 179.84 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.548 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 81.97 19.85 0.34 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.774 -179.746 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.548 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 91.13 -1.07 0.19 Allowed 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.141 179.896 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 5.7 mmt -123.0 134.87 54.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.915 0.388 . . . . 0.0 111.171 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.741 ' HB2' HD13 ' A' ' 117' ' ' ILE . 1.3 ptp -63.31 123.14 17.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.042 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -103.79 80.99 1.83 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.803 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.516 ' CA ' HG12 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -57.59 115.59 2.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.933 -179.989 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 3.6 mm -81.2 148.71 5.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.043 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.423 ' O ' ' C ' ' A' ' 129' ' ' ALA . 22.3 tt0 -112.26 124.78 53.2 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.851 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.489 ' CB ' ' HA ' ' A' ' 111' ' ' VAL . . . -35.46 107.19 0.05 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.17 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -95.28 3.98 53.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.142 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 10.1 tttt 175.82 121.19 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.908 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 86.8 p -47.32 135.03 10.94 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.793 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.506 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -164.84 -171.12 30.7 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.578 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.617 ' N ' HG23 ' A' ' 155' ' ' ILE . 24.3 m -136.09 107.41 6.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.614 0.245 . . . . 0.0 111.073 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.499 ' HA ' HG12 ' A' ' 155' ' ' ILE . 75.4 t -39.83 139.77 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 121.04 -0.264 . . . . 0.0 110.501 179.594 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.718 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.1 OUTLIER -122.84 -19.93 6.02 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.583 -0.28 . . . . 0.0 111.119 -179.47 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.718 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 161.13 154.04 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.385 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.68 ' N ' HD13 ' A' ' 138' ' ' ILE . 0.0 OUTLIER -100.75 86.54 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.605 179.752 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.605 HD12 ' HB2' ' A' ' 151' ' ' PRO . 2.0 mt -43.24 -28.08 0.28 Allowed 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.192 0.52 . . . . 0.0 110.342 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 1.006 HG21 HD23 ' A' ' 152' ' ' LEU . 75.3 t -104.63 135.62 41.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.823 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.503 ' N ' ' OE1' ' A' ' 144' ' ' GLN . 10.0 mt-10 -66.49 97.06 0.4 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.395 179.656 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.544 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 73.1 p -35.92 138.99 0.16 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.677 -179.642 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.588 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 81.21 35.8 22.75 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.457 -0.878 . . . . 0.0 112.346 -179.799 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.709 ' C ' HG23 ' A' ' 90' ' ' THR . 1.2 pt20 -148.97 159.39 37.54 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 120.89 0.376 . . . . 0.0 111.144 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.854 ' O ' HG13 ' A' ' 146' ' ' VAL . 45.1 Cg_endo -68.27 178.76 3.39 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.748 2.298 . . . . 0.0 112.195 179.897 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.854 HG13 ' O ' ' A' ' 145' ' ' PRO . 1.2 m -170.47 -175.67 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.283 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.523 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -142.74 155.47 44.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.869 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 148' ' ' PHE . . . . . . . . . . . . . 64.7 t80 -42.32 140.99 1.04 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.924 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.437 ' HA ' ' HD2' ' A' ' 84' ' ' ARG . 7.8 t0 66.4 28.94 9.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.841 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.523 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 2.4 tp10 -109.13 73.68 0.56 Allowed Pre-proline 0 C--N 1.327 -0.375 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.848 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.605 ' HB2' HD12 ' A' ' 139' ' ' LEU . 51.3 Cg_exo -32.56 120.94 0.1 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.598 0 C-N-CA 123.001 2.468 . . . . 0.0 112.232 179.706 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 1.006 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -116.41 -64.38 1.32 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.6 -179.254 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.846 HG23 HD13 ' A' ' 103' ' ' ILE . 1.5 p -99.43 103.99 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.178 0.514 . . . . 0.0 111.584 -179.11 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.887 HG13 HG12 ' A' ' 82' ' ' ILE . 4.7 t -87.85 135.11 26.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.033 179.571 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.617 HG23 ' N ' ' A' ' 134' ' ' THR . 96.6 mt -138.0 135.33 45.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.205 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.48 ' HG3' ' HE2' ' A' ' 136' ' ' LYS . 0.4 OUTLIER . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.249 -0.882 . . . . 0.0 110.902 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.424 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.333 0 N-CA-C 112.644 -0.182 . . . . 0.0 112.644 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.524 ' O ' ' ND1' ' A' ' 81' ' ' HIS . 17.9 t-80 174.45 83.22 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.835 0.35 . . . . 0.0 110.928 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.727 HG12 HG13 ' A' ' 154' ' ' VAL . 23.4 mt -98.66 127.99 50.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.994 0.426 . . . . 0.0 110.819 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.921 HG21 HD13 ' A' ' 115' ' ' LEU . 3.5 t -83.52 56.9 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.408 -179.543 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.533 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 1.9 ptt85 -42.96 134.55 3.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.67 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.675 ' HB2' HD21 ' A' ' 152' ' ' LEU . 9.6 t -35.98 96.86 0.11 Allowed Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.896 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.412 ' N ' ' O ' ' A' ' 84' ' ' ARG . 87.9 Cg_exo -46.07 -27.05 4.03 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.742 2.295 . . . . 0.0 112.186 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.52 ' SD ' ' CB ' ' A' ' 120' ' ' ALA . 10.0 ptp -147.75 168.5 21.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.705 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.474 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 1.5 p -69.39 91.08 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.051 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -146.46 -133.3 2.46 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.397 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.97 HG23 ' HA ' ' A' ' 145' ' ' PRO . 1.2 m -136.29 153.74 51.08 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.782 0.325 . . . . 0.0 110.954 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.645 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 1.1 t80 -118.38 140.15 50.29 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.968 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.586 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 22.0 m-85 -140.15 163.41 32.81 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.061 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.564 ' HD2' ' CB ' ' A' ' 142' ' ' SER . 0.0 OUTLIER -130.08 13.09 5.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.914 179.729 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.36 109.27 2.98 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.897 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -74.72 -5.04 16.31 Favored 'Trans proline' 0 C--O 1.232 0.201 0 C-N-CA 122.812 2.341 . . . . 0.0 112.454 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.59 167.88 12.24 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.05 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -74.55 106.43 2.25 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.747 2.298 . . . . 0.0 112.247 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 74.21 31.74 1.07 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.835 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -76.78 -166.8 0.73 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.003 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.01 33.38 0.87 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.885 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 51.58 175.75 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.182 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.838 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -111.68 -34.59 6.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.967 179.998 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.905 HD13 ' CG2' ' A' ' 153' ' ' VAL . 1.0 OUTLIER -170.08 129.08 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.186 179.933 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.5 ' O ' ' N ' ' A' ' 106' ' ' GLY . 3.2 mt-10 -136.72 148.87 47.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.835 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.589 HG22 ' C ' ' A' ' 136' ' ' LYS . 52.6 t -35.78 92.55 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.064 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' GLY . . . . . 0.5 ' N ' ' O ' ' A' ' 104' ' ' GLU . . . 133.39 -0.31 4.26 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.536 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.477 ' O ' ' HA ' ' A' ' 134' ' ' THR . 0.0 OUTLIER -71.24 112.58 7.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.82 0.343 . . . . 0.0 110.83 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 31.6 mttt -82.37 79.76 8.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.046 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.653 HG11 HD13 ' A' ' 155' ' ' ILE . 1.4 p -78.03 164.08 3.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.974 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.565 ' N ' ' CG2' ' A' ' 109' ' ' VAL . 7.8 m120 -153.83 130.04 10.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.49 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.432 ' C ' ' O ' ' A' ' 110' ' ' ASN . 2.6 m -31.74 114.76 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.461 -179.822 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 111.87 9.24 21.08 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.488 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.432 ' O ' ' HA ' ' A' ' 128' ' ' GLU . 6.4 t0 -113.74 -148.86 0.44 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.794 0.33 . . . . 0.0 110.684 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.48 ' CG2' ' CE1' ' A' ' 102' ' ' PHE . 1.9 m -131.0 147.89 52.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.788 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.921 HD13 HG21 ' A' ' 83' ' ' VAL . 80.9 mt -116.46 -81.1 0.61 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.131 -179.749 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.483 ' HB2' ' O ' ' A' ' 92' ' ' TYR . 8.0 p -136.57 -176.13 4.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.282 -179.619 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.544 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.3 OUTLIER -102.52 117.89 48.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.18 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.661 HG12 ' O ' ' A' ' 125' ' ' ASN . 12.1 p -97.12 50.98 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.923 179.837 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.488 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.1 OUTLIER -35.91 96.43 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.96 -179.885 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.522 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -116.92 115.64 25.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.023 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.522 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 0.1 OUTLIER 84.06 18.18 0.2 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.821 -179.95 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.528 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 0.3 OUTLIER 85.43 26.14 0.07 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.963 179.998 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.488 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.9 OUTLIER -141.96 128.36 20.03 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.107 179.832 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.544 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 1.0 OUTLIER -66.68 131.55 46.21 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.906 179.884 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.661 ' O ' HG12 ' A' ' 118' ' ' VAL . 0.5 OUTLIER -125.99 88.39 2.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.825 -179.985 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.407 ' HB2' HG23 ' A' ' 114' ' ' THR . 4.3 pt20 -50.61 112.04 0.63 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.875 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.427 HG21 HG11 ' A' ' 83' ' ' VAL . 31.5 mm -72.53 137.78 22.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.083 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.432 ' HA ' ' O ' ' A' ' 113' ' ' ASP . 50.2 mt-10 -97.01 126.44 42.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.93 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.545 ' HB2' ' CG2' ' A' ' 109' ' ' VAL . . . -38.49 124.84 1.33 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.153 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -101.67 -13.59 17.73 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.846 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 9.8 tttp -168.05 120.02 0.85 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.807 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.411 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 90.3 p -42.74 121.59 2.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.714 179.806 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.408 ' HA3' ' CG2' ' A' ' 155' ' ' ILE . . . -157.56 -176.5 29.69 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.67 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.631 ' N ' HG23 ' A' ' 155' ' ' ILE . 24.2 m -131.86 110.78 11.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.582 0.229 . . . . 0.0 111.137 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.838 HG21 ' HB ' ' A' ' 103' ' ' ILE . 73.4 t -40.03 141.76 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 110.353 -0.24 . . . . 0.0 110.353 179.531 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.622 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 5.7 mmmt -126.19 -19.89 4.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.633 -179.459 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.622 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 169.49 161.18 0.06 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.834 0.349 . . . . 0.0 111.514 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.645 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -108.49 80.2 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.915 179.917 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.545 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 2.8 mt -41.33 -30.33 0.18 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.104 0.478 . . . . 0.0 109.919 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.989 HG21 HD23 ' A' ' 152' ' ' LEU . 71.7 t -98.64 139.19 21.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.827 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.486 ' O ' ' CG ' ' A' ' 144' ' ' GLN . 6.7 mt-10 -70.59 98.14 1.44 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.351 179.654 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.564 ' CB ' ' HD2' ' A' ' 93' ' ' ARG . 35.5 p -35.83 154.36 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.703 -179.65 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.582 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 62.69 38.12 95.93 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.33 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.486 ' CG ' ' O ' ' A' ' 141' ' ' GLU . 12.3 mm-40 -150.48 145.27 18.29 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 120.931 0.396 . . . . 0.0 111.042 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.97 ' HA ' HG23 ' A' ' 90' ' ' THR . 52.4 Cg_exo -54.81 173.04 0.29 Allowed 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.755 2.303 . . . . 0.0 112.17 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.722 HG11 ' CD2' ' A' ' 152' ' ' LEU . 0.4 OUTLIER -165.76 175.86 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.042 179.939 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.509 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 0.8 OUTLIER -135.26 162.17 33.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.991 -179.935 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.464 ' HA ' ' O ' ' A' ' 85' ' ' SER . 6.8 t80 -48.65 141.49 7.08 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.789 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 65.42 29.78 11.19 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.775 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.563 ' HG2' HG12 ' A' ' 146' ' ' VAL . 1.2 tp10 -108.16 73.36 0.44 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.762 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.689 ' O ' HG23 ' A' ' 140' ' ' VAL . 55.7 Cg_exo -32.2 119.35 0.09 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 123.013 2.475 . . . . 0.0 112.145 179.701 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.989 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -116.82 -71.32 0.74 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.545 -179.298 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.905 ' CG2' HD13 ' A' ' 103' ' ' ILE . 1.6 p -93.69 105.32 16.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 121.159 0.504 . . . . 0.0 111.732 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.727 HG13 HG12 ' A' ' 82' ' ' ILE . 41.5 t -84.16 135.38 24.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.861 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.812 HD11 HD22 ' A' ' 115' ' ' LEU . 95.6 mt -133.64 135.63 55.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.362 -179.707 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.443 ' HB2' ' HD3' ' A' ' 136' ' ' LYS . 1.7 tt0 . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.18 -0.914 . . . . 0.0 110.871 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.473 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.774 -0.13 . . . . 0.0 112.774 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.621 ' C ' HD13 ' A' ' 82' ' ' ILE . 13.4 t-80 171.9 83.85 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.754 0.311 . . . . 0.0 110.582 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 1.034 HD12 HG13 ' A' ' 154' ' ' VAL . 0.0 OUTLIER -103.08 -178.42 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.97 0.414 . . . . 0.0 111.184 -179.995 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.809 HG23 HG13 ' A' ' 153' ' ' VAL . 11.3 t -130.41 32.45 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.763 179.696 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.556 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 4.7 ptt180 -30.41 119.92 0.18 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.283 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.48 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 0.7 OUTLIER -36.48 103.14 0.24 Allowed Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.94 -179.771 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -51.54 -22.58 12.89 Favored 'Trans proline' 0 N--CA 1.464 -0.226 0 C-N-CA 122.653 2.235 . . . . 0.0 112.052 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.0 ptm -141.56 -176.79 4.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.789 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.466 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 15.1 t -82.29 93.5 2.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.046 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -146.22 -141.42 3.61 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.587 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.725 HG23 ' C ' ' A' ' 144' ' ' GLN . 42.4 m -136.57 141.84 43.35 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.792 0.329 . . . . 0.0 111.023 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.866 ' HB2' HD22 ' A' ' 152' ' ' LEU . 0.8 OUTLIER -100.74 146.24 27.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.961 -179.981 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.582 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 16.5 m-85 -143.16 162.61 35.11 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.904 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.543 ' CD ' ' HB3' ' A' ' 142' ' ' SER . 9.5 ptm180 -139.75 31.53 2.04 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.874 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.493 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 68.7 p -145.74 122.15 5.92 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.507 ' HG2' ' CB ' ' A' ' 99' ' ' ALA . 55.7 Cg_endo -70.36 -21.48 30.65 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.701 2.268 . . . . 0.0 112.358 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 15.2 m -162.8 152.97 13.67 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.081 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_exo -49.63 -20.76 4.65 Favored 'Trans proline' 0 C--O 1.232 0.215 0 C-N-CA 122.8 2.333 . . . . 0.0 112.284 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -138.31 72.7 1.41 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.815 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.507 ' CB ' ' HG2' ' A' ' 95' ' ' PRO . . . -137.1 -154.87 0.57 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.197 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -113.15 36.51 3.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.846 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.493 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 62.06 -178.44 0.13 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.115 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.915 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -104.17 -37.13 7.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.866 -179.964 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.915 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.3 OUTLIER -178.18 146.62 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.11 179.992 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -146.75 162.72 37.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.854 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.625 HG22 ' HA ' ' A' ' 137' ' ' ALA . 14.4 t -45.07 134.87 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.193 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 94.43 -11.95 69.55 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.543 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.426 ' O ' ' N ' ' A' ' 109' ' ' VAL . 3.6 tp60 -77.2 95.67 4.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.838 0.351 . . . . 0.0 110.892 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.9 mtmt -64.39 74.24 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.963 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.638 HG11 ' CD2' ' A' ' 115' ' ' LEU . 17.7 m -54.6 167.87 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.014 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.489 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 3.4 p-10 -157.31 131.26 8.2 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 121.174 0.512 . . . . 0.0 110.83 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.452 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 26.1 t -34.69 136.04 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.092 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 86.87 11.83 69.76 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.337 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.418 ' O ' ' C ' ' A' ' 114' ' ' THR . 26.4 t70 -124.69 102.53 7.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.783 0.325 . . . . 0.0 110.867 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.418 ' C ' ' O ' ' A' ' 113' ' ' ASP . 1.6 m -35.52 113.02 0.18 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.154 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.638 ' CD2' HG11 ' A' ' 109' ' ' VAL . 19.2 mt -69.77 -87.53 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.648 179.734 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.727 ' HB3' HD11 ' A' ' 103' ' ' ILE . 9.1 p -135.32 -166.52 1.85 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.681 179.729 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.966 HD13 ' HB3' ' A' ' 124' ' ' MET . 1.7 mt -126.48 153.77 35.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.595 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.634 HG13 ' O ' ' A' ' 90' ' ' THR . 46.7 t -141.04 103.12 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.965 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.512 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.5 OUTLIER -62.04 69.96 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.118 -179.773 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.518 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -92.81 145.31 24.5 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.904 179.833 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.518 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 9.1 ptp 51.96 21.03 1.37 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.737 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.511 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 1.6 tmtt? 80.28 52.03 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.877 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.486 ' HG3' ' O ' ' A' ' 120' ' ' ALA . 0.2 OUTLIER -172.0 133.13 0.7 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.091 179.804 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.966 ' HB3' HD13 ' A' ' 117' ' ' ILE . 45.2 mtt -67.54 97.16 0.57 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.951 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -79.43 82.08 5.61 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.779 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.547 ' CA ' HG12 ' A' ' 117' ' ' ILE . 4.3 pt20 -58.28 107.71 0.52 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.863 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.467 ' N ' ' O ' ' A' ' 116' ' ' CYS . 7.3 mm -74.99 162.51 4.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.164 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.425 ' N ' HG22 ' A' ' 127' ' ' ILE . 1.6 tt0 -130.04 141.1 50.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.852 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.452 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -46.24 113.65 0.66 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.995 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.402 ' OD1' ' N ' ' A' ' 130' ' ' ASP . 0.4 OUTLIER -101.09 11.09 40.18 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.936 -179.952 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 14.7 tttt 169.99 117.39 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.836 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.489 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 34.8 p -44.25 111.15 0.27 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.781 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -145.96 -175.46 19.02 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.554 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.752 ' C ' HG23 ' A' ' 155' ' ' ILE . 20.7 m -129.54 109.38 10.98 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.645 0.26 . . . . 0.0 111.215 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.56 ' N ' HG23 ' A' ' 155' ' ' ILE . 95.5 t -43.29 143.64 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.626 -0.261 . . . . 0.0 110.364 179.474 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.711 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 1.3 mmmp? -123.72 -18.69 5.99 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.233 -179.55 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.711 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 162.79 164.31 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.888 0.375 . . . . 0.0 111.582 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.65 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -107.11 87.58 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.693 179.787 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.764 HD12 ' HB2' ' A' ' 151' ' ' PRO . 1.8 mt -43.0 -27.77 0.22 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.112 0.482 . . . . 0.0 110.437 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 1.037 HG21 HD23 ' A' ' 152' ' ' LEU . 55.6 t -106.64 140.4 24.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.924 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.522 ' O ' ' CG ' ' A' ' 144' ' ' GLN . 6.6 mt-10 -69.38 98.15 1.05 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.252 179.492 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.543 ' HB3' ' CD ' ' A' ' 93' ' ' ARG . 55.5 p -34.0 150.6 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.732 -179.469 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.582 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 67.33 35.86 88.4 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.383 -0.913 . . . . 0.0 112.149 -179.775 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.725 ' C ' HG23 ' A' ' 90' ' ' THR . 29.2 mm-40 -147.91 154.06 43.04 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 120.86 0.362 . . . . 0.0 111.103 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.693 ' O ' HG13 ' A' ' 146' ' ' VAL . 59.8 Cg_endo -72.29 173.67 12.69 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.823 2.349 . . . . 0.0 112.344 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.868 HG21 HD21 ' A' ' 152' ' ' LEU . 10.5 m -163.65 -173.74 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.071 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.528 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 6.3 pt-20 -140.16 174.08 10.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.966 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.48 ' HA ' ' O ' ' A' ' 85' ' ' SER . 17.1 t80 -50.19 147.59 4.07 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.881 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 53.94 33.36 17.16 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.918 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 19.7 tp10 -109.45 74.74 0.7 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.741 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.815 ' O ' HG23 ' A' ' 140' ' ' VAL . 69.7 Cg_exo -36.34 128.98 0.43 Allowed 'Trans proline' 0 N--CA 1.46 -0.487 0 C-N-CA 122.705 2.27 . . . . 0.0 111.794 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 1.037 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -122.22 -48.91 2.07 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 111.866 0.321 . . . . 0.0 111.866 -179.059 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.809 HG13 HG23 ' A' ' 83' ' ' VAL . 1.6 p -116.94 113.45 42.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 121.026 0.441 . . . . 0.0 111.423 -179.375 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 1.034 HG13 HD12 ' A' ' 82' ' ' ILE . 1.6 t -93.84 144.6 9.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.073 179.77 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.752 HG23 ' C ' ' A' ' 134' ' ' THR . 60.3 mt -144.18 141.86 24.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.146 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.52 ' HB2' ' CE ' ' A' ' 136' ' ' LYS . 15.7 tt0 . . . . . 0 C--O 1.251 1.16 0 CA-C-O 118.224 -0.893 . . . . 0.0 110.823 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.446 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.452 -0.251 0 N-CA-C 112.623 -0.191 . . . . 0.0 112.623 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.676 ' CD2' ' HE2' ' A' ' 131' ' ' LYS . 14.6 t-80 170.38 86.12 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.799 0.333 . . . . 0.0 110.817 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.509 HG23 ' O ' ' A' ' 153' ' ' VAL . 0.3 OUTLIER -101.76 159.22 4.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 121.03 0.443 . . . . 0.0 111.176 -179.941 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.839 HG12 ' HB ' ' A' ' 153' ' ' VAL . 4.4 p -109.43 46.64 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.132 -179.855 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.498 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 7.4 ptt180 -31.0 136.64 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.247 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.566 ' N ' HD21 ' A' ' 152' ' ' LEU . 0.3 OUTLIER -43.34 106.42 0.49 Allowed Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.055 -179.734 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -56.71 -20.97 37.22 Favored 'Trans proline' 0 C--O 1.231 0.14 0 C-N-CA 122.736 2.29 . . . . 0.0 111.98 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -155.99 -175.7 5.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.855 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 3.5 m -82.78 76.32 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.168 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -129.96 -146.24 5.97 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.539 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.83 HG23 ' HA ' ' A' ' 145' ' ' PRO . 1.5 m -131.55 154.39 48.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.707 0.289 . . . . 0.0 110.904 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.937 ' CD2' HD12 ' A' ' 152' ' ' LEU . 0.3 OUTLIER -115.39 146.61 41.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.948 0.404 . . . . 0.0 111.25 -179.859 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.579 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 24.0 m-85 -144.04 164.96 29.11 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.862 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.671 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 16.6 ptt180 -149.73 21.92 0.9 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.713 179.8 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.459 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 72.6 p -147.14 86.11 6.63 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.866 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -67.95 -20.89 44.39 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.746 2.297 . . . . 0.0 112.39 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.845 ' OG ' ' HB2' ' A' ' 99' ' ' ALA . 0.0 OUTLIER -120.39 145.04 39.61 Favored Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.958 179.934 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_exo -50.7 -41.48 53.9 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.752 2.301 . . . . 0.0 112.344 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -134.16 60.42 1.7 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.845 ' HB2' ' OG ' ' A' ' 96' ' ' SER . . . -111.14 -169.9 1.54 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.096 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 100' ' ' LYS . . . . . 0.427 ' N ' ' CD ' ' A' ' 100' ' ' LYS . 0.4 OUTLIER -93.71 24.64 3.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.833 179.984 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.671 ' HB1' ' O ' ' A' ' 93' ' ' ARG . . . 67.13 -178.37 0.21 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.061 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.72 ' O ' HD13 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -89.09 -59.27 2.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.591 179.79 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.936 HG22 HG21 ' A' ' 135' ' ' VAL . 24.6 mm -154.15 94.74 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.908 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -94.66 165.72 12.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.961 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.487 ' CG2' ' O ' ' A' ' 136' ' ' LYS . 2.1 p -53.58 101.62 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.066 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 141.11 -29.86 2.28 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.523 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.423 ' HA ' ' OE1' ' A' ' 107' ' ' GLN . 1.9 mp0 -72.04 121.17 18.73 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.782 0.325 . . . . 0.0 110.861 179.903 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 1.8 mttt -86.36 97.31 10.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.959 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.789 HG11 ' CD2' ' A' ' 115' ' ' LEU . 15.3 m -61.48 176.74 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.123 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.511 ' HA ' ' CB ' ' A' ' 132' ' ' SER . 66.0 m-20 -168.89 133.81 1.57 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.672 179.862 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.428 ' C ' ' O ' ' A' ' 110' ' ' ASN . 0.2 OUTLIER -35.14 123.79 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.128 179.89 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 91.65 21.12 35.08 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.444 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.43 ' O ' ' C ' ' A' ' 114' ' ' THR . 20.1 t0 -132.37 107.21 8.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.707 0.289 . . . . 0.0 110.87 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.537 ' CG2' ' HB2' ' A' ' 126' ' ' GLN . 2.4 m -34.16 132.9 0.24 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.025 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.789 ' CD2' HG11 ' A' ' 109' ' ' VAL . 18.0 mt -89.07 -83.0 0.24 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.992 -179.858 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 116' ' ' CYS . . . . . . . . . . . . . 19.0 p -135.91 -166.2 1.83 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.039 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.553 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.3 OUTLIER -113.58 114.49 46.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.21 -179.883 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.974 HG12 ' O ' ' A' ' 125' ' ' ASN . 9.1 p -103.49 58.26 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.831 179.746 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.486 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.5 OUTLIER -34.72 91.32 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.115 -179.778 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' A' ' 118' ' ' VAL . . . -108.4 145.77 34.05 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.009 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.473 ' HG2' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 46.85 24.86 0.39 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.574 -179.868 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.497 ' O ' ' CG ' ' A' ' 123' ' ' MET . 0.0 OUTLIER 79.33 50.21 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.886 -179.917 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.497 ' CG ' ' O ' ' A' ' 122' ' ' LYS . 40.5 mtp -162.28 125.56 2.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.081 179.798 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.553 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -60.28 77.96 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.994 179.947 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.974 ' O ' HG12 ' A' ' 118' ' ' VAL . 1.0 OUTLIER -70.54 73.65 0.53 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.754 179.919 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.537 ' HB2' ' CG2' ' A' ' 114' ' ' THR . 0.0 OUTLIER -50.22 131.59 23.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.015 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.55 HG22 ' N ' ' A' ' 128' ' ' GLU . 35.3 mm -94.03 161.64 2.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.08 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.55 ' N ' HG22 ' A' ' 127' ' ' ILE . 5.8 mt-10 -127.99 142.24 51.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.978 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -62.38 136.81 58.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.085 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -115.87 -8.02 11.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.035 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.676 ' HE2' ' CD2' ' A' ' 81' ' ' HIS . 0.3 OUTLIER -159.94 35.3 0.18 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.839 179.96 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.511 ' CB ' ' HA ' ' A' ' 110' ' ' ASN . 96.1 p 43.64 -171.7 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.767 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.548 ' N ' HG23 ' A' ' 109' ' ' VAL . . . 148.22 -156.84 27.09 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.54 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.541 ' N ' HG12 ' A' ' 155' ' ' ILE . 85.7 m -162.81 110.01 1.24 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.721 0.296 . . . . 0.0 110.91 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.936 HG21 HG22 ' A' ' 103' ' ' ILE . 70.1 t -47.21 144.13 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.893 0.378 . . . . 0.0 111.015 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.548 ' HD3' HG11 ' A' ' 154' ' ' VAL . 0.0 OUTLIER -114.83 -35.82 4.68 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 121.494 0.664 . . . . 0.0 109.451 -179.95 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.642 ' O ' HG23 ' A' ' 154' ' ' VAL . . . 179.65 136.65 0.11 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 114.97 -1.014 . . . . 0.0 111.052 -179.724 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.936 HG21 ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -88.92 85.38 2.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.927 0.394 . . . . 0.0 110.555 179.695 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.422 ' C ' ' O ' ' A' ' 138' ' ' ILE . 10.8 mt -37.16 -31.26 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.485 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.604 HG21 ' HB3' ' A' ' 152' ' ' LEU . 42.9 t -94.32 143.31 11.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.177 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.472 ' O ' ' HB3' ' A' ' 144' ' ' GLN . 27.3 mt-10 -77.59 105.36 8.69 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.917 179.235 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.539 ' HB3' ' CD ' ' A' ' 93' ' ' ARG . 24.4 p -34.45 135.82 0.16 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.765 -179.342 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.579 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 83.64 34.79 18.32 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.41 -0.9 . . . . 0.0 111.93 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.472 ' HB3' ' O ' ' A' ' 141' ' ' GLU . 1.0 OUTLIER -143.42 145.28 31.23 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 120.88 0.372 . . . . 0.0 110.976 -179.658 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.83 ' HA ' HG23 ' A' ' 90' ' ' THR . 57.2 Cg_endo -71.2 171.97 14.94 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.789 2.326 . . . . 0.0 112.204 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.548 ' CG2' ' HB2' ' A' ' 85' ' ' SER . 6.0 m -153.44 -165.12 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.192 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.517 ' O ' ' CG ' ' A' ' 150' ' ' GLU . 3.3 mt-10 -146.03 157.88 43.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.043 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.469 ' HA ' ' O ' ' A' ' 85' ' ' SER . 3.4 t80 -47.39 135.05 11.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.912 179.949 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.416 ' N ' ' CD1' ' A' ' 148' ' ' PHE . 58.1 t0 67.4 34.8 4.57 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.939 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.565 ' O ' HD23 ' A' ' 152' ' ' LEU . 14.6 mm-40 -115.29 75.43 4.48 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.857 179.769 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.498 ' HA ' ' HA ' ' A' ' 84' ' ' ARG . 71.2 Cg_exo -36.61 125.53 0.41 Allowed 'Trans proline' 0 N--CA 1.459 -0.528 0 C-N-CA 122.75 2.3 . . . . 0.0 111.637 179.51 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.937 HD12 ' CD2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -129.29 -36.24 1.72 Allowed 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 120.962 0.411 . . . . 0.0 110.98 -179.005 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.839 ' HB ' HG12 ' A' ' 83' ' ' VAL . 1.3 t -115.99 109.46 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.347 -178.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.642 HG23 ' O ' ' A' ' 137' ' ' ALA . 1.4 t -98.46 119.04 45.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.612 179.429 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.541 HG12 ' N ' ' A' ' 134' ' ' THR . 0.0 OUTLIER -110.1 154.66 11.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.863 -179.772 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.467 ' N ' ' O ' ' A' ' 134' ' ' THR . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.241 -0.885 . . . . 0.0 110.939 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.469 -0.252 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.49 ' N ' ' O ' ' A' ' 155' ' ' ILE . 35.5 t-80 -178.87 79.79 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.802 0.334 . . . . 0.0 110.874 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 1.069 HD12 HG13 ' A' ' 154' ' ' VAL . 0.2 OUTLIER -92.04 -176.14 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.031 179.845 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.859 HG23 HG13 ' A' ' 153' ' ' VAL . 2.1 t -142.02 41.56 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.859 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.537 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -33.84 132.81 0.22 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.088 -179.845 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.985 ' OG ' HD21 ' A' ' 152' ' ' LEU . 1.5 m -44.44 103.91 0.36 Allowed Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.903 -179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_exo -50.98 -20.04 6.56 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.586 2.191 . . . . 0.0 112.064 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.621 ' SD ' ' HB1' ' A' ' 120' ' ' ALA . 14.9 ptm -150.34 166.73 29.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.681 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.47 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 1.5 p -68.14 95.9 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.004 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -147.56 -133.0 2.31 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.579 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.672 HG23 ' C ' ' A' ' 144' ' ' GLN . 24.3 m -140.43 151.19 44.7 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.831 0.348 . . . . 0.0 110.884 -179.889 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.776 ' CB ' HD22 ' A' ' 152' ' ' LEU . 0.4 OUTLIER -118.22 151.47 37.56 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.828 179.953 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.581 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 23.4 m-85 -147.24 168.76 20.91 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.789 -0.642 . . . . 0.0 111.0 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.468 ' O ' ' N ' ' A' ' 102' ' ' PHE . 0.0 OUTLIER -135.66 18.07 3.32 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.688 179.742 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.622 ' O ' HD11 ' A' ' 117' ' ' ILE . 2.1 p -132.6 108.73 13.24 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.815 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.59 ' HG3' ' CD1' ' A' ' 102' ' ' PHE . 51.8 Cg_exo -53.72 -18.06 11.43 Favored 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.743 2.296 . . . . 0.0 112.3 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.408 ' CB ' ' HD2' ' A' ' 97' ' ' PRO . 0.4 OUTLIER -178.96 167.95 0.88 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.902 -179.963 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.515 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 59.2 Cg_endo -72.29 113.77 3.8 Favored 'Trans proline' 0 N--CA 1.464 -0.215 0 C-N-CA 122.735 2.29 . . . . 0.0 112.361 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.515 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 0.6 OUTLIER 85.15 49.96 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.914 179.934 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -125.88 -163.58 1.23 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.093 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 1.2 mtpp -101.15 38.05 1.64 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.9 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.414 ' C ' ' HD3' ' A' ' 95' ' ' PRO . . . 54.15 175.76 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.084 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.909 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -100.75 -34.56 9.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.945 179.952 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.909 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.3 OUTLIER -179.05 144.04 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.035 179.922 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.471 ' O ' HG11 ' A' ' 135' ' ' VAL . 2.3 mt-10 -146.33 148.33 32.27 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.948 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.529 HG22 ' HA ' ' A' ' 137' ' ' ALA . 3.9 t -35.36 123.82 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.109 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 111.48 -24.97 14.36 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.323 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.65 ' O ' HG12 ' A' ' 135' ' ' VAL . 22.4 tp60 -82.25 117.24 22.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.784 0.326 . . . . 0.0 110.814 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 134' ' ' THR . 0.0 OUTLIER -81.69 100.0 9.23 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.037 -179.885 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.651 HG11 ' CD2' ' A' ' 115' ' ' LEU . 7.7 m -59.27 176.09 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.019 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.432 ' CG ' ' O ' ' A' ' 109' ' ' VAL . 21.3 m120 -163.15 131.31 3.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.036 0.446 . . . . 0.0 110.766 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.517 ' CG1' ' HA ' ' A' ' 131' ' ' LYS . 33.2 m -35.42 138.4 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.011 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 80.74 16.42 75.39 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.333 -179.791 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -124.41 102.62 7.75 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.865 0.364 . . . . 0.0 110.848 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.703 HG23 ' HB2' ' A' ' 126' ' ' GLN . 9.0 m -40.54 110.77 0.16 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.022 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.651 ' CD2' HG11 ' A' ' 109' ' ' VAL . 20.6 mt -65.96 -87.42 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.802 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.549 ' SG ' HG11 ' A' ' 153' ' ' VAL . 0.8 OUTLIER -124.7 -171.28 2.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.768 179.904 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.622 HD11 ' O ' ' A' ' 94' ' ' THR . 0.3 OUTLIER -106.01 113.57 43.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.203 -179.932 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.761 ' O ' HG12 ' A' ' 118' ' ' VAL . 75.7 t -97.3 59.22 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.036 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.475 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.4 OUTLIER -39.1 90.76 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.039 -179.798 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.621 ' HB1' ' SD ' ' A' ' 87' ' ' MET . . . -110.55 144.6 39.15 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.958 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.5 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.1 OUTLIER 56.2 17.03 2.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.892 -179.917 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.5 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.6 OUTLIER 83.41 53.4 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.925 -179.995 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.481 ' HG2' ' O ' ' A' ' 120' ' ' ALA . 3.1 ptt? -173.07 133.45 0.53 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.991 179.769 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.536 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -53.04 96.14 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.019 179.945 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.425 ' O ' ' C ' ' A' ' 126' ' ' GLN . 4.2 t30 -88.18 65.18 8.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.847 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.703 ' HB2' HG23 ' A' ' 114' ' ' THR . 0.0 OUTLIER -35.12 154.46 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.065 -179.857 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.542 HG12 HG23 ' A' ' 118' ' ' VAL . 47.0 mm -121.97 120.3 61.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.22 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 58.4 mm-40 -83.11 119.77 24.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.777 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.453 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -41.61 114.39 0.51 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.164 -179.88 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -74.76 -27.0 60.16 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.721 179.878 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.517 ' HA ' ' CG1' ' A' ' 111' ' ' VAL . 0.0 OUTLIER -165.05 136.13 4.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.812 179.954 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.428 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.2 t -45.84 132.75 8.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.79 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.513 ' O ' ' N ' ' A' ' 109' ' ' VAL . . . -159.03 176.44 35.85 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.604 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.865 ' C ' HG23 ' A' ' 155' ' ' ILE . 13.8 m -122.88 108.21 12.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.663 0.268 . . . . 0.0 111.263 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.65 HG12 ' O ' ' A' ' 107' ' ' GLN . 2.8 p -49.16 144.68 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.517 -0.311 . . . . 0.0 110.566 179.515 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.662 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 1.1 mmmp? -124.14 -19.24 5.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.632 0.253 . . . . 0.0 111.234 -179.553 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.662 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 166.3 163.23 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.843 0.354 . . . . 0.0 111.433 -179.779 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.641 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.1 OUTLIER -105.23 85.46 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.74 179.626 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.721 HD13 ' HB2' ' A' ' 151' ' ' PRO . 12.4 mt -42.49 -28.03 0.19 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.969 0.414 . . . . 0.0 110.231 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 1.038 HG21 HD23 ' A' ' 152' ' ' LEU . 52.2 t -104.59 141.81 19.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.78 179.593 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 142' ' ' SER . 6.5 mt-10 -69.75 97.12 1.04 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.58 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.461 ' HB2' ' HD2' ' A' ' 93' ' ' ARG . 0.3 OUTLIER -36.93 135.22 0.46 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.627 -179.957 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.581 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 85.81 38.09 8.96 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.534 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.672 ' C ' HG23 ' A' ' 90' ' ' THR . 4.1 pt20 -155.64 163.61 24.08 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.884 0.373 . . . . 0.0 111.155 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.912 ' O ' HG13 ' A' ' 146' ' ' VAL . 55.4 Cg_endo -70.47 -168.78 0.32 Allowed 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.762 2.308 . . . . 0.0 112.646 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.918 HG11 HD23 ' A' ' 152' ' ' LEU . 0.2 OUTLIER -175.72 -174.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.965 -179.982 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.47 ' HA ' ' HA ' ' A' ' 88' ' ' VAL . 4.0 mt-10 -145.6 157.37 43.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.933 0.396 . . . . 0.0 111.089 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.446 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 1.2 t80 -42.94 125.13 3.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.946 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.446 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 2.4 t0 79.61 31.95 0.24 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.951 0.405 . . . . 0.0 110.606 -179.804 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.726 ' HG2' HG12 ' A' ' 146' ' ' VAL . 44.1 tp10 -111.03 74.99 1.05 Allowed Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.879 179.861 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.812 ' O ' HG23 ' A' ' 140' ' ' VAL . 63.3 Cg_exo -35.93 122.75 0.27 Allowed 'Trans proline' 0 N--CA 1.459 -0.508 0 C-N-CA 122.812 2.341 . . . . 0.0 112.084 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 1.038 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -116.66 -54.09 2.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.619 -179.208 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.859 HG13 HG23 ' A' ' 83' ' ' VAL . 1.3 p -108.07 108.72 25.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.121 0.486 . . . . 0.0 111.339 -179.262 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 1.069 HG13 HD12 ' A' ' 82' ' ' ILE . 6.0 t -91.14 138.96 18.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.976 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.865 HG23 ' C ' ' A' ' 134' ' ' THR . 37.3 mt -141.3 141.1 31.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.18 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.52 ' HB2' ' CG ' ' A' ' 136' ' ' LYS . 10.6 tt0 . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.248 -0.882 . . . . 0.0 110.877 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.305 0 N-CA-C 112.422 -0.271 . . . . 0.0 112.422 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.486 ' N ' ' O ' ' A' ' 155' ' ' ILE . 34.6 t-80 -172.52 77.62 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.806 0.336 . . . . 0.0 110.925 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.907 HG12 HG13 ' A' ' 154' ' ' VAL . 10.2 mt -99.22 150.92 4.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.955 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.81 HG23 HG13 ' A' ' 153' ' ' VAL . 4.5 t -96.91 59.93 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.15 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.492 ' O ' ' N ' ' A' ' 86' ' ' PRO . 4.2 mmt85 -28.88 103.3 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.025 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.946 ' CA ' HD11 ' A' ' 152' ' ' LEU . 0.4 OUTLIER -32.12 91.95 0.05 OUTLIER Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.251 -179.789 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.878 ' HD2' HG11 ' A' ' 118' ' ' VAL . 77.5 Cg_exo -50.22 140.21 34.01 Favored 'Trans proline' 0 N--CA 1.464 -0.25 0 C-N-CA 122.755 2.303 . . . . 0.0 112.058 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.458 ' O ' ' O ' ' A' ' 86' ' ' PRO . 7.6 ptm 41.22 -167.09 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.465 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.648 HG22 ' CG ' ' A' ' 147' ' ' GLU . 72.5 t -90.32 114.49 28.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.783 0.325 . . . . 0.0 111.208 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -165.02 -164.11 19.69 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.537 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.749 HG23 ' CA ' ' A' ' 145' ' ' PRO . 1.9 m -115.48 151.56 34.58 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.853 0.359 . . . . 0.0 110.901 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.948 ' HB2' HD22 ' A' ' 152' ' ' LEU . 2.9 t80 -110.78 141.96 43.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.954 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.583 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 21.0 m-85 -142.41 157.49 44.72 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.808 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.519 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 1.7 ptm180 -134.39 20.88 3.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.398 179.568 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.583 ' O ' HD11 ' A' ' 117' ' ' ILE . 69.2 p -123.05 121.84 27.09 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.694 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.433 ' HG2' ' HB3' ' A' ' 99' ' ' ALA . 50.8 Cg_exo -53.07 -59.76 0.93 Allowed 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.685 2.257 . . . . 0.0 112.336 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.581 ' CB ' ' CD ' ' A' ' 97' ' ' PRO . 0.9 OUTLIER 170.99 -66.04 0.0 OUTLIER Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 121.191 0.519 . . . . 0.0 111.106 179.869 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.581 ' CD ' ' CB ' ' A' ' 96' ' ' SER . 46.5 Cg_endo -68.94 53.6 0.81 Allowed 'Trans proline' 0 C--N 1.333 -0.268 0 C-N-CA 123.37 2.713 . . . . 0.0 112.496 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.432 ' C ' ' O ' ' A' ' 97' ' ' PRO . 4.5 p30 35.18 45.2 0.18 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.033 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.433 ' HB3' ' HG2' ' A' ' 95' ' ' PRO . . . -71.68 -160.13 0.05 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.087 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' LYS . . . . . 0.57 ' O ' ' HB3' ' A' ' 101' ' ' ALA . 0.4 OUTLIER -90.77 27.48 1.77 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.842 179.921 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.57 ' HB3' ' O ' ' A' ' 100' ' ' LYS . . . 75.68 155.85 0.17 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.071 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.666 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -69.11 -37.51 78.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.49 179.885 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.666 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.9 pp -163.34 157.67 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.934 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -154.79 147.57 24.41 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.056 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.736 HG23 ' HA ' ' A' ' 136' ' ' LYS . 2.0 p -44.2 109.4 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.05 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 126.38 -18.07 6.5 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.397 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -85.48 106.37 16.77 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.842 0.353 . . . . 0.0 110.867 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' A' ' 109' ' ' VAL . 2.4 mttp -67.03 79.53 0.12 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.908 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.71 HG22 ' O ' ' A' ' 133' ' ' GLY . 22.1 m -45.8 175.55 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.109 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.445 ' HA ' ' HB2' ' A' ' 132' ' ' SER . 1.7 p-10 -165.27 135.02 3.58 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 121.026 0.441 . . . . 0.0 110.742 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.468 ' HA ' ' HB3' ' A' ' 129' ' ' ALA . 20.2 t -34.82 137.24 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 115.711 -0.677 . . . . 0.0 111.077 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 81.31 16.22 74.61 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.414 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 114' ' ' THR . 9.0 t0 -122.54 101.71 7.64 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.814 0.34 . . . . 0.0 110.952 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.451 ' HA ' ' O ' ' A' ' 127' ' ' ILE . 1.5 m -35.4 108.7 0.07 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.898 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.51 ' N ' ' O ' ' A' ' 127' ' ' ILE . 14.7 mt -62.24 -67.04 0.45 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.791 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.498 ' SG ' ' N ' ' A' ' 117' ' ' ILE . 2.5 p -162.46 -154.47 0.31 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.942 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.583 HD11 ' O ' ' A' ' 94' ' ' THR . 0.1 OUTLIER -122.23 119.37 58.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.282 -179.85 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.878 HG11 ' HD2' ' A' ' 86' ' ' PRO . 2.4 t -109.21 58.46 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.801 179.644 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.486 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.4 OUTLIER -34.74 104.11 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.165 -179.703 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.524 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -121.81 108.91 14.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.995 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.532 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 86.16 17.8 0.11 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.676 -179.802 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.541 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 5.0 tmtm? 87.61 26.58 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.861 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.486 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 1.1 mmm -139.85 124.81 18.56 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.927 0.394 . . . . 0.0 111.157 179.768 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.554 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -55.55 102.97 0.08 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.875 179.762 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.449 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 9.8 t30 -84.78 65.21 9.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.813 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.439 ' HA ' ' O ' ' A' ' 116' ' ' CYS . 6.7 pt20 -45.79 118.99 2.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.96 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.547 HD11 HG21 ' A' ' 118' ' ' VAL . 3.7 mm -94.2 151.66 3.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.005 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -126.65 130.45 50.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.922 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.468 ' HB3' ' HA ' ' A' ' 111' ' ' VAL . . . -42.44 134.07 3.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.111 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.446 ' OD1' ' O ' ' A' ' 130' ' ' ASP . 10.5 t70 -118.44 -0.24 11.47 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.076 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.458 ' O ' ' O ' ' A' ' 132' ' ' SER . 1.3 ptmt -170.73 29.61 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.941 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.458 ' O ' ' O ' ' A' ' 131' ' ' LYS . 0.9 OUTLIER 47.38 -179.52 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.743 -179.815 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.71 ' O ' HG22 ' A' ' 109' ' ' VAL . . . 152.01 174.19 22.42 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.625 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.711 ' N ' HG23 ' A' ' 155' ' ' ILE . 27.5 m -120.94 110.68 16.58 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.553 0.216 . . . . 0.0 111.235 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.545 ' HA ' ' CG1' ' A' ' 155' ' ' ILE . 61.3 t -49.77 145.66 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.63 -0.259 . . . . 0.0 110.32 179.461 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.736 ' HA ' HG23 ' A' ' 105' ' ' VAL . 50.9 mmtt -125.38 -18.04 5.44 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 121.049 -0.26 . . . . 0.0 111.643 -179.417 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.696 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 164.66 153.46 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.927 0.394 . . . . 0.0 111.857 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.737 ' N ' HD13 ' A' ' 138' ' ' ILE . 0.0 OUTLIER -95.7 77.9 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.419 179.499 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.739 HD12 HG22 ' A' ' 154' ' ' VAL . 3.9 mt -38.44 -30.86 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.118 0.485 . . . . 0.0 110.223 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.94 HG21 HD23 ' A' ' 152' ' ' LEU . 55.3 t -102.93 138.32 27.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.818 179.725 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.518 ' O ' ' CG ' ' A' ' 144' ' ' GLN . 1.7 mt-10 -68.92 106.5 2.75 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.385 179.801 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.507 ' HB3' ' CG ' ' A' ' 93' ' ' ARG . 6.3 p -36.41 152.07 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.697 -179.554 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.583 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 56.99 43.86 92.97 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.395 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.595 ' C ' HG23 ' A' ' 90' ' ' THR . 61.6 mm-40 -147.39 137.95 12.71 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.895 0.378 . . . . 0.0 111.245 -179.769 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.749 ' CA ' HG23 ' A' ' 90' ' ' THR . 57.1 Cg_endo -70.64 156.18 61.55 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.691 2.261 . . . . 0.0 112.266 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.923 HG21 HD21 ' A' ' 152' ' ' LEU . 4.1 m -152.24 -156.51 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.208 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.648 ' CG ' HG22 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -147.57 174.31 11.87 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.95 -179.943 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.444 ' HA ' ' O ' ' A' ' 85' ' ' SER . 25.4 t80 -53.84 150.81 7.12 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.87 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.418 ' O ' ' HD3' ' A' ' 151' ' ' PRO . 84.1 m-20 60.2 23.6 12.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.928 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.477 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 4.6 tt0 -107.17 74.51 0.4 Allowed Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.815 179.738 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.854 ' O ' HG23 ' A' ' 140' ' ' VAL . 62.9 Cg_exo -35.51 127.92 0.3 Allowed 'Trans proline' 0 N--CA 1.459 -0.542 0 C-N-CA 122.996 2.464 . . . . 0.0 112.5 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.948 HD22 ' HB2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -120.89 -59.97 1.69 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.273 -179.729 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.81 HG13 HG23 ' A' ' 83' ' ' VAL . 1.4 p -102.93 101.88 12.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.202 -179.663 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.907 HG13 HG12 ' A' ' 82' ' ' ILE . 17.0 t -87.11 136.0 23.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.811 -0.632 . . . . 0.0 111.292 179.844 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.711 HG23 ' N ' ' A' ' 134' ' ' THR . 22.8 mt -140.34 139.85 35.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.049 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.528 ' HB3' ' CE ' ' A' ' 136' ' ' LYS . 6.0 tp10 . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.243 -0.884 . . . . 0.0 110.841 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.443 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.33 0 N-CA-C 112.517 -0.233 . . . . 0.0 112.517 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.449 ' N ' ' O ' ' A' ' 155' ' ' ILE . 20.6 t-80 171.89 83.94 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.896 0.379 . . . . 0.0 110.964 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.826 HG12 HG13 ' A' ' 154' ' ' VAL . 6.8 mt -100.67 147.05 8.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.017 0.436 . . . . 0.0 110.999 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.845 HG23 HG13 ' A' ' 153' ' ' VAL . 3.5 t -93.36 45.31 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.993 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.474 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -34.61 127.39 0.48 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.8 -179.978 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.511 ' OG ' HG23 ' A' ' 146' ' ' VAL . 5.3 t -34.83 107.68 0.32 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.956 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -63.74 -20.95 69.64 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.791 2.327 . . . . 0.0 111.945 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 9.9 ptp -154.37 172.59 17.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.781 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.701 ' O ' HG23 ' A' ' 88' ' ' VAL . 30.7 m -66.7 87.71 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.057 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.58 ' O ' HG22 ' A' ' 146' ' ' VAL . . . -147.82 -161.16 9.33 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.635 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.654 ' CG2' ' CE1' ' A' ' 92' ' ' TYR . 5.3 m -117.48 140.6 49.39 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.893 0.378 . . . . 0.0 111.124 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.958 ' HB2' HD22 ' A' ' 152' ' ' LEU . 14.4 t80 -89.3 143.02 27.15 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.269 179.453 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.654 ' CE1' ' CG2' ' A' ' 90' ' ' THR . 18.5 m-85 -139.91 148.81 42.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.888 0.375 . . . . 0.0 111.22 -179.521 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.466 ' O ' ' N ' ' A' ' 102' ' ' PHE . 0.7 OUTLIER -135.11 13.18 3.58 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.809 179.818 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 52.5 p -141.49 110.3 6.28 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.954 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.1 -39.45 5.85 Favored 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 122.725 2.283 . . . . 0.0 112.414 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -129.72 148.98 71.66 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.92 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.33 -34.74 71.96 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.693 2.262 . . . . 0.0 112.294 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -118.63 42.46 2.75 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.856 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -100.26 -154.86 0.49 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.094 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.19 36.78 4.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.863 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.461 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 56.67 165.67 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.117 179.846 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.912 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -89.22 -34.63 16.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.964 179.994 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.912 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.2 OUTLIER 176.49 127.34 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.104 -179.912 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.84 165.6 17.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.807 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.542 ' HA ' HG12 ' A' ' 135' ' ' VAL . 1.9 p -44.28 119.59 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.927 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 114.25 -14.05 21.12 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.374 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.494 ' HG3' HG22 ' A' ' 103' ' ' ILE . 2.4 mm-40 -74.26 126.02 29.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.827 0.346 . . . . 0.0 110.887 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.0 74.03 5.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.855 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.475 HG23 ' H ' ' A' ' 133' ' ' GLY . 22.1 m -47.14 172.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.984 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.474 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 27.2 m120 -163.95 131.13 3.31 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.022 0.439 . . . . 0.0 110.72 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.517 HG23 ' O ' ' A' ' 111' ' ' VAL . 33.8 m -35.54 118.72 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.022 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 100.91 15.51 28.47 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.317 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.471 ' HB2' ' O ' ' A' ' 110' ' ' ASN . 0.3 OUTLIER -125.2 103.92 8.23 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.854 0.359 . . . . 0.0 110.669 179.993 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.549 ' CG2' ' HB3' ' A' ' 126' ' ' GLN . 2.3 m -33.92 122.14 0.46 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.149 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.477 ' O ' HG12 ' A' ' 103' ' ' ILE . 15.1 mt -78.24 -86.08 0.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.929 179.959 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.56 ' SG ' HG11 ' A' ' 153' ' ' VAL . 0.5 OUTLIER -135.04 -174.33 3.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.101 -179.904 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 1.028 HG22 ' CB ' ' A' ' 124' ' ' MET . 0.1 OUTLIER -104.86 129.45 57.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.016 -179.954 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 124' ' ' MET . 6.0 t -123.06 100.89 8.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.591 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.577 ' HG2' ' CE2' ' A' ' 92' ' ' TYR . 1.0 OUTLIER -100.16 117.71 34.98 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.522 179.571 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.523 ' O ' ' CB ' ' A' ' 121' ' ' MET . . . -112.55 47.27 1.1 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.468 -179.512 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.523 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 6.1 ptm 155.13 -39.42 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.267 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.497 ' HD2' ' HG2' ' A' ' 123' ' ' MET . 0.0 OUTLIER 172.48 -28.44 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.042 -179.971 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.528 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.8 OUTLIER -97.61 127.27 43.43 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.945 179.498 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 124' ' ' MET . . . . . 1.028 ' CB ' HG22 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -93.94 153.62 18.12 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.366 -179.249 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.508 ' O ' ' N ' ' A' ' 127' ' ' ILE . 59.5 t-20 -114.04 101.92 9.68 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.192 179.617 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.549 ' HB3' ' CG2' ' A' ' 114' ' ' THR . 0.7 OUTLIER -62.65 69.23 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.786 -179.721 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.508 ' N ' ' O ' ' A' ' 125' ' ' ASN . 26.1 mm -37.06 147.28 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.132 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.41 ' O ' ' C ' ' A' ' 129' ' ' ALA . 10.2 pt-20 -116.03 128.73 55.95 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.755 179.858 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -35.48 116.15 0.35 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.238 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -87.3 -12.61 46.01 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.739 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.477 ' HG3' ' O ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -174.28 126.52 0.34 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.764 179.96 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.474 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 8.0 t -41.83 124.87 2.71 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.779 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.475 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -152.21 176.01 30.66 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.548 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.738 ' C ' HG23 ' A' ' 155' ' ' ILE . 13.1 m -125.15 108.26 11.6 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.701 0.286 . . . . 0.0 111.288 -179.828 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.542 HG12 ' HA ' ' A' ' 105' ' ' VAL . 19.0 t -44.2 144.97 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.624 179.435 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.708 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 21.3 mtpt -123.7 -18.49 6.07 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.225 -179.567 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.708 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 163.11 161.56 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.976 0.417 . . . . 0.0 111.631 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.641 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.6 OUTLIER -111.93 85.0 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.894 179.753 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.632 HD12 ' HB2' ' A' ' 151' ' ' PRO . 8.5 mt -49.12 -38.35 24.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.99 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 1.004 HG21 HD23 ' A' ' 152' ' ' LEU . 49.2 t -83.6 143.7 11.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.146 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.485 ' O ' ' C ' ' A' ' 142' ' ' SER . 17.2 mt-10 -74.5 78.15 1.94 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.06 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.502 ' HA ' ' CE2' ' A' ' 91' ' ' PHE . 11.6 p 21.77 -114.56 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 115.285 -0.871 . . . . 0.0 111.815 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.584 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -62.81 80.84 0.03 OUTLIER Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.839 -0.696 . . . . 0.0 113.043 -179.794 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.479 ' O ' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -157.56 144.15 13.12 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-O 121.078 0.466 . . . . 0.0 111.435 179.593 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.433 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 27.6 Cg_endo -62.4 151.57 81.98 Favored 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.974 2.449 . . . . 0.0 112.546 -179.792 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.734 HG11 ' CD2' ' A' ' 152' ' ' LEU . 18.3 m -143.93 -173.16 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.883 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.437 ' O ' ' C ' ' A' ' 148' ' ' PHE . 0.1 OUTLIER -150.26 149.64 30.43 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.899 179.992 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.499 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 2.0 t80 -34.33 124.15 0.5 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.822 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.499 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 17.4 t0 83.94 27.14 0.09 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.593 -179.607 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.416 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 44.0 tp10 -110.33 73.73 0.79 Allowed Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.908 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.811 ' O ' HG23 ' A' ' 140' ' ' VAL . 68.6 Cg_exo -34.18 127.59 0.18 Allowed 'Trans proline' 0 N--CA 1.459 -0.559 0 C-N-CA 122.825 2.35 . . . . 0.0 112.044 179.681 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 1.004 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -122.46 -64.98 1.14 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.525 -179.425 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.845 HG13 HG23 ' A' ' 83' ' ' VAL . 1.6 p -103.92 102.89 14.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.254 -179.469 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.826 HG13 HG12 ' A' ' 82' ' ' ILE . 10.3 t -83.47 142.67 13.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 115.76 -0.654 . . . . 0.0 111.275 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.738 HG23 ' C ' ' A' ' 134' ' ' THR . 27.5 mt -144.48 141.47 23.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.994 179.858 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.545 ' CA ' ' HD2' ' A' ' 136' ' ' LYS . 3.0 tt0 . . . . . 0 C--O 1.249 1.036 0 CA-C-O 118.283 -0.865 . . . . 0.0 110.919 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.457 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.328 0 N-CA-C 112.442 -0.263 . . . . 0.0 112.442 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.587 ' CD2' ' HE3' ' A' ' 131' ' ' LYS . 17.1 t-80 172.53 84.19 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.788 0.328 . . . . 0.0 110.983 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.748 HG12 HG13 ' A' ' 154' ' ' VAL . 29.8 mt -92.26 116.62 33.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.07 0.462 . . . . 0.0 110.836 179.727 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.966 HG21 HD13 ' A' ' 115' ' ' LEU . 2.0 t -69.85 59.79 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.244 -179.701 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.532 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -47.53 135.08 11.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.725 179.823 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.511 ' HB3' HD21 ' A' ' 152' ' ' LEU . 1.3 p -39.3 104.63 0.32 Allowed Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.996 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 37.4 Cg_endo -66.18 -7.18 16.51 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.656 2.237 . . . . 0.0 112.018 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.453 ' HG3' ' CB ' ' A' ' 120' ' ' ALA . 2.0 ptm -155.72 168.3 27.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.641 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 7.1 m -71.87 60.16 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.124 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.652 ' O ' HG22 ' A' ' 146' ' ' VAL . . . -116.96 -165.69 13.93 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.454 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.635 HG23 ' C ' ' A' ' 144' ' ' GLN . 24.4 m -108.99 156.92 19.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.987 0.422 . . . . 0.0 111.024 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.684 ' CZ ' HG21 ' A' ' 138' ' ' ILE . 11.9 t80 -106.77 140.68 39.22 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.263 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.578 ' CD2' ' OE1' ' A' ' 119' ' ' GLU . 17.6 m-85 -143.13 151.09 40.32 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.971 0.415 . . . . 0.0 111.063 179.607 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.713 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 18.2 ptt180 -132.11 23.92 4.54 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.663 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.473 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 63.5 p -150.57 107.11 3.1 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.868 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.21 -16.11 31.68 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.651 2.234 . . . . 0.0 112.221 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -142.93 159.64 55.77 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.918 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -53.32 -63.33 0.24 Allowed 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.806 2.337 . . . . 0.0 112.341 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -110.99 79.79 1.24 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.876 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -135.2 -166.91 1.91 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.102 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.09 38.09 1.27 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.928 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.713 ' HB1' ' O ' ' A' ' 93' ' ' ARG . . . 49.39 -177.18 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.239 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.852 ' O ' HD13 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -90.11 -61.44 1.68 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.126 179.55 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.852 HD13 ' O ' ' A' ' 102' ' ' PHE . 2.2 mm -153.52 145.03 14.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.7 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -147.45 162.84 38.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.738 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.494 HG13 ' HA ' ' A' ' 136' ' ' LYS . 6.0 t -47.32 119.68 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.995 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 120.15 -27.04 6.86 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.249 -179.71 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.83 112.49 18.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.759 0.314 . . . . 0.0 110.807 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.465 ' O ' ' O ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -79.49 81.83 5.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.843 179.998 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.897 HG22 ' O ' ' A' ' 133' ' ' GLY . 14.7 m -45.28 176.11 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.003 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.432 ' HA ' ' HB2' ' A' ' 132' ' ' SER . 73.3 m-80 -163.19 131.1 3.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.615 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.524 ' HA ' ' HB3' ' A' ' 129' ' ' ALA . 2.3 p -37.58 155.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.968 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' GLY . . . . . 0.437 ' N ' HG22 ' A' ' 111' ' ' VAL . . . 75.78 -0.08 62.6 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.339 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.464 ' O ' ' HA ' ' A' ' 128' ' ' GLU . 2.5 t0 -107.17 -149.53 0.43 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.691 0.282 . . . . 0.0 110.689 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.76 HG21 ' CZ ' ' A' ' 102' ' ' PHE . 6.1 m -135.73 150.4 49.51 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.89 0.376 . . . . 0.0 111.012 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.966 HD13 HG21 ' A' ' 83' ' ' VAL . 83.0 mt -106.81 -79.74 0.57 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.892 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 116' ' ' CYS . . . . . . . . . . . . . 14.9 p -134.51 -166.1 1.76 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.97 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 1.024 HG22 ' OE2' ' A' ' 119' ' ' GLU . 0.3 OUTLIER -115.01 125.22 72.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.297 -179.725 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.497 HG21 HD11 ' A' ' 127' ' ' ILE . 54.7 t -108.58 95.0 3.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.449 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 1.024 ' OE2' HG22 ' A' ' 117' ' ' ILE . 0.5 OUTLIER -102.76 105.0 15.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.877 -179.083 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.598 ' HB2' ' HA3' ' A' ' 89' ' ' GLY . . . -126.57 48.01 2.22 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.709 -179.684 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.557 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 152.55 51.88 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.25 179.907 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.486 ' HD3' ' O ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 56.14 18.2 3.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.343 -179.313 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.487 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 1.7 mtt -141.24 122.8 15.1 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.821 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.575 ' CB ' HG22 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -75.15 171.82 13.47 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.428 -0.806 . . . . 0.0 111.44 -179.839 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.463 ' HB2' ' HB ' ' A' ' 118' ' ' VAL . 3.5 m120 -151.49 83.79 1.3 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.473 179.73 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.562 ' HB2' HG23 ' A' ' 114' ' ' THR . 3.2 pt20 -50.23 113.41 0.86 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.06 -179.67 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.821 HG21 HG11 ' A' ' 83' ' ' VAL . 18.8 mm -81.42 95.65 2.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.919 179.802 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.478 ' HA ' ' HA ' ' A' ' 114' ' ' THR . 1.4 mt-10 -72.05 144.08 48.87 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.115 -179.773 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.524 ' HB3' ' HA ' ' A' ' 111' ' ' VAL . . . -68.67 142.46 55.05 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.831 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 55.7 p30 -126.74 1.87 6.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.341 -0.391 . . . . 0.0 111.08 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.587 ' HE3' ' CD2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -158.83 22.21 0.21 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.092 -179.927 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.478 ' O ' ' NZ ' ' A' ' 131' ' ' LYS . 1.1 p 49.94 173.56 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.783 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.897 ' O ' HG22 ' A' ' 109' ' ' VAL . . . 156.56 176.02 28.18 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.571 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.773 ' C ' HG23 ' A' ' 155' ' ' ILE . 25.9 m -127.78 119.56 25.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.582 0.229 . . . . 0.0 111.307 -179.765 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.595 HG21 HG22 ' A' ' 103' ' ' ILE . 73.3 t -52.36 144.7 3.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 179.172 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.65 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 22.4 mmmt -125.17 -18.77 5.32 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.685 0.279 . . . . 0.0 111.422 -179.431 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.799 ' C ' HD13 ' A' ' 138' ' ' ILE . . . 167.05 156.78 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.178 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.799 HD13 ' C ' ' A' ' 137' ' ' ALA . 0.2 OUTLIER -109.88 84.58 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.032 179.821 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.564 ' N ' HD23 ' A' ' 139' ' ' LEU . 3.6 mt -47.13 -25.86 0.98 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.415 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.967 HG21 HD23 ' A' ' 152' ' ' LEU . 78.3 t -104.8 149.47 8.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.735 179.71 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.534 ' HB2' ' CG ' ' A' ' 144' ' ' GLN . 4.1 mm-40 -52.55 -170.99 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.376 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.522 ' O ' ' O ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -84.87 -55.41 4.1 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 120.837 -0.345 . . . . 0.0 111.509 -179.789 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.561 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -128.16 103.14 0.61 Allowed Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.857 -179.342 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.635 ' C ' HG23 ' A' ' 90' ' ' THR . 0.0 OUTLIER -174.05 144.17 0.98 Allowed Pre-proline 0 C--N 1.326 -0.413 0 CA-C-O 121.034 0.445 . . . . 0.0 111.18 179.669 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 144' ' ' GLN . 43.7 Cg_exo -56.58 142.97 90.06 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.83 2.353 . . . . 0.0 112.036 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.916 HG11 ' CD2' ' A' ' 152' ' ' LEU . 4.8 m -128.86 179.52 3.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.157 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.458 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 1.3 mt-10 -129.82 141.4 50.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.73 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.46 ' HA ' ' O ' ' A' ' 85' ' ' SER . 34.5 t80 -35.45 137.52 0.18 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.903 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.468 ' HA ' ' HD2' ' A' ' 84' ' ' ARG . 0.6 OUTLIER 72.32 26.13 2.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.756 -179.799 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.465 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 6.7 tp10 -106.81 73.96 0.35 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.869 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.753 ' O ' HG23 ' A' ' 140' ' ' VAL . 61.0 Cg_exo -34.19 122.19 0.15 Allowed 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.869 2.379 . . . . 0.0 111.96 179.581 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.967 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -118.57 -66.61 1.06 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.563 -179.215 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.542 HG13 ' HB ' ' A' ' 83' ' ' VAL . 0.8 OUTLIER -96.7 106.22 18.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.289 -179.393 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.748 HG13 HG12 ' A' ' 82' ' ' ILE . 34.5 t -87.51 134.45 27.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.291 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.773 HG23 ' C ' ' A' ' 134' ' ' THR . 72.0 mt -135.73 140.02 45.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.987 179.785 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.55 ' CG ' ' HB ' ' A' ' 134' ' ' THR . 10.0 pt-20 . . . . . 0 C--O 1.249 1.027 0 CA-C-O 118.26 -0.876 . . . . 0.0 110.88 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.484 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.45 -0.386 0 N-CA-C 112.533 -0.227 . . . . 0.0 112.533 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.484 ' HB2' ' O ' ' A' ' 80' ' ' GLY . 34.0 t-80 173.74 83.7 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.763 0.316 . . . . 0.0 110.901 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.932 HD12 HG13 ' A' ' 154' ' ' VAL . 0.0 OUTLIER -97.74 -179.2 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.56 179.617 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.798 ' CG2' HG13 ' A' ' 153' ' ' VAL . 48.7 t -117.62 2.87 7.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.365 179.728 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.493 ' C ' ' O ' ' A' ' 83' ' ' VAL . 0.9 OUTLIER 23.97 98.22 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.486 179.858 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.653 ' HB2' HD21 ' A' ' 152' ' ' LEU . 4.1 t -34.37 95.81 0.09 OUTLIER Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.795 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.519 ' O ' ' CD1' ' A' ' 148' ' ' PHE . 18.8 Cg_endo -58.91 -74.45 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.638 2.225 . . . . 0.0 111.9 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.584 ' HE3' ' HB2' ' A' ' 120' ' ' ALA . 6.0 mtm -70.77 156.51 39.43 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.783 179.645 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.775 HG22 ' O ' ' A' ' 88' ' ' VAL . 2.6 p -79.43 57.74 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.048 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -114.34 -148.2 9.69 Favored Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.38 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.898 HG23 ' O ' ' A' ' 144' ' ' GLN . 16.9 m -122.91 144.22 49.37 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-O 121.087 0.47 . . . . 0.0 111.24 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.881 ' HB2' HD22 ' A' ' 152' ' ' LEU . 29.5 t80 -83.34 142.62 30.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.615 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.56 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 12.1 m-85 -144.88 153.68 41.84 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.428 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 0.6 OUTLIER -139.73 32.83 2.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.845 179.845 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.488 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -148.5 109.5 3.61 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.881 179.902 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 94' ' ' THR . 37.7 Cg_endo -66.22 -38.9 19.5 Favored 'Trans proline' 0 C--O 1.231 0.137 0 C-N-CA 122.752 2.301 . . . . 0.0 112.272 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.459 ' OG ' ' HD2' ' A' ' 97' ' ' PRO . 0.2 OUTLIER -129.02 168.78 14.86 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.9 179.995 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.459 ' HD2' ' OG ' ' A' ' 96' ' ' SER . 52.9 Cg_exo -52.29 -53.98 5.99 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.787 2.325 . . . . 0.0 112.221 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -124.5 71.79 1.17 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.874 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -119.09 -166.9 1.31 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.128 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -92.85 29.05 1.89 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.768 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.488 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 60.81 170.84 0.1 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.001 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.871 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -87.15 -43.26 12.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.849 -179.996 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.871 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.1 pp -169.79 134.0 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.04 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.595 ' O ' HG11 ' A' ' 135' ' ' VAL . 5.7 mt-10 -137.5 157.8 45.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.966 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.609 HG22 ' HA ' ' A' ' 137' ' ' ALA . 3.0 t -38.55 125.36 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.078 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 106' ' ' GLY . . . . . 0.438 ' N ' HG13 ' A' ' 135' ' ' VAL . . . 109.45 -28.05 11.47 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.466 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.542 ' O ' HG12 ' A' ' 135' ' ' VAL . 5.6 tp60 -71.61 109.74 5.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.807 0.337 . . . . 0.0 110.867 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 134' ' ' THR . 4.0 mttt -74.47 91.43 2.26 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.014 -179.862 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.938 HG11 ' CD2' ' A' ' 115' ' ' LEU . 0.0 OUTLIER -50.37 174.88 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.911 179.889 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.542 ' O ' ' HB3' ' A' ' 129' ' ' ALA . 6.9 m120 -162.53 131.33 4.15 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.09 0.472 . . . . 0.0 110.719 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.621 HG12 ' HA ' ' A' ' 131' ' ' LYS . 34.5 m -34.79 137.38 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.071 179.8 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 65.56 30.26 77.04 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.497 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.484 ' CB ' ' O ' ' A' ' 110' ' ' ASN . 11.1 t70 -125.52 104.86 8.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.743 0.306 . . . . 0.0 110.735 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.471 HG23 ' HB2' ' A' ' 126' ' ' GLN . 1.6 m -34.34 128.48 0.42 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.045 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.938 ' CD2' HG11 ' A' ' 109' ' ' VAL . 11.1 mt -95.15 -83.31 0.36 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.789 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.519 ' CB ' ' O ' ' A' ' 92' ' ' TYR . 0.5 OUTLIER -132.36 -169.26 2.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.673 179.927 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.541 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.2 OUTLIER -111.65 123.81 67.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.211 179.895 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.777 HG21 HD11 ' A' ' 127' ' ' ILE . 96.5 t -113.73 74.64 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.218 179.4 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.583 ' CG ' ' HB ' ' A' ' 90' ' ' THR . 2.4 pt-20 -58.31 89.96 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.286 -179.333 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.584 ' HB2' ' HE3' ' A' ' 87' ' ' MET . . . -94.17 116.9 29.36 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.449 179.515 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.571 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.3 OUTLIER 90.25 -33.1 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.648 -179.344 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.571 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 150.34 -13.46 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.02 179.903 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.508 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 2.5 ptt? -106.57 134.32 49.9 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.91 0.386 . . . . 0.0 111.164 -179.623 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.541 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 2.4 ptm -55.51 133.31 50.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.135 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.451 ' OD1' ' HE2' ' A' ' 87' ' ' MET . 2.0 t-20 -120.27 68.6 0.85 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.669 179.823 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.471 ' HB2' HG23 ' A' ' 114' ' ' THR . 0.2 OUTLIER -43.01 131.86 4.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.844 -179.836 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.777 HD11 HG21 ' A' ' 118' ' ' VAL . 57.7 mt -95.18 149.59 4.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.245 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -108.55 131.58 54.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.888 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.542 ' HB3' ' O ' ' A' ' 110' ' ' ASN . . . -45.28 110.03 0.21 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.161 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -68.51 -20.4 64.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.796 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.621 ' HA ' HG12 ' A' ' 111' ' ' VAL . 0.0 OUTLIER -179.0 137.04 0.14 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.776 179.945 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.411 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 24.6 t -41.31 127.3 2.88 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.805 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.493 ' O ' ' N ' ' A' ' 109' ' ' VAL . . . -161.67 -178.94 36.02 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.613 -0.804 . . . . 0.0 112.63 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.879 ' C ' HG23 ' A' ' 155' ' ' ILE . 16.5 m -129.43 108.62 10.42 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.645 0.259 . . . . 0.0 111.419 -179.755 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.595 HG11 ' O ' ' A' ' 104' ' ' GLU . 2.2 p -49.13 144.12 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 179.284 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.596 ' C ' HG13 ' A' ' 105' ' ' VAL . 4.5 mmtt -122.25 -20.28 6.23 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 121.05 -0.26 . . . . 0.0 111.456 -179.232 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.609 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 175.35 175.32 0.23 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.054 0.454 . . . . 0.0 111.798 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.656 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 1.2 mm -125.82 85.09 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.861 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.841 HD21 HG21 ' A' ' 154' ' ' VAL . 5.9 mt -50.79 -21.73 1.8 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.768 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 1.038 HG21 HD23 ' A' ' 152' ' ' LEU . 69.9 t -108.11 151.44 10.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.254 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.446 ' O ' ' C ' ' A' ' 142' ' ' SER . 39.6 mt-10 -64.17 135.75 56.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.942 179.19 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.505 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -32.17 -61.35 0.25 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.595 -179.272 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.56 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -125.11 103.34 0.72 Allowed Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.505 -0.855 . . . . 0.0 112.895 -179.619 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.898 ' O ' HG23 ' A' ' 90' ' ' THR . 6.4 pt20 -170.94 153.81 4.02 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-O 120.938 0.399 . . . . 0.0 111.215 179.718 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.417 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 37.0 Cg_endo -65.92 140.03 59.07 Favored 'Trans proline' 0 C--O 1.232 0.209 0 C-N-CA 122.843 2.362 . . . . 0.0 112.534 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.857 HG11 ' CD2' ' A' ' 152' ' ' LEU . 26.7 m -130.32 -171.68 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.893 179.864 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.422 ' O ' ' C ' ' A' ' 148' ' ' PHE . 2.5 tm-20 -130.11 137.92 50.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.971 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.521 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 1.5 t80 -35.72 120.01 0.57 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.744 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.521 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 5.4 t70 86.19 31.38 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.887 0.375 . . . . 0.0 110.524 -179.553 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.482 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 5.8 tp10 -107.18 75.1 0.42 Allowed Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.66 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.776 ' HB3' HG21 ' A' ' 82' ' ' ILE . 48.5 Cg_exo -30.58 109.71 0.04 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.723 0 C-N-CA 123.159 2.573 . . . . 0.0 112.377 179.69 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 1.038 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -104.68 -56.1 2.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.315 -179.412 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.798 HG13 ' CG2' ' A' ' 83' ' ' VAL . 0.9 OUTLIER -103.43 111.8 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.402 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.45 -179.185 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.932 HG13 HD12 ' A' ' 82' ' ' ILE . 3.1 t -91.77 145.1 7.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.863 179.763 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.879 HG23 ' C ' ' A' ' 134' ' ' THR . 4.4 mt -138.53 147.68 25.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.433 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.528 ' HB2' ' CE ' ' A' ' 136' ' ' LYS . 6.8 tp10 . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.271 -0.871 . . . . 0.0 110.844 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.265 0 N-CA-C 112.489 -0.244 . . . . 0.0 112.489 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.51 ' N ' ' O ' ' A' ' 155' ' ' ILE . 25.6 t-80 -177.98 79.39 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.776 0.322 . . . . 0.0 110.871 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.854 HG12 HG13 ' A' ' 154' ' ' VAL . 16.7 mt -95.54 143.05 12.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.157 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.528 ' HB ' ' CG1' ' A' ' 153' ' ' VAL . 2.2 t -103.34 54.32 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.21 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.517 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 2.1 ptt180 -38.21 141.97 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.803 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.648 ' CA ' HD11 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -35.52 95.6 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.94 -179.974 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.441 ' N ' ' O ' ' A' ' 84' ' ' ARG . 66.7 Cg_exo -50.63 -20.2 6.1 Favored 'Trans proline' 0 N--CA 1.466 -0.143 0 C-N-CA 122.648 2.232 . . . . 0.0 112.157 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.485 ' SD ' ' CB ' ' A' ' 120' ' ' ALA . 2.2 ptm -162.76 177.52 9.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.723 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.651 HG22 ' CG ' ' A' ' 147' ' ' GLU . 93.3 t -70.77 97.66 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.145 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.704 ' O ' HG23 ' A' ' 146' ' ' VAL . . . -162.04 -166.86 21.58 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.37 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.799 HG23 ' N ' ' A' ' 145' ' ' PRO . 3.6 m -109.52 126.96 54.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.789 0.328 . . . . 0.0 110.883 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.633 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 2.7 t80 -82.15 140.1 33.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.796 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.583 ' CE2' ' HG2' ' A' ' 119' ' ' GLU . 18.7 m-85 -137.92 152.9 49.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.934 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.537 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 0.7 OUTLIER -134.27 18.57 3.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.818 179.808 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.464 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 5.4 p -145.44 106.43 4.38 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.803 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.593 ' HG3' ' CG ' ' A' ' 102' ' ' PHE . 27.9 Cg_exo -61.98 -9.63 15.08 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.776 2.317 . . . . 0.0 112.429 -179.837 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.513 ' HB3' ' HB2' ' A' ' 99' ' ' ALA . 1.5 t -172.23 153.84 3.13 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.912 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_exo -55.84 -50.88 11.06 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.722 2.281 . . . . 0.0 112.269 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -106.29 56.52 0.66 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.513 ' HB2' ' HB3' ' A' ' 96' ' ' SER . . . -121.08 -160.78 0.86 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.123 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 2.0 mmmt -103.99 24.26 11.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.002 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.464 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 57.81 162.64 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.073 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.913 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -88.42 -41.38 12.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.981 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.913 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.8 OUTLIER -175.53 150.29 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-O 120.939 0.4 . . . . 0.0 111.271 179.668 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -152.06 158.62 43.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.683 179.775 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.657 ' HA ' HG12 ' A' ' 135' ' ' VAL . 6.8 p -48.24 105.26 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.166 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 123.9 -0.03 9.1 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.369 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.4 mm-40 -77.99 144.02 37.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.751 0.31 . . . . 0.0 110.98 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -98.94 90.73 4.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.907 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.736 HG11 ' CD2' ' A' ' 115' ' ' LEU . 15.6 m -87.89 159.63 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.105 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.47 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 31.9 m-80 -162.35 130.39 3.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.067 0.46 . . . . 0.0 110.776 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.461 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 24.6 m -35.84 123.49 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.224 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 108.44 3.06 33.07 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.559 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -113.42 -149.39 0.45 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.766 0.317 . . . . 0.0 110.685 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.68 HG21 ' OE1' ' A' ' 126' ' ' GLN . 5.5 m -136.23 132.23 35.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.924 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.736 ' CD2' HG11 ' A' ' 109' ' ' VAL . 75.4 mt -92.43 -84.71 0.27 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.916 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.517 ' HA ' ' CG ' ' A' ' 102' ' ' PHE . 2.3 p -143.78 -167.13 2.51 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.037 -179.894 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.85 HD13 ' HB2' ' A' ' 124' ' ' MET . 2.8 mt -131.59 150.44 34.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.812 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.594 HG22 ' HA ' ' A' ' 91' ' ' PHE . 53.6 t -143.93 103.22 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.856 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.583 ' HG2' ' CE2' ' A' ' 92' ' ' TYR . 6.8 pt-20 -58.6 82.28 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.146 -179.681 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.54 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -95.67 99.92 11.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.663 179.627 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.54 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 88.43 30.96 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.563 -179.53 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.505 ' HB3' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 75.8 30.49 0.76 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.217 -179.996 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.497 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 18.6 mmt -149.39 124.77 10.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.967 0.413 . . . . 0.0 110.906 179.558 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.85 ' HB2' HD13 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -59.75 103.18 0.19 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.148 -179.824 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 31.4 t30 -83.31 80.68 9.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.547 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.68 ' OE1' HG21 ' A' ' 114' ' ' THR . 17.3 tt0 -56.81 124.03 17.07 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.94 -179.837 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.499 HG22 HD12 ' A' ' 115' ' ' LEU . 15.3 mm -91.17 120.35 39.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.136 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -90.93 143.16 27.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.882 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -57.05 116.73 3.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.047 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -117.42 14.35 14.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.811 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.403 ' HD2' ' O ' ' A' ' 132' ' ' SER . 0.0 OUTLIER -179.39 102.99 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.69 -180.0 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.47 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 0.9 OUTLIER -42.77 122.59 2.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.616 179.897 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.471 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -156.25 -167.32 17.42 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.615 -179.846 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.627 ' N ' HG23 ' A' ' 155' ' ' ILE . 21.3 m -140.16 112.42 7.75 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.511 0.196 . . . . 0.0 111.169 -179.791 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.657 HG12 ' HA ' ' A' ' 105' ' ' VAL . 38.3 t -44.85 140.14 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.243 179.365 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.701 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 1.0 OUTLIER -122.42 -17.01 7.17 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.755 0.312 . . . . 0.0 111.152 -179.263 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.701 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 162.41 148.17 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.486 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.777 ' N ' HD13 ' A' ' 138' ' ' ILE . 0.0 OUTLIER -94.92 86.18 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.498 179.649 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.931 HD12 ' HB2' ' A' ' 151' ' ' PRO . 0.6 OUTLIER -40.81 -29.41 0.1 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.094 0.473 . . . . 0.0 110.207 -179.87 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.961 ' CG2' HD23 ' A' ' 152' ' ' LEU . 56.1 t -106.99 137.98 35.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.863 179.843 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.471 ' O ' ' HG2' ' A' ' 144' ' ' GLN . 3.4 mt-10 -67.65 98.11 0.67 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.219 179.513 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.537 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 24.2 p -34.15 135.87 0.14 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.899 -179.588 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.581 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 84.24 34.34 17.63 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.323 -179.663 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.653 ' C ' HG23 ' A' ' 90' ' ' THR . 37.8 mm-40 -146.2 144.8 22.27 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 120.898 0.38 . . . . 0.0 111.144 -179.736 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.873 ' O ' HG13 ' A' ' 146' ' ' VAL . 52.5 Cg_exo -55.32 177.26 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.862 2.375 . . . . 0.0 112.325 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.873 HG13 ' O ' ' A' ' 145' ' ' PRO . 0.2 OUTLIER -173.31 -174.42 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.193 -179.997 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.651 ' CG ' HG22 ' A' ' 88' ' ' VAL . 8.8 tt0 -155.71 158.5 38.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.903 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.473 ' HA ' ' O ' ' A' ' 85' ' ' SER . 42.5 t80 -42.42 138.84 1.65 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.967 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 74.67 24.1 1.73 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.524 ' CG ' ' O ' ' A' ' 147' ' ' GLU . 67.4 mm-40 -115.12 73.3 3.37 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.841 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.931 ' HB2' HD12 ' A' ' 139' ' ' LEU . 62.7 Cg_exo -33.75 129.04 0.16 Allowed 'Trans proline' 0 N--CA 1.458 -0.567 0 C-N-CA 122.974 2.449 . . . . 0.0 112.165 179.648 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 0.961 HD23 ' CG2' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -125.49 -71.67 0.69 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.727 -179.349 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.528 ' CG1' ' HB ' ' A' ' 83' ' ' VAL . 1.7 p -93.77 104.0 15.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.873 -179.085 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.854 HG13 HG12 ' A' ' 82' ' ' ILE . 21.4 t -89.13 133.1 32.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.814 179.333 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.627 HG23 ' N ' ' A' ' 134' ' ' THR . 97.1 mt -135.43 134.16 52.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.146 -179.727 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.518 ' CB ' ' HD3' ' A' ' 136' ' ' LYS . 1.2 tm-20 . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.259 -0.877 . . . . 0.0 110.898 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.542 ' CA ' ' HB2' ' A' ' 156' ' ' GLU . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.558 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 34.2 t60 -169.49 75.65 0.09 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.811 0.338 . . . . 0.0 110.812 179.814 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.902 HG12 HG13 ' A' ' 154' ' ' VAL . 6.2 mt -93.25 150.44 3.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.105 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.745 HG23 HG13 ' A' ' 153' ' ' VAL . 3.1 t -102.43 46.55 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.037 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.516 ' CD ' ' O ' ' A' ' 84' ' ' ARG . 0.0 OUTLIER -35.48 131.92 0.45 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.859 179.965 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.571 ' HB3' HD21 ' A' ' 152' ' ' LEU . 95.2 p -36.56 99.16 0.17 Allowed Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.968 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 20.1 Cg_endo -60.97 -11.98 20.57 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.619 2.213 . . . . 0.0 111.97 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.405 ' O ' ' N ' ' A' ' 89' ' ' GLY . 1.0 OUTLIER -160.58 167.76 26.42 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.607 179.856 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.742 ' O ' HG23 ' A' ' 88' ' ' VAL . 26.4 m -66.49 69.66 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.007 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 87' ' ' MET . . . -121.67 -150.83 8.36 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.639 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 90' ' ' THR . . . . . 1.015 HG23 ' C ' ' A' ' 144' ' ' GLN . 97.9 m -131.95 128.45 38.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.961 0.41 . . . . 0.0 111.028 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 1.063 ' HB2' HD22 ' A' ' 152' ' ' LEU . 69.8 t80 -68.75 143.49 54.65 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.526 179.724 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.601 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 7.8 m-30 -149.06 125.77 11.11 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.897 0.379 . . . . 0.0 110.85 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.506 ' HA ' ' HB2' ' A' ' 102' ' ' PHE . 39.8 ptt85 -117.54 22.52 12.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.883 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.52 112.24 5.03 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.962 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.52 -38.86 3.05 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.689 2.259 . . . . 0.0 112.333 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -130.38 161.64 59.31 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.849 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.46 ' O ' ' HB3' ' A' ' 98' ' ' ASP . 38.4 Cg_endo -66.83 102.92 0.66 Allowed 'Trans proline' 0 C--O 1.231 0.13 0 C-N-CA 122.722 2.282 . . . . 0.0 112.362 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.46 ' HB3' ' O ' ' A' ' 97' ' ' PRO . 9.3 t70 80.16 35.29 0.14 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.884 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -88.74 -155.31 0.33 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.012 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.93 27.97 3.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.801 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 54.48 174.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.054 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.916 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -99.51 -35.2 9.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.874 179.972 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.916 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.2 pp -179.03 123.53 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.987 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.44 ' O ' ' HB3' ' A' ' 107' ' ' GLN . 1.7 mt-10 -141.34 164.7 29.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.949 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 38.7 t -37.09 135.38 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.118 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 87.78 -24.5 10.47 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.557 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.512 ' HG2' HG22 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -71.66 94.62 1.36 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.84 0.352 . . . . 0.0 110.842 -179.967 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 10.5 mttm -75.53 105.16 6.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.906 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.762 HG11 HD23 ' A' ' 115' ' ' LEU . 5.5 m -80.04 173.44 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.177 -179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.484 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 4.5 p-10 -152.62 129.87 11.25 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.756 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.459 ' HA ' ' CB ' ' A' ' 129' ' ' ALA . 7.5 p -43.26 143.17 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.582 -0.735 . . . . 0.0 111.081 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 90.12 -2.13 81.07 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.412 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -105.98 -146.81 0.39 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.571 0.224 . . . . 0.0 110.63 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 3.9 m -130.13 120.36 24.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.789 0.328 . . . . 0.0 111.016 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.762 HD23 HG11 ' A' ' 109' ' ' VAL . 15.8 mt -77.06 -85.35 0.06 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.793 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.496 ' HB3' HD11 ' A' ' 103' ' ' ILE . 5.0 p -148.14 171.09 16.46 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.795 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.999 HD13 ' HB3' ' A' ' 124' ' ' MET . 3.7 mt -105.24 152.58 7.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.834 -179.874 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.458 ' HA ' ' O ' ' A' ' 90' ' ' THR . 55.6 t -144.04 103.23 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.052 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.494 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 1.9 mt-10 -65.54 100.78 0.53 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.151 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -83.26 -77.09 0.26 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.377 0.608 . . . . 0.0 111.071 179.795 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.531 ' O ' ' CG ' ' A' ' 122' ' ' LYS . 7.6 ptm -91.37 32.71 1.03 Allowed 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.367 179.695 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.531 ' CG ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 90.47 2.73 0.16 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.817 -179.63 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.48 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 4.9 ptm -116.78 133.58 55.84 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.841 179.785 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.999 ' HB3' HD13 ' A' ' 117' ' ' ILE . 3.3 mpp? -55.85 120.09 6.82 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.872 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.423 ' HB2' ' O ' ' A' ' 118' ' ' VAL . 35.8 t30 -102.3 73.44 1.35 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.947 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.547 ' CA ' HG12 ' A' ' 117' ' ' ILE . 15.4 pt20 -51.75 130.9 29.77 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.039 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 31.2 mm -103.59 136.79 34.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.094 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -95.41 145.32 25.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.883 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.459 ' CB ' ' HA ' ' A' ' 111' ' ' VAL . . . -64.78 121.63 15.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.062 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -94.88 -8.86 36.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.988 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -173.99 134.12 0.45 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.829 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.484 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 88.7 p -49.81 119.14 3.29 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.646 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -141.83 -176.77 16.34 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.628 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.635 ' N ' HG23 ' A' ' 155' ' ' ILE . 23.4 m -136.17 109.34 7.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.631 0.253 . . . . 0.0 111.139 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.489 HG22 HG12 ' A' ' 155' ' ' ILE . 67.1 t -48.27 142.49 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.289 179.4 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.554 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 55.1 mtpt -126.93 -19.8 4.35 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 121.042 -0.263 . . . . 0.0 111.705 -179.258 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.686 ' C ' HD13 ' A' ' 138' ' ' ILE . . . 173.62 162.52 0.16 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.025 0.44 . . . . 0.0 111.773 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.686 HD13 ' C ' ' A' ' 137' ' ' ALA . 0.6 OUTLIER -116.59 80.08 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.752 179.656 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.493 HD12 ' HB2' ' A' ' 151' ' ' PRO . 13.3 mt -47.99 -23.28 0.75 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.856 -179.822 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 0.985 HG21 HD23 ' A' ' 152' ' ' LEU . 53.5 t -108.16 143.34 18.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.235 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.491 ' HB2' ' HG2' ' A' ' 144' ' ' GLN . 4.9 mt-10 -59.61 136.06 57.87 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.922 179.31 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.48 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -30.61 -63.5 0.14 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.817 -179.259 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.601 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -124.06 103.54 0.77 Allowed Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.528 -0.844 . . . . 0.0 113.028 -179.393 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 1.015 ' C ' HG23 ' A' ' 90' ' ' THR . 0.0 OUTLIER -169.98 145.93 2.53 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-O 120.904 0.383 . . . . 0.0 111.149 179.616 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.434 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 39.0 Cg_exo -56.94 144.59 88.49 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.751 2.301 . . . . 0.0 112.066 179.803 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.635 HG11 ' CD2' ' A' ' 152' ' ' LEU . 0.2 OUTLIER -136.23 -174.21 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.201 -179.926 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.447 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -143.75 142.59 30.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.929 179.915 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.49 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 4.4 t80 -34.68 129.71 0.41 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.072 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.49 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.7 t70 83.01 23.6 0.15 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.918 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.447 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 25.7 mm-40 -109.54 74.28 0.68 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.835 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.848 ' O ' HG23 ' A' ' 140' ' ' VAL . 53.6 Cg_exo -33.71 126.38 0.15 Allowed 'Trans proline' 0 N--CA 1.458 -0.605 0 C-N-CA 122.866 2.377 . . . . 0.0 112.14 179.607 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 1.063 HD22 ' HB2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -117.89 -68.42 0.92 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.607 -179.175 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.749 HG21 HD13 ' A' ' 103' ' ' ILE . 1.3 p -102.45 106.22 19.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.418 -179.217 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.902 HG13 HG12 ' A' ' 82' ' ' ILE . 4.2 t -87.89 130.2 37.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.05 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.635 HG23 ' N ' ' A' ' 134' ' ' THR . 91.3 mt -132.99 131.87 58.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.215 -179.788 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.542 ' HB2' ' CA ' ' A' ' 80' ' ' GLY . 14.9 tt0 . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.259 -0.877 . . . . 0.0 110.96 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.435 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.45 -0.371 0 N-CA-C 112.336 -0.306 . . . . 0.0 112.336 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.52 ' N ' ' O ' ' A' ' 155' ' ' ILE . 30.4 t-80 175.56 82.42 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.759 0.314 . . . . 0.0 110.943 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 0.879 HG12 HG13 ' A' ' 154' ' ' VAL . 10.8 mt -98.73 123.14 51.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.074 0.464 . . . . 0.0 110.976 179.79 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.618 ' CG2' HG13 ' A' ' 153' ' ' VAL . 2.0 t -76.29 57.55 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.762 -0.653 . . . . 0.0 111.312 -179.693 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.518 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -35.39 119.42 0.51 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.723 -179.977 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 85' ' ' SER . . . . . 1.019 ' CA ' HD11 ' A' ' 152' ' ' LEU . 0.3 OUTLIER -35.26 104.84 0.26 Allowed Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.177 -179.755 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.458 ' O ' ' O ' ' A' ' 87' ' ' MET . 32.6 Cg_endo -64.14 138.57 62.37 Favored 'Trans proline' 0 C--O 1.231 0.145 0 C-N-CA 122.62 2.213 . . . . 0.0 111.654 179.508 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.458 ' O ' ' O ' ' A' ' 86' ' ' PRO . 3.9 ptp 42.3 -167.81 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.354 -179.613 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.781 HG22 ' HG2' ' A' ' 147' ' ' GLU . 52.4 t -88.36 106.96 17.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.847 0.356 . . . . 0.0 111.203 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -157.54 -158.05 8.74 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.582 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.69 ' O ' HG13 ' A' ' 118' ' ' VAL . 4.4 m -123.89 148.74 46.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.909 0.385 . . . . 0.0 111.088 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.663 ' CZ ' HG21 ' A' ' 138' ' ' ILE . 46.8 t80 -90.99 140.6 29.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.042 -0.527 . . . . 0.0 109.927 179.307 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.594 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 11.3 m-85 -146.19 123.05 11.3 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.975 0.417 . . . . 0.0 111.169 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.495 ' HA ' ' HB2' ' A' ' 102' ' ' PHE . 41.3 ptt85 -116.04 39.35 3.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.673 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 31.2 p -150.86 115.6 3.23 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.022 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.408 ' HD3' ' C ' ' A' ' 101' ' ' ALA . 58.7 Cg_endo -71.85 -29.58 15.2 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.738 2.292 . . . . 0.0 112.204 179.883 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -143.35 158.88 56.94 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.875 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_exo -52.44 -38.74 74.58 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.69 2.26 . . . . 0.0 112.263 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 -129.05 60.34 1.55 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.922 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -116.14 -168.95 1.51 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.14 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' LYS . . . . . 0.481 ' NZ ' ' HB2' ' A' ' 100' ' ' LYS . 0.8 OUTLIER -91.4 27.04 2.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.978 179.951 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 101' ' ' ALA . . . . . 0.48 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 65.42 178.59 0.2 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.192 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.863 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -95.22 -31.88 13.29 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.709 179.9 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.863 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.1 OUTLIER 169.42 138.49 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.21 179.621 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.828 ' O ' HG11 ' A' ' 135' ' ' VAL . 5.3 pt-20 -140.78 160.0 40.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.0 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.442 ' HB ' ' HA ' ' A' ' 137' ' ' ALA . 7.7 p -43.57 123.14 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.217 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' GLY . . . . . 0.482 ' H ' HG13 ' A' ' 135' ' ' VAL . . . 111.07 -19.98 24.42 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.446 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.829 ' O ' HG12 ' A' ' 135' ' ' VAL . 0.2 OUTLIER -87.47 113.6 23.33 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.801 0.334 . . . . 0.0 110.859 179.975 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 1.1 pttt -75.84 117.1 17.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.896 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.76 HG11 ' CD2' ' A' ' 115' ' ' LEU . 35.2 m -86.78 168.41 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.087 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.485 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 2.5 p-10 -160.11 132.14 6.21 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 121.129 0.49 . . . . 0.0 110.696 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.641 HG13 ' O ' ' A' ' 129' ' ' ALA . 4.1 t -36.86 139.87 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.963 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 88.99 7.38 70.54 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.27 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.461 ' O ' ' N ' ' A' ' 115' ' ' LEU . 6.8 m-20 -123.63 103.2 8.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.857 0.36 . . . . 0.0 110.835 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.414 ' C ' ' O ' ' A' ' 113' ' ' ASP . 4.3 m -37.23 94.72 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.925 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.76 ' CD2' HG11 ' A' ' 109' ' ' VAL . 9.9 mt -47.87 -91.0 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.703 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.633 ' HB3' HD11 ' A' ' 103' ' ' ILE . 2.0 p -138.33 155.95 48.09 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.851 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.678 HD13 ' HB2' ' A' ' 124' ' ' MET . 3.7 mt -89.79 153.21 3.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.025 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.69 HG13 ' O ' ' A' ' 90' ' ' THR . 86.3 t -145.23 101.08 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.852 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.515 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 2.4 mm-40 -55.27 84.49 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.243 -179.779 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.48 ' O ' ' HG3' ' A' ' 121' ' ' MET . . . -103.04 145.68 29.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.722 179.7 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.48 ' HG3' ' O ' ' A' ' 120' ' ' ALA . 2.2 ptm 45.53 26.82 0.34 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.035 0.445 . . . . 0.0 110.252 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.525 ' O ' ' CE ' ' A' ' 122' ' ' LYS . 0.1 OUTLIER 77.89 45.1 0.08 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.746 -179.698 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.51 ' N ' ' OE1' ' A' ' 119' ' ' GLU . 11.1 mtt -162.21 127.84 3.47 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.992 179.713 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.678 ' HB2' HD13 ' A' ' 117' ' ' ILE . 0.9 OUTLIER -57.68 87.18 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.56 179.61 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 12.6 t-20 -65.59 79.9 0.07 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.945 -179.799 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' GLN . . . . . 0.456 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -57.16 118.87 5.48 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.87 179.99 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.475 ' O ' ' N ' ' A' ' 115' ' ' LEU . 34.7 mm -84.77 134.26 27.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.042 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 128' ' ' GLU . . . . . 0.404 ' OE2' ' HG2' ' A' ' 126' ' ' GLN . 3.8 mm-40 -108.08 116.55 32.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.957 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.641 ' O ' HG13 ' A' ' 111' ' ' VAL . . . -37.8 113.49 0.28 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.131 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 42.9 p-10 -93.96 -14.36 26.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.935 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 15.6 ptmt -162.37 126.07 3.05 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.783 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.485 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 5.3 p -46.39 120.01 2.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.993 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.513 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -143.59 -168.59 12.26 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.433 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.568 ' N ' HG23 ' A' ' 155' ' ' ILE . 17.4 m -143.81 107.31 4.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.684 0.278 . . . . 0.0 111.25 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.829 HG12 ' O ' ' A' ' 107' ' ' GLN . 7.1 p -45.73 141.15 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.301 179.43 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.688 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 20.6 mtpt -120.82 -18.65 7.58 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.711 0.291 . . . . 0.0 111.111 -179.522 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.688 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 163.71 153.31 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.983 0.42 . . . . 0.0 111.765 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.663 HG21 ' CZ ' ' A' ' 91' ' ' PHE . 0.1 OUTLIER -108.31 79.35 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.545 179.684 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 8.2 mt -44.93 -25.96 0.37 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.722 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 1.045 HG21 HD23 ' A' ' 152' ' ' LEU . 62.3 t -102.85 146.71 10.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.009 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.556 ' O ' ' CD2' ' A' ' 91' ' ' PHE . 15.4 mt-10 -51.25 -174.84 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.172 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.492 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -82.18 -55.4 4.57 Favored 'General case' 0 C--N 1.324 -0.529 0 C-N-CA 120.881 -0.327 . . . . 0.0 110.921 179.935 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.594 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -126.5 103.1 0.66 Allowed Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.577 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.631 ' O ' HG23 ' A' ' 90' ' ' THR . 0.0 OUTLIER -165.03 151.56 9.21 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-O 120.948 0.404 . . . . 0.0 111.352 179.92 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.501 ' O ' ' NE2' ' A' ' 144' ' ' GLN . 30.7 Cg_endo -63.72 131.17 30.29 Favored 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.97 2.447 . . . . 0.0 112.48 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 0.525 HG11 ' CD2' ' A' ' 152' ' ' LEU . 0.2 OUTLIER -133.05 176.81 8.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.896 179.886 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.781 ' HG2' HG22 ' A' ' 88' ' ' VAL . 2.3 mt-10 -133.41 156.86 46.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.969 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.484 ' HA ' ' O ' ' A' ' 85' ' ' SER . 8.3 t80 -40.57 153.6 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.895 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.453 ' OD1' ' O ' ' A' ' 149' ' ' ASP . 1.0 OUTLIER 54.8 28.04 9.73 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.529 179.806 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.54 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 11.0 tp10 -107.23 74.35 0.4 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.702 179.492 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.608 ' O ' HG23 ' A' ' 140' ' ' VAL . 48.8 Cg_exo -31.35 129.13 0.08 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 123.138 2.559 . . . . 0.0 112.362 179.758 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 1.045 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -130.16 -68.91 0.69 Allowed 'General case' 0 C--O 1.232 0.181 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.694 -179.484 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.623 HG11 ' SG ' ' A' ' 116' ' ' CYS . 1.5 p -99.65 101.78 12.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.606 -178.941 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 0.879 HG13 HG12 ' A' ' 82' ' ' ILE . 23.8 t -81.86 138.49 19.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.0 179.602 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.568 HG23 ' N ' ' A' ' 134' ' ' THR . 83.6 mt -139.05 136.62 42.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.285 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.449 ' CA ' ' HD2' ' A' ' 136' ' ' LYS . 0.5 OUTLIER . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.282 -0.866 . . . . 0.0 110.927 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.488 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.452 -0.299 0 N-CA-C 112.592 -0.203 . . . . 0.0 112.592 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' HIS . . . . . 0.509 ' N ' ' O ' ' A' ' 155' ' ' ILE . 25.5 t-80 171.21 83.98 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.778 0.323 . . . . 0.0 110.797 -179.864 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ILE . . . . . 1.015 HD12 HG13 ' A' ' 154' ' ' VAL . 0.2 OUTLIER -88.02 -177.52 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.992 0.425 . . . . 0.0 111.001 179.909 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.914 ' CG2' HG13 ' A' ' 153' ' ' VAL . 1.7 t -140.92 39.17 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.705 179.603 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' ARG . . . . . 0.546 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 1.7 ptt-85 -34.07 127.42 0.42 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.979 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' SER . . . . . 0.438 ' HB3' HD21 ' A' ' 152' ' ' LEU . 0.9 OUTLIER -38.37 112.02 0.64 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.883 179.986 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 86' ' ' PRO . . . . . 0.424 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 25.9 Cg_endo -61.96 -11.27 20.65 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.669 2.246 . . . . 0.0 111.945 179.853 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' MET . . . . . 0.573 ' SD ' ' HB1' ' A' ' 120' ' ' ALA . 5.6 ptm -156.59 177.09 11.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.598 179.844 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' VAL . . . . . 0.424 HG12 ' H ' ' A' ' 88' ' ' VAL . 1.7 p -80.43 94.18 2.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.082 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -143.64 -123.42 1.74 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.613 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' THR . . . . . 0.673 HG21 ' CZ ' ' A' ' 92' ' ' TYR . 38.5 m -150.9 150.78 31.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.861 0.362 . . . . 0.0 110.996 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' PHE . . . . . 0.652 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 0.8 OUTLIER -116.89 143.27 45.89 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.931 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 92' ' ' TYR . . . . . 0.673 ' CZ ' HG21 ' A' ' 90' ' ' THR . 22.5 m-85 -142.9 163.17 33.52 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.029 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 93' ' ' ARG . . . . . 0.488 ' HG2' ' HB2' ' A' ' 142' ' ' SER . 29.0 ptt180 -143.83 24.69 1.67 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.752 179.695 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 94' ' ' THR . . . . . 0.4 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 0.0 OUTLIER -156.51 91.99 2.52 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.767 179.833 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 94' ' ' THR . 45.2 Cg_endo -68.47 -25.32 35.46 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.785 2.323 . . . . 0.0 112.565 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 96' ' ' SER . . . . . 0.415 ' HA ' ' HD3' ' A' ' 97' ' ' PRO . 0.9 OUTLIER -135.57 133.13 20.06 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 120.966 0.413 . . . . 0.0 111.057 -179.896 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.483 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 52.1 Cg_exo -54.55 109.98 0.46 Allowed 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.803 2.335 . . . . 0.0 112.23 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' ASP . . . . . 0.483 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 10.4 t70 81.6 46.67 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.823 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' ALA . . . . . 0.404 ' HB2' ' HB2' ' A' ' 96' ' ' SER . . . -107.2 -166.47 1.16 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.081 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -90.41 23.51 2.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.795 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 56.88 159.7 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.146 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' PHE . . . . . 0.849 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -87.63 -37.79 16.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.82 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 103' ' ' ILE . . . . . 0.849 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.6 OUTLIER -170.19 110.03 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.134 -179.999 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 104' ' ' GLU . . . . . 0.504 ' N ' ' OE1' ' A' ' 104' ' ' GLU . 12.5 pm0 -121.73 162.3 21.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.852 179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.613 HG22 ' HA ' ' A' ' 137' ' ' ALA . 4.4 t -45.36 97.74 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.091 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.02 -8.97 6.03 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.513 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.432 ' O ' ' N ' ' A' ' 109' ' ' VAL . 29.7 tp60 -70.64 99.59 1.69 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.793 0.33 . . . . 0.0 110.881 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' LYS . . . . . 0.444 ' O ' ' O ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -67.67 61.06 0.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.962 -179.984 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.808 HG22 ' O ' ' A' ' 133' ' ' GLY . 16.9 m -42.09 168.15 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.047 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 110' ' ' ASN . . . . . 0.511 ' ND2' ' HB2' ' A' ' 132' ' ' SER . 23.0 m120 -167.18 132.99 2.13 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.579 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.572 HG12 ' C ' ' A' ' 130' ' ' ASP . 18.1 m -34.05 136.34 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.172 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 81.33 14.97 77.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.303 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 113' ' ' ASP . . . . . 0.422 ' O ' ' C ' ' A' ' 114' ' ' THR . 0.8 OUTLIER -128.51 105.88 8.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.854 0.359 . . . . 0.0 110.824 179.957 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 114' ' ' THR . . . . . 0.422 ' C ' ' O ' ' A' ' 113' ' ' ASP . 1.3 m -35.18 127.93 0.54 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.033 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 115' ' ' LEU . . . . . 0.556 HD12 HG22 ' A' ' 127' ' ' ILE . 14.7 mt -87.63 -83.95 0.2 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.908 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 116' ' ' CYS . . . . . 0.53 ' HB3' HD11 ' A' ' 103' ' ' ILE . 21.4 p -135.2 -165.51 1.69 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.917 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 117' ' ' ILE . . . . . 0.566 ' CG2' ' CB ' ' A' ' 124' ' ' MET . 0.2 OUTLIER -113.7 113.92 45.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.212 -179.988 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.498 ' HB ' ' HB3' ' A' ' 125' ' ' ASN . 25.8 t -103.47 55.1 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.82 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 119' ' ' GLU . . . . . 0.479 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.2 OUTLIER -35.44 98.8 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.093 -179.842 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 120' ' ' ALA . . . . . 0.573 ' HB1' ' SD ' ' A' ' 87' ' ' MET . . . -118.16 110.27 17.39 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.923 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 121' ' ' MET . . . . . 0.544 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.3 OUTLIER 87.07 21.42 0.06 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.855 -179.908 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.544 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 89.69 0.81 0.26 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.252 179.907 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.479 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.4 OUTLIER -119.86 133.58 55.53 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.854 0.359 . . . . 0.0 111.138 179.942 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.566 ' CB ' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -64.22 112.63 3.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.051 179.87 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.498 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 0.8 OUTLIER -86.7 74.93 9.74 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.656 179.715 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -48.88 112.27 0.59 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.005 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 127' ' ' ILE . . . . . 0.556 HG22 HD12 ' A' ' 115' ' ' LEU . 3.9 mm -90.94 145.5 7.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.044 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -122.61 123.65 41.67 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.985 -179.873 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 129' ' ' ALA . . . . . 0.503 ' HA ' HD11 ' A' ' 115' ' ' LEU . . . -38.95 142.58 0.21 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.119 179.874 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 130' ' ' ASP . . . . . 0.572 ' C ' HG12 ' A' ' 111' ' ' VAL . 0.5 OUTLIER -121.49 -7.56 9.18 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.042 179.997 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.497 ' HD3' ' CD2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -160.13 23.88 0.17 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.769 179.991 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 132' ' ' SER . . . . . 0.511 ' HB2' ' ND2' ' A' ' 110' ' ' ASN . 1.3 p 53.66 -176.57 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.632 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 133' ' ' GLY . . . . . 0.808 ' O ' HG22 ' A' ' 109' ' ' VAL . . . 150.13 167.09 14.0 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.575 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 134' ' ' THR . . . . . 0.75 ' N ' HG23 ' A' ' 155' ' ' ILE . 18.8 m -116.57 110.74 18.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.658 0.266 . . . . 0.0 111.18 -179.902 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.51 HG12 ' HA ' ' A' ' 105' ' ' VAL . 95.0 t -47.22 142.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.472 179.51 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.652 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.2 OUTLIER -124.83 -19.18 5.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.424 -179.399 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 137' ' ' ALA . . . . . 0.694 ' C ' HD13 ' A' ' 138' ' ' ILE . . . 167.23 155.97 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.835 0.35 . . . . 0.0 111.351 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 138' ' ' ILE . . . . . 0.785 ' N ' HD13 ' A' ' 138' ' ' ILE . 0.0 OUTLIER -106.94 82.92 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.948 179.835 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 139' ' ' LEU . . . . . 0.917 HD21 HG21 ' A' ' 154' ' ' VAL . 6.6 mt -41.2 -34.96 0.53 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 121.168 0.508 . . . . 0.0 109.97 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 140' ' ' VAL . . . . . 1.056 HG21 HD23 ' A' ' 152' ' ' LEU . 59.0 t -92.18 136.86 23.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.701 179.648 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 141' ' ' GLU . . . . . 0.484 ' O ' ' HG2' ' A' ' 144' ' ' GLN . 4.5 mt-10 -70.22 100.19 1.64 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.443 179.817 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.488 ' HB2' ' HG2' ' A' ' 93' ' ' ARG . 5.9 p -36.13 147.66 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.682 -179.698 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 143' ' ' GLY . . . . . 0.579 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 71.97 35.29 61.44 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.451 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 144' ' ' GLN . . . . . 0.576 HE21 HG13 ' A' ' 140' ' ' VAL . 0.7 OUTLIER -149.03 153.48 38.27 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.883 0.373 . . . . 0.0 111.115 -179.913 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 145' ' ' PRO . . . . . 0.525 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 57.3 Cg_endo -70.64 164.13 36.49 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.939 2.426 . . . . 0.0 112.268 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 146' ' ' VAL . . . . . 1.117 HG11 ' CD2' ' A' ' 152' ' ' LEU . 29.3 m -143.99 -179.38 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.195 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.452 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.5 OUTLIER -137.49 160.54 38.85 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.068 -179.853 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 148' ' ' PHE . . . . . 0.421 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 1.2 t80 -44.52 121.88 2.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.843 179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 149' ' ' ASP . . . . . 0.421 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 4.9 t0 78.24 34.92 0.27 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.74 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 150' ' ' GLU . . . . . 0.452 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 3.9 tp10 -107.36 74.15 0.4 Allowed Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.94 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 151' ' ' PRO . . . . . 0.765 ' O ' HG23 ' A' ' 140' ' ' VAL . 61.6 Cg_exo -34.7 119.65 0.14 Allowed 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 122.79 2.327 . . . . 0.0 111.915 179.577 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 152' ' ' LEU . . . . . 1.117 ' CD2' HG11 ' A' ' 146' ' ' VAL . 0.0 OUTLIER -116.06 -70.69 0.78 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.746 -179.163 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 153' ' ' VAL . . . . . 0.914 HG13 ' CG2' ' A' ' 83' ' ' VAL . 1.4 p -93.06 109.95 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.252 0 CA-C-O 121.152 0.501 . . . . 0.0 111.836 -179.13 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 154' ' ' VAL . . . . . 1.015 HG13 HD12 ' A' ' 82' ' ' ILE . 4.1 t -92.3 132.79 35.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.638 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.75 HG23 ' N ' ' A' ' 134' ' ' THR . 39.5 mt -132.73 140.0 48.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.229 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.512 ' HB2' ' CD ' ' A' ' 136' ' ' LYS . 31.7 tt0 . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.22 -0.895 . . . . 0.0 110.943 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.742 0.306 . . . . 0.0 111.014 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -114.09 74.48 0.87 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.045 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.532 ' O ' HG22 ' A' ' 78' ' ' ILE . 0.6 OUTLIER -168.41 -173.9 2.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.916 179.976 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.627 ' O ' HG23 ' A' ' 78' ' ' ILE . 0.1 OUTLIER 70.07 11.42 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 121.136 0.493 . . . . 0.0 111.036 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 3.4 m -53.43 121.61 8.01 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.841 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -51.62 -79.06 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.456 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.514 ' N ' ' O ' ' A' ' 155' ' ' ILE . 25.6 t-80 -175.9 77.66 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.767 0.318 . . . . 0.0 110.888 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.998 HD12 HG13 ' A' ' 154' ' ' VAL . 0.1 OUTLIER -84.26 178.9 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 120.914 0.388 . . . . 0.0 111.08 179.868 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.737 ' CG2' HG13 ' A' ' 153' ' ' VAL . 25.2 t -130.42 37.98 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.903 179.686 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.526 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 10.9 ptt-85 -34.07 119.01 0.39 Allowed 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.906 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.489 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 3.7 t -34.86 104.46 0.25 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.984 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -47.2 -22.35 2.3 Favored 'Trans proline' 0 N--CA 1.465 -0.192 0 C-N-CA 122.678 2.252 . . . . 0.0 112.093 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -151.41 -168.93 3.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.545 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.632 HG12 ' O ' ' A' ' 88' ' ' VAL . 67.5 t -77.76 56.91 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.04 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.462 ' O ' HG23 ' A' ' 146' ' ' VAL . . . -103.55 -153.33 23.62 Favored Glycine 0 C--N 1.332 0.319 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.438 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.733 HG23 ' O ' ' A' ' 144' ' ' GLN . 17.8 m -130.68 145.17 51.86 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.901 0.382 . . . . 0.0 111.221 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.995 ' HB2' HD22 ' A' ' 152' ' ' LEU . 36.0 t80 -91.91 145.86 24.21 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.249 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.619 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 10.2 m-85 -146.65 154.29 41.29 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.003 0.43 . . . . 0.0 111.286 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.445 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 6.7 ptt85 -144.65 25.14 1.5 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.609 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.479 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 0.9 OUTLIER -151.17 100.04 3.03 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.905 179.909 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 94' ' ' THR . 47.5 Cg_endo -68.95 -32.46 22.02 Favored 'Trans proline' 0 C--O 1.231 0.133 0 C-N-CA 122.76 2.307 . . . . 0.0 112.213 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.534 ' CB ' ' HB2' ' A' ' 99' ' ' ALA . 0.4 OUTLIER -123.1 141.18 35.16 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.822 179.86 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -52.51 106.61 0.15 Allowed 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.732 2.288 . . . . 0.0 112.401 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 43.5 t0 71.24 34.7 1.72 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.043 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.534 ' HB2' ' CB ' ' A' ' 96' ' ' SER . . . -86.93 -154.94 0.25 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.976 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.401 ' HA ' ' HD2' ' A' ' 100' ' ' LYS . 16.5 mmmt -94.83 23.52 5.43 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.832 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.479 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 56.86 167.08 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.019 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.958 ' O ' HD13 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -81.44 -51.68 8.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.677 179.868 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.958 HD13 ' O ' ' A' ' 102' ' ' PHE . 0.4 OUTLIER -152.59 148.25 14.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.023 179.759 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -143.39 149.17 37.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.838 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.428 HG13 ' HA ' ' A' ' 136' ' ' LYS . 16.7 t -44.59 123.37 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.053 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 123.98 -33.59 3.83 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.367 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.41 ' HA ' ' OE1' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -74.87 142.41 44.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.829 0.347 . . . . 0.0 110.748 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -103.58 101.61 11.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.067 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.782 ' CG2' ' HB2' ' A' ' 129' ' ' ALA . 2.3 p -66.23 164.39 2.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.775 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.587 ' N ' HG22 ' A' ' 109' ' ' VAL . 3.2 m120 -155.99 133.31 10.8 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-O 120.882 0.372 . . . . 0.0 110.376 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.47 ' C ' ' O ' ' A' ' 110' ' ' ASN . 2.4 t -26.16 123.41 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.518 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 85.92 21.5 52.69 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.216 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.487 ' HB2' ' O ' ' A' ' 110' ' ' ASN . 26.8 t0 -119.49 102.78 8.9 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.823 0.344 . . . . 0.0 110.832 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.467 HG23 ' HB2' ' A' ' 126' ' ' GLN . 1.4 m -41.28 132.16 2.64 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.912 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.524 ' O ' ' CG1' ' A' ' 103' ' ' ILE . 56.4 mt -96.5 -86.25 0.32 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.829 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.643 ' SG ' HG11 ' A' ' 153' ' ' VAL . 0.6 OUTLIER -131.94 -175.59 3.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.04 -179.945 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.537 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.1 OUTLIER -104.11 127.02 58.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.95 179.942 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.588 ' O ' HG12 ' A' ' 118' ' ' VAL . 58.8 t -108.31 60.25 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.942 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.484 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.3 OUTLIER -43.05 88.56 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.247 -179.888 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.545 ' O ' ' CB ' ' A' ' 121' ' ' MET . . . -92.65 109.55 20.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.718 179.735 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.557 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.8 OUTLIER 90.18 -29.59 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.763 -179.683 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.557 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 150.04 -15.95 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.88 179.622 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.484 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.4 OUTLIER -101.08 134.54 43.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.049 -179.662 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.537 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -55.25 145.34 21.89 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.125 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.493 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 1.0 OUTLIER -134.4 65.95 1.55 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.571 179.797 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.467 ' HB2' HG23 ' A' ' 114' ' ' THR . 4.8 pm0 -38.85 145.1 0.1 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.049 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.47 ' O ' ' N ' ' A' ' 115' ' ' LEU . 29.2 mm -117.18 130.62 71.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.986 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -105.56 128.11 53.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.079 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.782 ' HB2' ' CG2' ' A' ' 109' ' ' VAL . . . -44.32 147.24 0.57 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.922 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -114.06 -15.41 12.28 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.51 ' HD3' ' CD2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -163.22 36.86 0.1 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.086 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.6 t 55.92 -174.9 0.05 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.582 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.492 ' N ' HG13 ' A' ' 109' ' ' VAL . . . 149.71 -178.88 26.92 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.604 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.621 ' N ' HG23 ' A' ' 155' ' ' ILE . 26.7 m -136.27 117.38 14.4 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.611 0.243 . . . . 0.0 111.17 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.468 ' HA ' HG12 ' A' ' 155' ' ' ILE . 97.7 t -49.92 140.45 3.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.476 179.452 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.64 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 27.7 mmmt -125.02 -19.65 5.14 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.576 -0.284 . . . . 0.0 111.376 -179.461 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.64 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 168.51 159.96 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.888 0.375 . . . . 0.0 111.584 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.656 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -110.72 83.62 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.815 179.83 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.656 HD21 HG21 ' A' ' 154' ' ' VAL . 4.7 mt -44.27 -34.87 2.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.081 0.467 . . . . 0.0 110.336 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.979 HG21 HD23 ' A' ' 152' ' ' LEU . 52.1 t -96.54 160.86 2.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.626 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.529 ' N ' HG12 ' A' ' 140' ' ' VAL . 3.0 mm-40 -58.75 -149.54 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.506 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -103.43 -63.61 1.16 Allowed 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.695 179.393 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.619 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -124.88 97.37 0.53 Allowed Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.632 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.733 ' O ' HG23 ' A' ' 90' ' ' THR . 0.0 OUTLIER -166.53 156.3 10.41 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.954 0.407 . . . . 0.0 110.998 179.839 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.443 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 35.4 Cg_exo -59.86 160.15 22.66 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.827 2.351 . . . . 0.0 112.277 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.804 HG12 ' HG2' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -152.66 176.19 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.06 179.878 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.488 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 3.8 tt0 -126.71 145.11 50.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.996 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.541 ' CE2' ' OD1' ' A' ' 149' ' ' ASP . 16.9 t80 -34.96 139.4 0.09 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.91 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.541 ' OD1' ' CE2' ' A' ' 148' ' ' PHE . 1.6 m-20 68.6 27.45 6.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.788 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.804 ' HG2' HG12 ' A' ' 146' ' ' VAL . 7.0 tp10 -105.38 74.63 0.28 Allowed Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.897 179.864 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.912 ' O ' HG23 ' A' ' 140' ' ' VAL . 64.3 Cg_exo -35.84 131.99 0.3 Allowed 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 122.924 2.416 . . . . 0.0 112.086 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.995 HD22 ' HB2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -123.61 -58.91 1.57 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.355 -179.345 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.737 HG13 ' CG2' ' A' ' 83' ' ' VAL . 1.6 p -108.75 111.82 37.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.066 -179.581 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.998 HG13 HD12 ' A' ' 82' ' ' ILE . 2.5 t -88.27 136.88 22.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.23 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.621 HG23 ' N ' ' A' ' 134' ' ' THR . 9.0 mt -134.56 138.42 49.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.019 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.528 ' CG ' ' HB ' ' A' ' 134' ' ' THR . 0.9 OUTLIER . . . . . 0 C--O 1.249 1.044 0 CA-C-O 118.172 -0.918 . . . . 0.0 110.904 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.442 ' O ' ' O ' ' A' ' 76' ' ' ALA . . . . . . . . 0 N--CA 1.457 -0.116 0 CA-C-O 120.828 0.347 . . . . 0.0 111.106 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.442 ' O ' ' O ' ' A' ' 75' ' ' ALA . . . 57.63 149.83 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.027 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -63.6 116.07 5.31 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.86 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.674 ' H ' HD12 ' A' ' 78' ' ' ILE . 0.1 OUTLIER -103.53 -11.94 9.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.141 -179.991 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.479 ' HB3' ' O ' ' A' ' 78' ' ' ILE . 1.6 p 173.9 -152.07 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.474 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -164.77 -140.95 2.99 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.568 179.77 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.694 ' CD2' ' HD3' ' A' ' 131' ' ' LYS . 36.0 t-80 174.38 82.29 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.78 0.324 . . . . 0.0 110.877 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.859 HG12 HG13 ' A' ' 154' ' ' VAL . 4.6 mt -115.58 151.7 17.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.117 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.92 HG12 ' CG1' ' A' ' 153' ' ' VAL . 3.6 p -109.85 44.24 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.026 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.519 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -33.51 131.48 0.23 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.092 -179.943 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.584 ' HB3' HD21 ' A' ' 152' ' ' LEU . 4.4 p -35.83 97.51 0.13 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.873 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 14.2 Cg_endo -57.41 -14.95 17.66 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.608 2.205 . . . . 0.0 111.87 179.846 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.51 ' SD ' ' HB1' ' A' ' 120' ' ' ALA . 0.3 OUTLIER -151.31 164.96 35.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.47 179.718 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.655 HG22 ' O ' ' A' ' 88' ' ' VAL . 1.7 p -71.01 77.9 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.975 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -127.65 -128.58 3.13 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.545 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.525 ' HA ' ' HA ' ' A' ' 145' ' ' PRO . 8.3 m -147.44 134.49 20.36 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.773 0.32 . . . . 0.0 110.924 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.911 ' CB ' HD22 ' A' ' 152' ' ' LEU . 1.7 t80 -95.69 144.76 25.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.781 179.846 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.59 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 12.8 m-85 -141.04 160.07 40.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.061 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.523 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 0.8 OUTLIER -142.22 24.8 1.94 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.689 179.885 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.424 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 82.5 p -132.29 101.98 14.5 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.799 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.552 ' HB3' ' CE1' ' A' ' 102' ' ' PHE . 41.1 Cg_endo -67.37 -43.44 5.98 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.828 2.352 . . . . 0.0 112.403 -179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -129.95 160.45 65.09 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.06 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.449 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 55.9 Cg_endo -70.73 106.98 1.94 Allowed 'Trans proline' 0 N--CA 1.464 -0.208 0 C-N-CA 122.72 2.28 . . . . 0.0 112.319 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.449 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 18.7 t70 80.24 43.58 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.918 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -109.04 -160.39 0.72 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.029 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 1.1 mtpp -93.65 23.02 4.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.844 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.44 ' HB1' ' O ' ' A' ' 93' ' ' ARG . . . 64.34 176.83 0.18 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.013 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.895 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -85.69 -42.14 14.53 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.714 179.942 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.895 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.1 pp -172.68 145.78 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.959 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.44 ' O ' ' HB2' ' A' ' 107' ' ' GLN . 5.9 pt-20 -149.99 167.69 26.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.906 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.592 HG22 ' C ' ' A' ' 136' ' ' LYS . 89.9 t -45.56 128.02 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.104 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 100.42 -13.74 59.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.508 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.44 ' HB2' ' O ' ' A' ' 104' ' ' GLU . 0.0 OUTLIER -72.93 114.98 11.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.853 0.358 . . . . 0.0 110.935 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.445 ' O ' ' ND2' ' A' ' 110' ' ' ASN . 17.6 mttt -81.95 83.57 7.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.925 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.893 HG11 HD23 ' A' ' 115' ' ' LEU . 3.0 m -68.04 165.09 2.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.038 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.479 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 2.6 m-80 -157.74 130.39 7.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.101 0.477 . . . . 0.0 110.789 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.486 HG13 ' N ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -33.87 112.37 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.536 -0.757 . . . . 0.0 111.174 -179.984 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 110.39 13.0 15.87 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.844 -0.694 . . . . 0.0 112.385 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.476 ' O ' ' N ' ' A' ' 115' ' ' LEU . 17.3 t0 -122.58 103.04 8.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.753 0.311 . . . . 0.0 110.724 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.432 ' C ' ' O ' ' A' ' 113' ' ' ASP . 2.0 m -34.13 93.29 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.113 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.893 HD23 HG11 ' A' ' 109' ' ' VAL . 8.3 mt -50.05 -76.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.699 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.45 ' HA ' ' CG ' ' A' ' 102' ' ' PHE . 14.1 p -146.9 -155.66 0.64 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.653 179.76 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.979 HD13 ' HB3' ' A' ' 124' ' ' MET . 2.3 mt -136.71 152.86 29.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.691 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.513 ' O ' ' N ' ' A' ' 120' ' ' ALA . 92.3 t -139.59 88.5 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.205 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.579 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -51.16 85.8 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.916 179.99 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 118' ' ' VAL . . . -104.4 140.2 38.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.517 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 50.64 22.13 1.03 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.577 -179.726 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.535 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 86.17 36.41 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.859 -179.803 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.481 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 32.4 mmm -151.33 129.27 11.72 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.076 179.752 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.979 ' HB3' HD13 ' A' ' 117' ' ' ILE . 33.0 mtt -67.13 93.39 0.29 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.945 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -70.7 76.86 0.6 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.889 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.49 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 17.3 pt20 -55.39 108.67 0.45 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.859 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.504 HG21 HG21 ' A' ' 83' ' ' VAL . 12.8 mm -74.53 151.41 6.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.053 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -123.51 123.23 40.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.91 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -41.0 124.95 2.29 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.89 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -113.26 15.0 19.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.917 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.694 ' HD3' ' CD2' ' A' ' 81' ' ' HIS . 2.0 tmtt? 176.35 105.32 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.864 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.479 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 2.4 t -37.06 114.59 0.33 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.622 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.496 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -147.31 -173.49 18.5 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.732 -179.758 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.621 ' N ' HG23 ' A' ' 155' ' ' ILE . 19.7 m -128.73 108.55 10.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.662 0.268 . . . . 0.0 111.251 -179.685 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.534 ' HA ' ' CG1' ' A' ' 155' ' ' ILE . 69.9 t -39.29 144.81 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 179.224 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.72 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 38.4 mtpt -121.45 -20.58 6.56 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.666 0.269 . . . . 0.0 111.117 -179.583 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.72 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 160.81 165.29 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.382 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.639 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -107.93 81.8 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.624 179.595 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.747 HD12 ' HB2' ' A' ' 151' ' ' PRO . 2.4 mt -41.55 -29.07 0.15 Allowed 'General case' 0 CA--C 1.52 -0.211 0 CA-C-O 121.064 0.459 . . . . 0.0 110.467 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.981 HG21 HD23 ' A' ' 152' ' ' LEU . 54.8 t -102.85 137.36 31.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.771 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.434 ' O ' ' C ' ' A' ' 142' ' ' SER . 5.9 mt-10 -66.73 94.11 0.29 Allowed 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.349 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.523 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 77.4 p -34.95 137.44 0.13 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.816 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.59 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 84.02 35.82 14.6 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.529 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.506 ' O ' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -155.33 159.36 31.78 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.983 0.42 . . . . 0.0 111.125 -179.881 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.525 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 45.5 Cg_endo -68.65 178.37 3.95 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.79 2.327 . . . . 0.0 112.47 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.94 HG11 ' CD2' ' A' ' 152' ' ' LEU . 0.0 OUTLIER -157.86 -173.82 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.066 -179.944 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.461 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 1.8 tt0 -140.59 148.43 40.93 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.982 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.43 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 66.7 t80 -37.66 122.62 0.97 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.868 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.43 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 7.1 t70 79.81 35.54 0.15 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.894 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.461 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 1.8 mt-10 -112.64 74.48 1.64 Allowed Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.845 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.747 ' HB2' HD12 ' A' ' 139' ' ' LEU . 52.6 Cg_exo -32.95 120.45 0.1 Allowed 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 122.926 2.417 . . . . 0.0 111.834 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.981 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -109.62 -60.69 1.74 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.979 -179.102 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.92 ' CG1' HG12 ' A' ' 83' ' ' VAL . 2.3 p -111.96 110.35 31.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.066 0.46 . . . . 0.0 111.531 -179.275 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.859 HG13 HG12 ' A' ' 82' ' ' ILE . 4.9 t -92.2 145.49 7.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.354 179.811 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.621 HG23 ' N ' ' A' ' 134' ' ' THR . 35.8 mt -142.7 138.4 28.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.063 179.909 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.461 ' CA ' ' HD2' ' A' ' 136' ' ' LYS . 2.2 tm-20 . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.217 -0.897 . . . . 0.0 110.914 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.479 ' O ' ' HB3' ' A' ' 76' ' ' ALA . . . . . . . . 0 N--CA 1.458 -0.069 0 CA-C-O 120.823 0.344 . . . . 0.0 111.026 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.479 ' HB3' ' O ' ' A' ' 75' ' ' ALA . . . 70.55 127.14 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.133 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 46.34 61.46 2.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.984 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.513 HD12 ' HA ' ' A' ' 78' ' ' ILE . 2.9 tp -81.63 -0.78 4.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.306 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -42.28 133.79 3.07 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.961 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.486 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -75.52 -142.0 0.98 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.487 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.511 ' N ' ' O ' ' A' ' 155' ' ' ILE . 16.1 t-80 167.69 86.34 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.784 0.326 . . . . 0.0 110.672 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.565 HG21 ' HB3' ' A' ' 151' ' ' PRO . 0.3 OUTLIER -85.07 164.23 2.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 121.05 0.453 . . . . 0.0 111.101 179.962 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.6 ' O ' HD12 ' A' ' 152' ' ' LEU . 4.3 t -120.01 49.35 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.295 -179.828 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.56 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 5.2 ptt180 -48.41 136.04 13.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.892 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.798 ' HB3' HG21 ' A' ' 146' ' ' VAL . 24.1 p -45.19 111.91 1.43 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.798 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.654 ' HD2' HG11 ' A' ' 118' ' ' VAL . 24.7 Cg_endo -61.51 -10.21 15.66 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.652 2.235 . . . . 0.0 112.139 179.751 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.411 ' SD ' ' HG2' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -160.3 -170.46 2.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.687 179.902 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 60.2 t -86.62 84.18 2.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.071 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.46 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -135.27 -138.97 3.96 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.699 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' THR . . . . . 1.017 HG23 ' C ' ' A' ' 144' ' ' GLN . 62.0 m -141.33 141.2 33.88 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.85 0.357 . . . . 0.0 111.036 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.825 ' CZ ' HG21 ' A' ' 138' ' ' ILE . 18.2 t80 -86.64 144.73 27.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.749 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.579 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 16.0 m-85 -146.49 159.09 43.86 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.856 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.582 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 1.6 ptt85 -149.3 21.28 0.95 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.85 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.453 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 33.5 p -149.75 107.69 3.28 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.839 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.442 ' HG2' ' CB ' ' A' ' 99' ' ' ALA . 58.9 Cg_endo -72.07 -15.73 28.97 Favored 'Trans proline' 0 N--CA 1.465 -0.199 0 C-N-CA 122.776 2.318 . . . . 0.0 112.369 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.36 149.13 6.28 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.999 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_exo -51.32 -25.82 19.13 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.802 2.335 . . . . 0.0 112.282 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -125.68 51.2 1.75 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.789 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.442 ' CB ' ' HG2' ' A' ' 95' ' ' PRO . . . -114.34 -162.39 0.81 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.28 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.46 ' O ' ' O ' ' A' ' 101' ' ' ALA . 2.0 ptmt -115.16 24.2 11.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.881 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.582 ' HB1' ' O ' ' A' ' 93' ' ' ARG . . . 50.13 172.35 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.14 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.577 ' CE2' HG12 ' A' ' 117' ' ' ILE . 11.6 m-30 -98.56 -45.42 6.09 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.84 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.838 HD11 HG21 ' A' ' 153' ' ' VAL . 2.5 pp -160.14 141.74 4.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.176 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.469 ' HG2' ' HB2' ' A' ' 107' ' ' GLN . 15.2 pt-20 -132.18 171.64 13.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.919 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.632 HG13 ' O ' ' A' ' 105' ' ' VAL . 9.5 p -56.29 114.89 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.207 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 92.52 0.62 69.6 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.614 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.469 ' HB2' ' HG2' ' A' ' 104' ' ' GLU . 4.4 tp-100 -74.57 115.17 13.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.82 0.343 . . . . 0.0 110.845 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.09 129.1 37.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.97 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.421 ' O ' ' CG ' ' A' ' 110' ' ' ASN . 28.5 m -112.19 172.99 2.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.275 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.451 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 4.0 m120 -162.36 130.95 4.13 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-O 121.12 0.486 . . . . 0.0 110.657 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.707 HG12 ' N ' ' A' ' 131' ' ' LYS . 27.3 m -41.46 126.87 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.137 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 113.16 -1.95 25.41 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.534 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -112.21 -148.32 0.43 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.685 0.278 . . . . 0.0 110.616 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.8 134.01 44.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.936 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.609 HD12 HG22 ' A' ' 127' ' ' ILE . 61.5 mt -87.35 -72.64 0.51 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.809 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.404 ' HB2' ' O ' ' A' ' 92' ' ' TYR . 0.8 OUTLIER -155.74 -174.91 5.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.856 179.941 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.577 HG12 ' CE2' ' A' ' 102' ' ' PHE . 0.0 OUTLIER -110.31 115.8 50.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.179 -179.879 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.654 HG11 ' HD2' ' A' ' 86' ' ' PRO . 1.7 t -99.27 56.69 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.677 179.671 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.482 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.4 OUTLIER -33.85 93.98 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.224 -179.606 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.495 ' O ' ' HG3' ' A' ' 121' ' ' MET . . . -110.76 138.76 46.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.897 179.751 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.511 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 62.71 13.17 6.18 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.796 -179.95 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.511 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.1 OUTLIER 85.44 53.42 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.866 -179.881 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.482 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.2 OUTLIER -171.11 132.79 0.84 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.988 179.884 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -49.46 125.28 10.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.977 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.463 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 1.7 t-20 -107.92 60.4 0.61 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.719 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.403 ' C ' ' O ' ' A' ' 125' ' ' ASN . 13.6 pt20 -36.58 131.1 0.7 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.877 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.609 HG22 HD12 ' A' ' 115' ' ' LEU . 37.2 mm -111.05 118.1 56.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.173 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 14.8 mm-40 -88.32 124.86 34.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.95 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -44.96 116.08 1.02 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.081 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -101.41 12.72 36.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.797 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.707 ' N ' HG12 ' A' ' 111' ' ' VAL . 0.3 OUTLIER 179.51 122.91 0.06 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.758 -179.954 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.451 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.4 t -56.41 126.75 27.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.71 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.431 ' HA3' ' CG2' ' A' ' 155' ' ' ILE . . . -157.17 -173.38 25.52 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.587 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.626 ' N ' HG23 ' A' ' 155' ' ' ILE . 61.6 m -135.51 108.79 7.79 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.765 0.317 . . . . 0.0 111.066 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.514 ' HA ' ' HA ' ' A' ' 155' ' ' ILE . 94.7 t -46.65 143.89 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.612 179.602 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.554 ' HD2' ' CG1' ' A' ' 154' ' ' VAL . 0.0 OUTLIER -115.03 -35.56 4.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 121.317 0.579 . . . . 0.0 109.729 -179.934 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.638 ' O ' HG23 ' A' ' 154' ' ' VAL . . . 177.64 142.41 0.09 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.164 -0.925 . . . . 0.0 111.36 -179.667 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.863 HG23 HG22 ' A' ' 153' ' ' VAL . 0.0 OUTLIER -88.93 86.88 2.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.249 179.421 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.431 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 75.9 mt -41.62 -28.45 0.14 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.438 -179.653 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.931 HG21 HD23 ' A' ' 152' ' ' LEU . 54.5 t -102.07 158.42 4.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.102 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.506 ' N ' HG12 ' A' ' 140' ' ' VAL . 1.1 mm-40 -59.56 -146.84 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 178.784 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.501 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -101.73 -59.6 1.67 Allowed 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.623 -0.431 . . . . 0.0 110.913 179.404 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.569 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -125.48 102.34 0.66 Allowed Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.64 -179.78 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 1.017 ' C ' HG23 ' A' ' 90' ' ' THR . 0.0 OUTLIER -167.99 136.64 1.96 Allowed Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 120.959 0.409 . . . . 0.0 111.259 179.766 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.502 ' N ' HG23 ' A' ' 90' ' ' THR . 50.5 Cg_exo -53.28 154.06 15.42 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.849 2.366 . . . . 0.0 112.405 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.798 HG21 ' HB3' ' A' ' 85' ' ' SER . 4.5 m -144.87 -156.48 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.999 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.573 ' N ' HG23 ' A' ' 146' ' ' VAL . 24.5 mt-10 -149.28 150.86 33.22 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.969 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.458 ' HA ' ' O ' ' A' ' 85' ' ' SER . 37.5 t80 -42.75 141.4 1.08 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.805 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 66.13 29.47 9.85 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.772 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 0.8 OUTLIER -110.06 74.66 0.81 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.897 179.886 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.565 ' HB3' HG21 ' A' ' 82' ' ' ILE . 58.4 Cg_exo -32.89 135.56 0.08 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.579 0 C-N-CA 122.898 2.399 . . . . 0.0 111.999 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.931 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -134.32 -37.69 0.86 Allowed 'General case' 0 N--CA 1.453 -0.282 0 CA-C-O 121.024 0.44 . . . . 0.0 110.657 -179.511 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.863 HG22 HG23 ' A' ' 138' ' ' ILE . 2.3 t -128.34 115.64 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.595 -178.743 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.638 HG23 ' O ' ' A' ' 137' ' ' ALA . 1.2 t -97.18 127.07 49.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.017 179.505 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.626 HG23 ' N ' ' A' ' 134' ' ' THR . 7.9 mt -121.88 149.05 25.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.272 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.217 -0.897 . . . . 0.0 110.947 -179.901 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.824 0.345 . . . . 0.0 111.116 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.559 ' HB1' ' OG ' ' A' ' 79' ' ' SER . . . -66.82 98.23 0.53 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.186 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.736 ' O ' HG22 ' A' ' 78' ' ' ILE . 52.5 mt-10 -103.52 99.25 9.06 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.83 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.736 HG22 ' O ' ' A' ' 77' ' ' GLU . 0.3 OUTLIER 67.72 14.23 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.98 -179.96 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.559 ' OG ' ' HB1' ' A' ' 76' ' ' ALA . 53.1 m -32.22 90.43 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.351 -0.841 . . . . 0.0 111.033 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.526 ' N ' ' O ' ' A' ' 78' ' ' ILE . . . 172.44 -153.29 18.69 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.27 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.52 ' N ' ' O ' ' A' ' 155' ' ' ILE . 39.0 t-80 -176.49 77.98 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.808 0.337 . . . . 0.0 111.009 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.881 HG12 HG13 ' A' ' 154' ' ' VAL . 18.5 mt -96.36 140.84 16.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.002 0.43 . . . . 0.0 111.07 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.865 HG23 HG13 ' A' ' 153' ' ' VAL . 1.8 t -91.69 48.7 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.104 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.485 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 7.1 ptt-85 -35.49 130.63 0.51 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.843 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.46 ' OG ' ' O ' ' A' ' 87' ' ' MET . 28.4 t -35.45 94.36 0.07 OUTLIER Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.038 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.462 ' N ' ' O ' ' A' ' 84' ' ' ARG . 51.3 Cg_exo -53.98 -24.98 34.25 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.662 2.242 . . . . 0.0 112.04 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.496 ' SD ' ' CB ' ' A' ' 120' ' ' ALA . 14.5 ptp -157.0 176.37 12.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.712 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 69.2 t -71.97 85.88 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.171 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.48 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -137.72 -150.87 5.77 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.572 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.622 ' CG2' ' CZ ' ' A' ' 92' ' ' TYR . 3.0 m -129.09 130.87 47.05 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.913 0.387 . . . . 0.0 111.043 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.779 ' HB2' HD22 ' A' ' 152' ' ' LEU . 53.2 t80 -76.52 146.87 38.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.562 179.765 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.644 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 14.7 m-85 -150.45 154.76 38.27 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.921 0.391 . . . . 0.0 110.872 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.507 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 4.1 ptm180 -142.28 34.53 1.5 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.866 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.482 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 18.3 p -149.44 110.6 3.41 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.882 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -67.83 -24.85 39.86 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.697 2.265 . . . . 0.0 112.196 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -141.42 143.84 31.59 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.876 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -50.18 -19.77 4.71 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.701 2.267 . . . . 0.0 112.37 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -143.72 74.19 1.42 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -140.07 -155.57 0.6 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.137 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.412 ' O ' ' HB3' ' A' ' 101' ' ' ALA . 0.0 OUTLIER -104.68 36.94 2.26 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.812 -179.961 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.507 ' HB1' ' O ' ' A' ' 93' ' ' ARG . . . 66.56 -174.05 0.19 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.049 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.717 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -104.22 -46.14 4.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.94 179.942 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.717 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.9 pp -164.68 131.39 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.123 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 18.0 pt-20 -132.29 170.08 15.56 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.883 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.629 ' HA ' HG12 ' A' ' 135' ' ' VAL . 3.6 t -53.13 128.2 12.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.029 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.52 -14.93 50.27 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.357 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -80.35 102.27 9.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.817 0.341 . . . . 0.0 110.901 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.419 ' HA ' ' O ' ' A' ' 133' ' ' GLY . 0.0 OUTLIER -73.37 75.7 1.38 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.974 -179.88 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.674 HG11 ' CD2' ' A' ' 115' ' ' LEU . 32.6 m -48.81 174.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.001 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.454 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 18.1 m-80 -162.36 130.31 3.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.008 0.433 . . . . 0.0 110.717 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.566 HG12 ' N ' ' A' ' 131' ' ' LYS . 34.0 m -37.94 145.93 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.126 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 92.73 -6.04 76.92 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.421 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -105.63 -146.25 0.39 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.672 0.272 . . . . 0.0 110.573 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 6.5 m -145.16 116.61 8.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.814 0.34 . . . . 0.0 111.023 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.674 ' CD2' HG11 ' A' ' 109' ' ' VAL . 94.8 mt -69.23 -86.53 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.753 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.805 ' SG ' HG11 ' A' ' 153' ' ' VAL . 0.6 OUTLIER -135.17 -171.26 2.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.812 179.913 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.751 HG21 ' HG2' ' A' ' 124' ' ' MET . 0.1 OUTLIER -110.82 123.26 66.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.073 -180.0 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.657 ' O ' HG12 ' A' ' 118' ' ' VAL . 87.3 t -105.99 58.32 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.753 179.662 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.479 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.5 OUTLIER -33.71 101.57 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.307 -179.658 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.518 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -122.99 149.37 44.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.745 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.518 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 5.4 ptm 50.71 21.72 0.97 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.944 0.402 . . . . 0.0 110.611 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.442 ' O ' ' HE3' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 77.56 60.12 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.246 -179.983 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.481 ' HG2' ' O ' ' A' ' 120' ' ' ALA . 2.9 ptt? -175.33 128.68 0.27 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.069 0.461 . . . . 0.0 111.151 179.497 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.751 ' HG2' HG21 ' A' ' 117' ' ' ILE . 1.7 mtp -53.29 95.03 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.979 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -82.08 70.93 9.11 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.83 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 84.9 mt-30 -51.89 120.9 5.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.947 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.476 HG12 HG23 ' A' ' 118' ' ' VAL . 41.4 mm -88.39 109.8 20.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.184 -179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 129' ' ' ALA . 1.4 pt-20 -74.4 124.64 26.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.84 179.899 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.452 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -36.19 112.29 0.17 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.113 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.0 14.26 32.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.759 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.566 ' N ' HG12 ' A' ' 111' ' ' VAL . 0.3 OUTLIER 169.19 118.85 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.938 -179.979 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.454 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 25.3 p -49.5 129.58 19.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.857 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.419 ' O ' ' HA ' ' A' ' 108' ' ' LYS . . . -158.28 -178.1 31.99 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.642 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.63 ' N ' HG23 ' A' ' 155' ' ' ILE . 23.4 m -129.81 108.7 10.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.58 0.229 . . . . 0.0 111.152 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.629 HG12 ' HA ' ' A' ' 105' ' ' VAL . 69.9 t -42.25 142.44 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 110.295 -0.261 . . . . 0.0 110.295 179.504 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.68 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 5.8 mmmt -124.88 -18.66 5.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.677 0.275 . . . . 0.0 111.342 -179.426 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.68 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 165.17 154.22 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.841 0.353 . . . . 0.0 111.448 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.659 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -106.0 78.7 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.79 179.922 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.533 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 22.0 mt -42.14 -29.49 0.24 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.149 0.5 . . . . 0.0 110.385 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 1.085 HG21 HD23 ' A' ' 152' ' ' LEU . 55.4 t -100.7 161.89 3.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.694 179.73 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.554 ' N ' HG12 ' A' ' 140' ' ' VAL . 1.8 mm-40 -58.49 -149.13 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.345 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.49 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 35.8 m -107.67 -63.94 1.26 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.826 0.346 . . . . 0.0 110.893 179.605 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.644 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -123.44 90.47 0.42 Allowed Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.851 -179.783 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.474 ' C ' HG23 ' A' ' 90' ' ' THR . 36.3 mm-40 -156.57 156.34 29.88 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-O 120.908 0.385 . . . . 0.0 110.969 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.432 ' HD2' ' HB3' ' A' ' 144' ' ' GLN . 48.6 Cg_endo -69.26 120.98 7.77 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.681 2.254 . . . . 0.0 112.132 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.912 HG11 ' CD2' ' A' ' 152' ' ' LEU . 18.3 m -105.92 -173.83 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.123 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.491 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 6.2 mm-40 -140.7 144.41 35.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.031 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.446 ' HA ' ' O ' ' A' ' 85' ' ' SER . 63.9 t80 -35.7 137.94 0.18 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.051 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 7.9 t70 69.67 27.78 4.63 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.891 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.491 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 1.2 tp10 -108.87 73.79 0.53 Allowed Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.833 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.894 ' O ' HG23 ' A' ' 140' ' ' VAL . 61.4 Cg_exo -34.18 123.2 0.16 Allowed 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.804 2.336 . . . . 0.0 112.042 179.674 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 1.085 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -120.64 -70.86 0.76 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.699 -179.254 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.865 HG13 HG23 ' A' ' 83' ' ' VAL . 1.3 p -97.04 106.24 18.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.559 -179.146 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.881 HG13 HG12 ' A' ' 82' ' ' ILE . 23.4 t -89.33 133.41 31.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.865 179.349 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.63 HG23 ' N ' ' A' ' 134' ' ' THR . 82.9 mt -134.38 135.37 54.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.191 -179.799 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.486 ' HB2' ' CD ' ' A' ' 136' ' ' LYS . 0.7 OUTLIER . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.228 -0.891 . . . . 0.0 110.939 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.814 0.34 . . . . 0.0 111.136 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -106.54 -176.79 3.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.062 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -41.25 150.11 0.09 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.897 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.427 ' O ' ' C ' ' A' ' 79' ' ' SER . 0.8 OUTLIER -114.31 21.69 6.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.084 -179.939 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.427 ' C ' ' O ' ' A' ' 78' ' ' ILE . 0.3 OUTLIER 35.69 43.5 0.17 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.96 179.952 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.479 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -139.07 -162.35 9.09 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.462 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.512 ' O ' ' ND1' ' A' ' 81' ' ' HIS . 11.9 t-80 173.11 83.07 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.827 0.346 . . . . 0.0 110.823 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 1.014 HG12 HG13 ' A' ' 154' ' ' VAL . 1.6 mt -118.17 151.05 20.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.071 0.462 . . . . 0.0 111.31 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.788 ' CG2' HD13 ' A' ' 115' ' ' LEU . 20.4 t -95.19 37.69 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.168 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.55 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 20.1 ptt85 -37.2 127.77 0.98 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.711 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.49 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 0.2 OUTLIER -45.33 109.38 0.92 Allowed Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.726 179.96 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -61.61 -13.22 28.59 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.72 2.28 . . . . 0.0 112.126 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 1.9 ptp -150.08 -159.58 1.05 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.821 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.449 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 5.2 m -92.25 87.27 2.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.103 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.476 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -141.99 -163.5 9.65 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.468 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.796 HG23 ' C ' ' A' ' 144' ' ' GLN . 25.8 m -119.98 145.41 46.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.843 0.354 . . . . 0.0 110.881 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.861 ' CB ' HD22 ' A' ' 152' ' ' LEU . 1.0 OUTLIER -102.08 147.71 26.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.031 -179.839 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.578 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 23.3 m-85 -142.73 167.59 21.72 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.865 179.843 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.453 ' HD3' ' HB3' ' A' ' 142' ' ' SER . 32.1 ptt85 -152.96 21.23 0.58 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.689 179.866 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.503 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 6.5 p -155.24 113.67 2.29 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.753 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.403 ' HG2' ' CB ' ' A' ' 99' ' ' ALA . 49.2 Cg_endo -68.59 -39.15 9.64 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.702 2.268 . . . . 0.0 112.342 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.521 ' CB ' ' HD2' ' A' ' 97' ' ' PRO . 0.2 OUTLIER -135.23 172.49 7.13 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.914 -179.947 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.521 ' HD2' ' CB ' ' A' ' 96' ' ' SER . 51.9 Cg_endo -69.22 -27.61 28.83 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.725 2.283 . . . . 0.0 112.284 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -135.46 39.63 2.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.874 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.403 ' CB ' ' HG2' ' A' ' 95' ' ' PRO . . . -95.28 -156.07 0.5 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.108 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.414 ' O ' ' CG ' ' A' ' 100' ' ' LYS . 0.0 OUTLIER -102.81 34.79 2.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.91 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.503 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 45.01 -158.87 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.179 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.572 ' CD2' HG12 ' A' ' 117' ' ' ILE . 0.1 OUTLIER -139.27 40.28 2.09 Favored 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.059 179.816 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.784 HD13 HG12 ' A' ' 109' ' ' VAL . 2.6 mt 87.07 122.04 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.113 -179.806 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.425 ' O ' ' HB ' ' A' ' 135' ' ' VAL . 1.7 pt-20 -131.17 -175.75 3.79 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.905 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.548 HG22 ' HA ' ' A' ' 137' ' ' ALA . 46.7 t -53.31 134.06 15.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.079 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 93.22 -26.91 12.9 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.399 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.485 ' O ' HG23 ' A' ' 134' ' ' THR . 6.7 tp60 -72.35 131.63 42.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.803 0.335 . . . . 0.0 110.832 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.42 118.91 33.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.963 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.784 HG12 HD13 ' A' ' 103' ' ' ILE . 4.4 m -89.97 178.35 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.06 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.432 ' CG ' ' O ' ' A' ' 109' ' ' VAL . 18.4 m120 -164.71 131.27 2.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.068 0.461 . . . . 0.0 110.641 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.473 ' HA ' ' HB3' ' A' ' 129' ' ' ALA . 34.7 m -38.65 159.51 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.123 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 79.63 -6.04 59.31 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.499 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -108.88 -147.49 0.41 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.708 0.289 . . . . 0.0 110.651 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 14.4 m -135.93 150.12 49.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.847 0.356 . . . . 0.0 110.854 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.788 HD13 ' CG2' ' A' ' 83' ' ' VAL . 49.4 mt -96.95 -75.58 0.54 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.881 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.488 ' SG ' HG11 ' A' ' 153' ' ' VAL . 0.0 OUTLIER -148.4 -168.31 3.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.803 -179.916 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.572 HG12 ' CD2' ' A' ' 102' ' ' PHE . 0.1 OUTLIER -108.63 120.29 59.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.178 179.926 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.517 ' O ' ' CB ' ' A' ' 125' ' ' ASN . 11.1 t -118.43 73.38 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.03 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.543 ' HG2' ' CE2' ' A' ' 92' ' ' TYR . 0.9 OUTLIER -59.32 119.55 7.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.832 -179.953 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -94.0 -70.26 0.71 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.28 0.562 . . . . 0.0 111.365 -179.834 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.532 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 1.9 ptp -92.53 36.21 1.01 Allowed 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.447 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.538 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 0.4 OUTLIER 88.54 -7.74 0.5 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.87 -179.814 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.485 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 6.2 mtt -107.72 128.07 54.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.956 0.407 . . . . 0.0 110.896 179.68 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.539 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 1.0 OUTLIER -43.83 149.67 0.3 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.148 -179.867 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.517 ' CB ' ' O ' ' A' ' 118' ' ' VAL . 30.1 t-20 -129.58 74.25 1.57 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.572 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 9.9 pt20 -47.06 112.85 0.57 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.051 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 23.2 mm -92.8 105.92 17.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.103 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -70.21 143.2 52.28 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.932 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.473 ' HB3' ' HA ' ' A' ' 111' ' ' VAL . . . -66.04 119.22 11.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.123 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.421 ' C ' HG12 ' A' ' 111' ' ' VAL . 0.4 OUTLIER -97.8 -10.63 24.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.911 179.919 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.421 ' O ' ' C ' ' A' ' 132' ' ' SER . 10.0 tttt -161.61 109.47 1.45 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.918 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 131' ' ' LYS . 4.8 p -36.04 141.18 0.1 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.958 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.494 ' O ' ' N ' ' A' ' 109' ' ' VAL . . . -169.45 -165.12 26.31 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.521 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.53 ' N ' HG12 ' A' ' 155' ' ' ILE . 55.9 m -150.97 110.08 3.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.672 0.272 . . . . 0.0 110.938 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.58 HG21 HG22 ' A' ' 103' ' ' ILE . 61.8 t -41.86 141.34 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.843 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.519 ' HG2' ' N ' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -114.51 -35.88 4.77 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 121.456 0.646 . . . . 0.0 109.462 179.934 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.594 ' C ' HD13 ' A' ' 138' ' ' ILE . . . -175.44 155.01 1.75 Allowed 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.775 -179.579 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.787 ' N ' HD13 ' A' ' 138' ' ' ILE . 0.0 OUTLIER -103.06 84.35 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.406 179.648 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 1.013 HD11 HG22 ' A' ' 154' ' ' VAL . 0.2 OUTLIER -41.59 -28.81 0.15 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.106 0.479 . . . . 0.0 110.278 -179.872 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.988 HG21 HD23 ' A' ' 152' ' ' LEU . 79.7 t -103.38 134.45 44.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.826 179.753 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.449 ' O ' ' C ' ' A' ' 142' ' ' SER . 13.6 mt-10 -67.5 100.77 0.9 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.161 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.453 ' HB3' ' HD3' ' A' ' 93' ' ' ARG . 6.9 p -34.41 134.96 0.18 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.783 -179.524 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.578 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 80.72 39.31 14.31 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.583 -0.817 . . . . 0.0 112.255 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.796 ' C ' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -148.78 139.55 13.6 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 120.977 0.417 . . . . 0.0 111.076 -179.947 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.672 ' N ' HG23 ' A' ' 90' ' ' THR . 31.3 Cg_exo -59.03 158.75 24.14 Favored 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 122.845 2.363 . . . . 0.0 112.389 -179.725 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.926 HG11 ' CD2' ' A' ' 152' ' ' LEU . 19.7 m -147.22 -173.5 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.981 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.478 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.3 OUTLIER -138.06 174.44 10.56 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.933 179.956 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.501 ' CD1' ' HB2' ' A' ' 149' ' ' ASP . 1.3 p90 -55.2 140.31 39.21 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.834 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.501 ' HB2' ' CD1' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 59.41 34.4 22.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.867 0.365 . . . . 0.0 110.902 179.994 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.541 ' OE2' HG22 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -109.46 74.68 0.69 Allowed Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.88 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.601 ' O ' HG23 ' A' ' 140' ' ' VAL . 57.2 Cg_exo -33.43 133.93 0.11 Allowed 'Trans proline' 0 N--CA 1.459 -0.553 0 C-N-CA 122.926 2.417 . . . . 0.0 112.104 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.988 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -128.29 -50.7 1.3 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.739 -179.194 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.66 HG13 HG23 ' A' ' 83' ' ' VAL . 2.3 p -117.93 112.23 37.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.899 0.381 . . . . 0.0 111.541 -179.1 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 1.014 HG13 HG12 ' A' ' 82' ' ' ILE . 0.7 OUTLIER -96.0 129.81 45.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.888 179.523 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.571 HD11 HG11 ' A' ' 109' ' ' VAL . 0.0 OUTLIER -113.28 157.58 13.92 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.778 -179.934 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.448 ' N ' ' O ' ' A' ' 134' ' ' THR . 29.1 tt0 . . . . . 0 C--O 1.25 1.101 0 CA-C-O 118.211 -0.9 . . . . 0.0 110.976 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.82 0.343 . . . . 0.0 111.023 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . 40.21 51.64 2.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.11 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -143.74 111.81 6.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.002 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -80.49 -3.14 6.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 121.06 0.457 . . . . 0.0 111.389 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.61 83.94 5.53 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.877 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.458 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . 166.64 -178.34 41.08 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.609 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.587 ' ND1' HD12 ' A' ' 155' ' ' ILE . 14.9 t-80 172.78 83.36 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.773 0.32 . . . . 0.0 110.721 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.979 HD12 HG13 ' A' ' 154' ' ' VAL . 0.0 OUTLIER -97.73 176.46 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.145 179.977 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.723 HG12 ' CG1' ' A' ' 153' ' ' VAL . 2.3 p -132.45 28.18 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.811 179.557 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.545 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 6.2 ptt180 -25.97 120.42 0.07 Allowed 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.542 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.483 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 0.2 OUTLIER -38.58 116.25 0.93 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.835 -179.855 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.08 -9.31 25.7 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.634 2.222 . . . . 0.0 111.919 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 13.6 ptm -151.24 -168.96 3.25 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.626 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.676 ' O ' HG23 ' A' ' 88' ' ' VAL . 32.3 m -88.81 83.01 2.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.132 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.445 ' C ' HG22 ' A' ' 146' ' ' VAL . . . -126.17 -140.56 5.32 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.612 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.672 HG21 ' CZ ' ' A' ' 92' ' ' TYR . 4.9 m -146.73 128.06 14.88 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.008 0.432 . . . . 0.0 111.274 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 1.021 ' HB2' HD22 ' A' ' 152' ' ' LEU . 30.2 t80 -75.5 139.1 41.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.125 179.36 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.672 ' CZ ' HG21 ' A' ' 90' ' ' THR . 12.7 m-85 -142.67 156.35 45.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.927 0.394 . . . . 0.0 111.213 -179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 23.8 ptt85 -142.62 40.85 1.57 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.805 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -146.57 95.23 4.63 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.858 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.452 ' HD3' ' N ' ' A' ' 102' ' ' PHE . 49.7 Cg_endo -69.15 -38.84 8.53 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.817 2.345 . . . . 0.0 112.407 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.93 ' HB2' ' HB2' ' A' ' 99' ' ' ALA . 70.4 m -129.53 160.85 62.41 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.963 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.4 101.06 0.06 OUTLIER 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.717 2.278 . . . . 0.0 112.285 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 63.54 36.39 11.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.861 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.93 ' HB2' ' HB2' ' A' ' 96' ' ' SER . . . -76.56 -158.02 0.09 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.157 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.419 ' O ' ' HB3' ' A' ' 101' ' ' ALA . 0.6 OUTLIER -89.35 23.34 2.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.99 179.972 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 100' ' ' LYS . . . 67.85 159.65 0.16 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.185 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.686 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -84.65 -46.01 11.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.81 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.686 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.1 pp -163.63 112.03 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.039 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.459 ' O ' ' HB2' ' A' ' 107' ' ' GLN . 10.2 pt-20 -123.72 172.35 8.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.909 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.814 HG22 ' HA ' ' A' ' 137' ' ' ALA . 21.3 t -51.97 119.06 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.179 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 107.44 -4.86 35.15 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.522 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.476 ' HG3' ' HA ' ' A' ' 103' ' ' ILE . 1.6 mm-40 -73.8 129.64 38.33 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.771 0.319 . . . . 0.0 110.987 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.423 ' O ' ' ND2' ' A' ' 110' ' ' ASN . 6.0 mttt -98.8 72.11 1.94 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.885 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.675 HG11 HD22 ' A' ' 115' ' ' LEU . 6.0 m -48.86 167.03 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.023 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.509 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 9.6 m-80 -159.87 129.87 5.45 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.083 0.468 . . . . 0.0 110.82 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.629 HG23 ' O ' ' A' ' 111' ' ' VAL . 5.0 m -34.99 115.37 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.056 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 99.96 12.69 39.23 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.344 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.423 ' O ' ' C ' ' A' ' 114' ' ' THR . 1.8 t70 -123.7 103.1 8.19 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.824 0.345 . . . . 0.0 110.811 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.525 ' CG2' ' HB2' ' A' ' 126' ' ' GLN . 3.2 m -35.06 132.91 0.33 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.066 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.675 HD22 HG11 ' A' ' 109' ' ' VAL . 67.1 mt -93.68 -81.63 0.36 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.843 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.412 ' SG ' HD11 ' A' ' 103' ' ' ILE . 0.5 OUTLIER -133.16 -172.89 3.05 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.701 179.894 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.532 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.2 OUTLIER -110.79 123.71 66.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.136 179.975 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.523 ' O ' ' N ' ' A' ' 120' ' ' ALA . 23.6 t -103.42 55.81 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.725 179.773 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.474 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.1 OUTLIER -31.38 89.0 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.721 -179.689 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 118' ' ' VAL . . . -88.82 134.24 34.0 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.141 179.25 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.554 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 2.8 ptt? 50.37 22.89 1.09 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.242 -179.337 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.554 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 96.21 -10.18 0.09 Allowed 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.544 179.698 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.515 ' O ' ' N ' ' A' ' 120' ' ' ALA . 12.5 ptm -99.18 131.69 45.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.157 0.503 . . . . 0.0 111.35 -179.766 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.532 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 1.4 ptt? -55.16 130.5 42.27 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.914 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.488 ' HB2' ' O ' ' A' ' 118' ' ' VAL . 0.7 OUTLIER -121.92 65.34 0.91 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.955 -179.967 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.525 ' HB2' ' CG2' ' A' ' 114' ' ' THR . 2.6 pm0 -39.2 144.36 0.14 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.918 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.55 HG21 HG21 ' A' ' 83' ' ' VAL . 31.8 mm -113.1 123.03 68.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.079 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 129' ' ' ALA . 5.5 mt-10 -85.23 118.39 24.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.843 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.428 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.94 127.81 0.7 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.002 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -100.57 -10.81 20.63 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.974 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.54 ' HD2' ' CD2' ' A' ' 81' ' ' HIS . 2.0 tmtt? -168.86 123.22 0.86 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.004 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.509 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.0 OUTLIER -51.26 112.39 0.73 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.396 179.729 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.58 ' HA3' HG21 ' A' ' 155' ' ' ILE . . . -145.28 -179.83 21.86 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.713 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.679 ' N ' HG23 ' A' ' 155' ' ' ILE . 29.9 m -122.4 112.32 17.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.693 0.282 . . . . 0.0 111.396 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.506 ' HA ' ' HA ' ' A' ' 155' ' ' ILE . 85.7 t -46.56 144.34 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.524 179.293 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.543 ' CD ' ' HB ' ' A' ' 154' ' ' VAL . 0.0 OUTLIER -114.52 -35.75 4.81 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-O 121.496 0.665 . . . . 0.0 109.682 -179.809 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.814 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 179.62 172.71 0.94 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.951 -179.672 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.754 HD13 ' C ' ' A' ' 137' ' ' ALA . 0.6 OUTLIER -119.09 82.9 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.059 179.843 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.562 ' N ' HD23 ' A' ' 139' ' ' LEU . 3.8 mt -41.09 -29.53 0.12 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.2 0.524 . . . . 0.0 110.073 179.724 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 1.056 HG21 HD23 ' A' ' 152' ' ' LEU . 54.5 t -100.08 158.9 3.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.555 179.538 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.498 ' N ' HG12 ' A' ' 140' ' ' VAL . 2.8 mt-10 -58.81 -150.43 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.067 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.499 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -102.49 -60.75 1.49 Allowed 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 120.81 -0.356 . . . . 0.0 110.822 179.623 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.635 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -127.07 89.09 0.34 Allowed Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.793 -179.779 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.462 ' C ' HG23 ' A' ' 90' ' ' THR . 25.2 mm-40 -153.09 155.61 32.08 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 120.997 0.427 . . . . 0.0 110.979 179.77 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.456 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 39.6 Cg_exo -56.81 153.29 37.77 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.855 2.37 . . . . 0.0 112.391 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.816 HG11 ' CD2' ' A' ' 152' ' ' LEU . 31.1 m -141.45 -173.08 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.967 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.48 ' O ' ' HG2' ' A' ' 150' ' ' GLU . 1.0 OUTLIER -146.82 144.58 29.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.896 0.379 . . . . 0.0 111.16 -179.94 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.483 ' HA ' ' O ' ' A' ' 85' ' ' SER . 5.5 p90 -35.62 124.35 0.67 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.953 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.442 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 79.46 33.22 0.22 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.824 -179.945 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.48 ' HG2' ' O ' ' A' ' 147' ' ' GLU . 13.0 mm-40 -109.26 75.23 0.69 Allowed Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.867 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.687 ' O ' HG23 ' A' ' 140' ' ' VAL . 75.1 Cg_exo -37.38 129.15 0.68 Allowed 'Trans proline' 0 N--CA 1.461 -0.413 0 C-N-CA 122.774 2.316 . . . . 0.0 111.925 179.594 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 1.056 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -123.27 -61.1 1.44 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.635 -179.3 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.723 ' CG1' HG12 ' A' ' 83' ' ' VAL . 2.1 p -108.26 120.91 60.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 121.172 0.511 . . . . 0.0 111.292 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.979 HG13 HD12 ' A' ' 82' ' ' ILE . 0.2 OUTLIER -100.55 137.92 26.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.219 -179.98 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.679 HG23 ' N ' ' A' ' 134' ' ' THR . 45.6 mt -123.43 147.16 27.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.229 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.402 ' O ' ' HG2' ' A' ' 156' ' ' GLU . 2.1 tt0 . . . . . 0 C--O 1.248 1.018 0 CA-C-O 118.323 -0.846 . . . . 0.0 110.922 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.435 ' O ' ' HB3' ' A' ' 76' ' ' ALA . . . . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.826 0.346 . . . . 0.0 111.154 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.435 ' HB3' ' O ' ' A' ' 75' ' ' ALA . . . 67.8 129.16 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.038 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -62.84 158.95 17.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.926 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.429 ' O ' ' C ' ' A' ' 79' ' ' SER . 2.0 mt -112.85 21.05 6.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.143 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.429 ' C ' ' O ' ' A' ' 78' ' ' ILE . 3.2 p 35.72 71.18 0.13 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.918 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -127.68 150.45 18.26 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.647 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.504 ' O ' ' ND1' ' A' ' 81' ' ' HIS . 23.7 t-80 -170.03 76.15 0.08 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.847 0.355 . . . . 0.0 110.802 179.838 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.836 HG12 HG13 ' A' ' 154' ' ' VAL . 5.1 mt -101.86 155.07 4.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.066 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.77 HG23 HG13 ' A' ' 153' ' ' VAL . 4.0 t -102.42 51.2 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.969 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.533 ' CD ' ' O ' ' A' ' 84' ' ' ARG . 0.5 OUTLIER -35.48 133.19 0.38 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.875 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.492 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 11.2 p -39.41 98.6 0.17 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.757 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.422 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 12.2 Cg_endo -56.3 -15.44 14.84 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.506 2.137 . . . . 0.0 111.91 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.411 ' O ' ' N ' ' A' ' 89' ' ' GLY . 5.2 ptp -160.29 172.38 17.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.534 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.595 ' O ' HG23 ' A' ' 88' ' ' VAL . 27.2 m -67.32 68.33 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.037 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 87' ' ' MET . . . -119.04 -155.68 9.88 Favored Glycine 0 C--N 1.331 0.289 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.648 -179.793 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.896 HG23 ' O ' ' A' ' 144' ' ' GLN . 20.2 m -131.5 124.85 31.0 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.908 0.385 . . . . 0.0 111.07 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.933 ' HB2' HD22 ' A' ' 152' ' ' LEU . 72.4 t80 -62.61 141.95 58.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.52 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.589 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 5.6 m-30 -148.37 127.73 13.06 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.964 0.412 . . . . 0.0 110.919 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.488 ' HA ' ' HB2' ' A' ' 102' ' ' PHE . 0.1 OUTLIER -124.27 25.52 7.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.825 179.857 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 2.7 p -149.21 108.16 3.4 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.882 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.34 -44.1 1.85 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.82 2.346 . . . . 0.0 112.309 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.747 ' HB2' ' HB2' ' A' ' 99' ' ' ALA . 0.1 OUTLIER -110.64 166.93 9.83 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.928 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.485 ' HD2' ' OG ' ' A' ' 96' ' ' SER . 51.1 Cg_endo -69.42 -25.56 30.05 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.737 2.291 . . . . 0.0 112.224 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -136.17 26.86 3.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.817 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.747 ' HB2' ' HB2' ' A' ' 96' ' ' SER . . . -71.49 -163.92 0.1 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.121 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.486 ' O ' ' HB3' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -103.83 20.75 17.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.921 179.854 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.486 ' HB3' ' O ' ' A' ' 100' ' ' LYS . . . 71.47 162.9 0.26 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.274 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.616 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -84.93 -37.42 20.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.765 179.922 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.616 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.2 pp -161.29 158.56 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.019 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.437 ' O ' ' HB3' ' A' ' 107' ' ' GLN . 0.2 OUTLIER -140.42 151.23 44.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.906 -179.989 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.802 HG23 ' C ' ' A' ' 136' ' ' LYS . 4.8 p -54.08 127.94 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.199 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 93.83 -9.77 72.9 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.521 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.516 ' O ' ' N ' ' A' ' 109' ' ' VAL . 2.7 tp-100 -68.93 99.83 1.11 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.855 0.36 . . . . 0.0 110.801 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.43 ' HA ' ' HA ' ' A' ' 134' ' ' THR . 0.0 OUTLIER -59.26 75.62 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.952 -179.839 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.516 ' N ' ' O ' ' A' ' 107' ' ' GLN . 6.6 m -53.28 172.0 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.008 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.489 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 3.9 p-10 -163.06 133.03 4.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.058 0.456 . . . . 0.0 110.947 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.48 HG12 ' N ' ' A' ' 131' ' ' LYS . 29.3 m -38.25 130.18 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.131 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 101.95 2.01 52.02 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.417 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.434 ' O ' ' N ' ' A' ' 115' ' ' LEU . 4.2 t70 -117.93 99.22 6.77 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.777 0.322 . . . . 0.0 110.859 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.469 ' HA ' ' HA ' ' A' ' 128' ' ' GLU . 6.5 m -35.41 96.11 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.004 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.464 ' N ' ' O ' ' A' ' 127' ' ' ILE . 7.1 mt -46.4 -89.98 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.75 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.467 ' O ' ' N ' ' A' ' 127' ' ' ILE . 0.5 OUTLIER -136.86 -168.91 2.36 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.687 -179.992 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.998 HD13 ' HB2' ' A' ' 124' ' ' MET . 2.2 mt -125.83 153.83 34.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.885 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.457 ' HA ' ' O ' ' A' ' 90' ' ' THR . 27.5 t -142.61 101.64 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.872 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.544 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.5 OUTLIER -62.7 89.66 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.201 -179.799 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.449 ' O ' ' C ' ' A' ' 121' ' ' MET . . . -69.28 -136.07 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.649 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.482 ' O ' ' HB2' ' A' ' 122' ' ' LYS . 0.0 OUTLIER -34.14 -39.84 0.08 Allowed 'General case' 0 CA--C 1.519 -0.224 0 CA-C-O 121.444 0.64 . . . . 0.0 110.173 179.608 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.519 ' CG ' ' O ' ' A' ' 122' ' ' LYS . 0.1 OUTLIER 169.27 38.21 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.873 179.482 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.407 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 36.8 mmm -146.93 131.87 18.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.045 -179.422 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.998 ' HB2' HD13 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -64.47 101.44 0.45 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.836 179.994 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.457 ' HB2' ' O ' ' A' ' 118' ' ' VAL . 0.9 OUTLIER -77.07 83.28 3.58 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.877 179.946 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.546 ' CA ' HG12 ' A' ' 117' ' ' ILE . 7.8 pt20 -64.29 103.92 0.69 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.959 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.467 ' N ' ' O ' ' A' ' 116' ' ' CYS . 17.3 mm -75.38 139.09 19.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.04 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.469 ' HA ' ' HA ' ' A' ' 114' ' ' THR . 2.2 mt-10 -110.4 122.05 46.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.923 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.409 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -36.78 114.89 0.33 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.064 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -107.82 17.19 22.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.48 ' N ' HG12 ' A' ' 111' ' ' VAL . 1.9 ttmt 177.32 113.5 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.9 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.489 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 15.6 p -43.51 121.31 2.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.758 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.414 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -152.2 -171.52 19.92 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.599 -179.802 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.582 ' N ' HG23 ' A' ' 155' ' ' ILE . 21.8 m -140.14 107.81 5.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.582 0.229 . . . . 0.0 111.239 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.672 HG12 ' HA ' ' A' ' 105' ' ' VAL . 92.5 t -41.79 142.71 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.437 179.459 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.802 ' C ' HG23 ' A' ' 105' ' ' VAL . 30.5 mtpt -124.91 -18.93 5.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.455 -179.478 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.631 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 169.15 155.38 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.935 0.398 . . . . 0.0 111.622 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.639 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -111.11 77.44 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.61 179.792 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 9.7 mt -46.25 -24.92 0.53 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.965 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.994 HG21 HD23 ' A' ' 152' ' ' LEU . 45.3 t -104.13 144.18 14.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.239 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.494 ' HB2' ' HG2' ' A' ' 144' ' ' GLN . 4.7 mt-10 -62.35 137.62 58.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.069 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.504 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -31.58 -62.33 0.2 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.621 -179.331 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.589 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -125.58 104.21 0.75 Allowed Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.483 -0.865 . . . . 0.0 112.995 -179.483 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.896 ' O ' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -167.62 156.16 8.72 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-O 120.93 0.395 . . . . 0.0 111.137 179.553 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.435 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 37.8 Cg_endo -66.31 138.38 50.8 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.807 2.338 . . . . 0.0 112.329 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.613 HG11 ' CD2' ' A' ' 152' ' ' LEU . 1.5 m -132.14 -174.77 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.089 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.431 ' O ' ' C ' ' A' ' 148' ' ' PHE . 18.5 mt-10 -145.7 144.03 30.13 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.929 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.492 ' HA ' ' O ' ' A' ' 85' ' ' SER . 39.6 t80 -34.5 135.02 0.18 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.947 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 76.3 23.96 1.15 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.709 -179.829 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.476 ' HG2' HG12 ' A' ' 146' ' ' VAL . 4.5 tp10 -109.93 74.26 0.76 Allowed Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.788 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.752 ' O ' HG23 ' A' ' 140' ' ' VAL . 63.3 Cg_exo -33.27 130.57 0.13 Allowed 'Trans proline' 0 N--CA 1.457 -0.635 0 C-N-CA 122.888 2.392 . . . . 0.0 112.116 179.652 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.994 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -121.86 -72.2 0.7 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.555 -179.231 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.77 HG13 HG23 ' A' ' 83' ' ' VAL . 1.2 p -96.61 102.92 14.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.226 0.536 . . . . 0.0 111.37 -179.38 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.836 HG13 HG12 ' A' ' 82' ' ' ILE . 6.3 t -83.38 138.64 18.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.017 179.675 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.582 HG23 ' N ' ' A' ' 134' ' ' THR . 17.9 mt -136.72 143.2 35.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.352 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.503 ' CB ' ' HD2' ' A' ' 136' ' ' LYS . 29.5 tt0 . . . . . 0 C--O 1.25 1.094 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.881 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.073 0 CA-C-O 120.799 0.333 . . . . 0.0 111.147 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -81.11 151.12 28.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.135 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -132.6 82.35 2.0 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.92 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.589 ' O ' HD13 ' A' ' 78' ' ' ILE . 0.0 OUTLIER -99.71 3.43 10.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.087 0.47 . . . . 0.0 111.292 179.967 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -78.63 84.26 4.75 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.901 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.417 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -70.84 -67.13 1.97 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.475 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.524 ' N ' ' O ' ' A' ' 155' ' ' ILE . 19.7 t-80 175.85 82.21 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.789 0.328 . . . . 0.0 110.849 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.887 HG12 HG13 ' A' ' 154' ' ' VAL . 7.1 mt -98.93 157.27 3.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.087 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.834 HG23 HG13 ' A' ' 153' ' ' VAL . 1.9 t -113.67 53.91 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.148 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.532 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -41.08 134.6 2.0 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.855 179.938 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.463 ' N ' HD11 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -35.86 109.23 0.4 Allowed Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.855 -179.916 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.453 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 35.4 Cg_endo -64.74 -8.56 18.01 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.744 2.296 . . . . 0.0 112.109 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -167.85 176.17 6.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.757 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.761 ' O ' HG23 ' A' ' 88' ' ' VAL . 32.6 m -71.42 82.83 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.129 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.431 ' O ' HG23 ' A' ' 146' ' ' VAL . . . -142.78 -159.06 7.78 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.581 -179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.709 HG23 ' C ' ' A' ' 144' ' ' GLN . 23.2 m -116.62 142.98 46.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.785 0.326 . . . . 0.0 110.803 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.738 ' HB2' HD22 ' A' ' 152' ' ' LEU . 2.6 t80 -100.23 140.16 34.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.588 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 19.9 m-85 -138.66 145.9 40.99 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.987 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.544 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 0.0 OUTLIER -125.49 28.24 6.31 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.852 179.846 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.477 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 12.1 p -146.96 115.5 4.36 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.847 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.434 ' HG2' ' CB ' ' A' ' 99' ' ' ALA . 55.5 Cg_endo -69.93 -39.44 6.17 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.685 2.257 . . . . 0.0 112.376 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.718 ' CB ' ' HB2' ' A' ' 99' ' ' ALA . 0.3 OUTLIER -129.16 160.57 63.19 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.952 179.998 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.407 ' HD2' ' OG ' ' A' ' 96' ' ' SER . 51.6 Cg_exo -52.58 -37.14 73.7 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.72 2.28 . . . . 0.0 112.332 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.411 ' CG ' ' O ' ' A' ' 98' ' ' ASP . 34.9 t0 -131.45 32.39 4.2 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.885 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.718 ' HB2' ' CB ' ' A' ' 96' ' ' SER . . . -76.24 -158.27 0.09 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.061 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.436 ' O ' ' HB3' ' A' ' 101' ' ' ALA . 6.1 ptmt -104.72 23.6 13.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.917 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.477 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 68.65 166.31 0.26 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.187 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.724 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -93.78 -34.02 13.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.818 179.915 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.846 HD13 HG23 ' A' ' 153' ' ' VAL . 1.0 OUTLIER -164.84 150.37 2.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.134 179.913 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -155.17 146.89 23.25 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.961 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.558 HG13 ' HA ' ' A' ' 136' ' ' LYS . 3.0 t -54.11 116.45 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.148 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 129.5 -36.31 2.4 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.546 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.452 ' OE1' ' HA ' ' A' ' 103' ' ' ILE . 12.7 pt20 -76.38 130.08 37.53 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.842 0.354 . . . . 0.0 110.895 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.434 ' HA ' ' HA ' ' A' ' 134' ' ' THR . 2.6 mtpt -90.23 91.4 8.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.949 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.897 HG11 ' CD2' ' A' ' 115' ' ' LEU . 15.4 m -51.5 173.44 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.074 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.435 ' CG ' ' O ' ' A' ' 109' ' ' VAL . 75.1 m-80 -163.6 130.54 3.34 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.691 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.489 ' HA ' ' CB ' ' A' ' 129' ' ' ALA . 3.2 t -37.45 135.43 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.073 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 89.59 7.9 68.52 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.519 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 114' ' ' THR . 91.1 m-20 -121.08 101.98 8.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.933 0.397 . . . . 0.0 110.783 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.435 ' CG2' ' HB2' ' A' ' 126' ' ' GLN . 1.7 m -35.25 101.66 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.104 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.897 ' CD2' HG11 ' A' ' 109' ' ' VAL . 7.7 mt -56.77 -83.66 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.63 179.785 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.465 ' HB3' HG12 ' A' ' 103' ' ' ILE . 0.8 OUTLIER -144.34 178.21 8.08 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.764 179.804 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.741 HD13 ' HB2' ' A' ' 124' ' ' MET . 4.2 mt -111.01 152.47 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.013 0.435 . . . . 0.0 110.803 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.627 HG13 ' O ' ' A' ' 90' ' ' THR . 94.5 t -140.72 94.93 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.898 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.566 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.8 OUTLIER -50.51 84.83 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.103 -179.834 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.531 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -103.76 114.39 28.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.833 179.84 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.548 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 81.97 19.85 0.34 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.774 -179.746 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.548 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 91.13 -1.07 0.19 Allowed 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.141 179.896 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 5.7 mmt -123.0 134.87 54.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.915 0.388 . . . . 0.0 111.171 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.741 ' HB2' HD13 ' A' ' 117' ' ' ILE . 1.3 ptp -63.31 123.14 17.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.042 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -103.79 80.99 1.83 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.803 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.516 ' CA ' HG12 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -57.59 115.59 2.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.933 -179.989 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 3.6 mm -81.2 148.71 5.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.043 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.423 ' O ' ' C ' ' A' ' 129' ' ' ALA . 22.3 tt0 -112.26 124.78 53.2 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.851 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.489 ' CB ' ' HA ' ' A' ' 111' ' ' VAL . . . -35.46 107.19 0.05 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.17 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -95.28 3.98 53.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.142 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 10.1 tttt 175.82 121.19 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.908 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 86.8 p -47.32 135.03 10.94 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.793 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.506 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -164.84 -171.12 30.7 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.578 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.617 ' N ' HG23 ' A' ' 155' ' ' ILE . 24.3 m -136.09 107.41 6.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.614 0.245 . . . . 0.0 111.073 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.499 ' HA ' HG12 ' A' ' 155' ' ' ILE . 75.4 t -39.83 139.77 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 121.04 -0.264 . . . . 0.0 110.501 179.594 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.718 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.1 OUTLIER -122.84 -19.93 6.02 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.583 -0.28 . . . . 0.0 111.119 -179.47 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.718 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 161.13 154.04 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.385 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.68 ' N ' HD13 ' A' ' 138' ' ' ILE . 0.0 OUTLIER -100.75 86.54 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.605 179.752 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.605 HD12 ' HB2' ' A' ' 151' ' ' PRO . 2.0 mt -43.24 -28.08 0.28 Allowed 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.192 0.52 . . . . 0.0 110.342 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 1.006 HG21 HD23 ' A' ' 152' ' ' LEU . 75.3 t -104.63 135.62 41.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.823 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.503 ' N ' ' OE1' ' A' ' 144' ' ' GLN . 10.0 mt-10 -66.49 97.06 0.4 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.395 179.656 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.544 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 73.1 p -35.92 138.99 0.16 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.677 -179.642 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.588 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 81.21 35.8 22.75 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.457 -0.878 . . . . 0.0 112.346 -179.799 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.709 ' C ' HG23 ' A' ' 90' ' ' THR . 1.2 pt20 -148.97 159.39 37.54 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 120.89 0.376 . . . . 0.0 111.144 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.854 ' O ' HG13 ' A' ' 146' ' ' VAL . 45.1 Cg_endo -68.27 178.76 3.39 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.748 2.298 . . . . 0.0 112.195 179.897 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.854 HG13 ' O ' ' A' ' 145' ' ' PRO . 1.2 m -170.47 -175.67 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.283 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.523 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -142.74 155.47 44.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.869 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 148' ' ' PHE . . . . . . . . . . . . . 64.7 t80 -42.32 140.99 1.04 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.924 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.437 ' HA ' ' HD2' ' A' ' 84' ' ' ARG . 7.8 t0 66.4 28.94 9.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.841 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.523 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 2.4 tp10 -109.13 73.68 0.56 Allowed Pre-proline 0 C--N 1.327 -0.375 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.848 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.605 ' HB2' HD12 ' A' ' 139' ' ' LEU . 51.3 Cg_exo -32.56 120.94 0.1 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.598 0 C-N-CA 123.001 2.468 . . . . 0.0 112.232 179.706 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 1.006 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -116.41 -64.38 1.32 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.6 -179.254 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.846 HG23 HD13 ' A' ' 103' ' ' ILE . 1.5 p -99.43 103.99 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.178 0.514 . . . . 0.0 111.584 -179.11 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.887 HG13 HG12 ' A' ' 82' ' ' ILE . 4.7 t -87.85 135.11 26.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.033 179.571 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.617 HG23 ' N ' ' A' ' 134' ' ' THR . 96.6 mt -138.0 135.33 45.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.205 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.48 ' HG3' ' HE2' ' A' ' 136' ' ' LYS . 0.4 OUTLIER . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.249 -0.882 . . . . 0.0 110.902 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.83 0.348 . . . . 0.0 111.192 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -164.58 107.95 0.9 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.141 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 176.14 114.68 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.822 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.425 ' O ' ' C ' ' A' ' 79' ' ' SER . 3.7 tt -79.4 -5.29 7.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.506 -179.83 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.43 ' O ' ' HA ' ' A' ' 156' ' ' GLU . 35.4 p 33.67 75.13 0.05 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.006 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.424 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -110.45 170.84 14.27 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.644 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.524 ' O ' ' ND1' ' A' ' 81' ' ' HIS . 17.9 t-80 174.45 83.22 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.835 0.35 . . . . 0.0 110.928 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.727 HG12 HG13 ' A' ' 154' ' ' VAL . 23.4 mt -98.66 127.99 50.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.994 0.426 . . . . 0.0 110.819 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.921 HG21 HD13 ' A' ' 115' ' ' LEU . 3.5 t -83.52 56.9 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.408 -179.543 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.533 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 1.9 ptt85 -42.96 134.55 3.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.67 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.675 ' HB2' HD21 ' A' ' 152' ' ' LEU . 9.6 t -35.98 96.86 0.11 Allowed Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.896 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.412 ' N ' ' O ' ' A' ' 84' ' ' ARG . 87.9 Cg_exo -46.07 -27.05 4.03 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.742 2.295 . . . . 0.0 112.186 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.52 ' SD ' ' CB ' ' A' ' 120' ' ' ALA . 10.0 ptp -147.75 168.5 21.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.705 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.474 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 1.5 p -69.39 91.08 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.051 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -146.46 -133.3 2.46 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.397 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.97 HG23 ' HA ' ' A' ' 145' ' ' PRO . 1.2 m -136.29 153.74 51.08 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.782 0.325 . . . . 0.0 110.954 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.645 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 1.1 t80 -118.38 140.15 50.29 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.968 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.586 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 22.0 m-85 -140.15 163.41 32.81 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.061 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.564 ' HD2' ' CB ' ' A' ' 142' ' ' SER . 0.0 OUTLIER -130.08 13.09 5.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.914 179.729 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.36 109.27 2.98 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.897 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -74.72 -5.04 16.31 Favored 'Trans proline' 0 C--O 1.232 0.201 0 C-N-CA 122.812 2.341 . . . . 0.0 112.454 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.59 167.88 12.24 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.05 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -74.55 106.43 2.25 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.747 2.298 . . . . 0.0 112.247 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 74.21 31.74 1.07 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.835 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -76.78 -166.8 0.73 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.003 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.01 33.38 0.87 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.885 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 51.58 175.75 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.182 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.838 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -111.68 -34.59 6.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.967 179.998 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.905 HD13 ' CG2' ' A' ' 153' ' ' VAL . 1.0 OUTLIER -170.08 129.08 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.186 179.933 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.5 ' O ' ' N ' ' A' ' 106' ' ' GLY . 3.2 mt-10 -136.72 148.87 47.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.835 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.589 HG22 ' C ' ' A' ' 136' ' ' LYS . 52.6 t -35.78 92.55 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.064 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLY . . . . . 0.5 ' N ' ' O ' ' A' ' 104' ' ' GLU . . . 133.39 -0.31 4.26 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.536 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.477 ' O ' ' HA ' ' A' ' 134' ' ' THR . 0.0 OUTLIER -71.24 112.58 7.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.82 0.343 . . . . 0.0 110.83 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 31.6 mttt -82.37 79.76 8.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.046 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.653 HG11 HD13 ' A' ' 155' ' ' ILE . 1.4 p -78.03 164.08 3.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.974 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.565 ' N ' ' CG2' ' A' ' 109' ' ' VAL . 7.8 m120 -153.83 130.04 10.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.49 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.432 ' C ' ' O ' ' A' ' 110' ' ' ASN . 2.6 m -31.74 114.76 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.461 -179.822 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 111.87 9.24 21.08 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.488 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.432 ' O ' ' HA ' ' A' ' 128' ' ' GLU . 6.4 t0 -113.74 -148.86 0.44 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.794 0.33 . . . . 0.0 110.684 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.48 ' CG2' ' CE1' ' A' ' 102' ' ' PHE . 1.9 m -131.0 147.89 52.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.788 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.921 HD13 HG21 ' A' ' 83' ' ' VAL . 80.9 mt -116.46 -81.1 0.61 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.131 -179.749 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.483 ' HB2' ' O ' ' A' ' 92' ' ' TYR . 8.0 p -136.57 -176.13 4.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.282 -179.619 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.544 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.3 OUTLIER -102.52 117.89 48.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.18 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.661 HG12 ' O ' ' A' ' 125' ' ' ASN . 12.1 p -97.12 50.98 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.923 179.837 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.488 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.1 OUTLIER -35.91 96.43 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.96 -179.885 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.522 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -116.92 115.64 25.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.023 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.522 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 0.1 OUTLIER 84.06 18.18 0.2 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.821 -179.95 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.528 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 0.3 OUTLIER 85.43 26.14 0.07 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.963 179.998 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.488 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.9 OUTLIER -141.96 128.36 20.03 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.107 179.832 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.544 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 1.0 OUTLIER -66.68 131.55 46.21 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.906 179.884 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.661 ' O ' HG12 ' A' ' 118' ' ' VAL . 0.5 OUTLIER -125.99 88.39 2.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.825 -179.985 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.407 ' HB2' HG23 ' A' ' 114' ' ' THR . 4.3 pt20 -50.61 112.04 0.63 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.875 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.427 HG21 HG11 ' A' ' 83' ' ' VAL . 31.5 mm -72.53 137.78 22.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.083 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.432 ' HA ' ' O ' ' A' ' 113' ' ' ASP . 50.2 mt-10 -97.01 126.44 42.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.93 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.545 ' HB2' ' CG2' ' A' ' 109' ' ' VAL . . . -38.49 124.84 1.33 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.153 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -101.67 -13.59 17.73 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.846 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 9.8 tttp -168.05 120.02 0.85 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.807 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.411 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 90.3 p -42.74 121.59 2.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.714 179.806 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.408 ' HA3' ' CG2' ' A' ' 155' ' ' ILE . . . -157.56 -176.5 29.69 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.67 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.631 ' N ' HG23 ' A' ' 155' ' ' ILE . 24.2 m -131.86 110.78 11.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.582 0.229 . . . . 0.0 111.137 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.838 HG21 ' HB ' ' A' ' 103' ' ' ILE . 73.4 t -40.03 141.76 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 110.353 -0.24 . . . . 0.0 110.353 179.531 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.622 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 5.7 mmmt -126.19 -19.89 4.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.633 -179.459 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.622 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 169.49 161.18 0.06 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.834 0.349 . . . . 0.0 111.514 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.645 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -108.49 80.2 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.915 179.917 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.545 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 2.8 mt -41.33 -30.33 0.18 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.104 0.478 . . . . 0.0 109.919 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.989 HG21 HD23 ' A' ' 152' ' ' LEU . 71.7 t -98.64 139.19 21.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.827 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.486 ' O ' ' CG ' ' A' ' 144' ' ' GLN . 6.7 mt-10 -70.59 98.14 1.44 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.351 179.654 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.564 ' CB ' ' HD2' ' A' ' 93' ' ' ARG . 35.5 p -35.83 154.36 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.703 -179.65 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.582 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 62.69 38.12 95.93 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.33 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.486 ' CG ' ' O ' ' A' ' 141' ' ' GLU . 12.3 mm-40 -150.48 145.27 18.29 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 120.931 0.396 . . . . 0.0 111.042 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.97 ' HA ' HG23 ' A' ' 90' ' ' THR . 52.4 Cg_exo -54.81 173.04 0.29 Allowed 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.755 2.303 . . . . 0.0 112.17 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.722 HG11 ' CD2' ' A' ' 152' ' ' LEU . 0.4 OUTLIER -165.76 175.86 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.042 179.939 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.509 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 0.8 OUTLIER -135.26 162.17 33.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.991 -179.935 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.464 ' HA ' ' O ' ' A' ' 85' ' ' SER . 6.8 t80 -48.65 141.49 7.08 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.789 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 65.42 29.78 11.19 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.775 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.563 ' HG2' HG12 ' A' ' 146' ' ' VAL . 1.2 tp10 -108.16 73.36 0.44 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.762 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.689 ' O ' HG23 ' A' ' 140' ' ' VAL . 55.7 Cg_exo -32.2 119.35 0.09 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 123.013 2.475 . . . . 0.0 112.145 179.701 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.989 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -116.82 -71.32 0.74 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.545 -179.298 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.905 ' CG2' HD13 ' A' ' 103' ' ' ILE . 1.6 p -93.69 105.32 16.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 121.159 0.504 . . . . 0.0 111.732 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.727 HG13 HG12 ' A' ' 82' ' ' ILE . 41.5 t -84.16 135.38 24.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.861 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.812 HD11 HD22 ' A' ' 115' ' ' LEU . 95.6 mt -133.64 135.63 55.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.362 -179.707 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.443 ' HB2' ' HD3' ' A' ' 136' ' ' LYS . 1.7 tt0 . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.18 -0.914 . . . . 0.0 110.871 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.695 ' O ' ' HB3' ' A' ' 76' ' ' ALA . . . . . . . . 0 N--CA 1.457 -0.123 0 CA-C-O 120.839 0.352 . . . . 0.0 111.101 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.695 ' HB3' ' O ' ' A' ' 75' ' ' ALA . . . 84.77 -11.95 0.76 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER 45.2 40.3 4.86 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.972 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.633 HG22 ' O ' ' A' ' 78' ' ' ILE . 2.6 mm -121.2 -0.27 7.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.404 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.466 ' C ' ' O ' ' A' ' 78' ' ' ILE . 5.7 t 30.12 42.58 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.235 179.832 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.473 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -83.09 159.22 37.25 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.774 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.621 ' C ' HD13 ' A' ' 82' ' ' ILE . 13.4 t-80 171.9 83.85 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.754 0.311 . . . . 0.0 110.582 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 1.034 HD12 HG13 ' A' ' 154' ' ' VAL . 0.0 OUTLIER -103.08 -178.42 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.97 0.414 . . . . 0.0 111.184 -179.995 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.809 HG23 HG13 ' A' ' 153' ' ' VAL . 11.3 t -130.41 32.45 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.763 179.696 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.556 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 4.7 ptt180 -30.41 119.92 0.18 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.283 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.48 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 0.7 OUTLIER -36.48 103.14 0.24 Allowed Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.94 -179.771 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -51.54 -22.58 12.89 Favored 'Trans proline' 0 N--CA 1.464 -0.226 0 C-N-CA 122.653 2.235 . . . . 0.0 112.052 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.0 ptm -141.56 -176.79 4.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.789 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.466 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 15.1 t -82.29 93.5 2.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.046 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -146.22 -141.42 3.61 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.587 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.725 HG23 ' C ' ' A' ' 144' ' ' GLN . 42.4 m -136.57 141.84 43.35 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.792 0.329 . . . . 0.0 111.023 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.866 ' HB2' HD22 ' A' ' 152' ' ' LEU . 0.8 OUTLIER -100.74 146.24 27.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.961 -179.981 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.582 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 16.5 m-85 -143.16 162.61 35.11 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.904 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.543 ' CD ' ' HB3' ' A' ' 142' ' ' SER . 9.5 ptm180 -139.75 31.53 2.04 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.874 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.493 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 68.7 p -145.74 122.15 5.92 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.507 ' HG2' ' CB ' ' A' ' 99' ' ' ALA . 55.7 Cg_endo -70.36 -21.48 30.65 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.701 2.268 . . . . 0.0 112.358 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 15.2 m -162.8 152.97 13.67 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.081 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_exo -49.63 -20.76 4.65 Favored 'Trans proline' 0 C--O 1.232 0.215 0 C-N-CA 122.8 2.333 . . . . 0.0 112.284 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -138.31 72.7 1.41 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.815 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.507 ' CB ' ' HG2' ' A' ' 95' ' ' PRO . . . -137.1 -154.87 0.57 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.197 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -113.15 36.51 3.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.846 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.493 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 62.06 -178.44 0.13 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.115 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.915 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -104.17 -37.13 7.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.866 -179.964 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.915 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.3 OUTLIER -178.18 146.62 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.11 179.992 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -146.75 162.72 37.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.854 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.625 HG22 ' HA ' ' A' ' 137' ' ' ALA . 14.4 t -45.07 134.87 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.193 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 94.43 -11.95 69.55 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.543 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.426 ' O ' ' N ' ' A' ' 109' ' ' VAL . 3.6 tp60 -77.2 95.67 4.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.838 0.351 . . . . 0.0 110.892 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.9 mtmt -64.39 74.24 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.963 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.638 HG11 ' CD2' ' A' ' 115' ' ' LEU . 17.7 m -54.6 167.87 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.014 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.489 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 3.4 p-10 -157.31 131.26 8.2 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 121.174 0.512 . . . . 0.0 110.83 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.452 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 26.1 t -34.69 136.04 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.092 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 86.87 11.83 69.76 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.337 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.418 ' O ' ' C ' ' A' ' 114' ' ' THR . 26.4 t70 -124.69 102.53 7.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.783 0.325 . . . . 0.0 110.867 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.418 ' C ' ' O ' ' A' ' 113' ' ' ASP . 1.6 m -35.52 113.02 0.18 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.154 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.638 ' CD2' HG11 ' A' ' 109' ' ' VAL . 19.2 mt -69.77 -87.53 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.648 179.734 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.727 ' HB3' HD11 ' A' ' 103' ' ' ILE . 9.1 p -135.32 -166.52 1.85 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.681 179.729 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.966 HD13 ' HB3' ' A' ' 124' ' ' MET . 1.7 mt -126.48 153.77 35.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.595 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.634 HG13 ' O ' ' A' ' 90' ' ' THR . 46.7 t -141.04 103.12 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.965 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.512 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.5 OUTLIER -62.04 69.96 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.118 -179.773 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.518 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -92.81 145.31 24.5 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.904 179.833 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.518 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 9.1 ptp 51.96 21.03 1.37 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.737 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.511 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 1.6 tmtt? 80.28 52.03 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.877 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.486 ' HG3' ' O ' ' A' ' 120' ' ' ALA . 0.2 OUTLIER -172.0 133.13 0.7 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.091 179.804 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.966 ' HB3' HD13 ' A' ' 117' ' ' ILE . 45.2 mtt -67.54 97.16 0.57 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.951 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -79.43 82.08 5.61 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.779 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.547 ' CA ' HG12 ' A' ' 117' ' ' ILE . 4.3 pt20 -58.28 107.71 0.52 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.863 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.467 ' N ' ' O ' ' A' ' 116' ' ' CYS . 7.3 mm -74.99 162.51 4.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.164 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.425 ' N ' HG22 ' A' ' 127' ' ' ILE . 1.6 tt0 -130.04 141.1 50.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.852 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.452 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -46.24 113.65 0.66 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.995 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.402 ' OD1' ' N ' ' A' ' 130' ' ' ASP . 0.4 OUTLIER -101.09 11.09 40.18 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.936 -179.952 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 14.7 tttt 169.99 117.39 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.836 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.489 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 34.8 p -44.25 111.15 0.27 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.781 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -145.96 -175.46 19.02 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.554 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.752 ' C ' HG23 ' A' ' 155' ' ' ILE . 20.7 m -129.54 109.38 10.98 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.645 0.26 . . . . 0.0 111.215 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.56 ' N ' HG23 ' A' ' 155' ' ' ILE . 95.5 t -43.29 143.64 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.626 -0.261 . . . . 0.0 110.364 179.474 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.711 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 1.3 mmmp? -123.72 -18.69 5.99 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.233 -179.55 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.711 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 162.79 164.31 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.888 0.375 . . . . 0.0 111.582 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.65 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -107.11 87.58 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.693 179.787 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.764 HD12 ' HB2' ' A' ' 151' ' ' PRO . 1.8 mt -43.0 -27.77 0.22 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.112 0.482 . . . . 0.0 110.437 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 1.037 HG21 HD23 ' A' ' 152' ' ' LEU . 55.6 t -106.64 140.4 24.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.924 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.522 ' O ' ' CG ' ' A' ' 144' ' ' GLN . 6.6 mt-10 -69.38 98.15 1.05 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.252 179.492 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.543 ' HB3' ' CD ' ' A' ' 93' ' ' ARG . 55.5 p -34.0 150.6 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.732 -179.469 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.582 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 67.33 35.86 88.4 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.383 -0.913 . . . . 0.0 112.149 -179.775 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.725 ' C ' HG23 ' A' ' 90' ' ' THR . 29.2 mm-40 -147.91 154.06 43.04 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 120.86 0.362 . . . . 0.0 111.103 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.693 ' O ' HG13 ' A' ' 146' ' ' VAL . 59.8 Cg_endo -72.29 173.67 12.69 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.823 2.349 . . . . 0.0 112.344 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.868 HG21 HD21 ' A' ' 152' ' ' LEU . 10.5 m -163.65 -173.74 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.071 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.528 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 6.3 pt-20 -140.16 174.08 10.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.966 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.48 ' HA ' ' O ' ' A' ' 85' ' ' SER . 17.1 t80 -50.19 147.59 4.07 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.881 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 53.94 33.36 17.16 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.918 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 19.7 tp10 -109.45 74.74 0.7 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.741 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.815 ' O ' HG23 ' A' ' 140' ' ' VAL . 69.7 Cg_exo -36.34 128.98 0.43 Allowed 'Trans proline' 0 N--CA 1.46 -0.487 0 C-N-CA 122.705 2.27 . . . . 0.0 111.794 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 1.037 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -122.22 -48.91 2.07 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 111.866 0.321 . . . . 0.0 111.866 -179.059 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.809 HG13 HG23 ' A' ' 83' ' ' VAL . 1.6 p -116.94 113.45 42.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 121.026 0.441 . . . . 0.0 111.423 -179.375 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 1.034 HG13 HD12 ' A' ' 82' ' ' ILE . 1.6 t -93.84 144.6 9.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.073 179.77 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.752 HG23 ' C ' ' A' ' 134' ' ' THR . 60.3 mt -144.18 141.86 24.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.146 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.52 ' HB2' ' CE ' ' A' ' 136' ' ' LYS . 15.7 tt0 . . . . . 0 C--O 1.251 1.16 0 CA-C-O 118.224 -0.893 . . . . 0.0 110.823 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.803 0.335 . . . . 0.0 111.078 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . 65.1 -175.7 0.18 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.157 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 15.5 mm-40 -120.54 144.06 48.26 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.87 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.434 HG22 ' O ' ' A' ' 78' ' ' ILE . 1.6 mp -137.7 24.27 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.13 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.7 m 48.81 47.63 21.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.012 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.446 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . 73.54 -133.82 18.28 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.623 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.676 ' CD2' ' HE2' ' A' ' 131' ' ' LYS . 14.6 t-80 170.38 86.12 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.799 0.333 . . . . 0.0 110.817 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.509 HG23 ' O ' ' A' ' 153' ' ' VAL . 0.3 OUTLIER -101.76 159.22 4.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 121.03 0.443 . . . . 0.0 111.176 -179.941 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.839 HG12 ' HB ' ' A' ' 153' ' ' VAL . 4.4 p -109.43 46.64 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.132 -179.855 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.498 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 7.4 ptt180 -31.0 136.64 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.247 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.566 ' N ' HD21 ' A' ' 152' ' ' LEU . 0.3 OUTLIER -43.34 106.42 0.49 Allowed Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.055 -179.734 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -56.71 -20.97 37.22 Favored 'Trans proline' 0 C--O 1.231 0.14 0 C-N-CA 122.736 2.29 . . . . 0.0 111.98 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -155.99 -175.7 5.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.855 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 3.5 m -82.78 76.32 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.168 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -129.96 -146.24 5.97 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.539 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.83 HG23 ' HA ' ' A' ' 145' ' ' PRO . 1.5 m -131.55 154.39 48.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.707 0.289 . . . . 0.0 110.904 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.937 ' CD2' HD12 ' A' ' 152' ' ' LEU . 0.3 OUTLIER -115.39 146.61 41.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.948 0.404 . . . . 0.0 111.25 -179.859 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.579 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 24.0 m-85 -144.04 164.96 29.11 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.862 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.671 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 16.6 ptt180 -149.73 21.92 0.9 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.713 179.8 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.459 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 72.6 p -147.14 86.11 6.63 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.866 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -67.95 -20.89 44.39 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.746 2.297 . . . . 0.0 112.39 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.845 ' OG ' ' HB2' ' A' ' 99' ' ' ALA . 0.0 OUTLIER -120.39 145.04 39.61 Favored Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.958 179.934 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_exo -50.7 -41.48 53.9 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.752 2.301 . . . . 0.0 112.344 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -134.16 60.42 1.7 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.845 ' HB2' ' OG ' ' A' ' 96' ' ' SER . . . -111.14 -169.9 1.54 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.096 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.427 ' N ' ' CD ' ' A' ' 100' ' ' LYS . 0.4 OUTLIER -93.71 24.64 3.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.833 179.984 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.671 ' HB1' ' O ' ' A' ' 93' ' ' ARG . . . 67.13 -178.37 0.21 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.061 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.72 ' O ' HD13 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -89.09 -59.27 2.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.591 179.79 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.936 HG22 HG21 ' A' ' 135' ' ' VAL . 24.6 mm -154.15 94.74 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.908 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -94.66 165.72 12.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.961 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.487 ' CG2' ' O ' ' A' ' 136' ' ' LYS . 2.1 p -53.58 101.62 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.066 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 141.11 -29.86 2.28 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.523 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.423 ' HA ' ' OE1' ' A' ' 107' ' ' GLN . 1.9 mp0 -72.04 121.17 18.73 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.782 0.325 . . . . 0.0 110.861 179.903 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 1.8 mttt -86.36 97.31 10.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.959 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.789 HG11 ' CD2' ' A' ' 115' ' ' LEU . 15.3 m -61.48 176.74 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.123 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.511 ' HA ' ' CB ' ' A' ' 132' ' ' SER . 66.0 m-20 -168.89 133.81 1.57 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.672 179.862 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.428 ' C ' ' O ' ' A' ' 110' ' ' ASN . 0.2 OUTLIER -35.14 123.79 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.128 179.89 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 91.65 21.12 35.08 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.444 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.43 ' O ' ' C ' ' A' ' 114' ' ' THR . 20.1 t0 -132.37 107.21 8.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.707 0.289 . . . . 0.0 110.87 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.537 ' CG2' ' HB2' ' A' ' 126' ' ' GLN . 2.4 m -34.16 132.9 0.24 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.025 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.789 ' CD2' HG11 ' A' ' 109' ' ' VAL . 18.0 mt -89.07 -83.0 0.24 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.992 -179.858 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 116' ' ' CYS . . . . . . . . . . . . . 19.0 p -135.91 -166.2 1.83 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.039 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.553 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.3 OUTLIER -113.58 114.49 46.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.21 -179.883 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.974 HG12 ' O ' ' A' ' 125' ' ' ASN . 9.1 p -103.49 58.26 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.831 179.746 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.486 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.5 OUTLIER -34.72 91.32 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.115 -179.778 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' A' ' 118' ' ' VAL . . . -108.4 145.77 34.05 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.009 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.473 ' HG2' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 46.85 24.86 0.39 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.574 -179.868 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.497 ' O ' ' CG ' ' A' ' 123' ' ' MET . 0.0 OUTLIER 79.33 50.21 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.886 -179.917 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.497 ' CG ' ' O ' ' A' ' 122' ' ' LYS . 40.5 mtp -162.28 125.56 2.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.081 179.798 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.553 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -60.28 77.96 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.994 179.947 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.974 ' O ' HG12 ' A' ' 118' ' ' VAL . 1.0 OUTLIER -70.54 73.65 0.53 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.754 179.919 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.537 ' HB2' ' CG2' ' A' ' 114' ' ' THR . 0.0 OUTLIER -50.22 131.59 23.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.015 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.55 HG22 ' N ' ' A' ' 128' ' ' GLU . 35.3 mm -94.03 161.64 2.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.08 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.55 ' N ' HG22 ' A' ' 127' ' ' ILE . 5.8 mt-10 -127.99 142.24 51.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.978 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -62.38 136.81 58.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.085 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -115.87 -8.02 11.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.035 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.676 ' HE2' ' CD2' ' A' ' 81' ' ' HIS . 0.3 OUTLIER -159.94 35.3 0.18 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.839 179.96 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.511 ' CB ' ' HA ' ' A' ' 110' ' ' ASN . 96.1 p 43.64 -171.7 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.767 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.548 ' N ' HG23 ' A' ' 109' ' ' VAL . . . 148.22 -156.84 27.09 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.54 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.541 ' N ' HG12 ' A' ' 155' ' ' ILE . 85.7 m -162.81 110.01 1.24 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.721 0.296 . . . . 0.0 110.91 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.936 HG21 HG22 ' A' ' 103' ' ' ILE . 70.1 t -47.21 144.13 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.893 0.378 . . . . 0.0 111.015 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.548 ' HD3' HG11 ' A' ' 154' ' ' VAL . 0.0 OUTLIER -114.83 -35.82 4.68 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 121.494 0.664 . . . . 0.0 109.451 -179.95 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.642 ' O ' HG23 ' A' ' 154' ' ' VAL . . . 179.65 136.65 0.11 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 114.97 -1.014 . . . . 0.0 111.052 -179.724 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.936 HG21 ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -88.92 85.38 2.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.927 0.394 . . . . 0.0 110.555 179.695 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.422 ' C ' ' O ' ' A' ' 138' ' ' ILE . 10.8 mt -37.16 -31.26 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.485 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.604 HG21 ' HB3' ' A' ' 152' ' ' LEU . 42.9 t -94.32 143.31 11.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.177 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.472 ' O ' ' HB3' ' A' ' 144' ' ' GLN . 27.3 mt-10 -77.59 105.36 8.69 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.917 179.235 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.539 ' HB3' ' CD ' ' A' ' 93' ' ' ARG . 24.4 p -34.45 135.82 0.16 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.765 -179.342 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.579 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 83.64 34.79 18.32 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.41 -0.9 . . . . 0.0 111.93 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.472 ' HB3' ' O ' ' A' ' 141' ' ' GLU . 1.0 OUTLIER -143.42 145.28 31.23 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 120.88 0.372 . . . . 0.0 110.976 -179.658 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.83 ' HA ' HG23 ' A' ' 90' ' ' THR . 57.2 Cg_endo -71.2 171.97 14.94 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.789 2.326 . . . . 0.0 112.204 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.548 ' CG2' ' HB2' ' A' ' 85' ' ' SER . 6.0 m -153.44 -165.12 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.192 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.517 ' O ' ' CG ' ' A' ' 150' ' ' GLU . 3.3 mt-10 -146.03 157.88 43.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.043 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.469 ' HA ' ' O ' ' A' ' 85' ' ' SER . 3.4 t80 -47.39 135.05 11.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.912 179.949 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.416 ' N ' ' CD1' ' A' ' 148' ' ' PHE . 58.1 t0 67.4 34.8 4.57 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.939 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.565 ' O ' HD23 ' A' ' 152' ' ' LEU . 14.6 mm-40 -115.29 75.43 4.48 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.857 179.769 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.498 ' HA ' ' HA ' ' A' ' 84' ' ' ARG . 71.2 Cg_exo -36.61 125.53 0.41 Allowed 'Trans proline' 0 N--CA 1.459 -0.528 0 C-N-CA 122.75 2.3 . . . . 0.0 111.637 179.51 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.937 HD12 ' CD2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -129.29 -36.24 1.72 Allowed 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 120.962 0.411 . . . . 0.0 110.98 -179.005 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.839 ' HB ' HG12 ' A' ' 83' ' ' VAL . 1.3 t -115.99 109.46 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.347 -178.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.642 HG23 ' O ' ' A' ' 137' ' ' ALA . 1.4 t -98.46 119.04 45.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.612 179.429 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.541 HG12 ' N ' ' A' ' 134' ' ' THR . 0.0 OUTLIER -110.1 154.66 11.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.863 -179.772 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.467 ' N ' ' O ' ' A' ' 134' ' ' THR . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.241 -0.885 . . . . 0.0 110.939 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' A' ' 76' ' ' ALA . . . . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.83 0.347 . . . . 0.0 111.132 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' A' ' 75' ' ' ALA . . . 37.3 -158.02 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.071 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.435 ' H ' HD12 ' A' ' 78' ' ' ILE . 0.5 OUTLIER -128.73 27.26 5.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.816 179.985 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.584 HG22 ' O ' ' A' ' 78' ' ' ILE . 3.4 mp -142.78 21.35 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.083 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 78' ' ' ILE . 35.4 t 35.93 46.57 0.36 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.951 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 63.46 -139.7 44.02 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.469 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.49 ' N ' ' O ' ' A' ' 155' ' ' ILE . 35.5 t-80 -178.87 79.79 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.802 0.334 . . . . 0.0 110.874 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 1.069 HD12 HG13 ' A' ' 154' ' ' VAL . 0.2 OUTLIER -92.04 -176.14 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.031 179.845 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.859 HG23 HG13 ' A' ' 153' ' ' VAL . 2.1 t -142.02 41.56 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.859 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.537 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -33.84 132.81 0.22 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.088 -179.845 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.985 ' OG ' HD21 ' A' ' 152' ' ' LEU . 1.5 m -44.44 103.91 0.36 Allowed Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.903 -179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_exo -50.98 -20.04 6.56 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.586 2.191 . . . . 0.0 112.064 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.621 ' SD ' ' HB1' ' A' ' 120' ' ' ALA . 14.9 ptm -150.34 166.73 29.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.681 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.47 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 1.5 p -68.14 95.9 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.004 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -147.56 -133.0 2.31 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.579 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.672 HG23 ' C ' ' A' ' 144' ' ' GLN . 24.3 m -140.43 151.19 44.7 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.831 0.348 . . . . 0.0 110.884 -179.889 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.776 ' CB ' HD22 ' A' ' 152' ' ' LEU . 0.4 OUTLIER -118.22 151.47 37.56 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.828 179.953 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.581 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 23.4 m-85 -147.24 168.76 20.91 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.789 -0.642 . . . . 0.0 111.0 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.468 ' O ' ' N ' ' A' ' 102' ' ' PHE . 0.0 OUTLIER -135.66 18.07 3.32 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.688 179.742 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.622 ' O ' HD11 ' A' ' 117' ' ' ILE . 2.1 p -132.6 108.73 13.24 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.815 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.59 ' HG3' ' CD1' ' A' ' 102' ' ' PHE . 51.8 Cg_exo -53.72 -18.06 11.43 Favored 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.743 2.296 . . . . 0.0 112.3 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.408 ' CB ' ' HD2' ' A' ' 97' ' ' PRO . 0.4 OUTLIER -178.96 167.95 0.88 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.902 -179.963 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.515 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 59.2 Cg_endo -72.29 113.77 3.8 Favored 'Trans proline' 0 N--CA 1.464 -0.215 0 C-N-CA 122.735 2.29 . . . . 0.0 112.361 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.515 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 0.6 OUTLIER 85.15 49.96 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.914 179.934 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -125.88 -163.58 1.23 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.093 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 1.2 mtpp -101.15 38.05 1.64 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.9 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.414 ' C ' ' HD3' ' A' ' 95' ' ' PRO . . . 54.15 175.76 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.084 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.909 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -100.75 -34.56 9.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.945 179.952 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.909 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.3 OUTLIER -179.05 144.04 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.035 179.922 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.471 ' O ' HG11 ' A' ' 135' ' ' VAL . 2.3 mt-10 -146.33 148.33 32.27 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.948 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.529 HG22 ' HA ' ' A' ' 137' ' ' ALA . 3.9 t -35.36 123.82 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.109 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 111.48 -24.97 14.36 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.323 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.65 ' O ' HG12 ' A' ' 135' ' ' VAL . 22.4 tp60 -82.25 117.24 22.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.784 0.326 . . . . 0.0 110.814 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 134' ' ' THR . 0.0 OUTLIER -81.69 100.0 9.23 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.037 -179.885 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.651 HG11 ' CD2' ' A' ' 115' ' ' LEU . 7.7 m -59.27 176.09 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.019 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.432 ' CG ' ' O ' ' A' ' 109' ' ' VAL . 21.3 m120 -163.15 131.31 3.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.036 0.446 . . . . 0.0 110.766 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.517 ' CG1' ' HA ' ' A' ' 131' ' ' LYS . 33.2 m -35.42 138.4 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.011 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 80.74 16.42 75.39 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.333 -179.791 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -124.41 102.62 7.75 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.865 0.364 . . . . 0.0 110.848 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.703 HG23 ' HB2' ' A' ' 126' ' ' GLN . 9.0 m -40.54 110.77 0.16 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.022 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.651 ' CD2' HG11 ' A' ' 109' ' ' VAL . 20.6 mt -65.96 -87.42 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.802 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.549 ' SG ' HG11 ' A' ' 153' ' ' VAL . 0.8 OUTLIER -124.7 -171.28 2.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.768 179.904 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.622 HD11 ' O ' ' A' ' 94' ' ' THR . 0.3 OUTLIER -106.01 113.57 43.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.203 -179.932 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.761 ' O ' HG12 ' A' ' 118' ' ' VAL . 75.7 t -97.3 59.22 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.036 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.475 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.4 OUTLIER -39.1 90.76 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.039 -179.798 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.621 ' HB1' ' SD ' ' A' ' 87' ' ' MET . . . -110.55 144.6 39.15 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.958 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.5 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.1 OUTLIER 56.2 17.03 2.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.892 -179.917 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.5 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.6 OUTLIER 83.41 53.4 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.925 -179.995 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.481 ' HG2' ' O ' ' A' ' 120' ' ' ALA . 3.1 ptt? -173.07 133.45 0.53 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.991 179.769 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.536 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -53.04 96.14 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.019 179.945 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.425 ' O ' ' C ' ' A' ' 126' ' ' GLN . 4.2 t30 -88.18 65.18 8.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.847 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.703 ' HB2' HG23 ' A' ' 114' ' ' THR . 0.0 OUTLIER -35.12 154.46 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.065 -179.857 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.542 HG12 HG23 ' A' ' 118' ' ' VAL . 47.0 mm -121.97 120.3 61.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.22 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 58.4 mm-40 -83.11 119.77 24.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.777 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.453 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -41.61 114.39 0.51 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.164 -179.88 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -74.76 -27.0 60.16 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.721 179.878 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.517 ' HA ' ' CG1' ' A' ' 111' ' ' VAL . 0.0 OUTLIER -165.05 136.13 4.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.812 179.954 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.428 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.2 t -45.84 132.75 8.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.79 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.513 ' O ' ' N ' ' A' ' 109' ' ' VAL . . . -159.03 176.44 35.85 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.604 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.865 ' C ' HG23 ' A' ' 155' ' ' ILE . 13.8 m -122.88 108.21 12.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.663 0.268 . . . . 0.0 111.263 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.65 HG12 ' O ' ' A' ' 107' ' ' GLN . 2.8 p -49.16 144.68 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.517 -0.311 . . . . 0.0 110.566 179.515 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.662 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 1.1 mmmp? -124.14 -19.24 5.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.632 0.253 . . . . 0.0 111.234 -179.553 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.662 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 166.3 163.23 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.843 0.354 . . . . 0.0 111.433 -179.779 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.641 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.1 OUTLIER -105.23 85.46 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.74 179.626 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.721 HD13 ' HB2' ' A' ' 151' ' ' PRO . 12.4 mt -42.49 -28.03 0.19 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.969 0.414 . . . . 0.0 110.231 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 1.038 HG21 HD23 ' A' ' 152' ' ' LEU . 52.2 t -104.59 141.81 19.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.78 179.593 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 142' ' ' SER . 6.5 mt-10 -69.75 97.12 1.04 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.58 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.461 ' HB2' ' HD2' ' A' ' 93' ' ' ARG . 0.3 OUTLIER -36.93 135.22 0.46 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.627 -179.957 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.581 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 85.81 38.09 8.96 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.534 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.672 ' C ' HG23 ' A' ' 90' ' ' THR . 4.1 pt20 -155.64 163.61 24.08 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.884 0.373 . . . . 0.0 111.155 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.912 ' O ' HG13 ' A' ' 146' ' ' VAL . 55.4 Cg_endo -70.47 -168.78 0.32 Allowed 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.762 2.308 . . . . 0.0 112.646 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.918 HG11 HD23 ' A' ' 152' ' ' LEU . 0.2 OUTLIER -175.72 -174.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.965 -179.982 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.47 ' HA ' ' HA ' ' A' ' 88' ' ' VAL . 4.0 mt-10 -145.6 157.37 43.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.933 0.396 . . . . 0.0 111.089 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.446 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 1.2 t80 -42.94 125.13 3.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.946 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.446 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 2.4 t0 79.61 31.95 0.24 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.951 0.405 . . . . 0.0 110.606 -179.804 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.726 ' HG2' HG12 ' A' ' 146' ' ' VAL . 44.1 tp10 -111.03 74.99 1.05 Allowed Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.879 179.861 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.812 ' O ' HG23 ' A' ' 140' ' ' VAL . 63.3 Cg_exo -35.93 122.75 0.27 Allowed 'Trans proline' 0 N--CA 1.459 -0.508 0 C-N-CA 122.812 2.341 . . . . 0.0 112.084 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 1.038 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -116.66 -54.09 2.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.619 -179.208 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.859 HG13 HG23 ' A' ' 83' ' ' VAL . 1.3 p -108.07 108.72 25.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.121 0.486 . . . . 0.0 111.339 -179.262 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 1.069 HG13 HD12 ' A' ' 82' ' ' ILE . 6.0 t -91.14 138.96 18.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.976 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.865 HG23 ' C ' ' A' ' 134' ' ' THR . 37.3 mt -141.3 141.1 31.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.18 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.52 ' HB2' ' CG ' ' A' ' 136' ' ' LYS . 10.6 tt0 . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.248 -0.882 . . . . 0.0 110.877 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.791 0.329 . . . . 0.0 111.094 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -68.87 173.07 5.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.044 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 71.22 152.34 0.11 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.819 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.458 HD12 ' HA ' ' A' ' 78' ' ' ILE . 2.2 tp -79.92 -1.23 4.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.116 0.484 . . . . 0.0 111.41 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.444 ' O ' ' OE2' ' A' ' 156' ' ' GLU . 0.1 OUTLIER 47.26 35.77 4.09 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.966 179.905 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -160.1 -147.06 4.78 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.422 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.486 ' N ' ' O ' ' A' ' 155' ' ' ILE . 34.6 t-80 -172.52 77.62 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.806 0.336 . . . . 0.0 110.925 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.907 HG12 HG13 ' A' ' 154' ' ' VAL . 10.2 mt -99.22 150.92 4.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.955 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.81 HG23 HG13 ' A' ' 153' ' ' VAL . 4.5 t -96.91 59.93 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.15 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.492 ' O ' ' N ' ' A' ' 86' ' ' PRO . 4.2 mmt85 -28.88 103.3 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.025 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.946 ' CA ' HD11 ' A' ' 152' ' ' LEU . 0.4 OUTLIER -32.12 91.95 0.05 OUTLIER Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.251 -179.789 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.878 ' HD2' HG11 ' A' ' 118' ' ' VAL . 77.5 Cg_exo -50.22 140.21 34.01 Favored 'Trans proline' 0 N--CA 1.464 -0.25 0 C-N-CA 122.755 2.303 . . . . 0.0 112.058 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.458 ' O ' ' O ' ' A' ' 86' ' ' PRO . 7.6 ptm 41.22 -167.09 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.465 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.648 HG22 ' CG ' ' A' ' 147' ' ' GLU . 72.5 t -90.32 114.49 28.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.783 0.325 . . . . 0.0 111.208 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -165.02 -164.11 19.69 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.537 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.749 HG23 ' CA ' ' A' ' 145' ' ' PRO . 1.9 m -115.48 151.56 34.58 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.853 0.359 . . . . 0.0 110.901 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.948 ' HB2' HD22 ' A' ' 152' ' ' LEU . 2.9 t80 -110.78 141.96 43.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.954 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.583 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 21.0 m-85 -142.41 157.49 44.72 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.808 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.519 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 1.7 ptm180 -134.39 20.88 3.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.398 179.568 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.583 ' O ' HD11 ' A' ' 117' ' ' ILE . 69.2 p -123.05 121.84 27.09 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.694 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.433 ' HG2' ' HB3' ' A' ' 99' ' ' ALA . 50.8 Cg_exo -53.07 -59.76 0.93 Allowed 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.685 2.257 . . . . 0.0 112.336 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.581 ' CB ' ' CD ' ' A' ' 97' ' ' PRO . 0.9 OUTLIER 170.99 -66.04 0.0 OUTLIER Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 121.191 0.519 . . . . 0.0 111.106 179.869 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.581 ' CD ' ' CB ' ' A' ' 96' ' ' SER . 46.5 Cg_endo -68.94 53.6 0.81 Allowed 'Trans proline' 0 C--N 1.333 -0.268 0 C-N-CA 123.37 2.713 . . . . 0.0 112.496 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.432 ' C ' ' O ' ' A' ' 97' ' ' PRO . 4.5 p30 35.18 45.2 0.18 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.033 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.433 ' HB3' ' HG2' ' A' ' 95' ' ' PRO . . . -71.68 -160.13 0.05 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.087 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.57 ' O ' ' HB3' ' A' ' 101' ' ' ALA . 0.4 OUTLIER -90.77 27.48 1.77 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.842 179.921 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.57 ' HB3' ' O ' ' A' ' 100' ' ' LYS . . . 75.68 155.85 0.17 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.071 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.666 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -69.11 -37.51 78.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.49 179.885 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.666 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.9 pp -163.34 157.67 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.934 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -154.79 147.57 24.41 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.056 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.736 HG23 ' HA ' ' A' ' 136' ' ' LYS . 2.0 p -44.2 109.4 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.05 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 126.38 -18.07 6.5 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.397 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -85.48 106.37 16.77 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.842 0.353 . . . . 0.0 110.867 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' A' ' 109' ' ' VAL . 2.4 mttp -67.03 79.53 0.12 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.908 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.71 HG22 ' O ' ' A' ' 133' ' ' GLY . 22.1 m -45.8 175.55 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.109 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.445 ' HA ' ' HB2' ' A' ' 132' ' ' SER . 1.7 p-10 -165.27 135.02 3.58 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 121.026 0.441 . . . . 0.0 110.742 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.468 ' HA ' ' HB3' ' A' ' 129' ' ' ALA . 20.2 t -34.82 137.24 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 115.711 -0.677 . . . . 0.0 111.077 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 81.31 16.22 74.61 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.414 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 114' ' ' THR . 9.0 t0 -122.54 101.71 7.64 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.814 0.34 . . . . 0.0 110.952 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.451 ' HA ' ' O ' ' A' ' 127' ' ' ILE . 1.5 m -35.4 108.7 0.07 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.898 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.51 ' N ' ' O ' ' A' ' 127' ' ' ILE . 14.7 mt -62.24 -67.04 0.45 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.791 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.498 ' SG ' ' N ' ' A' ' 117' ' ' ILE . 2.5 p -162.46 -154.47 0.31 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.942 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.583 HD11 ' O ' ' A' ' 94' ' ' THR . 0.1 OUTLIER -122.23 119.37 58.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.282 -179.85 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.878 HG11 ' HD2' ' A' ' 86' ' ' PRO . 2.4 t -109.21 58.46 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.801 179.644 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.486 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.4 OUTLIER -34.74 104.11 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.165 -179.703 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.524 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -121.81 108.91 14.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.995 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.532 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 86.16 17.8 0.11 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.676 -179.802 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.541 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 5.0 tmtm? 87.61 26.58 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.861 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.486 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 1.1 mmm -139.85 124.81 18.56 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.927 0.394 . . . . 0.0 111.157 179.768 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.554 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -55.55 102.97 0.08 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.875 179.762 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.449 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 9.8 t30 -84.78 65.21 9.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.813 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.439 ' HA ' ' O ' ' A' ' 116' ' ' CYS . 6.7 pt20 -45.79 118.99 2.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.96 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.547 HD11 HG21 ' A' ' 118' ' ' VAL . 3.7 mm -94.2 151.66 3.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.005 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -126.65 130.45 50.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.922 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.468 ' HB3' ' HA ' ' A' ' 111' ' ' VAL . . . -42.44 134.07 3.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.111 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.446 ' OD1' ' O ' ' A' ' 130' ' ' ASP . 10.5 t70 -118.44 -0.24 11.47 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.076 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.458 ' O ' ' O ' ' A' ' 132' ' ' SER . 1.3 ptmt -170.73 29.61 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.941 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.458 ' O ' ' O ' ' A' ' 131' ' ' LYS . 0.9 OUTLIER 47.38 -179.52 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.743 -179.815 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.71 ' O ' HG22 ' A' ' 109' ' ' VAL . . . 152.01 174.19 22.42 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.625 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.711 ' N ' HG23 ' A' ' 155' ' ' ILE . 27.5 m -120.94 110.68 16.58 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.553 0.216 . . . . 0.0 111.235 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.545 ' HA ' ' CG1' ' A' ' 155' ' ' ILE . 61.3 t -49.77 145.66 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.63 -0.259 . . . . 0.0 110.32 179.461 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.736 ' HA ' HG23 ' A' ' 105' ' ' VAL . 50.9 mmtt -125.38 -18.04 5.44 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 121.049 -0.26 . . . . 0.0 111.643 -179.417 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.696 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 164.66 153.46 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.927 0.394 . . . . 0.0 111.857 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.737 ' N ' HD13 ' A' ' 138' ' ' ILE . 0.0 OUTLIER -95.7 77.9 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.419 179.499 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.739 HD12 HG22 ' A' ' 154' ' ' VAL . 3.9 mt -38.44 -30.86 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.118 0.485 . . . . 0.0 110.223 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.94 HG21 HD23 ' A' ' 152' ' ' LEU . 55.3 t -102.93 138.32 27.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.818 179.725 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.518 ' O ' ' CG ' ' A' ' 144' ' ' GLN . 1.7 mt-10 -68.92 106.5 2.75 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.385 179.801 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.507 ' HB3' ' CG ' ' A' ' 93' ' ' ARG . 6.3 p -36.41 152.07 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.697 -179.554 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.583 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 56.99 43.86 92.97 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.395 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.595 ' C ' HG23 ' A' ' 90' ' ' THR . 61.6 mm-40 -147.39 137.95 12.71 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.895 0.378 . . . . 0.0 111.245 -179.769 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.749 ' CA ' HG23 ' A' ' 90' ' ' THR . 57.1 Cg_endo -70.64 156.18 61.55 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.691 2.261 . . . . 0.0 112.266 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.923 HG21 HD21 ' A' ' 152' ' ' LEU . 4.1 m -152.24 -156.51 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.208 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.648 ' CG ' HG22 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -147.57 174.31 11.87 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.95 -179.943 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.444 ' HA ' ' O ' ' A' ' 85' ' ' SER . 25.4 t80 -53.84 150.81 7.12 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.87 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.418 ' O ' ' HD3' ' A' ' 151' ' ' PRO . 84.1 m-20 60.2 23.6 12.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.928 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.477 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 4.6 tt0 -107.17 74.51 0.4 Allowed Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.815 179.738 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.854 ' O ' HG23 ' A' ' 140' ' ' VAL . 62.9 Cg_exo -35.51 127.92 0.3 Allowed 'Trans proline' 0 N--CA 1.459 -0.542 0 C-N-CA 122.996 2.464 . . . . 0.0 112.5 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.948 HD22 ' HB2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -120.89 -59.97 1.69 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.273 -179.729 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.81 HG13 HG23 ' A' ' 83' ' ' VAL . 1.4 p -102.93 101.88 12.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.202 -179.663 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.907 HG13 HG12 ' A' ' 82' ' ' ILE . 17.0 t -87.11 136.0 23.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.811 -0.632 . . . . 0.0 111.292 179.844 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.711 HG23 ' N ' ' A' ' 134' ' ' THR . 22.8 mt -140.34 139.85 35.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.049 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.528 ' HB3' ' CE ' ' A' ' 136' ' ' LYS . 6.0 tp10 . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.243 -0.884 . . . . 0.0 110.841 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.782 0.325 . . . . 0.0 111.125 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . 61.2 121.18 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.092 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER 66.01 -175.29 0.18 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.943 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.488 HD12 ' N ' ' A' ' 78' ' ' ILE . 1.3 mp -131.05 23.76 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.071 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 68.15 93.87 0.07 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.002 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.443 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -124.0 -142.93 6.11 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.517 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.449 ' N ' ' O ' ' A' ' 155' ' ' ILE . 20.6 t-80 171.89 83.94 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.896 0.379 . . . . 0.0 110.964 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.826 HG12 HG13 ' A' ' 154' ' ' VAL . 6.8 mt -100.67 147.05 8.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.017 0.436 . . . . 0.0 110.999 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.845 HG23 HG13 ' A' ' 153' ' ' VAL . 3.5 t -93.36 45.31 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.993 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.474 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -34.61 127.39 0.48 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.8 -179.978 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.511 ' OG ' HG23 ' A' ' 146' ' ' VAL . 5.3 t -34.83 107.68 0.32 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.956 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -63.74 -20.95 69.64 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.791 2.327 . . . . 0.0 111.945 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 9.9 ptp -154.37 172.59 17.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.781 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.701 ' O ' HG23 ' A' ' 88' ' ' VAL . 30.7 m -66.7 87.71 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.057 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.58 ' O ' HG22 ' A' ' 146' ' ' VAL . . . -147.82 -161.16 9.33 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.635 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.654 ' CG2' ' CE1' ' A' ' 92' ' ' TYR . 5.3 m -117.48 140.6 49.39 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.893 0.378 . . . . 0.0 111.124 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.958 ' HB2' HD22 ' A' ' 152' ' ' LEU . 14.4 t80 -89.3 143.02 27.15 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.269 179.453 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.654 ' CE1' ' CG2' ' A' ' 90' ' ' THR . 18.5 m-85 -139.91 148.81 42.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.888 0.375 . . . . 0.0 111.22 -179.521 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.466 ' O ' ' N ' ' A' ' 102' ' ' PHE . 0.7 OUTLIER -135.11 13.18 3.58 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.809 179.818 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 52.5 p -141.49 110.3 6.28 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.954 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.1 -39.45 5.85 Favored 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 122.725 2.283 . . . . 0.0 112.414 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -129.72 148.98 71.66 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.92 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.33 -34.74 71.96 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.693 2.262 . . . . 0.0 112.294 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -118.63 42.46 2.75 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.856 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -100.26 -154.86 0.49 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.094 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.19 36.78 4.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.863 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.461 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 56.67 165.67 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.117 179.846 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.912 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -89.22 -34.63 16.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.964 179.994 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.912 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.2 OUTLIER 176.49 127.34 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.104 -179.912 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.84 165.6 17.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.807 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.542 ' HA ' HG12 ' A' ' 135' ' ' VAL . 1.9 p -44.28 119.59 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.927 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 114.25 -14.05 21.12 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.374 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.494 ' HG3' HG22 ' A' ' 103' ' ' ILE . 2.4 mm-40 -74.26 126.02 29.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.827 0.346 . . . . 0.0 110.887 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.0 74.03 5.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.855 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.475 HG23 ' H ' ' A' ' 133' ' ' GLY . 22.1 m -47.14 172.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.984 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.474 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 27.2 m120 -163.95 131.13 3.31 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.022 0.439 . . . . 0.0 110.72 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.517 HG23 ' O ' ' A' ' 111' ' ' VAL . 33.8 m -35.54 118.72 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.022 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 100.91 15.51 28.47 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.317 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.471 ' HB2' ' O ' ' A' ' 110' ' ' ASN . 0.3 OUTLIER -125.2 103.92 8.23 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.854 0.359 . . . . 0.0 110.669 179.993 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.549 ' CG2' ' HB3' ' A' ' 126' ' ' GLN . 2.3 m -33.92 122.14 0.46 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.149 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.477 ' O ' HG12 ' A' ' 103' ' ' ILE . 15.1 mt -78.24 -86.08 0.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.929 179.959 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.56 ' SG ' HG11 ' A' ' 153' ' ' VAL . 0.5 OUTLIER -135.04 -174.33 3.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.101 -179.904 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 1.028 HG22 ' CB ' ' A' ' 124' ' ' MET . 0.1 OUTLIER -104.86 129.45 57.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.016 -179.954 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 124' ' ' MET . 6.0 t -123.06 100.89 8.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.591 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.577 ' HG2' ' CE2' ' A' ' 92' ' ' TYR . 1.0 OUTLIER -100.16 117.71 34.98 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.522 179.571 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.523 ' O ' ' CB ' ' A' ' 121' ' ' MET . . . -112.55 47.27 1.1 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.468 -179.512 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.523 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 6.1 ptm 155.13 -39.42 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.267 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.497 ' HD2' ' HG2' ' A' ' 123' ' ' MET . 0.0 OUTLIER 172.48 -28.44 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.042 -179.971 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.528 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.8 OUTLIER -97.61 127.27 43.43 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.945 179.498 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 124' ' ' MET . . . . . 1.028 ' CB ' HG22 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -93.94 153.62 18.12 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.366 -179.249 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.508 ' O ' ' N ' ' A' ' 127' ' ' ILE . 59.5 t-20 -114.04 101.92 9.68 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.192 179.617 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.549 ' HB3' ' CG2' ' A' ' 114' ' ' THR . 0.7 OUTLIER -62.65 69.23 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.786 -179.721 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.508 ' N ' ' O ' ' A' ' 125' ' ' ASN . 26.1 mm -37.06 147.28 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.132 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.41 ' O ' ' C ' ' A' ' 129' ' ' ALA . 10.2 pt-20 -116.03 128.73 55.95 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.755 179.858 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -35.48 116.15 0.35 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.238 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -87.3 -12.61 46.01 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.739 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.477 ' HG3' ' O ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -174.28 126.52 0.34 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.764 179.96 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.474 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 8.0 t -41.83 124.87 2.71 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.779 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.475 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -152.21 176.01 30.66 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.548 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.738 ' C ' HG23 ' A' ' 155' ' ' ILE . 13.1 m -125.15 108.26 11.6 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.701 0.286 . . . . 0.0 111.288 -179.828 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.542 HG12 ' HA ' ' A' ' 105' ' ' VAL . 19.0 t -44.2 144.97 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.624 179.435 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.708 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 21.3 mtpt -123.7 -18.49 6.07 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.225 -179.567 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.708 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 163.11 161.56 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.976 0.417 . . . . 0.0 111.631 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.641 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.6 OUTLIER -111.93 85.0 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.894 179.753 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.632 HD12 ' HB2' ' A' ' 151' ' ' PRO . 8.5 mt -49.12 -38.35 24.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.99 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 1.004 HG21 HD23 ' A' ' 152' ' ' LEU . 49.2 t -83.6 143.7 11.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.146 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.485 ' O ' ' C ' ' A' ' 142' ' ' SER . 17.2 mt-10 -74.5 78.15 1.94 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.06 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.502 ' HA ' ' CE2' ' A' ' 91' ' ' PHE . 11.6 p 21.77 -114.56 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 115.285 -0.871 . . . . 0.0 111.815 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.584 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -62.81 80.84 0.03 OUTLIER Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.839 -0.696 . . . . 0.0 113.043 -179.794 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.479 ' O ' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -157.56 144.15 13.12 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-O 121.078 0.466 . . . . 0.0 111.435 179.593 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.433 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 27.6 Cg_endo -62.4 151.57 81.98 Favored 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.974 2.449 . . . . 0.0 112.546 -179.792 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.734 HG11 ' CD2' ' A' ' 152' ' ' LEU . 18.3 m -143.93 -173.16 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.883 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.437 ' O ' ' C ' ' A' ' 148' ' ' PHE . 0.1 OUTLIER -150.26 149.64 30.43 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.899 179.992 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.499 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 2.0 t80 -34.33 124.15 0.5 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.822 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.499 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 17.4 t0 83.94 27.14 0.09 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.593 -179.607 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.416 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 44.0 tp10 -110.33 73.73 0.79 Allowed Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.908 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.811 ' O ' HG23 ' A' ' 140' ' ' VAL . 68.6 Cg_exo -34.18 127.59 0.18 Allowed 'Trans proline' 0 N--CA 1.459 -0.559 0 C-N-CA 122.825 2.35 . . . . 0.0 112.044 179.681 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 1.004 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -122.46 -64.98 1.14 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.525 -179.425 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.845 HG13 HG23 ' A' ' 83' ' ' VAL . 1.6 p -103.92 102.89 14.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.254 -179.469 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.826 HG13 HG12 ' A' ' 82' ' ' ILE . 10.3 t -83.47 142.67 13.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 115.76 -0.654 . . . . 0.0 111.275 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.738 HG23 ' C ' ' A' ' 134' ' ' THR . 27.5 mt -144.48 141.47 23.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.994 179.858 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.545 ' CA ' ' HD2' ' A' ' 136' ' ' LYS . 3.0 tt0 . . . . . 0 C--O 1.249 1.036 0 CA-C-O 118.283 -0.865 . . . . 0.0 110.919 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.753 0.311 . . . . 0.0 111.148 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -173.9 73.9 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.108 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -118.52 116.09 25.94 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.901 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.449 ' O ' ' O ' ' A' ' 79' ' ' SER . 0.9 OUTLIER -80.55 -11.85 12.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.277 -179.975 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.449 ' O ' ' O ' ' A' ' 78' ' ' ILE . 0.3 OUTLIER 33.87 -154.46 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.107 179.934 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.457 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -135.02 -123.27 2.32 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.442 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.587 ' CD2' ' HE3' ' A' ' 131' ' ' LYS . 17.1 t-80 172.53 84.19 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.788 0.328 . . . . 0.0 110.983 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.748 HG12 HG13 ' A' ' 154' ' ' VAL . 29.8 mt -92.26 116.62 33.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.07 0.462 . . . . 0.0 110.836 179.727 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.966 HG21 HD13 ' A' ' 115' ' ' LEU . 2.0 t -69.85 59.79 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.244 -179.701 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.532 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -47.53 135.08 11.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.725 179.823 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.511 ' HB3' HD21 ' A' ' 152' ' ' LEU . 1.3 p -39.3 104.63 0.32 Allowed Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.996 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 37.4 Cg_endo -66.18 -7.18 16.51 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.656 2.237 . . . . 0.0 112.018 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.453 ' HG3' ' CB ' ' A' ' 120' ' ' ALA . 2.0 ptm -155.72 168.3 27.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.641 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 7.1 m -71.87 60.16 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.124 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.652 ' O ' HG22 ' A' ' 146' ' ' VAL . . . -116.96 -165.69 13.93 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.454 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.635 HG23 ' C ' ' A' ' 144' ' ' GLN . 24.4 m -108.99 156.92 19.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.987 0.422 . . . . 0.0 111.024 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.684 ' CZ ' HG21 ' A' ' 138' ' ' ILE . 11.9 t80 -106.77 140.68 39.22 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.263 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.578 ' CD2' ' OE1' ' A' ' 119' ' ' GLU . 17.6 m-85 -143.13 151.09 40.32 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.971 0.415 . . . . 0.0 111.063 179.607 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.713 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 18.2 ptt180 -132.11 23.92 4.54 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.663 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.473 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 63.5 p -150.57 107.11 3.1 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.868 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.21 -16.11 31.68 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.651 2.234 . . . . 0.0 112.221 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -142.93 159.64 55.77 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.918 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -53.32 -63.33 0.24 Allowed 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.806 2.337 . . . . 0.0 112.341 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -110.99 79.79 1.24 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.876 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -135.2 -166.91 1.91 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.102 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.09 38.09 1.27 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.928 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.713 ' HB1' ' O ' ' A' ' 93' ' ' ARG . . . 49.39 -177.18 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.239 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.852 ' O ' HD13 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -90.11 -61.44 1.68 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.126 179.55 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.852 HD13 ' O ' ' A' ' 102' ' ' PHE . 2.2 mm -153.52 145.03 14.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.7 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -147.45 162.84 38.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.738 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.494 HG13 ' HA ' ' A' ' 136' ' ' LYS . 6.0 t -47.32 119.68 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.995 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 120.15 -27.04 6.86 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.249 -179.71 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.83 112.49 18.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.759 0.314 . . . . 0.0 110.807 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.465 ' O ' ' O ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -79.49 81.83 5.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.843 179.998 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.897 HG22 ' O ' ' A' ' 133' ' ' GLY . 14.7 m -45.28 176.11 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.003 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.432 ' HA ' ' HB2' ' A' ' 132' ' ' SER . 73.3 m-80 -163.19 131.1 3.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.615 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.524 ' HA ' ' HB3' ' A' ' 129' ' ' ALA . 2.3 p -37.58 155.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.968 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.437 ' N ' HG22 ' A' ' 111' ' ' VAL . . . 75.78 -0.08 62.6 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.339 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.464 ' O ' ' HA ' ' A' ' 128' ' ' GLU . 2.5 t0 -107.17 -149.53 0.43 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.691 0.282 . . . . 0.0 110.689 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.76 HG21 ' CZ ' ' A' ' 102' ' ' PHE . 6.1 m -135.73 150.4 49.51 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.89 0.376 . . . . 0.0 111.012 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.966 HD13 HG21 ' A' ' 83' ' ' VAL . 83.0 mt -106.81 -79.74 0.57 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.892 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 116' ' ' CYS . . . . . . . . . . . . . 14.9 p -134.51 -166.1 1.76 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.97 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 1.024 HG22 ' OE2' ' A' ' 119' ' ' GLU . 0.3 OUTLIER -115.01 125.22 72.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.297 -179.725 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.497 HG21 HD11 ' A' ' 127' ' ' ILE . 54.7 t -108.58 95.0 3.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.449 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 1.024 ' OE2' HG22 ' A' ' 117' ' ' ILE . 0.5 OUTLIER -102.76 105.0 15.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.877 -179.083 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.598 ' HB2' ' HA3' ' A' ' 89' ' ' GLY . . . -126.57 48.01 2.22 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.709 -179.684 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.557 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 152.55 51.88 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.25 179.907 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.486 ' HD3' ' O ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 56.14 18.2 3.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.343 -179.313 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.487 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 1.7 mtt -141.24 122.8 15.1 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.821 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.575 ' CB ' HG22 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -75.15 171.82 13.47 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.428 -0.806 . . . . 0.0 111.44 -179.839 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.463 ' HB2' ' HB ' ' A' ' 118' ' ' VAL . 3.5 m120 -151.49 83.79 1.3 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.473 179.73 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.562 ' HB2' HG23 ' A' ' 114' ' ' THR . 3.2 pt20 -50.23 113.41 0.86 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.06 -179.67 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.821 HG21 HG11 ' A' ' 83' ' ' VAL . 18.8 mm -81.42 95.65 2.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.919 179.802 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.478 ' HA ' ' HA ' ' A' ' 114' ' ' THR . 1.4 mt-10 -72.05 144.08 48.87 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.115 -179.773 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.524 ' HB3' ' HA ' ' A' ' 111' ' ' VAL . . . -68.67 142.46 55.05 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.831 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 55.7 p30 -126.74 1.87 6.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.341 -0.391 . . . . 0.0 111.08 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.587 ' HE3' ' CD2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -158.83 22.21 0.21 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.092 -179.927 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.478 ' O ' ' NZ ' ' A' ' 131' ' ' LYS . 1.1 p 49.94 173.56 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.783 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.897 ' O ' HG22 ' A' ' 109' ' ' VAL . . . 156.56 176.02 28.18 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.571 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.773 ' C ' HG23 ' A' ' 155' ' ' ILE . 25.9 m -127.78 119.56 25.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.582 0.229 . . . . 0.0 111.307 -179.765 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.595 HG21 HG22 ' A' ' 103' ' ' ILE . 73.3 t -52.36 144.7 3.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 179.172 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.65 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 22.4 mmmt -125.17 -18.77 5.32 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.685 0.279 . . . . 0.0 111.422 -179.431 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.799 ' C ' HD13 ' A' ' 138' ' ' ILE . . . 167.05 156.78 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.178 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.799 HD13 ' C ' ' A' ' 137' ' ' ALA . 0.2 OUTLIER -109.88 84.58 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.032 179.821 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.564 ' N ' HD23 ' A' ' 139' ' ' LEU . 3.6 mt -47.13 -25.86 0.98 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.415 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.967 HG21 HD23 ' A' ' 152' ' ' LEU . 78.3 t -104.8 149.47 8.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.735 179.71 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.534 ' HB2' ' CG ' ' A' ' 144' ' ' GLN . 4.1 mm-40 -52.55 -170.99 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.376 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.522 ' O ' ' O ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -84.87 -55.41 4.1 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 120.837 -0.345 . . . . 0.0 111.509 -179.789 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.561 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -128.16 103.14 0.61 Allowed Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.857 -179.342 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.635 ' C ' HG23 ' A' ' 90' ' ' THR . 0.0 OUTLIER -174.05 144.17 0.98 Allowed Pre-proline 0 C--N 1.326 -0.413 0 CA-C-O 121.034 0.445 . . . . 0.0 111.18 179.669 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 144' ' ' GLN . 43.7 Cg_exo -56.58 142.97 90.06 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.83 2.353 . . . . 0.0 112.036 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.916 HG11 ' CD2' ' A' ' 152' ' ' LEU . 4.8 m -128.86 179.52 3.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.157 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.458 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 1.3 mt-10 -129.82 141.4 50.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.73 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.46 ' HA ' ' O ' ' A' ' 85' ' ' SER . 34.5 t80 -35.45 137.52 0.18 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.903 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.468 ' HA ' ' HD2' ' A' ' 84' ' ' ARG . 0.6 OUTLIER 72.32 26.13 2.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.756 -179.799 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.465 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 6.7 tp10 -106.81 73.96 0.35 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.869 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.753 ' O ' HG23 ' A' ' 140' ' ' VAL . 61.0 Cg_exo -34.19 122.19 0.15 Allowed 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.869 2.379 . . . . 0.0 111.96 179.581 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.967 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -118.57 -66.61 1.06 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.563 -179.215 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.542 HG13 ' HB ' ' A' ' 83' ' ' VAL . 0.8 OUTLIER -96.7 106.22 18.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.289 -179.393 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.748 HG13 HG12 ' A' ' 82' ' ' ILE . 34.5 t -87.51 134.45 27.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.291 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.773 HG23 ' C ' ' A' ' 134' ' ' THR . 72.0 mt -135.73 140.02 45.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.987 179.785 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.55 ' CG ' ' HB ' ' A' ' 134' ' ' THR . 10.0 pt-20 . . . . . 0 C--O 1.249 1.027 0 CA-C-O 118.26 -0.876 . . . . 0.0 110.88 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ALA . . . . . 0.472 ' O ' ' HB3' ' A' ' 76' ' ' ALA . . . . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.809 0.338 . . . . 0.0 111.042 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.472 ' HB3' ' O ' ' A' ' 75' ' ' ALA . . . 69.97 34.14 2.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.109 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -167.01 141.16 3.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.919 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.508 HG22 ' O ' ' A' ' 78' ' ' ILE . 8.5 mt -121.02 24.11 4.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.139 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 49.44 60.62 3.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.982 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.484 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -130.29 -176.89 14.6 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.533 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.484 ' HB2' ' O ' ' A' ' 80' ' ' GLY . 34.0 t-80 173.74 83.7 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.763 0.316 . . . . 0.0 110.901 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.932 HD12 HG13 ' A' ' 154' ' ' VAL . 0.0 OUTLIER -97.74 -179.2 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.56 179.617 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.798 ' CG2' HG13 ' A' ' 153' ' ' VAL . 48.7 t -117.62 2.87 7.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.365 179.728 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.493 ' C ' ' O ' ' A' ' 83' ' ' VAL . 0.9 OUTLIER 23.97 98.22 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.486 179.858 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.653 ' HB2' HD21 ' A' ' 152' ' ' LEU . 4.1 t -34.37 95.81 0.09 OUTLIER Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.795 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.519 ' O ' ' CD1' ' A' ' 148' ' ' PHE . 18.8 Cg_endo -58.91 -74.45 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.638 2.225 . . . . 0.0 111.9 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.584 ' HE3' ' HB2' ' A' ' 120' ' ' ALA . 6.0 mtm -70.77 156.51 39.43 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.783 179.645 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.775 HG22 ' O ' ' A' ' 88' ' ' VAL . 2.6 p -79.43 57.74 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.048 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -114.34 -148.2 9.69 Favored Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.38 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.898 HG23 ' O ' ' A' ' 144' ' ' GLN . 16.9 m -122.91 144.22 49.37 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-O 121.087 0.47 . . . . 0.0 111.24 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.881 ' HB2' HD22 ' A' ' 152' ' ' LEU . 29.5 t80 -83.34 142.62 30.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.615 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.56 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 12.1 m-85 -144.88 153.68 41.84 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.428 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 0.6 OUTLIER -139.73 32.83 2.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.845 179.845 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.488 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -148.5 109.5 3.61 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.881 179.902 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 94' ' ' THR . 37.7 Cg_endo -66.22 -38.9 19.5 Favored 'Trans proline' 0 C--O 1.231 0.137 0 C-N-CA 122.752 2.301 . . . . 0.0 112.272 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.459 ' OG ' ' HD2' ' A' ' 97' ' ' PRO . 0.2 OUTLIER -129.02 168.78 14.86 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.9 179.995 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.459 ' HD2' ' OG ' ' A' ' 96' ' ' SER . 52.9 Cg_exo -52.29 -53.98 5.99 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.787 2.325 . . . . 0.0 112.221 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -124.5 71.79 1.17 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.874 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -119.09 -166.9 1.31 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.128 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -92.85 29.05 1.89 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.768 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.488 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 60.81 170.84 0.1 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.001 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.871 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -87.15 -43.26 12.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.849 -179.996 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.871 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.1 pp -169.79 134.0 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.04 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.595 ' O ' HG11 ' A' ' 135' ' ' VAL . 5.7 mt-10 -137.5 157.8 45.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.966 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.609 HG22 ' HA ' ' A' ' 137' ' ' ALA . 3.0 t -38.55 125.36 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.078 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' GLY . . . . . 0.438 ' N ' HG13 ' A' ' 135' ' ' VAL . . . 109.45 -28.05 11.47 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.466 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.542 ' O ' HG12 ' A' ' 135' ' ' VAL . 5.6 tp60 -71.61 109.74 5.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.807 0.337 . . . . 0.0 110.867 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 134' ' ' THR . 4.0 mttt -74.47 91.43 2.26 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.014 -179.862 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.938 HG11 ' CD2' ' A' ' 115' ' ' LEU . 0.0 OUTLIER -50.37 174.88 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.911 179.889 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.542 ' O ' ' HB3' ' A' ' 129' ' ' ALA . 6.9 m120 -162.53 131.33 4.15 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.09 0.472 . . . . 0.0 110.719 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.621 HG12 ' HA ' ' A' ' 131' ' ' LYS . 34.5 m -34.79 137.38 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.071 179.8 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 65.56 30.26 77.04 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.497 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.484 ' CB ' ' O ' ' A' ' 110' ' ' ASN . 11.1 t70 -125.52 104.86 8.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.743 0.306 . . . . 0.0 110.735 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.471 HG23 ' HB2' ' A' ' 126' ' ' GLN . 1.6 m -34.34 128.48 0.42 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.045 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.938 ' CD2' HG11 ' A' ' 109' ' ' VAL . 11.1 mt -95.15 -83.31 0.36 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.789 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.519 ' CB ' ' O ' ' A' ' 92' ' ' TYR . 0.5 OUTLIER -132.36 -169.26 2.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.673 179.927 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.541 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.2 OUTLIER -111.65 123.81 67.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.211 179.895 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.777 HG21 HD11 ' A' ' 127' ' ' ILE . 96.5 t -113.73 74.64 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.218 179.4 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.583 ' CG ' ' HB ' ' A' ' 90' ' ' THR . 2.4 pt-20 -58.31 89.96 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.286 -179.333 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.584 ' HB2' ' HE3' ' A' ' 87' ' ' MET . . . -94.17 116.9 29.36 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.449 179.515 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.571 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.3 OUTLIER 90.25 -33.1 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.648 -179.344 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.571 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 150.34 -13.46 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.02 179.903 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.508 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 2.5 ptt? -106.57 134.32 49.9 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.91 0.386 . . . . 0.0 111.164 -179.623 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.541 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 2.4 ptm -55.51 133.31 50.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.135 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.451 ' OD1' ' HE2' ' A' ' 87' ' ' MET . 2.0 t-20 -120.27 68.6 0.85 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.669 179.823 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.471 ' HB2' HG23 ' A' ' 114' ' ' THR . 0.2 OUTLIER -43.01 131.86 4.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.844 -179.836 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.777 HD11 HG21 ' A' ' 118' ' ' VAL . 57.7 mt -95.18 149.59 4.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.245 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -108.55 131.58 54.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.888 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.542 ' HB3' ' O ' ' A' ' 110' ' ' ASN . . . -45.28 110.03 0.21 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.161 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -68.51 -20.4 64.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.796 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.621 ' HA ' HG12 ' A' ' 111' ' ' VAL . 0.0 OUTLIER -179.0 137.04 0.14 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.776 179.945 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.411 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 24.6 t -41.31 127.3 2.88 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.805 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.493 ' O ' ' N ' ' A' ' 109' ' ' VAL . . . -161.67 -178.94 36.02 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.613 -0.804 . . . . 0.0 112.63 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.879 ' C ' HG23 ' A' ' 155' ' ' ILE . 16.5 m -129.43 108.62 10.42 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.645 0.259 . . . . 0.0 111.419 -179.755 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.595 HG11 ' O ' ' A' ' 104' ' ' GLU . 2.2 p -49.13 144.12 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 179.284 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.596 ' C ' HG13 ' A' ' 105' ' ' VAL . 4.5 mmtt -122.25 -20.28 6.23 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 121.05 -0.26 . . . . 0.0 111.456 -179.232 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.609 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 175.35 175.32 0.23 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.054 0.454 . . . . 0.0 111.798 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.656 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 1.2 mm -125.82 85.09 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.861 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.841 HD21 HG21 ' A' ' 154' ' ' VAL . 5.9 mt -50.79 -21.73 1.8 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.768 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 1.038 HG21 HD23 ' A' ' 152' ' ' LEU . 69.9 t -108.11 151.44 10.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.254 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.446 ' O ' ' C ' ' A' ' 142' ' ' SER . 39.6 mt-10 -64.17 135.75 56.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.942 179.19 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.505 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -32.17 -61.35 0.25 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.595 -179.272 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.56 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -125.11 103.34 0.72 Allowed Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.505 -0.855 . . . . 0.0 112.895 -179.619 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.898 ' O ' HG23 ' A' ' 90' ' ' THR . 6.4 pt20 -170.94 153.81 4.02 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-O 120.938 0.399 . . . . 0.0 111.215 179.718 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.417 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 37.0 Cg_endo -65.92 140.03 59.07 Favored 'Trans proline' 0 C--O 1.232 0.209 0 C-N-CA 122.843 2.362 . . . . 0.0 112.534 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.857 HG11 ' CD2' ' A' ' 152' ' ' LEU . 26.7 m -130.32 -171.68 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.893 179.864 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.422 ' O ' ' C ' ' A' ' 148' ' ' PHE . 2.5 tm-20 -130.11 137.92 50.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.971 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.521 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 1.5 t80 -35.72 120.01 0.57 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.744 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.521 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 5.4 t70 86.19 31.38 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.887 0.375 . . . . 0.0 110.524 -179.553 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.482 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 5.8 tp10 -107.18 75.1 0.42 Allowed Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.66 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.776 ' HB3' HG21 ' A' ' 82' ' ' ILE . 48.5 Cg_exo -30.58 109.71 0.04 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.723 0 C-N-CA 123.159 2.573 . . . . 0.0 112.377 179.69 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 1.038 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -104.68 -56.1 2.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.315 -179.412 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.798 HG13 ' CG2' ' A' ' 83' ' ' VAL . 0.9 OUTLIER -103.43 111.8 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.402 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.45 -179.185 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.932 HG13 HD12 ' A' ' 82' ' ' ILE . 3.1 t -91.77 145.1 7.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.863 179.763 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.879 HG23 ' C ' ' A' ' 134' ' ' THR . 4.4 mt -138.53 147.68 25.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.433 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.528 ' HB2' ' CE ' ' A' ' 136' ' ' LYS . 6.8 tp10 . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.271 -0.871 . . . . 0.0 110.844 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.88 0.371 . . . . 0.0 111.108 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -129.42 170.59 13.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.106 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -131.75 65.99 1.56 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.9 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 5.7 tt -105.02 2.08 10.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.08 0.467 . . . . 0.0 111.397 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 43.32 34.09 0.68 Allowed 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.878 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -79.59 -158.66 15.34 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.489 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.51 ' N ' ' O ' ' A' ' 155' ' ' ILE . 25.6 t-80 -177.98 79.39 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.776 0.322 . . . . 0.0 110.871 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.854 HG12 HG13 ' A' ' 154' ' ' VAL . 16.7 mt -95.54 143.05 12.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.157 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.528 ' HB ' ' CG1' ' A' ' 153' ' ' VAL . 2.2 t -103.34 54.32 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.21 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.517 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 2.1 ptt180 -38.21 141.97 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.803 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.648 ' CA ' HD11 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -35.52 95.6 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.94 -179.974 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.441 ' N ' ' O ' ' A' ' 84' ' ' ARG . 66.7 Cg_exo -50.63 -20.2 6.1 Favored 'Trans proline' 0 N--CA 1.466 -0.143 0 C-N-CA 122.648 2.232 . . . . 0.0 112.157 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.485 ' SD ' ' CB ' ' A' ' 120' ' ' ALA . 2.2 ptm -162.76 177.52 9.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.723 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.651 HG22 ' CG ' ' A' ' 147' ' ' GLU . 93.3 t -70.77 97.66 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.145 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.704 ' O ' HG23 ' A' ' 146' ' ' VAL . . . -162.04 -166.86 21.58 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.37 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.799 HG23 ' N ' ' A' ' 145' ' ' PRO . 3.6 m -109.52 126.96 54.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.789 0.328 . . . . 0.0 110.883 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.633 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 2.7 t80 -82.15 140.1 33.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.796 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.583 ' CE2' ' HG2' ' A' ' 119' ' ' GLU . 18.7 m-85 -137.92 152.9 49.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.934 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.537 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 0.7 OUTLIER -134.27 18.57 3.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.818 179.808 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.464 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 5.4 p -145.44 106.43 4.38 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.803 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.593 ' HG3' ' CG ' ' A' ' 102' ' ' PHE . 27.9 Cg_exo -61.98 -9.63 15.08 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.776 2.317 . . . . 0.0 112.429 -179.837 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.513 ' HB3' ' HB2' ' A' ' 99' ' ' ALA . 1.5 t -172.23 153.84 3.13 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.912 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_exo -55.84 -50.88 11.06 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.722 2.281 . . . . 0.0 112.269 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -106.29 56.52 0.66 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.513 ' HB2' ' HB3' ' A' ' 96' ' ' SER . . . -121.08 -160.78 0.86 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.123 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 2.0 mmmt -103.99 24.26 11.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.002 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.464 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 57.81 162.64 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.073 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.913 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -88.42 -41.38 12.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.981 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.913 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.8 OUTLIER -175.53 150.29 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-O 120.939 0.4 . . . . 0.0 111.271 179.668 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -152.06 158.62 43.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.683 179.775 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.657 ' HA ' HG12 ' A' ' 135' ' ' VAL . 6.8 p -48.24 105.26 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.166 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 123.9 -0.03 9.1 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.369 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.4 mm-40 -77.99 144.02 37.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.751 0.31 . . . . 0.0 110.98 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -98.94 90.73 4.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.907 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.736 HG11 ' CD2' ' A' ' 115' ' ' LEU . 15.6 m -87.89 159.63 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.105 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.47 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 31.9 m-80 -162.35 130.39 3.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.067 0.46 . . . . 0.0 110.776 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.461 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 24.6 m -35.84 123.49 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.224 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 108.44 3.06 33.07 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.559 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -113.42 -149.39 0.45 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.766 0.317 . . . . 0.0 110.685 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.68 HG21 ' OE1' ' A' ' 126' ' ' GLN . 5.5 m -136.23 132.23 35.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.924 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.736 ' CD2' HG11 ' A' ' 109' ' ' VAL . 75.4 mt -92.43 -84.71 0.27 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.916 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.517 ' HA ' ' CG ' ' A' ' 102' ' ' PHE . 2.3 p -143.78 -167.13 2.51 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.037 -179.894 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.85 HD13 ' HB2' ' A' ' 124' ' ' MET . 2.8 mt -131.59 150.44 34.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.812 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.594 HG22 ' HA ' ' A' ' 91' ' ' PHE . 53.6 t -143.93 103.22 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.856 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.583 ' HG2' ' CE2' ' A' ' 92' ' ' TYR . 6.8 pt-20 -58.6 82.28 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.146 -179.681 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.54 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -95.67 99.92 11.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.663 179.627 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.54 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 88.43 30.96 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.563 -179.53 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.505 ' HB3' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 75.8 30.49 0.76 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.217 -179.996 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.497 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 18.6 mmt -149.39 124.77 10.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.967 0.413 . . . . 0.0 110.906 179.558 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.85 ' HB2' HD13 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -59.75 103.18 0.19 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.148 -179.824 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 31.4 t30 -83.31 80.68 9.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.547 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.68 ' OE1' HG21 ' A' ' 114' ' ' THR . 17.3 tt0 -56.81 124.03 17.07 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.94 -179.837 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.499 HG22 HD12 ' A' ' 115' ' ' LEU . 15.3 mm -91.17 120.35 39.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.136 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -90.93 143.16 27.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.882 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -57.05 116.73 3.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.047 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -117.42 14.35 14.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.811 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.403 ' HD2' ' O ' ' A' ' 132' ' ' SER . 0.0 OUTLIER -179.39 102.99 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.69 -180.0 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.47 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 0.9 OUTLIER -42.77 122.59 2.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.616 179.897 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.471 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -156.25 -167.32 17.42 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.615 -179.846 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.627 ' N ' HG23 ' A' ' 155' ' ' ILE . 21.3 m -140.16 112.42 7.75 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.511 0.196 . . . . 0.0 111.169 -179.791 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.657 HG12 ' HA ' ' A' ' 105' ' ' VAL . 38.3 t -44.85 140.14 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.243 179.365 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.701 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 1.0 OUTLIER -122.42 -17.01 7.17 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.755 0.312 . . . . 0.0 111.152 -179.263 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.701 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 162.41 148.17 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.486 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.777 ' N ' HD13 ' A' ' 138' ' ' ILE . 0.0 OUTLIER -94.92 86.18 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.498 179.649 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.931 HD12 ' HB2' ' A' ' 151' ' ' PRO . 0.6 OUTLIER -40.81 -29.41 0.1 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.094 0.473 . . . . 0.0 110.207 -179.87 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.961 ' CG2' HD23 ' A' ' 152' ' ' LEU . 56.1 t -106.99 137.98 35.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.863 179.843 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.471 ' O ' ' HG2' ' A' ' 144' ' ' GLN . 3.4 mt-10 -67.65 98.11 0.67 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.219 179.513 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.537 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 24.2 p -34.15 135.87 0.14 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.899 -179.588 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.581 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 84.24 34.34 17.63 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.323 -179.663 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.653 ' C ' HG23 ' A' ' 90' ' ' THR . 37.8 mm-40 -146.2 144.8 22.27 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 120.898 0.38 . . . . 0.0 111.144 -179.736 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.873 ' O ' HG13 ' A' ' 146' ' ' VAL . 52.5 Cg_exo -55.32 177.26 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.862 2.375 . . . . 0.0 112.325 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.873 HG13 ' O ' ' A' ' 145' ' ' PRO . 0.2 OUTLIER -173.31 -174.42 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.193 -179.997 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.651 ' CG ' HG22 ' A' ' 88' ' ' VAL . 8.8 tt0 -155.71 158.5 38.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.903 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.473 ' HA ' ' O ' ' A' ' 85' ' ' SER . 42.5 t80 -42.42 138.84 1.65 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.967 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 74.67 24.1 1.73 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.524 ' CG ' ' O ' ' A' ' 147' ' ' GLU . 67.4 mm-40 -115.12 73.3 3.37 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.841 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.931 ' HB2' HD12 ' A' ' 139' ' ' LEU . 62.7 Cg_exo -33.75 129.04 0.16 Allowed 'Trans proline' 0 N--CA 1.458 -0.567 0 C-N-CA 122.974 2.449 . . . . 0.0 112.165 179.648 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 0.961 HD23 ' CG2' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -125.49 -71.67 0.69 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.727 -179.349 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.528 ' CG1' ' HB ' ' A' ' 83' ' ' VAL . 1.7 p -93.77 104.0 15.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.873 -179.085 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.854 HG13 HG12 ' A' ' 82' ' ' ILE . 21.4 t -89.13 133.1 32.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.814 179.333 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.627 HG23 ' N ' ' A' ' 134' ' ' THR . 97.1 mt -135.43 134.16 52.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.146 -179.727 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.518 ' CB ' ' HD3' ' A' ' 136' ' ' LYS . 1.2 tm-20 . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.259 -0.877 . . . . 0.0 110.898 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.853 0.358 . . . . 0.0 111.173 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -166.74 40.94 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.062 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 50.0 tt0 -171.46 29.61 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.994 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.409 HD12 ' HA ' ' A' ' 78' ' ' ILE . 2.9 tp -81.58 -1.94 5.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.515 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' SER . . . . . 0.411 ' O ' ' C ' ' A' ' 80' ' ' GLY . 4.6 t -96.08 27.37 3.67 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.866 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.542 ' CA ' ' HB2' ' A' ' 156' ' ' GLU . . . 36.6 -114.62 0.22 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.487 -179.895 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.558 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 34.2 t60 -169.49 75.65 0.09 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.811 0.338 . . . . 0.0 110.812 179.814 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.902 HG12 HG13 ' A' ' 154' ' ' VAL . 6.2 mt -93.25 150.44 3.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.105 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.745 HG23 HG13 ' A' ' 153' ' ' VAL . 3.1 t -102.43 46.55 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.037 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.516 ' CD ' ' O ' ' A' ' 84' ' ' ARG . 0.0 OUTLIER -35.48 131.92 0.45 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.859 179.965 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.571 ' HB3' HD21 ' A' ' 152' ' ' LEU . 95.2 p -36.56 99.16 0.17 Allowed Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.968 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 20.1 Cg_endo -60.97 -11.98 20.57 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.619 2.213 . . . . 0.0 111.97 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.405 ' O ' ' N ' ' A' ' 89' ' ' GLY . 1.0 OUTLIER -160.58 167.76 26.42 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.607 179.856 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.742 ' O ' HG23 ' A' ' 88' ' ' VAL . 26.4 m -66.49 69.66 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.007 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 87' ' ' MET . . . -121.67 -150.83 8.36 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.639 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' THR . . . . . 1.015 HG23 ' C ' ' A' ' 144' ' ' GLN . 97.9 m -131.95 128.45 38.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.961 0.41 . . . . 0.0 111.028 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 1.063 ' HB2' HD22 ' A' ' 152' ' ' LEU . 69.8 t80 -68.75 143.49 54.65 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.526 179.724 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.601 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 7.8 m-30 -149.06 125.77 11.11 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.897 0.379 . . . . 0.0 110.85 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.506 ' HA ' ' HB2' ' A' ' 102' ' ' PHE . 39.8 ptt85 -117.54 22.52 12.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.883 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.52 112.24 5.03 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.962 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.52 -38.86 3.05 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.689 2.259 . . . . 0.0 112.333 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -130.38 161.64 59.31 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.849 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.46 ' O ' ' HB3' ' A' ' 98' ' ' ASP . 38.4 Cg_endo -66.83 102.92 0.66 Allowed 'Trans proline' 0 C--O 1.231 0.13 0 C-N-CA 122.722 2.282 . . . . 0.0 112.362 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.46 ' HB3' ' O ' ' A' ' 97' ' ' PRO . 9.3 t70 80.16 35.29 0.14 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.884 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -88.74 -155.31 0.33 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.012 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.93 27.97 3.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.801 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 54.48 174.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.054 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.916 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -99.51 -35.2 9.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.874 179.972 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.916 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.2 pp -179.03 123.53 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.987 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.44 ' O ' ' HB3' ' A' ' 107' ' ' GLN . 1.7 mt-10 -141.34 164.7 29.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.949 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 38.7 t -37.09 135.38 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.118 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 87.78 -24.5 10.47 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.557 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.512 ' HG2' HG22 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -71.66 94.62 1.36 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.84 0.352 . . . . 0.0 110.842 -179.967 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 10.5 mttm -75.53 105.16 6.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.906 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.762 HG11 HD23 ' A' ' 115' ' ' LEU . 5.5 m -80.04 173.44 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.177 -179.942 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.484 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 4.5 p-10 -152.62 129.87 11.25 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.756 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.459 ' HA ' ' CB ' ' A' ' 129' ' ' ALA . 7.5 p -43.26 143.17 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.582 -0.735 . . . . 0.0 111.081 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 90.12 -2.13 81.07 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.412 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -105.98 -146.81 0.39 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.571 0.224 . . . . 0.0 110.63 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 3.9 m -130.13 120.36 24.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.789 0.328 . . . . 0.0 111.016 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.762 HD23 HG11 ' A' ' 109' ' ' VAL . 15.8 mt -77.06 -85.35 0.06 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.793 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.496 ' HB3' HD11 ' A' ' 103' ' ' ILE . 5.0 p -148.14 171.09 16.46 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.795 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.999 HD13 ' HB3' ' A' ' 124' ' ' MET . 3.7 mt -105.24 152.58 7.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.834 -179.874 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.458 ' HA ' ' O ' ' A' ' 90' ' ' THR . 55.6 t -144.04 103.23 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.052 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.494 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 1.9 mt-10 -65.54 100.78 0.53 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.151 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -83.26 -77.09 0.26 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.377 0.608 . . . . 0.0 111.071 179.795 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.531 ' O ' ' CG ' ' A' ' 122' ' ' LYS . 7.6 ptm -91.37 32.71 1.03 Allowed 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.367 179.695 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.531 ' CG ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 90.47 2.73 0.16 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.817 -179.63 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.48 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 4.9 ptm -116.78 133.58 55.84 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.841 179.785 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.999 ' HB3' HD13 ' A' ' 117' ' ' ILE . 3.3 mpp? -55.85 120.09 6.82 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.872 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.423 ' HB2' ' O ' ' A' ' 118' ' ' VAL . 35.8 t30 -102.3 73.44 1.35 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.947 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.547 ' CA ' HG12 ' A' ' 117' ' ' ILE . 15.4 pt20 -51.75 130.9 29.77 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.039 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 31.2 mm -103.59 136.79 34.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.094 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -95.41 145.32 25.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.883 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.459 ' CB ' ' HA ' ' A' ' 111' ' ' VAL . . . -64.78 121.63 15.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.062 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -94.88 -8.86 36.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.988 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -173.99 134.12 0.45 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.829 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.484 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 88.7 p -49.81 119.14 3.29 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.646 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -141.83 -176.77 16.34 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.628 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.635 ' N ' HG23 ' A' ' 155' ' ' ILE . 23.4 m -136.17 109.34 7.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.631 0.253 . . . . 0.0 111.139 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.489 HG22 HG12 ' A' ' 155' ' ' ILE . 67.1 t -48.27 142.49 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.289 179.4 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.554 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 55.1 mtpt -126.93 -19.8 4.35 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 121.042 -0.263 . . . . 0.0 111.705 -179.258 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.686 ' C ' HD13 ' A' ' 138' ' ' ILE . . . 173.62 162.52 0.16 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.025 0.44 . . . . 0.0 111.773 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.686 HD13 ' C ' ' A' ' 137' ' ' ALA . 0.6 OUTLIER -116.59 80.08 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.752 179.656 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.493 HD12 ' HB2' ' A' ' 151' ' ' PRO . 13.3 mt -47.99 -23.28 0.75 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.856 -179.822 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 0.985 HG21 HD23 ' A' ' 152' ' ' LEU . 53.5 t -108.16 143.34 18.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.235 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.491 ' HB2' ' HG2' ' A' ' 144' ' ' GLN . 4.9 mt-10 -59.61 136.06 57.87 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.922 179.31 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.48 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -30.61 -63.5 0.14 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.817 -179.259 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.601 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -124.06 103.54 0.77 Allowed Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.528 -0.844 . . . . 0.0 113.028 -179.393 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 1.015 ' C ' HG23 ' A' ' 90' ' ' THR . 0.0 OUTLIER -169.98 145.93 2.53 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-O 120.904 0.383 . . . . 0.0 111.149 179.616 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.434 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 39.0 Cg_exo -56.94 144.59 88.49 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.751 2.301 . . . . 0.0 112.066 179.803 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.635 HG11 ' CD2' ' A' ' 152' ' ' LEU . 0.2 OUTLIER -136.23 -174.21 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.201 -179.926 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.447 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -143.75 142.59 30.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.929 179.915 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.49 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 4.4 t80 -34.68 129.71 0.41 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.072 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.49 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.7 t70 83.01 23.6 0.15 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.918 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.447 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 25.7 mm-40 -109.54 74.28 0.68 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.835 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.848 ' O ' HG23 ' A' ' 140' ' ' VAL . 53.6 Cg_exo -33.71 126.38 0.15 Allowed 'Trans proline' 0 N--CA 1.458 -0.605 0 C-N-CA 122.866 2.377 . . . . 0.0 112.14 179.607 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 1.063 HD22 ' HB2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -117.89 -68.42 0.92 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.607 -179.175 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.749 HG21 HD13 ' A' ' 103' ' ' ILE . 1.3 p -102.45 106.22 19.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.418 -179.217 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.902 HG13 HG12 ' A' ' 82' ' ' ILE . 4.2 t -87.89 130.2 37.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.05 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.635 HG23 ' N ' ' A' ' 134' ' ' THR . 91.3 mt -132.99 131.87 58.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.215 -179.788 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.542 ' HB2' ' CA ' ' A' ' 80' ' ' GLY . 14.9 tt0 . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.259 -0.877 . . . . 0.0 110.96 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.845 0.355 . . . . 0.0 111.051 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -152.95 -161.39 1.28 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.064 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -179.79 136.22 0.12 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.861 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -119.48 23.02 5.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.042 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 23.8 t 48.88 97.71 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.91 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.435 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -117.74 -174.56 16.72 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.336 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.52 ' N ' ' O ' ' A' ' 155' ' ' ILE . 30.4 t-80 175.56 82.42 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.759 0.314 . . . . 0.0 110.943 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 0.879 HG12 HG13 ' A' ' 154' ' ' VAL . 10.8 mt -98.73 123.14 51.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.074 0.464 . . . . 0.0 110.976 179.79 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.618 ' CG2' HG13 ' A' ' 153' ' ' VAL . 2.0 t -76.29 57.55 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.762 -0.653 . . . . 0.0 111.312 -179.693 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.518 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -35.39 119.42 0.51 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.723 -179.977 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 85' ' ' SER . . . . . 1.019 ' CA ' HD11 ' A' ' 152' ' ' LEU . 0.3 OUTLIER -35.26 104.84 0.26 Allowed Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.177 -179.755 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.458 ' O ' ' O ' ' A' ' 87' ' ' MET . 32.6 Cg_endo -64.14 138.57 62.37 Favored 'Trans proline' 0 C--O 1.231 0.145 0 C-N-CA 122.62 2.213 . . . . 0.0 111.654 179.508 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.458 ' O ' ' O ' ' A' ' 86' ' ' PRO . 3.9 ptp 42.3 -167.81 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.354 -179.613 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.781 HG22 ' HG2' ' A' ' 147' ' ' GLU . 52.4 t -88.36 106.96 17.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.847 0.356 . . . . 0.0 111.203 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -157.54 -158.05 8.74 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.582 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.69 ' O ' HG13 ' A' ' 118' ' ' VAL . 4.4 m -123.89 148.74 46.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.909 0.385 . . . . 0.0 111.088 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.663 ' CZ ' HG21 ' A' ' 138' ' ' ILE . 46.8 t80 -90.99 140.6 29.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.042 -0.527 . . . . 0.0 109.927 179.307 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.594 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 11.3 m-85 -146.19 123.05 11.3 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.975 0.417 . . . . 0.0 111.169 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.495 ' HA ' ' HB2' ' A' ' 102' ' ' PHE . 41.3 ptt85 -116.04 39.35 3.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.673 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 31.2 p -150.86 115.6 3.23 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.022 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.408 ' HD3' ' C ' ' A' ' 101' ' ' ALA . 58.7 Cg_endo -71.85 -29.58 15.2 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.738 2.292 . . . . 0.0 112.204 179.883 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -143.35 158.88 56.94 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.875 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_exo -52.44 -38.74 74.58 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.69 2.26 . . . . 0.0 112.263 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 -129.05 60.34 1.55 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.922 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -116.14 -168.95 1.51 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.14 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' LYS . . . . . 0.481 ' NZ ' ' HB2' ' A' ' 100' ' ' LYS . 0.8 OUTLIER -91.4 27.04 2.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.978 179.951 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ALA . . . . . 0.48 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 65.42 178.59 0.2 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.192 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.863 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -95.22 -31.88 13.29 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.709 179.9 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.863 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.1 OUTLIER 169.42 138.49 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.21 179.621 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.828 ' O ' HG11 ' A' ' 135' ' ' VAL . 5.3 pt-20 -140.78 160.0 40.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.0 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.442 ' HB ' ' HA ' ' A' ' 137' ' ' ALA . 7.7 p -43.57 123.14 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.217 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' GLY . . . . . 0.482 ' H ' HG13 ' A' ' 135' ' ' VAL . . . 111.07 -19.98 24.42 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.446 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.829 ' O ' HG12 ' A' ' 135' ' ' VAL . 0.2 OUTLIER -87.47 113.6 23.33 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.801 0.334 . . . . 0.0 110.859 179.975 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 1.1 pttt -75.84 117.1 17.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.896 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.76 HG11 ' CD2' ' A' ' 115' ' ' LEU . 35.2 m -86.78 168.41 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.087 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.485 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 2.5 p-10 -160.11 132.14 6.21 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 121.129 0.49 . . . . 0.0 110.696 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.641 HG13 ' O ' ' A' ' 129' ' ' ALA . 4.1 t -36.86 139.87 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.963 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 88.99 7.38 70.54 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.27 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.461 ' O ' ' N ' ' A' ' 115' ' ' LEU . 6.8 m-20 -123.63 103.2 8.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.857 0.36 . . . . 0.0 110.835 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.414 ' C ' ' O ' ' A' ' 113' ' ' ASP . 4.3 m -37.23 94.72 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.925 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.76 ' CD2' HG11 ' A' ' 109' ' ' VAL . 9.9 mt -47.87 -91.0 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.703 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.633 ' HB3' HD11 ' A' ' 103' ' ' ILE . 2.0 p -138.33 155.95 48.09 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.851 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.678 HD13 ' HB2' ' A' ' 124' ' ' MET . 3.7 mt -89.79 153.21 3.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.025 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.69 HG13 ' O ' ' A' ' 90' ' ' THR . 86.3 t -145.23 101.08 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.852 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.515 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 2.4 mm-40 -55.27 84.49 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.243 -179.779 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.48 ' O ' ' HG3' ' A' ' 121' ' ' MET . . . -103.04 145.68 29.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.722 179.7 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.48 ' HG3' ' O ' ' A' ' 120' ' ' ALA . 2.2 ptm 45.53 26.82 0.34 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.035 0.445 . . . . 0.0 110.252 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.525 ' O ' ' CE ' ' A' ' 122' ' ' LYS . 0.1 OUTLIER 77.89 45.1 0.08 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.746 -179.698 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.51 ' N ' ' OE1' ' A' ' 119' ' ' GLU . 11.1 mtt -162.21 127.84 3.47 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.992 179.713 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.678 ' HB2' HD13 ' A' ' 117' ' ' ILE . 0.9 OUTLIER -57.68 87.18 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.56 179.61 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 12.6 t-20 -65.59 79.9 0.07 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.945 -179.799 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' GLN . . . . . 0.456 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -57.16 118.87 5.48 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.87 179.99 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.475 ' O ' ' N ' ' A' ' 115' ' ' LEU . 34.7 mm -84.77 134.26 27.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.042 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' GLU . . . . . 0.404 ' OE2' ' HG2' ' A' ' 126' ' ' GLN . 3.8 mm-40 -108.08 116.55 32.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.957 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.641 ' O ' HG13 ' A' ' 111' ' ' VAL . . . -37.8 113.49 0.28 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.131 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 42.9 p-10 -93.96 -14.36 26.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.935 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 15.6 ptmt -162.37 126.07 3.05 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.783 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.485 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 5.3 p -46.39 120.01 2.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.993 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.513 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -143.59 -168.59 12.26 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.433 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.568 ' N ' HG23 ' A' ' 155' ' ' ILE . 17.4 m -143.81 107.31 4.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.684 0.278 . . . . 0.0 111.25 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.829 HG12 ' O ' ' A' ' 107' ' ' GLN . 7.1 p -45.73 141.15 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.301 179.43 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.688 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 20.6 mtpt -120.82 -18.65 7.58 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.711 0.291 . . . . 0.0 111.111 -179.522 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.688 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 163.71 153.31 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.983 0.42 . . . . 0.0 111.765 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.663 HG21 ' CZ ' ' A' ' 91' ' ' PHE . 0.1 OUTLIER -108.31 79.35 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.545 179.684 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 8.2 mt -44.93 -25.96 0.37 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.722 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 1.045 HG21 HD23 ' A' ' 152' ' ' LEU . 62.3 t -102.85 146.71 10.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.009 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.556 ' O ' ' CD2' ' A' ' 91' ' ' PHE . 15.4 mt-10 -51.25 -174.84 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.172 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.492 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -82.18 -55.4 4.57 Favored 'General case' 0 C--N 1.324 -0.529 0 C-N-CA 120.881 -0.327 . . . . 0.0 110.921 179.935 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.594 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -126.5 103.1 0.66 Allowed Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.577 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.631 ' O ' HG23 ' A' ' 90' ' ' THR . 0.0 OUTLIER -165.03 151.56 9.21 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-O 120.948 0.404 . . . . 0.0 111.352 179.92 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.501 ' O ' ' NE2' ' A' ' 144' ' ' GLN . 30.7 Cg_endo -63.72 131.17 30.29 Favored 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.97 2.447 . . . . 0.0 112.48 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 0.525 HG11 ' CD2' ' A' ' 152' ' ' LEU . 0.2 OUTLIER -133.05 176.81 8.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.896 179.886 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.781 ' HG2' HG22 ' A' ' 88' ' ' VAL . 2.3 mt-10 -133.41 156.86 46.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.969 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.484 ' HA ' ' O ' ' A' ' 85' ' ' SER . 8.3 t80 -40.57 153.6 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.895 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.453 ' OD1' ' O ' ' A' ' 149' ' ' ASP . 1.0 OUTLIER 54.8 28.04 9.73 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.529 179.806 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.54 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 11.0 tp10 -107.23 74.35 0.4 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.702 179.492 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.608 ' O ' HG23 ' A' ' 140' ' ' VAL . 48.8 Cg_exo -31.35 129.13 0.08 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 123.138 2.559 . . . . 0.0 112.362 179.758 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 1.045 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -130.16 -68.91 0.69 Allowed 'General case' 0 C--O 1.232 0.181 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.694 -179.484 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.623 HG11 ' SG ' ' A' ' 116' ' ' CYS . 1.5 p -99.65 101.78 12.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.606 -178.941 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 0.879 HG13 HG12 ' A' ' 82' ' ' ILE . 23.8 t -81.86 138.49 19.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.0 179.602 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.568 HG23 ' N ' ' A' ' 134' ' ' THR . 83.6 mt -139.05 136.62 42.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.285 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.449 ' CA ' ' HD2' ' A' ' 136' ' ' LYS . 0.5 OUTLIER . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.282 -0.866 . . . . 0.0 110.927 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.114 0 CA-C-O 120.791 0.329 . . . . 0.0 111.003 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . 64.11 -81.12 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.062 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -91.58 131.48 36.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.903 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.457 HG22 ' O ' ' A' ' 78' ' ' ILE . 7.0 mt -139.26 24.01 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.16 -179.931 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 64.19 22.4 12.84 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.996 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.488 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . 67.54 -150.1 51.26 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.592 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' HIS . . . . . 0.509 ' N ' ' O ' ' A' ' 155' ' ' ILE . 25.5 t-80 171.21 83.98 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.778 0.323 . . . . 0.0 110.797 -179.864 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ILE . . . . . 1.015 HD12 HG13 ' A' ' 154' ' ' VAL . 0.2 OUTLIER -88.02 -177.52 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.992 0.425 . . . . 0.0 111.001 179.909 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.914 ' CG2' HG13 ' A' ' 153' ' ' VAL . 1.7 t -140.92 39.17 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.705 179.603 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' ARG . . . . . 0.546 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 1.7 ptt-85 -34.07 127.42 0.42 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.979 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' SER . . . . . 0.438 ' HB3' HD21 ' A' ' 152' ' ' LEU . 0.9 OUTLIER -38.37 112.02 0.64 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.883 179.986 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 86' ' ' PRO . . . . . 0.424 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 25.9 Cg_endo -61.96 -11.27 20.65 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.669 2.246 . . . . 0.0 111.945 179.853 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' MET . . . . . 0.573 ' SD ' ' HB1' ' A' ' 120' ' ' ALA . 5.6 ptm -156.59 177.09 11.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.598 179.844 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' VAL . . . . . 0.424 HG12 ' H ' ' A' ' 88' ' ' VAL . 1.7 p -80.43 94.18 2.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.082 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -143.64 -123.42 1.74 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.613 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.673 HG21 ' CZ ' ' A' ' 92' ' ' TYR . 38.5 m -150.9 150.78 31.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.861 0.362 . . . . 0.0 110.996 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' PHE . . . . . 0.652 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 0.8 OUTLIER -116.89 143.27 45.89 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.931 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 92' ' ' TYR . . . . . 0.673 ' CZ ' HG21 ' A' ' 90' ' ' THR . 22.5 m-85 -142.9 163.17 33.52 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.029 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' ARG . . . . . 0.488 ' HG2' ' HB2' ' A' ' 142' ' ' SER . 29.0 ptt180 -143.83 24.69 1.67 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.752 179.695 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' THR . . . . . 0.4 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 0.0 OUTLIER -156.51 91.99 2.52 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.767 179.833 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 94' ' ' THR . 45.2 Cg_endo -68.47 -25.32 35.46 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.785 2.323 . . . . 0.0 112.565 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.415 ' HA ' ' HD3' ' A' ' 97' ' ' PRO . 0.9 OUTLIER -135.57 133.13 20.06 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 120.966 0.413 . . . . 0.0 111.057 -179.896 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.483 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 52.1 Cg_exo -54.55 109.98 0.46 Allowed 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.803 2.335 . . . . 0.0 112.23 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' ASP . . . . . 0.483 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 10.4 t70 81.6 46.67 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.823 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' ALA . . . . . 0.404 ' HB2' ' HB2' ' A' ' 96' ' ' SER . . . -107.2 -166.47 1.16 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.081 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -90.41 23.51 2.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.795 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 56.88 159.7 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.146 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' PHE . . . . . 0.849 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -87.63 -37.79 16.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.82 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 103' ' ' ILE . . . . . 0.849 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.6 OUTLIER -170.19 110.03 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.134 -179.999 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 104' ' ' GLU . . . . . 0.504 ' N ' ' OE1' ' A' ' 104' ' ' GLU . 12.5 pm0 -121.73 162.3 21.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.852 179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.613 HG22 ' HA ' ' A' ' 137' ' ' ALA . 4.4 t -45.36 97.74 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.091 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.02 -8.97 6.03 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.513 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.432 ' O ' ' N ' ' A' ' 109' ' ' VAL . 29.7 tp60 -70.64 99.59 1.69 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.793 0.33 . . . . 0.0 110.881 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.444 ' O ' ' O ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -67.67 61.06 0.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.962 -179.984 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.808 HG22 ' O ' ' A' ' 133' ' ' GLY . 16.9 m -42.09 168.15 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.047 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' ASN . . . . . 0.511 ' ND2' ' HB2' ' A' ' 132' ' ' SER . 23.0 m120 -167.18 132.99 2.13 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.579 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.572 HG12 ' C ' ' A' ' 130' ' ' ASP . 18.1 m -34.05 136.34 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.172 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 81.33 14.97 77.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.303 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' ASP . . . . . 0.422 ' O ' ' C ' ' A' ' 114' ' ' THR . 0.8 OUTLIER -128.51 105.88 8.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.854 0.359 . . . . 0.0 110.824 179.957 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 114' ' ' THR . . . . . 0.422 ' C ' ' O ' ' A' ' 113' ' ' ASP . 1.3 m -35.18 127.93 0.54 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.033 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 115' ' ' LEU . . . . . 0.556 HD12 HG22 ' A' ' 127' ' ' ILE . 14.7 mt -87.63 -83.95 0.2 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.908 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 116' ' ' CYS . . . . . 0.53 ' HB3' HD11 ' A' ' 103' ' ' ILE . 21.4 p -135.2 -165.51 1.69 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.917 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' ILE . . . . . 0.566 ' CG2' ' CB ' ' A' ' 124' ' ' MET . 0.2 OUTLIER -113.7 113.92 45.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.212 -179.988 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.498 ' HB ' ' HB3' ' A' ' 125' ' ' ASN . 25.8 t -103.47 55.1 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.82 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 119' ' ' GLU . . . . . 0.479 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.2 OUTLIER -35.44 98.8 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.093 -179.842 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 120' ' ' ALA . . . . . 0.573 ' HB1' ' SD ' ' A' ' 87' ' ' MET . . . -118.16 110.27 17.39 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.923 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' MET . . . . . 0.544 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.3 OUTLIER 87.07 21.42 0.06 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.855 -179.908 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.544 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 89.69 0.81 0.26 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.252 179.907 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.479 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.4 OUTLIER -119.86 133.58 55.53 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.854 0.359 . . . . 0.0 111.138 179.942 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.566 ' CB ' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -64.22 112.63 3.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.051 179.87 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.498 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 0.8 OUTLIER -86.7 74.93 9.74 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.656 179.715 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -48.88 112.27 0.59 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.005 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 127' ' ' ILE . . . . . 0.556 HG22 HD12 ' A' ' 115' ' ' LEU . 3.9 mm -90.94 145.5 7.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.044 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -122.61 123.65 41.67 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.985 -179.873 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' ALA . . . . . 0.503 ' HA ' HD11 ' A' ' 115' ' ' LEU . . . -38.95 142.58 0.21 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.119 179.874 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 130' ' ' ASP . . . . . 0.572 ' C ' HG12 ' A' ' 111' ' ' VAL . 0.5 OUTLIER -121.49 -7.56 9.18 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.042 179.997 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.497 ' HD3' ' CD2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -160.13 23.88 0.17 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.769 179.991 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 132' ' ' SER . . . . . 0.511 ' HB2' ' ND2' ' A' ' 110' ' ' ASN . 1.3 p 53.66 -176.57 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.632 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 133' ' ' GLY . . . . . 0.808 ' O ' HG22 ' A' ' 109' ' ' VAL . . . 150.13 167.09 14.0 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.575 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 134' ' ' THR . . . . . 0.75 ' N ' HG23 ' A' ' 155' ' ' ILE . 18.8 m -116.57 110.74 18.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.658 0.266 . . . . 0.0 111.18 -179.902 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.51 HG12 ' HA ' ' A' ' 105' ' ' VAL . 95.0 t -47.22 142.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.472 179.51 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.652 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.2 OUTLIER -124.83 -19.18 5.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.424 -179.399 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 137' ' ' ALA . . . . . 0.694 ' C ' HD13 ' A' ' 138' ' ' ILE . . . 167.23 155.97 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.835 0.35 . . . . 0.0 111.351 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 138' ' ' ILE . . . . . 0.785 ' N ' HD13 ' A' ' 138' ' ' ILE . 0.0 OUTLIER -106.94 82.92 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.948 179.835 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 139' ' ' LEU . . . . . 0.917 HD21 HG21 ' A' ' 154' ' ' VAL . 6.6 mt -41.2 -34.96 0.53 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 121.168 0.508 . . . . 0.0 109.97 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 140' ' ' VAL . . . . . 1.056 HG21 HD23 ' A' ' 152' ' ' LEU . 59.0 t -92.18 136.86 23.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.701 179.648 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 141' ' ' GLU . . . . . 0.484 ' O ' ' HG2' ' A' ' 144' ' ' GLN . 4.5 mt-10 -70.22 100.19 1.64 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.443 179.817 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.488 ' HB2' ' HG2' ' A' ' 93' ' ' ARG . 5.9 p -36.13 147.66 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.682 -179.698 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 143' ' ' GLY . . . . . 0.579 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 71.97 35.29 61.44 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.451 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 144' ' ' GLN . . . . . 0.576 HE21 HG13 ' A' ' 140' ' ' VAL . 0.7 OUTLIER -149.03 153.48 38.27 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.883 0.373 . . . . 0.0 111.115 -179.913 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 145' ' ' PRO . . . . . 0.525 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 57.3 Cg_endo -70.64 164.13 36.49 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.939 2.426 . . . . 0.0 112.268 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 146' ' ' VAL . . . . . 1.117 HG11 ' CD2' ' A' ' 152' ' ' LEU . 29.3 m -143.99 -179.38 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.195 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.452 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.5 OUTLIER -137.49 160.54 38.85 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.068 -179.853 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 148' ' ' PHE . . . . . 0.421 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 1.2 t80 -44.52 121.88 2.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.843 179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 149' ' ' ASP . . . . . 0.421 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 4.9 t0 78.24 34.92 0.27 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.74 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 150' ' ' GLU . . . . . 0.452 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 3.9 tp10 -107.36 74.15 0.4 Allowed Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.94 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 151' ' ' PRO . . . . . 0.765 ' O ' HG23 ' A' ' 140' ' ' VAL . 61.6 Cg_exo -34.7 119.65 0.14 Allowed 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 122.79 2.327 . . . . 0.0 111.915 179.577 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 152' ' ' LEU . . . . . 1.117 ' CD2' HG11 ' A' ' 146' ' ' VAL . 0.0 OUTLIER -116.06 -70.69 0.78 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.746 -179.163 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 153' ' ' VAL . . . . . 0.914 HG13 ' CG2' ' A' ' 83' ' ' VAL . 1.4 p -93.06 109.95 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.252 0 CA-C-O 121.152 0.501 . . . . 0.0 111.836 -179.13 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 154' ' ' VAL . . . . . 1.015 HG13 HD12 ' A' ' 82' ' ' ILE . 4.1 t -92.3 132.79 35.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.638 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.75 HG23 ' N ' ' A' ' 134' ' ' THR . 39.5 mt -132.73 140.0 48.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.229 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.512 ' HB2' ' CD ' ' A' ' 136' ' ' LYS . 31.7 tt0 . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.22 -0.895 . . . . 0.0 110.943 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 N-CA-C 112.456 -0.258 . . . . 0.0 112.456 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.578 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 36.6 t60 -175.9 77.66 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.767 0.318 . . . . 0.0 110.888 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.998 HD12 HG13 ' A' ' 154' ' ' VAL . 0.1 OUTLIER -84.26 178.9 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 120.914 0.388 . . . . 0.0 111.08 179.868 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.737 ' CG2' HG13 ' A' ' 153' ' ' VAL . 25.2 t -130.42 37.98 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.903 179.686 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.526 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 10.9 ptt-85 -34.07 119.01 0.39 Allowed 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.906 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.489 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 3.7 t -34.86 104.46 0.25 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.984 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -47.2 -22.35 2.3 Favored 'Trans proline' 0 N--CA 1.465 -0.192 0 C-N-CA 122.678 2.252 . . . . 0.0 112.093 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -151.41 -168.93 3.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.545 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.632 HG12 ' O ' ' A' ' 88' ' ' VAL . 67.5 t -77.76 56.91 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.04 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.462 ' O ' HG23 ' A' ' 146' ' ' VAL . . . -103.55 -153.33 23.62 Favored Glycine 0 C--N 1.332 0.319 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.438 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.733 HG23 ' O ' ' A' ' 144' ' ' GLN . 17.8 m -130.68 145.17 51.86 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.901 0.382 . . . . 0.0 111.221 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.995 ' HB2' HD22 ' A' ' 152' ' ' LEU . 36.0 t80 -91.91 145.86 24.21 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.249 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.619 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 10.2 m-85 -146.65 154.29 41.29 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.003 0.43 . . . . 0.0 111.286 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.445 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 6.7 ptt85 -144.65 25.14 1.5 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.609 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.479 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 0.9 OUTLIER -151.17 100.04 3.03 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.905 179.909 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 94' ' ' THR . 47.5 Cg_endo -68.95 -32.46 22.02 Favored 'Trans proline' 0 C--O 1.231 0.133 0 C-N-CA 122.76 2.307 . . . . 0.0 112.213 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.534 ' CB ' ' HB2' ' A' ' 99' ' ' ALA . 0.4 OUTLIER -123.1 141.18 35.16 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.822 179.86 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -52.51 106.61 0.15 Allowed 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.732 2.288 . . . . 0.0 112.401 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 43.5 t0 71.24 34.7 1.72 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.043 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.534 ' HB2' ' CB ' ' A' ' 96' ' ' SER . . . -86.93 -154.94 0.25 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.976 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . 0.401 ' HA ' ' HD2' ' A' ' 100' ' ' LYS . 16.5 mmmt -94.83 23.52 5.43 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.832 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.479 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 56.86 167.08 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.019 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.958 ' O ' HD13 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -81.44 -51.68 8.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.677 179.868 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.958 HD13 ' O ' ' A' ' 102' ' ' PHE . 0.4 OUTLIER -152.59 148.25 14.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.023 179.759 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -143.39 149.17 37.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.838 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.428 HG13 ' HA ' ' A' ' 136' ' ' LYS . 16.7 t -44.59 123.37 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.053 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 123.98 -33.59 3.83 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.367 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.41 ' HA ' ' OE1' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -74.87 142.41 44.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.829 0.347 . . . . 0.0 110.748 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -103.58 101.61 11.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.067 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.782 ' CG2' ' HB2' ' A' ' 129' ' ' ALA . 2.3 p -66.23 164.39 2.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.775 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.587 ' N ' HG22 ' A' ' 109' ' ' VAL . 3.2 m120 -155.99 133.31 10.8 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-O 120.882 0.372 . . . . 0.0 110.376 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.47 ' C ' ' O ' ' A' ' 110' ' ' ASN . 2.4 t -26.16 123.41 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.518 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 85.92 21.5 52.69 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.216 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.487 ' HB2' ' O ' ' A' ' 110' ' ' ASN . 26.8 t0 -119.49 102.78 8.9 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.823 0.344 . . . . 0.0 110.832 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.467 HG23 ' HB2' ' A' ' 126' ' ' GLN . 1.4 m -41.28 132.16 2.64 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.912 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.524 ' O ' ' CG1' ' A' ' 103' ' ' ILE . 56.4 mt -96.5 -86.25 0.32 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.829 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.643 ' SG ' HG11 ' A' ' 153' ' ' VAL . 0.6 OUTLIER -131.94 -175.59 3.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.04 -179.945 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.537 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.1 OUTLIER -104.11 127.02 58.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.95 179.942 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.588 ' O ' HG12 ' A' ' 118' ' ' VAL . 58.8 t -108.31 60.25 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.942 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.484 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.3 OUTLIER -43.05 88.56 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.247 -179.888 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.545 ' O ' ' CB ' ' A' ' 121' ' ' MET . . . -92.65 109.55 20.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.718 179.735 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.557 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.8 OUTLIER 90.18 -29.59 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.763 -179.683 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.557 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 150.04 -15.95 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.88 179.622 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.484 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.4 OUTLIER -101.08 134.54 43.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.049 -179.662 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.537 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -55.25 145.34 21.89 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.125 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.493 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 1.0 OUTLIER -134.4 65.95 1.55 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.571 179.797 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.467 ' HB2' HG23 ' A' ' 114' ' ' THR . 4.8 pm0 -38.85 145.1 0.1 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.049 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.47 ' O ' ' N ' ' A' ' 115' ' ' LEU . 29.2 mm -117.18 130.62 71.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.986 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -105.56 128.11 53.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.079 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.782 ' HB2' ' CG2' ' A' ' 109' ' ' VAL . . . -44.32 147.24 0.57 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.922 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -114.06 -15.41 12.28 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.451 ' HG2' ' O ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -163.22 36.86 0.1 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.086 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.6 t 55.92 -174.9 0.05 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.582 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.492 ' N ' HG13 ' A' ' 109' ' ' VAL . . . 149.71 -178.88 26.92 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.604 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.621 ' N ' HG23 ' A' ' 155' ' ' ILE . 26.7 m -136.27 117.38 14.4 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.611 0.243 . . . . 0.0 111.17 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.468 ' HA ' HG12 ' A' ' 155' ' ' ILE . 97.7 t -49.92 140.45 3.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.476 179.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.64 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 27.7 mmmt -125.02 -19.65 5.14 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.576 -0.284 . . . . 0.0 111.376 -179.461 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.64 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 168.51 159.96 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.888 0.375 . . . . 0.0 111.584 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.656 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -110.72 83.62 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.815 179.83 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.656 HD21 HG21 ' A' ' 154' ' ' VAL . 4.7 mt -44.27 -34.87 2.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.081 0.467 . . . . 0.0 110.336 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.979 HG21 HD23 ' A' ' 152' ' ' LEU . 52.1 t -96.54 160.86 2.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.626 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.529 ' N ' HG12 ' A' ' 140' ' ' VAL . 3.0 mm-40 -58.75 -149.54 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.506 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -103.43 -63.61 1.16 Allowed 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.695 179.393 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.619 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -124.88 97.37 0.53 Allowed Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.632 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.733 ' O ' HG23 ' A' ' 90' ' ' THR . 0.0 OUTLIER -166.53 156.3 10.41 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.954 0.407 . . . . 0.0 110.998 179.839 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.443 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 35.4 Cg_exo -59.86 160.15 22.66 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.827 2.351 . . . . 0.0 112.277 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.804 HG12 ' HG2' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -152.66 176.19 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.06 179.878 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.488 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 3.8 tt0 -126.71 145.11 50.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.996 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.541 ' CE2' ' OD1' ' A' ' 149' ' ' ASP . 16.9 t80 -34.96 139.4 0.09 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.91 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.541 ' OD1' ' CE2' ' A' ' 148' ' ' PHE . 1.6 m-20 68.6 27.45 6.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.788 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.804 ' HG2' HG12 ' A' ' 146' ' ' VAL . 7.0 tp10 -105.38 74.63 0.28 Allowed Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.897 179.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.912 ' O ' HG23 ' A' ' 140' ' ' VAL . 64.3 Cg_exo -35.84 131.99 0.3 Allowed 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 122.924 2.416 . . . . 0.0 112.086 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.995 HD22 ' HB2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -123.61 -58.91 1.57 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.355 -179.345 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.737 HG13 ' CG2' ' A' ' 83' ' ' VAL . 1.6 p -108.75 111.82 37.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.066 -179.581 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.998 HG13 HD12 ' A' ' 82' ' ' ILE . 2.5 t -88.27 136.88 22.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.23 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.621 HG23 ' N ' ' A' ' 134' ' ' THR . 9.0 mt -134.56 138.42 49.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.019 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.528 ' CG ' ' HB ' ' A' ' 134' ' ' THR . 0.9 OUTLIER . . . . . 0 C--O 1.249 1.044 0 CA-C-O 118.172 -0.918 . . . . 0.0 110.904 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.45 -0.379 0 N-CA-C 112.568 -0.213 . . . . 0.0 112.568 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.488 ' ND1' ' HD3' ' A' ' 131' ' ' LYS . 18.2 t60 174.38 82.29 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.78 0.324 . . . . 0.0 110.877 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.859 HG12 HG13 ' A' ' 154' ' ' VAL . 4.6 mt -115.58 151.7 17.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.117 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.92 HG12 ' CG1' ' A' ' 153' ' ' VAL . 3.6 p -109.85 44.24 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.026 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.519 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -33.51 131.48 0.23 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.092 -179.943 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.584 ' HB3' HD21 ' A' ' 152' ' ' LEU . 4.4 p -35.83 97.51 0.13 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.873 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 14.2 Cg_endo -57.41 -14.95 17.66 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.608 2.205 . . . . 0.0 111.87 179.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.51 ' SD ' ' HB1' ' A' ' 120' ' ' ALA . 0.3 OUTLIER -151.31 164.96 35.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.47 179.718 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.655 HG22 ' O ' ' A' ' 88' ' ' VAL . 1.7 p -71.01 77.9 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.975 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -127.65 -128.58 3.13 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.545 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.525 ' HA ' ' HA ' ' A' ' 145' ' ' PRO . 8.3 m -147.44 134.49 20.36 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.773 0.32 . . . . 0.0 110.924 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.911 ' CB ' HD22 ' A' ' 152' ' ' LEU . 1.7 t80 -95.69 144.76 25.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.781 179.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.59 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 12.8 m-85 -141.04 160.07 40.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.061 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.523 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 0.8 OUTLIER -142.22 24.8 1.94 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.689 179.885 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.424 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 82.5 p -132.29 101.98 14.5 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.799 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.552 ' HB3' ' CE1' ' A' ' 102' ' ' PHE . 41.1 Cg_endo -67.37 -43.44 5.98 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.828 2.352 . . . . 0.0 112.403 -179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -129.95 160.45 65.09 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.06 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.449 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 55.9 Cg_endo -70.73 106.98 1.94 Allowed 'Trans proline' 0 N--CA 1.464 -0.208 0 C-N-CA 122.72 2.28 . . . . 0.0 112.319 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.449 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 18.7 t70 80.24 43.58 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.918 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -109.04 -160.39 0.72 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.029 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 1.1 mtpp -93.65 23.02 4.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.844 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.44 ' HB1' ' O ' ' A' ' 93' ' ' ARG . . . 64.34 176.83 0.18 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.013 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.895 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -85.69 -42.14 14.53 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.714 179.942 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.895 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.1 pp -172.68 145.78 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.959 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.44 ' O ' ' HB2' ' A' ' 107' ' ' GLN . 5.9 pt-20 -149.99 167.69 26.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.906 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.592 HG22 ' C ' ' A' ' 136' ' ' LYS . 89.9 t -45.56 128.02 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.104 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 100.42 -13.74 59.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.508 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.44 ' HB2' ' O ' ' A' ' 104' ' ' GLU . 0.0 OUTLIER -72.93 114.98 11.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.853 0.358 . . . . 0.0 110.935 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.445 ' O ' ' ND2' ' A' ' 110' ' ' ASN . 17.6 mttt -81.95 83.57 7.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.925 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.893 HG11 HD23 ' A' ' 115' ' ' LEU . 3.0 m -68.04 165.09 2.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.038 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.479 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 2.6 m-80 -157.74 130.39 7.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.101 0.477 . . . . 0.0 110.789 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.486 HG13 ' N ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -33.87 112.37 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.536 -0.757 . . . . 0.0 111.174 -179.984 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 110.39 13.0 15.87 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.844 -0.694 . . . . 0.0 112.385 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.476 ' O ' ' N ' ' A' ' 115' ' ' LEU . 17.3 t0 -122.58 103.04 8.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.753 0.311 . . . . 0.0 110.724 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.432 ' C ' ' O ' ' A' ' 113' ' ' ASP . 2.0 m -34.13 93.29 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.113 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.893 HD23 HG11 ' A' ' 109' ' ' VAL . 8.3 mt -50.05 -76.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.699 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.45 ' HA ' ' CG ' ' A' ' 102' ' ' PHE . 14.1 p -146.9 -155.66 0.64 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.653 179.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.979 HD13 ' HB3' ' A' ' 124' ' ' MET . 2.3 mt -136.71 152.86 29.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.691 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.513 ' O ' ' N ' ' A' ' 120' ' ' ALA . 92.3 t -139.59 88.5 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.205 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.579 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -51.16 85.8 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.916 179.99 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 118' ' ' VAL . . . -104.4 140.2 38.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.517 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 50.64 22.13 1.03 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.577 -179.726 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.535 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 86.17 36.41 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.859 -179.803 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.481 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 32.4 mmm -151.33 129.27 11.72 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.076 179.752 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.979 ' HB3' HD13 ' A' ' 117' ' ' ILE . 33.0 mtt -67.13 93.39 0.29 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.945 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -70.7 76.86 0.6 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.889 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.49 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 17.3 pt20 -55.39 108.67 0.45 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.859 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.504 HG21 HG21 ' A' ' 83' ' ' VAL . 12.8 mm -74.53 151.41 6.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.053 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -123.51 123.23 40.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.91 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -41.0 124.95 2.29 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.89 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -113.26 15.0 19.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.917 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.488 ' HD3' ' ND1' ' A' ' 81' ' ' HIS . 2.0 tmtt? 176.35 105.32 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.864 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.479 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 2.4 t -37.06 114.59 0.33 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.622 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.496 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -147.31 -173.49 18.5 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.732 -179.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.621 ' N ' HG23 ' A' ' 155' ' ' ILE . 19.7 m -128.73 108.55 10.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.662 0.268 . . . . 0.0 111.251 -179.685 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.534 ' HA ' ' CG1' ' A' ' 155' ' ' ILE . 69.9 t -39.29 144.81 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 179.224 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.72 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 38.4 mtpt -121.45 -20.58 6.56 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.666 0.269 . . . . 0.0 111.117 -179.583 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.72 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 160.81 165.29 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.382 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.639 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -107.93 81.8 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.624 179.595 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.747 HD12 ' HB2' ' A' ' 151' ' ' PRO . 2.4 mt -41.55 -29.07 0.15 Allowed 'General case' 0 CA--C 1.52 -0.211 0 CA-C-O 121.064 0.459 . . . . 0.0 110.467 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.981 HG21 HD23 ' A' ' 152' ' ' LEU . 54.8 t -102.85 137.36 31.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.771 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.434 ' O ' ' C ' ' A' ' 142' ' ' SER . 5.9 mt-10 -66.73 94.11 0.29 Allowed 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.349 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.523 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 77.4 p -34.95 137.44 0.13 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.816 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.59 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 84.02 35.82 14.6 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.529 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.506 ' O ' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -155.33 159.36 31.78 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.983 0.42 . . . . 0.0 111.125 -179.881 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.525 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 45.5 Cg_endo -68.65 178.37 3.95 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.79 2.327 . . . . 0.0 112.47 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.94 HG11 ' CD2' ' A' ' 152' ' ' LEU . 0.0 OUTLIER -157.86 -173.82 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.066 -179.944 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.461 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 1.8 tt0 -140.59 148.43 40.93 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.982 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.43 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 66.7 t80 -37.66 122.62 0.97 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.868 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.43 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 7.1 t70 79.81 35.54 0.15 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.894 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.461 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 1.8 mt-10 -112.64 74.48 1.64 Allowed Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.845 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.747 ' HB2' HD12 ' A' ' 139' ' ' LEU . 52.6 Cg_exo -32.95 120.45 0.1 Allowed 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 122.926 2.417 . . . . 0.0 111.834 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.981 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -109.62 -60.69 1.74 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.979 -179.102 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.92 ' CG1' HG12 ' A' ' 83' ' ' VAL . 2.3 p -111.96 110.35 31.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.066 0.46 . . . . 0.0 111.531 -179.275 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.859 HG13 HG12 ' A' ' 82' ' ' ILE . 4.9 t -92.2 145.49 7.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.354 179.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.621 HG23 ' N ' ' A' ' 134' ' ' THR . 35.8 mt -142.7 138.4 28.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.063 179.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.461 ' CA ' ' HD2' ' A' ' 136' ' ' LYS . 2.2 tm-20 . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.217 -0.897 . . . . 0.0 110.914 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.486 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.365 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.525 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 22.2 t60 167.69 86.34 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.784 0.326 . . . . 0.0 110.672 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.565 HG21 ' HB3' ' A' ' 151' ' ' PRO . 0.3 OUTLIER -85.07 164.23 2.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 121.05 0.453 . . . . 0.0 111.101 179.962 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.6 ' O ' HD12 ' A' ' 152' ' ' LEU . 4.3 t -120.01 49.35 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.295 -179.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.56 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 5.2 ptt180 -48.41 136.04 13.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.892 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.798 ' HB3' HG21 ' A' ' 146' ' ' VAL . 24.1 p -45.19 111.91 1.43 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.798 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.654 ' HD2' HG11 ' A' ' 118' ' ' VAL . 24.7 Cg_endo -61.51 -10.21 15.66 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.652 2.235 . . . . 0.0 112.139 179.751 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.411 ' SD ' ' HG2' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -160.3 -170.46 2.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.687 179.902 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 60.2 t -86.62 84.18 2.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.071 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.46 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -135.27 -138.97 3.96 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.699 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 1.017 HG23 ' C ' ' A' ' 144' ' ' GLN . 62.0 m -141.33 141.2 33.88 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.85 0.357 . . . . 0.0 111.036 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.825 ' CZ ' HG21 ' A' ' 138' ' ' ILE . 18.2 t80 -86.64 144.73 27.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.749 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.579 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 16.0 m-85 -146.49 159.09 43.86 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.856 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.582 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 1.6 ptt85 -149.3 21.28 0.95 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.85 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.453 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 33.5 p -149.75 107.69 3.28 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.839 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.442 ' HG2' ' CB ' ' A' ' 99' ' ' ALA . 58.9 Cg_endo -72.07 -15.73 28.97 Favored 'Trans proline' 0 N--CA 1.465 -0.199 0 C-N-CA 122.776 2.318 . . . . 0.0 112.369 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.36 149.13 6.28 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.999 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_exo -51.32 -25.82 19.13 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.802 2.335 . . . . 0.0 112.282 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -125.68 51.2 1.75 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.789 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.442 ' CB ' ' HG2' ' A' ' 95' ' ' PRO . . . -114.34 -162.39 0.81 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.28 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . 0.46 ' O ' ' O ' ' A' ' 101' ' ' ALA . 2.0 ptmt -115.16 24.2 11.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.881 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.582 ' HB1' ' O ' ' A' ' 93' ' ' ARG . . . 50.13 172.35 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.14 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.577 ' CE2' HG12 ' A' ' 117' ' ' ILE . 11.6 m-30 -98.56 -45.42 6.09 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.84 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.838 HD11 HG21 ' A' ' 153' ' ' VAL . 2.5 pp -160.14 141.74 4.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.176 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.469 ' HG2' ' HB2' ' A' ' 107' ' ' GLN . 15.2 pt-20 -132.18 171.64 13.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.919 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.632 HG13 ' O ' ' A' ' 105' ' ' VAL . 9.5 p -56.29 114.89 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.207 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 92.52 0.62 69.6 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.614 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.469 ' HB2' ' HG2' ' A' ' 104' ' ' GLU . 4.4 tp-100 -74.57 115.17 13.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.82 0.343 . . . . 0.0 110.845 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.09 129.1 37.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.97 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.421 ' O ' ' CG ' ' A' ' 110' ' ' ASN . 28.5 m -112.19 172.99 2.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.275 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.451 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 4.0 m120 -162.36 130.95 4.13 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-O 121.12 0.486 . . . . 0.0 110.657 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.707 HG12 ' N ' ' A' ' 131' ' ' LYS . 27.3 m -41.46 126.87 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.137 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 113.16 -1.95 25.41 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.534 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -112.21 -148.32 0.43 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.685 0.278 . . . . 0.0 110.616 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.8 134.01 44.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.936 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.609 HD12 HG22 ' A' ' 127' ' ' ILE . 61.5 mt -87.35 -72.64 0.51 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.809 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.404 ' HB2' ' O ' ' A' ' 92' ' ' TYR . 0.8 OUTLIER -155.74 -174.91 5.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.856 179.941 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.577 HG12 ' CE2' ' A' ' 102' ' ' PHE . 0.0 OUTLIER -110.31 115.8 50.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.179 -179.879 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.654 HG11 ' HD2' ' A' ' 86' ' ' PRO . 1.7 t -99.27 56.69 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.677 179.671 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.482 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.4 OUTLIER -33.85 93.98 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.224 -179.606 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.495 ' O ' ' HG3' ' A' ' 121' ' ' MET . . . -110.76 138.76 46.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.897 179.751 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.511 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 62.71 13.17 6.18 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.796 -179.95 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.511 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.1 OUTLIER 85.44 53.42 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.866 -179.881 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.482 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.2 OUTLIER -171.11 132.79 0.84 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.988 179.884 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -49.46 125.28 10.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.977 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.463 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 1.7 t-20 -107.92 60.4 0.61 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.719 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.403 ' C ' ' O ' ' A' ' 125' ' ' ASN . 13.6 pt20 -36.58 131.1 0.7 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.877 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.609 HG22 HD12 ' A' ' 115' ' ' LEU . 37.2 mm -111.05 118.1 56.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.173 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 14.8 mm-40 -88.32 124.86 34.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.95 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -44.96 116.08 1.02 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.081 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -101.41 12.72 36.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.797 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.707 ' N ' HG12 ' A' ' 111' ' ' VAL . 0.3 OUTLIER 179.51 122.91 0.06 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.758 -179.954 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.451 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.4 t -56.41 126.75 27.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.71 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.431 ' HA3' ' CG2' ' A' ' 155' ' ' ILE . . . -157.17 -173.38 25.52 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.587 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.626 ' N ' HG23 ' A' ' 155' ' ' ILE . 61.6 m -135.51 108.79 7.79 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.765 0.317 . . . . 0.0 111.066 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.514 ' HA ' ' HA ' ' A' ' 155' ' ' ILE . 94.7 t -46.65 143.89 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.612 179.602 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.554 ' HD2' ' CG1' ' A' ' 154' ' ' VAL . 0.0 OUTLIER -115.03 -35.56 4.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 121.317 0.579 . . . . 0.0 109.729 -179.934 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.638 ' O ' HG23 ' A' ' 154' ' ' VAL . . . 177.64 142.41 0.09 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.164 -0.925 . . . . 0.0 111.36 -179.667 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.863 HG23 HG22 ' A' ' 153' ' ' VAL . 0.0 OUTLIER -88.93 86.88 2.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.249 179.421 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.431 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 75.9 mt -41.62 -28.45 0.14 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.438 -179.653 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.931 HG21 HD23 ' A' ' 152' ' ' LEU . 54.5 t -102.07 158.42 4.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.102 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.506 ' N ' HG12 ' A' ' 140' ' ' VAL . 1.1 mm-40 -59.56 -146.84 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 178.784 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.501 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -101.73 -59.6 1.67 Allowed 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.623 -0.431 . . . . 0.0 110.913 179.404 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.569 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -125.48 102.34 0.66 Allowed Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.64 -179.78 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 1.017 ' C ' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -167.99 136.64 1.96 Allowed Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 120.959 0.409 . . . . 0.0 111.259 179.766 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.502 ' N ' HG23 ' A' ' 90' ' ' THR . 50.5 Cg_exo -53.28 154.06 15.42 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.849 2.366 . . . . 0.0 112.405 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.798 HG21 ' HB3' ' A' ' 85' ' ' SER . 4.5 m -144.87 -156.48 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.999 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.573 ' N ' HG23 ' A' ' 146' ' ' VAL . 24.5 mt-10 -149.28 150.86 33.22 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.969 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.458 ' HA ' ' O ' ' A' ' 85' ' ' SER . 37.5 t80 -42.75 141.4 1.08 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.805 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 66.13 29.47 9.85 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.772 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 0.8 OUTLIER -110.06 74.66 0.81 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.897 179.886 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.565 ' HB3' HG21 ' A' ' 82' ' ' ILE . 58.4 Cg_exo -32.89 135.56 0.08 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.579 0 C-N-CA 122.898 2.399 . . . . 0.0 111.999 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.931 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -134.32 -37.69 0.86 Allowed 'General case' 0 N--CA 1.453 -0.282 0 CA-C-O 121.024 0.44 . . . . 0.0 110.657 -179.511 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.863 HG22 HG23 ' A' ' 138' ' ' ILE . 2.3 t -128.34 115.64 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.595 -178.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.638 HG23 ' O ' ' A' ' 137' ' ' ALA . 1.2 t -97.18 127.07 49.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.017 179.505 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.626 HG23 ' N ' ' A' ' 134' ' ' THR . 7.9 mt -121.88 149.05 25.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.272 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.217 -0.897 . . . . 0.0 110.947 -179.901 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.379 0 N-CA-C 112.27 -0.332 . . . . 0.0 112.27 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.52 ' N ' ' O ' ' A' ' 155' ' ' ILE . 27.6 t60 -176.49 77.98 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.808 0.337 . . . . 0.0 111.009 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.881 HG12 HG13 ' A' ' 154' ' ' VAL . 18.5 mt -96.36 140.84 16.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.002 0.43 . . . . 0.0 111.07 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.865 HG23 HG13 ' A' ' 153' ' ' VAL . 1.8 t -91.69 48.7 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.104 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.485 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 7.1 ptt-85 -35.49 130.63 0.51 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.843 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.46 ' OG ' ' O ' ' A' ' 87' ' ' MET . 28.4 t -35.45 94.36 0.07 OUTLIER Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.038 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.462 ' N ' ' O ' ' A' ' 84' ' ' ARG . 51.3 Cg_exo -53.98 -24.98 34.25 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.662 2.242 . . . . 0.0 112.04 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.496 ' SD ' ' CB ' ' A' ' 120' ' ' ALA . 14.5 ptp -157.0 176.37 12.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.712 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 69.2 t -71.97 85.88 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.171 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.48 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -137.72 -150.87 5.77 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.572 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.622 ' CG2' ' CZ ' ' A' ' 92' ' ' TYR . 3.0 m -129.09 130.87 47.05 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.913 0.387 . . . . 0.0 111.043 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.779 ' HB2' HD22 ' A' ' 152' ' ' LEU . 53.2 t80 -76.52 146.87 38.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.562 179.765 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.644 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 14.7 m-85 -150.45 154.76 38.27 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.921 0.391 . . . . 0.0 110.872 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.507 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 4.1 ptm180 -142.28 34.53 1.5 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.866 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.482 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 18.3 p -149.44 110.6 3.41 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.882 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -67.83 -24.85 39.86 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.697 2.265 . . . . 0.0 112.196 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -141.42 143.84 31.59 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.876 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -50.18 -19.77 4.71 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.701 2.267 . . . . 0.0 112.37 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -143.72 74.19 1.42 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -140.07 -155.57 0.6 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.137 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . 0.412 ' O ' ' HB3' ' A' ' 101' ' ' ALA . 0.0 OUTLIER -104.68 36.94 2.26 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.812 -179.961 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.507 ' HB1' ' O ' ' A' ' 93' ' ' ARG . . . 66.56 -174.05 0.19 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.049 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.717 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -104.22 -46.14 4.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.94 179.942 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.717 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.9 pp -164.68 131.39 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.123 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 18.0 pt-20 -132.29 170.08 15.56 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.883 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.629 ' HA ' HG12 ' A' ' 135' ' ' VAL . 3.6 t -53.13 128.2 12.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.029 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.52 -14.93 50.27 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.357 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -80.35 102.27 9.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.817 0.341 . . . . 0.0 110.901 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.419 ' HA ' ' O ' ' A' ' 133' ' ' GLY . 0.0 OUTLIER -73.37 75.7 1.38 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.974 -179.88 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.674 HG11 ' CD2' ' A' ' 115' ' ' LEU . 32.6 m -48.81 174.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.001 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.454 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 18.1 m-80 -162.36 130.31 3.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.008 0.433 . . . . 0.0 110.717 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.566 HG12 ' N ' ' A' ' 131' ' ' LYS . 34.0 m -37.94 145.93 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.126 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 92.73 -6.04 76.92 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.421 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -105.63 -146.25 0.39 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.672 0.272 . . . . 0.0 110.573 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 6.5 m -145.16 116.61 8.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.814 0.34 . . . . 0.0 111.023 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.674 ' CD2' HG11 ' A' ' 109' ' ' VAL . 94.8 mt -69.23 -86.53 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.753 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.805 ' SG ' HG11 ' A' ' 153' ' ' VAL . 0.6 OUTLIER -135.17 -171.26 2.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.812 179.913 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.751 HG21 ' HG2' ' A' ' 124' ' ' MET . 0.1 OUTLIER -110.82 123.26 66.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.073 -180.0 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.657 ' O ' HG12 ' A' ' 118' ' ' VAL . 87.3 t -105.99 58.32 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.753 179.662 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.479 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.5 OUTLIER -33.71 101.57 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.307 -179.658 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.518 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -122.99 149.37 44.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.745 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.518 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 5.4 ptm 50.71 21.72 0.97 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.944 0.402 . . . . 0.0 110.611 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.442 ' O ' ' HE3' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 77.56 60.12 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.246 -179.983 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.481 ' HG2' ' O ' ' A' ' 120' ' ' ALA . 2.9 ptt? -175.33 128.68 0.27 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.069 0.461 . . . . 0.0 111.151 179.497 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.751 ' HG2' HG21 ' A' ' 117' ' ' ILE . 1.7 mtp -53.29 95.03 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.979 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -82.08 70.93 9.11 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.83 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 84.9 mt-30 -51.89 120.9 5.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.947 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.476 HG12 HG23 ' A' ' 118' ' ' VAL . 41.4 mm -88.39 109.8 20.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.184 -179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 129' ' ' ALA . 1.4 pt-20 -74.4 124.64 26.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.84 179.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.452 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -36.19 112.29 0.17 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.113 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.0 14.26 32.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.759 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.566 ' N ' HG12 ' A' ' 111' ' ' VAL . 0.3 OUTLIER 169.19 118.85 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.938 -179.979 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.454 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 25.3 p -49.5 129.58 19.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.857 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.419 ' O ' ' HA ' ' A' ' 108' ' ' LYS . . . -158.28 -178.1 31.99 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.642 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.63 ' N ' HG23 ' A' ' 155' ' ' ILE . 23.4 m -129.81 108.7 10.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.58 0.229 . . . . 0.0 111.152 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.629 HG12 ' HA ' ' A' ' 105' ' ' VAL . 69.9 t -42.25 142.44 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 110.295 -0.261 . . . . 0.0 110.295 179.504 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.68 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 5.8 mmmt -124.88 -18.66 5.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.677 0.275 . . . . 0.0 111.342 -179.426 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.68 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 165.17 154.22 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.841 0.353 . . . . 0.0 111.448 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.659 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -106.0 78.7 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.79 179.922 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.533 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 22.0 mt -42.14 -29.49 0.24 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.149 0.5 . . . . 0.0 110.385 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 1.085 HG21 HD23 ' A' ' 152' ' ' LEU . 55.4 t -100.7 161.89 3.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.694 179.73 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.554 ' N ' HG12 ' A' ' 140' ' ' VAL . 1.8 mm-40 -58.49 -149.13 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.345 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.49 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 35.8 m -107.67 -63.94 1.26 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.826 0.346 . . . . 0.0 110.893 179.605 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.644 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -123.44 90.47 0.42 Allowed Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.851 -179.783 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.474 ' C ' HG23 ' A' ' 90' ' ' THR . 36.3 mm-40 -156.57 156.34 29.88 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-O 120.908 0.385 . . . . 0.0 110.969 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.432 ' HD2' ' HB3' ' A' ' 144' ' ' GLN . 48.6 Cg_endo -69.26 120.98 7.77 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.681 2.254 . . . . 0.0 112.132 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.912 HG11 ' CD2' ' A' ' 152' ' ' LEU . 18.3 m -105.92 -173.83 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.123 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.491 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 6.2 mm-40 -140.7 144.41 35.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.031 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.446 ' HA ' ' O ' ' A' ' 85' ' ' SER . 63.9 t80 -35.7 137.94 0.18 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.051 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 7.9 t70 69.67 27.78 4.63 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.891 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.491 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 1.2 tp10 -108.87 73.79 0.53 Allowed Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.833 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.894 ' O ' HG23 ' A' ' 140' ' ' VAL . 61.4 Cg_exo -34.18 123.2 0.16 Allowed 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.804 2.336 . . . . 0.0 112.042 179.674 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 1.085 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -120.64 -70.86 0.76 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.699 -179.254 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.865 HG13 HG23 ' A' ' 83' ' ' VAL . 1.3 p -97.04 106.24 18.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.559 -179.146 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.881 HG13 HG12 ' A' ' 82' ' ' ILE . 23.4 t -89.33 133.41 31.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.865 179.349 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.63 HG23 ' N ' ' A' ' 134' ' ' THR . 82.9 mt -134.38 135.37 54.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.191 -179.799 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.486 ' HB2' ' CD ' ' A' ' 136' ' ' LYS . 0.7 OUTLIER . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.228 -0.891 . . . . 0.0 110.939 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.479 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.452 -0.283 0 N-CA-C 112.462 -0.255 . . . . 0.0 112.462 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.512 ' O ' ' ND1' ' A' ' 81' ' ' HIS . 11.9 t-80 173.11 83.07 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.827 0.346 . . . . 0.0 110.823 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 1.014 HG12 HG13 ' A' ' 154' ' ' VAL . 1.6 mt -118.17 151.05 20.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.071 0.462 . . . . 0.0 111.31 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.788 ' CG2' HD13 ' A' ' 115' ' ' LEU . 20.4 t -95.19 37.69 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.168 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.55 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 20.1 ptt85 -37.2 127.77 0.98 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.711 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.49 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 0.2 OUTLIER -45.33 109.38 0.92 Allowed Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.726 179.96 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -61.61 -13.22 28.59 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.72 2.28 . . . . 0.0 112.126 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 1.9 ptp -150.08 -159.58 1.05 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.821 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.449 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 5.2 m -92.25 87.27 2.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.103 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.476 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -141.99 -163.5 9.65 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.468 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.796 HG23 ' C ' ' A' ' 144' ' ' GLN . 25.8 m -119.98 145.41 46.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.843 0.354 . . . . 0.0 110.881 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.861 ' CB ' HD22 ' A' ' 152' ' ' LEU . 1.0 OUTLIER -102.08 147.71 26.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.031 -179.839 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.578 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 23.3 m-85 -142.73 167.59 21.72 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.865 179.843 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.453 ' HD3' ' HB3' ' A' ' 142' ' ' SER . 32.1 ptt85 -152.96 21.23 0.58 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.689 179.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.503 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 6.5 p -155.24 113.67 2.29 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.753 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.403 ' HG2' ' CB ' ' A' ' 99' ' ' ALA . 49.2 Cg_endo -68.59 -39.15 9.64 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.702 2.268 . . . . 0.0 112.342 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.521 ' CB ' ' HD2' ' A' ' 97' ' ' PRO . 0.2 OUTLIER -135.23 172.49 7.13 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.914 -179.947 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.521 ' HD2' ' CB ' ' A' ' 96' ' ' SER . 51.9 Cg_endo -69.22 -27.61 28.83 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.725 2.283 . . . . 0.0 112.284 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -135.46 39.63 2.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.874 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.403 ' CB ' ' HG2' ' A' ' 95' ' ' PRO . . . -95.28 -156.07 0.5 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.108 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . 0.414 ' O ' ' CG ' ' A' ' 100' ' ' LYS . 0.0 OUTLIER -102.81 34.79 2.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.91 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.503 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 45.01 -158.87 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.179 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.572 ' CD2' HG12 ' A' ' 117' ' ' ILE . 0.1 OUTLIER -139.27 40.28 2.09 Favored 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.059 179.816 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.784 HD13 HG12 ' A' ' 109' ' ' VAL . 2.6 mt 87.07 122.04 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.113 -179.806 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.425 ' O ' ' HB ' ' A' ' 135' ' ' VAL . 1.7 pt-20 -131.17 -175.75 3.79 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.905 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.548 HG22 ' HA ' ' A' ' 137' ' ' ALA . 46.7 t -53.31 134.06 15.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.079 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 93.22 -26.91 12.9 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.399 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.485 ' O ' HG23 ' A' ' 134' ' ' THR . 6.7 tp60 -72.35 131.63 42.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.803 0.335 . . . . 0.0 110.832 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.42 118.91 33.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.963 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.784 HG12 HD13 ' A' ' 103' ' ' ILE . 4.4 m -89.97 178.35 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.06 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.432 ' CG ' ' O ' ' A' ' 109' ' ' VAL . 18.4 m120 -164.71 131.27 2.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.068 0.461 . . . . 0.0 110.641 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.473 ' HA ' ' HB3' ' A' ' 129' ' ' ALA . 34.7 m -38.65 159.51 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.123 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 79.63 -6.04 59.31 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.499 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -108.88 -147.49 0.41 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.708 0.289 . . . . 0.0 110.651 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 14.4 m -135.93 150.12 49.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.847 0.356 . . . . 0.0 110.854 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.788 HD13 ' CG2' ' A' ' 83' ' ' VAL . 49.4 mt -96.95 -75.58 0.54 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.881 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.488 ' SG ' HG11 ' A' ' 153' ' ' VAL . 0.0 OUTLIER -148.4 -168.31 3.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.803 -179.916 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.572 HG12 ' CD2' ' A' ' 102' ' ' PHE . 0.1 OUTLIER -108.63 120.29 59.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.178 179.926 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.517 ' O ' ' CB ' ' A' ' 125' ' ' ASN . 11.1 t -118.43 73.38 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.03 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.543 ' HG2' ' CE2' ' A' ' 92' ' ' TYR . 0.9 OUTLIER -59.32 119.55 7.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.832 -179.953 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -94.0 -70.26 0.71 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.28 0.562 . . . . 0.0 111.365 -179.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.532 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 1.9 ptp -92.53 36.21 1.01 Allowed 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.447 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.538 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 0.4 OUTLIER 88.54 -7.74 0.5 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.87 -179.814 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.485 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 6.2 mtt -107.72 128.07 54.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.956 0.407 . . . . 0.0 110.896 179.68 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.539 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 1.0 OUTLIER -43.83 149.67 0.3 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.148 -179.867 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.517 ' CB ' ' O ' ' A' ' 118' ' ' VAL . 30.1 t-20 -129.58 74.25 1.57 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.572 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 9.9 pt20 -47.06 112.85 0.57 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.051 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 23.2 mm -92.8 105.92 17.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.103 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -70.21 143.2 52.28 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.932 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.473 ' HB3' ' HA ' ' A' ' 111' ' ' VAL . . . -66.04 119.22 11.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.123 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.421 ' C ' HG12 ' A' ' 111' ' ' VAL . 0.4 OUTLIER -97.8 -10.63 24.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.911 179.919 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.421 ' O ' ' C ' ' A' ' 132' ' ' SER . 10.0 tttt -161.61 109.47 1.45 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.918 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 131' ' ' LYS . 4.8 p -36.04 141.18 0.1 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.958 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.494 ' O ' ' N ' ' A' ' 109' ' ' VAL . . . -169.45 -165.12 26.31 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.521 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.53 ' N ' HG12 ' A' ' 155' ' ' ILE . 55.9 m -150.97 110.08 3.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.672 0.272 . . . . 0.0 110.938 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.58 HG21 HG22 ' A' ' 103' ' ' ILE . 61.8 t -41.86 141.34 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.843 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.519 ' HG2' ' N ' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -114.51 -35.88 4.77 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 121.456 0.646 . . . . 0.0 109.462 179.934 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.594 ' C ' HD13 ' A' ' 138' ' ' ILE . . . -175.44 155.01 1.75 Allowed 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.775 -179.579 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.787 ' N ' HD13 ' A' ' 138' ' ' ILE . 0.0 OUTLIER -103.06 84.35 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.406 179.648 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 1.013 HD11 HG22 ' A' ' 154' ' ' VAL . 0.2 OUTLIER -41.59 -28.81 0.15 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.106 0.479 . . . . 0.0 110.278 -179.872 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.988 HG21 HD23 ' A' ' 152' ' ' LEU . 79.7 t -103.38 134.45 44.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.826 179.753 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.449 ' O ' ' C ' ' A' ' 142' ' ' SER . 13.6 mt-10 -67.5 100.77 0.9 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.161 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.453 ' HB3' ' HD3' ' A' ' 93' ' ' ARG . 6.9 p -34.41 134.96 0.18 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.783 -179.524 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.578 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 80.72 39.31 14.31 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.583 -0.817 . . . . 0.0 112.255 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.796 ' C ' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -148.78 139.55 13.6 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 120.977 0.417 . . . . 0.0 111.076 -179.947 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.672 ' N ' HG23 ' A' ' 90' ' ' THR . 31.3 Cg_exo -59.03 158.75 24.14 Favored 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 122.845 2.363 . . . . 0.0 112.389 -179.725 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.926 HG11 ' CD2' ' A' ' 152' ' ' LEU . 19.7 m -147.22 -173.5 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.981 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.478 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.3 OUTLIER -138.06 174.44 10.56 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.933 179.956 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.501 ' CD1' ' HB2' ' A' ' 149' ' ' ASP . 1.3 p90 -55.2 140.31 39.21 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.834 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.501 ' HB2' ' CD1' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 59.41 34.4 22.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.867 0.365 . . . . 0.0 110.902 179.994 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.541 ' OE2' HG22 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -109.46 74.68 0.69 Allowed Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.88 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.601 ' O ' HG23 ' A' ' 140' ' ' VAL . 57.2 Cg_exo -33.43 133.93 0.11 Allowed 'Trans proline' 0 N--CA 1.459 -0.553 0 C-N-CA 122.926 2.417 . . . . 0.0 112.104 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.988 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -128.29 -50.7 1.3 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.739 -179.194 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.66 HG13 HG23 ' A' ' 83' ' ' VAL . 2.3 p -117.93 112.23 37.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.899 0.381 . . . . 0.0 111.541 -179.1 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 1.014 HG13 HG12 ' A' ' 82' ' ' ILE . 0.7 OUTLIER -96.0 129.81 45.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.888 179.523 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.571 HD11 HG11 ' A' ' 109' ' ' VAL . 0.0 OUTLIER -113.28 157.58 13.92 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.778 -179.934 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.448 ' N ' ' O ' ' A' ' 134' ' ' THR . 29.1 tt0 . . . . . 0 C--O 1.25 1.101 0 CA-C-O 118.211 -0.9 . . . . 0.0 110.976 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.458 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.45 -0.372 0 N-CA-C 112.609 -0.196 . . . . 0.0 112.609 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.587 ' ND1' HD12 ' A' ' 155' ' ' ILE . 14.9 t-80 172.78 83.36 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.773 0.32 . . . . 0.0 110.721 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.979 HD12 HG13 ' A' ' 154' ' ' VAL . 0.0 OUTLIER -97.73 176.46 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.145 179.977 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.723 HG12 ' CG1' ' A' ' 153' ' ' VAL . 2.3 p -132.45 28.18 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.811 179.557 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.545 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 6.2 ptt180 -25.97 120.42 0.07 Allowed 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.542 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.483 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 0.2 OUTLIER -38.58 116.25 0.93 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.835 -179.855 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.08 -9.31 25.7 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.634 2.222 . . . . 0.0 111.919 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 13.6 ptm -151.24 -168.96 3.25 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.626 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.676 ' O ' HG23 ' A' ' 88' ' ' VAL . 32.3 m -88.81 83.01 2.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.132 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.445 ' C ' HG22 ' A' ' 146' ' ' VAL . . . -126.17 -140.56 5.32 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.612 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.672 HG21 ' CZ ' ' A' ' 92' ' ' TYR . 4.9 m -146.73 128.06 14.88 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.008 0.432 . . . . 0.0 111.274 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 1.021 ' HB2' HD22 ' A' ' 152' ' ' LEU . 30.2 t80 -75.5 139.1 41.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.125 179.36 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.672 ' CZ ' HG21 ' A' ' 90' ' ' THR . 12.7 m-85 -142.67 156.35 45.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.927 0.394 . . . . 0.0 111.213 -179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 23.8 ptt85 -142.62 40.85 1.57 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.805 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -146.57 95.23 4.63 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.858 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.452 ' HD3' ' N ' ' A' ' 102' ' ' PHE . 49.7 Cg_endo -69.15 -38.84 8.53 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.817 2.345 . . . . 0.0 112.407 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.93 ' HB2' ' HB2' ' A' ' 99' ' ' ALA . 70.4 m -129.53 160.85 62.41 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.963 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.4 101.06 0.06 OUTLIER 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.717 2.278 . . . . 0.0 112.285 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 63.54 36.39 11.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.861 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.93 ' HB2' ' HB2' ' A' ' 96' ' ' SER . . . -76.56 -158.02 0.09 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.157 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . 0.419 ' O ' ' HB3' ' A' ' 101' ' ' ALA . 0.6 OUTLIER -89.35 23.34 2.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.99 179.972 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 100' ' ' LYS . . . 67.85 159.65 0.16 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.185 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.686 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -84.65 -46.01 11.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.81 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.686 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.1 pp -163.63 112.03 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.039 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.459 ' O ' ' HB2' ' A' ' 107' ' ' GLN . 10.2 pt-20 -123.72 172.35 8.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.909 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.814 HG22 ' HA ' ' A' ' 137' ' ' ALA . 21.3 t -51.97 119.06 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.179 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 107.44 -4.86 35.15 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.522 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.476 ' HG3' ' HA ' ' A' ' 103' ' ' ILE . 1.6 mm-40 -73.8 129.64 38.33 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.771 0.319 . . . . 0.0 110.987 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.423 ' O ' ' ND2' ' A' ' 110' ' ' ASN . 6.0 mttt -98.8 72.11 1.94 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.885 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.675 HG11 HD22 ' A' ' 115' ' ' LEU . 6.0 m -48.86 167.03 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.023 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.509 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 9.6 m-80 -159.87 129.87 5.45 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.083 0.468 . . . . 0.0 110.82 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.629 HG23 ' O ' ' A' ' 111' ' ' VAL . 5.0 m -34.99 115.37 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.056 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 99.96 12.69 39.23 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.344 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.423 ' O ' ' C ' ' A' ' 114' ' ' THR . 1.8 t70 -123.7 103.1 8.19 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.824 0.345 . . . . 0.0 110.811 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.525 ' CG2' ' HB2' ' A' ' 126' ' ' GLN . 3.2 m -35.06 132.91 0.33 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.066 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.675 HD22 HG11 ' A' ' 109' ' ' VAL . 67.1 mt -93.68 -81.63 0.36 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.843 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.412 ' SG ' HD11 ' A' ' 103' ' ' ILE . 0.5 OUTLIER -133.16 -172.89 3.05 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.701 179.894 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.532 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.2 OUTLIER -110.79 123.71 66.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.136 179.975 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.523 ' O ' ' N ' ' A' ' 120' ' ' ALA . 23.6 t -103.42 55.81 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.725 179.773 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.474 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.1 OUTLIER -31.38 89.0 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.721 -179.689 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 118' ' ' VAL . . . -88.82 134.24 34.0 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.141 179.25 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.554 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 2.8 ptt? 50.37 22.89 1.09 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.242 -179.337 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.554 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 96.21 -10.18 0.09 Allowed 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.544 179.698 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.515 ' O ' ' N ' ' A' ' 120' ' ' ALA . 12.5 ptm -99.18 131.69 45.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.157 0.503 . . . . 0.0 111.35 -179.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.532 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 1.4 ptt? -55.16 130.5 42.27 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.914 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.488 ' HB2' ' O ' ' A' ' 118' ' ' VAL . 0.7 OUTLIER -121.92 65.34 0.91 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.955 -179.967 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.525 ' HB2' ' CG2' ' A' ' 114' ' ' THR . 2.6 pm0 -39.2 144.36 0.14 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.918 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.55 HG21 HG21 ' A' ' 83' ' ' VAL . 31.8 mm -113.1 123.03 68.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.079 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 129' ' ' ALA . 5.5 mt-10 -85.23 118.39 24.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.843 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.428 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.94 127.81 0.7 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.002 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -100.57 -10.81 20.63 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.974 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.54 ' HD2' ' CD2' ' A' ' 81' ' ' HIS . 2.0 tmtt? -168.86 123.22 0.86 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.004 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.509 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.0 OUTLIER -51.26 112.39 0.73 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.396 179.729 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.58 ' HA3' HG21 ' A' ' 155' ' ' ILE . . . -145.28 -179.83 21.86 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.713 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.679 ' N ' HG23 ' A' ' 155' ' ' ILE . 29.9 m -122.4 112.32 17.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.693 0.282 . . . . 0.0 111.396 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.506 ' HA ' ' HA ' ' A' ' 155' ' ' ILE . 85.7 t -46.56 144.34 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.524 179.293 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.543 ' CD ' ' HB ' ' A' ' 154' ' ' VAL . 0.0 OUTLIER -114.52 -35.75 4.81 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-O 121.496 0.665 . . . . 0.0 109.682 -179.809 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.814 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 179.62 172.71 0.94 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.951 -179.672 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.754 HD13 ' C ' ' A' ' 137' ' ' ALA . 0.6 OUTLIER -119.09 82.9 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.059 179.843 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.562 ' N ' HD23 ' A' ' 139' ' ' LEU . 3.8 mt -41.09 -29.53 0.12 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.2 0.524 . . . . 0.0 110.073 179.724 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 1.056 HG21 HD23 ' A' ' 152' ' ' LEU . 54.5 t -100.08 158.9 3.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.555 179.538 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.498 ' N ' HG12 ' A' ' 140' ' ' VAL . 2.8 mt-10 -58.81 -150.43 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.067 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.499 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -102.49 -60.75 1.49 Allowed 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 120.81 -0.356 . . . . 0.0 110.822 179.623 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.635 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -127.07 89.09 0.34 Allowed Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.793 -179.779 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.462 ' C ' HG23 ' A' ' 90' ' ' THR . 25.2 mm-40 -153.09 155.61 32.08 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 120.997 0.427 . . . . 0.0 110.979 179.77 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.456 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 39.6 Cg_exo -56.81 153.29 37.77 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.855 2.37 . . . . 0.0 112.391 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.816 HG11 ' CD2' ' A' ' 152' ' ' LEU . 31.1 m -141.45 -173.08 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.967 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.48 ' O ' ' HG2' ' A' ' 150' ' ' GLU . 1.0 OUTLIER -146.82 144.58 29.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.896 0.379 . . . . 0.0 111.16 -179.94 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.483 ' HA ' ' O ' ' A' ' 85' ' ' SER . 5.5 p90 -35.62 124.35 0.67 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.953 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.442 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 79.46 33.22 0.22 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.824 -179.945 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.48 ' HG2' ' O ' ' A' ' 147' ' ' GLU . 13.0 mm-40 -109.26 75.23 0.69 Allowed Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.867 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.687 ' O ' HG23 ' A' ' 140' ' ' VAL . 75.1 Cg_exo -37.38 129.15 0.68 Allowed 'Trans proline' 0 N--CA 1.461 -0.413 0 C-N-CA 122.774 2.316 . . . . 0.0 111.925 179.594 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 1.056 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -123.27 -61.1 1.44 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.635 -179.3 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.723 ' CG1' HG12 ' A' ' 83' ' ' VAL . 2.1 p -108.26 120.91 60.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 121.172 0.511 . . . . 0.0 111.292 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.979 HG13 HD12 ' A' ' 82' ' ' ILE . 0.2 OUTLIER -100.55 137.92 26.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.219 -179.98 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.679 HG23 ' N ' ' A' ' 134' ' ' THR . 45.6 mt -123.43 147.16 27.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.229 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.402 ' O ' ' HG2' ' A' ' 156' ' ' GLU . 2.1 tt0 . . . . . 0 C--O 1.248 1.018 0 CA-C-O 118.323 -0.846 . . . . 0.0 110.922 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.34 0 N-CA-C 112.647 -0.181 . . . . 0.0 112.647 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.504 ' O ' ' ND1' ' A' ' 81' ' ' HIS . 23.7 t-80 -170.03 76.15 0.08 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.847 0.355 . . . . 0.0 110.802 179.838 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.836 HG12 HG13 ' A' ' 154' ' ' VAL . 5.1 mt -101.86 155.07 4.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.066 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.77 HG23 HG13 ' A' ' 153' ' ' VAL . 4.0 t -102.42 51.2 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.969 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.533 ' CD ' ' O ' ' A' ' 84' ' ' ARG . 0.5 OUTLIER -35.48 133.19 0.38 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.875 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.492 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 11.2 p -39.41 98.6 0.17 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.757 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.422 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 12.2 Cg_endo -56.3 -15.44 14.84 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.506 2.137 . . . . 0.0 111.91 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.411 ' O ' ' N ' ' A' ' 89' ' ' GLY . 5.2 ptp -160.29 172.38 17.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.534 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.595 ' O ' HG23 ' A' ' 88' ' ' VAL . 27.2 m -67.32 68.33 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.037 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 87' ' ' MET . . . -119.04 -155.68 9.88 Favored Glycine 0 C--N 1.331 0.289 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.648 -179.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.896 HG23 ' O ' ' A' ' 144' ' ' GLN . 20.2 m -131.5 124.85 31.0 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.908 0.385 . . . . 0.0 111.07 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.933 ' HB2' HD22 ' A' ' 152' ' ' LEU . 72.4 t80 -62.61 141.95 58.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.52 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.589 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 5.6 m-30 -148.37 127.73 13.06 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.964 0.412 . . . . 0.0 110.919 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.488 ' HA ' ' HB2' ' A' ' 102' ' ' PHE . 0.1 OUTLIER -124.27 25.52 7.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.825 179.857 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 2.7 p -149.21 108.16 3.4 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.882 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.34 -44.1 1.85 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.82 2.346 . . . . 0.0 112.309 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.747 ' HB2' ' HB2' ' A' ' 99' ' ' ALA . 0.1 OUTLIER -110.64 166.93 9.83 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.928 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.485 ' HD2' ' OG ' ' A' ' 96' ' ' SER . 51.1 Cg_endo -69.42 -25.56 30.05 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.737 2.291 . . . . 0.0 112.224 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -136.17 26.86 3.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.817 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.747 ' HB2' ' HB2' ' A' ' 96' ' ' SER . . . -71.49 -163.92 0.1 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.121 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . 0.486 ' O ' ' HB3' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -103.83 20.75 17.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.921 179.854 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.486 ' HB3' ' O ' ' A' ' 100' ' ' LYS . . . 71.47 162.9 0.26 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.274 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.616 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -84.93 -37.42 20.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.765 179.922 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.616 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.2 pp -161.29 158.56 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.019 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.437 ' O ' ' HB3' ' A' ' 107' ' ' GLN . 0.2 OUTLIER -140.42 151.23 44.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.906 -179.989 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.802 HG23 ' C ' ' A' ' 136' ' ' LYS . 4.8 p -54.08 127.94 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.199 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 93.83 -9.77 72.9 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.521 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.516 ' O ' ' N ' ' A' ' 109' ' ' VAL . 2.7 tp-100 -68.93 99.83 1.11 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.855 0.36 . . . . 0.0 110.801 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.43 ' HA ' ' HA ' ' A' ' 134' ' ' THR . 0.0 OUTLIER -59.26 75.62 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.952 -179.839 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.516 ' N ' ' O ' ' A' ' 107' ' ' GLN . 6.6 m -53.28 172.0 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.008 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.489 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 3.9 p-10 -163.06 133.03 4.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.058 0.456 . . . . 0.0 110.947 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.48 HG12 ' N ' ' A' ' 131' ' ' LYS . 29.3 m -38.25 130.18 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.131 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 101.95 2.01 52.02 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.417 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.434 ' O ' ' N ' ' A' ' 115' ' ' LEU . 4.2 t70 -117.93 99.22 6.77 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.777 0.322 . . . . 0.0 110.859 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.469 ' HA ' ' HA ' ' A' ' 128' ' ' GLU . 6.5 m -35.41 96.11 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.004 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.464 ' N ' ' O ' ' A' ' 127' ' ' ILE . 7.1 mt -46.4 -89.98 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.75 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.467 ' O ' ' N ' ' A' ' 127' ' ' ILE . 0.5 OUTLIER -136.86 -168.91 2.36 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.687 -179.992 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.998 HD13 ' HB2' ' A' ' 124' ' ' MET . 2.2 mt -125.83 153.83 34.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.885 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.457 ' HA ' ' O ' ' A' ' 90' ' ' THR . 27.5 t -142.61 101.64 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.872 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.544 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.5 OUTLIER -62.7 89.66 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.201 -179.799 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.449 ' O ' ' C ' ' A' ' 121' ' ' MET . . . -69.28 -136.07 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.649 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.482 ' O ' ' HB2' ' A' ' 122' ' ' LYS . 0.0 OUTLIER -34.14 -39.84 0.08 Allowed 'General case' 0 CA--C 1.519 -0.224 0 CA-C-O 121.444 0.64 . . . . 0.0 110.173 179.608 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.519 ' CG ' ' O ' ' A' ' 122' ' ' LYS . 0.1 OUTLIER 169.27 38.21 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.873 179.482 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.407 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 36.8 mmm -146.93 131.87 18.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.045 -179.422 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.998 ' HB2' HD13 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -64.47 101.44 0.45 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.836 179.994 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.457 ' HB2' ' O ' ' A' ' 118' ' ' VAL . 0.9 OUTLIER -77.07 83.28 3.58 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.877 179.946 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.546 ' CA ' HG12 ' A' ' 117' ' ' ILE . 7.8 pt20 -64.29 103.92 0.69 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.959 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.467 ' N ' ' O ' ' A' ' 116' ' ' CYS . 17.3 mm -75.38 139.09 19.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.04 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.469 ' HA ' ' HA ' ' A' ' 114' ' ' THR . 2.2 mt-10 -110.4 122.05 46.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.923 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.409 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -36.78 114.89 0.33 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.064 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -107.82 17.19 22.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.48 ' N ' HG12 ' A' ' 111' ' ' VAL . 1.9 ttmt 177.32 113.5 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.9 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.489 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 15.6 p -43.51 121.31 2.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.758 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.414 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -152.2 -171.52 19.92 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.599 -179.802 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.582 ' N ' HG23 ' A' ' 155' ' ' ILE . 21.8 m -140.14 107.81 5.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.582 0.229 . . . . 0.0 111.239 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.672 HG12 ' HA ' ' A' ' 105' ' ' VAL . 92.5 t -41.79 142.71 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.437 179.459 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.802 ' C ' HG23 ' A' ' 105' ' ' VAL . 30.5 mtpt -124.91 -18.93 5.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.455 -179.478 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.631 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 169.15 155.38 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.935 0.398 . . . . 0.0 111.622 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.639 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -111.11 77.44 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.61 179.792 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 9.7 mt -46.25 -24.92 0.53 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.965 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.994 HG21 HD23 ' A' ' 152' ' ' LEU . 45.3 t -104.13 144.18 14.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.239 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.494 ' HB2' ' HG2' ' A' ' 144' ' ' GLN . 4.7 mt-10 -62.35 137.62 58.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.069 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.504 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -31.58 -62.33 0.2 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.621 -179.331 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.589 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -125.58 104.21 0.75 Allowed Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.483 -0.865 . . . . 0.0 112.995 -179.483 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.896 ' O ' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -167.62 156.16 8.72 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-O 120.93 0.395 . . . . 0.0 111.137 179.553 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.435 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 37.8 Cg_endo -66.31 138.38 50.8 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.807 2.338 . . . . 0.0 112.329 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.613 HG11 ' CD2' ' A' ' 152' ' ' LEU . 1.5 m -132.14 -174.77 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.089 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.431 ' O ' ' C ' ' A' ' 148' ' ' PHE . 18.5 mt-10 -145.7 144.03 30.13 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.929 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.492 ' HA ' ' O ' ' A' ' 85' ' ' SER . 39.6 t80 -34.5 135.02 0.18 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.947 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 76.3 23.96 1.15 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.709 -179.829 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.476 ' HG2' HG12 ' A' ' 146' ' ' VAL . 4.5 tp10 -109.93 74.26 0.76 Allowed Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.788 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.752 ' O ' HG23 ' A' ' 140' ' ' VAL . 63.3 Cg_exo -33.27 130.57 0.13 Allowed 'Trans proline' 0 N--CA 1.457 -0.635 0 C-N-CA 122.888 2.392 . . . . 0.0 112.116 179.652 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.994 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -121.86 -72.2 0.7 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.555 -179.231 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.77 HG13 HG23 ' A' ' 83' ' ' VAL . 1.2 p -96.61 102.92 14.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.226 0.536 . . . . 0.0 111.37 -179.38 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.836 HG13 HG12 ' A' ' 82' ' ' ILE . 6.3 t -83.38 138.64 18.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.017 179.675 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.582 HG23 ' N ' ' A' ' 134' ' ' THR . 17.9 mt -136.72 143.2 35.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.352 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.503 ' CB ' ' HD2' ' A' ' 136' ' ' LYS . 29.5 tt0 . . . . . 0 C--O 1.25 1.094 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.881 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.417 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.36 0 N-CA-C 112.475 -0.25 . . . . 0.0 112.475 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.524 ' N ' ' O ' ' A' ' 155' ' ' ILE . 19.7 t-80 175.85 82.21 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.789 0.328 . . . . 0.0 110.849 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.887 HG12 HG13 ' A' ' 154' ' ' VAL . 7.1 mt -98.93 157.27 3.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.087 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.834 HG23 HG13 ' A' ' 153' ' ' VAL . 1.9 t -113.67 53.91 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.148 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.532 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -41.08 134.6 2.0 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.855 179.938 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.463 ' N ' HD11 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -35.86 109.23 0.4 Allowed Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.855 -179.916 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.453 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 35.4 Cg_endo -64.74 -8.56 18.01 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.744 2.296 . . . . 0.0 112.109 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -167.85 176.17 6.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.757 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.761 ' O ' HG23 ' A' ' 88' ' ' VAL . 32.6 m -71.42 82.83 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.129 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.431 ' O ' HG23 ' A' ' 146' ' ' VAL . . . -142.78 -159.06 7.78 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.581 -179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.709 HG23 ' C ' ' A' ' 144' ' ' GLN . 23.2 m -116.62 142.98 46.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.785 0.326 . . . . 0.0 110.803 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.738 ' HB2' HD22 ' A' ' 152' ' ' LEU . 2.6 t80 -100.23 140.16 34.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.588 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 19.9 m-85 -138.66 145.9 40.99 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.987 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.544 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 0.0 OUTLIER -125.49 28.24 6.31 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.852 179.846 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.477 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 12.1 p -146.96 115.5 4.36 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.847 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.434 ' HG2' ' CB ' ' A' ' 99' ' ' ALA . 55.5 Cg_endo -69.93 -39.44 6.17 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.685 2.257 . . . . 0.0 112.376 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.718 ' CB ' ' HB2' ' A' ' 99' ' ' ALA . 0.3 OUTLIER -129.16 160.57 63.19 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.952 179.998 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.407 ' HD2' ' OG ' ' A' ' 96' ' ' SER . 51.6 Cg_exo -52.58 -37.14 73.7 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.72 2.28 . . . . 0.0 112.332 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.411 ' CG ' ' O ' ' A' ' 98' ' ' ASP . 34.9 t0 -131.45 32.39 4.2 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.885 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.718 ' HB2' ' CB ' ' A' ' 96' ' ' SER . . . -76.24 -158.27 0.09 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.061 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . 0.436 ' O ' ' HB3' ' A' ' 101' ' ' ALA . 6.1 ptmt -104.72 23.6 13.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.917 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.477 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 68.65 166.31 0.26 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.187 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.724 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -93.78 -34.02 13.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.818 179.915 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.846 HD13 HG23 ' A' ' 153' ' ' VAL . 1.0 OUTLIER -164.84 150.37 2.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.134 179.913 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -155.17 146.89 23.25 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.961 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.558 HG13 ' HA ' ' A' ' 136' ' ' LYS . 3.0 t -54.11 116.45 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.148 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 129.5 -36.31 2.4 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.546 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.452 ' OE1' ' HA ' ' A' ' 103' ' ' ILE . 12.7 pt20 -76.38 130.08 37.53 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.842 0.354 . . . . 0.0 110.895 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.434 ' HA ' ' HA ' ' A' ' 134' ' ' THR . 2.6 mtpt -90.23 91.4 8.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.949 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.897 HG11 ' CD2' ' A' ' 115' ' ' LEU . 15.4 m -51.5 173.44 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.074 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.435 ' CG ' ' O ' ' A' ' 109' ' ' VAL . 75.1 m-80 -163.6 130.54 3.34 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.691 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.489 ' HA ' ' CB ' ' A' ' 129' ' ' ALA . 3.2 t -37.45 135.43 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.073 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 89.59 7.9 68.52 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.519 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 114' ' ' THR . 91.1 m-20 -121.08 101.98 8.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.933 0.397 . . . . 0.0 110.783 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.435 ' CG2' ' HB2' ' A' ' 126' ' ' GLN . 1.7 m -35.25 101.66 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.104 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.897 ' CD2' HG11 ' A' ' 109' ' ' VAL . 7.7 mt -56.77 -83.66 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.63 179.785 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.465 ' HB3' HG12 ' A' ' 103' ' ' ILE . 0.8 OUTLIER -144.34 178.21 8.08 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.764 179.804 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.741 HD13 ' HB2' ' A' ' 124' ' ' MET . 4.2 mt -111.01 152.47 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.013 0.435 . . . . 0.0 110.803 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.627 HG13 ' O ' ' A' ' 90' ' ' THR . 94.5 t -140.72 94.93 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.898 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.566 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.8 OUTLIER -50.51 84.83 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.103 -179.834 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.531 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -103.76 114.39 28.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.833 179.84 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.548 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 81.97 19.85 0.34 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.774 -179.746 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.548 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 91.13 -1.07 0.19 Allowed 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.141 179.896 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 5.7 mmt -123.0 134.87 54.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.915 0.388 . . . . 0.0 111.171 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.741 ' HB2' HD13 ' A' ' 117' ' ' ILE . 1.3 ptp -63.31 123.14 17.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.042 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -103.79 80.99 1.83 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.803 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.516 ' CA ' HG12 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -57.59 115.59 2.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.933 -179.989 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 3.6 mm -81.2 148.71 5.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.043 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.423 ' O ' ' C ' ' A' ' 129' ' ' ALA . 22.3 tt0 -112.26 124.78 53.2 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.851 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.489 ' CB ' ' HA ' ' A' ' 111' ' ' VAL . . . -35.46 107.19 0.05 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.17 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -95.28 3.98 53.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.142 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 10.1 tttt 175.82 121.19 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.908 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 86.8 p -47.32 135.03 10.94 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.793 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.506 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -164.84 -171.12 30.7 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.578 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.617 ' N ' HG23 ' A' ' 155' ' ' ILE . 24.3 m -136.09 107.41 6.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.614 0.245 . . . . 0.0 111.073 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.499 ' HA ' HG12 ' A' ' 155' ' ' ILE . 75.4 t -39.83 139.77 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 121.04 -0.264 . . . . 0.0 110.501 179.594 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.718 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.1 OUTLIER -122.84 -19.93 6.02 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.583 -0.28 . . . . 0.0 111.119 -179.47 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.718 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 161.13 154.04 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.385 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.68 ' N ' HD13 ' A' ' 138' ' ' ILE . 0.0 OUTLIER -100.75 86.54 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.605 179.752 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.605 HD12 ' HB2' ' A' ' 151' ' ' PRO . 2.0 mt -43.24 -28.08 0.28 Allowed 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.192 0.52 . . . . 0.0 110.342 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 1.006 HG21 HD23 ' A' ' 152' ' ' LEU . 75.3 t -104.63 135.62 41.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.823 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.503 ' N ' ' OE1' ' A' ' 144' ' ' GLN . 10.0 mt-10 -66.49 97.06 0.4 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.395 179.656 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.544 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 73.1 p -35.92 138.99 0.16 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.677 -179.642 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.588 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 81.21 35.8 22.75 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.457 -0.878 . . . . 0.0 112.346 -179.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.709 ' C ' HG23 ' A' ' 90' ' ' THR . 1.2 pt20 -148.97 159.39 37.54 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 120.89 0.376 . . . . 0.0 111.144 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.854 ' O ' HG13 ' A' ' 146' ' ' VAL . 45.1 Cg_endo -68.27 178.76 3.39 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.748 2.298 . . . . 0.0 112.195 179.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.854 HG13 ' O ' ' A' ' 145' ' ' PRO . 1.2 m -170.47 -175.67 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.283 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.523 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -142.74 155.47 44.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.869 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . . . . . . . . . 64.7 t80 -42.32 140.99 1.04 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.924 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.437 ' HA ' ' HD2' ' A' ' 84' ' ' ARG . 7.8 t0 66.4 28.94 9.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.841 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.523 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 2.4 tp10 -109.13 73.68 0.56 Allowed Pre-proline 0 C--N 1.327 -0.375 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.848 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.605 ' HB2' HD12 ' A' ' 139' ' ' LEU . 51.3 Cg_exo -32.56 120.94 0.1 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.598 0 C-N-CA 123.001 2.468 . . . . 0.0 112.232 179.706 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 1.006 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -116.41 -64.38 1.32 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.6 -179.254 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.846 HG23 HD13 ' A' ' 103' ' ' ILE . 1.5 p -99.43 103.99 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.178 0.514 . . . . 0.0 111.584 -179.11 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.887 HG13 HG12 ' A' ' 82' ' ' ILE . 4.7 t -87.85 135.11 26.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.033 179.571 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.617 HG23 ' N ' ' A' ' 134' ' ' THR . 96.6 mt -138.0 135.33 45.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.205 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.48 ' HG3' ' HE2' ' A' ' 136' ' ' LYS . 0.4 OUTLIER . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.249 -0.882 . . . . 0.0 110.902 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.424 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.333 0 N-CA-C 112.644 -0.182 . . . . 0.0 112.644 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.524 ' O ' ' ND1' ' A' ' 81' ' ' HIS . 17.9 t-80 174.45 83.22 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.835 0.35 . . . . 0.0 110.928 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.727 HG12 HG13 ' A' ' 154' ' ' VAL . 23.4 mt -98.66 127.99 50.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.994 0.426 . . . . 0.0 110.819 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.921 HG21 HD13 ' A' ' 115' ' ' LEU . 3.5 t -83.52 56.9 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.408 -179.543 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.533 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 1.9 ptt85 -42.96 134.55 3.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.67 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.675 ' HB2' HD21 ' A' ' 152' ' ' LEU . 9.6 t -35.98 96.86 0.11 Allowed Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.896 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.412 ' N ' ' O ' ' A' ' 84' ' ' ARG . 87.9 Cg_exo -46.07 -27.05 4.03 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.742 2.295 . . . . 0.0 112.186 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.52 ' SD ' ' CB ' ' A' ' 120' ' ' ALA . 10.0 ptp -147.75 168.5 21.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.705 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.474 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 1.5 p -69.39 91.08 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.051 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -146.46 -133.3 2.46 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.397 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.97 HG23 ' HA ' ' A' ' 145' ' ' PRO . 1.2 m -136.29 153.74 51.08 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.782 0.325 . . . . 0.0 110.954 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.645 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 1.1 t80 -118.38 140.15 50.29 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.968 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.586 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 22.0 m-85 -140.15 163.41 32.81 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.061 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.564 ' HD2' ' CB ' ' A' ' 142' ' ' SER . 0.0 OUTLIER -130.08 13.09 5.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.914 179.729 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.36 109.27 2.98 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.897 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -74.72 -5.04 16.31 Favored 'Trans proline' 0 C--O 1.232 0.201 0 C-N-CA 122.812 2.341 . . . . 0.0 112.454 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.59 167.88 12.24 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.05 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -74.55 106.43 2.25 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.747 2.298 . . . . 0.0 112.247 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 74.21 31.74 1.07 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.835 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -76.78 -166.8 0.73 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.003 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.01 33.38 0.87 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.885 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 51.58 175.75 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.182 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.838 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -111.68 -34.59 6.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.967 179.998 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.905 HD13 ' CG2' ' A' ' 153' ' ' VAL . 1.0 OUTLIER -170.08 129.08 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.186 179.933 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.5 ' O ' ' N ' ' A' ' 106' ' ' GLY . 3.2 mt-10 -136.72 148.87 47.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.835 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.589 HG22 ' C ' ' A' ' 136' ' ' LYS . 52.6 t -35.78 92.55 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.064 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . 0.5 ' N ' ' O ' ' A' ' 104' ' ' GLU . . . 133.39 -0.31 4.26 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.536 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.477 ' O ' ' HA ' ' A' ' 134' ' ' THR . 0.0 OUTLIER -71.24 112.58 7.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.82 0.343 . . . . 0.0 110.83 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 31.6 mttt -82.37 79.76 8.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.046 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.653 HG11 HD13 ' A' ' 155' ' ' ILE . 1.4 p -78.03 164.08 3.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.974 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.565 ' N ' ' CG2' ' A' ' 109' ' ' VAL . 7.8 m120 -153.83 130.04 10.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.49 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.432 ' C ' ' O ' ' A' ' 110' ' ' ASN . 2.6 m -31.74 114.76 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.461 -179.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 111.87 9.24 21.08 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.488 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.432 ' O ' ' HA ' ' A' ' 128' ' ' GLU . 6.4 t0 -113.74 -148.86 0.44 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.794 0.33 . . . . 0.0 110.684 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.48 ' CG2' ' CE1' ' A' ' 102' ' ' PHE . 1.9 m -131.0 147.89 52.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.788 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.921 HD13 HG21 ' A' ' 83' ' ' VAL . 80.9 mt -116.46 -81.1 0.61 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.131 -179.749 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.483 ' HB2' ' O ' ' A' ' 92' ' ' TYR . 8.0 p -136.57 -176.13 4.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.282 -179.619 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.544 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.3 OUTLIER -102.52 117.89 48.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.18 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.661 HG12 ' O ' ' A' ' 125' ' ' ASN . 12.1 p -97.12 50.98 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.923 179.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.488 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.1 OUTLIER -35.91 96.43 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.96 -179.885 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.522 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -116.92 115.64 25.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.023 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.522 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 0.1 OUTLIER 84.06 18.18 0.2 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.821 -179.95 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.528 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 0.3 OUTLIER 85.43 26.14 0.07 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.963 179.998 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.488 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.9 OUTLIER -141.96 128.36 20.03 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.107 179.832 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.544 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 1.0 OUTLIER -66.68 131.55 46.21 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.906 179.884 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.661 ' O ' HG12 ' A' ' 118' ' ' VAL . 0.5 OUTLIER -125.99 88.39 2.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.825 -179.985 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.407 ' HB2' HG23 ' A' ' 114' ' ' THR . 4.3 pt20 -50.61 112.04 0.63 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.875 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.427 HG21 HG11 ' A' ' 83' ' ' VAL . 31.5 mm -72.53 137.78 22.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.083 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.432 ' HA ' ' O ' ' A' ' 113' ' ' ASP . 50.2 mt-10 -97.01 126.44 42.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.93 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.545 ' HB2' ' CG2' ' A' ' 109' ' ' VAL . . . -38.49 124.84 1.33 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.153 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -101.67 -13.59 17.73 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.846 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 9.8 tttp -168.05 120.02 0.85 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.807 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.411 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 90.3 p -42.74 121.59 2.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.714 179.806 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.408 ' HA3' ' CG2' ' A' ' 155' ' ' ILE . . . -157.56 -176.5 29.69 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.67 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.631 ' N ' HG23 ' A' ' 155' ' ' ILE . 24.2 m -131.86 110.78 11.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.582 0.229 . . . . 0.0 111.137 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.838 HG21 ' HB ' ' A' ' 103' ' ' ILE . 73.4 t -40.03 141.76 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 110.353 -0.24 . . . . 0.0 110.353 179.531 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.622 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 5.7 mmmt -126.19 -19.89 4.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.633 -179.459 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.622 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 169.49 161.18 0.06 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.834 0.349 . . . . 0.0 111.514 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.645 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -108.49 80.2 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.915 179.917 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.545 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 2.8 mt -41.33 -30.33 0.18 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.104 0.478 . . . . 0.0 109.919 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.989 HG21 HD23 ' A' ' 152' ' ' LEU . 71.7 t -98.64 139.19 21.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.827 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.486 ' O ' ' CG ' ' A' ' 144' ' ' GLN . 6.7 mt-10 -70.59 98.14 1.44 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.351 179.654 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.564 ' CB ' ' HD2' ' A' ' 93' ' ' ARG . 35.5 p -35.83 154.36 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.703 -179.65 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.582 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 62.69 38.12 95.93 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.33 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.486 ' CG ' ' O ' ' A' ' 141' ' ' GLU . 12.3 mm-40 -150.48 145.27 18.29 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 120.931 0.396 . . . . 0.0 111.042 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.97 ' HA ' HG23 ' A' ' 90' ' ' THR . 52.4 Cg_exo -54.81 173.04 0.29 Allowed 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.755 2.303 . . . . 0.0 112.17 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.722 HG11 ' CD2' ' A' ' 152' ' ' LEU . 0.4 OUTLIER -165.76 175.86 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.042 179.939 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.509 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 0.8 OUTLIER -135.26 162.17 33.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.991 -179.935 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.464 ' HA ' ' O ' ' A' ' 85' ' ' SER . 6.8 t80 -48.65 141.49 7.08 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.789 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 65.42 29.78 11.19 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.775 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.563 ' HG2' HG12 ' A' ' 146' ' ' VAL . 1.2 tp10 -108.16 73.36 0.44 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.762 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.689 ' O ' HG23 ' A' ' 140' ' ' VAL . 55.7 Cg_exo -32.2 119.35 0.09 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 123.013 2.475 . . . . 0.0 112.145 179.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.989 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -116.82 -71.32 0.74 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.545 -179.298 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.905 ' CG2' HD13 ' A' ' 103' ' ' ILE . 1.6 p -93.69 105.32 16.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 121.159 0.504 . . . . 0.0 111.732 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.727 HG13 HG12 ' A' ' 82' ' ' ILE . 41.5 t -84.16 135.38 24.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.861 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.812 HD11 HD22 ' A' ' 115' ' ' LEU . 95.6 mt -133.64 135.63 55.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.362 -179.707 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.443 ' HB2' ' HD3' ' A' ' 136' ' ' LYS . 1.7 tt0 . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.18 -0.914 . . . . 0.0 110.871 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.473 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.332 0 N-CA-C 112.774 -0.13 . . . . 0.0 112.774 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.621 ' C ' HD13 ' A' ' 82' ' ' ILE . 13.4 t-80 171.9 83.85 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.754 0.311 . . . . 0.0 110.582 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 1.034 HD12 HG13 ' A' ' 154' ' ' VAL . 0.0 OUTLIER -103.08 -178.42 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.97 0.414 . . . . 0.0 111.184 -179.995 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.809 HG23 HG13 ' A' ' 153' ' ' VAL . 11.3 t -130.41 32.45 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.763 179.696 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.556 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 4.7 ptt180 -30.41 119.92 0.18 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.283 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.48 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 0.7 OUTLIER -36.48 103.14 0.24 Allowed Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.94 -179.771 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -51.54 -22.58 12.89 Favored 'Trans proline' 0 N--CA 1.464 -0.226 0 C-N-CA 122.653 2.235 . . . . 0.0 112.052 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.0 ptm -141.56 -176.79 4.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.789 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.466 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 15.1 t -82.29 93.5 2.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.046 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -146.22 -141.42 3.61 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.587 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.725 HG23 ' C ' ' A' ' 144' ' ' GLN . 42.4 m -136.57 141.84 43.35 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.792 0.329 . . . . 0.0 111.023 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.866 ' HB2' HD22 ' A' ' 152' ' ' LEU . 0.8 OUTLIER -100.74 146.24 27.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.961 -179.981 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.582 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 16.5 m-85 -143.16 162.61 35.11 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.904 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.543 ' CD ' ' HB3' ' A' ' 142' ' ' SER . 9.5 ptm180 -139.75 31.53 2.04 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.874 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.493 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 68.7 p -145.74 122.15 5.92 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.507 ' HG2' ' CB ' ' A' ' 99' ' ' ALA . 55.7 Cg_endo -70.36 -21.48 30.65 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.701 2.268 . . . . 0.0 112.358 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 15.2 m -162.8 152.97 13.67 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.081 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_exo -49.63 -20.76 4.65 Favored 'Trans proline' 0 C--O 1.232 0.215 0 C-N-CA 122.8 2.333 . . . . 0.0 112.284 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -138.31 72.7 1.41 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.815 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.507 ' CB ' ' HG2' ' A' ' 95' ' ' PRO . . . -137.1 -154.87 0.57 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.197 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -113.15 36.51 3.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.846 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.493 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 62.06 -178.44 0.13 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.115 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.915 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -104.17 -37.13 7.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.866 -179.964 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.915 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.3 OUTLIER -178.18 146.62 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.11 179.992 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -146.75 162.72 37.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.854 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.625 HG22 ' HA ' ' A' ' 137' ' ' ALA . 14.4 t -45.07 134.87 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.193 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 94.43 -11.95 69.55 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.543 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.426 ' O ' ' N ' ' A' ' 109' ' ' VAL . 3.6 tp60 -77.2 95.67 4.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.838 0.351 . . . . 0.0 110.892 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.9 mtmt -64.39 74.24 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.963 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.638 HG11 ' CD2' ' A' ' 115' ' ' LEU . 17.7 m -54.6 167.87 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.014 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.489 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 3.4 p-10 -157.31 131.26 8.2 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 121.174 0.512 . . . . 0.0 110.83 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.452 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 26.1 t -34.69 136.04 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.092 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 86.87 11.83 69.76 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.337 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.418 ' O ' ' C ' ' A' ' 114' ' ' THR . 26.4 t70 -124.69 102.53 7.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.783 0.325 . . . . 0.0 110.867 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.418 ' C ' ' O ' ' A' ' 113' ' ' ASP . 1.6 m -35.52 113.02 0.18 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.154 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.638 ' CD2' HG11 ' A' ' 109' ' ' VAL . 19.2 mt -69.77 -87.53 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.648 179.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.727 ' HB3' HD11 ' A' ' 103' ' ' ILE . 9.1 p -135.32 -166.52 1.85 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.681 179.729 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.966 HD13 ' HB3' ' A' ' 124' ' ' MET . 1.7 mt -126.48 153.77 35.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.595 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.634 HG13 ' O ' ' A' ' 90' ' ' THR . 46.7 t -141.04 103.12 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.965 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.512 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.5 OUTLIER -62.04 69.96 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.118 -179.773 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.518 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -92.81 145.31 24.5 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.904 179.833 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.518 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 9.1 ptp 51.96 21.03 1.37 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.737 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.511 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 1.6 tmtt? 80.28 52.03 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.877 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.486 ' HG3' ' O ' ' A' ' 120' ' ' ALA . 0.2 OUTLIER -172.0 133.13 0.7 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.091 179.804 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.966 ' HB3' HD13 ' A' ' 117' ' ' ILE . 45.2 mtt -67.54 97.16 0.57 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.951 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -79.43 82.08 5.61 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.779 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.547 ' CA ' HG12 ' A' ' 117' ' ' ILE . 4.3 pt20 -58.28 107.71 0.52 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.863 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.467 ' N ' ' O ' ' A' ' 116' ' ' CYS . 7.3 mm -74.99 162.51 4.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.164 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.425 ' N ' HG22 ' A' ' 127' ' ' ILE . 1.6 tt0 -130.04 141.1 50.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.852 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.452 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -46.24 113.65 0.66 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.995 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.402 ' OD1' ' N ' ' A' ' 130' ' ' ASP . 0.4 OUTLIER -101.09 11.09 40.18 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.936 -179.952 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 14.7 tttt 169.99 117.39 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.836 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.489 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 34.8 p -44.25 111.15 0.27 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.781 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -145.96 -175.46 19.02 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.554 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.752 ' C ' HG23 ' A' ' 155' ' ' ILE . 20.7 m -129.54 109.38 10.98 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.645 0.26 . . . . 0.0 111.215 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.56 ' N ' HG23 ' A' ' 155' ' ' ILE . 95.5 t -43.29 143.64 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.626 -0.261 . . . . 0.0 110.364 179.474 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.711 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 1.3 mmmp? -123.72 -18.69 5.99 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.233 -179.55 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.711 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 162.79 164.31 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.888 0.375 . . . . 0.0 111.582 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.65 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -107.11 87.58 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.693 179.787 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.764 HD12 ' HB2' ' A' ' 151' ' ' PRO . 1.8 mt -43.0 -27.77 0.22 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.112 0.482 . . . . 0.0 110.437 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 1.037 HG21 HD23 ' A' ' 152' ' ' LEU . 55.6 t -106.64 140.4 24.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.924 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.522 ' O ' ' CG ' ' A' ' 144' ' ' GLN . 6.6 mt-10 -69.38 98.15 1.05 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.252 179.492 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.543 ' HB3' ' CD ' ' A' ' 93' ' ' ARG . 55.5 p -34.0 150.6 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.732 -179.469 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.582 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 67.33 35.86 88.4 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.383 -0.913 . . . . 0.0 112.149 -179.775 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.725 ' C ' HG23 ' A' ' 90' ' ' THR . 29.2 mm-40 -147.91 154.06 43.04 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 120.86 0.362 . . . . 0.0 111.103 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.693 ' O ' HG13 ' A' ' 146' ' ' VAL . 59.8 Cg_endo -72.29 173.67 12.69 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.823 2.349 . . . . 0.0 112.344 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.868 HG21 HD21 ' A' ' 152' ' ' LEU . 10.5 m -163.65 -173.74 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.071 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.528 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 6.3 pt-20 -140.16 174.08 10.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.966 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.48 ' HA ' ' O ' ' A' ' 85' ' ' SER . 17.1 t80 -50.19 147.59 4.07 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.881 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 53.94 33.36 17.16 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.918 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 19.7 tp10 -109.45 74.74 0.7 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.741 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.815 ' O ' HG23 ' A' ' 140' ' ' VAL . 69.7 Cg_exo -36.34 128.98 0.43 Allowed 'Trans proline' 0 N--CA 1.46 -0.487 0 C-N-CA 122.705 2.27 . . . . 0.0 111.794 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 1.037 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -122.22 -48.91 2.07 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 111.866 0.321 . . . . 0.0 111.866 -179.059 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.809 HG13 HG23 ' A' ' 83' ' ' VAL . 1.6 p -116.94 113.45 42.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 121.026 0.441 . . . . 0.0 111.423 -179.375 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 1.034 HG13 HD12 ' A' ' 82' ' ' ILE . 1.6 t -93.84 144.6 9.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.073 179.77 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.752 HG23 ' C ' ' A' ' 134' ' ' THR . 60.3 mt -144.18 141.86 24.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.146 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.52 ' HB2' ' CE ' ' A' ' 136' ' ' LYS . 15.7 tt0 . . . . . 0 C--O 1.251 1.16 0 CA-C-O 118.224 -0.893 . . . . 0.0 110.823 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.446 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.452 -0.251 0 N-CA-C 112.623 -0.191 . . . . 0.0 112.623 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.55 ' CD2' ' CG2' ' A' ' 155' ' ' ILE . 21.2 t60 170.38 86.12 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.799 0.333 . . . . 0.0 110.817 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.509 HG23 ' O ' ' A' ' 153' ' ' VAL . 0.3 OUTLIER -101.76 159.22 4.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 121.03 0.443 . . . . 0.0 111.176 -179.941 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.839 HG12 ' HB ' ' A' ' 153' ' ' VAL . 4.4 p -109.43 46.64 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.132 -179.855 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.498 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 7.4 ptt180 -31.0 136.64 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.247 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.566 ' N ' HD21 ' A' ' 152' ' ' LEU . 0.3 OUTLIER -43.34 106.42 0.49 Allowed Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.055 -179.734 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -56.71 -20.97 37.22 Favored 'Trans proline' 0 C--O 1.231 0.14 0 C-N-CA 122.736 2.29 . . . . 0.0 111.98 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -155.99 -175.7 5.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.855 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 3.5 m -82.78 76.32 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.168 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -129.96 -146.24 5.97 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.539 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.83 HG23 ' HA ' ' A' ' 145' ' ' PRO . 1.5 m -131.55 154.39 48.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.707 0.289 . . . . 0.0 110.904 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.937 ' CD2' HD12 ' A' ' 152' ' ' LEU . 0.3 OUTLIER -115.39 146.61 41.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.948 0.404 . . . . 0.0 111.25 -179.859 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.579 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 24.0 m-85 -144.04 164.96 29.11 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.862 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.671 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 16.6 ptt180 -149.73 21.92 0.9 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.713 179.8 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.459 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 72.6 p -147.14 86.11 6.63 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.866 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -67.95 -20.89 44.39 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.746 2.297 . . . . 0.0 112.39 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.845 ' OG ' ' HB2' ' A' ' 99' ' ' ALA . 0.0 OUTLIER -120.39 145.04 39.61 Favored Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.958 179.934 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_exo -50.7 -41.48 53.9 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.752 2.301 . . . . 0.0 112.344 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -134.16 60.42 1.7 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.845 ' HB2' ' OG ' ' A' ' 96' ' ' SER . . . -111.14 -169.9 1.54 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.096 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . 0.427 ' N ' ' CD ' ' A' ' 100' ' ' LYS . 0.4 OUTLIER -93.71 24.64 3.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.833 179.984 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.671 ' HB1' ' O ' ' A' ' 93' ' ' ARG . . . 67.13 -178.37 0.21 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.061 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.72 ' O ' HD13 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -89.09 -59.27 2.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.591 179.79 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.936 HG22 HG21 ' A' ' 135' ' ' VAL . 24.6 mm -154.15 94.74 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.908 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -94.66 165.72 12.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.961 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.487 ' CG2' ' O ' ' A' ' 136' ' ' LYS . 2.1 p -53.58 101.62 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.066 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 141.11 -29.86 2.28 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.523 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.423 ' HA ' ' OE1' ' A' ' 107' ' ' GLN . 1.9 mp0 -72.04 121.17 18.73 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.782 0.325 . . . . 0.0 110.861 179.903 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 1.8 mttt -86.36 97.31 10.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.959 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.789 HG11 ' CD2' ' A' ' 115' ' ' LEU . 15.3 m -61.48 176.74 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.123 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.511 ' HA ' ' CB ' ' A' ' 132' ' ' SER . 66.0 m-20 -168.89 133.81 1.57 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.672 179.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.428 ' C ' ' O ' ' A' ' 110' ' ' ASN . 0.2 OUTLIER -35.14 123.79 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.128 179.89 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 91.65 21.12 35.08 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.444 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.43 ' O ' ' C ' ' A' ' 114' ' ' THR . 20.1 t0 -132.37 107.21 8.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.707 0.289 . . . . 0.0 110.87 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.537 ' CG2' ' HB2' ' A' ' 126' ' ' GLN . 2.4 m -34.16 132.9 0.24 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.025 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.789 ' CD2' HG11 ' A' ' 109' ' ' VAL . 18.0 mt -89.07 -83.0 0.24 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.992 -179.858 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . . . . . . . . . 19.0 p -135.91 -166.2 1.83 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.039 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.553 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.3 OUTLIER -113.58 114.49 46.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.21 -179.883 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.974 HG12 ' O ' ' A' ' 125' ' ' ASN . 9.1 p -103.49 58.26 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.831 179.746 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.486 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.5 OUTLIER -34.72 91.32 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.115 -179.778 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' A' ' 118' ' ' VAL . . . -108.4 145.77 34.05 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.009 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.473 ' HG2' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 46.85 24.86 0.39 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.574 -179.868 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.497 ' O ' ' CG ' ' A' ' 123' ' ' MET . 0.0 OUTLIER 79.33 50.21 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.886 -179.917 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.497 ' CG ' ' O ' ' A' ' 122' ' ' LYS . 40.5 mtp -162.28 125.56 2.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.081 179.798 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.553 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -60.28 77.96 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.994 179.947 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.974 ' O ' HG12 ' A' ' 118' ' ' VAL . 1.0 OUTLIER -70.54 73.65 0.53 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.754 179.919 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.537 ' HB2' ' CG2' ' A' ' 114' ' ' THR . 0.0 OUTLIER -50.22 131.59 23.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.015 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.55 HG22 ' N ' ' A' ' 128' ' ' GLU . 35.3 mm -94.03 161.64 2.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.08 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.55 ' N ' HG22 ' A' ' 127' ' ' ILE . 5.8 mt-10 -127.99 142.24 51.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.978 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -62.38 136.81 58.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.085 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -115.87 -8.02 11.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.035 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.477 ' HE2' ' ND1' ' A' ' 81' ' ' HIS . 0.3 OUTLIER -159.94 35.3 0.18 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.839 179.96 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.511 ' CB ' ' HA ' ' A' ' 110' ' ' ASN . 96.1 p 43.64 -171.7 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.767 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.548 ' N ' HG23 ' A' ' 109' ' ' VAL . . . 148.22 -156.84 27.09 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.54 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.541 ' N ' HG12 ' A' ' 155' ' ' ILE . 85.7 m -162.81 110.01 1.24 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.721 0.296 . . . . 0.0 110.91 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.936 HG21 HG22 ' A' ' 103' ' ' ILE . 70.1 t -47.21 144.13 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.893 0.378 . . . . 0.0 111.015 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.548 ' HD3' HG11 ' A' ' 154' ' ' VAL . 0.0 OUTLIER -114.83 -35.82 4.68 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 121.494 0.664 . . . . 0.0 109.451 -179.95 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.642 ' O ' HG23 ' A' ' 154' ' ' VAL . . . 179.65 136.65 0.11 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 114.97 -1.014 . . . . 0.0 111.052 -179.724 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.936 HG21 ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -88.92 85.38 2.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.927 0.394 . . . . 0.0 110.555 179.695 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.422 ' C ' ' O ' ' A' ' 138' ' ' ILE . 10.8 mt -37.16 -31.26 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.485 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.604 HG21 ' HB3' ' A' ' 152' ' ' LEU . 42.9 t -94.32 143.31 11.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.177 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.472 ' O ' ' HB3' ' A' ' 144' ' ' GLN . 27.3 mt-10 -77.59 105.36 8.69 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.917 179.235 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.539 ' HB3' ' CD ' ' A' ' 93' ' ' ARG . 24.4 p -34.45 135.82 0.16 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.765 -179.342 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.579 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 83.64 34.79 18.32 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.41 -0.9 . . . . 0.0 111.93 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.472 ' HB3' ' O ' ' A' ' 141' ' ' GLU . 1.0 OUTLIER -143.42 145.28 31.23 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 120.88 0.372 . . . . 0.0 110.976 -179.658 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.83 ' HA ' HG23 ' A' ' 90' ' ' THR . 57.2 Cg_endo -71.2 171.97 14.94 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.789 2.326 . . . . 0.0 112.204 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.548 ' CG2' ' HB2' ' A' ' 85' ' ' SER . 6.0 m -153.44 -165.12 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.192 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.517 ' O ' ' CG ' ' A' ' 150' ' ' GLU . 3.3 mt-10 -146.03 157.88 43.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.043 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.469 ' HA ' ' O ' ' A' ' 85' ' ' SER . 3.4 t80 -47.39 135.05 11.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.912 179.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.416 ' N ' ' CD1' ' A' ' 148' ' ' PHE . 58.1 t0 67.4 34.8 4.57 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.939 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.565 ' O ' HD23 ' A' ' 152' ' ' LEU . 14.6 mm-40 -115.29 75.43 4.48 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.857 179.769 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.498 ' HA ' ' HA ' ' A' ' 84' ' ' ARG . 71.2 Cg_exo -36.61 125.53 0.41 Allowed 'Trans proline' 0 N--CA 1.459 -0.528 0 C-N-CA 122.75 2.3 . . . . 0.0 111.637 179.51 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.937 HD12 ' CD2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -129.29 -36.24 1.72 Allowed 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 120.962 0.411 . . . . 0.0 110.98 -179.005 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.839 ' HB ' HG12 ' A' ' 83' ' ' VAL . 1.3 t -115.99 109.46 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.347 -178.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.642 HG23 ' O ' ' A' ' 137' ' ' ALA . 1.4 t -98.46 119.04 45.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.612 179.429 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.55 ' CG2' ' CD2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -110.1 154.66 11.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.863 -179.772 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.467 ' N ' ' O ' ' A' ' 134' ' ' THR . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.241 -0.885 . . . . 0.0 110.939 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.469 -0.252 . . . . 0.0 112.469 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.616 ' HD2' HD12 ' A' ' 155' ' ' ILE . 24.5 t60 -178.87 79.79 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.802 0.334 . . . . 0.0 110.874 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 1.069 HD12 HG13 ' A' ' 154' ' ' VAL . 0.2 OUTLIER -92.04 -176.14 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.031 179.845 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.859 HG23 HG13 ' A' ' 153' ' ' VAL . 2.1 t -142.02 41.56 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.859 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.537 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -33.84 132.81 0.22 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.088 -179.845 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.985 ' OG ' HD21 ' A' ' 152' ' ' LEU . 1.5 m -44.44 103.91 0.36 Allowed Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.903 -179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_exo -50.98 -20.04 6.56 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.586 2.191 . . . . 0.0 112.064 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.621 ' SD ' ' HB1' ' A' ' 120' ' ' ALA . 14.9 ptm -150.34 166.73 29.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.681 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.47 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 1.5 p -68.14 95.9 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.004 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -147.56 -133.0 2.31 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.579 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.672 HG23 ' C ' ' A' ' 144' ' ' GLN . 24.3 m -140.43 151.19 44.7 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.831 0.348 . . . . 0.0 110.884 -179.889 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.776 ' CB ' HD22 ' A' ' 152' ' ' LEU . 0.4 OUTLIER -118.22 151.47 37.56 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.828 179.953 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.581 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 23.4 m-85 -147.24 168.76 20.91 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.789 -0.642 . . . . 0.0 111.0 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.468 ' O ' ' N ' ' A' ' 102' ' ' PHE . 0.0 OUTLIER -135.66 18.07 3.32 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.688 179.742 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.622 ' O ' HD11 ' A' ' 117' ' ' ILE . 2.1 p -132.6 108.73 13.24 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.815 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.59 ' HG3' ' CD1' ' A' ' 102' ' ' PHE . 51.8 Cg_exo -53.72 -18.06 11.43 Favored 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.743 2.296 . . . . 0.0 112.3 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.408 ' CB ' ' HD2' ' A' ' 97' ' ' PRO . 0.4 OUTLIER -178.96 167.95 0.88 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.902 -179.963 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.515 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 59.2 Cg_endo -72.29 113.77 3.8 Favored 'Trans proline' 0 N--CA 1.464 -0.215 0 C-N-CA 122.735 2.29 . . . . 0.0 112.361 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.515 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 0.6 OUTLIER 85.15 49.96 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.914 179.934 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -125.88 -163.58 1.23 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.093 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 1.2 mtpp -101.15 38.05 1.64 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.9 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.414 ' C ' ' HD3' ' A' ' 95' ' ' PRO . . . 54.15 175.76 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.084 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.909 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -100.75 -34.56 9.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.945 179.952 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.909 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.3 OUTLIER -179.05 144.04 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.035 179.922 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.471 ' O ' HG11 ' A' ' 135' ' ' VAL . 2.3 mt-10 -146.33 148.33 32.27 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.948 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.529 HG22 ' HA ' ' A' ' 137' ' ' ALA . 3.9 t -35.36 123.82 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.109 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 111.48 -24.97 14.36 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.323 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.65 ' O ' HG12 ' A' ' 135' ' ' VAL . 22.4 tp60 -82.25 117.24 22.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.784 0.326 . . . . 0.0 110.814 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 134' ' ' THR . 0.0 OUTLIER -81.69 100.0 9.23 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.037 -179.885 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.651 HG11 ' CD2' ' A' ' 115' ' ' LEU . 7.7 m -59.27 176.09 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.019 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.432 ' CG ' ' O ' ' A' ' 109' ' ' VAL . 21.3 m120 -163.15 131.31 3.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.036 0.446 . . . . 0.0 110.766 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.517 ' CG1' ' HA ' ' A' ' 131' ' ' LYS . 33.2 m -35.42 138.4 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.011 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 80.74 16.42 75.39 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.333 -179.791 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -124.41 102.62 7.75 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.865 0.364 . . . . 0.0 110.848 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.703 HG23 ' HB2' ' A' ' 126' ' ' GLN . 9.0 m -40.54 110.77 0.16 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.022 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.651 ' CD2' HG11 ' A' ' 109' ' ' VAL . 20.6 mt -65.96 -87.42 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.802 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.549 ' SG ' HG11 ' A' ' 153' ' ' VAL . 0.8 OUTLIER -124.7 -171.28 2.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.768 179.904 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.622 HD11 ' O ' ' A' ' 94' ' ' THR . 0.3 OUTLIER -106.01 113.57 43.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.203 -179.932 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.761 ' O ' HG12 ' A' ' 118' ' ' VAL . 75.7 t -97.3 59.22 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.036 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.475 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.4 OUTLIER -39.1 90.76 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.039 -179.798 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.621 ' HB1' ' SD ' ' A' ' 87' ' ' MET . . . -110.55 144.6 39.15 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.958 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.5 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.1 OUTLIER 56.2 17.03 2.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.892 -179.917 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.5 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.6 OUTLIER 83.41 53.4 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.925 -179.995 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.481 ' HG2' ' O ' ' A' ' 120' ' ' ALA . 3.1 ptt? -173.07 133.45 0.53 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.991 179.769 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.536 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -53.04 96.14 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.019 179.945 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.425 ' O ' ' C ' ' A' ' 126' ' ' GLN . 4.2 t30 -88.18 65.18 8.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.847 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.703 ' HB2' HG23 ' A' ' 114' ' ' THR . 0.0 OUTLIER -35.12 154.46 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.065 -179.857 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.542 HG12 HG23 ' A' ' 118' ' ' VAL . 47.0 mm -121.97 120.3 61.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.22 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 58.4 mm-40 -83.11 119.77 24.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.777 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.453 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -41.61 114.39 0.51 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.164 -179.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -74.76 -27.0 60.16 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.721 179.878 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.517 ' HA ' ' CG1' ' A' ' 111' ' ' VAL . 0.0 OUTLIER -165.05 136.13 4.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.812 179.954 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.428 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.2 t -45.84 132.75 8.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.79 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.513 ' O ' ' N ' ' A' ' 109' ' ' VAL . . . -159.03 176.44 35.85 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.604 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.865 ' C ' HG23 ' A' ' 155' ' ' ILE . 13.8 m -122.88 108.21 12.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.663 0.268 . . . . 0.0 111.263 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.65 HG12 ' O ' ' A' ' 107' ' ' GLN . 2.8 p -49.16 144.68 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.517 -0.311 . . . . 0.0 110.566 179.515 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.662 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 1.1 mmmp? -124.14 -19.24 5.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.632 0.253 . . . . 0.0 111.234 -179.553 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.662 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 166.3 163.23 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.843 0.354 . . . . 0.0 111.433 -179.779 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.641 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.1 OUTLIER -105.23 85.46 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.74 179.626 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.721 HD13 ' HB2' ' A' ' 151' ' ' PRO . 12.4 mt -42.49 -28.03 0.19 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.969 0.414 . . . . 0.0 110.231 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 1.038 HG21 HD23 ' A' ' 152' ' ' LEU . 52.2 t -104.59 141.81 19.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.78 179.593 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 142' ' ' SER . 6.5 mt-10 -69.75 97.12 1.04 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.58 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.461 ' HB2' ' HD2' ' A' ' 93' ' ' ARG . 0.3 OUTLIER -36.93 135.22 0.46 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.627 -179.957 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.581 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 85.81 38.09 8.96 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.534 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.672 ' C ' HG23 ' A' ' 90' ' ' THR . 4.1 pt20 -155.64 163.61 24.08 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.884 0.373 . . . . 0.0 111.155 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.912 ' O ' HG13 ' A' ' 146' ' ' VAL . 55.4 Cg_endo -70.47 -168.78 0.32 Allowed 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.762 2.308 . . . . 0.0 112.646 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.918 HG11 HD23 ' A' ' 152' ' ' LEU . 0.2 OUTLIER -175.72 -174.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.965 -179.982 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.47 ' HA ' ' HA ' ' A' ' 88' ' ' VAL . 4.0 mt-10 -145.6 157.37 43.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.933 0.396 . . . . 0.0 111.089 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.446 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 1.2 t80 -42.94 125.13 3.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.946 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.446 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 2.4 t0 79.61 31.95 0.24 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.951 0.405 . . . . 0.0 110.606 -179.804 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.726 ' HG2' HG12 ' A' ' 146' ' ' VAL . 44.1 tp10 -111.03 74.99 1.05 Allowed Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.879 179.861 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.812 ' O ' HG23 ' A' ' 140' ' ' VAL . 63.3 Cg_exo -35.93 122.75 0.27 Allowed 'Trans proline' 0 N--CA 1.459 -0.508 0 C-N-CA 122.812 2.341 . . . . 0.0 112.084 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 1.038 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -116.66 -54.09 2.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.619 -179.208 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.859 HG13 HG23 ' A' ' 83' ' ' VAL . 1.3 p -108.07 108.72 25.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.121 0.486 . . . . 0.0 111.339 -179.262 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 1.069 HG13 HD12 ' A' ' 82' ' ' ILE . 6.0 t -91.14 138.96 18.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.976 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.865 HG23 ' C ' ' A' ' 134' ' ' THR . 37.3 mt -141.3 141.1 31.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.18 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.52 ' HB2' ' CG ' ' A' ' 136' ' ' LYS . 10.6 tt0 . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.248 -0.882 . . . . 0.0 110.877 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.305 0 N-CA-C 112.422 -0.271 . . . . 0.0 112.422 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.526 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 30.6 t60 -172.52 77.62 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.806 0.336 . . . . 0.0 110.925 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.907 HG12 HG13 ' A' ' 154' ' ' VAL . 10.2 mt -99.22 150.92 4.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.955 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.81 HG23 HG13 ' A' ' 153' ' ' VAL . 4.5 t -96.91 59.93 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.15 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.492 ' O ' ' N ' ' A' ' 86' ' ' PRO . 4.2 mmt85 -28.88 103.3 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.025 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.946 ' CA ' HD11 ' A' ' 152' ' ' LEU . 0.4 OUTLIER -32.12 91.95 0.05 OUTLIER Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.251 -179.789 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.878 ' HD2' HG11 ' A' ' 118' ' ' VAL . 77.5 Cg_exo -50.22 140.21 34.01 Favored 'Trans proline' 0 N--CA 1.464 -0.25 0 C-N-CA 122.755 2.303 . . . . 0.0 112.058 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.458 ' O ' ' O ' ' A' ' 86' ' ' PRO . 7.6 ptm 41.22 -167.09 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.465 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.648 HG22 ' CG ' ' A' ' 147' ' ' GLU . 72.5 t -90.32 114.49 28.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.783 0.325 . . . . 0.0 111.208 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -165.02 -164.11 19.69 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.537 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.749 HG23 ' CA ' ' A' ' 145' ' ' PRO . 1.9 m -115.48 151.56 34.58 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.853 0.359 . . . . 0.0 110.901 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.948 ' HB2' HD22 ' A' ' 152' ' ' LEU . 2.9 t80 -110.78 141.96 43.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.954 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.583 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 21.0 m-85 -142.41 157.49 44.72 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.808 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.519 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 1.7 ptm180 -134.39 20.88 3.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.398 179.568 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.583 ' O ' HD11 ' A' ' 117' ' ' ILE . 69.2 p -123.05 121.84 27.09 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.694 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.433 ' HG2' ' HB3' ' A' ' 99' ' ' ALA . 50.8 Cg_exo -53.07 -59.76 0.93 Allowed 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.685 2.257 . . . . 0.0 112.336 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.581 ' CB ' ' CD ' ' A' ' 97' ' ' PRO . 0.9 OUTLIER 170.99 -66.04 0.0 OUTLIER Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 121.191 0.519 . . . . 0.0 111.106 179.869 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.581 ' CD ' ' CB ' ' A' ' 96' ' ' SER . 46.5 Cg_endo -68.94 53.6 0.81 Allowed 'Trans proline' 0 C--N 1.333 -0.268 0 C-N-CA 123.37 2.713 . . . . 0.0 112.496 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.432 ' C ' ' O ' ' A' ' 97' ' ' PRO . 4.5 p30 35.18 45.2 0.18 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.033 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.433 ' HB3' ' HG2' ' A' ' 95' ' ' PRO . . . -71.68 -160.13 0.05 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.087 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . 0.57 ' O ' ' HB3' ' A' ' 101' ' ' ALA . 0.4 OUTLIER -90.77 27.48 1.77 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.842 179.921 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.57 ' HB3' ' O ' ' A' ' 100' ' ' LYS . . . 75.68 155.85 0.17 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.071 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.666 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -69.11 -37.51 78.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.49 179.885 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.666 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.9 pp -163.34 157.67 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.934 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -154.79 147.57 24.41 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.056 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.736 HG23 ' HA ' ' A' ' 136' ' ' LYS . 2.0 p -44.2 109.4 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.05 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 126.38 -18.07 6.5 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.397 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -85.48 106.37 16.77 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.842 0.353 . . . . 0.0 110.867 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' A' ' 109' ' ' VAL . 2.4 mttp -67.03 79.53 0.12 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.908 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.71 HG22 ' O ' ' A' ' 133' ' ' GLY . 22.1 m -45.8 175.55 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.109 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.445 ' HA ' ' HB2' ' A' ' 132' ' ' SER . 1.7 p-10 -165.27 135.02 3.58 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 121.026 0.441 . . . . 0.0 110.742 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.468 ' HA ' ' HB3' ' A' ' 129' ' ' ALA . 20.2 t -34.82 137.24 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 115.711 -0.677 . . . . 0.0 111.077 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 81.31 16.22 74.61 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.414 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 114' ' ' THR . 9.0 t0 -122.54 101.71 7.64 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.814 0.34 . . . . 0.0 110.952 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.451 ' HA ' ' O ' ' A' ' 127' ' ' ILE . 1.5 m -35.4 108.7 0.07 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.898 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.51 ' N ' ' O ' ' A' ' 127' ' ' ILE . 14.7 mt -62.24 -67.04 0.45 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.791 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.498 ' SG ' ' N ' ' A' ' 117' ' ' ILE . 2.5 p -162.46 -154.47 0.31 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.942 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.583 HD11 ' O ' ' A' ' 94' ' ' THR . 0.1 OUTLIER -122.23 119.37 58.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.282 -179.85 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.878 HG11 ' HD2' ' A' ' 86' ' ' PRO . 2.4 t -109.21 58.46 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.801 179.644 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.486 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.4 OUTLIER -34.74 104.11 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.165 -179.703 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.524 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -121.81 108.91 14.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.995 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.532 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 86.16 17.8 0.11 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.676 -179.802 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.541 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 5.0 tmtm? 87.61 26.58 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.861 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.486 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 1.1 mmm -139.85 124.81 18.56 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.927 0.394 . . . . 0.0 111.157 179.768 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.554 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -55.55 102.97 0.08 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.875 179.762 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.449 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 9.8 t30 -84.78 65.21 9.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.813 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.439 ' HA ' ' O ' ' A' ' 116' ' ' CYS . 6.7 pt20 -45.79 118.99 2.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.96 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.547 HD11 HG21 ' A' ' 118' ' ' VAL . 3.7 mm -94.2 151.66 3.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.005 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -126.65 130.45 50.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.922 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.468 ' HB3' ' HA ' ' A' ' 111' ' ' VAL . . . -42.44 134.07 3.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.111 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.446 ' OD1' ' O ' ' A' ' 130' ' ' ASP . 10.5 t70 -118.44 -0.24 11.47 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.076 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.458 ' O ' ' O ' ' A' ' 132' ' ' SER . 1.3 ptmt -170.73 29.61 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.941 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.458 ' O ' ' O ' ' A' ' 131' ' ' LYS . 0.9 OUTLIER 47.38 -179.52 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.743 -179.815 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.71 ' O ' HG22 ' A' ' 109' ' ' VAL . . . 152.01 174.19 22.42 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.625 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.711 ' N ' HG23 ' A' ' 155' ' ' ILE . 27.5 m -120.94 110.68 16.58 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.553 0.216 . . . . 0.0 111.235 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.545 ' HA ' ' CG1' ' A' ' 155' ' ' ILE . 61.3 t -49.77 145.66 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.63 -0.259 . . . . 0.0 110.32 179.461 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.736 ' HA ' HG23 ' A' ' 105' ' ' VAL . 50.9 mmtt -125.38 -18.04 5.44 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 121.049 -0.26 . . . . 0.0 111.643 -179.417 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.696 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 164.66 153.46 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.927 0.394 . . . . 0.0 111.857 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.737 ' N ' HD13 ' A' ' 138' ' ' ILE . 0.0 OUTLIER -95.7 77.9 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.419 179.499 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.739 HD12 HG22 ' A' ' 154' ' ' VAL . 3.9 mt -38.44 -30.86 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.118 0.485 . . . . 0.0 110.223 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.94 HG21 HD23 ' A' ' 152' ' ' LEU . 55.3 t -102.93 138.32 27.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.818 179.725 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.518 ' O ' ' CG ' ' A' ' 144' ' ' GLN . 1.7 mt-10 -68.92 106.5 2.75 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.385 179.801 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.507 ' HB3' ' CG ' ' A' ' 93' ' ' ARG . 6.3 p -36.41 152.07 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.697 -179.554 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.583 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 56.99 43.86 92.97 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.395 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.595 ' C ' HG23 ' A' ' 90' ' ' THR . 61.6 mm-40 -147.39 137.95 12.71 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.895 0.378 . . . . 0.0 111.245 -179.769 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.749 ' CA ' HG23 ' A' ' 90' ' ' THR . 57.1 Cg_endo -70.64 156.18 61.55 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.691 2.261 . . . . 0.0 112.266 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.923 HG21 HD21 ' A' ' 152' ' ' LEU . 4.1 m -152.24 -156.51 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.208 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.648 ' CG ' HG22 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -147.57 174.31 11.87 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.95 -179.943 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.444 ' HA ' ' O ' ' A' ' 85' ' ' SER . 25.4 t80 -53.84 150.81 7.12 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.87 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.418 ' O ' ' HD3' ' A' ' 151' ' ' PRO . 84.1 m-20 60.2 23.6 12.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.928 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.477 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 4.6 tt0 -107.17 74.51 0.4 Allowed Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.815 179.738 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.854 ' O ' HG23 ' A' ' 140' ' ' VAL . 62.9 Cg_exo -35.51 127.92 0.3 Allowed 'Trans proline' 0 N--CA 1.459 -0.542 0 C-N-CA 122.996 2.464 . . . . 0.0 112.5 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.948 HD22 ' HB2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -120.89 -59.97 1.69 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.273 -179.729 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.81 HG13 HG23 ' A' ' 83' ' ' VAL . 1.4 p -102.93 101.88 12.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.202 -179.663 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.907 HG13 HG12 ' A' ' 82' ' ' ILE . 17.0 t -87.11 136.0 23.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.811 -0.632 . . . . 0.0 111.292 179.844 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.711 HG23 ' N ' ' A' ' 134' ' ' THR . 22.8 mt -140.34 139.85 35.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.049 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.528 ' HB3' ' CE ' ' A' ' 136' ' ' LYS . 6.0 tp10 . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.243 -0.884 . . . . 0.0 110.841 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.443 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.33 0 N-CA-C 112.517 -0.233 . . . . 0.0 112.517 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.536 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 26.8 t60 171.89 83.94 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.896 0.379 . . . . 0.0 110.964 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.826 HG12 HG13 ' A' ' 154' ' ' VAL . 6.8 mt -100.67 147.05 8.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.017 0.436 . . . . 0.0 110.999 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.845 HG23 HG13 ' A' ' 153' ' ' VAL . 3.5 t -93.36 45.31 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.993 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.474 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -34.61 127.39 0.48 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.8 -179.978 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.511 ' OG ' HG23 ' A' ' 146' ' ' VAL . 5.3 t -34.83 107.68 0.32 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.956 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -63.74 -20.95 69.64 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.791 2.327 . . . . 0.0 111.945 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 9.9 ptp -154.37 172.59 17.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.781 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.701 ' O ' HG23 ' A' ' 88' ' ' VAL . 30.7 m -66.7 87.71 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.057 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.58 ' O ' HG22 ' A' ' 146' ' ' VAL . . . -147.82 -161.16 9.33 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.635 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.654 ' CG2' ' CE1' ' A' ' 92' ' ' TYR . 5.3 m -117.48 140.6 49.39 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.893 0.378 . . . . 0.0 111.124 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.958 ' HB2' HD22 ' A' ' 152' ' ' LEU . 14.4 t80 -89.3 143.02 27.15 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.269 179.453 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.654 ' CE1' ' CG2' ' A' ' 90' ' ' THR . 18.5 m-85 -139.91 148.81 42.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.888 0.375 . . . . 0.0 111.22 -179.521 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.466 ' O ' ' N ' ' A' ' 102' ' ' PHE . 0.7 OUTLIER -135.11 13.18 3.58 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.809 179.818 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 52.5 p -141.49 110.3 6.28 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.954 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.1 -39.45 5.85 Favored 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 122.725 2.283 . . . . 0.0 112.414 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -129.72 148.98 71.66 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.92 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.33 -34.74 71.96 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.693 2.262 . . . . 0.0 112.294 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -118.63 42.46 2.75 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.856 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -100.26 -154.86 0.49 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.094 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.19 36.78 4.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.863 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.461 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 56.67 165.67 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.117 179.846 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.912 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -89.22 -34.63 16.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.964 179.994 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.912 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.2 OUTLIER 176.49 127.34 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.104 -179.912 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.84 165.6 17.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.807 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.542 ' HA ' HG12 ' A' ' 135' ' ' VAL . 1.9 p -44.28 119.59 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.927 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 114.25 -14.05 21.12 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.374 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.494 ' HG3' HG22 ' A' ' 103' ' ' ILE . 2.4 mm-40 -74.26 126.02 29.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.827 0.346 . . . . 0.0 110.887 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.0 74.03 5.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.855 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.475 HG23 ' H ' ' A' ' 133' ' ' GLY . 22.1 m -47.14 172.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.984 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.474 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 27.2 m120 -163.95 131.13 3.31 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.022 0.439 . . . . 0.0 110.72 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.517 HG23 ' O ' ' A' ' 111' ' ' VAL . 33.8 m -35.54 118.72 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.022 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 100.91 15.51 28.47 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.317 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.471 ' HB2' ' O ' ' A' ' 110' ' ' ASN . 0.3 OUTLIER -125.2 103.92 8.23 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.854 0.359 . . . . 0.0 110.669 179.993 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.549 ' CG2' ' HB3' ' A' ' 126' ' ' GLN . 2.3 m -33.92 122.14 0.46 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.149 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.477 ' O ' HG12 ' A' ' 103' ' ' ILE . 15.1 mt -78.24 -86.08 0.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.929 179.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.56 ' SG ' HG11 ' A' ' 153' ' ' VAL . 0.5 OUTLIER -135.04 -174.33 3.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.101 -179.904 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 1.028 HG22 ' CB ' ' A' ' 124' ' ' MET . 0.1 OUTLIER -104.86 129.45 57.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.016 -179.954 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 124' ' ' MET . 6.0 t -123.06 100.89 8.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.591 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.577 ' HG2' ' CE2' ' A' ' 92' ' ' TYR . 1.0 OUTLIER -100.16 117.71 34.98 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.522 179.571 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.523 ' O ' ' CB ' ' A' ' 121' ' ' MET . . . -112.55 47.27 1.1 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.468 -179.512 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.523 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 6.1 ptm 155.13 -39.42 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.267 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.497 ' HD2' ' HG2' ' A' ' 123' ' ' MET . 0.0 OUTLIER 172.48 -28.44 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.042 -179.971 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.528 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.8 OUTLIER -97.61 127.27 43.43 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.945 179.498 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 1.028 ' CB ' HG22 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -93.94 153.62 18.12 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.366 -179.249 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.508 ' O ' ' N ' ' A' ' 127' ' ' ILE . 59.5 t-20 -114.04 101.92 9.68 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.192 179.617 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.549 ' HB3' ' CG2' ' A' ' 114' ' ' THR . 0.7 OUTLIER -62.65 69.23 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.786 -179.721 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.508 ' N ' ' O ' ' A' ' 125' ' ' ASN . 26.1 mm -37.06 147.28 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.132 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.41 ' O ' ' C ' ' A' ' 129' ' ' ALA . 10.2 pt-20 -116.03 128.73 55.95 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.755 179.858 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -35.48 116.15 0.35 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.238 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -87.3 -12.61 46.01 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.739 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.477 ' HG3' ' O ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -174.28 126.52 0.34 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.764 179.96 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.474 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 8.0 t -41.83 124.87 2.71 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.779 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.475 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -152.21 176.01 30.66 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.548 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.738 ' C ' HG23 ' A' ' 155' ' ' ILE . 13.1 m -125.15 108.26 11.6 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.701 0.286 . . . . 0.0 111.288 -179.828 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.542 HG12 ' HA ' ' A' ' 105' ' ' VAL . 19.0 t -44.2 144.97 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.624 179.435 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.708 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 21.3 mtpt -123.7 -18.49 6.07 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.225 -179.567 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.708 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 163.11 161.56 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.976 0.417 . . . . 0.0 111.631 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.641 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.6 OUTLIER -111.93 85.0 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.894 179.753 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.632 HD12 ' HB2' ' A' ' 151' ' ' PRO . 8.5 mt -49.12 -38.35 24.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.99 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 1.004 HG21 HD23 ' A' ' 152' ' ' LEU . 49.2 t -83.6 143.7 11.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.146 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.485 ' O ' ' C ' ' A' ' 142' ' ' SER . 17.2 mt-10 -74.5 78.15 1.94 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.06 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.502 ' HA ' ' CE2' ' A' ' 91' ' ' PHE . 11.6 p 21.77 -114.56 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 115.285 -0.871 . . . . 0.0 111.815 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.584 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -62.81 80.84 0.03 OUTLIER Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.839 -0.696 . . . . 0.0 113.043 -179.794 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.479 ' O ' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -157.56 144.15 13.12 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-O 121.078 0.466 . . . . 0.0 111.435 179.593 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.433 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 27.6 Cg_endo -62.4 151.57 81.98 Favored 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.974 2.449 . . . . 0.0 112.546 -179.792 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.734 HG11 ' CD2' ' A' ' 152' ' ' LEU . 18.3 m -143.93 -173.16 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.883 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.437 ' O ' ' C ' ' A' ' 148' ' ' PHE . 0.1 OUTLIER -150.26 149.64 30.43 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.899 179.992 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.499 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 2.0 t80 -34.33 124.15 0.5 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.822 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.499 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 17.4 t0 83.94 27.14 0.09 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.593 -179.607 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.416 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 44.0 tp10 -110.33 73.73 0.79 Allowed Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.908 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.811 ' O ' HG23 ' A' ' 140' ' ' VAL . 68.6 Cg_exo -34.18 127.59 0.18 Allowed 'Trans proline' 0 N--CA 1.459 -0.559 0 C-N-CA 122.825 2.35 . . . . 0.0 112.044 179.681 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 1.004 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -122.46 -64.98 1.14 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.525 -179.425 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.845 HG13 HG23 ' A' ' 83' ' ' VAL . 1.6 p -103.92 102.89 14.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.254 -179.469 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.826 HG13 HG12 ' A' ' 82' ' ' ILE . 10.3 t -83.47 142.67 13.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 115.76 -0.654 . . . . 0.0 111.275 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.738 HG23 ' C ' ' A' ' 134' ' ' THR . 27.5 mt -144.48 141.47 23.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.994 179.858 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.545 ' CA ' ' HD2' ' A' ' 136' ' ' LYS . 3.0 tt0 . . . . . 0 C--O 1.249 1.036 0 CA-C-O 118.283 -0.865 . . . . 0.0 110.919 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.457 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.451 -0.328 0 N-CA-C 112.442 -0.263 . . . . 0.0 112.442 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.587 ' CD2' ' HE3' ' A' ' 131' ' ' LYS . 17.1 t-80 172.53 84.19 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.788 0.328 . . . . 0.0 110.983 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.748 HG12 HG13 ' A' ' 154' ' ' VAL . 29.8 mt -92.26 116.62 33.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.07 0.462 . . . . 0.0 110.836 179.727 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.966 HG21 HD13 ' A' ' 115' ' ' LEU . 2.0 t -69.85 59.79 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.244 -179.701 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.532 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -47.53 135.08 11.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.725 179.823 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.511 ' HB3' HD21 ' A' ' 152' ' ' LEU . 1.3 p -39.3 104.63 0.32 Allowed Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.996 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 37.4 Cg_endo -66.18 -7.18 16.51 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.656 2.237 . . . . 0.0 112.018 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.453 ' HG3' ' CB ' ' A' ' 120' ' ' ALA . 2.0 ptm -155.72 168.3 27.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.641 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 7.1 m -71.87 60.16 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.124 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.652 ' O ' HG22 ' A' ' 146' ' ' VAL . . . -116.96 -165.69 13.93 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.454 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.635 HG23 ' C ' ' A' ' 144' ' ' GLN . 24.4 m -108.99 156.92 19.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.987 0.422 . . . . 0.0 111.024 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.684 ' CZ ' HG21 ' A' ' 138' ' ' ILE . 11.9 t80 -106.77 140.68 39.22 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.263 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.578 ' CD2' ' OE1' ' A' ' 119' ' ' GLU . 17.6 m-85 -143.13 151.09 40.32 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.971 0.415 . . . . 0.0 111.063 179.607 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.713 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 18.2 ptt180 -132.11 23.92 4.54 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.663 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.473 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 63.5 p -150.57 107.11 3.1 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.868 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.21 -16.11 31.68 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.651 2.234 . . . . 0.0 112.221 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -142.93 159.64 55.77 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.918 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -53.32 -63.33 0.24 Allowed 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.806 2.337 . . . . 0.0 112.341 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -110.99 79.79 1.24 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.876 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -135.2 -166.91 1.91 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.102 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.09 38.09 1.27 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.928 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.713 ' HB1' ' O ' ' A' ' 93' ' ' ARG . . . 49.39 -177.18 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.239 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.852 ' O ' HD13 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -90.11 -61.44 1.68 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.126 179.55 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.852 HD13 ' O ' ' A' ' 102' ' ' PHE . 2.2 mm -153.52 145.03 14.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.7 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -147.45 162.84 38.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.738 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.494 HG13 ' HA ' ' A' ' 136' ' ' LYS . 6.0 t -47.32 119.68 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.995 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 120.15 -27.04 6.86 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.249 -179.71 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.83 112.49 18.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.759 0.314 . . . . 0.0 110.807 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.465 ' O ' ' O ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -79.49 81.83 5.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.843 179.998 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.897 HG22 ' O ' ' A' ' 133' ' ' GLY . 14.7 m -45.28 176.11 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.003 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 109' ' ' VAL . 35.0 m120 -163.19 131.1 3.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.615 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.524 ' HA ' ' HB3' ' A' ' 129' ' ' ALA . 2.3 p -37.58 155.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.968 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . 0.437 ' N ' HG22 ' A' ' 111' ' ' VAL . . . 75.78 -0.08 62.6 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.339 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.464 ' O ' ' HA ' ' A' ' 128' ' ' GLU . 2.5 t0 -107.17 -149.53 0.43 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.691 0.282 . . . . 0.0 110.689 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.76 HG21 ' CZ ' ' A' ' 102' ' ' PHE . 6.1 m -135.73 150.4 49.51 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.89 0.376 . . . . 0.0 111.012 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.966 HD13 HG21 ' A' ' 83' ' ' VAL . 83.0 mt -106.81 -79.74 0.57 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.892 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . . . . . . . . . 14.9 p -134.51 -166.1 1.76 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.97 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 1.024 HG22 ' OE2' ' A' ' 119' ' ' GLU . 0.3 OUTLIER -115.01 125.22 72.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.297 -179.725 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.497 HG21 HD11 ' A' ' 127' ' ' ILE . 54.7 t -108.58 95.0 3.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.449 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 1.024 ' OE2' HG22 ' A' ' 117' ' ' ILE . 0.5 OUTLIER -102.76 105.0 15.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.877 -179.083 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.598 ' HB2' ' HA3' ' A' ' 89' ' ' GLY . . . -126.57 48.01 2.22 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.709 -179.684 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.557 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 152.55 51.88 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.25 179.907 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.486 ' HD3' ' O ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 56.14 18.2 3.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.343 -179.313 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.487 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 1.7 mtt -141.24 122.8 15.1 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.821 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.575 ' CB ' HG22 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -75.15 171.82 13.47 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.428 -0.806 . . . . 0.0 111.44 -179.839 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.463 ' HB2' ' HB ' ' A' ' 118' ' ' VAL . 3.5 m120 -151.49 83.79 1.3 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.473 179.73 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.562 ' HB2' HG23 ' A' ' 114' ' ' THR . 3.2 pt20 -50.23 113.41 0.86 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.06 -179.67 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.821 HG21 HG11 ' A' ' 83' ' ' VAL . 18.8 mm -81.42 95.65 2.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.919 179.802 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.478 ' HA ' ' HA ' ' A' ' 114' ' ' THR . 1.4 mt-10 -72.05 144.08 48.87 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.115 -179.773 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.524 ' HB3' ' HA ' ' A' ' 111' ' ' VAL . . . -68.67 142.46 55.05 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.831 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 55.7 p30 -126.74 1.87 6.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.341 -0.391 . . . . 0.0 111.08 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.587 ' HE3' ' CD2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -158.83 22.21 0.21 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.092 -179.927 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.478 ' O ' ' NZ ' ' A' ' 131' ' ' LYS . 1.1 p 49.94 173.56 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.783 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.897 ' O ' HG22 ' A' ' 109' ' ' VAL . . . 156.56 176.02 28.18 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.571 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.773 ' C ' HG23 ' A' ' 155' ' ' ILE . 25.9 m -127.78 119.56 25.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.582 0.229 . . . . 0.0 111.307 -179.765 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.595 HG21 HG22 ' A' ' 103' ' ' ILE . 73.3 t -52.36 144.7 3.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 179.172 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.65 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 22.4 mmmt -125.17 -18.77 5.32 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.685 0.279 . . . . 0.0 111.422 -179.431 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.799 ' C ' HD13 ' A' ' 138' ' ' ILE . . . 167.05 156.78 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.178 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.799 HD13 ' C ' ' A' ' 137' ' ' ALA . 0.2 OUTLIER -109.88 84.58 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.032 179.821 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.564 ' N ' HD23 ' A' ' 139' ' ' LEU . 3.6 mt -47.13 -25.86 0.98 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.415 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.967 HG21 HD23 ' A' ' 152' ' ' LEU . 78.3 t -104.8 149.47 8.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.735 179.71 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.534 ' HB2' ' CG ' ' A' ' 144' ' ' GLN . 4.1 mm-40 -52.55 -170.99 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.376 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.522 ' O ' ' O ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -84.87 -55.41 4.1 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 120.837 -0.345 . . . . 0.0 111.509 -179.789 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.561 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -128.16 103.14 0.61 Allowed Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.857 -179.342 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.635 ' C ' HG23 ' A' ' 90' ' ' THR . 0.0 OUTLIER -174.05 144.17 0.98 Allowed Pre-proline 0 C--N 1.326 -0.413 0 CA-C-O 121.034 0.445 . . . . 0.0 111.18 179.669 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 144' ' ' GLN . 43.7 Cg_exo -56.58 142.97 90.06 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.83 2.353 . . . . 0.0 112.036 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.916 HG11 ' CD2' ' A' ' 152' ' ' LEU . 4.8 m -128.86 179.52 3.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.157 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.458 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 1.3 mt-10 -129.82 141.4 50.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.73 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.46 ' HA ' ' O ' ' A' ' 85' ' ' SER . 34.5 t80 -35.45 137.52 0.18 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.903 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.468 ' HA ' ' HD2' ' A' ' 84' ' ' ARG . 0.6 OUTLIER 72.32 26.13 2.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.756 -179.799 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.465 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 6.7 tp10 -106.81 73.96 0.35 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.869 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.753 ' O ' HG23 ' A' ' 140' ' ' VAL . 61.0 Cg_exo -34.19 122.19 0.15 Allowed 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.869 2.379 . . . . 0.0 111.96 179.581 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.967 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -118.57 -66.61 1.06 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.563 -179.215 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.542 HG13 ' HB ' ' A' ' 83' ' ' VAL . 0.8 OUTLIER -96.7 106.22 18.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.289 -179.393 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.748 HG13 HG12 ' A' ' 82' ' ' ILE . 34.5 t -87.51 134.45 27.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.291 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.773 HG23 ' C ' ' A' ' 134' ' ' THR . 72.0 mt -135.73 140.02 45.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.987 179.785 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.55 ' CG ' ' HB ' ' A' ' 134' ' ' THR . 10.0 pt-20 . . . . . 0 C--O 1.249 1.027 0 CA-C-O 118.26 -0.876 . . . . 0.0 110.88 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.484 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.45 -0.386 0 N-CA-C 112.533 -0.227 . . . . 0.0 112.533 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.594 ' CD2' ' HB ' ' A' ' 155' ' ' ILE . 16.1 t60 173.74 83.7 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.763 0.316 . . . . 0.0 110.901 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.932 HD12 HG13 ' A' ' 154' ' ' VAL . 0.0 OUTLIER -97.74 -179.2 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.56 179.617 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.798 ' CG2' HG13 ' A' ' 153' ' ' VAL . 48.7 t -117.62 2.87 7.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.365 179.728 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.493 ' C ' ' O ' ' A' ' 83' ' ' VAL . 0.9 OUTLIER 23.97 98.22 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.486 179.858 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.653 ' HB2' HD21 ' A' ' 152' ' ' LEU . 4.1 t -34.37 95.81 0.09 OUTLIER Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.795 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.519 ' O ' ' CD1' ' A' ' 148' ' ' PHE . 18.8 Cg_endo -58.91 -74.45 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.638 2.225 . . . . 0.0 111.9 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.584 ' HE3' ' HB2' ' A' ' 120' ' ' ALA . 6.0 mtm -70.77 156.51 39.43 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.783 179.645 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.775 HG22 ' O ' ' A' ' 88' ' ' VAL . 2.6 p -79.43 57.74 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.048 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -114.34 -148.2 9.69 Favored Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.38 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.898 HG23 ' O ' ' A' ' 144' ' ' GLN . 16.9 m -122.91 144.22 49.37 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-O 121.087 0.47 . . . . 0.0 111.24 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.881 ' HB2' HD22 ' A' ' 152' ' ' LEU . 29.5 t80 -83.34 142.62 30.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.615 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.56 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 12.1 m-85 -144.88 153.68 41.84 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.428 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 0.6 OUTLIER -139.73 32.83 2.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.845 179.845 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.488 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -148.5 109.5 3.61 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.881 179.902 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 94' ' ' THR . 37.7 Cg_endo -66.22 -38.9 19.5 Favored 'Trans proline' 0 C--O 1.231 0.137 0 C-N-CA 122.752 2.301 . . . . 0.0 112.272 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.459 ' OG ' ' HD2' ' A' ' 97' ' ' PRO . 0.2 OUTLIER -129.02 168.78 14.86 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.9 179.995 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.459 ' HD2' ' OG ' ' A' ' 96' ' ' SER . 52.9 Cg_exo -52.29 -53.98 5.99 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.787 2.325 . . . . 0.0 112.221 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -124.5 71.79 1.17 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.874 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -119.09 -166.9 1.31 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.128 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -92.85 29.05 1.89 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.768 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.488 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 60.81 170.84 0.1 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.001 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.871 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -87.15 -43.26 12.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.849 -179.996 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.871 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.1 pp -169.79 134.0 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.04 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.595 ' O ' HG11 ' A' ' 135' ' ' VAL . 5.7 mt-10 -137.5 157.8 45.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.966 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.609 HG22 ' HA ' ' A' ' 137' ' ' ALA . 3.0 t -38.55 125.36 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.078 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . 0.438 ' N ' HG13 ' A' ' 135' ' ' VAL . . . 109.45 -28.05 11.47 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.466 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.542 ' O ' HG12 ' A' ' 135' ' ' VAL . 5.6 tp60 -71.61 109.74 5.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.807 0.337 . . . . 0.0 110.867 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 134' ' ' THR . 4.0 mttt -74.47 91.43 2.26 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.014 -179.862 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.938 HG11 ' CD2' ' A' ' 115' ' ' LEU . 0.0 OUTLIER -50.37 174.88 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.911 179.889 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.542 ' O ' ' HB3' ' A' ' 129' ' ' ALA . 6.9 m120 -162.53 131.33 4.15 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.09 0.472 . . . . 0.0 110.719 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.621 HG12 ' HA ' ' A' ' 131' ' ' LYS . 34.5 m -34.79 137.38 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.071 179.8 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 65.56 30.26 77.04 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.497 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.484 ' CB ' ' O ' ' A' ' 110' ' ' ASN . 11.1 t70 -125.52 104.86 8.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.743 0.306 . . . . 0.0 110.735 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.471 HG23 ' HB2' ' A' ' 126' ' ' GLN . 1.6 m -34.34 128.48 0.42 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.045 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.938 ' CD2' HG11 ' A' ' 109' ' ' VAL . 11.1 mt -95.15 -83.31 0.36 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.789 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.519 ' CB ' ' O ' ' A' ' 92' ' ' TYR . 0.5 OUTLIER -132.36 -169.26 2.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.673 179.927 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.541 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.2 OUTLIER -111.65 123.81 67.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.211 179.895 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.777 HG21 HD11 ' A' ' 127' ' ' ILE . 96.5 t -113.73 74.64 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.218 179.4 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.583 ' CG ' ' HB ' ' A' ' 90' ' ' THR . 2.4 pt-20 -58.31 89.96 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.286 -179.333 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.584 ' HB2' ' HE3' ' A' ' 87' ' ' MET . . . -94.17 116.9 29.36 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.449 179.515 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.571 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.3 OUTLIER 90.25 -33.1 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.648 -179.344 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.571 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 150.34 -13.46 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.02 179.903 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.508 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 2.5 ptt? -106.57 134.32 49.9 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.91 0.386 . . . . 0.0 111.164 -179.623 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.541 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 2.4 ptm -55.51 133.31 50.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.135 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.451 ' OD1' ' HE2' ' A' ' 87' ' ' MET . 2.0 t-20 -120.27 68.6 0.85 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.669 179.823 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.471 ' HB2' HG23 ' A' ' 114' ' ' THR . 0.2 OUTLIER -43.01 131.86 4.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.844 -179.836 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.777 HD11 HG21 ' A' ' 118' ' ' VAL . 57.7 mt -95.18 149.59 4.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.245 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -108.55 131.58 54.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.888 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.542 ' HB3' ' O ' ' A' ' 110' ' ' ASN . . . -45.28 110.03 0.21 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.161 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -68.51 -20.4 64.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.796 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.621 ' HA ' HG12 ' A' ' 111' ' ' VAL . 0.0 OUTLIER -179.0 137.04 0.14 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.776 179.945 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.411 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 24.6 t -41.31 127.3 2.88 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.805 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.493 ' O ' ' N ' ' A' ' 109' ' ' VAL . . . -161.67 -178.94 36.02 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.613 -0.804 . . . . 0.0 112.63 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.879 ' C ' HG23 ' A' ' 155' ' ' ILE . 16.5 m -129.43 108.62 10.42 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.645 0.259 . . . . 0.0 111.419 -179.755 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.595 HG11 ' O ' ' A' ' 104' ' ' GLU . 2.2 p -49.13 144.12 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 179.284 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.596 ' C ' HG13 ' A' ' 105' ' ' VAL . 4.5 mmtt -122.25 -20.28 6.23 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 121.05 -0.26 . . . . 0.0 111.456 -179.232 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.609 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 175.35 175.32 0.23 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.054 0.454 . . . . 0.0 111.798 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.656 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 1.2 mm -125.82 85.09 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.861 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.841 HD21 HG21 ' A' ' 154' ' ' VAL . 5.9 mt -50.79 -21.73 1.8 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.768 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 1.038 HG21 HD23 ' A' ' 152' ' ' LEU . 69.9 t -108.11 151.44 10.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.254 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.446 ' O ' ' C ' ' A' ' 142' ' ' SER . 39.6 mt-10 -64.17 135.75 56.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.942 179.19 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.505 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -32.17 -61.35 0.25 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.595 -179.272 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.56 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -125.11 103.34 0.72 Allowed Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.505 -0.855 . . . . 0.0 112.895 -179.619 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.898 ' O ' HG23 ' A' ' 90' ' ' THR . 6.4 pt20 -170.94 153.81 4.02 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-O 120.938 0.399 . . . . 0.0 111.215 179.718 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.417 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 37.0 Cg_endo -65.92 140.03 59.07 Favored 'Trans proline' 0 C--O 1.232 0.209 0 C-N-CA 122.843 2.362 . . . . 0.0 112.534 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.857 HG11 ' CD2' ' A' ' 152' ' ' LEU . 26.7 m -130.32 -171.68 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.893 179.864 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.422 ' O ' ' C ' ' A' ' 148' ' ' PHE . 2.5 tm-20 -130.11 137.92 50.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.971 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.521 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 1.5 t80 -35.72 120.01 0.57 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.744 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.521 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 5.4 t70 86.19 31.38 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.887 0.375 . . . . 0.0 110.524 -179.553 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.482 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 5.8 tp10 -107.18 75.1 0.42 Allowed Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.66 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.776 ' HB3' HG21 ' A' ' 82' ' ' ILE . 48.5 Cg_exo -30.58 109.71 0.04 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.723 0 C-N-CA 123.159 2.573 . . . . 0.0 112.377 179.69 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 1.038 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -104.68 -56.1 2.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.315 -179.412 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.798 HG13 ' CG2' ' A' ' 83' ' ' VAL . 0.9 OUTLIER -103.43 111.8 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.402 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.45 -179.185 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.932 HG13 HD12 ' A' ' 82' ' ' ILE . 3.1 t -91.77 145.1 7.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.863 179.763 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.879 HG23 ' C ' ' A' ' 134' ' ' THR . 4.4 mt -138.53 147.68 25.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.433 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.528 ' HB2' ' CE ' ' A' ' 136' ' ' LYS . 6.8 tp10 . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.271 -0.871 . . . . 0.0 110.844 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.265 0 N-CA-C 112.489 -0.244 . . . . 0.0 112.489 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.549 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 31.8 t60 -177.98 79.39 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.776 0.322 . . . . 0.0 110.871 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.854 HG12 HG13 ' A' ' 154' ' ' VAL . 16.7 mt -95.54 143.05 12.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.157 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.528 ' HB ' ' CG1' ' A' ' 153' ' ' VAL . 2.2 t -103.34 54.32 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.21 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.517 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 2.1 ptt180 -38.21 141.97 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.803 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.648 ' CA ' HD11 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -35.52 95.6 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.94 -179.974 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.441 ' N ' ' O ' ' A' ' 84' ' ' ARG . 66.7 Cg_exo -50.63 -20.2 6.1 Favored 'Trans proline' 0 N--CA 1.466 -0.143 0 C-N-CA 122.648 2.232 . . . . 0.0 112.157 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.485 ' SD ' ' CB ' ' A' ' 120' ' ' ALA . 2.2 ptm -162.76 177.52 9.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.723 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.651 HG22 ' CG ' ' A' ' 147' ' ' GLU . 93.3 t -70.77 97.66 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.145 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.704 ' O ' HG23 ' A' ' 146' ' ' VAL . . . -162.04 -166.86 21.58 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.37 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.799 HG23 ' N ' ' A' ' 145' ' ' PRO . 3.6 m -109.52 126.96 54.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.789 0.328 . . . . 0.0 110.883 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.633 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 2.7 t80 -82.15 140.1 33.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.796 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.583 ' CE2' ' HG2' ' A' ' 119' ' ' GLU . 18.7 m-85 -137.92 152.9 49.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.934 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.537 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 0.7 OUTLIER -134.27 18.57 3.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.818 179.808 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.464 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 5.4 p -145.44 106.43 4.38 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.803 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.593 ' HG3' ' CG ' ' A' ' 102' ' ' PHE . 27.9 Cg_exo -61.98 -9.63 15.08 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.776 2.317 . . . . 0.0 112.429 -179.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.513 ' HB3' ' HB2' ' A' ' 99' ' ' ALA . 1.5 t -172.23 153.84 3.13 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.912 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_exo -55.84 -50.88 11.06 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.722 2.281 . . . . 0.0 112.269 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -106.29 56.52 0.66 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.513 ' HB2' ' HB3' ' A' ' 96' ' ' SER . . . -121.08 -160.78 0.86 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.123 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 2.0 mmmt -103.99 24.26 11.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.002 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.464 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 57.81 162.64 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.073 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.913 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -88.42 -41.38 12.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.981 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.913 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.8 OUTLIER -175.53 150.29 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-O 120.939 0.4 . . . . 0.0 111.271 179.668 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -152.06 158.62 43.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.683 179.775 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.657 ' HA ' HG12 ' A' ' 135' ' ' VAL . 6.8 p -48.24 105.26 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.166 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 123.9 -0.03 9.1 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.369 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.4 mm-40 -77.99 144.02 37.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.751 0.31 . . . . 0.0 110.98 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -98.94 90.73 4.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.907 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.736 HG11 ' CD2' ' A' ' 115' ' ' LEU . 15.6 m -87.89 159.63 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.105 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.47 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 31.9 m-80 -162.35 130.39 3.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.067 0.46 . . . . 0.0 110.776 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.461 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 24.6 m -35.84 123.49 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.224 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 108.44 3.06 33.07 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.559 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -113.42 -149.39 0.45 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.766 0.317 . . . . 0.0 110.685 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.68 HG21 ' OE1' ' A' ' 126' ' ' GLN . 5.5 m -136.23 132.23 35.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.924 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.736 ' CD2' HG11 ' A' ' 109' ' ' VAL . 75.4 mt -92.43 -84.71 0.27 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.916 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.517 ' HA ' ' CG ' ' A' ' 102' ' ' PHE . 2.3 p -143.78 -167.13 2.51 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.037 -179.894 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.85 HD13 ' HB2' ' A' ' 124' ' ' MET . 2.8 mt -131.59 150.44 34.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.812 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.594 HG22 ' HA ' ' A' ' 91' ' ' PHE . 53.6 t -143.93 103.22 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.856 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.583 ' HG2' ' CE2' ' A' ' 92' ' ' TYR . 6.8 pt-20 -58.6 82.28 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.146 -179.681 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.54 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -95.67 99.92 11.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.663 179.627 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.54 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 88.43 30.96 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.563 -179.53 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.505 ' HB3' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 75.8 30.49 0.76 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.217 -179.996 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.497 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 18.6 mmt -149.39 124.77 10.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.967 0.413 . . . . 0.0 110.906 179.558 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.85 ' HB2' HD13 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -59.75 103.18 0.19 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.148 -179.824 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 31.4 t30 -83.31 80.68 9.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.547 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.68 ' OE1' HG21 ' A' ' 114' ' ' THR . 17.3 tt0 -56.81 124.03 17.07 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.94 -179.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.499 HG22 HD12 ' A' ' 115' ' ' LEU . 15.3 mm -91.17 120.35 39.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.136 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -90.93 143.16 27.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.882 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -57.05 116.73 3.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.047 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -117.42 14.35 14.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.811 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.465 ' HB3' ' CE1' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -179.39 102.99 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.69 -180.0 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.47 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 0.9 OUTLIER -42.77 122.59 2.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.616 179.897 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.471 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -156.25 -167.32 17.42 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.615 -179.846 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.627 ' N ' HG23 ' A' ' 155' ' ' ILE . 21.3 m -140.16 112.42 7.75 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.511 0.196 . . . . 0.0 111.169 -179.791 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.657 HG12 ' HA ' ' A' ' 105' ' ' VAL . 38.3 t -44.85 140.14 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.243 179.365 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.701 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 1.0 OUTLIER -122.42 -17.01 7.17 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.755 0.312 . . . . 0.0 111.152 -179.263 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.701 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 162.41 148.17 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.486 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.777 ' N ' HD13 ' A' ' 138' ' ' ILE . 0.0 OUTLIER -94.92 86.18 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.498 179.649 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.931 HD12 ' HB2' ' A' ' 151' ' ' PRO . 0.6 OUTLIER -40.81 -29.41 0.1 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.094 0.473 . . . . 0.0 110.207 -179.87 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.961 ' CG2' HD23 ' A' ' 152' ' ' LEU . 56.1 t -106.99 137.98 35.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.863 179.843 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.471 ' O ' ' HG2' ' A' ' 144' ' ' GLN . 3.4 mt-10 -67.65 98.11 0.67 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.219 179.513 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.537 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 24.2 p -34.15 135.87 0.14 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.899 -179.588 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.581 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 84.24 34.34 17.63 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.323 -179.663 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.653 ' C ' HG23 ' A' ' 90' ' ' THR . 37.8 mm-40 -146.2 144.8 22.27 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 120.898 0.38 . . . . 0.0 111.144 -179.736 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.873 ' O ' HG13 ' A' ' 146' ' ' VAL . 52.5 Cg_exo -55.32 177.26 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.862 2.375 . . . . 0.0 112.325 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.873 HG13 ' O ' ' A' ' 145' ' ' PRO . 0.2 OUTLIER -173.31 -174.42 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.193 -179.997 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.651 ' CG ' HG22 ' A' ' 88' ' ' VAL . 8.8 tt0 -155.71 158.5 38.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.903 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.473 ' HA ' ' O ' ' A' ' 85' ' ' SER . 42.5 t80 -42.42 138.84 1.65 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.967 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 74.67 24.1 1.73 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.524 ' CG ' ' O ' ' A' ' 147' ' ' GLU . 67.4 mm-40 -115.12 73.3 3.37 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.841 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.931 ' HB2' HD12 ' A' ' 139' ' ' LEU . 62.7 Cg_exo -33.75 129.04 0.16 Allowed 'Trans proline' 0 N--CA 1.458 -0.567 0 C-N-CA 122.974 2.449 . . . . 0.0 112.165 179.648 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 0.961 HD23 ' CG2' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -125.49 -71.67 0.69 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.727 -179.349 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.528 ' CG1' ' HB ' ' A' ' 83' ' ' VAL . 1.7 p -93.77 104.0 15.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.873 -179.085 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.854 HG13 HG12 ' A' ' 82' ' ' ILE . 21.4 t -89.13 133.1 32.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.814 179.333 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.627 HG23 ' N ' ' A' ' 134' ' ' THR . 97.1 mt -135.43 134.16 52.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.146 -179.727 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.518 ' CB ' ' HD3' ' A' ' 136' ' ' LYS . 1.2 tm-20 . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.259 -0.877 . . . . 0.0 110.898 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.542 ' CA ' ' HB2' ' A' ' 156' ' ' GLU . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.487 -0.245 . . . . 0.0 112.487 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.558 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 34.2 t60 -169.49 75.65 0.09 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.811 0.338 . . . . 0.0 110.812 179.814 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.902 HG12 HG13 ' A' ' 154' ' ' VAL . 6.2 mt -93.25 150.44 3.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.105 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.745 HG23 HG13 ' A' ' 153' ' ' VAL . 3.1 t -102.43 46.55 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.037 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.516 ' CD ' ' O ' ' A' ' 84' ' ' ARG . 0.0 OUTLIER -35.48 131.92 0.45 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.859 179.965 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.571 ' HB3' HD21 ' A' ' 152' ' ' LEU . 95.2 p -36.56 99.16 0.17 Allowed Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.968 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 20.1 Cg_endo -60.97 -11.98 20.57 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.619 2.213 . . . . 0.0 111.97 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.405 ' O ' ' N ' ' A' ' 89' ' ' GLY . 1.0 OUTLIER -160.58 167.76 26.42 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.607 179.856 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.742 ' O ' HG23 ' A' ' 88' ' ' VAL . 26.4 m -66.49 69.66 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.007 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 87' ' ' MET . . . -121.67 -150.83 8.36 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.639 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 1.015 HG23 ' C ' ' A' ' 144' ' ' GLN . 97.9 m -131.95 128.45 38.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.961 0.41 . . . . 0.0 111.028 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 1.063 ' HB2' HD22 ' A' ' 152' ' ' LEU . 69.8 t80 -68.75 143.49 54.65 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.526 179.724 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.601 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 7.8 m-30 -149.06 125.77 11.11 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.897 0.379 . . . . 0.0 110.85 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.506 ' HA ' ' HB2' ' A' ' 102' ' ' PHE . 39.8 ptt85 -117.54 22.52 12.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.883 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.52 112.24 5.03 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.962 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.52 -38.86 3.05 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.689 2.259 . . . . 0.0 112.333 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -130.38 161.64 59.31 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.849 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.46 ' O ' ' HB3' ' A' ' 98' ' ' ASP . 38.4 Cg_endo -66.83 102.92 0.66 Allowed 'Trans proline' 0 C--O 1.231 0.13 0 C-N-CA 122.722 2.282 . . . . 0.0 112.362 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.46 ' HB3' ' O ' ' A' ' 97' ' ' PRO . 9.3 t70 80.16 35.29 0.14 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.884 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -88.74 -155.31 0.33 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.012 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.93 27.97 3.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.801 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 54.48 174.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.054 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.916 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -99.51 -35.2 9.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.874 179.972 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.916 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.2 pp -179.03 123.53 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.987 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.44 ' O ' ' HB3' ' A' ' 107' ' ' GLN . 1.7 mt-10 -141.34 164.7 29.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.949 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 38.7 t -37.09 135.38 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.118 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 87.78 -24.5 10.47 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.557 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.512 ' HG2' HG22 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -71.66 94.62 1.36 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.84 0.352 . . . . 0.0 110.842 -179.967 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 10.5 mttm -75.53 105.16 6.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.906 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.762 HG11 HD23 ' A' ' 115' ' ' LEU . 5.5 m -80.04 173.44 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.177 -179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.484 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 4.5 p-10 -152.62 129.87 11.25 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.756 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.459 ' HA ' ' CB ' ' A' ' 129' ' ' ALA . 7.5 p -43.26 143.17 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.582 -0.735 . . . . 0.0 111.081 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 90.12 -2.13 81.07 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.412 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -105.98 -146.81 0.39 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.571 0.224 . . . . 0.0 110.63 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 3.9 m -130.13 120.36 24.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.789 0.328 . . . . 0.0 111.016 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.762 HD23 HG11 ' A' ' 109' ' ' VAL . 15.8 mt -77.06 -85.35 0.06 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.793 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.496 ' HB3' HD11 ' A' ' 103' ' ' ILE . 5.0 p -148.14 171.09 16.46 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.795 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.999 HD13 ' HB3' ' A' ' 124' ' ' MET . 3.7 mt -105.24 152.58 7.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.834 -179.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.458 ' HA ' ' O ' ' A' ' 90' ' ' THR . 55.6 t -144.04 103.23 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.052 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.494 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 1.9 mt-10 -65.54 100.78 0.53 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.151 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -83.26 -77.09 0.26 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.377 0.608 . . . . 0.0 111.071 179.795 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.531 ' O ' ' CG ' ' A' ' 122' ' ' LYS . 7.6 ptm -91.37 32.71 1.03 Allowed 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.367 179.695 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.531 ' CG ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 90.47 2.73 0.16 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.817 -179.63 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.48 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 4.9 ptm -116.78 133.58 55.84 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.841 179.785 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.999 ' HB3' HD13 ' A' ' 117' ' ' ILE . 3.3 mpp? -55.85 120.09 6.82 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.872 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.423 ' HB2' ' O ' ' A' ' 118' ' ' VAL . 35.8 t30 -102.3 73.44 1.35 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.947 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.547 ' CA ' HG12 ' A' ' 117' ' ' ILE . 15.4 pt20 -51.75 130.9 29.77 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.039 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 31.2 mm -103.59 136.79 34.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.094 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -95.41 145.32 25.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.883 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.459 ' CB ' ' HA ' ' A' ' 111' ' ' VAL . . . -64.78 121.63 15.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.062 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -94.88 -8.86 36.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.988 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -173.99 134.12 0.45 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.829 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.484 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 88.7 p -49.81 119.14 3.29 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.646 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -141.83 -176.77 16.34 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.628 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.635 ' N ' HG23 ' A' ' 155' ' ' ILE . 23.4 m -136.17 109.34 7.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.631 0.253 . . . . 0.0 111.139 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.489 HG22 HG12 ' A' ' 155' ' ' ILE . 67.1 t -48.27 142.49 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.289 179.4 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.554 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 55.1 mtpt -126.93 -19.8 4.35 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 121.042 -0.263 . . . . 0.0 111.705 -179.258 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.686 ' C ' HD13 ' A' ' 138' ' ' ILE . . . 173.62 162.52 0.16 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.025 0.44 . . . . 0.0 111.773 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.686 HD13 ' C ' ' A' ' 137' ' ' ALA . 0.6 OUTLIER -116.59 80.08 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.752 179.656 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.493 HD12 ' HB2' ' A' ' 151' ' ' PRO . 13.3 mt -47.99 -23.28 0.75 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.856 -179.822 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 0.985 HG21 HD23 ' A' ' 152' ' ' LEU . 53.5 t -108.16 143.34 18.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.235 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.491 ' HB2' ' HG2' ' A' ' 144' ' ' GLN . 4.9 mt-10 -59.61 136.06 57.87 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.922 179.31 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.48 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -30.61 -63.5 0.14 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.817 -179.259 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.601 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -124.06 103.54 0.77 Allowed Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.528 -0.844 . . . . 0.0 113.028 -179.393 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 1.015 ' C ' HG23 ' A' ' 90' ' ' THR . 0.0 OUTLIER -169.98 145.93 2.53 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-O 120.904 0.383 . . . . 0.0 111.149 179.616 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.434 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 39.0 Cg_exo -56.94 144.59 88.49 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.751 2.301 . . . . 0.0 112.066 179.803 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.635 HG11 ' CD2' ' A' ' 152' ' ' LEU . 0.2 OUTLIER -136.23 -174.21 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.201 -179.926 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.447 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -143.75 142.59 30.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.929 179.915 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.49 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 4.4 t80 -34.68 129.71 0.41 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.072 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.49 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.7 t70 83.01 23.6 0.15 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.918 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.447 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 25.7 mm-40 -109.54 74.28 0.68 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.835 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.848 ' O ' HG23 ' A' ' 140' ' ' VAL . 53.6 Cg_exo -33.71 126.38 0.15 Allowed 'Trans proline' 0 N--CA 1.458 -0.605 0 C-N-CA 122.866 2.377 . . . . 0.0 112.14 179.607 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 1.063 HD22 ' HB2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -117.89 -68.42 0.92 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.607 -179.175 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.749 HG21 HD13 ' A' ' 103' ' ' ILE . 1.3 p -102.45 106.22 19.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.418 -179.217 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.902 HG13 HG12 ' A' ' 82' ' ' ILE . 4.2 t -87.89 130.2 37.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.05 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.635 HG23 ' N ' ' A' ' 134' ' ' THR . 91.3 mt -132.99 131.87 58.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.215 -179.788 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.542 ' HB2' ' CA ' ' A' ' 80' ' ' GLY . 14.9 tt0 . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.259 -0.877 . . . . 0.0 110.96 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.435 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.45 -0.371 0 N-CA-C 112.336 -0.306 . . . . 0.0 112.336 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.52 ' N ' ' O ' ' A' ' 155' ' ' ILE . 23.7 t60 175.56 82.42 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.759 0.314 . . . . 0.0 110.943 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 0.879 HG12 HG13 ' A' ' 154' ' ' VAL . 10.8 mt -98.73 123.14 51.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.074 0.464 . . . . 0.0 110.976 179.79 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.618 ' CG2' HG13 ' A' ' 153' ' ' VAL . 2.0 t -76.29 57.55 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.762 -0.653 . . . . 0.0 111.312 -179.693 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.518 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -35.39 119.42 0.51 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.723 -179.977 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 1.019 ' CA ' HD11 ' A' ' 152' ' ' LEU . 0.3 OUTLIER -35.26 104.84 0.26 Allowed Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.177 -179.755 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.458 ' O ' ' O ' ' A' ' 87' ' ' MET . 32.6 Cg_endo -64.14 138.57 62.37 Favored 'Trans proline' 0 C--O 1.231 0.145 0 C-N-CA 122.62 2.213 . . . . 0.0 111.654 179.508 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.458 ' O ' ' O ' ' A' ' 86' ' ' PRO . 3.9 ptp 42.3 -167.81 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.354 -179.613 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.781 HG22 ' HG2' ' A' ' 147' ' ' GLU . 52.4 t -88.36 106.96 17.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.847 0.356 . . . . 0.0 111.203 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -157.54 -158.05 8.74 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.582 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.69 ' O ' HG13 ' A' ' 118' ' ' VAL . 4.4 m -123.89 148.74 46.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.909 0.385 . . . . 0.0 111.088 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.663 ' CZ ' HG21 ' A' ' 138' ' ' ILE . 46.8 t80 -90.99 140.6 29.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.042 -0.527 . . . . 0.0 109.927 179.307 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.594 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 11.3 m-85 -146.19 123.05 11.3 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.975 0.417 . . . . 0.0 111.169 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.495 ' HA ' ' HB2' ' A' ' 102' ' ' PHE . 41.3 ptt85 -116.04 39.35 3.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.673 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 31.2 p -150.86 115.6 3.23 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.022 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.408 ' HD3' ' C ' ' A' ' 101' ' ' ALA . 58.7 Cg_endo -71.85 -29.58 15.2 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.738 2.292 . . . . 0.0 112.204 179.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -143.35 158.88 56.94 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.875 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_exo -52.44 -38.74 74.58 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.69 2.26 . . . . 0.0 112.263 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 -129.05 60.34 1.55 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.922 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -116.14 -168.95 1.51 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.14 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . 0.481 ' NZ ' ' HB2' ' A' ' 100' ' ' LYS . 0.8 OUTLIER -91.4 27.04 2.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.978 179.951 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . 0.48 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 65.42 178.59 0.2 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.192 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.863 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -95.22 -31.88 13.29 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.709 179.9 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.863 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.1 OUTLIER 169.42 138.49 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.21 179.621 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.828 ' O ' HG11 ' A' ' 135' ' ' VAL . 5.3 pt-20 -140.78 160.0 40.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.0 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.442 ' HB ' ' HA ' ' A' ' 137' ' ' ALA . 7.7 p -43.57 123.14 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.217 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . 0.482 ' H ' HG13 ' A' ' 135' ' ' VAL . . . 111.07 -19.98 24.42 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.446 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.829 ' O ' HG12 ' A' ' 135' ' ' VAL . 0.2 OUTLIER -87.47 113.6 23.33 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.801 0.334 . . . . 0.0 110.859 179.975 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 1.1 pttt -75.84 117.1 17.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.896 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.76 HG11 ' CD2' ' A' ' 115' ' ' LEU . 35.2 m -86.78 168.41 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.087 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.485 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 2.5 p-10 -160.11 132.14 6.21 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 121.129 0.49 . . . . 0.0 110.696 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.641 HG13 ' O ' ' A' ' 129' ' ' ALA . 4.1 t -36.86 139.87 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.963 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 88.99 7.38 70.54 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.27 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.461 ' O ' ' N ' ' A' ' 115' ' ' LEU . 6.8 m-20 -123.63 103.2 8.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.857 0.36 . . . . 0.0 110.835 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.414 ' C ' ' O ' ' A' ' 113' ' ' ASP . 4.3 m -37.23 94.72 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.925 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.76 ' CD2' HG11 ' A' ' 109' ' ' VAL . 9.9 mt -47.87 -91.0 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.703 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.633 ' HB3' HD11 ' A' ' 103' ' ' ILE . 2.0 p -138.33 155.95 48.09 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.851 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.678 HD13 ' HB2' ' A' ' 124' ' ' MET . 3.7 mt -89.79 153.21 3.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.025 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.69 HG13 ' O ' ' A' ' 90' ' ' THR . 86.3 t -145.23 101.08 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.852 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.515 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 2.4 mm-40 -55.27 84.49 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.243 -179.779 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.48 ' O ' ' HG3' ' A' ' 121' ' ' MET . . . -103.04 145.68 29.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.722 179.7 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.48 ' HG3' ' O ' ' A' ' 120' ' ' ALA . 2.2 ptm 45.53 26.82 0.34 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.035 0.445 . . . . 0.0 110.252 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.525 ' O ' ' CE ' ' A' ' 122' ' ' LYS . 0.1 OUTLIER 77.89 45.1 0.08 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.746 -179.698 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.51 ' N ' ' OE1' ' A' ' 119' ' ' GLU . 11.1 mtt -162.21 127.84 3.47 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.992 179.713 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.678 ' HB2' HD13 ' A' ' 117' ' ' ILE . 0.9 OUTLIER -57.68 87.18 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.56 179.61 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 12.6 t-20 -65.59 79.9 0.07 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.945 -179.799 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . 0.456 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -57.16 118.87 5.48 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.87 179.99 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.475 ' O ' ' N ' ' A' ' 115' ' ' LEU . 34.7 mm -84.77 134.26 27.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.042 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . 0.404 ' OE2' ' HG2' ' A' ' 126' ' ' GLN . 3.8 mm-40 -108.08 116.55 32.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.957 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.641 ' O ' HG13 ' A' ' 111' ' ' VAL . . . -37.8 113.49 0.28 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.131 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 42.9 p-10 -93.96 -14.36 26.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.935 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 15.6 ptmt -162.37 126.07 3.05 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.783 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.485 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 5.3 p -46.39 120.01 2.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.993 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.513 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -143.59 -168.59 12.26 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.433 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.568 ' N ' HG23 ' A' ' 155' ' ' ILE . 17.4 m -143.81 107.31 4.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.684 0.278 . . . . 0.0 111.25 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.829 HG12 ' O ' ' A' ' 107' ' ' GLN . 7.1 p -45.73 141.15 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.301 179.43 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.688 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 20.6 mtpt -120.82 -18.65 7.58 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.711 0.291 . . . . 0.0 111.111 -179.522 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.688 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 163.71 153.31 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.983 0.42 . . . . 0.0 111.765 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.663 HG21 ' CZ ' ' A' ' 91' ' ' PHE . 0.1 OUTLIER -108.31 79.35 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.545 179.684 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 8.2 mt -44.93 -25.96 0.37 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.722 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 1.045 HG21 HD23 ' A' ' 152' ' ' LEU . 62.3 t -102.85 146.71 10.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.009 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.556 ' O ' ' CD2' ' A' ' 91' ' ' PHE . 15.4 mt-10 -51.25 -174.84 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.172 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.492 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -82.18 -55.4 4.57 Favored 'General case' 0 C--N 1.324 -0.529 0 C-N-CA 120.881 -0.327 . . . . 0.0 110.921 179.935 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.594 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -126.5 103.1 0.66 Allowed Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.577 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.631 ' O ' HG23 ' A' ' 90' ' ' THR . 0.0 OUTLIER -165.03 151.56 9.21 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-O 120.948 0.404 . . . . 0.0 111.352 179.92 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.501 ' O ' ' NE2' ' A' ' 144' ' ' GLN . 30.7 Cg_endo -63.72 131.17 30.29 Favored 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.97 2.447 . . . . 0.0 112.48 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 0.525 HG11 ' CD2' ' A' ' 152' ' ' LEU . 0.2 OUTLIER -133.05 176.81 8.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.896 179.886 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.781 ' HG2' HG22 ' A' ' 88' ' ' VAL . 2.3 mt-10 -133.41 156.86 46.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.969 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.484 ' HA ' ' O ' ' A' ' 85' ' ' SER . 8.3 t80 -40.57 153.6 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.895 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.453 ' OD1' ' O ' ' A' ' 149' ' ' ASP . 1.0 OUTLIER 54.8 28.04 9.73 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.529 179.806 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.54 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 11.0 tp10 -107.23 74.35 0.4 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.702 179.492 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.608 ' O ' HG23 ' A' ' 140' ' ' VAL . 48.8 Cg_exo -31.35 129.13 0.08 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 123.138 2.559 . . . . 0.0 112.362 179.758 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 1.045 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -130.16 -68.91 0.69 Allowed 'General case' 0 C--O 1.232 0.181 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.694 -179.484 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.623 HG11 ' SG ' ' A' ' 116' ' ' CYS . 1.5 p -99.65 101.78 12.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.606 -178.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 0.879 HG13 HG12 ' A' ' 82' ' ' ILE . 23.8 t -81.86 138.49 19.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.0 179.602 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.568 HG23 ' N ' ' A' ' 134' ' ' THR . 83.6 mt -139.05 136.62 42.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.285 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.449 ' CA ' ' HD2' ' A' ' 136' ' ' LYS . 0.5 OUTLIER . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.282 -0.866 . . . . 0.0 110.927 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.488 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . . . . . . 0 N--CA 1.452 -0.299 0 N-CA-C 112.592 -0.203 . . . . 0.0 112.592 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' HIS . . . . . 0.509 ' N ' ' O ' ' A' ' 155' ' ' ILE . 24.7 t60 171.21 83.98 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.778 0.323 . . . . 0.0 110.797 -179.864 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . 1.015 HD12 HG13 ' A' ' 154' ' ' VAL . 0.2 OUTLIER -88.02 -177.52 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.992 0.425 . . . . 0.0 111.001 179.909 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.914 ' CG2' HG13 ' A' ' 153' ' ' VAL . 1.7 t -140.92 39.17 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.705 179.603 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' ARG . . . . . 0.546 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 1.7 ptt-85 -34.07 127.42 0.42 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.979 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . 0.438 ' HB3' HD21 ' A' ' 152' ' ' LEU . 0.9 OUTLIER -38.37 112.02 0.64 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.883 179.986 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' PRO . . . . . 0.424 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 25.9 Cg_endo -61.96 -11.27 20.65 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.669 2.246 . . . . 0.0 111.945 179.853 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . 0.573 ' SD ' ' HB1' ' A' ' 120' ' ' ALA . 5.6 ptm -156.59 177.09 11.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.598 179.844 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' VAL . . . . . 0.424 HG12 ' H ' ' A' ' 88' ' ' VAL . 1.7 p -80.43 94.18 2.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.082 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -143.64 -123.42 1.74 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.613 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' THR . . . . . 0.673 HG21 ' CZ ' ' A' ' 92' ' ' TYR . 38.5 m -150.9 150.78 31.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.861 0.362 . . . . 0.0 110.996 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' PHE . . . . . 0.652 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 0.8 OUTLIER -116.89 143.27 45.89 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.931 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' TYR . . . . . 0.673 ' CZ ' HG21 ' A' ' 90' ' ' THR . 22.5 m-85 -142.9 163.17 33.52 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.029 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' ARG . . . . . 0.488 ' HG2' ' HB2' ' A' ' 142' ' ' SER . 29.0 ptt180 -143.83 24.69 1.67 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.752 179.695 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' THR . . . . . 0.4 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 0.0 OUTLIER -156.51 91.99 2.52 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.767 179.833 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 94' ' ' THR . 45.2 Cg_endo -68.47 -25.32 35.46 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.785 2.323 . . . . 0.0 112.565 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . 0.415 ' HA ' ' HD3' ' A' ' 97' ' ' PRO . 0.9 OUTLIER -135.57 133.13 20.06 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 120.966 0.413 . . . . 0.0 111.057 -179.896 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.483 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 52.1 Cg_exo -54.55 109.98 0.46 Allowed 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.803 2.335 . . . . 0.0 112.23 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' ASP . . . . . 0.483 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 10.4 t70 81.6 46.67 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.823 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' ALA . . . . . 0.404 ' HB2' ' HB2' ' A' ' 96' ' ' SER . . . -107.2 -166.47 1.16 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.081 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -90.41 23.51 2.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.795 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 56.88 159.7 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.146 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' PHE . . . . . 0.849 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -87.63 -37.79 16.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.82 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' ILE . . . . . 0.849 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.6 OUTLIER -170.19 110.03 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.134 -179.999 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' GLU . . . . . 0.504 ' N ' ' OE1' ' A' ' 104' ' ' GLU . 12.5 pm0 -121.73 162.3 21.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.852 179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.613 HG22 ' HA ' ' A' ' 137' ' ' ALA . 4.4 t -45.36 97.74 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.091 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.02 -8.97 6.03 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.513 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.432 ' O ' ' N ' ' A' ' 109' ' ' VAL . 29.7 tp60 -70.64 99.59 1.69 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.793 0.33 . . . . 0.0 110.881 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' LYS . . . . . 0.444 ' O ' ' O ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -67.67 61.06 0.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.962 -179.984 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.808 HG22 ' O ' ' A' ' 133' ' ' GLY . 16.9 m -42.09 168.15 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.047 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' ASN . . . . . 0.511 ' ND2' ' HB2' ' A' ' 132' ' ' SER . 23.0 m120 -167.18 132.99 2.13 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.579 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.572 HG12 ' C ' ' A' ' 130' ' ' ASP . 18.1 m -34.05 136.34 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.172 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 81.33 14.97 77.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.303 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' ASP . . . . . 0.422 ' O ' ' C ' ' A' ' 114' ' ' THR . 0.8 OUTLIER -128.51 105.88 8.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.854 0.359 . . . . 0.0 110.824 179.957 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' THR . . . . . 0.422 ' C ' ' O ' ' A' ' 113' ' ' ASP . 1.3 m -35.18 127.93 0.54 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.033 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' LEU . . . . . 0.556 HD12 HG22 ' A' ' 127' ' ' ILE . 14.7 mt -87.63 -83.95 0.2 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.908 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' CYS . . . . . 0.53 ' HB3' HD11 ' A' ' 103' ' ' ILE . 21.4 p -135.2 -165.51 1.69 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.917 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' ILE . . . . . 0.566 ' CG2' ' CB ' ' A' ' 124' ' ' MET . 0.2 OUTLIER -113.7 113.92 45.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.212 -179.988 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.498 ' HB ' ' HB3' ' A' ' 125' ' ' ASN . 25.8 t -103.47 55.1 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.82 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' GLU . . . . . 0.479 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.2 OUTLIER -35.44 98.8 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.093 -179.842 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' ALA . . . . . 0.573 ' HB1' ' SD ' ' A' ' 87' ' ' MET . . . -118.16 110.27 17.39 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.923 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' MET . . . . . 0.544 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.3 OUTLIER 87.07 21.42 0.06 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.855 -179.908 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.544 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 89.69 0.81 0.26 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.252 179.907 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.479 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.4 OUTLIER -119.86 133.58 55.53 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.854 0.359 . . . . 0.0 111.138 179.942 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.566 ' CB ' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -64.22 112.63 3.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.051 179.87 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.498 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 0.8 OUTLIER -86.7 74.93 9.74 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.656 179.715 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -48.88 112.27 0.59 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.005 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' ILE . . . . . 0.556 HG22 HD12 ' A' ' 115' ' ' LEU . 3.9 mm -90.94 145.5 7.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.044 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -122.61 123.65 41.67 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.985 -179.873 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' ALA . . . . . 0.503 ' HA ' HD11 ' A' ' 115' ' ' LEU . . . -38.95 142.58 0.21 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.119 179.874 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' ASP . . . . . 0.572 ' C ' HG12 ' A' ' 111' ' ' VAL . 0.5 OUTLIER -121.49 -7.56 9.18 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.042 179.997 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.485 ' NZ ' ' O ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -160.13 23.88 0.17 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.769 179.991 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' SER . . . . . 0.511 ' HB2' ' ND2' ' A' ' 110' ' ' ASN . 1.3 p 53.66 -176.57 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.632 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' GLY . . . . . 0.808 ' O ' HG22 ' A' ' 109' ' ' VAL . . . 150.13 167.09 14.0 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.575 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . 0.75 ' N ' HG23 ' A' ' 155' ' ' ILE . 18.8 m -116.57 110.74 18.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.658 0.266 . . . . 0.0 111.18 -179.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.51 HG12 ' HA ' ' A' ' 105' ' ' VAL . 95.0 t -47.22 142.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.472 179.51 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.652 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.2 OUTLIER -124.83 -19.18 5.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.424 -179.399 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . 0.694 ' C ' HD13 ' A' ' 138' ' ' ILE . . . 167.23 155.97 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.835 0.35 . . . . 0.0 111.351 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' ILE . . . . . 0.785 ' N ' HD13 ' A' ' 138' ' ' ILE . 0.0 OUTLIER -106.94 82.92 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.948 179.835 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' LEU . . . . . 0.917 HD21 HG21 ' A' ' 154' ' ' VAL . 6.6 mt -41.2 -34.96 0.53 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 121.168 0.508 . . . . 0.0 109.97 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' VAL . . . . . 1.056 HG21 HD23 ' A' ' 152' ' ' LEU . 59.0 t -92.18 136.86 23.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.701 179.648 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . 0.484 ' O ' ' HG2' ' A' ' 144' ' ' GLN . 4.5 mt-10 -70.22 100.19 1.64 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.443 179.817 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.488 ' HB2' ' HG2' ' A' ' 93' ' ' ARG . 5.9 p -36.13 147.66 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.682 -179.698 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' GLY . . . . . 0.579 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 71.97 35.29 61.44 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.451 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' GLN . . . . . 0.576 HE21 HG13 ' A' ' 140' ' ' VAL . 0.7 OUTLIER -149.03 153.48 38.27 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.883 0.373 . . . . 0.0 111.115 -179.913 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' PRO . . . . . 0.525 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 57.3 Cg_endo -70.64 164.13 36.49 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.939 2.426 . . . . 0.0 112.268 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' VAL . . . . . 1.117 HG11 ' CD2' ' A' ' 152' ' ' LEU . 29.3 m -143.99 -179.38 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.195 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.452 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.5 OUTLIER -137.49 160.54 38.85 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.068 -179.853 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' PHE . . . . . 0.421 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 1.2 t80 -44.52 121.88 2.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.843 179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' ASP . . . . . 0.421 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 4.9 t0 78.24 34.92 0.27 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.74 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' GLU . . . . . 0.452 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 3.9 tp10 -107.36 74.15 0.4 Allowed Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.94 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' PRO . . . . . 0.765 ' O ' HG23 ' A' ' 140' ' ' VAL . 61.6 Cg_exo -34.7 119.65 0.14 Allowed 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 122.79 2.327 . . . . 0.0 111.915 179.577 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' LEU . . . . . 1.117 ' CD2' HG11 ' A' ' 146' ' ' VAL . 0.0 OUTLIER -116.06 -70.69 0.78 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.746 -179.163 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' VAL . . . . . 0.914 HG13 ' CG2' ' A' ' 83' ' ' VAL . 1.4 p -93.06 109.95 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.252 0 CA-C-O 121.152 0.501 . . . . 0.0 111.836 -179.13 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' VAL . . . . . 1.015 HG13 HD12 ' A' ' 82' ' ' ILE . 4.1 t -92.3 132.79 35.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.638 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.75 HG23 ' N ' ' A' ' 134' ' ' THR . 39.5 mt -132.73 140.0 48.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.229 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.512 ' HB2' ' CD ' ' A' ' 136' ' ' LYS . 31.7 tt0 . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.22 -0.895 . . . . 0.0 110.943 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.742 0.306 . . . . 0.0 111.014 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -114.09 74.48 0.87 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.045 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.532 ' O ' HG22 ' A' ' 78' ' ' ILE . 0.6 OUTLIER -168.41 -173.9 2.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.916 179.976 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.627 ' O ' HG23 ' A' ' 78' ' ' ILE . 0.1 OUTLIER 70.07 11.42 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 121.136 0.493 . . . . 0.0 111.036 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 3.4 m -53.43 121.61 8.01 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 115.679 -0.691 . . . . 0.0 110.841 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -51.62 -79.06 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.456 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.578 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 36.6 t60 -175.9 77.66 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.767 0.318 . . . . 0.0 110.888 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.998 HD12 HG13 ' A' ' 154' ' ' VAL . 0.1 OUTLIER -84.26 178.9 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 120.914 0.388 . . . . 0.0 111.08 179.868 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.737 ' CG2' HG13 ' A' ' 153' ' ' VAL . 25.2 t -130.42 37.98 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.903 179.686 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.526 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 10.9 ptt-85 -34.07 119.01 0.39 Allowed 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.906 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.489 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 3.7 t -34.86 104.46 0.25 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.984 -179.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -47.2 -22.35 2.3 Favored 'Trans proline' 0 N--CA 1.465 -0.192 0 C-N-CA 122.678 2.252 . . . . 0.0 112.093 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -151.41 -168.93 3.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.545 179.805 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.632 HG12 ' O ' ' A' ' 88' ' ' VAL . 67.5 t -77.76 56.91 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.04 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.462 ' O ' HG23 ' A' ' 146' ' ' VAL . . . -103.55 -153.33 23.62 Favored Glycine 0 C--N 1.332 0.319 0 C-N-CA 120.678 -0.772 . . . . 0.0 112.438 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.733 HG23 ' O ' ' A' ' 144' ' ' GLN . 17.8 m -130.68 145.17 51.86 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.901 0.382 . . . . 0.0 111.221 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.995 ' HB2' HD22 ' A' ' 152' ' ' LEU . 36.0 t80 -91.91 145.86 24.21 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.249 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.619 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 10.2 m-85 -146.65 154.29 41.29 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.003 0.43 . . . . 0.0 111.286 -179.792 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.445 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 6.7 ptt85 -144.65 25.14 1.5 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.609 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.479 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 0.9 OUTLIER -151.17 100.04 3.03 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.905 179.909 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 94' ' ' THR . 47.5 Cg_endo -68.95 -32.46 22.02 Favored 'Trans proline' 0 C--O 1.231 0.133 0 C-N-CA 122.76 2.307 . . . . 0.0 112.213 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.534 ' CB ' ' HB2' ' A' ' 99' ' ' ALA . 0.4 OUTLIER -123.1 141.18 35.16 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.822 179.86 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -52.51 106.61 0.15 Allowed 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.732 2.288 . . . . 0.0 112.401 -179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 43.5 t0 71.24 34.7 1.72 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.043 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.534 ' HB2' ' CB ' ' A' ' 96' ' ' SER . . . -86.93 -154.94 0.25 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.976 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.401 ' HA ' ' HD2' ' A' ' 100' ' ' LYS . 16.5 mmmt -94.83 23.52 5.43 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.832 179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.479 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 56.86 167.08 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.114 -0.494 . . . . 0.0 111.019 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.958 ' O ' HD13 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -81.44 -51.68 8.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.677 179.868 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.958 HD13 ' O ' ' A' ' 102' ' ' PHE . 0.4 OUTLIER -152.59 148.25 14.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.023 179.759 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -143.39 149.17 37.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.838 179.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.428 HG13 ' HA ' ' A' ' 136' ' ' LYS . 16.7 t -44.59 123.37 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.053 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 123.98 -33.59 3.83 Favored Glycine 0 N--CA 1.45 -0.389 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.367 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.41 ' HA ' ' OE1' ' A' ' 107' ' ' GLN . 0.7 OUTLIER -74.87 142.41 44.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.829 0.347 . . . . 0.0 110.748 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 7.1 mttm -103.58 101.61 11.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.067 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.782 ' CG2' ' HB2' ' A' ' 129' ' ' ALA . 2.3 p -66.23 164.39 2.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.775 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.587 ' N ' HG22 ' A' ' 109' ' ' VAL . 3.2 m120 -155.99 133.31 10.8 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-O 120.882 0.372 . . . . 0.0 110.376 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.47 ' C ' ' O ' ' A' ' 110' ' ' ASN . 2.4 t -26.16 123.41 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.515 -0.766 . . . . 0.0 111.518 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 85.92 21.5 52.69 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.216 -179.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.487 ' HB2' ' O ' ' A' ' 110' ' ' ASN . 26.8 t0 -119.49 102.78 8.9 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.823 0.344 . . . . 0.0 110.832 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.467 HG23 ' HB2' ' A' ' 126' ' ' GLN . 1.4 m -41.28 132.16 2.64 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.912 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.524 ' O ' ' CG1' ' A' ' 103' ' ' ILE . 56.4 mt -96.5 -86.25 0.32 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.829 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.643 ' SG ' HG11 ' A' ' 153' ' ' VAL . 0.6 OUTLIER -131.94 -175.59 3.78 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.04 -179.945 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.537 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.1 OUTLIER -104.11 127.02 58.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.95 179.942 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.588 ' O ' HG12 ' A' ' 118' ' ' VAL . 58.8 t -108.31 60.25 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.942 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.484 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.3 OUTLIER -43.05 88.56 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.247 -179.888 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.545 ' O ' ' CB ' ' A' ' 121' ' ' MET . . . -92.65 109.55 20.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.718 179.735 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.557 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.8 OUTLIER 90.18 -29.59 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.763 -179.683 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.557 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 150.04 -15.95 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.88 179.622 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.484 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.4 OUTLIER -101.08 134.54 43.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.049 -179.662 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.537 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -55.25 145.34 21.89 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.005 -0.543 . . . . 0.0 111.125 -179.951 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.493 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 1.0 OUTLIER -134.4 65.95 1.55 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.571 179.797 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.467 ' HB2' HG23 ' A' ' 114' ' ' THR . 4.8 pm0 -38.85 145.1 0.1 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.022 -0.535 . . . . 0.0 111.049 -179.767 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.47 ' O ' ' N ' ' A' ' 115' ' ' LEU . 29.2 mm -117.18 130.62 71.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.986 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -105.56 128.11 53.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.406 -0.361 . . . . 0.0 111.079 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.782 ' HB2' ' CG2' ' A' ' 109' ' ' VAL . . . -44.32 147.24 0.57 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.922 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -114.06 -15.41 12.28 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.451 ' HG2' ' O ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -163.22 36.86 0.1 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.086 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.472 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.6 t 55.92 -174.9 0.05 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.582 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.492 ' N ' HG13 ' A' ' 109' ' ' VAL . . . 149.71 -178.88 26.92 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.576 -0.821 . . . . 0.0 112.604 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.621 ' N ' HG23 ' A' ' 155' ' ' ILE . 26.7 m -136.27 117.38 14.4 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.611 0.243 . . . . 0.0 111.17 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.468 ' HA ' HG12 ' A' ' 155' ' ' ILE . 97.7 t -49.92 140.45 3.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.476 179.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.64 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 27.7 mmmt -125.02 -19.65 5.14 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.576 -0.284 . . . . 0.0 111.376 -179.461 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.64 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 168.51 159.96 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.888 0.375 . . . . 0.0 111.584 -179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.656 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -110.72 83.62 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.815 179.83 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.656 HD21 HG21 ' A' ' 154' ' ' VAL . 4.7 mt -44.27 -34.87 2.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.081 0.467 . . . . 0.0 110.336 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.979 HG21 HD23 ' A' ' 152' ' ' LEU . 52.1 t -96.54 160.86 2.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.626 179.731 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.529 ' N ' HG12 ' A' ' 140' ' ' VAL . 3.0 mm-40 -58.75 -149.54 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.506 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -103.43 -63.61 1.16 Allowed 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 120.825 -0.35 . . . . 0.0 110.695 179.393 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.619 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -124.88 97.37 0.53 Allowed Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.632 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.733 ' O ' HG23 ' A' ' 90' ' ' THR . 0.0 OUTLIER -166.53 156.3 10.41 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 120.954 0.407 . . . . 0.0 110.998 179.839 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.443 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 35.4 Cg_exo -59.86 160.15 22.66 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.827 2.351 . . . . 0.0 112.277 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.804 HG12 ' HG2' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -152.66 176.19 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.06 179.878 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.488 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 3.8 tt0 -126.71 145.11 50.72 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.996 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.541 ' CE2' ' OD1' ' A' ' 149' ' ' ASP . 16.9 t80 -34.96 139.4 0.09 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.91 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.541 ' OD1' ' CE2' ' A' ' 148' ' ' PHE . 1.6 m-20 68.6 27.45 6.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.788 179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.804 ' HG2' HG12 ' A' ' 146' ' ' VAL . 7.0 tp10 -105.38 74.63 0.28 Allowed Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.897 179.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.912 ' O ' HG23 ' A' ' 140' ' ' VAL . 64.3 Cg_exo -35.84 131.99 0.3 Allowed 'Trans proline' 0 N--CA 1.458 -0.586 0 C-N-CA 122.924 2.416 . . . . 0.0 112.086 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.995 HD22 ' HB2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -123.61 -58.91 1.57 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.355 -179.345 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.737 HG13 ' CG2' ' A' ' 83' ' ' VAL . 1.6 p -108.75 111.82 37.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.066 -179.581 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.998 HG13 HD12 ' A' ' 82' ' ' ILE . 2.5 t -88.27 136.88 22.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.23 -179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.621 HG23 ' N ' ' A' ' 134' ' ' THR . 9.0 mt -134.56 138.42 49.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.019 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.528 ' CG ' ' HB ' ' A' ' 134' ' ' THR . 0.9 OUTLIER . . . . . 0 C--O 1.249 1.044 0 CA-C-O 118.172 -0.918 . . . . 0.0 110.904 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.442 ' O ' ' O ' ' A' ' 76' ' ' ALA . . . . . . . . 0 N--CA 1.457 -0.116 0 CA-C-O 120.828 0.347 . . . . 0.0 111.106 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.442 ' O ' ' O ' ' A' ' 75' ' ' ALA . . . 57.63 149.83 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.027 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -63.6 116.07 5.31 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.86 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.674 ' H ' HD12 ' A' ' 78' ' ' ILE . 0.1 OUTLIER -103.53 -11.94 9.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.141 -179.991 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.479 ' HB3' ' O ' ' A' ' 78' ' ' ILE . 1.6 p 173.9 -152.07 0.01 OUTLIER 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.474 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -164.77 -140.95 2.99 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.568 179.77 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.488 ' ND1' ' HD3' ' A' ' 131' ' ' LYS . 18.2 t60 174.38 82.29 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.78 0.324 . . . . 0.0 110.877 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.859 HG12 HG13 ' A' ' 154' ' ' VAL . 4.6 mt -115.58 151.7 17.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.117 179.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.92 HG12 ' CG1' ' A' ' 153' ' ' VAL . 3.6 p -109.85 44.24 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.026 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.519 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -33.51 131.48 0.23 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.092 -179.943 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.584 ' HB3' HD21 ' A' ' 152' ' ' LEU . 4.4 p -35.83 97.51 0.13 Allowed Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.873 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 14.2 Cg_endo -57.41 -14.95 17.66 Favored 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.608 2.205 . . . . 0.0 111.87 179.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.51 ' SD ' ' HB1' ' A' ' 120' ' ' ALA . 0.3 OUTLIER -151.31 164.96 35.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.47 179.718 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.655 HG22 ' O ' ' A' ' 88' ' ' VAL . 1.7 p -71.01 77.9 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.975 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -127.65 -128.58 3.13 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.545 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.525 ' HA ' ' HA ' ' A' ' 145' ' ' PRO . 8.3 m -147.44 134.49 20.36 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.773 0.32 . . . . 0.0 110.924 -179.827 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.911 ' CB ' HD22 ' A' ' 152' ' ' LEU . 1.7 t80 -95.69 144.76 25.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.781 179.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.59 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 12.8 m-85 -141.04 160.07 40.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.061 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.523 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 0.8 OUTLIER -142.22 24.8 1.94 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.689 179.885 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.424 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 82.5 p -132.29 101.98 14.5 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.799 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.552 ' HB3' ' CE1' ' A' ' 102' ' ' PHE . 41.1 Cg_endo -67.37 -43.44 5.98 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.828 2.352 . . . . 0.0 112.403 -179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -129.95 160.45 65.09 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.06 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.449 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 55.9 Cg_endo -70.73 106.98 1.94 Allowed 'Trans proline' 0 N--CA 1.464 -0.208 0 C-N-CA 122.72 2.28 . . . . 0.0 112.319 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.449 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 18.7 t70 80.24 43.58 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.918 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -109.04 -160.39 0.72 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.029 179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 1.1 mtpp -93.65 23.02 4.95 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.844 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.44 ' HB1' ' O ' ' A' ' 93' ' ' ARG . . . 64.34 176.83 0.18 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.013 -179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.895 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -85.69 -42.14 14.53 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.714 179.942 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.895 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.1 pp -172.68 145.78 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.959 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.44 ' O ' ' HB2' ' A' ' 107' ' ' GLN . 5.9 pt-20 -149.99 167.69 26.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.906 179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.592 HG22 ' C ' ' A' ' 136' ' ' LYS . 89.9 t -45.56 128.02 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.104 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 100.42 -13.74 59.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.508 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.44 ' HB2' ' O ' ' A' ' 104' ' ' GLU . 0.0 OUTLIER -72.93 114.98 11.69 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.853 0.358 . . . . 0.0 110.935 179.993 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.445 ' O ' ' ND2' ' A' ' 110' ' ' ASN . 17.6 mttt -81.95 83.57 7.2 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.925 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.893 HG11 HD23 ' A' ' 115' ' ' LEU . 3.0 m -68.04 165.09 2.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.038 179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.479 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 2.6 m-80 -157.74 130.39 7.36 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.101 0.477 . . . . 0.0 110.789 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.486 HG13 ' N ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -33.87 112.37 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 CA-C-N 115.536 -0.757 . . . . 0.0 111.174 -179.984 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 110.39 13.0 15.87 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.844 -0.694 . . . . 0.0 112.385 -179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.476 ' O ' ' N ' ' A' ' 115' ' ' LEU . 17.3 t0 -122.58 103.04 8.43 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.753 0.311 . . . . 0.0 110.724 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.432 ' C ' ' O ' ' A' ' 113' ' ' ASP . 2.0 m -34.13 93.29 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.113 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.893 HD23 HG11 ' A' ' 109' ' ' VAL . 8.3 mt -50.05 -76.15 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.699 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.45 ' HA ' ' CG ' ' A' ' 102' ' ' PHE . 14.1 p -146.9 -155.66 0.64 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.653 179.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.979 HD13 ' HB3' ' A' ' 124' ' ' MET . 2.3 mt -136.71 152.86 29.48 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.691 179.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.513 ' O ' ' N ' ' A' ' 120' ' ' ALA . 92.3 t -139.59 88.5 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.205 -179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.579 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -51.16 85.8 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.916 179.99 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.513 ' N ' ' O ' ' A' ' 118' ' ' VAL . . . -104.4 140.2 38.26 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.889 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.517 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 50.64 22.13 1.03 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.577 -179.726 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.535 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 86.17 36.41 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.859 -179.803 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.481 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 32.4 mmm -151.33 129.27 11.72 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.076 179.752 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.979 ' HB3' HD13 ' A' ' 117' ' ' ILE . 33.0 mtt -67.13 93.39 0.29 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.945 -179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -70.7 76.86 0.6 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.889 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.49 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 17.3 pt20 -55.39 108.67 0.45 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.859 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.504 HG21 HG21 ' A' ' 83' ' ' VAL . 12.8 mm -74.53 151.41 6.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.053 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -123.51 123.23 40.16 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.91 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -41.0 124.95 2.29 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.89 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -113.26 15.0 19.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.917 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.488 ' HD3' ' ND1' ' A' ' 81' ' ' HIS . 2.0 tmtt? 176.35 105.32 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.864 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.479 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 2.4 t -37.06 114.59 0.33 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.622 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.496 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -147.31 -173.49 18.5 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.732 -179.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.621 ' N ' HG23 ' A' ' 155' ' ' ILE . 19.7 m -128.73 108.55 10.56 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.662 0.268 . . . . 0.0 111.251 -179.685 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.534 ' HA ' ' CG1' ' A' ' 155' ' ' ILE . 69.9 t -39.29 144.81 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 110.215 -0.291 . . . . 0.0 110.215 179.224 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.72 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 38.4 mtpt -121.45 -20.58 6.56 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.666 0.269 . . . . 0.0 111.117 -179.583 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.72 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 160.81 165.29 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.382 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.639 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -107.93 81.8 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.624 179.595 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.747 HD12 ' HB2' ' A' ' 151' ' ' PRO . 2.4 mt -41.55 -29.07 0.15 Allowed 'General case' 0 CA--C 1.52 -0.211 0 CA-C-O 121.064 0.459 . . . . 0.0 110.467 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.981 HG21 HD23 ' A' ' 152' ' ' LEU . 54.8 t -102.85 137.36 31.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.771 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.434 ' O ' ' C ' ' A' ' 142' ' ' SER . 5.9 mt-10 -66.73 94.11 0.29 Allowed 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.349 179.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.523 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 77.4 p -34.95 137.44 0.13 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.816 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.59 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 84.02 35.82 14.6 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.529 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.506 ' O ' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -155.33 159.36 31.78 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 120.983 0.42 . . . . 0.0 111.125 -179.881 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.525 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 45.5 Cg_endo -68.65 178.37 3.95 Favored 'Trans proline' 0 C--N 1.342 0.227 0 C-N-CA 122.79 2.327 . . . . 0.0 112.47 -179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.94 HG11 ' CD2' ' A' ' 152' ' ' LEU . 0.0 OUTLIER -157.86 -173.82 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.066 -179.944 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.461 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 1.8 tt0 -140.59 148.43 40.93 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.982 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.43 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 66.7 t80 -37.66 122.62 0.97 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.868 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.43 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 7.1 t70 79.81 35.54 0.15 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.894 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.461 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 1.8 mt-10 -112.64 74.48 1.64 Allowed Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.845 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.747 ' HB2' HD12 ' A' ' 139' ' ' LEU . 52.6 Cg_exo -32.95 120.45 0.1 Allowed 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 122.926 2.417 . . . . 0.0 111.834 179.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.981 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -109.62 -60.69 1.74 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.979 -179.102 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.92 ' CG1' HG12 ' A' ' 83' ' ' VAL . 2.3 p -111.96 110.35 31.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.066 0.46 . . . . 0.0 111.531 -179.275 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.859 HG13 HG12 ' A' ' 82' ' ' ILE . 4.9 t -92.2 145.49 7.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.354 179.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.621 HG23 ' N ' ' A' ' 134' ' ' THR . 35.8 mt -142.7 138.4 28.22 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.063 179.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.461 ' CA ' ' HD2' ' A' ' 136' ' ' LYS . 2.2 tm-20 . . . . . 0 C--O 1.249 1.067 0 CA-C-O 118.217 -0.897 . . . . 0.0 110.914 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.479 ' O ' ' HB3' ' A' ' 76' ' ' ALA . . . . . . . . 0 N--CA 1.458 -0.069 0 CA-C-O 120.823 0.344 . . . . 0.0 111.026 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.479 ' HB3' ' O ' ' A' ' 75' ' ' ALA . . . 70.55 127.14 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.133 179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 46.34 61.46 2.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.984 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.513 HD12 ' HA ' ' A' ' 78' ' ' ILE . 2.9 tp -81.63 -0.78 4.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.306 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -42.28 133.79 3.07 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.961 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.486 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -75.52 -142.0 0.98 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.487 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.525 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 22.2 t60 167.69 86.34 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.784 0.326 . . . . 0.0 110.672 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.565 HG21 ' HB3' ' A' ' 151' ' ' PRO . 0.3 OUTLIER -85.07 164.23 2.55 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-O 121.05 0.453 . . . . 0.0 111.101 179.962 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.6 ' O ' HD12 ' A' ' 152' ' ' LEU . 4.3 t -120.01 49.35 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.295 -179.828 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.56 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 5.2 ptt180 -48.41 136.04 13.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.892 -179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.798 ' HB3' HG21 ' A' ' 146' ' ' VAL . 24.1 p -45.19 111.91 1.43 Allowed Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.798 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.654 ' HD2' HG11 ' A' ' 118' ' ' VAL . 24.7 Cg_endo -61.51 -10.21 15.66 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.652 2.235 . . . . 0.0 112.139 179.751 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.411 ' SD ' ' HG2' ' A' ' 86' ' ' PRO . 0.0 OUTLIER -160.3 -170.46 2.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.687 179.902 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 60.2 t -86.62 84.18 2.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.071 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.46 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -135.27 -138.97 3.96 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.699 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 1.017 HG23 ' C ' ' A' ' 144' ' ' GLN . 62.0 m -141.33 141.2 33.88 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.85 0.357 . . . . 0.0 111.036 -179.878 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.825 ' CZ ' HG21 ' A' ' 138' ' ' ILE . 18.2 t80 -86.64 144.73 27.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.749 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.579 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 16.0 m-85 -146.49 159.09 43.86 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.856 179.832 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.582 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 1.6 ptt85 -149.3 21.28 0.95 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.85 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.453 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 33.5 p -149.75 107.69 3.28 Favored Pre-proline 0 C--N 1.33 -0.245 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.839 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.442 ' HG2' ' CB ' ' A' ' 99' ' ' ALA . 58.9 Cg_endo -72.07 -15.73 28.97 Favored 'Trans proline' 0 N--CA 1.465 -0.199 0 C-N-CA 122.776 2.318 . . . . 0.0 112.369 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.36 149.13 6.28 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.999 -179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_exo -51.32 -25.82 19.13 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.802 2.335 . . . . 0.0 112.282 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -125.68 51.2 1.75 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.789 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.442 ' CB ' ' HG2' ' A' ' 95' ' ' PRO . . . -114.34 -162.39 0.81 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.28 -179.874 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.46 ' O ' ' O ' ' A' ' 101' ' ' ALA . 2.0 ptmt -115.16 24.2 11.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.881 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.582 ' HB1' ' O ' ' A' ' 93' ' ' ARG . . . 50.13 172.35 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.14 -179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.577 ' CE2' HG12 ' A' ' 117' ' ' ILE . 11.6 m-30 -98.56 -45.42 6.09 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.84 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.838 HD11 HG21 ' A' ' 153' ' ' VAL . 2.5 pp -160.14 141.74 4.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.176 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.469 ' HG2' ' HB2' ' A' ' 107' ' ' GLN . 15.2 pt-20 -132.18 171.64 13.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.919 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.632 HG13 ' O ' ' A' ' 105' ' ' VAL . 9.5 p -56.29 114.89 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.207 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 92.52 0.62 69.6 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.614 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.469 ' HB2' ' HG2' ' A' ' 104' ' ' GLU . 4.4 tp-100 -74.57 115.17 13.82 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.82 0.343 . . . . 0.0 110.845 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.09 129.1 37.7 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.97 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.421 ' O ' ' CG ' ' A' ' 110' ' ' ASN . 28.5 m -112.19 172.99 2.76 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.275 179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.451 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 4.0 m120 -162.36 130.95 4.13 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-O 121.12 0.486 . . . . 0.0 110.657 179.871 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.707 HG12 ' N ' ' A' ' 131' ' ' LYS . 27.3 m -41.46 126.87 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.756 -0.657 . . . . 0.0 111.137 -179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 113.16 -1.95 25.41 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.534 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -112.21 -148.32 0.43 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.685 0.278 . . . . 0.0 110.616 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.8 134.01 44.13 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.936 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.609 HD12 HG22 ' A' ' 127' ' ' ILE . 61.5 mt -87.35 -72.64 0.51 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.809 179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.404 ' HB2' ' O ' ' A' ' 92' ' ' TYR . 0.8 OUTLIER -155.74 -174.91 5.17 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.856 179.941 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.577 HG12 ' CE2' ' A' ' 102' ' ' PHE . 0.0 OUTLIER -110.31 115.8 50.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.179 -179.879 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.654 HG11 ' HD2' ' A' ' 86' ' ' PRO . 1.7 t -99.27 56.69 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.677 179.671 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.482 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.4 OUTLIER -33.85 93.98 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.224 -179.606 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.495 ' O ' ' HG3' ' A' ' 121' ' ' MET . . . -110.76 138.76 46.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.897 179.751 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.511 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 62.71 13.17 6.18 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.796 -179.95 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.511 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.1 OUTLIER 85.44 53.42 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.866 -179.881 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.482 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.2 OUTLIER -171.11 132.79 0.84 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.988 179.884 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -49.46 125.28 10.9 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.977 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.463 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 1.7 t-20 -107.92 60.4 0.61 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.719 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.403 ' C ' ' O ' ' A' ' 125' ' ' ASN . 13.6 pt20 -36.58 131.1 0.7 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.877 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.609 HG22 HD12 ' A' ' 115' ' ' LEU . 37.2 mm -111.05 118.1 56.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.173 -179.927 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 14.8 mm-40 -88.32 124.86 34.32 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.95 179.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.463 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -44.96 116.08 1.02 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.081 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 2.4 p30 -101.41 12.72 36.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.797 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.707 ' N ' HG12 ' A' ' 111' ' ' VAL . 0.3 OUTLIER 179.51 122.91 0.06 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.758 -179.954 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.451 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.4 t -56.41 126.75 27.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.71 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.431 ' HA3' ' CG2' ' A' ' 155' ' ' ILE . . . -157.17 -173.38 25.52 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 120.621 -0.8 . . . . 0.0 112.587 -179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.626 ' N ' HG23 ' A' ' 155' ' ' ILE . 61.6 m -135.51 108.79 7.79 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.765 0.317 . . . . 0.0 111.066 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.514 ' HA ' ' HA ' ' A' ' 155' ' ' ILE . 94.7 t -46.65 143.89 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.612 179.602 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.554 ' HD2' ' CG1' ' A' ' 154' ' ' VAL . 0.0 OUTLIER -115.03 -35.56 4.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 CA-C-O 121.317 0.579 . . . . 0.0 109.729 -179.934 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.638 ' O ' HG23 ' A' ' 154' ' ' VAL . . . 177.64 142.41 0.09 Allowed 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.164 -0.925 . . . . 0.0 111.36 -179.667 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.863 HG23 HG22 ' A' ' 153' ' ' VAL . 0.0 OUTLIER -88.93 86.88 2.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.249 179.421 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.431 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 75.9 mt -41.62 -28.45 0.14 Allowed 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.438 -179.653 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.931 HG21 HD23 ' A' ' 152' ' ' LEU . 54.5 t -102.07 158.42 4.44 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.102 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.506 ' N ' HG12 ' A' ' 140' ' ' VAL . 1.1 mm-40 -59.56 -146.84 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 178.784 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.501 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -101.73 -59.6 1.67 Allowed 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 120.623 -0.431 . . . . 0.0 110.913 179.404 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.569 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -125.48 102.34 0.66 Allowed Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.64 -179.78 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 1.017 ' C ' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -167.99 136.64 1.96 Allowed Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 120.959 0.409 . . . . 0.0 111.259 179.766 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.502 ' N ' HG23 ' A' ' 90' ' ' THR . 50.5 Cg_exo -53.28 154.06 15.42 Favored 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.849 2.366 . . . . 0.0 112.405 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.798 HG21 ' HB3' ' A' ' 85' ' ' SER . 4.5 m -144.87 -156.48 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.999 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.573 ' N ' HG23 ' A' ' 146' ' ' VAL . 24.5 mt-10 -149.28 150.86 33.22 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.969 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.458 ' HA ' ' O ' ' A' ' 85' ' ' SER . 37.5 t80 -42.75 141.4 1.08 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.805 179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 66.13 29.47 9.85 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.772 -179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.527 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 0.8 OUTLIER -110.06 74.66 0.81 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.897 179.886 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.565 ' HB3' HG21 ' A' ' 82' ' ' ILE . 58.4 Cg_exo -32.89 135.56 0.08 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.579 0 C-N-CA 122.898 2.399 . . . . 0.0 111.999 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.931 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -134.32 -37.69 0.86 Allowed 'General case' 0 N--CA 1.453 -0.282 0 CA-C-O 121.024 0.44 . . . . 0.0 110.657 -179.511 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.863 HG22 HG23 ' A' ' 138' ' ' ILE . 2.3 t -128.34 115.64 38.84 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.551 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.595 -178.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.638 HG23 ' O ' ' A' ' 137' ' ' ALA . 1.2 t -97.18 127.07 49.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.683 -0.69 . . . . 0.0 111.017 179.505 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.626 HG23 ' N ' ' A' ' 134' ' ' THR . 7.9 mt -121.88 149.05 25.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.272 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 25.4 tt0 . . . . . 0 C--O 1.248 1.026 0 CA-C-O 118.217 -0.897 . . . . 0.0 110.947 -179.901 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.824 0.345 . . . . 0.0 111.116 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.559 ' HB1' ' OG ' ' A' ' 79' ' ' SER . . . -66.82 98.23 0.53 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.186 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.736 ' O ' HG22 ' A' ' 78' ' ' ILE . 52.5 mt-10 -103.52 99.25 9.06 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.83 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.736 HG22 ' O ' ' A' ' 77' ' ' GLU . 0.3 OUTLIER 67.72 14.23 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.98 -179.96 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.559 ' OG ' ' HB1' ' A' ' 76' ' ' ALA . 53.1 m -32.22 90.43 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.351 -0.841 . . . . 0.0 111.033 -179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.526 ' N ' ' O ' ' A' ' 78' ' ' ILE . . . 172.44 -153.29 18.69 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.27 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.52 ' N ' ' O ' ' A' ' 155' ' ' ILE . 27.6 t60 -176.49 77.98 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.808 0.337 . . . . 0.0 111.009 179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.881 HG12 HG13 ' A' ' 154' ' ' VAL . 18.5 mt -96.36 140.84 16.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.002 0.43 . . . . 0.0 111.07 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.865 HG23 HG13 ' A' ' 153' ' ' VAL . 1.8 t -91.69 48.7 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.104 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.485 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 7.1 ptt-85 -35.49 130.63 0.51 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.843 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.46 ' OG ' ' O ' ' A' ' 87' ' ' MET . 28.4 t -35.45 94.36 0.07 OUTLIER Pre-proline 0 C--N 1.329 -0.294 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.038 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.462 ' N ' ' O ' ' A' ' 84' ' ' ARG . 51.3 Cg_exo -53.98 -24.98 34.25 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.662 2.242 . . . . 0.0 112.04 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.496 ' SD ' ' CB ' ' A' ' 120' ' ' ALA . 14.5 ptp -157.0 176.37 12.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.712 179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 69.2 t -71.97 85.88 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.171 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.48 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -137.72 -150.87 5.77 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.572 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.622 ' CG2' ' CZ ' ' A' ' 92' ' ' TYR . 3.0 m -129.09 130.87 47.05 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.913 0.387 . . . . 0.0 111.043 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.779 ' HB2' HD22 ' A' ' 152' ' ' LEU . 53.2 t80 -76.52 146.87 38.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.562 179.765 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.644 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 14.7 m-85 -150.45 154.76 38.27 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.921 0.391 . . . . 0.0 110.872 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.507 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 4.1 ptm180 -142.28 34.53 1.5 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.866 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.482 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 18.3 p -149.44 110.6 3.41 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.882 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -67.83 -24.85 39.86 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.697 2.265 . . . . 0.0 112.196 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -141.42 143.84 31.59 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.876 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_exo -50.18 -19.77 4.71 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.701 2.267 . . . . 0.0 112.37 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -143.72 74.19 1.42 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.916 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -140.07 -155.57 0.6 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.137 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.412 ' O ' ' HB3' ' A' ' 101' ' ' ALA . 0.0 OUTLIER -104.68 36.94 2.26 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.812 -179.961 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.507 ' HB1' ' O ' ' A' ' 93' ' ' ARG . . . 66.56 -174.05 0.19 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.049 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.717 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -104.22 -46.14 4.51 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.94 179.942 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.717 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.9 pp -164.68 131.39 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.123 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 18.0 pt-20 -132.29 170.08 15.56 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.883 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.629 ' HA ' HG12 ' A' ' 135' ' ' VAL . 3.6 t -53.13 128.2 12.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.029 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 104.52 -14.93 50.27 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.357 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -80.35 102.27 9.47 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.817 0.341 . . . . 0.0 110.901 179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.419 ' HA ' ' O ' ' A' ' 133' ' ' GLY . 0.0 OUTLIER -73.37 75.7 1.38 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.974 -179.88 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.674 HG11 ' CD2' ' A' ' 115' ' ' LEU . 32.6 m -48.81 174.4 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.001 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.454 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 18.1 m-80 -162.36 130.31 3.96 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.008 0.433 . . . . 0.0 110.717 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.566 HG12 ' N ' ' A' ' 131' ' ' LYS . 34.0 m -37.94 145.93 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.126 179.92 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 92.73 -6.04 76.92 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.421 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -105.63 -146.25 0.39 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.672 0.272 . . . . 0.0 110.573 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 6.5 m -145.16 116.61 8.04 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.814 0.34 . . . . 0.0 111.023 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.674 ' CD2' HG11 ' A' ' 109' ' ' VAL . 94.8 mt -69.23 -86.53 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.753 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.805 ' SG ' HG11 ' A' ' 153' ' ' VAL . 0.6 OUTLIER -135.17 -171.26 2.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.812 179.913 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.751 HG21 ' HG2' ' A' ' 124' ' ' MET . 0.1 OUTLIER -110.82 123.26 66.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.073 -180.0 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.657 ' O ' HG12 ' A' ' 118' ' ' VAL . 87.3 t -105.99 58.32 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.753 179.662 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.479 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.5 OUTLIER -33.71 101.57 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.307 -179.658 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.518 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -122.99 149.37 44.39 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.745 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.518 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 5.4 ptm 50.71 21.72 0.97 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.944 0.402 . . . . 0.0 110.611 -179.739 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.442 ' O ' ' HE3' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 77.56 60.12 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.023 -0.535 . . . . 0.0 111.246 -179.983 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.481 ' HG2' ' O ' ' A' ' 120' ' ' ALA . 2.9 ptt? -175.33 128.68 0.27 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.069 0.461 . . . . 0.0 111.151 179.497 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.751 ' HG2' HG21 ' A' ' 117' ' ' ILE . 1.7 mtp -53.29 95.03 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.679 -0.692 . . . . 0.0 110.979 179.866 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -82.08 70.93 9.11 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.83 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 84.9 mt-30 -51.89 120.9 5.79 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.947 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.476 HG12 HG23 ' A' ' 118' ' ' VAL . 41.4 mm -88.39 109.8 20.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.184 -179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 129' ' ' ALA . 1.4 pt-20 -74.4 124.64 26.89 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.84 179.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.452 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -36.19 112.29 0.17 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.113 -179.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -101.0 14.26 32.55 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.759 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.566 ' N ' HG12 ' A' ' 111' ' ' VAL . 0.3 OUTLIER 169.19 118.85 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.938 -179.979 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.454 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 25.3 p -49.5 129.58 19.19 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.857 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.419 ' O ' ' HA ' ' A' ' 108' ' ' LYS . . . -158.28 -178.1 31.99 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.642 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.63 ' N ' HG23 ' A' ' 155' ' ' ILE . 23.4 m -129.81 108.7 10.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.58 0.229 . . . . 0.0 111.152 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.629 HG12 ' HA ' ' A' ' 105' ' ' VAL . 69.9 t -42.25 142.44 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 N-CA-C 110.295 -0.261 . . . . 0.0 110.295 179.504 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.68 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 5.8 mmmt -124.88 -18.66 5.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.677 0.275 . . . . 0.0 111.342 -179.426 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.68 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 165.17 154.22 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.841 0.353 . . . . 0.0 111.448 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.659 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -106.0 78.7 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.79 179.922 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.533 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 22.0 mt -42.14 -29.49 0.24 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.149 0.5 . . . . 0.0 110.385 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 1.085 HG21 HD23 ' A' ' 152' ' ' LEU . 55.4 t -100.7 161.89 3.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.694 179.73 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.554 ' N ' HG12 ' A' ' 140' ' ' VAL . 1.8 mm-40 -58.49 -149.13 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 179.345 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.49 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 35.8 m -107.67 -63.94 1.26 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.826 0.346 . . . . 0.0 110.893 179.605 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.644 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -123.44 90.47 0.42 Allowed Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 120.679 -0.772 . . . . 0.0 112.851 -179.783 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.474 ' C ' HG23 ' A' ' 90' ' ' THR . 36.3 mm-40 -156.57 156.34 29.88 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-O 120.908 0.385 . . . . 0.0 110.969 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.432 ' HD2' ' HB3' ' A' ' 144' ' ' GLN . 48.6 Cg_endo -69.26 120.98 7.77 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.681 2.254 . . . . 0.0 112.132 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.912 HG11 ' CD2' ' A' ' 152' ' ' LEU . 18.3 m -105.92 -173.83 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.123 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.491 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 6.2 mm-40 -140.7 144.41 35.59 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.031 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.446 ' HA ' ' O ' ' A' ' 85' ' ' SER . 63.9 t80 -35.7 137.94 0.18 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.051 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 7.9 t70 69.67 27.78 4.63 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.891 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.491 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 1.2 tp10 -108.87 73.79 0.53 Allowed Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.833 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.894 ' O ' HG23 ' A' ' 140' ' ' VAL . 61.4 Cg_exo -34.18 123.2 0.16 Allowed 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.804 2.336 . . . . 0.0 112.042 179.674 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 1.085 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -120.64 -70.86 0.76 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.699 -179.254 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.865 HG13 HG23 ' A' ' 83' ' ' VAL . 1.3 p -97.04 106.24 18.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.559 -179.146 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.881 HG13 HG12 ' A' ' 82' ' ' ILE . 23.4 t -89.33 133.41 31.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.865 179.349 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.63 HG23 ' N ' ' A' ' 134' ' ' THR . 82.9 mt -134.38 135.37 54.16 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.191 -179.799 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.486 ' HB2' ' CD ' ' A' ' 136' ' ' LYS . 0.7 OUTLIER . . . . . 0 C--O 1.248 1.006 0 CA-C-O 118.228 -0.891 . . . . 0.0 110.939 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.147 0 CA-C-O 120.814 0.34 . . . . 0.0 111.136 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -106.54 -176.79 3.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.062 179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -41.25 150.11 0.09 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.897 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.427 ' O ' ' C ' ' A' ' 79' ' ' SER . 0.8 OUTLIER -114.31 21.69 6.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.084 -179.939 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.427 ' C ' ' O ' ' A' ' 78' ' ' ILE . 0.3 OUTLIER 35.69 43.5 0.17 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.96 179.952 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.479 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -139.07 -162.35 9.09 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.462 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.512 ' O ' ' ND1' ' A' ' 81' ' ' HIS . 11.9 t-80 173.11 83.07 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.827 0.346 . . . . 0.0 110.823 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 1.014 HG12 HG13 ' A' ' 154' ' ' VAL . 1.6 mt -118.17 151.05 20.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 121.071 0.462 . . . . 0.0 111.31 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.788 ' CG2' HD13 ' A' ' 115' ' ' LEU . 20.4 t -95.19 37.69 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.513 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.168 -179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.55 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 20.1 ptt85 -37.2 127.77 0.98 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.711 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.49 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 0.2 OUTLIER -45.33 109.38 0.92 Allowed Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.726 179.96 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -61.61 -13.22 28.59 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.72 2.28 . . . . 0.0 112.126 -179.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 1.9 ptp -150.08 -159.58 1.05 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.821 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.449 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 5.2 m -92.25 87.27 2.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.103 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.476 ' O ' ' N ' ' A' ' 146' ' ' VAL . . . -141.99 -163.5 9.65 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.468 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.796 HG23 ' C ' ' A' ' 144' ' ' GLN . 25.8 m -119.98 145.41 46.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.843 0.354 . . . . 0.0 110.881 179.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.861 ' CB ' HD22 ' A' ' 152' ' ' LEU . 1.0 OUTLIER -102.08 147.71 26.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.031 -179.839 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.578 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 23.3 m-85 -142.73 167.59 21.72 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.865 179.843 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.453 ' HD3' ' HB3' ' A' ' 142' ' ' SER . 32.1 ptt85 -152.96 21.23 0.58 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.689 179.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.503 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 6.5 p -155.24 113.67 2.29 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.753 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.403 ' HG2' ' CB ' ' A' ' 99' ' ' ALA . 49.2 Cg_endo -68.59 -39.15 9.64 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.702 2.268 . . . . 0.0 112.342 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.521 ' CB ' ' HD2' ' A' ' 97' ' ' PRO . 0.2 OUTLIER -135.23 172.49 7.13 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.914 -179.947 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.521 ' HD2' ' CB ' ' A' ' 96' ' ' SER . 51.9 Cg_endo -69.22 -27.61 28.83 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.725 2.283 . . . . 0.0 112.284 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -135.46 39.63 2.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.874 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.403 ' CB ' ' HG2' ' A' ' 95' ' ' PRO . . . -95.28 -156.07 0.5 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.108 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.414 ' O ' ' CG ' ' A' ' 100' ' ' LYS . 0.0 OUTLIER -102.81 34.79 2.7 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.91 179.971 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.503 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 45.01 -158.87 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.108 -0.497 . . . . 0.0 111.179 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.572 ' CD2' HG12 ' A' ' 117' ' ' ILE . 0.1 OUTLIER -139.27 40.28 2.09 Favored 'General case' 0 CA--C 1.517 -0.322 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.059 179.816 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.784 HD13 HG12 ' A' ' 109' ' ' VAL . 2.6 mt 87.07 122.04 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.113 -179.806 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.425 ' O ' ' HB ' ' A' ' 135' ' ' VAL . 1.7 pt-20 -131.17 -175.75 3.79 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.905 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.548 HG22 ' HA ' ' A' ' 137' ' ' ALA . 46.7 t -53.31 134.06 15.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.079 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 93.22 -26.91 12.9 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.636 -0.792 . . . . 0.0 112.399 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.485 ' O ' HG23 ' A' ' 134' ' ' THR . 6.7 tp60 -72.35 131.63 42.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.803 0.335 . . . . 0.0 110.832 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.42 118.91 33.91 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.963 179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.784 HG12 HD13 ' A' ' 103' ' ' ILE . 4.4 m -89.97 178.35 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.06 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.432 ' CG ' ' O ' ' A' ' 109' ' ' VAL . 18.4 m120 -164.71 131.27 2.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.068 0.461 . . . . 0.0 110.641 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.473 ' HA ' ' HB3' ' A' ' 129' ' ' ALA . 34.7 m -38.65 159.51 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-N 115.809 -0.632 . . . . 0.0 111.123 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 79.63 -6.04 59.31 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.499 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 2.2 m-20 -108.88 -147.49 0.41 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.708 0.289 . . . . 0.0 110.651 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 14.4 m -135.93 150.12 49.18 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.847 0.356 . . . . 0.0 110.854 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.788 HD13 ' CG2' ' A' ' 83' ' ' VAL . 49.4 mt -96.95 -75.58 0.54 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.881 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.488 ' SG ' HG11 ' A' ' 153' ' ' VAL . 0.0 OUTLIER -148.4 -168.31 3.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.803 -179.916 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.572 HG12 ' CD2' ' A' ' 102' ' ' PHE . 0.1 OUTLIER -108.63 120.29 59.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.178 179.926 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.517 ' O ' ' CB ' ' A' ' 125' ' ' ASN . 11.1 t -118.43 73.38 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.03 179.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.543 ' HG2' ' CE2' ' A' ' 92' ' ' TYR . 0.9 OUTLIER -59.32 119.55 7.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.832 -179.953 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -94.0 -70.26 0.71 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.28 0.562 . . . . 0.0 111.365 -179.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.532 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 1.9 ptp -92.53 36.21 1.01 Allowed 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.447 179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.538 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 0.4 OUTLIER 88.54 -7.74 0.5 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.87 -179.814 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.485 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 6.2 mtt -107.72 128.07 54.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.956 0.407 . . . . 0.0 110.896 179.68 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.539 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 1.0 OUTLIER -43.83 149.67 0.3 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.148 -179.867 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.517 ' CB ' ' O ' ' A' ' 118' ' ' VAL . 30.1 t-20 -129.58 74.25 1.57 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.572 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 9.9 pt20 -47.06 112.85 0.57 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.051 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 23.2 mm -92.8 105.92 17.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.103 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -70.21 143.2 52.28 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.932 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.473 ' HB3' ' HA ' ' A' ' 111' ' ' VAL . . . -66.04 119.22 11.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.123 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.421 ' C ' HG12 ' A' ' 111' ' ' VAL . 0.4 OUTLIER -97.8 -10.63 24.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.911 179.919 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.421 ' O ' ' C ' ' A' ' 132' ' ' SER . 10.0 tttt -161.61 109.47 1.45 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.918 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.421 ' C ' ' O ' ' A' ' 131' ' ' LYS . 4.8 p -36.04 141.18 0.1 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.958 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.494 ' O ' ' N ' ' A' ' 109' ' ' VAL . . . -169.45 -165.12 26.31 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.521 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.53 ' N ' HG12 ' A' ' 155' ' ' ILE . 55.9 m -150.97 110.08 3.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.672 0.272 . . . . 0.0 110.938 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.58 HG21 HG22 ' A' ' 103' ' ' ILE . 61.8 t -41.86 141.34 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.843 179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.519 ' HG2' ' N ' ' A' ' 137' ' ' ALA . 0.0 OUTLIER -114.51 -35.88 4.77 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 121.456 0.646 . . . . 0.0 109.462 179.934 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.594 ' C ' HD13 ' A' ' 138' ' ' ILE . . . -175.44 155.01 1.75 Allowed 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.775 -179.579 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.787 ' N ' HD13 ' A' ' 138' ' ' ILE . 0.0 OUTLIER -103.06 84.35 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.406 179.648 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 1.013 HD11 HG22 ' A' ' 154' ' ' VAL . 0.2 OUTLIER -41.59 -28.81 0.15 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.106 0.479 . . . . 0.0 110.278 -179.872 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.988 HG21 HD23 ' A' ' 152' ' ' LEU . 79.7 t -103.38 134.45 44.5 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.826 179.753 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.449 ' O ' ' C ' ' A' ' 142' ' ' SER . 13.6 mt-10 -67.5 100.77 0.9 Allowed 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.161 179.667 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.453 ' HB3' ' HD3' ' A' ' 93' ' ' ARG . 6.9 p -34.41 134.96 0.18 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.783 -179.524 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.578 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 80.72 39.31 14.31 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.583 -0.817 . . . . 0.0 112.255 -179.776 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.796 ' C ' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -148.78 139.55 13.6 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 120.977 0.417 . . . . 0.0 111.076 -179.947 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.672 ' N ' HG23 ' A' ' 90' ' ' THR . 31.3 Cg_exo -59.03 158.75 24.14 Favored 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 122.845 2.363 . . . . 0.0 112.389 -179.725 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.926 HG11 ' CD2' ' A' ' 152' ' ' LEU . 19.7 m -147.22 -173.5 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.981 179.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.478 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.3 OUTLIER -138.06 174.44 10.56 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.933 179.956 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.501 ' CD1' ' HB2' ' A' ' 149' ' ' ASP . 1.3 p90 -55.2 140.31 39.21 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.834 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.501 ' HB2' ' CD1' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 59.41 34.4 22.69 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.867 0.365 . . . . 0.0 110.902 179.994 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.541 ' OE2' HG22 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -109.46 74.68 0.69 Allowed Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.88 179.943 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.601 ' O ' HG23 ' A' ' 140' ' ' VAL . 57.2 Cg_exo -33.43 133.93 0.11 Allowed 'Trans proline' 0 N--CA 1.459 -0.553 0 C-N-CA 122.926 2.417 . . . . 0.0 112.104 179.587 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.988 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -128.29 -50.7 1.3 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.447 -0.342 . . . . 0.0 111.739 -179.194 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.66 HG13 HG23 ' A' ' 83' ' ' VAL . 2.3 p -117.93 112.23 37.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.899 0.381 . . . . 0.0 111.541 -179.1 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 1.014 HG13 HG12 ' A' ' 82' ' ' ILE . 0.7 OUTLIER -96.0 129.81 45.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.888 179.523 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.571 HD11 HG11 ' A' ' 109' ' ' VAL . 0.0 OUTLIER -113.28 157.58 13.92 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.229 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.778 -179.934 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.448 ' N ' ' O ' ' A' ' 134' ' ' THR . 29.1 tt0 . . . . . 0 C--O 1.25 1.101 0 CA-C-O 118.211 -0.9 . . . . 0.0 110.976 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.82 0.343 . . . . 0.0 111.023 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . 40.21 51.64 2.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.11 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -143.74 111.81 6.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.002 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -80.49 -3.14 6.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 121.06 0.457 . . . . 0.0 111.389 -179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -79.61 83.94 5.53 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.877 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.458 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . 166.64 -178.34 41.08 Favored Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.609 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.587 ' ND1' HD12 ' A' ' 155' ' ' ILE . 14.9 t-80 172.78 83.36 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.773 0.32 . . . . 0.0 110.721 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.979 HD12 HG13 ' A' ' 154' ' ' VAL . 0.0 OUTLIER -97.73 176.46 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.145 179.977 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.723 HG12 ' CG1' ' A' ' 153' ' ' VAL . 2.3 p -132.45 28.18 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.811 179.557 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.545 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 6.2 ptt180 -25.97 120.42 0.07 Allowed 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 115.784 -0.643 . . . . 0.0 111.542 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.483 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 0.2 OUTLIER -38.58 116.25 0.93 Allowed Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.835 -179.855 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -70.08 -9.31 25.7 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.634 2.222 . . . . 0.0 111.919 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 13.6 ptm -151.24 -168.96 3.25 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.626 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.676 ' O ' HG23 ' A' ' 88' ' ' VAL . 32.3 m -88.81 83.01 2.15 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.132 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.445 ' C ' HG22 ' A' ' 146' ' ' VAL . . . -126.17 -140.56 5.32 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.612 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.672 HG21 ' CZ ' ' A' ' 92' ' ' TYR . 4.9 m -146.73 128.06 14.88 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.008 0.432 . . . . 0.0 111.274 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 1.021 ' HB2' HD22 ' A' ' 152' ' ' LEU . 30.2 t80 -75.5 139.1 41.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.125 179.36 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.672 ' CZ ' HG21 ' A' ' 90' ' ' THR . 12.7 m-85 -142.67 156.35 45.03 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.927 0.394 . . . . 0.0 111.213 -179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . . . . . . . . . 23.8 ptt85 -142.62 40.85 1.57 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.805 179.84 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -146.57 95.23 4.63 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.858 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.452 ' HD3' ' N ' ' A' ' 102' ' ' PHE . 49.7 Cg_endo -69.15 -38.84 8.53 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.817 2.345 . . . . 0.0 112.407 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.93 ' HB2' ' HB2' ' A' ' 99' ' ' ALA . 70.4 m -129.53 160.85 62.41 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.963 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.4 101.06 0.06 OUTLIER 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.717 2.278 . . . . 0.0 112.285 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 63.54 36.39 11.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.861 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.93 ' HB2' ' HB2' ' A' ' 96' ' ' SER . . . -76.56 -158.02 0.09 Allowed 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.134 -0.485 . . . . 0.0 111.157 -179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.419 ' O ' ' HB3' ' A' ' 101' ' ' ALA . 0.6 OUTLIER -89.35 23.34 2.56 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.99 179.972 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.419 ' HB3' ' O ' ' A' ' 100' ' ' LYS . . . 67.85 159.65 0.16 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.185 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.686 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -84.65 -46.01 11.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.81 -179.953 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.686 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.1 pp -163.63 112.03 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.039 179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.459 ' O ' ' HB2' ' A' ' 107' ' ' GLN . 10.2 pt-20 -123.72 172.35 8.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.909 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.814 HG22 ' HA ' ' A' ' 137' ' ' ALA . 21.3 t -51.97 119.06 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.179 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 107.44 -4.86 35.15 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.522 179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.476 ' HG3' ' HA ' ' A' ' 103' ' ' ILE . 1.6 mm-40 -73.8 129.64 38.33 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.771 0.319 . . . . 0.0 110.987 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.423 ' O ' ' ND2' ' A' ' 110' ' ' ASN . 6.0 mttt -98.8 72.11 1.94 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.885 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.675 HG11 HD22 ' A' ' 115' ' ' LEU . 6.0 m -48.86 167.03 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.023 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.509 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 9.6 m-80 -159.87 129.87 5.45 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.083 0.468 . . . . 0.0 110.82 179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.629 HG23 ' O ' ' A' ' 111' ' ' VAL . 5.0 m -34.99 115.37 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.654 -0.703 . . . . 0.0 111.056 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 99.96 12.69 39.23 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.344 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.423 ' O ' ' C ' ' A' ' 114' ' ' THR . 1.8 t70 -123.7 103.1 8.19 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.824 0.345 . . . . 0.0 110.811 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.525 ' CG2' ' HB2' ' A' ' 126' ' ' GLN . 3.2 m -35.06 132.91 0.33 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.024 -0.534 . . . . 0.0 111.066 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.675 HD22 HG11 ' A' ' 109' ' ' VAL . 67.1 mt -93.68 -81.63 0.36 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.843 179.895 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.412 ' SG ' HD11 ' A' ' 103' ' ' ILE . 0.5 OUTLIER -133.16 -172.89 3.05 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.701 179.894 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.532 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.2 OUTLIER -110.79 123.71 66.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.136 179.975 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.523 ' O ' ' N ' ' A' ' 120' ' ' ALA . 23.6 t -103.42 55.81 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.725 179.773 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.474 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.1 OUTLIER -31.38 89.0 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.721 -179.689 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 118' ' ' VAL . . . -88.82 134.24 34.0 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.141 179.25 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.554 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 2.8 ptt? 50.37 22.89 1.09 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.242 -179.337 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.554 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 96.21 -10.18 0.09 Allowed 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.544 179.698 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.515 ' O ' ' N ' ' A' ' 120' ' ' ALA . 12.5 ptm -99.18 131.69 45.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.157 0.503 . . . . 0.0 111.35 -179.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.532 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 1.4 ptt? -55.16 130.5 42.27 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.914 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.488 ' HB2' ' O ' ' A' ' 118' ' ' VAL . 0.7 OUTLIER -121.92 65.34 0.91 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.955 -179.967 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.525 ' HB2' ' CG2' ' A' ' 114' ' ' THR . 2.6 pm0 -39.2 144.36 0.14 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.918 179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.55 HG21 HG21 ' A' ' 83' ' ' VAL . 31.8 mm -113.1 123.03 68.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.079 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.428 ' O ' ' C ' ' A' ' 129' ' ' ALA . 5.5 mt-10 -85.23 118.39 24.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.843 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.428 ' C ' ' O ' ' A' ' 128' ' ' GLU . . . -35.94 127.81 0.7 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.002 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -100.57 -10.81 20.63 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.974 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.54 ' HD2' ' CD2' ' A' ' 81' ' ' HIS . 2.0 tmtt? -168.86 123.22 0.86 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.293 -0.412 . . . . 0.0 111.004 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.509 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.0 OUTLIER -51.26 112.39 0.73 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.396 179.729 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.58 ' HA3' HG21 ' A' ' 155' ' ' ILE . . . -145.28 -179.83 21.86 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.569 -0.824 . . . . 0.0 112.713 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.679 ' N ' HG23 ' A' ' 155' ' ' ILE . 29.9 m -122.4 112.32 17.94 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.693 0.282 . . . . 0.0 111.396 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.506 ' HA ' ' HA ' ' A' ' 155' ' ' ILE . 85.7 t -46.56 144.34 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.506 -0.315 . . . . 0.0 110.524 179.293 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.543 ' CD ' ' HB ' ' A' ' 154' ' ' VAL . 0.0 OUTLIER -114.52 -35.75 4.81 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-O 121.496 0.665 . . . . 0.0 109.682 -179.809 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.814 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 179.62 172.71 0.94 Allowed 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.951 -179.672 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.754 HD13 ' C ' ' A' ' 137' ' ' ALA . 0.6 OUTLIER -119.09 82.9 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-N 116.288 -0.415 . . . . 0.0 111.059 179.843 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.562 ' N ' HD23 ' A' ' 139' ' ' LEU . 3.8 mt -41.09 -29.53 0.12 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.2 0.524 . . . . 0.0 110.073 179.724 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 1.056 HG21 HD23 ' A' ' 152' ' ' LEU . 54.5 t -100.08 158.9 3.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.555 179.538 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.498 ' N ' HG12 ' A' ' 140' ' ' VAL . 2.8 mt-10 -58.81 -150.43 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.067 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.499 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -102.49 -60.75 1.49 Allowed 'General case' 0 C--N 1.324 -0.502 0 C-N-CA 120.81 -0.356 . . . . 0.0 110.822 179.623 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.635 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -127.07 89.09 0.34 Allowed Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.626 -0.797 . . . . 0.0 112.793 -179.779 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.462 ' C ' HG23 ' A' ' 90' ' ' THR . 25.2 mm-40 -153.09 155.61 32.08 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 120.997 0.427 . . . . 0.0 110.979 179.77 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.456 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 39.6 Cg_exo -56.81 153.29 37.77 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.855 2.37 . . . . 0.0 112.391 179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.816 HG11 ' CD2' ' A' ' 152' ' ' LEU . 31.1 m -141.45 -173.08 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.967 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.48 ' O ' ' HG2' ' A' ' 150' ' ' GLU . 1.0 OUTLIER -146.82 144.58 29.44 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.896 0.379 . . . . 0.0 111.16 -179.94 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.483 ' HA ' ' O ' ' A' ' 85' ' ' SER . 5.5 p90 -35.62 124.35 0.67 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.953 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.442 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 0.4 OUTLIER 79.46 33.22 0.22 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.824 -179.945 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.48 ' HG2' ' O ' ' A' ' 147' ' ' GLU . 13.0 mm-40 -109.26 75.23 0.69 Allowed Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.867 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.687 ' O ' HG23 ' A' ' 140' ' ' VAL . 75.1 Cg_exo -37.38 129.15 0.68 Allowed 'Trans proline' 0 N--CA 1.461 -0.413 0 C-N-CA 122.774 2.316 . . . . 0.0 111.925 179.594 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 1.056 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -123.27 -61.1 1.44 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.635 -179.3 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.723 ' CG1' HG12 ' A' ' 83' ' ' VAL . 2.1 p -108.26 120.91 60.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 121.172 0.511 . . . . 0.0 111.292 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.979 HG13 HD12 ' A' ' 82' ' ' ILE . 0.2 OUTLIER -100.55 137.92 26.49 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.446 -0.797 . . . . 0.0 111.219 -179.98 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.679 HG23 ' N ' ' A' ' 134' ' ' THR . 45.6 mt -123.43 147.16 27.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.229 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.402 ' O ' ' HG2' ' A' ' 156' ' ' GLU . 2.1 tt0 . . . . . 0 C--O 1.248 1.018 0 CA-C-O 118.323 -0.846 . . . . 0.0 110.922 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.435 ' O ' ' HB3' ' A' ' 76' ' ' ALA . . . . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.826 0.346 . . . . 0.0 111.154 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.435 ' HB3' ' O ' ' A' ' 75' ' ' ALA . . . 67.8 129.16 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.038 179.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -62.84 158.95 17.65 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.926 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.429 ' O ' ' C ' ' A' ' 79' ' ' SER . 2.0 mt -112.85 21.05 6.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.143 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.429 ' C ' ' O ' ' A' ' 78' ' ' ILE . 3.2 p 35.72 71.18 0.13 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.918 179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -127.68 150.45 18.26 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.673 -0.775 . . . . 0.0 112.647 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.504 ' O ' ' ND1' ' A' ' 81' ' ' HIS . 23.7 t-80 -170.03 76.15 0.08 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.847 0.355 . . . . 0.0 110.802 179.838 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.836 HG12 HG13 ' A' ' 154' ' ' VAL . 5.1 mt -101.86 155.07 4.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.066 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.77 HG23 HG13 ' A' ' 153' ' ' VAL . 4.0 t -102.42 51.2 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.969 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.533 ' CD ' ' O ' ' A' ' 84' ' ' ARG . 0.5 OUTLIER -35.48 133.19 0.38 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.875 179.998 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.492 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 11.2 p -39.41 98.6 0.17 Allowed Pre-proline 0 C--N 1.328 -0.359 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.757 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.422 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 12.2 Cg_endo -56.3 -15.44 14.84 Favored 'Trans proline' 0 C--N 1.342 0.231 0 C-N-CA 122.506 2.137 . . . . 0.0 111.91 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.411 ' O ' ' N ' ' A' ' 89' ' ' GLY . 5.2 ptp -160.29 172.38 17.44 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.534 179.713 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.595 ' O ' HG23 ' A' ' 88' ' ' VAL . 27.2 m -67.32 68.33 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.037 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 87' ' ' MET . . . -119.04 -155.68 9.88 Favored Glycine 0 C--N 1.331 0.289 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.648 -179.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.896 HG23 ' O ' ' A' ' 144' ' ' GLN . 20.2 m -131.5 124.85 31.0 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.908 0.385 . . . . 0.0 111.07 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.933 ' HB2' HD22 ' A' ' 152' ' ' LEU . 72.4 t80 -62.61 141.95 58.25 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.52 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.589 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 5.6 m-30 -148.37 127.73 13.06 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.964 0.412 . . . . 0.0 110.919 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.488 ' HA ' ' HB2' ' A' ' 102' ' ' PHE . 0.1 OUTLIER -124.27 25.52 7.72 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.825 179.857 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 2.7 p -149.21 108.16 3.4 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.882 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -70.34 -44.1 1.85 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.82 2.346 . . . . 0.0 112.309 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.747 ' HB2' ' HB2' ' A' ' 99' ' ' ALA . 0.1 OUTLIER -110.64 166.93 9.83 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.928 -179.993 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.485 ' HD2' ' OG ' ' A' ' 96' ' ' SER . 51.1 Cg_endo -69.42 -25.56 30.05 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.737 2.291 . . . . 0.0 112.224 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -136.17 26.86 3.22 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.817 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.747 ' HB2' ' HB2' ' A' ' 96' ' ' SER . . . -71.49 -163.92 0.1 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.121 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.486 ' O ' ' HB3' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -103.83 20.75 17.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.921 179.854 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.486 ' HB3' ' O ' ' A' ' 100' ' ' LYS . . . 71.47 162.9 0.26 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.274 179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.616 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -84.93 -37.42 20.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.765 179.922 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.616 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.2 pp -161.29 158.56 2.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.019 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.437 ' O ' ' HB3' ' A' ' 107' ' ' GLN . 0.2 OUTLIER -140.42 151.23 44.74 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.906 -179.989 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.802 HG23 ' C ' ' A' ' 136' ' ' LYS . 4.8 p -54.08 127.94 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.199 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 93.83 -9.77 72.9 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.644 -0.789 . . . . 0.0 112.521 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.516 ' O ' ' N ' ' A' ' 109' ' ' VAL . 2.7 tp-100 -68.93 99.83 1.11 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.855 0.36 . . . . 0.0 110.801 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.43 ' HA ' ' HA ' ' A' ' 134' ' ' THR . 0.0 OUTLIER -59.26 75.62 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.952 -179.839 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.516 ' N ' ' O ' ' A' ' 107' ' ' GLN . 6.6 m -53.28 172.0 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.008 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.489 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 3.9 p-10 -163.06 133.03 4.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.058 0.456 . . . . 0.0 110.947 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.48 HG12 ' N ' ' A' ' 131' ' ' LYS . 29.3 m -38.25 130.18 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.586 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.131 179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 101.95 2.01 52.02 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.689 -0.767 . . . . 0.0 112.417 -179.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.434 ' O ' ' N ' ' A' ' 115' ' ' LEU . 4.2 t70 -117.93 99.22 6.77 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.777 0.322 . . . . 0.0 110.859 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.469 ' HA ' ' HA ' ' A' ' 128' ' ' GLU . 6.5 m -35.41 96.11 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.004 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.464 ' N ' ' O ' ' A' ' 127' ' ' ILE . 7.1 mt -46.4 -89.98 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.75 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.467 ' O ' ' N ' ' A' ' 127' ' ' ILE . 0.5 OUTLIER -136.86 -168.91 2.36 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.687 -179.992 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.998 HD13 ' HB2' ' A' ' 124' ' ' MET . 2.2 mt -125.83 153.83 34.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.885 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.457 ' HA ' ' O ' ' A' ' 90' ' ' THR . 27.5 t -142.61 101.64 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.872 179.832 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.544 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.5 OUTLIER -62.7 89.66 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.201 -179.799 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.449 ' O ' ' C ' ' A' ' 121' ' ' MET . . . -69.28 -136.07 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.649 179.715 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.482 ' O ' ' HB2' ' A' ' 122' ' ' LYS . 0.0 OUTLIER -34.14 -39.84 0.08 Allowed 'General case' 0 CA--C 1.519 -0.224 0 CA-C-O 121.444 0.64 . . . . 0.0 110.173 179.608 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.519 ' CG ' ' O ' ' A' ' 122' ' ' LYS . 0.1 OUTLIER 169.27 38.21 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.873 179.482 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.407 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 36.8 mmm -146.93 131.87 18.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.045 -179.422 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.998 ' HB2' HD13 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -64.47 101.44 0.45 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.836 179.994 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.457 ' HB2' ' O ' ' A' ' 118' ' ' VAL . 0.9 OUTLIER -77.07 83.28 3.58 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.877 179.946 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.546 ' CA ' HG12 ' A' ' 117' ' ' ILE . 7.8 pt20 -64.29 103.92 0.69 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.959 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.467 ' N ' ' O ' ' A' ' 116' ' ' CYS . 17.3 mm -75.38 139.09 19.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.04 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.469 ' HA ' ' HA ' ' A' ' 114' ' ' THR . 2.2 mt-10 -110.4 122.05 46.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.923 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.409 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -36.78 114.89 0.33 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.064 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -107.82 17.19 22.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.48 ' N ' HG12 ' A' ' 111' ' ' VAL . 1.9 ttmt 177.32 113.5 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.9 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.489 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 15.6 p -43.51 121.31 2.23 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.758 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.414 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -152.2 -171.52 19.92 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.665 -0.778 . . . . 0.0 112.599 -179.802 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.582 ' N ' HG23 ' A' ' 155' ' ' ILE . 21.8 m -140.14 107.81 5.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.582 0.229 . . . . 0.0 111.239 -179.752 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.672 HG12 ' HA ' ' A' ' 105' ' ' VAL . 92.5 t -41.79 142.71 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.593 -0.276 . . . . 0.0 110.437 179.459 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.802 ' C ' HG23 ' A' ' 105' ' ' VAL . 30.5 mtpt -124.91 -18.93 5.38 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.621 -0.263 . . . . 0.0 111.455 -179.478 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.631 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 169.15 155.38 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.935 0.398 . . . . 0.0 111.622 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.639 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -111.11 77.44 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.61 179.792 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 9.7 mt -46.25 -24.92 0.53 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.965 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.994 HG21 HD23 ' A' ' 152' ' ' LEU . 45.3 t -104.13 144.18 14.74 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.239 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.494 ' HB2' ' HG2' ' A' ' 144' ' ' GLN . 4.7 mt-10 -62.35 137.62 58.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.069 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.504 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -31.58 -62.33 0.2 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.621 -179.331 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.589 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -125.58 104.21 0.75 Allowed Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.483 -0.865 . . . . 0.0 112.995 -179.483 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.896 ' O ' HG23 ' A' ' 90' ' ' THR . 0.6 OUTLIER -167.62 156.16 8.72 Favored Pre-proline 0 C--N 1.327 -0.402 0 CA-C-O 120.93 0.395 . . . . 0.0 111.137 179.553 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.435 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 37.8 Cg_endo -66.31 138.38 50.8 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.807 2.338 . . . . 0.0 112.329 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.613 HG11 ' CD2' ' A' ' 152' ' ' LEU . 1.5 m -132.14 -174.77 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.089 179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.431 ' O ' ' C ' ' A' ' 148' ' ' PHE . 18.5 mt-10 -145.7 144.03 30.13 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.929 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.492 ' HA ' ' O ' ' A' ' 85' ' ' SER . 39.6 t80 -34.5 135.02 0.18 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.947 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 76.3 23.96 1.15 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.709 -179.829 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.476 ' HG2' HG12 ' A' ' 146' ' ' VAL . 4.5 tp10 -109.93 74.26 0.76 Allowed Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.788 -180.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.752 ' O ' HG23 ' A' ' 140' ' ' VAL . 63.3 Cg_exo -33.27 130.57 0.13 Allowed 'Trans proline' 0 N--CA 1.457 -0.635 0 C-N-CA 122.888 2.392 . . . . 0.0 112.116 179.652 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.994 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -121.86 -72.2 0.7 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.555 -179.231 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.77 HG13 HG23 ' A' ' 83' ' ' VAL . 1.2 p -96.61 102.92 14.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.226 0.536 . . . . 0.0 111.37 -179.38 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.836 HG13 HG12 ' A' ' 82' ' ' ILE . 6.3 t -83.38 138.64 18.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.017 179.675 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.582 HG23 ' N ' ' A' ' 134' ' ' THR . 17.9 mt -136.72 143.2 35.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.352 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.503 ' CB ' ' HD2' ' A' ' 136' ' ' LYS . 29.5 tt0 . . . . . 0 C--O 1.25 1.094 0 CA-C-O 118.19 -0.91 . . . . 0.0 110.881 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.458 -0.073 0 CA-C-O 120.799 0.333 . . . . 0.0 111.147 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -81.11 151.12 28.45 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.135 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -132.6 82.35 2.0 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.92 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.589 ' O ' HD13 ' A' ' 78' ' ' ILE . 0.0 OUTLIER -99.71 3.43 10.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.087 0.47 . . . . 0.0 111.292 179.967 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -78.63 84.26 4.75 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.901 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.417 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -70.84 -67.13 1.97 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.475 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.524 ' N ' ' O ' ' A' ' 155' ' ' ILE . 19.7 t-80 175.85 82.21 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.789 0.328 . . . . 0.0 110.849 -179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.887 HG12 HG13 ' A' ' 154' ' ' VAL . 7.1 mt -98.93 157.27 3.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.087 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.834 HG23 HG13 ' A' ' 153' ' ' VAL . 1.9 t -113.67 53.91 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.148 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.532 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -41.08 134.6 2.0 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.855 179.938 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.463 ' N ' HD11 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -35.86 109.23 0.4 Allowed Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.855 -179.916 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.453 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 35.4 Cg_endo -64.74 -8.56 18.01 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.744 2.296 . . . . 0.0 112.109 179.943 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -167.85 176.17 6.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.757 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.761 ' O ' HG23 ' A' ' 88' ' ' VAL . 32.6 m -71.42 82.83 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.129 -179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.431 ' O ' HG23 ' A' ' 146' ' ' VAL . . . -142.78 -159.06 7.78 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.581 -179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.709 HG23 ' C ' ' A' ' 144' ' ' GLN . 23.2 m -116.62 142.98 46.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.785 0.326 . . . . 0.0 110.803 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.738 ' HB2' HD22 ' A' ' 152' ' ' LEU . 2.6 t80 -100.23 140.16 34.88 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.277 -0.42 . . . . 0.0 110.893 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.588 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 19.9 m-85 -138.66 145.9 40.99 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.987 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.544 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 0.0 OUTLIER -125.49 28.24 6.31 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.852 179.846 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.477 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 12.1 p -146.96 115.5 4.36 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.847 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.434 ' HG2' ' CB ' ' A' ' 99' ' ' ALA . 55.5 Cg_endo -69.93 -39.44 6.17 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.685 2.257 . . . . 0.0 112.376 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.718 ' CB ' ' HB2' ' A' ' 99' ' ' ALA . 0.3 OUTLIER -129.16 160.57 63.19 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.952 179.998 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.407 ' HD2' ' OG ' ' A' ' 96' ' ' SER . 51.6 Cg_exo -52.58 -37.14 73.7 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.72 2.28 . . . . 0.0 112.332 179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.411 ' CG ' ' O ' ' A' ' 98' ' ' ASP . 34.9 t0 -131.45 32.39 4.2 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.885 179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.718 ' HB2' ' CB ' ' A' ' 96' ' ' SER . . . -76.24 -158.27 0.09 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.061 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.436 ' O ' ' HB3' ' A' ' 101' ' ' ALA . 6.1 ptmt -104.72 23.6 13.13 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.917 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.477 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 68.65 166.31 0.26 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.187 179.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.724 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -93.78 -34.02 13.36 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.818 179.915 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.846 HD13 HG23 ' A' ' 153' ' ' VAL . 1.0 OUTLIER -164.84 150.37 2.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.134 179.913 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -155.17 146.89 23.25 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.961 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.558 HG13 ' HA ' ' A' ' 136' ' ' LYS . 3.0 t -54.11 116.45 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.148 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 129.5 -36.31 2.4 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.546 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.452 ' OE1' ' HA ' ' A' ' 103' ' ' ILE . 12.7 pt20 -76.38 130.08 37.53 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.842 0.354 . . . . 0.0 110.895 -179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.434 ' HA ' ' HA ' ' A' ' 134' ' ' THR . 2.6 mtpt -90.23 91.4 8.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.949 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.897 HG11 ' CD2' ' A' ' 115' ' ' LEU . 15.4 m -51.5 173.44 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.074 -179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.435 ' CG ' ' O ' ' A' ' 109' ' ' VAL . 75.1 m-80 -163.6 130.54 3.34 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.691 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.489 ' HA ' ' CB ' ' A' ' 129' ' ' ALA . 3.2 t -37.45 135.43 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 115.841 -0.618 . . . . 0.0 111.073 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 89.59 7.9 68.52 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.651 -0.785 . . . . 0.0 112.519 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 114' ' ' THR . 91.1 m-20 -121.08 101.98 8.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.933 0.397 . . . . 0.0 110.783 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.435 ' CG2' ' HB2' ' A' ' 126' ' ' GLN . 1.7 m -35.25 101.66 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.104 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.897 ' CD2' HG11 ' A' ' 109' ' ' VAL . 7.7 mt -56.77 -83.66 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.63 179.785 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.465 ' HB3' HG12 ' A' ' 103' ' ' ILE . 0.8 OUTLIER -144.34 178.21 8.08 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.764 179.804 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.741 HD13 ' HB2' ' A' ' 124' ' ' MET . 4.2 mt -111.01 152.47 12.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.013 0.435 . . . . 0.0 110.803 179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.627 HG13 ' O ' ' A' ' 90' ' ' THR . 94.5 t -140.72 94.93 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.898 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.566 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.8 OUTLIER -50.51 84.83 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.103 -179.834 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.531 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -103.76 114.39 28.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.833 179.84 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.548 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 81.97 19.85 0.34 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.774 -179.746 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.548 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 91.13 -1.07 0.19 Allowed 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.141 179.896 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 5.7 mmt -123.0 134.87 54.3 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.915 0.388 . . . . 0.0 111.171 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.741 ' HB2' HD13 ' A' ' 117' ' ' ILE . 1.3 ptp -63.31 123.14 17.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.042 179.851 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -103.79 80.99 1.83 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.803 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.516 ' CA ' HG12 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -57.59 115.59 2.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.933 -179.989 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 3.6 mm -81.2 148.71 5.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.043 179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.423 ' O ' ' C ' ' A' ' 129' ' ' ALA . 22.3 tt0 -112.26 124.78 53.2 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.851 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.489 ' CB ' ' HA ' ' A' ' 111' ' ' VAL . . . -35.46 107.19 0.05 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.17 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -95.28 3.98 53.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.142 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 10.1 tttt 175.82 121.19 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.908 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . . . . . . . . . 86.8 p -47.32 135.03 10.94 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.793 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.506 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -164.84 -171.12 30.7 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.578 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.617 ' N ' HG23 ' A' ' 155' ' ' ILE . 24.3 m -136.09 107.41 6.84 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.614 0.245 . . . . 0.0 111.073 -179.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.499 ' HA ' HG12 ' A' ' 155' ' ' ILE . 75.4 t -39.83 139.77 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 121.04 -0.264 . . . . 0.0 110.501 179.594 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.718 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.1 OUTLIER -122.84 -19.93 6.02 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.583 -0.28 . . . . 0.0 111.119 -179.47 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.718 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 161.13 154.04 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.385 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.68 ' N ' HD13 ' A' ' 138' ' ' ILE . 0.0 OUTLIER -100.75 86.54 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.605 179.752 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.605 HD12 ' HB2' ' A' ' 151' ' ' PRO . 2.0 mt -43.24 -28.08 0.28 Allowed 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 121.192 0.52 . . . . 0.0 110.342 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 1.006 HG21 HD23 ' A' ' 152' ' ' LEU . 75.3 t -104.63 135.62 41.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.823 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.503 ' N ' ' OE1' ' A' ' 144' ' ' GLN . 10.0 mt-10 -66.49 97.06 0.4 Allowed 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.395 179.656 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.544 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 73.1 p -35.92 138.99 0.16 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.677 -179.642 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.588 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 81.21 35.8 22.75 Favored Glycine 0 N--CA 1.448 -0.501 0 C-N-CA 120.457 -0.878 . . . . 0.0 112.346 -179.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.709 ' C ' HG23 ' A' ' 90' ' ' THR . 1.2 pt20 -148.97 159.39 37.54 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 120.89 0.376 . . . . 0.0 111.144 -179.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.854 ' O ' HG13 ' A' ' 146' ' ' VAL . 45.1 Cg_endo -68.27 178.76 3.39 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.748 2.298 . . . . 0.0 112.195 179.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.854 HG13 ' O ' ' A' ' 145' ' ' PRO . 1.2 m -170.47 -175.67 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.283 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.523 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -142.74 155.47 44.86 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.869 179.993 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . . . . . . . . . 64.7 t80 -42.32 140.99 1.04 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.924 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.437 ' HA ' ' HD2' ' A' ' 84' ' ' ARG . 7.8 t0 66.4 28.94 9.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.841 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.523 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 2.4 tp10 -109.13 73.68 0.56 Allowed Pre-proline 0 C--N 1.327 -0.375 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.848 179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.605 ' HB2' HD12 ' A' ' 139' ' ' LEU . 51.3 Cg_exo -32.56 120.94 0.1 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.598 0 C-N-CA 123.001 2.468 . . . . 0.0 112.232 179.706 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 1.006 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -116.41 -64.38 1.32 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.6 -179.254 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.846 HG23 HD13 ' A' ' 103' ' ' ILE . 1.5 p -99.43 103.99 15.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.178 0.514 . . . . 0.0 111.584 -179.11 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.887 HG13 HG12 ' A' ' 82' ' ' ILE . 4.7 t -87.85 135.11 26.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.033 179.571 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.617 HG23 ' N ' ' A' ' 134' ' ' THR . 96.6 mt -138.0 135.33 45.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.205 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.48 ' HG3' ' HE2' ' A' ' 136' ' ' LYS . 0.4 OUTLIER . . . . . 0 C--O 1.249 1.048 0 CA-C-O 118.249 -0.882 . . . . 0.0 110.902 179.916 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.83 0.348 . . . . 0.0 111.192 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -164.58 107.95 0.9 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.141 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 176.14 114.68 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.822 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.425 ' O ' ' C ' ' A' ' 79' ' ' SER . 3.7 tt -79.4 -5.29 7.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.506 -179.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.43 ' O ' ' HA ' ' A' ' 156' ' ' GLU . 35.4 p 33.67 75.13 0.05 Allowed 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.006 179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.424 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -110.45 170.84 14.27 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.644 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.524 ' O ' ' ND1' ' A' ' 81' ' ' HIS . 17.9 t-80 174.45 83.22 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.835 0.35 . . . . 0.0 110.928 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.727 HG12 HG13 ' A' ' 154' ' ' VAL . 23.4 mt -98.66 127.99 50.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 120.994 0.426 . . . . 0.0 110.819 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.921 HG21 HD13 ' A' ' 115' ' ' LEU . 3.5 t -83.52 56.9 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.408 -179.543 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.533 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 1.9 ptt85 -42.96 134.55 3.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.67 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.675 ' HB2' HD21 ' A' ' 152' ' ' LEU . 9.6 t -35.98 96.86 0.11 Allowed Pre-proline 0 C--N 1.328 -0.355 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.896 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.412 ' N ' ' O ' ' A' ' 84' ' ' ARG . 87.9 Cg_exo -46.07 -27.05 4.03 Favored 'Trans proline' 0 N--CA 1.464 -0.213 0 C-N-CA 122.742 2.295 . . . . 0.0 112.186 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.52 ' SD ' ' CB ' ' A' ' 120' ' ' ALA . 10.0 ptp -147.75 168.5 21.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.954 -0.567 . . . . 0.0 110.705 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.474 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 1.5 p -69.39 91.08 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.051 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -146.46 -133.3 2.46 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.81 -0.71 . . . . 0.0 112.397 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.97 HG23 ' HA ' ' A' ' 145' ' ' PRO . 1.2 m -136.29 153.74 51.08 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.782 0.325 . . . . 0.0 110.954 179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.645 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 1.1 t80 -118.38 140.15 50.29 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.968 -179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.586 ' CD1' ' O ' ' A' ' 91' ' ' PHE . 22.0 m-85 -140.15 163.41 32.81 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.061 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.564 ' HD2' ' CB ' ' A' ' 142' ' ' SER . 0.0 OUTLIER -130.08 13.09 5.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.914 179.729 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.36 109.27 2.98 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.897 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -74.72 -5.04 16.31 Favored 'Trans proline' 0 C--O 1.232 0.201 0 C-N-CA 122.812 2.341 . . . . 0.0 112.454 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.59 167.88 12.24 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.05 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -74.55 106.43 2.25 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.747 2.298 . . . . 0.0 112.247 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 74.21 31.74 1.07 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.835 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -76.78 -166.8 0.73 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.312 -0.403 . . . . 0.0 111.003 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.01 33.38 0.87 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.885 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 51.58 175.75 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.182 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.838 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -111.68 -34.59 6.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.967 179.998 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.905 HD13 ' CG2' ' A' ' 153' ' ' VAL . 1.0 OUTLIER -170.08 129.08 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.186 179.933 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.5 ' O ' ' N ' ' A' ' 106' ' ' GLY . 3.2 mt-10 -136.72 148.87 47.55 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.835 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.589 HG22 ' C ' ' A' ' 136' ' ' LYS . 52.6 t -35.78 92.55 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.064 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . 0.5 ' N ' ' O ' ' A' ' 104' ' ' GLU . . . 133.39 -0.31 4.26 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.536 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.477 ' O ' ' HA ' ' A' ' 134' ' ' THR . 0.0 OUTLIER -71.24 112.58 7.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.82 0.343 . . . . 0.0 110.83 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 31.6 mttt -82.37 79.76 8.74 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.467 . . . . 0.0 111.046 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.653 HG11 HD13 ' A' ' 155' ' ' ILE . 1.4 p -78.03 164.08 3.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.974 179.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.565 ' N ' ' CG2' ' A' ' 109' ' ' VAL . 7.8 m120 -153.83 130.04 10.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.49 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.432 ' C ' ' O ' ' A' ' 110' ' ' ASN . 2.6 m -31.74 114.76 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.461 -179.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 111.87 9.24 21.08 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.488 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.432 ' O ' ' HA ' ' A' ' 128' ' ' GLU . 6.4 t0 -113.74 -148.86 0.44 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.794 0.33 . . . . 0.0 110.684 -179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.48 ' CG2' ' CE1' ' A' ' 102' ' ' PHE . 1.9 m -131.0 147.89 52.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.788 179.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.921 HD13 HG21 ' A' ' 83' ' ' VAL . 80.9 mt -116.46 -81.1 0.61 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.131 -179.749 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.483 ' HB2' ' O ' ' A' ' 92' ' ' TYR . 8.0 p -136.57 -176.13 4.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.282 -179.619 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.544 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.3 OUTLIER -102.52 117.89 48.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.18 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.661 HG12 ' O ' ' A' ' 125' ' ' ASN . 12.1 p -97.12 50.98 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.923 179.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.488 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.1 OUTLIER -35.91 96.43 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.96 -179.885 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.522 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -116.92 115.64 25.87 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.023 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.522 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 0.1 OUTLIER 84.06 18.18 0.2 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.821 -179.95 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.528 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 0.3 OUTLIER 85.43 26.14 0.07 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.963 179.998 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.488 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.9 OUTLIER -141.96 128.36 20.03 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.107 179.832 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.544 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 1.0 OUTLIER -66.68 131.55 46.21 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.906 179.884 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.661 ' O ' HG12 ' A' ' 118' ' ' VAL . 0.5 OUTLIER -125.99 88.39 2.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.825 -179.985 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.407 ' HB2' HG23 ' A' ' 114' ' ' THR . 4.3 pt20 -50.61 112.04 0.63 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.875 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.427 HG21 HG11 ' A' ' 83' ' ' VAL . 31.5 mm -72.53 137.78 22.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.083 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.432 ' HA ' ' O ' ' A' ' 113' ' ' ASP . 50.2 mt-10 -97.01 126.44 42.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.93 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.545 ' HB2' ' CG2' ' A' ' 109' ' ' VAL . . . -38.49 124.84 1.33 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.153 179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -101.67 -13.59 17.73 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.846 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 9.8 tttp -168.05 120.02 0.85 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.807 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.411 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 90.3 p -42.74 121.59 2.08 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.714 179.806 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.408 ' HA3' ' CG2' ' A' ' 155' ' ' ILE . . . -157.56 -176.5 29.69 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.552 -0.832 . . . . 0.0 112.67 -179.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.631 ' N ' HG23 ' A' ' 155' ' ' ILE . 24.2 m -131.86 110.78 11.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.582 0.229 . . . . 0.0 111.137 -179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.838 HG21 ' HB ' ' A' ' 103' ' ' ILE . 73.4 t -40.03 141.76 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 110.353 -0.24 . . . . 0.0 110.353 179.531 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.622 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 5.7 mmmt -126.19 -19.89 4.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.674 -0.239 . . . . 0.0 111.633 -179.459 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.622 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 169.49 161.18 0.06 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.834 0.349 . . . . 0.0 111.514 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.645 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -108.49 80.2 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.915 179.917 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.545 ' HG ' ' CG2' ' A' ' 154' ' ' VAL . 2.8 mt -41.33 -30.33 0.18 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.104 0.478 . . . . 0.0 109.919 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.989 HG21 HD23 ' A' ' 152' ' ' LEU . 71.7 t -98.64 139.19 21.12 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.53 -0.759 . . . . 0.0 110.827 179.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.486 ' O ' ' CG ' ' A' ' 144' ' ' GLN . 6.7 mt-10 -70.59 98.14 1.44 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.351 179.654 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.564 ' CB ' ' HD2' ' A' ' 93' ' ' ARG . 35.5 p -35.83 154.36 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.703 -179.65 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.582 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 62.69 38.12 95.93 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.33 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.486 ' CG ' ' O ' ' A' ' 141' ' ' GLU . 12.3 mm-40 -150.48 145.27 18.29 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 120.931 0.396 . . . . 0.0 111.042 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.97 ' HA ' HG23 ' A' ' 90' ' ' THR . 52.4 Cg_exo -54.81 173.04 0.29 Allowed 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.755 2.303 . . . . 0.0 112.17 179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.722 HG11 ' CD2' ' A' ' 152' ' ' LEU . 0.4 OUTLIER -165.76 175.86 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.042 179.939 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.509 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 0.8 OUTLIER -135.26 162.17 33.32 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.991 -179.935 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.464 ' HA ' ' O ' ' A' ' 85' ' ' SER . 6.8 t80 -48.65 141.49 7.08 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.789 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 65.42 29.78 11.19 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.775 -179.851 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.563 ' HG2' HG12 ' A' ' 146' ' ' VAL . 1.2 tp10 -108.16 73.36 0.44 Allowed Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.762 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.689 ' O ' HG23 ' A' ' 140' ' ' VAL . 55.7 Cg_exo -32.2 119.35 0.09 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 123.013 2.475 . . . . 0.0 112.145 179.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.989 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -116.82 -71.32 0.74 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.545 -179.298 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.905 ' CG2' HD13 ' A' ' 103' ' ' ILE . 1.6 p -93.69 105.32 16.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 121.159 0.504 . . . . 0.0 111.732 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.727 HG13 HG12 ' A' ' 82' ' ' ILE . 41.5 t -84.16 135.38 24.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.861 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.812 HD11 HD22 ' A' ' 115' ' ' LEU . 95.6 mt -133.64 135.63 55.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.362 -179.707 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.443 ' HB2' ' HD3' ' A' ' 136' ' ' LYS . 1.7 tt0 . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.18 -0.914 . . . . 0.0 110.871 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.695 ' O ' ' HB3' ' A' ' 76' ' ' ALA . . . . . . . . 0 N--CA 1.457 -0.123 0 CA-C-O 120.839 0.352 . . . . 0.0 111.101 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.695 ' HB3' ' O ' ' A' ' 75' ' ' ALA . . . 84.77 -11.95 0.76 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 -179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER 45.2 40.3 4.86 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.972 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.633 HG22 ' O ' ' A' ' 78' ' ' ILE . 2.6 mm -121.2 -0.27 7.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.404 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.466 ' C ' ' O ' ' A' ' 78' ' ' ILE . 5.7 t 30.12 42.58 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.235 179.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.473 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -83.09 159.22 37.25 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.781 -0.724 . . . . 0.0 112.774 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.621 ' C ' HD13 ' A' ' 82' ' ' ILE . 13.4 t-80 171.9 83.85 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 120.754 0.311 . . . . 0.0 110.582 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 1.034 HD12 HG13 ' A' ' 154' ' ' VAL . 0.0 OUTLIER -103.08 -178.42 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.97 0.414 . . . . 0.0 111.184 -179.995 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.809 HG23 HG13 ' A' ' 153' ' ' VAL . 11.3 t -130.41 32.45 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.763 179.696 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.556 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 4.7 ptt180 -30.41 119.92 0.18 Allowed 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.916 -0.584 . . . . 0.0 111.283 -179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.48 ' O ' ' HA ' ' A' ' 148' ' ' PHE . 0.7 OUTLIER -36.48 103.14 0.24 Allowed Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.94 -179.771 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -51.54 -22.58 12.89 Favored 'Trans proline' 0 N--CA 1.464 -0.226 0 C-N-CA 122.653 2.235 . . . . 0.0 112.052 179.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.0 ptm -141.56 -176.79 4.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.789 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.466 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 15.1 t -82.29 93.5 2.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.046 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -146.22 -141.42 3.61 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.587 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.725 HG23 ' C ' ' A' ' 144' ' ' GLN . 42.4 m -136.57 141.84 43.35 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.792 0.329 . . . . 0.0 111.023 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.866 ' HB2' HD22 ' A' ' 152' ' ' LEU . 0.8 OUTLIER -100.74 146.24 27.48 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.961 -179.981 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.582 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 16.5 m-85 -143.16 162.61 35.11 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.904 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.543 ' CD ' ' HB3' ' A' ' 142' ' ' SER . 9.5 ptm180 -139.75 31.53 2.04 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.874 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.493 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 68.7 p -145.74 122.15 5.92 Favored Pre-proline 0 C--N 1.33 -0.262 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.875 179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.507 ' HG2' ' CB ' ' A' ' 99' ' ' ALA . 55.7 Cg_endo -70.36 -21.48 30.65 Favored 'Trans proline' 0 C--N 1.342 0.229 0 C-N-CA 122.701 2.268 . . . . 0.0 112.358 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 15.2 m -162.8 152.97 13.67 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.081 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 75.8 Cg_exo -49.63 -20.76 4.65 Favored 'Trans proline' 0 C--O 1.232 0.215 0 C-N-CA 122.8 2.333 . . . . 0.0 112.284 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -138.31 72.7 1.41 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.815 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.507 ' CB ' ' HG2' ' A' ' 95' ' ' PRO . . . -137.1 -154.87 0.57 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.197 179.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -113.15 36.51 3.5 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.846 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.493 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 62.06 -178.44 0.13 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.115 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.915 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -104.17 -37.13 7.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.866 -179.964 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.915 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.3 OUTLIER -178.18 146.62 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.11 179.992 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -146.75 162.72 37.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.854 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.625 HG22 ' HA ' ' A' ' 137' ' ' ALA . 14.4 t -45.07 134.87 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.193 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 94.43 -11.95 69.55 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.543 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.426 ' O ' ' N ' ' A' ' 109' ' ' VAL . 3.6 tp60 -77.2 95.67 4.35 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.838 0.351 . . . . 0.0 110.892 -179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.9 mtmt -64.39 74.24 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.963 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.638 HG11 ' CD2' ' A' ' 115' ' ' LEU . 17.7 m -54.6 167.87 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.291 -0.413 . . . . 0.0 111.014 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.489 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 3.4 p-10 -157.31 131.26 8.2 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-O 121.174 0.512 . . . . 0.0 110.83 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.452 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 26.1 t -34.69 136.04 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 115.541 -0.754 . . . . 0.0 111.092 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 86.87 11.83 69.76 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.337 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.418 ' O ' ' C ' ' A' ' 114' ' ' THR . 26.4 t70 -124.69 102.53 7.64 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.783 0.325 . . . . 0.0 110.867 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.418 ' C ' ' O ' ' A' ' 113' ' ' ASP . 1.6 m -35.52 113.02 0.18 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.154 -179.951 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.638 ' CD2' HG11 ' A' ' 109' ' ' VAL . 19.2 mt -69.77 -87.53 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.648 179.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.727 ' HB3' HD11 ' A' ' 103' ' ' ILE . 9.1 p -135.32 -166.52 1.85 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.681 179.729 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.966 HD13 ' HB3' ' A' ' 124' ' ' MET . 1.7 mt -126.48 153.77 35.43 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.595 179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.634 HG13 ' O ' ' A' ' 90' ' ' THR . 46.7 t -141.04 103.12 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.965 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.512 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 0.5 OUTLIER -62.04 69.96 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.118 -179.773 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.518 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -92.81 145.31 24.5 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.904 179.833 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.518 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 9.1 ptp 51.96 21.03 1.37 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.737 -179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.511 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 1.6 tmtt? 80.28 52.03 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.877 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.486 ' HG3' ' O ' ' A' ' 120' ' ' ALA . 0.2 OUTLIER -172.0 133.13 0.7 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.091 179.804 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.966 ' HB3' HD13 ' A' ' 117' ' ' ILE . 45.2 mtt -67.54 97.16 0.57 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.951 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -79.43 82.08 5.61 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.779 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.547 ' CA ' HG12 ' A' ' 117' ' ' ILE . 4.3 pt20 -58.28 107.71 0.52 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.863 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.467 ' N ' ' O ' ' A' ' 116' ' ' CYS . 7.3 mm -74.99 162.51 4.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.164 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.425 ' N ' HG22 ' A' ' 127' ' ' ILE . 1.6 tt0 -130.04 141.1 50.76 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.852 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.452 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -46.24 113.65 0.66 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.995 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.402 ' OD1' ' N ' ' A' ' 130' ' ' ASP . 0.4 OUTLIER -101.09 11.09 40.18 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.936 -179.952 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 14.7 tttt 169.99 117.39 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.836 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.489 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 34.8 p -44.25 111.15 0.27 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.781 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -145.96 -175.46 19.02 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.668 -0.777 . . . . 0.0 112.554 -179.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.752 ' C ' HG23 ' A' ' 155' ' ' ILE . 20.7 m -129.54 109.38 10.98 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.645 0.26 . . . . 0.0 111.215 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.56 ' N ' HG23 ' A' ' 155' ' ' ILE . 95.5 t -43.29 143.64 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.626 -0.261 . . . . 0.0 110.364 179.474 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.711 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 1.3 mmmp? -123.72 -18.69 5.99 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.498 -0.319 . . . . 0.0 111.233 -179.55 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.711 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 162.79 164.31 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.888 0.375 . . . . 0.0 111.582 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.65 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -107.11 87.58 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.693 179.787 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.764 HD12 ' HB2' ' A' ' 151' ' ' PRO . 1.8 mt -43.0 -27.77 0.22 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.112 0.482 . . . . 0.0 110.437 -179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 1.037 HG21 HD23 ' A' ' 152' ' ' LEU . 55.6 t -106.64 140.4 24.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.723 -0.672 . . . . 0.0 110.924 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.522 ' O ' ' CG ' ' A' ' 144' ' ' GLN . 6.6 mt-10 -69.38 98.15 1.05 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.252 179.492 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.543 ' HB3' ' CD ' ' A' ' 93' ' ' ARG . 55.5 p -34.0 150.6 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.732 -179.469 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.582 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 67.33 35.86 88.4 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.383 -0.913 . . . . 0.0 112.149 -179.775 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.725 ' C ' HG23 ' A' ' 90' ' ' THR . 29.2 mm-40 -147.91 154.06 43.04 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 120.86 0.362 . . . . 0.0 111.103 -179.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.693 ' O ' HG13 ' A' ' 146' ' ' VAL . 59.8 Cg_endo -72.29 173.67 12.69 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.823 2.349 . . . . 0.0 112.344 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.868 HG21 HD21 ' A' ' 152' ' ' LEU . 10.5 m -163.65 -173.74 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.071 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.528 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 6.3 pt-20 -140.16 174.08 10.87 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.966 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.48 ' HA ' ' O ' ' A' ' 85' ' ' SER . 17.1 t80 -50.19 147.59 4.07 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.881 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 53.94 33.36 17.16 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.918 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.528 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 19.7 tp10 -109.45 74.74 0.7 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.741 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.815 ' O ' HG23 ' A' ' 140' ' ' VAL . 69.7 Cg_exo -36.34 128.98 0.43 Allowed 'Trans proline' 0 N--CA 1.46 -0.487 0 C-N-CA 122.705 2.27 . . . . 0.0 111.794 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 1.037 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -122.22 -48.91 2.07 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 111.866 0.321 . . . . 0.0 111.866 -179.059 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.809 HG13 HG23 ' A' ' 83' ' ' VAL . 1.6 p -116.94 113.45 42.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 121.026 0.441 . . . . 0.0 111.423 -179.375 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 1.034 HG13 HD12 ' A' ' 82' ' ' ILE . 1.6 t -93.84 144.6 9.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.073 179.77 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.752 HG23 ' C ' ' A' ' 134' ' ' THR . 60.3 mt -144.18 141.86 24.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.146 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.52 ' HB2' ' CE ' ' A' ' 136' ' ' LYS . 15.7 tt0 . . . . . 0 C--O 1.251 1.16 0 CA-C-O 118.224 -0.893 . . . . 0.0 110.823 -179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.803 0.335 . . . . 0.0 111.078 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . 65.1 -175.7 0.18 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.157 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 15.5 mm-40 -120.54 144.06 48.26 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.87 -179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.434 HG22 ' O ' ' A' ' 78' ' ' ILE . 1.6 mp -137.7 24.27 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.13 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.7 m 48.81 47.63 21.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.147 -0.478 . . . . 0.0 111.012 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.446 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . 73.54 -133.82 18.28 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.623 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.55 ' CD2' ' CG2' ' A' ' 155' ' ' ILE . 21.2 t60 170.38 86.12 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.799 0.333 . . . . 0.0 110.817 -179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.509 HG23 ' O ' ' A' ' 153' ' ' VAL . 0.3 OUTLIER -101.76 159.22 4.2 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 121.03 0.443 . . . . 0.0 111.176 -179.941 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.839 HG12 ' HB ' ' A' ' 153' ' ' VAL . 4.4 p -109.43 46.64 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.774 -0.648 . . . . 0.0 111.132 -179.855 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.498 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 7.4 ptt180 -31.0 136.64 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.247 -179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.566 ' N ' HD21 ' A' ' 152' ' ' LEU . 0.3 OUTLIER -43.34 106.42 0.49 Allowed Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.055 -179.734 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_exo -56.71 -20.97 37.22 Favored 'Trans proline' 0 C--O 1.231 0.14 0 C-N-CA 122.736 2.29 . . . . 0.0 111.98 179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -155.99 -175.7 5.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.015 -0.538 . . . . 0.0 110.855 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 3.5 m -82.78 76.32 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.168 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -129.96 -146.24 5.97 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.539 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.83 HG23 ' HA ' ' A' ' 145' ' ' PRO . 1.5 m -131.55 154.39 48.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.707 0.289 . . . . 0.0 110.904 179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.937 ' CD2' HD12 ' A' ' 152' ' ' LEU . 0.3 OUTLIER -115.39 146.61 41.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.948 0.404 . . . . 0.0 111.25 -179.859 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.579 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 24.0 m-85 -144.04 164.96 29.11 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.862 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.671 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 16.6 ptt180 -149.73 21.92 0.9 Allowed 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.713 179.8 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.459 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 72.6 p -147.14 86.11 6.63 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.866 179.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -67.95 -20.89 44.39 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.746 2.297 . . . . 0.0 112.39 179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.845 ' OG ' ' HB2' ' A' ' 99' ' ' ALA . 0.0 OUTLIER -120.39 145.04 39.61 Favored Pre-proline 0 C--N 1.33 -0.253 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.958 179.934 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_exo -50.7 -41.48 53.9 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.752 2.301 . . . . 0.0 112.344 179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -134.16 60.42 1.7 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 179.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.845 ' HB2' ' OG ' ' A' ' 96' ' ' SER . . . -111.14 -169.9 1.54 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.096 179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.427 ' N ' ' CD ' ' A' ' 100' ' ' LYS . 0.4 OUTLIER -93.71 24.64 3.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.833 179.984 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.671 ' HB1' ' O ' ' A' ' 93' ' ' ARG . . . 67.13 -178.37 0.21 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.061 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.72 ' O ' HD13 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -89.09 -59.27 2.27 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.591 179.79 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.936 HG22 HG21 ' A' ' 135' ' ' VAL . 24.6 mm -154.15 94.74 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.908 179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -94.66 165.72 12.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.961 -179.835 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.487 ' CG2' ' O ' ' A' ' 136' ' ' LYS . 2.1 p -53.58 101.62 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.066 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 141.11 -29.86 2.28 Favored Glycine 0 N--CA 1.45 -0.387 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.523 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.423 ' HA ' ' OE1' ' A' ' 107' ' ' GLN . 1.9 mp0 -72.04 121.17 18.73 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.782 0.325 . . . . 0.0 110.861 179.903 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 1.8 mttt -86.36 97.31 10.35 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.959 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.789 HG11 ' CD2' ' A' ' 115' ' ' LEU . 15.3 m -61.48 176.74 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.123 179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.511 ' HA ' ' CB ' ' A' ' 132' ' ' SER . 66.0 m-20 -168.89 133.81 1.57 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.672 179.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.428 ' C ' ' O ' ' A' ' 110' ' ' ASN . 0.2 OUTLIER -35.14 123.79 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.128 179.89 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 91.65 21.12 35.08 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.444 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.43 ' O ' ' C ' ' A' ' 114' ' ' THR . 20.1 t0 -132.37 107.21 8.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.707 0.289 . . . . 0.0 110.87 179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.537 ' CG2' ' HB2' ' A' ' 126' ' ' GLN . 2.4 m -34.16 132.9 0.24 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.025 -180.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.789 ' CD2' HG11 ' A' ' 109' ' ' VAL . 18.0 mt -89.07 -83.0 0.24 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.992 -179.858 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . . . . . . . . . 19.0 p -135.91 -166.2 1.83 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.039 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.553 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.3 OUTLIER -113.58 114.49 46.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.21 -179.883 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.974 HG12 ' O ' ' A' ' 125' ' ' ASN . 9.1 p -103.49 58.26 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.831 179.746 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.486 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.5 OUTLIER -34.72 91.32 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.115 -179.778 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.512 ' N ' ' O ' ' A' ' 118' ' ' VAL . . . -108.4 145.77 34.05 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.009 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.473 ' HG2' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 46.85 24.86 0.39 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.574 -179.868 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.497 ' O ' ' CG ' ' A' ' 123' ' ' MET . 0.0 OUTLIER 79.33 50.21 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.886 -179.917 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.497 ' CG ' ' O ' ' A' ' 122' ' ' LYS . 40.5 mtp -162.28 125.56 2.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.081 179.798 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.553 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -60.28 77.96 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.74 -0.664 . . . . 0.0 110.994 179.947 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.974 ' O ' HG12 ' A' ' 118' ' ' VAL . 1.0 OUTLIER -70.54 73.65 0.53 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.754 179.919 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.537 ' HB2' ' CG2' ' A' ' 114' ' ' THR . 0.0 OUTLIER -50.22 131.59 23.82 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.015 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.55 HG22 ' N ' ' A' ' 128' ' ' GLU . 35.3 mm -94.03 161.64 2.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.08 179.766 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.55 ' N ' HG22 ' A' ' 127' ' ' ILE . 5.8 mt-10 -127.99 142.24 51.3 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.978 -179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . . . . . . . . . . . -62.38 136.81 58.08 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.085 -179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 19.0 m-20 -115.87 -8.02 11.98 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.035 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.477 ' HE2' ' ND1' ' A' ' 81' ' ' HIS . 0.3 OUTLIER -159.94 35.3 0.18 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.839 179.96 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.511 ' CB ' ' HA ' ' A' ' 110' ' ' ASN . 96.1 p 43.64 -171.7 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.767 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.548 ' N ' HG23 ' A' ' 109' ' ' VAL . . . 148.22 -156.84 27.09 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.54 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.541 ' N ' HG12 ' A' ' 155' ' ' ILE . 85.7 m -162.81 110.01 1.24 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.721 0.296 . . . . 0.0 110.91 -179.913 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.936 HG21 HG22 ' A' ' 103' ' ' ILE . 70.1 t -47.21 144.13 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.893 0.378 . . . . 0.0 111.015 179.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.548 ' HD3' HG11 ' A' ' 154' ' ' VAL . 0.0 OUTLIER -114.83 -35.82 4.68 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 121.494 0.664 . . . . 0.0 109.451 -179.95 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.642 ' O ' HG23 ' A' ' 154' ' ' VAL . . . 179.65 136.65 0.11 Allowed 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 114.97 -1.014 . . . . 0.0 111.052 -179.724 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.936 HG21 ' CZ ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -88.92 85.38 2.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.927 0.394 . . . . 0.0 110.555 179.695 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.422 ' C ' ' O ' ' A' ' 138' ' ' ILE . 10.8 mt -37.16 -31.26 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.485 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.604 HG21 ' HB3' ' A' ' 152' ' ' LEU . 42.9 t -94.32 143.31 11.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.486 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.177 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.472 ' O ' ' HB3' ' A' ' 144' ' ' GLN . 27.3 mt-10 -77.59 105.36 8.69 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.917 179.235 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.539 ' HB3' ' CD ' ' A' ' 93' ' ' ARG . 24.4 p -34.45 135.82 0.16 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.765 -179.342 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.579 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 83.64 34.79 18.32 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.41 -0.9 . . . . 0.0 111.93 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.472 ' HB3' ' O ' ' A' ' 141' ' ' GLU . 1.0 OUTLIER -143.42 145.28 31.23 Favored Pre-proline 0 C--N 1.332 -0.186 0 CA-C-O 120.88 0.372 . . . . 0.0 110.976 -179.658 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.83 ' HA ' HG23 ' A' ' 90' ' ' THR . 57.2 Cg_endo -71.2 171.97 14.94 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.789 2.326 . . . . 0.0 112.204 179.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.548 ' CG2' ' HB2' ' A' ' 85' ' ' SER . 6.0 m -153.44 -165.12 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.192 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.517 ' O ' ' CG ' ' A' ' 150' ' ' GLU . 3.3 mt-10 -146.03 157.88 43.87 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.043 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.469 ' HA ' ' O ' ' A' ' 85' ' ' SER . 3.4 t80 -47.39 135.05 11.12 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.912 179.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.416 ' N ' ' CD1' ' A' ' 148' ' ' PHE . 58.1 t0 67.4 34.8 4.57 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.939 -179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.565 ' O ' HD23 ' A' ' 152' ' ' LEU . 14.6 mm-40 -115.29 75.43 4.48 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.857 179.769 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.498 ' HA ' ' HA ' ' A' ' 84' ' ' ARG . 71.2 Cg_exo -36.61 125.53 0.41 Allowed 'Trans proline' 0 N--CA 1.459 -0.528 0 C-N-CA 122.75 2.3 . . . . 0.0 111.637 179.51 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.937 HD12 ' CD2' ' A' ' 91' ' ' PHE . 0.2 OUTLIER -129.29 -36.24 1.72 Allowed 'General case' 0 N--CA 1.451 -0.423 0 CA-C-O 120.962 0.411 . . . . 0.0 110.98 -179.005 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.839 ' HB ' HG12 ' A' ' 83' ' ' VAL . 1.3 t -115.99 109.46 28.24 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.542 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.347 -178.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.642 HG23 ' O ' ' A' ' 137' ' ' ALA . 1.4 t -98.46 119.04 45.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.612 179.429 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.55 ' CG2' ' CD2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -110.1 154.66 11.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.863 -179.772 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.467 ' N ' ' O ' ' A' ' 134' ' ' THR . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.058 0 CA-C-O 118.241 -0.885 . . . . 0.0 110.939 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' A' ' 76' ' ' ALA . . . . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.83 0.347 . . . . 0.0 111.132 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.412 ' O ' ' O ' ' A' ' 75' ' ' ALA . . . 37.3 -158.02 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.071 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.435 ' H ' HD12 ' A' ' 78' ' ' ILE . 0.5 OUTLIER -128.73 27.26 5.51 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.816 179.985 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.584 HG22 ' O ' ' A' ' 78' ' ' ILE . 3.4 mp -142.78 21.35 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.083 179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.418 ' C ' ' O ' ' A' ' 78' ' ' ILE . 35.4 t 35.93 46.57 0.36 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.951 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . 63.46 -139.7 44.02 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.469 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.616 ' HD2' HD12 ' A' ' 155' ' ' ILE . 24.5 t60 -178.87 79.79 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.802 0.334 . . . . 0.0 110.874 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 1.069 HD12 HG13 ' A' ' 154' ' ' VAL . 0.2 OUTLIER -92.04 -176.14 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.031 179.845 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.859 HG23 HG13 ' A' ' 153' ' ' VAL . 2.1 t -142.02 41.56 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.859 179.693 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.537 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -33.84 132.81 0.22 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.088 -179.845 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.985 ' OG ' HD21 ' A' ' 152' ' ' LEU . 1.5 m -44.44 103.91 0.36 Allowed Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.903 -179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_exo -50.98 -20.04 6.56 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.586 2.191 . . . . 0.0 112.064 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.621 ' SD ' ' HB1' ' A' ' 120' ' ' ALA . 14.9 ptm -150.34 166.73 29.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.681 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.47 ' HA ' ' HA ' ' A' ' 147' ' ' GLU . 1.5 p -68.14 95.9 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.004 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -147.56 -133.0 2.31 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.579 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.672 HG23 ' C ' ' A' ' 144' ' ' GLN . 24.3 m -140.43 151.19 44.7 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.831 0.348 . . . . 0.0 110.884 -179.889 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.776 ' CB ' HD22 ' A' ' 152' ' ' LEU . 0.4 OUTLIER -118.22 151.47 37.56 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.828 179.953 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.581 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 23.4 m-85 -147.24 168.76 20.91 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 115.789 -0.642 . . . . 0.0 111.0 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.468 ' O ' ' N ' ' A' ' 102' ' ' PHE . 0.0 OUTLIER -135.66 18.07 3.32 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.688 179.742 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.622 ' O ' HD11 ' A' ' 117' ' ' ILE . 2.1 p -132.6 108.73 13.24 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.815 179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.59 ' HG3' ' CD1' ' A' ' 102' ' ' PHE . 51.8 Cg_exo -53.72 -18.06 11.43 Favored 'Trans proline' 0 C--O 1.231 0.144 0 C-N-CA 122.743 2.296 . . . . 0.0 112.3 -179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.408 ' CB ' ' HD2' ' A' ' 97' ' ' PRO . 0.4 OUTLIER -178.96 167.95 0.88 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.902 -179.963 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.515 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 59.2 Cg_endo -72.29 113.77 3.8 Favored 'Trans proline' 0 N--CA 1.464 -0.215 0 C-N-CA 122.735 2.29 . . . . 0.0 112.361 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.515 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 0.6 OUTLIER 85.15 49.96 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.914 179.934 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -125.88 -163.58 1.23 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.093 179.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 1.2 mtpp -101.15 38.05 1.64 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.9 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.414 ' C ' ' HD3' ' A' ' 95' ' ' PRO . . . 54.15 175.76 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.084 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.909 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -100.75 -34.56 9.79 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.945 179.952 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.909 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.3 OUTLIER -179.05 144.04 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.035 179.922 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.471 ' O ' HG11 ' A' ' 135' ' ' VAL . 2.3 mt-10 -146.33 148.33 32.27 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.948 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.529 HG22 ' HA ' ' A' ' 137' ' ' ALA . 3.9 t -35.36 123.82 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.109 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 111.48 -24.97 14.36 Favored Glycine 0 N--CA 1.45 -0.388 0 C-N-CA 120.705 -0.76 . . . . 0.0 112.323 -179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.65 ' O ' HG12 ' A' ' 135' ' ' VAL . 22.4 tp60 -82.25 117.24 22.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.784 0.326 . . . . 0.0 110.814 179.892 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.474 ' HA ' ' HA ' ' A' ' 134' ' ' THR . 0.0 OUTLIER -81.69 100.0 9.23 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.037 -179.885 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.651 HG11 ' CD2' ' A' ' 115' ' ' LEU . 7.7 m -59.27 176.09 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.019 179.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.432 ' CG ' ' O ' ' A' ' 109' ' ' VAL . 21.3 m120 -163.15 131.31 3.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.036 0.446 . . . . 0.0 110.766 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.517 ' CG1' ' HA ' ' A' ' 131' ' ' LYS . 33.2 m -35.42 138.4 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.011 179.832 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 80.74 16.42 75.39 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.333 -179.791 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -124.41 102.62 7.75 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.865 0.364 . . . . 0.0 110.848 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.703 HG23 ' HB2' ' A' ' 126' ' ' GLN . 9.0 m -40.54 110.77 0.16 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.022 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.651 ' CD2' HG11 ' A' ' 109' ' ' VAL . 20.6 mt -65.96 -87.42 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.802 179.845 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.549 ' SG ' HG11 ' A' ' 153' ' ' VAL . 0.8 OUTLIER -124.7 -171.28 2.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.768 179.904 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.622 HD11 ' O ' ' A' ' 94' ' ' THR . 0.3 OUTLIER -106.01 113.57 43.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.203 -179.932 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.761 ' O ' HG12 ' A' ' 118' ' ' VAL . 75.7 t -97.3 59.22 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.036 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.475 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.4 OUTLIER -39.1 90.76 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.039 -179.798 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.621 ' HB1' ' SD ' ' A' ' 87' ' ' MET . . . -110.55 144.6 39.15 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.958 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.5 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.1 OUTLIER 56.2 17.03 2.56 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.279 -0.418 . . . . 0.0 110.892 -179.917 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.5 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.6 OUTLIER 83.41 53.4 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.925 -179.995 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.481 ' HG2' ' O ' ' A' ' 120' ' ' ALA . 3.1 ptt? -173.07 133.45 0.53 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.991 179.769 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.536 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -53.04 96.14 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.019 179.945 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.425 ' O ' ' C ' ' A' ' 126' ' ' GLN . 4.2 t30 -88.18 65.18 8.01 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.811 179.847 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.703 ' HB2' HG23 ' A' ' 114' ' ' THR . 0.0 OUTLIER -35.12 154.46 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.065 -179.857 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.542 HG12 HG23 ' A' ' 118' ' ' VAL . 47.0 mm -121.97 120.3 61.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.22 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 58.4 mm-40 -83.11 119.77 24.92 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.777 179.882 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.453 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -41.61 114.39 0.51 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.164 -179.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -74.76 -27.0 60.16 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.721 179.878 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.517 ' HA ' ' CG1' ' A' ' 111' ' ' VAL . 0.0 OUTLIER -165.05 136.13 4.02 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.812 179.954 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.428 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 1.2 t -45.84 132.75 8.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.79 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.513 ' O ' ' N ' ' A' ' 109' ' ' VAL . . . -159.03 176.44 35.85 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.548 -0.834 . . . . 0.0 112.604 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.865 ' C ' HG23 ' A' ' 155' ' ' ILE . 13.8 m -122.88 108.21 12.73 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.663 0.268 . . . . 0.0 111.263 -179.918 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.65 HG12 ' O ' ' A' ' 107' ' ' GLN . 2.8 p -49.16 144.68 1.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.517 -0.311 . . . . 0.0 110.566 179.515 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.662 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 1.1 mmmp? -124.14 -19.24 5.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.632 0.253 . . . . 0.0 111.234 -179.553 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.662 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 166.3 163.23 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.843 0.354 . . . . 0.0 111.433 -179.779 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.641 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.1 OUTLIER -105.23 85.46 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.74 179.626 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.721 HD13 ' HB2' ' A' ' 151' ' ' PRO . 12.4 mt -42.49 -28.03 0.19 Allowed 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.969 0.414 . . . . 0.0 110.231 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 1.038 HG21 HD23 ' A' ' 152' ' ' LEU . 52.2 t -104.59 141.81 19.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 115.757 -0.656 . . . . 0.0 110.78 179.593 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.418 ' O ' ' C ' ' A' ' 142' ' ' SER . 6.5 mt-10 -69.75 97.12 1.04 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.58 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.461 ' HB2' ' HD2' ' A' ' 93' ' ' ARG . 0.3 OUTLIER -36.93 135.22 0.46 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.627 -179.957 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.581 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 85.81 38.09 8.96 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.534 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.672 ' C ' HG23 ' A' ' 90' ' ' THR . 4.1 pt20 -155.64 163.61 24.08 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 120.884 0.373 . . . . 0.0 111.155 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.912 ' O ' HG13 ' A' ' 146' ' ' VAL . 55.4 Cg_endo -70.47 -168.78 0.32 Allowed 'Trans proline' 0 C--N 1.343 0.271 0 C-N-CA 122.762 2.308 . . . . 0.0 112.646 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.918 HG11 HD23 ' A' ' 152' ' ' LEU . 0.2 OUTLIER -175.72 -174.02 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.965 -179.982 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.47 ' HA ' ' HA ' ' A' ' 88' ' ' VAL . 4.0 mt-10 -145.6 157.37 43.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.933 0.396 . . . . 0.0 111.089 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.446 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 1.2 t80 -42.94 125.13 3.4 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.976 -0.557 . . . . 0.0 110.946 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.446 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 2.4 t0 79.61 31.95 0.24 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.951 0.405 . . . . 0.0 110.606 -179.804 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.726 ' HG2' HG12 ' A' ' 146' ' ' VAL . 44.1 tp10 -111.03 74.99 1.05 Allowed Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.879 179.861 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.812 ' O ' HG23 ' A' ' 140' ' ' VAL . 63.3 Cg_exo -35.93 122.75 0.27 Allowed 'Trans proline' 0 N--CA 1.459 -0.508 0 C-N-CA 122.812 2.341 . . . . 0.0 112.084 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 1.038 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -116.66 -54.09 2.46 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.619 -179.208 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.859 HG13 HG23 ' A' ' 83' ' ' VAL . 1.3 p -108.07 108.72 25.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-O 121.121 0.486 . . . . 0.0 111.339 -179.262 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 1.069 HG13 HD12 ' A' ' 82' ' ' ILE . 6.0 t -91.14 138.96 18.51 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.976 179.592 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.865 HG23 ' C ' ' A' ' 134' ' ' THR . 37.3 mt -141.3 141.1 31.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.18 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.52 ' HB2' ' CG ' ' A' ' 136' ' ' LYS . 10.6 tt0 . . . . . 0 C--O 1.249 1.064 0 CA-C-O 118.248 -0.882 . . . . 0.0 110.877 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.12 0 CA-C-O 120.791 0.329 . . . . 0.0 111.094 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -68.87 173.07 5.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.044 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 71.22 152.34 0.11 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.136 -0.483 . . . . 0.0 110.819 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.458 HD12 ' HA ' ' A' ' 78' ' ' ILE . 2.2 tp -79.92 -1.23 4.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 121.116 0.484 . . . . 0.0 111.41 179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.444 ' O ' ' OE2' ' A' ' 156' ' ' GLU . 0.1 OUTLIER 47.26 35.77 4.09 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.966 179.905 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -160.1 -147.06 4.78 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.422 -179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.526 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 30.6 t60 -172.52 77.62 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.806 0.336 . . . . 0.0 110.925 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.907 HG12 HG13 ' A' ' 154' ' ' VAL . 10.2 mt -99.22 150.92 4.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.955 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.81 HG23 HG13 ' A' ' 153' ' ' VAL . 4.5 t -96.91 59.93 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.15 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.492 ' O ' ' N ' ' A' ' 86' ' ' PRO . 4.2 mmt85 -28.88 103.3 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 115.856 -0.611 . . . . 0.0 111.025 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.946 ' CA ' HD11 ' A' ' 152' ' ' LEU . 0.4 OUTLIER -32.12 91.95 0.05 OUTLIER Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.05 -0.523 . . . . 0.0 111.251 -179.789 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.878 ' HD2' HG11 ' A' ' 118' ' ' VAL . 77.5 Cg_exo -50.22 140.21 34.01 Favored 'Trans proline' 0 N--CA 1.464 -0.25 0 C-N-CA 122.755 2.303 . . . . 0.0 112.058 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.458 ' O ' ' O ' ' A' ' 86' ' ' PRO . 7.6 ptm 41.22 -167.09 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.465 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.648 HG22 ' CG ' ' A' ' 147' ' ' GLU . 72.5 t -90.32 114.49 28.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.783 0.325 . . . . 0.0 111.208 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -165.02 -164.11 19.69 Favored Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.537 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.749 HG23 ' CA ' ' A' ' 145' ' ' PRO . 1.9 m -115.48 151.56 34.58 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.853 0.359 . . . . 0.0 110.901 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.948 ' HB2' HD22 ' A' ' 152' ' ' LEU . 2.9 t80 -110.78 141.96 43.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.954 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.583 ' CE1' ' HA2' ' A' ' 143' ' ' GLY . 21.0 m-85 -142.41 157.49 44.72 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.808 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.519 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 1.7 ptm180 -134.39 20.88 3.67 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.398 179.568 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.583 ' O ' HD11 ' A' ' 117' ' ' ILE . 69.2 p -123.05 121.84 27.09 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.694 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.433 ' HG2' ' HB3' ' A' ' 99' ' ' ALA . 50.8 Cg_exo -53.07 -59.76 0.93 Allowed 'Trans proline' 0 C--N 1.341 0.143 0 C-N-CA 122.685 2.257 . . . . 0.0 112.336 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.581 ' CB ' ' CD ' ' A' ' 97' ' ' PRO . 0.9 OUTLIER 170.99 -66.04 0.0 OUTLIER Pre-proline 0 C--N 1.33 -0.261 0 CA-C-O 121.191 0.519 . . . . 0.0 111.106 179.869 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.581 ' CD ' ' CB ' ' A' ' 96' ' ' SER . 46.5 Cg_endo -68.94 53.6 0.81 Allowed 'Trans proline' 0 C--N 1.333 -0.268 0 C-N-CA 123.37 2.713 . . . . 0.0 112.496 -179.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.432 ' C ' ' O ' ' A' ' 97' ' ' PRO . 4.5 p30 35.18 45.2 0.18 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.033 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.433 ' HB3' ' HG2' ' A' ' 95' ' ' PRO . . . -71.68 -160.13 0.05 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.087 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.57 ' O ' ' HB3' ' A' ' 101' ' ' ALA . 0.4 OUTLIER -90.77 27.48 1.77 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.842 179.921 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.57 ' HB3' ' O ' ' A' ' 100' ' ' LYS . . . 75.68 155.85 0.17 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.071 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.666 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.2 OUTLIER -69.11 -37.51 78.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.266 -0.424 . . . . 0.0 110.49 179.885 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.666 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.9 pp -163.34 157.67 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.934 179.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -154.79 147.57 24.41 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.056 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.736 HG23 ' HA ' ' A' ' 136' ' ' LYS . 2.0 p -44.2 109.4 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.05 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 126.38 -18.07 6.5 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.397 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -85.48 106.37 16.77 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.842 0.353 . . . . 0.0 110.867 -179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' A' ' 109' ' ' VAL . 2.4 mttp -67.03 79.53 0.12 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.908 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.71 HG22 ' O ' ' A' ' 133' ' ' GLY . 22.1 m -45.8 175.55 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.109 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.445 ' HA ' ' HB2' ' A' ' 132' ' ' SER . 1.7 p-10 -165.27 135.02 3.58 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-O 121.026 0.441 . . . . 0.0 110.742 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.468 ' HA ' ' HB3' ' A' ' 129' ' ' ALA . 20.2 t -34.82 137.24 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-N 115.711 -0.677 . . . . 0.0 111.077 179.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 81.31 16.22 74.61 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.414 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 114' ' ' THR . 9.0 t0 -122.54 101.71 7.64 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.814 0.34 . . . . 0.0 110.952 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.451 ' HA ' ' O ' ' A' ' 127' ' ' ILE . 1.5 m -35.4 108.7 0.07 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.898 -179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.51 ' N ' ' O ' ' A' ' 127' ' ' ILE . 14.7 mt -62.24 -67.04 0.45 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.791 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.498 ' SG ' ' N ' ' A' ' 117' ' ' ILE . 2.5 p -162.46 -154.47 0.31 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.942 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.583 HD11 ' O ' ' A' ' 94' ' ' THR . 0.1 OUTLIER -122.23 119.37 58.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.282 -179.85 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.878 HG11 ' HD2' ' A' ' 86' ' ' PRO . 2.4 t -109.21 58.46 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.801 179.644 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.486 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.4 OUTLIER -34.74 104.11 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.165 -179.703 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.524 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -121.81 108.91 14.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.995 179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.532 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 86.16 17.8 0.11 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.676 -179.802 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.541 ' CD ' ' O ' ' A' ' 122' ' ' LYS . 5.0 tmtm? 87.61 26.58 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.861 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.486 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 1.1 mmm -139.85 124.81 18.56 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.927 0.394 . . . . 0.0 111.157 179.768 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.554 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -55.55 102.97 0.08 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.875 179.762 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.449 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 9.8 t30 -84.78 65.21 9.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.813 179.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.439 ' HA ' ' O ' ' A' ' 116' ' ' CYS . 6.7 pt20 -45.79 118.99 2.01 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.96 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.547 HD11 HG21 ' A' ' 118' ' ' VAL . 3.7 mm -94.2 151.66 3.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.005 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -126.65 130.45 50.47 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.922 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.468 ' HB3' ' HA ' ' A' ' 111' ' ' VAL . . . -42.44 134.07 3.11 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.111 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.446 ' OD1' ' O ' ' A' ' 130' ' ' ASP . 10.5 t70 -118.44 -0.24 11.47 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.076 179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.458 ' O ' ' O ' ' A' ' 132' ' ' SER . 1.3 ptmt -170.73 29.61 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.941 -179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.458 ' O ' ' O ' ' A' ' 131' ' ' LYS . 0.9 OUTLIER 47.38 -179.52 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.743 -179.815 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.71 ' O ' HG22 ' A' ' 109' ' ' VAL . . . 152.01 174.19 22.42 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.593 -0.813 . . . . 0.0 112.625 179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.711 ' N ' HG23 ' A' ' 155' ' ' ILE . 27.5 m -120.94 110.68 16.58 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.553 0.216 . . . . 0.0 111.235 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.545 ' HA ' ' CG1' ' A' ' 155' ' ' ILE . 61.3 t -49.77 145.66 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.63 -0.259 . . . . 0.0 110.32 179.461 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.736 ' HA ' HG23 ' A' ' 105' ' ' VAL . 50.9 mmtt -125.38 -18.04 5.44 Favored 'General case' 0 C--N 1.328 -0.366 0 C-N-CA 121.049 -0.26 . . . . 0.0 111.643 -179.417 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.696 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 164.66 153.46 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.927 0.394 . . . . 0.0 111.857 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.737 ' N ' HD13 ' A' ' 138' ' ' ILE . 0.0 OUTLIER -95.7 77.9 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.419 179.499 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.739 HD12 HG22 ' A' ' 154' ' ' VAL . 3.9 mt -38.44 -30.86 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.118 0.485 . . . . 0.0 110.223 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.94 HG21 HD23 ' A' ' 152' ' ' LEU . 55.3 t -102.93 138.32 27.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.818 179.725 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.518 ' O ' ' CG ' ' A' ' 144' ' ' GLN . 1.7 mt-10 -68.92 106.5 2.75 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.385 179.801 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.507 ' HB3' ' CG ' ' A' ' 93' ' ' ARG . 6.3 p -36.41 152.07 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.697 -179.554 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.583 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 56.99 43.86 92.97 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.456 -0.878 . . . . 0.0 112.395 -179.849 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.595 ' C ' HG23 ' A' ' 90' ' ' THR . 61.6 mm-40 -147.39 137.95 12.71 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 120.895 0.378 . . . . 0.0 111.245 -179.769 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.749 ' CA ' HG23 ' A' ' 90' ' ' THR . 57.1 Cg_endo -70.64 156.18 61.55 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.691 2.261 . . . . 0.0 112.266 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.923 HG21 HD21 ' A' ' 152' ' ' LEU . 4.1 m -152.24 -156.51 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.208 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.648 ' CG ' HG22 ' A' ' 88' ' ' VAL . 0.0 OUTLIER -147.57 174.31 11.87 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.95 -179.943 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.444 ' HA ' ' O ' ' A' ' 85' ' ' SER . 25.4 t80 -53.84 150.81 7.12 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.87 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.418 ' O ' ' HD3' ' A' ' 151' ' ' PRO . 84.1 m-20 60.2 23.6 12.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.928 179.959 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.477 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 4.6 tt0 -107.17 74.51 0.4 Allowed Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.815 179.738 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.854 ' O ' HG23 ' A' ' 140' ' ' VAL . 62.9 Cg_exo -35.51 127.92 0.3 Allowed 'Trans proline' 0 N--CA 1.459 -0.542 0 C-N-CA 122.996 2.464 . . . . 0.0 112.5 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.948 HD22 ' HB2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -120.89 -59.97 1.69 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.273 -179.729 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.81 HG13 HG23 ' A' ' 83' ' ' VAL . 1.4 p -102.93 101.88 12.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.202 -179.663 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.907 HG13 HG12 ' A' ' 82' ' ' ILE . 17.0 t -87.11 136.0 23.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 115.811 -0.632 . . . . 0.0 111.292 179.844 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.711 HG23 ' N ' ' A' ' 134' ' ' THR . 22.8 mt -140.34 139.85 35.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.049 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.528 ' HB3' ' CE ' ' A' ' 136' ' ' LYS . 6.0 tp10 . . . . . 0 C--O 1.249 1.045 0 CA-C-O 118.243 -0.884 . . . . 0.0 110.841 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.782 0.325 . . . . 0.0 111.125 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . 61.2 121.18 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.092 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER 66.01 -175.29 0.18 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.943 -179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.488 HD12 ' N ' ' A' ' 78' ' ' ILE . 1.3 mp -131.05 23.76 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.071 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 68.15 93.87 0.07 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.002 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.443 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -124.0 -142.93 6.11 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.517 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.536 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 26.8 t60 171.89 83.94 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.896 0.379 . . . . 0.0 110.964 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.826 HG12 HG13 ' A' ' 154' ' ' VAL . 6.8 mt -100.67 147.05 8.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.017 0.436 . . . . 0.0 110.999 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.845 HG23 HG13 ' A' ' 153' ' ' VAL . 3.5 t -93.36 45.31 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.993 179.99 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.474 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -34.61 127.39 0.48 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.8 -179.978 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.511 ' OG ' HG23 ' A' ' 146' ' ' VAL . 5.3 t -34.83 107.68 0.32 Allowed Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.956 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -63.74 -20.95 69.64 Favored 'Trans proline' 0 C--O 1.231 0.159 0 C-N-CA 122.791 2.327 . . . . 0.0 111.945 179.69 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 9.9 ptp -154.37 172.59 17.45 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.781 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.701 ' O ' HG23 ' A' ' 88' ' ' VAL . 30.7 m -66.7 87.71 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.057 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.58 ' O ' HG22 ' A' ' 146' ' ' VAL . . . -147.82 -161.16 9.33 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.635 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.654 ' CG2' ' CE1' ' A' ' 92' ' ' TYR . 5.3 m -117.48 140.6 49.39 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.893 0.378 . . . . 0.0 111.124 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.958 ' HB2' HD22 ' A' ' 152' ' ' LEU . 14.4 t80 -89.3 143.02 27.15 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.269 179.453 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.654 ' CE1' ' CG2' ' A' ' 90' ' ' THR . 18.5 m-85 -139.91 148.81 42.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.888 0.375 . . . . 0.0 111.22 -179.521 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.466 ' O ' ' N ' ' A' ' 102' ' ' PHE . 0.7 OUTLIER -135.11 13.18 3.58 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.809 179.818 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 52.5 p -141.49 110.3 6.28 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.954 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -70.1 -39.45 5.85 Favored 'Trans proline' 0 C--N 1.342 0.235 0 C-N-CA 122.725 2.283 . . . . 0.0 112.414 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -129.72 148.98 71.66 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.92 -179.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -53.33 -34.74 71.96 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.693 2.262 . . . . 0.0 112.294 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -118.63 42.46 2.75 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.856 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -100.26 -154.86 0.49 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.094 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.19 36.78 4.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.863 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.461 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 56.67 165.67 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.117 179.846 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.912 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -89.22 -34.63 16.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.964 179.994 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.912 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.2 OUTLIER 176.49 127.34 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.104 -179.912 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -123.84 165.6 17.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.807 179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.542 ' HA ' HG12 ' A' ' 135' ' ' VAL . 1.9 p -44.28 119.59 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.927 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 114.25 -14.05 21.12 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.374 -179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.494 ' HG3' HG22 ' A' ' 103' ' ' ILE . 2.4 mm-40 -74.26 126.02 29.7 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.827 0.346 . . . . 0.0 110.887 179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.0 74.03 5.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.855 179.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.475 HG23 ' H ' ' A' ' 133' ' ' GLY . 22.1 m -47.14 172.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.984 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.474 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 27.2 m120 -163.95 131.13 3.31 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.022 0.439 . . . . 0.0 110.72 179.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.517 HG23 ' O ' ' A' ' 111' ' ' VAL . 33.8 m -35.54 118.72 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.022 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 100.91 15.51 28.47 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.317 -179.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.471 ' HB2' ' O ' ' A' ' 110' ' ' ASN . 0.3 OUTLIER -125.2 103.92 8.23 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.854 0.359 . . . . 0.0 110.669 179.993 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.549 ' CG2' ' HB3' ' A' ' 126' ' ' GLN . 2.3 m -33.92 122.14 0.46 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.149 -179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.477 ' O ' HG12 ' A' ' 103' ' ' ILE . 15.1 mt -78.24 -86.08 0.07 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.929 179.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.56 ' SG ' HG11 ' A' ' 153' ' ' VAL . 0.5 OUTLIER -135.04 -174.33 3.57 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.101 -179.904 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 1.028 HG22 ' CB ' ' A' ' 124' ' ' MET . 0.1 OUTLIER -104.86 129.45 57.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.016 -179.954 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 124' ' ' MET . 6.0 t -123.06 100.89 8.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.372 -0.376 . . . . 0.0 111.591 -179.815 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.577 ' HG2' ' CE2' ' A' ' 92' ' ' TYR . 1.0 OUTLIER -100.16 117.71 34.98 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.522 179.571 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.523 ' O ' ' CB ' ' A' ' 121' ' ' MET . . . -112.55 47.27 1.1 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.468 -179.512 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.523 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 6.1 ptm 155.13 -39.42 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.267 179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.497 ' HD2' ' HG2' ' A' ' 123' ' ' MET . 0.0 OUTLIER 172.48 -28.44 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.042 -179.971 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.528 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.8 OUTLIER -97.61 127.27 43.43 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 115.881 -0.6 . . . . 0.0 109.945 179.498 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 1.028 ' CB ' HG22 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -93.94 153.62 18.12 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.366 -179.249 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.508 ' O ' ' N ' ' A' ' 127' ' ' ILE . 59.5 t-20 -114.04 101.92 9.68 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.192 179.617 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.549 ' HB3' ' CG2' ' A' ' 114' ' ' THR . 0.7 OUTLIER -62.65 69.23 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.786 -179.721 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.508 ' N ' ' O ' ' A' ' 125' ' ' ASN . 26.1 mm -37.06 147.28 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.132 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.41 ' O ' ' C ' ' A' ' 129' ' ' ALA . 10.2 pt-20 -116.03 128.73 55.95 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.755 179.858 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -35.48 116.15 0.35 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.238 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -87.3 -12.61 46.01 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.739 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.477 ' HG3' ' O ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -174.28 126.52 0.34 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.764 179.96 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.474 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 8.0 t -41.83 124.87 2.71 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.779 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.475 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -152.21 176.01 30.66 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.751 -0.737 . . . . 0.0 112.548 -179.856 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.738 ' C ' HG23 ' A' ' 155' ' ' ILE . 13.1 m -125.15 108.26 11.6 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.701 0.286 . . . . 0.0 111.288 -179.828 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.542 HG12 ' HA ' ' A' ' 105' ' ' VAL . 19.0 t -44.2 144.97 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.624 179.435 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.708 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 21.3 mtpt -123.7 -18.49 6.07 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.225 -179.567 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.708 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 163.11 161.56 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.976 0.417 . . . . 0.0 111.631 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.641 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 0.6 OUTLIER -111.93 85.0 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.894 179.753 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.632 HD12 ' HB2' ' A' ' 151' ' ' PRO . 8.5 mt -49.12 -38.35 24.66 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.99 -179.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 1.004 HG21 HD23 ' A' ' 152' ' ' LEU . 49.2 t -83.6 143.7 11.4 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.146 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.485 ' O ' ' C ' ' A' ' 142' ' ' SER . 17.2 mt-10 -74.5 78.15 1.94 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.06 -179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.502 ' HA ' ' CE2' ' A' ' 91' ' ' PHE . 11.6 p 21.77 -114.56 0.01 OUTLIER 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 115.285 -0.871 . . . . 0.0 111.815 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.584 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -62.81 80.84 0.03 OUTLIER Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.839 -0.696 . . . . 0.0 113.043 -179.794 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.479 ' O ' HG23 ' A' ' 90' ' ' THR . 0.5 OUTLIER -157.56 144.15 13.12 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-O 121.078 0.466 . . . . 0.0 111.435 179.593 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.433 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 27.6 Cg_endo -62.4 151.57 81.98 Favored 'Trans proline' 0 C--N 1.343 0.239 0 C-N-CA 122.974 2.449 . . . . 0.0 112.546 -179.792 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.734 HG11 ' CD2' ' A' ' 152' ' ' LEU . 18.3 m -143.93 -173.16 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.883 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.437 ' O ' ' C ' ' A' ' 148' ' ' PHE . 0.1 OUTLIER -150.26 149.64 30.43 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.899 179.992 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.499 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 2.0 t80 -34.33 124.15 0.5 Allowed 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.822 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.499 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 17.4 t0 83.94 27.14 0.09 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.593 -179.607 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.416 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 44.0 tp10 -110.33 73.73 0.79 Allowed Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.908 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.811 ' O ' HG23 ' A' ' 140' ' ' VAL . 68.6 Cg_exo -34.18 127.59 0.18 Allowed 'Trans proline' 0 N--CA 1.459 -0.559 0 C-N-CA 122.825 2.35 . . . . 0.0 112.044 179.681 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 1.004 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -122.46 -64.98 1.14 Allowed 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.525 -179.425 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.845 HG13 HG23 ' A' ' 83' ' ' VAL . 1.6 p -103.92 102.89 14.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.254 -179.469 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.826 HG13 HG12 ' A' ' 82' ' ' ILE . 10.3 t -83.47 142.67 13.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-N 115.76 -0.654 . . . . 0.0 111.275 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.738 HG23 ' C ' ' A' ' 134' ' ' THR . 27.5 mt -144.48 141.47 23.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.994 179.858 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.545 ' CA ' ' HD2' ' A' ' 136' ' ' LYS . 3.0 tt0 . . . . . 0 C--O 1.249 1.036 0 CA-C-O 118.283 -0.865 . . . . 0.0 110.919 -179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.753 0.311 . . . . 0.0 111.148 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -173.9 73.9 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.108 -179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -118.52 116.09 25.94 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.901 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.449 ' O ' ' O ' ' A' ' 79' ' ' SER . 0.9 OUTLIER -80.55 -11.85 12.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.277 -179.975 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.449 ' O ' ' O ' ' A' ' 78' ' ' ILE . 0.3 OUTLIER 33.87 -154.46 0.0 OUTLIER 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.107 179.934 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.457 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -135.02 -123.27 2.32 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.442 179.916 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.587 ' CD2' ' HE3' ' A' ' 131' ' ' LYS . 17.1 t-80 172.53 84.19 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.788 0.328 . . . . 0.0 110.983 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.748 HG12 HG13 ' A' ' 154' ' ' VAL . 29.8 mt -92.26 116.62 33.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-O 121.07 0.462 . . . . 0.0 110.836 179.727 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.966 HG21 HD13 ' A' ' 115' ' ' LEU . 2.0 t -69.85 59.79 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 115.67 -0.695 . . . . 0.0 111.244 -179.701 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.532 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -47.53 135.08 11.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.725 179.823 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.511 ' HB3' HD21 ' A' ' 152' ' ' LEU . 1.3 p -39.3 104.63 0.32 Allowed Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.996 179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 37.4 Cg_endo -66.18 -7.18 16.51 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.656 2.237 . . . . 0.0 112.018 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.453 ' HG3' ' CB ' ' A' ' 120' ' ' ALA . 2.0 ptm -155.72 168.3 27.61 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.641 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . . . . . . . . . 7.1 m -71.87 60.16 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.124 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.652 ' O ' HG22 ' A' ' 146' ' ' VAL . . . -116.96 -165.69 13.93 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.454 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.635 HG23 ' C ' ' A' ' 144' ' ' GLN . 24.4 m -108.99 156.92 19.17 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.987 0.422 . . . . 0.0 111.024 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.684 ' CZ ' HG21 ' A' ' 138' ' ' ILE . 11.9 t80 -106.77 140.68 39.22 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.263 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.578 ' CD2' ' OE1' ' A' ' 119' ' ' GLU . 17.6 m-85 -143.13 151.09 40.32 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.971 0.415 . . . . 0.0 111.063 179.607 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.713 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 18.2 ptt180 -132.11 23.92 4.54 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.663 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.473 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 63.5 p -150.57 107.11 3.1 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.868 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.21 -16.11 31.68 Favored 'Trans proline' 0 C--N 1.341 0.148 0 C-N-CA 122.651 2.234 . . . . 0.0 112.221 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -142.93 159.64 55.77 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.918 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -53.32 -63.33 0.24 Allowed 'Trans proline' 0 C--O 1.231 0.16 0 C-N-CA 122.806 2.337 . . . . 0.0 112.341 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -110.99 79.79 1.24 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.876 179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -135.2 -166.91 1.91 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.102 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.09 38.09 1.27 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.928 179.964 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.713 ' HB1' ' O ' ' A' ' 93' ' ' ARG . . . 49.39 -177.18 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.239 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.852 ' O ' HD13 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -90.11 -61.44 1.68 Allowed 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.126 179.55 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.852 HD13 ' O ' ' A' ' 102' ' ' PHE . 2.2 mm -153.52 145.03 14.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.7 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -147.45 162.84 38.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.738 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.494 HG13 ' HA ' ' A' ' 136' ' ' LYS . 6.0 t -47.32 119.68 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.995 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 120.15 -27.04 6.86 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.249 -179.71 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.83 112.49 18.26 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.759 0.314 . . . . 0.0 110.807 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.465 ' O ' ' O ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -79.49 81.83 5.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.843 179.998 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.897 HG22 ' O ' ' A' ' 133' ' ' GLY . 14.7 m -45.28 176.11 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.003 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.5 ' ND2' ' O ' ' A' ' 109' ' ' VAL . 35.0 m120 -163.19 131.1 3.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.615 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.524 ' HA ' ' HB3' ' A' ' 129' ' ' ALA . 2.3 p -37.58 155.41 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.968 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.437 ' N ' HG22 ' A' ' 111' ' ' VAL . . . 75.78 -0.08 62.6 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.63 -0.795 . . . . 0.0 112.339 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.464 ' O ' ' HA ' ' A' ' 128' ' ' GLU . 2.5 t0 -107.17 -149.53 0.43 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.691 0.282 . . . . 0.0 110.689 179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.76 HG21 ' CZ ' ' A' ' 102' ' ' PHE . 6.1 m -135.73 150.4 49.51 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.89 0.376 . . . . 0.0 111.012 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.966 HD13 HG21 ' A' ' 83' ' ' VAL . 83.0 mt -106.81 -79.74 0.57 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.892 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . . . . . . . . . 14.9 p -134.51 -166.1 1.76 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.97 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 1.024 HG22 ' OE2' ' A' ' 119' ' ' GLU . 0.3 OUTLIER -115.01 125.22 72.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 116.013 -0.54 . . . . 0.0 111.297 -179.725 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.497 HG21 HD11 ' A' ' 127' ' ' ILE . 54.7 t -108.58 95.0 3.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.449 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 1.024 ' OE2' HG22 ' A' ' 117' ' ' ILE . 0.5 OUTLIER -102.76 105.0 15.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.877 -179.083 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.598 ' HB2' ' HA3' ' A' ' 89' ' ' GLY . . . -126.57 48.01 2.22 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.449 -0.341 . . . . 0.0 111.709 -179.684 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.557 ' CB ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 152.55 51.88 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.25 179.907 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.486 ' HD3' ' O ' ' A' ' 122' ' ' LYS . 0.0 OUTLIER 56.14 18.2 3.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.343 -179.313 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.487 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 1.7 mtt -141.24 122.8 15.1 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.821 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.575 ' CB ' HG22 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -75.15 171.82 13.47 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.428 -0.806 . . . . 0.0 111.44 -179.839 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.463 ' HB2' ' HB ' ' A' ' 118' ' ' VAL . 3.5 m120 -151.49 83.79 1.3 Allowed 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.473 179.73 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.562 ' HB2' HG23 ' A' ' 114' ' ' THR . 3.2 pt20 -50.23 113.41 0.86 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.06 -179.67 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.821 HG21 HG11 ' A' ' 83' ' ' VAL . 18.8 mm -81.42 95.65 2.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.919 179.802 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.478 ' HA ' ' HA ' ' A' ' 114' ' ' THR . 1.4 mt-10 -72.05 144.08 48.87 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.115 -179.773 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.524 ' HB3' ' HA ' ' A' ' 111' ' ' VAL . . . -68.67 142.46 55.05 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.831 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 55.7 p30 -126.74 1.87 6.75 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.341 -0.391 . . . . 0.0 111.08 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.587 ' HE3' ' CD2' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -158.83 22.21 0.21 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.092 -179.927 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.478 ' O ' ' NZ ' ' A' ' 131' ' ' LYS . 1.1 p 49.94 173.56 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.783 179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.897 ' O ' HG22 ' A' ' 109' ' ' VAL . . . 156.56 176.02 28.18 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.571 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.773 ' C ' HG23 ' A' ' 155' ' ' ILE . 25.9 m -127.78 119.56 25.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.582 0.229 . . . . 0.0 111.307 -179.765 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.595 HG21 HG22 ' A' ' 103' ' ' ILE . 73.3 t -52.36 144.7 3.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 179.172 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.65 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 22.4 mmmt -125.17 -18.77 5.32 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.685 0.279 . . . . 0.0 111.422 -179.431 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.799 ' C ' HD13 ' A' ' 138' ' ' ILE . . . 167.05 156.78 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.398 -0.364 . . . . 0.0 111.178 -179.704 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.799 HD13 ' C ' ' A' ' 137' ' ' ALA . 0.2 OUTLIER -109.88 84.58 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.032 179.821 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.564 ' N ' HD23 ' A' ' 139' ' ' LEU . 3.6 mt -47.13 -25.86 0.98 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.415 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.967 HG21 HD23 ' A' ' 152' ' ' LEU . 78.3 t -104.8 149.47 8.29 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.735 179.71 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.534 ' HB2' ' CG ' ' A' ' 144' ' ' GLN . 4.1 mm-40 -52.55 -170.99 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 179.376 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.522 ' O ' ' O ' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -84.87 -55.41 4.1 Favored 'General case' 0 C--N 1.326 -0.441 0 C-N-CA 120.837 -0.345 . . . . 0.0 111.509 -179.789 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.561 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -128.16 103.14 0.61 Allowed Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.857 -179.342 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.635 ' C ' HG23 ' A' ' 90' ' ' THR . 0.0 OUTLIER -174.05 144.17 0.98 Allowed Pre-proline 0 C--N 1.326 -0.413 0 CA-C-O 121.034 0.445 . . . . 0.0 111.18 179.669 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 144' ' ' GLN . 43.7 Cg_exo -56.58 142.97 90.06 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.83 2.353 . . . . 0.0 112.036 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.916 HG11 ' CD2' ' A' ' 152' ' ' LEU . 4.8 m -128.86 179.52 3.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.157 -179.906 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.458 ' O ' ' CB ' ' A' ' 150' ' ' GLU . 1.3 mt-10 -129.82 141.4 50.85 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.73 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.46 ' HA ' ' O ' ' A' ' 85' ' ' SER . 34.5 t80 -35.45 137.52 0.18 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.903 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.468 ' HA ' ' HD2' ' A' ' 84' ' ' ARG . 0.6 OUTLIER 72.32 26.13 2.72 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.756 -179.799 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.465 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 6.7 tp10 -106.81 73.96 0.35 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.869 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.753 ' O ' HG23 ' A' ' 140' ' ' VAL . 61.0 Cg_exo -34.19 122.19 0.15 Allowed 'Trans proline' 0 N--CA 1.456 -0.692 0 C-N-CA 122.869 2.379 . . . . 0.0 111.96 179.581 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.967 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -118.57 -66.61 1.06 Allowed 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.563 -179.215 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.542 HG13 ' HB ' ' A' ' 83' ' ' VAL . 0.8 OUTLIER -96.7 106.22 18.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.289 -179.393 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.748 HG13 HG12 ' A' ' 82' ' ' ILE . 34.5 t -87.51 134.45 27.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-N 115.656 -0.702 . . . . 0.0 111.291 179.834 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.773 HG23 ' C ' ' A' ' 134' ' ' THR . 72.0 mt -135.73 140.02 45.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.987 179.785 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.55 ' CG ' ' HB ' ' A' ' 134' ' ' THR . 10.0 pt-20 . . . . . 0 C--O 1.249 1.027 0 CA-C-O 118.26 -0.876 . . . . 0.0 110.88 179.881 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . 0.472 ' O ' ' HB3' ' A' ' 76' ' ' ALA . . . . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.809 0.338 . . . . 0.0 111.042 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.472 ' HB3' ' O ' ' A' ' 75' ' ' ALA . . . 69.97 34.14 2.59 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.109 179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -167.01 141.16 3.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.919 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.508 HG22 ' O ' ' A' ' 78' ' ' ILE . 8.5 mt -121.02 24.11 4.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.139 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 49.44 60.62 3.64 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.982 -179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.484 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -130.29 -176.89 14.6 Favored Glycine 0 N--CA 1.45 -0.386 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.533 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.594 ' CD2' ' HB ' ' A' ' 155' ' ' ILE . 16.1 t60 173.74 83.7 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.763 0.316 . . . . 0.0 110.901 179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.932 HD12 HG13 ' A' ' 154' ' ' VAL . 0.0 OUTLIER -97.74 -179.2 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.56 179.617 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.798 ' CG2' HG13 ' A' ' 153' ' ' VAL . 48.7 t -117.62 2.87 7.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.365 179.728 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.493 ' C ' ' O ' ' A' ' 83' ' ' VAL . 0.9 OUTLIER 23.97 98.22 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 115.924 -0.58 . . . . 0.0 111.486 179.858 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.653 ' HB2' HD21 ' A' ' 152' ' ' LEU . 4.1 t -34.37 95.81 0.09 OUTLIER Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.795 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.519 ' O ' ' CD1' ' A' ' 148' ' ' PHE . 18.8 Cg_endo -58.91 -74.45 0.02 OUTLIER 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.638 2.225 . . . . 0.0 111.9 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.584 ' HE3' ' HB2' ' A' ' 120' ' ' ALA . 6.0 mtm -70.77 156.51 39.43 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.783 179.645 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.775 HG22 ' O ' ' A' ' 88' ' ' VAL . 2.6 p -79.43 57.74 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.048 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -114.34 -148.2 9.69 Favored Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.839 -0.696 . . . . 0.0 112.38 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.898 HG23 ' O ' ' A' ' 144' ' ' GLN . 16.9 m -122.91 144.22 49.37 Favored 'General case' 0 C--O 1.233 0.223 0 CA-C-O 121.087 0.47 . . . . 0.0 111.24 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.881 ' HB2' HD22 ' A' ' 152' ' ' LEU . 29.5 t80 -83.34 142.62 30.92 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.564 -0.744 . . . . 0.0 110.615 179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.56 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 12.1 m-85 -144.88 153.68 41.84 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.892 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.428 ' O ' ' HB1' ' A' ' 101' ' ' ALA . 0.6 OUTLIER -139.73 32.83 2.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.845 179.845 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.488 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 0.2 OUTLIER -148.5 109.5 3.61 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.881 179.902 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.414 ' HD2' ' HA ' ' A' ' 94' ' ' THR . 37.7 Cg_endo -66.22 -38.9 19.5 Favored 'Trans proline' 0 C--O 1.231 0.137 0 C-N-CA 122.752 2.301 . . . . 0.0 112.272 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.459 ' OG ' ' HD2' ' A' ' 97' ' ' PRO . 0.2 OUTLIER -129.02 168.78 14.86 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.9 179.995 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.459 ' HD2' ' OG ' ' A' ' 96' ' ' SER . 52.9 Cg_exo -52.29 -53.98 5.99 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.787 2.325 . . . . 0.0 112.221 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -124.5 71.79 1.17 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.874 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -119.09 -166.9 1.31 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.128 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -92.85 29.05 1.89 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.768 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.488 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 60.81 170.84 0.1 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.001 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.871 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -87.15 -43.26 12.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.849 -179.996 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.871 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.1 pp -169.79 134.0 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.04 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.595 ' O ' HG11 ' A' ' 135' ' ' VAL . 5.7 mt-10 -137.5 157.8 45.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.966 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.609 HG22 ' HA ' ' A' ' 137' ' ' ALA . 3.0 t -38.55 125.36 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.078 179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . 0.438 ' N ' HG13 ' A' ' 135' ' ' VAL . . . 109.45 -28.05 11.47 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.734 -0.745 . . . . 0.0 112.466 -179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.542 ' O ' HG12 ' A' ' 135' ' ' VAL . 5.6 tp60 -71.61 109.74 5.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.807 0.337 . . . . 0.0 110.867 179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.466 ' HA ' ' HA ' ' A' ' 134' ' ' THR . 4.0 mttt -74.47 91.43 2.26 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.014 -179.862 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.938 HG11 ' CD2' ' A' ' 115' ' ' LEU . 0.0 OUTLIER -50.37 174.88 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.911 179.889 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.542 ' O ' ' HB3' ' A' ' 129' ' ' ALA . 6.9 m120 -162.53 131.33 4.15 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.09 0.472 . . . . 0.0 110.719 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.621 HG12 ' HA ' ' A' ' 131' ' ' LYS . 34.5 m -34.79 137.38 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.071 179.8 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 65.56 30.26 77.04 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.643 -0.789 . . . . 0.0 112.497 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.484 ' CB ' ' O ' ' A' ' 110' ' ' ASN . 11.1 t70 -125.52 104.86 8.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.743 0.306 . . . . 0.0 110.735 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.471 HG23 ' HB2' ' A' ' 126' ' ' GLN . 1.6 m -34.34 128.48 0.42 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.045 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.938 ' CD2' HG11 ' A' ' 109' ' ' VAL . 11.1 mt -95.15 -83.31 0.36 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.789 179.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.519 ' CB ' ' O ' ' A' ' 92' ' ' TYR . 0.5 OUTLIER -132.36 -169.26 2.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.673 179.927 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.541 ' CG2' ' HB2' ' A' ' 124' ' ' MET . 0.2 OUTLIER -111.65 123.81 67.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.211 179.895 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.777 HG21 HD11 ' A' ' 127' ' ' ILE . 96.5 t -113.73 74.64 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.218 179.4 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.583 ' CG ' ' HB ' ' A' ' 90' ' ' THR . 2.4 pt-20 -58.31 89.96 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.286 -179.333 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.584 ' HB2' ' HE3' ' A' ' 87' ' ' MET . . . -94.17 116.9 29.36 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.449 179.515 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.571 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.3 OUTLIER 90.25 -33.1 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.648 -179.344 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.571 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 150.34 -13.46 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.02 179.903 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.508 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 2.5 ptt? -106.57 134.32 49.9 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.91 0.386 . . . . 0.0 111.164 -179.623 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.541 ' HB2' ' CG2' ' A' ' 117' ' ' ILE . 2.4 ptm -55.51 133.31 50.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.135 179.91 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.451 ' OD1' ' HE2' ' A' ' 87' ' ' MET . 2.0 t-20 -120.27 68.6 0.85 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.669 179.823 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.471 ' HB2' HG23 ' A' ' 114' ' ' THR . 0.2 OUTLIER -43.01 131.86 4.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.844 -179.836 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.777 HD11 HG21 ' A' ' 118' ' ' VAL . 57.7 mt -95.18 149.59 4.47 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.245 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -108.55 131.58 54.7 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.888 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.542 ' HB3' ' O ' ' A' ' 110' ' ' ASN . . . -45.28 110.03 0.21 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.161 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -68.51 -20.4 64.58 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.796 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.621 ' HA ' HG12 ' A' ' 111' ' ' VAL . 0.0 OUTLIER -179.0 137.04 0.14 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.776 179.945 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.411 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 24.6 t -41.31 127.3 2.88 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.805 179.822 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.493 ' O ' ' N ' ' A' ' 109' ' ' VAL . . . -161.67 -178.94 36.02 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.613 -0.804 . . . . 0.0 112.63 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.879 ' C ' HG23 ' A' ' 155' ' ' ILE . 16.5 m -129.43 108.62 10.42 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.645 0.259 . . . . 0.0 111.419 -179.755 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.595 HG11 ' O ' ' A' ' 104' ' ' GLU . 2.2 p -49.13 144.12 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 179.284 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.596 ' C ' HG13 ' A' ' 105' ' ' VAL . 4.5 mmtt -122.25 -20.28 6.23 Favored 'General case' 0 C--N 1.328 -0.365 0 C-N-CA 121.05 -0.26 . . . . 0.0 111.456 -179.232 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.609 ' HA ' HG22 ' A' ' 105' ' ' VAL . . . 175.35 175.32 0.23 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.054 0.454 . . . . 0.0 111.798 -179.781 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.656 ' CG2' ' CZ ' ' A' ' 91' ' ' PHE . 1.2 mm -125.82 85.09 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.861 179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.841 HD21 HG21 ' A' ' 154' ' ' VAL . 5.9 mt -50.79 -21.73 1.8 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.768 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 1.038 HG21 HD23 ' A' ' 152' ' ' LEU . 69.9 t -108.11 151.44 10.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.254 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.446 ' O ' ' C ' ' A' ' 142' ' ' SER . 39.6 mt-10 -64.17 135.75 56.6 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.942 179.19 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.505 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -32.17 -61.35 0.25 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.329 -0.396 . . . . 0.0 111.595 -179.272 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.56 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -125.11 103.34 0.72 Allowed Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 120.505 -0.855 . . . . 0.0 112.895 -179.619 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.898 ' O ' HG23 ' A' ' 90' ' ' THR . 6.4 pt20 -170.94 153.81 4.02 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-O 120.938 0.399 . . . . 0.0 111.215 179.718 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.417 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 37.0 Cg_endo -65.92 140.03 59.07 Favored 'Trans proline' 0 C--O 1.232 0.209 0 C-N-CA 122.843 2.362 . . . . 0.0 112.534 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.857 HG11 ' CD2' ' A' ' 152' ' ' LEU . 26.7 m -130.32 -171.68 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.893 179.864 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.422 ' O ' ' C ' ' A' ' 148' ' ' PHE . 2.5 tm-20 -130.11 137.92 50.41 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.971 -179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.521 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 1.5 t80 -35.72 120.01 0.57 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.744 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.521 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 5.4 t70 86.19 31.38 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.195 0 CA-C-O 120.887 0.375 . . . . 0.0 110.524 -179.553 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.482 ' O ' ' HG ' ' A' ' 152' ' ' LEU . 5.8 tp10 -107.18 75.1 0.42 Allowed Pre-proline 0 C--N 1.327 -0.389 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.66 179.794 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.776 ' HB3' HG21 ' A' ' 82' ' ' ILE . 48.5 Cg_exo -30.58 109.71 0.04 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.723 0 C-N-CA 123.159 2.573 . . . . 0.0 112.377 179.69 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 1.038 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -104.68 -56.1 2.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.315 -179.412 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.798 HG13 ' CG2' ' A' ' 83' ' ' VAL . 0.9 OUTLIER -103.43 111.8 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.402 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.45 -179.185 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.932 HG13 HD12 ' A' ' 82' ' ' ILE . 3.1 t -91.77 145.1 7.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.863 179.763 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.879 HG23 ' C ' ' A' ' 134' ' ' THR . 4.4 mt -138.53 147.68 25.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.433 -179.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.528 ' HB2' ' CE ' ' A' ' 136' ' ' LYS . 6.8 tp10 . . . . . 0 C--O 1.249 1.069 0 CA-C-O 118.271 -0.871 . . . . 0.0 110.844 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.88 0.371 . . . . 0.0 111.108 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -129.42 170.59 13.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.106 -179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -131.75 65.99 1.56 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.9 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 5.7 tt -105.02 2.08 10.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.08 0.467 . . . . 0.0 111.397 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 43.32 34.09 0.68 Allowed 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.878 -179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -79.59 -158.66 15.34 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.489 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.549 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 31.8 t60 -177.98 79.39 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.776 0.322 . . . . 0.0 110.871 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.854 HG12 HG13 ' A' ' 154' ' ' VAL . 16.7 mt -95.54 143.05 12.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.157 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.528 ' HB ' ' CG1' ' A' ' 153' ' ' VAL . 2.2 t -103.34 54.32 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.21 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.517 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 2.1 ptt180 -38.21 141.97 0.2 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.803 179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.648 ' CA ' HD11 ' A' ' 152' ' ' LEU . 0.1 OUTLIER -35.52 95.6 0.09 OUTLIER Pre-proline 0 C--N 1.329 -0.287 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.94 -179.974 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.441 ' N ' ' O ' ' A' ' 84' ' ' ARG . 66.7 Cg_exo -50.63 -20.2 6.1 Favored 'Trans proline' 0 N--CA 1.466 -0.143 0 C-N-CA 122.648 2.232 . . . . 0.0 112.157 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.485 ' SD ' ' CB ' ' A' ' 120' ' ' ALA . 2.2 ptm -162.76 177.52 9.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.723 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.651 HG22 ' CG ' ' A' ' 147' ' ' GLU . 93.3 t -70.77 97.66 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.145 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.704 ' O ' HG23 ' A' ' 146' ' ' VAL . . . -162.04 -166.86 21.58 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.37 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.799 HG23 ' N ' ' A' ' 145' ' ' PRO . 3.6 m -109.52 126.96 54.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.789 0.328 . . . . 0.0 110.883 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.633 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 2.7 t80 -82.15 140.1 33.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.796 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.583 ' CE2' ' HG2' ' A' ' 119' ' ' GLU . 18.7 m-85 -137.92 152.9 49.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.934 179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.537 ' HD3' ' CB ' ' A' ' 142' ' ' SER . 0.7 OUTLIER -134.27 18.57 3.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.818 179.808 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.464 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 5.4 p -145.44 106.43 4.38 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.803 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.593 ' HG3' ' CG ' ' A' ' 102' ' ' PHE . 27.9 Cg_exo -61.98 -9.63 15.08 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.776 2.317 . . . . 0.0 112.429 -179.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.513 ' HB3' ' HB2' ' A' ' 99' ' ' ALA . 1.5 t -172.23 153.84 3.13 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.912 179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_exo -55.84 -50.88 11.06 Favored 'Trans proline' 0 C--O 1.231 0.151 0 C-N-CA 122.722 2.281 . . . . 0.0 112.269 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 29.1 t70 -106.29 56.52 0.66 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.513 ' HB2' ' HB3' ' A' ' 96' ' ' SER . . . -121.08 -160.78 0.86 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.123 -179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 2.0 mmmt -103.99 24.26 11.64 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.002 -179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.464 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 57.81 162.64 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.073 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.913 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -88.42 -41.38 12.84 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.981 179.979 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.913 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.8 OUTLIER -175.53 150.29 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-O 120.939 0.4 . . . . 0.0 111.271 179.668 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -152.06 158.62 43.27 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.683 179.775 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.657 ' HA ' HG12 ' A' ' 135' ' ' VAL . 6.8 p -48.24 105.26 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.166 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 123.9 -0.03 9.1 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.369 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.4 mm-40 -77.99 144.02 37.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.751 0.31 . . . . 0.0 110.98 179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -98.94 90.73 4.74 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.907 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.736 HG11 ' CD2' ' A' ' 115' ' ' LEU . 15.6 m -87.89 159.63 2.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.105 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.47 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 31.9 m-80 -162.35 130.39 3.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.067 0.46 . . . . 0.0 110.776 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.461 ' HA ' ' O ' ' A' ' 129' ' ' ALA . 24.6 m -35.84 123.49 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.495 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.224 179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 108.44 3.06 33.07 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.559 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -113.42 -149.39 0.45 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.766 0.317 . . . . 0.0 110.685 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.68 HG21 ' OE1' ' A' ' 126' ' ' GLN . 5.5 m -136.23 132.23 35.57 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.924 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.736 ' CD2' HG11 ' A' ' 109' ' ' VAL . 75.4 mt -92.43 -84.71 0.27 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.916 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.517 ' HA ' ' CG ' ' A' ' 102' ' ' PHE . 2.3 p -143.78 -167.13 2.51 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.037 -179.894 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.85 HD13 ' HB2' ' A' ' 124' ' ' MET . 2.8 mt -131.59 150.44 34.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.812 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.594 HG22 ' HA ' ' A' ' 91' ' ' PHE . 53.6 t -143.93 103.22 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.856 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.583 ' HG2' ' CE2' ' A' ' 92' ' ' TYR . 6.8 pt-20 -58.6 82.28 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.146 -179.681 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.54 ' O ' ' CG ' ' A' ' 121' ' ' MET . . . -95.67 99.92 11.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.663 179.627 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.54 ' CG ' ' O ' ' A' ' 120' ' ' ALA . 0.0 OUTLIER 88.43 30.96 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.563 -179.53 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.505 ' HB3' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 75.8 30.49 0.76 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.217 -179.996 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.497 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 18.6 mmt -149.39 124.77 10.24 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.967 0.413 . . . . 0.0 110.906 179.558 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.85 ' HB2' HD13 ' A' ' 117' ' ' ILE . 0.0 OUTLIER -59.75 103.18 0.19 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.148 -179.824 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 31.4 t30 -83.31 80.68 9.0 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.547 179.721 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.68 ' OE1' HG21 ' A' ' 114' ' ' THR . 17.3 tt0 -56.81 124.03 17.07 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.94 -179.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.499 HG22 HD12 ' A' ' 115' ' ' LEU . 15.3 mm -91.17 120.35 39.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.136 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -90.93 143.16 27.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.882 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 111' ' ' VAL . . . -57.05 116.73 3.4 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.047 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -117.42 14.35 14.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.811 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.465 ' HB3' ' CE1' ' A' ' 81' ' ' HIS . 0.0 OUTLIER -179.39 102.99 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.69 -180.0 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.47 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 0.9 OUTLIER -42.77 122.59 2.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.616 179.897 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.471 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -156.25 -167.32 17.42 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.615 -179.846 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.627 ' N ' HG23 ' A' ' 155' ' ' ILE . 21.3 m -140.16 112.42 7.75 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.511 0.196 . . . . 0.0 111.169 -179.791 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.657 HG12 ' HA ' ' A' ' 105' ' ' VAL . 38.3 t -44.85 140.14 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 C-N-CA 120.905 -0.318 . . . . 0.0 110.243 179.365 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.701 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 1.0 OUTLIER -122.42 -17.01 7.17 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.755 0.312 . . . . 0.0 111.152 -179.263 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.701 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 162.41 148.17 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.486 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.777 ' N ' HD13 ' A' ' 138' ' ' ILE . 0.0 OUTLIER -94.92 86.18 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.498 179.649 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.931 HD12 ' HB2' ' A' ' 151' ' ' PRO . 0.6 OUTLIER -40.81 -29.41 0.1 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.094 0.473 . . . . 0.0 110.207 -179.87 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.961 ' CG2' HD23 ' A' ' 152' ' ' LEU . 56.1 t -106.99 137.98 35.12 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.863 179.843 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.471 ' O ' ' HG2' ' A' ' 144' ' ' GLN . 3.4 mt-10 -67.65 98.11 0.67 Allowed 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.219 179.513 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.537 ' CB ' ' HD3' ' A' ' 93' ' ' ARG . 24.2 p -34.15 135.87 0.14 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.899 -179.588 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.581 ' HA2' ' CE1' ' A' ' 92' ' ' TYR . . . 84.24 34.34 17.63 Favored Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.323 -179.663 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.653 ' C ' HG23 ' A' ' 90' ' ' THR . 37.8 mm-40 -146.2 144.8 22.27 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 120.898 0.38 . . . . 0.0 111.144 -179.736 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.873 ' O ' HG13 ' A' ' 146' ' ' VAL . 52.5 Cg_exo -55.32 177.26 0.12 Allowed 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.862 2.375 . . . . 0.0 112.325 179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.873 HG13 ' O ' ' A' ' 145' ' ' PRO . 0.2 OUTLIER -173.31 -174.42 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.193 -179.997 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.651 ' CG ' HG22 ' A' ' 88' ' ' VAL . 8.8 tt0 -155.71 158.5 38.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.903 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.473 ' HA ' ' O ' ' A' ' 85' ' ' SER . 42.5 t80 -42.42 138.84 1.65 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.967 -179.972 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 74.67 24.1 1.73 Allowed 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.923 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.524 ' CG ' ' O ' ' A' ' 147' ' ' GLU . 67.4 mm-40 -115.12 73.3 3.37 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.841 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.931 ' HB2' HD12 ' A' ' 139' ' ' LEU . 62.7 Cg_exo -33.75 129.04 0.16 Allowed 'Trans proline' 0 N--CA 1.458 -0.567 0 C-N-CA 122.974 2.449 . . . . 0.0 112.165 179.648 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 0.961 HD23 ' CG2' ' A' ' 140' ' ' VAL . 0.0 OUTLIER -125.49 -71.67 0.69 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.727 -179.349 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.528 ' CG1' ' HB ' ' A' ' 83' ' ' VAL . 1.7 p -93.77 104.0 15.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.873 -179.085 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.854 HG13 HG12 ' A' ' 82' ' ' ILE . 21.4 t -89.13 133.1 32.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.814 179.333 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.627 HG23 ' N ' ' A' ' 134' ' ' THR . 97.1 mt -135.43 134.16 52.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.146 -179.727 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.518 ' CB ' ' HD3' ' A' ' 136' ' ' LYS . 1.2 tm-20 . . . . . 0 C--O 1.249 1.034 0 CA-C-O 118.259 -0.877 . . . . 0.0 110.898 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.853 0.358 . . . . 0.0 111.173 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -166.74 40.94 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.062 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 50.0 tt0 -171.46 29.61 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.994 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.409 HD12 ' HA ' ' A' ' 78' ' ' ILE . 2.9 tp -81.58 -1.94 5.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.515 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . 0.411 ' O ' ' C ' ' A' ' 80' ' ' GLY . 4.6 t -96.08 27.37 3.67 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.866 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.542 ' CA ' ' HB2' ' A' ' 156' ' ' GLU . . . 36.6 -114.62 0.22 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.487 -179.895 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.558 ' O ' ' CD2' ' A' ' 81' ' ' HIS . 34.2 t60 -169.49 75.65 0.09 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.811 0.338 . . . . 0.0 110.812 179.814 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.902 HG12 HG13 ' A' ' 154' ' ' VAL . 6.2 mt -93.25 150.44 3.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.105 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.745 HG23 HG13 ' A' ' 153' ' ' VAL . 3.1 t -102.43 46.55 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.037 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.516 ' CD ' ' O ' ' A' ' 84' ' ' ARG . 0.0 OUTLIER -35.48 131.92 0.45 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.859 179.965 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.571 ' HB3' HD21 ' A' ' 152' ' ' LEU . 95.2 p -36.56 99.16 0.17 Allowed Pre-proline 0 C--N 1.328 -0.368 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.968 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 20.1 Cg_endo -60.97 -11.98 20.57 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.619 2.213 . . . . 0.0 111.97 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.405 ' O ' ' N ' ' A' ' 89' ' ' GLY . 1.0 OUTLIER -160.58 167.76 26.42 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.607 179.856 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.742 ' O ' HG23 ' A' ' 88' ' ' VAL . 26.4 m -66.49 69.66 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.007 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 87' ' ' MET . . . -121.67 -150.83 8.36 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.639 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 1.015 HG23 ' C ' ' A' ' 144' ' ' GLN . 97.9 m -131.95 128.45 38.49 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.961 0.41 . . . . 0.0 111.028 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 1.063 ' HB2' HD22 ' A' ' 152' ' ' LEU . 69.8 t80 -68.75 143.49 54.65 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.526 179.724 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.601 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 7.8 m-30 -149.06 125.77 11.11 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.897 0.379 . . . . 0.0 110.85 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.506 ' HA ' ' HB2' ' A' ' 102' ' ' PHE . 39.8 ptt85 -117.54 22.52 12.34 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.883 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.52 112.24 5.03 Favored Pre-proline 0 C--N 1.33 -0.257 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.962 -179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -72.52 -38.86 3.05 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.689 2.259 . . . . 0.0 112.333 179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -130.38 161.64 59.31 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.849 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.46 ' O ' ' HB3' ' A' ' 98' ' ' ASP . 38.4 Cg_endo -66.83 102.92 0.66 Allowed 'Trans proline' 0 C--O 1.231 0.13 0 C-N-CA 122.722 2.282 . . . . 0.0 112.362 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.46 ' HB3' ' O ' ' A' ' 97' ' ' PRO . 9.3 t70 80.16 35.29 0.14 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.884 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -88.74 -155.31 0.33 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.012 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.93 27.97 3.33 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.801 179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 54.48 174.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.054 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.916 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -99.51 -35.2 9.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.874 179.972 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.916 HG23 ' O ' ' A' ' 102' ' ' PHE . 1.2 pp -179.03 123.53 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.987 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.44 ' O ' ' HB3' ' A' ' 107' ' ' GLN . 1.7 mt-10 -141.34 164.7 29.53 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.949 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 38.7 t -37.09 135.38 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.118 -179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 87.78 -24.5 10.47 Favored Glycine 0 N--CA 1.45 -0.402 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.557 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.512 ' HG2' HG22 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -71.66 94.62 1.36 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.84 0.352 . . . . 0.0 110.842 -179.967 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 10.5 mttm -75.53 105.16 6.42 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.906 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.762 HG11 HD23 ' A' ' 115' ' ' LEU . 5.5 m -80.04 173.44 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.177 -179.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.484 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 4.5 p-10 -152.62 129.87 11.25 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.756 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.459 ' HA ' ' CB ' ' A' ' 129' ' ' ALA . 7.5 p -43.26 143.17 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.667 0 CA-C-N 115.582 -0.735 . . . . 0.0 111.081 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 90.12 -2.13 81.07 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.412 -179.861 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . . . . . . . . . 9.8 t0 -105.98 -146.81 0.39 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.571 0.224 . . . . 0.0 110.63 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . . . . . . . . . 3.9 m -130.13 120.36 24.48 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.789 0.328 . . . . 0.0 111.016 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.762 HD23 HG11 ' A' ' 109' ' ' VAL . 15.8 mt -77.06 -85.35 0.06 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.793 179.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.496 ' HB3' HD11 ' A' ' 103' ' ' ILE . 5.0 p -148.14 171.09 16.46 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.795 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.999 HD13 ' HB3' ' A' ' 124' ' ' MET . 3.7 mt -105.24 152.58 7.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.834 -179.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.458 ' HA ' ' O ' ' A' ' 90' ' ' THR . 55.6 t -144.04 103.23 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.052 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.494 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 1.9 mt-10 -65.54 100.78 0.53 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.151 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . . . . . . . . . . . -83.26 -77.09 0.26 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.377 0.608 . . . . 0.0 111.071 179.795 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.531 ' O ' ' CG ' ' A' ' 122' ' ' LYS . 7.6 ptm -91.37 32.71 1.03 Allowed 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.367 179.695 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.531 ' CG ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 90.47 2.73 0.16 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.817 -179.63 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.48 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 4.9 ptm -116.78 133.58 55.84 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.841 179.785 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.999 ' HB3' HD13 ' A' ' 117' ' ' ILE . 3.3 mpp? -55.85 120.09 6.82 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.872 179.921 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.423 ' HB2' ' O ' ' A' ' 118' ' ' VAL . 35.8 t30 -102.3 73.44 1.35 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.947 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.547 ' CA ' HG12 ' A' ' 117' ' ' ILE . 15.4 pt20 -51.75 130.9 29.77 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.039 -179.924 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . . . . . . . . . 31.2 mm -103.59 136.79 34.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.094 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 18.9 mt-10 -95.41 145.32 25.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.883 179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.459 ' CB ' ' HA ' ' A' ' 111' ' ' VAL . . . -64.78 121.63 15.02 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.062 -179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -94.88 -8.86 36.01 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.988 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -173.99 134.12 0.45 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.829 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.484 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 88.7 p -49.81 119.14 3.29 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.646 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . . . . . . . . . . . -141.83 -176.77 16.34 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.628 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.635 ' N ' HG23 ' A' ' 155' ' ' ILE . 23.4 m -136.17 109.34 7.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.631 0.253 . . . . 0.0 111.139 -179.901 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.489 HG22 HG12 ' A' ' 155' ' ' ILE . 67.1 t -48.27 142.49 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.525 -0.307 . . . . 0.0 110.289 179.4 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.554 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 55.1 mtpt -126.93 -19.8 4.35 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 121.042 -0.263 . . . . 0.0 111.705 -179.258 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.686 ' C ' HD13 ' A' ' 138' ' ' ILE . . . 173.62 162.52 0.16 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.025 0.44 . . . . 0.0 111.773 -179.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.686 HD13 ' C ' ' A' ' 137' ' ' ALA . 0.6 OUTLIER -116.59 80.08 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.752 179.656 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.493 HD12 ' HB2' ' A' ' 151' ' ' PRO . 13.3 mt -47.99 -23.28 0.75 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.856 -179.822 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 0.985 HG21 HD23 ' A' ' 152' ' ' LEU . 53.5 t -108.16 143.34 18.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.235 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.491 ' HB2' ' HG2' ' A' ' 144' ' ' GLN . 4.9 mt-10 -59.61 136.06 57.87 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.922 179.31 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.48 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -30.61 -63.5 0.14 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.817 -179.259 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.601 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -124.06 103.54 0.77 Allowed Glycine 0 N--CA 1.447 -0.61 0 C-N-CA 120.528 -0.844 . . . . 0.0 113.028 -179.393 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 1.015 ' C ' HG23 ' A' ' 90' ' ' THR . 0.0 OUTLIER -169.98 145.93 2.53 Favored Pre-proline 0 C--N 1.326 -0.443 0 CA-C-O 120.904 0.383 . . . . 0.0 111.149 179.616 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.434 ' HA ' ' OG1' ' A' ' 90' ' ' THR . 39.0 Cg_exo -56.94 144.59 88.49 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.751 2.301 . . . . 0.0 112.066 179.803 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.635 HG11 ' CD2' ' A' ' 152' ' ' LEU . 0.2 OUTLIER -136.23 -174.21 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.201 -179.926 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.447 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.0 OUTLIER -143.75 142.59 30.99 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.929 179.915 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.49 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 4.4 t80 -34.68 129.71 0.41 Allowed 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.072 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.49 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 1.7 t70 83.01 23.6 0.15 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.918 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.447 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 25.7 mm-40 -109.54 74.28 0.68 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.835 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.848 ' O ' HG23 ' A' ' 140' ' ' VAL . 53.6 Cg_exo -33.71 126.38 0.15 Allowed 'Trans proline' 0 N--CA 1.458 -0.605 0 C-N-CA 122.866 2.377 . . . . 0.0 112.14 179.607 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 1.063 HD22 ' HB2' ' A' ' 91' ' ' PHE . 0.0 OUTLIER -117.89 -68.42 0.92 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.607 -179.175 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.749 HG21 HD13 ' A' ' 103' ' ' ILE . 1.3 p -102.45 106.22 19.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.418 -179.217 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.902 HG13 HG12 ' A' ' 82' ' ' ILE . 4.2 t -87.89 130.2 37.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.05 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.635 HG23 ' N ' ' A' ' 134' ' ' THR . 91.3 mt -132.99 131.87 58.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.215 -179.788 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.542 ' HB2' ' CA ' ' A' ' 80' ' ' GLY . 14.9 tt0 . . . . . 0 C--O 1.249 1.056 0 CA-C-O 118.259 -0.877 . . . . 0.0 110.96 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.845 0.355 . . . . 0.0 111.051 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . -152.95 -161.39 1.28 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.064 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -179.79 136.22 0.12 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.861 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -119.48 23.02 5.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.042 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 23.8 t 48.88 97.71 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.91 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.435 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . -117.74 -174.56 16.72 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.336 179.853 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.52 ' N ' ' O ' ' A' ' 155' ' ' ILE . 23.7 t60 175.56 82.42 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.759 0.314 . . . . 0.0 110.943 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 0.879 HG12 HG13 ' A' ' 154' ' ' VAL . 10.8 mt -98.73 123.14 51.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-O 121.074 0.464 . . . . 0.0 110.976 179.79 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.618 ' CG2' HG13 ' A' ' 153' ' ' VAL . 2.0 t -76.29 57.55 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 115.762 -0.653 . . . . 0.0 111.312 -179.693 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.518 ' HA ' ' HA ' ' A' ' 151' ' ' PRO . 0.0 OUTLIER -35.39 119.42 0.51 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.723 -179.977 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 1.019 ' CA ' HD11 ' A' ' 152' ' ' LEU . 0.3 OUTLIER -35.26 104.84 0.26 Allowed Pre-proline 0 C--N 1.328 -0.342 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.177 -179.755 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.458 ' O ' ' O ' ' A' ' 87' ' ' MET . 32.6 Cg_endo -64.14 138.57 62.37 Favored 'Trans proline' 0 C--O 1.231 0.145 0 C-N-CA 122.62 2.213 . . . . 0.0 111.654 179.508 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.458 ' O ' ' O ' ' A' ' 86' ' ' PRO . 3.9 ptp 42.3 -167.81 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.354 -179.613 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.781 HG22 ' HG2' ' A' ' 147' ' ' GLU . 52.4 t -88.36 106.96 17.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 120.847 0.356 . . . . 0.0 111.203 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -157.54 -158.05 8.74 Favored Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.582 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.69 ' O ' HG13 ' A' ' 118' ' ' VAL . 4.4 m -123.89 148.74 46.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.909 0.385 . . . . 0.0 111.088 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.663 ' CZ ' HG21 ' A' ' 138' ' ' ILE . 46.8 t80 -90.99 140.6 29.68 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.042 -0.527 . . . . 0.0 109.927 179.307 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.594 ' CD1' ' HA2' ' A' ' 143' ' ' GLY . 11.3 m-85 -146.19 123.05 11.3 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.975 0.417 . . . . 0.0 111.169 -179.801 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.495 ' HA ' ' HB2' ' A' ' 102' ' ' PHE . 41.3 ptt85 -116.04 39.35 3.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.673 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.48 ' HA ' ' HA ' ' A' ' 101' ' ' ALA . 31.2 p -150.86 115.6 3.23 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.022 179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.408 ' HD3' ' C ' ' A' ' 101' ' ' ALA . 58.7 Cg_endo -71.85 -29.58 15.2 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.738 2.292 . . . . 0.0 112.204 179.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -143.35 158.88 56.94 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.875 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_exo -52.44 -38.74 74.58 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.69 2.26 . . . . 0.0 112.263 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 -129.05 60.34 1.55 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.922 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . . . . . . . . . . . -116.14 -168.95 1.51 Allowed 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.14 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . 0.481 ' NZ ' ' HB2' ' A' ' 100' ' ' LYS . 0.8 OUTLIER -91.4 27.04 2.06 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.978 179.951 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . 0.48 ' HA ' ' HA ' ' A' ' 94' ' ' THR . . . 65.42 178.59 0.2 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.192 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.863 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.1 OUTLIER -95.22 -31.88 13.29 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.709 179.9 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.863 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.1 OUTLIER 169.42 138.49 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.169 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.21 179.621 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.828 ' O ' HG11 ' A' ' 135' ' ' VAL . 5.3 pt-20 -140.78 160.0 40.98 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.0 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.442 ' HB ' ' HA ' ' A' ' 137' ' ' ALA . 7.7 p -43.57 123.14 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.217 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . 0.482 ' H ' HG13 ' A' ' 135' ' ' VAL . . . 111.07 -19.98 24.42 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.446 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.829 ' O ' HG12 ' A' ' 135' ' ' VAL . 0.2 OUTLIER -87.47 113.6 23.33 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.801 0.334 . . . . 0.0 110.859 179.975 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 1.1 pttt -75.84 117.1 17.22 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.896 -179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.76 HG11 ' CD2' ' A' ' 115' ' ' LEU . 35.2 m -86.78 168.41 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.087 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.485 ' HA ' ' HA ' ' A' ' 132' ' ' SER . 2.5 p-10 -160.11 132.14 6.21 Favored 'General case' 0 N--CA 1.452 -0.349 0 CA-C-O 121.129 0.49 . . . . 0.0 110.696 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.641 HG13 ' O ' ' A' ' 129' ' ' ALA . 4.1 t -36.86 139.87 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.963 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 88.99 7.38 70.54 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.27 -179.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.461 ' O ' ' N ' ' A' ' 115' ' ' LEU . 6.8 m-20 -123.63 103.2 8.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.857 0.36 . . . . 0.0 110.835 179.973 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.414 ' C ' ' O ' ' A' ' 113' ' ' ASP . 4.3 m -37.23 94.72 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.925 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.76 ' CD2' HG11 ' A' ' 109' ' ' VAL . 9.9 mt -47.87 -91.0 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.703 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.633 ' HB3' HD11 ' A' ' 103' ' ' ILE . 2.0 p -138.33 155.95 48.09 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.851 179.9 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.678 HD13 ' HB2' ' A' ' 124' ' ' MET . 3.7 mt -89.79 153.21 3.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.025 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.69 HG13 ' O ' ' A' ' 90' ' ' THR . 86.3 t -145.23 101.08 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.852 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.515 ' HB2' ' CE2' ' A' ' 92' ' ' TYR . 2.4 mm-40 -55.27 84.49 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.243 -179.779 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.48 ' O ' ' HG3' ' A' ' 121' ' ' MET . . . -103.04 145.68 29.51 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.722 179.7 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.48 ' HG3' ' O ' ' A' ' 120' ' ' ALA . 2.2 ptm 45.53 26.82 0.34 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.035 0.445 . . . . 0.0 110.252 -179.683 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.525 ' O ' ' CE ' ' A' ' 122' ' ' LYS . 0.1 OUTLIER 77.89 45.1 0.08 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.746 -179.698 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.51 ' N ' ' OE1' ' A' ' 119' ' ' GLU . 11.1 mtt -162.21 127.84 3.47 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.992 179.713 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.678 ' HB2' HD13 ' A' ' 117' ' ' ILE . 0.9 OUTLIER -57.68 87.18 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.56 179.61 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 12.6 t-20 -65.59 79.9 0.07 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.945 -179.799 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . 0.456 ' HA ' ' HA ' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -57.16 118.87 5.48 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.87 179.99 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.475 ' O ' ' N ' ' A' ' 115' ' ' LEU . 34.7 mm -84.77 134.26 27.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.042 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . 0.404 ' OE2' ' HG2' ' A' ' 126' ' ' GLN . 3.8 mm-40 -108.08 116.55 32.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.957 -179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.641 ' O ' HG13 ' A' ' 111' ' ' VAL . . . -37.8 113.49 0.28 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.131 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . . . . . . . . . 42.9 p-10 -93.96 -14.36 26.04 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.935 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 15.6 ptmt -162.37 126.07 3.05 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.783 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.485 ' HA ' ' HA ' ' A' ' 110' ' ' ASN . 5.3 p -46.39 120.01 2.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.993 179.997 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.513 ' H ' HG23 ' A' ' 109' ' ' VAL . . . -143.59 -168.59 12.26 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.433 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.568 ' N ' HG23 ' A' ' 155' ' ' ILE . 17.4 m -143.81 107.31 4.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.684 0.278 . . . . 0.0 111.25 -179.858 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.829 HG12 ' O ' ' A' ' 107' ' ' GLN . 7.1 p -45.73 141.15 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.301 179.43 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.688 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 20.6 mtpt -120.82 -18.65 7.58 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.711 0.291 . . . . 0.0 111.111 -179.522 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.688 ' HB2' ' O ' ' A' ' 136' ' ' LYS . . . 163.71 153.31 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.983 0.42 . . . . 0.0 111.765 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.663 HG21 ' CZ ' ' A' ' 91' ' ' PHE . 0.1 OUTLIER -108.31 79.35 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.545 179.684 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . . . . . . . . . 8.2 mt -44.93 -25.96 0.37 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.722 -179.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 1.045 HG21 HD23 ' A' ' 152' ' ' LEU . 62.3 t -102.85 146.71 10.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.865 -0.607 . . . . 0.0 111.009 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.556 ' O ' ' CD2' ' A' ' 91' ' ' PHE . 15.4 mt-10 -51.25 -174.84 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.172 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.492 ' O ' ' HA ' ' A' ' 92' ' ' TYR . 0.0 OUTLIER -82.18 -55.4 4.57 Favored 'General case' 0 C--N 1.324 -0.529 0 C-N-CA 120.881 -0.327 . . . . 0.0 110.921 179.935 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.594 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . -126.5 103.1 0.66 Allowed Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.8 -0.714 . . . . 0.0 112.577 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.631 ' O ' HG23 ' A' ' 90' ' ' THR . 0.0 OUTLIER -165.03 151.56 9.21 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-O 120.948 0.404 . . . . 0.0 111.352 179.92 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.501 ' O ' ' NE2' ' A' ' 144' ' ' GLN . 30.7 Cg_endo -63.72 131.17 30.29 Favored 'Trans proline' 0 C--O 1.231 0.141 0 C-N-CA 122.97 2.447 . . . . 0.0 112.48 179.881 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 0.525 HG11 ' CD2' ' A' ' 152' ' ' LEU . 0.2 OUTLIER -133.05 176.81 8.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.896 179.886 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.781 ' HG2' HG22 ' A' ' 88' ' ' VAL . 2.3 mt-10 -133.41 156.86 46.91 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.288 -0.414 . . . . 0.0 110.969 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.484 ' HA ' ' O ' ' A' ' 85' ' ' SER . 8.3 t80 -40.57 153.6 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.895 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.453 ' OD1' ' O ' ' A' ' 149' ' ' ASP . 1.0 OUTLIER 54.8 28.04 9.73 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 116.11 -0.495 . . . . 0.0 111.529 179.806 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.54 ' CB ' ' O ' ' A' ' 147' ' ' GLU . 11.0 tp10 -107.23 74.35 0.4 Allowed Pre-proline 0 C--N 1.329 -0.306 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.702 179.492 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.608 ' O ' HG23 ' A' ' 140' ' ' VAL . 48.8 Cg_exo -31.35 129.13 0.08 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.638 0 C-N-CA 123.138 2.559 . . . . 0.0 112.362 179.758 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 1.045 HD23 HG21 ' A' ' 140' ' ' VAL . 0.0 OUTLIER -130.16 -68.91 0.69 Allowed 'General case' 0 C--O 1.232 0.181 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.694 -179.484 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.623 HG11 ' SG ' ' A' ' 116' ' ' CYS . 1.5 p -99.65 101.78 12.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.606 -178.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 0.879 HG13 HG12 ' A' ' 82' ' ' ILE . 23.8 t -81.86 138.49 19.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.0 179.602 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.568 HG23 ' N ' ' A' ' 134' ' ' THR . 83.6 mt -139.05 136.62 42.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.285 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.449 ' CA ' ' HD2' ' A' ' 136' ' ' LYS . 0.5 OUTLIER . . . . . 0 C--O 1.248 1.01 0 CA-C-O 118.282 -0.866 . . . . 0.0 110.927 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.114 0 CA-C-O 120.791 0.329 . . . . 0.0 111.003 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . 64.11 -81.12 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.062 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -91.58 131.48 36.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.903 179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.457 HG22 ' O ' ' A' ' 78' ' ' ILE . 7.0 mt -139.26 24.01 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.16 -179.931 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 64.19 22.4 12.84 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.996 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.488 ' O ' ' HB2' ' A' ' 81' ' ' HIS . . . 67.54 -150.1 51.26 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.592 179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' HIS . . . . . 0.509 ' N ' ' O ' ' A' ' 155' ' ' ILE . 24.7 t60 171.21 83.98 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.778 0.323 . . . . 0.0 110.797 -179.864 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . 1.015 HD12 HG13 ' A' ' 154' ' ' VAL . 0.2 OUTLIER -88.02 -177.52 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 CA-C-O 120.992 0.425 . . . . 0.0 111.001 179.909 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.914 ' CG2' HG13 ' A' ' 153' ' ' VAL . 1.7 t -140.92 39.17 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.705 179.603 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' ARG . . . . . 0.546 ' HB3' ' CD ' ' A' ' 151' ' ' PRO . 1.7 ptt-85 -34.07 127.42 0.42 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.866 -0.607 . . . . 0.0 110.979 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . 0.438 ' HB3' HD21 ' A' ' 152' ' ' LEU . 0.9 OUTLIER -38.37 112.02 0.64 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.883 179.986 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . 0.424 ' HD2' ' HA ' ' A' ' 85' ' ' SER . 25.9 Cg_endo -61.96 -11.27 20.65 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.669 2.246 . . . . 0.0 111.945 179.853 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . 0.573 ' SD ' ' HB1' ' A' ' 120' ' ' ALA . 5.6 ptm -156.59 177.09 11.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.598 179.844 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' VAL . . . . . 0.424 HG12 ' H ' ' A' ' 88' ' ' VAL . 1.7 p -80.43 94.18 2.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.082 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -143.64 -123.42 1.74 Allowed Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.613 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.673 HG21 ' CZ ' ' A' ' 92' ' ' TYR . 38.5 m -150.9 150.78 31.28 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.861 0.362 . . . . 0.0 110.996 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' PHE . . . . . 0.652 ' CZ ' ' CG2' ' A' ' 138' ' ' ILE . 0.8 OUTLIER -116.89 143.27 45.89 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.931 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' TYR . . . . . 0.673 ' CZ ' HG21 ' A' ' 90' ' ' THR . 22.5 m-85 -142.9 163.17 33.52 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.029 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' ARG . . . . . 0.488 ' HG2' ' HB2' ' A' ' 142' ' ' SER . 29.0 ptt180 -143.83 24.69 1.67 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.752 179.695 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' THR . . . . . 0.4 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 0.0 OUTLIER -156.51 91.99 2.52 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.767 179.833 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 94' ' ' THR . 45.2 Cg_endo -68.47 -25.32 35.46 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.785 2.323 . . . . 0.0 112.565 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.415 ' HA ' ' HD3' ' A' ' 97' ' ' PRO . 0.9 OUTLIER -135.57 133.13 20.06 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 120.966 0.413 . . . . 0.0 111.057 -179.896 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.483 ' O ' ' CB ' ' A' ' 98' ' ' ASP . 52.1 Cg_exo -54.55 109.98 0.46 Allowed 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.803 2.335 . . . . 0.0 112.23 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' ASP . . . . . 0.483 ' CB ' ' O ' ' A' ' 97' ' ' PRO . 10.4 t70 81.6 46.67 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.823 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' ALA . . . . . 0.404 ' HB2' ' HB2' ' A' ' 96' ' ' SER . . . -107.2 -166.47 1.16 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.081 179.997 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -90.41 23.51 2.93 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.795 179.961 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' ALA . . . . . . . . . . . . . . . 56.88 159.7 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.146 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' PHE . . . . . 0.849 ' O ' HG23 ' A' ' 103' ' ' ILE . 0.0 OUTLIER -87.63 -37.79 16.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.82 179.993 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' ILE . . . . . 0.849 HG23 ' O ' ' A' ' 102' ' ' PHE . 0.6 OUTLIER -170.19 110.03 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.134 -179.999 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' GLU . . . . . 0.504 ' N ' ' OE1' ' A' ' 104' ' ' GLU . 12.5 pm0 -121.73 162.3 21.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.852 179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.613 HG22 ' HA ' ' A' ' 137' ' ' ALA . 4.4 t -45.36 97.74 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.091 -179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . 130.02 -8.97 6.03 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.513 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.432 ' O ' ' N ' ' A' ' 109' ' ' VAL . 29.7 tp60 -70.64 99.59 1.69 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.793 0.33 . . . . 0.0 110.881 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.444 ' O ' ' O ' ' A' ' 109' ' ' VAL . 0.0 OUTLIER -67.67 61.06 0.07 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.962 -179.984 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.808 HG22 ' O ' ' A' ' 133' ' ' GLY . 16.9 m -42.09 168.15 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.047 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' ASN . . . . . 0.511 ' ND2' ' HB2' ' A' ' 132' ' ' SER . 23.0 m120 -167.18 132.99 2.13 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.579 179.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.572 HG12 ' C ' ' A' ' 130' ' ' ASP . 18.1 m -34.05 136.34 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.172 179.994 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 81.33 14.97 77.7 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.303 -179.894 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' ASP . . . . . 0.422 ' O ' ' C ' ' A' ' 114' ' ' THR . 0.8 OUTLIER -128.51 105.88 8.6 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.854 0.359 . . . . 0.0 110.824 179.957 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' THR . . . . . 0.422 ' C ' ' O ' ' A' ' 113' ' ' ASP . 1.3 m -35.18 127.93 0.54 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.033 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' LEU . . . . . 0.556 HD12 HG22 ' A' ' 127' ' ' ILE . 14.7 mt -87.63 -83.95 0.2 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.908 -179.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' CYS . . . . . 0.53 ' HB3' HD11 ' A' ' 103' ' ' ILE . 21.4 p -135.2 -165.51 1.69 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.917 -179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' ILE . . . . . 0.566 ' CG2' ' CB ' ' A' ' 124' ' ' MET . 0.2 OUTLIER -113.7 113.92 45.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.212 -179.988 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.498 ' HB ' ' HB3' ' A' ' 125' ' ' ASN . 25.8 t -103.47 55.1 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.82 179.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' GLU . . . . . 0.479 ' HA ' ' O ' ' A' ' 123' ' ' MET . 0.2 OUTLIER -35.44 98.8 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.093 -179.842 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' ALA . . . . . 0.573 ' HB1' ' SD ' ' A' ' 87' ' ' MET . . . -118.16 110.27 17.39 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.923 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' MET . . . . . 0.544 ' O ' ' CB ' ' A' ' 122' ' ' LYS . 0.3 OUTLIER 87.07 21.42 0.06 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.855 -179.908 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.544 ' CB ' ' O ' ' A' ' 121' ' ' MET . 0.0 OUTLIER 89.69 0.81 0.26 Allowed 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.252 179.907 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.479 ' O ' ' HA ' ' A' ' 119' ' ' GLU . 0.4 OUTLIER -119.86 133.58 55.53 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.854 0.359 . . . . 0.0 111.138 179.942 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.566 ' CB ' ' CG2' ' A' ' 117' ' ' ILE . 0.0 OUTLIER -64.22 112.63 3.12 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.051 179.87 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.498 ' HB3' ' HB ' ' A' ' 118' ' ' VAL . 0.8 OUTLIER -86.7 74.93 9.74 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.656 179.715 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -48.88 112.27 0.59 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.005 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' ILE . . . . . 0.556 HG22 HD12 ' A' ' 115' ' ' LEU . 3.9 mm -90.94 145.5 7.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.044 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -122.61 123.65 41.67 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.985 -179.873 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' ALA . . . . . 0.503 ' HA ' HD11 ' A' ' 115' ' ' LEU . . . -38.95 142.58 0.21 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.119 179.874 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' ASP . . . . . 0.572 ' C ' HG12 ' A' ' 111' ' ' VAL . 0.5 OUTLIER -121.49 -7.56 9.18 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.042 179.997 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.485 ' NZ ' ' O ' ' A' ' 131' ' ' LYS . 0.0 OUTLIER -160.13 23.88 0.17 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.769 179.991 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' SER . . . . . 0.511 ' HB2' ' ND2' ' A' ' 110' ' ' ASN . 1.3 p 53.66 -176.57 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.632 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' GLY . . . . . 0.808 ' O ' HG22 ' A' ' 109' ' ' VAL . . . 150.13 167.09 14.0 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.575 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . 0.75 ' N ' HG23 ' A' ' 155' ' ' ILE . 18.8 m -116.57 110.74 18.95 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.658 0.266 . . . . 0.0 111.18 -179.902 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.51 HG12 ' HA ' ' A' ' 105' ' ' VAL . 95.0 t -47.22 142.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.595 -0.275 . . . . 0.0 110.472 179.51 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.652 ' O ' ' HB2' ' A' ' 137' ' ' ALA . 0.2 OUTLIER -124.83 -19.18 5.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.424 -179.399 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . 0.694 ' C ' HD13 ' A' ' 138' ' ' ILE . . . 167.23 155.97 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.835 0.35 . . . . 0.0 111.351 -179.682 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' ILE . . . . . 0.785 ' N ' HD13 ' A' ' 138' ' ' ILE . 0.0 OUTLIER -106.94 82.92 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.948 179.835 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' LEU . . . . . 0.917 HD21 HG21 ' A' ' 154' ' ' VAL . 6.6 mt -41.2 -34.96 0.53 Allowed 'General case' 0 C--N 1.332 -0.194 0 CA-C-O 121.168 0.508 . . . . 0.0 109.97 179.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' VAL . . . . . 1.056 HG21 HD23 ' A' ' 152' ' ' LEU . 59.0 t -92.18 136.86 23.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.496 -0.774 . . . . 0.0 110.701 179.648 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . 0.484 ' O ' ' HG2' ' A' ' 144' ' ' GLN . 4.5 mt-10 -70.22 100.19 1.64 Allowed 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.443 179.817 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.488 ' HB2' ' HG2' ' A' ' 93' ' ' ARG . 5.9 p -36.13 147.66 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.682 -179.698 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' GLY . . . . . 0.579 ' HA2' ' CD1' ' A' ' 92' ' ' TYR . . . 71.97 35.29 61.44 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.451 -179.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' GLN . . . . . 0.576 HE21 HG13 ' A' ' 140' ' ' VAL . 0.7 OUTLIER -149.03 153.48 38.27 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-O 120.883 0.373 . . . . 0.0 111.115 -179.913 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' PRO . . . . . 0.525 ' HA ' ' HA ' ' A' ' 90' ' ' THR . 57.3 Cg_endo -70.64 164.13 36.49 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.939 2.426 . . . . 0.0 112.268 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' VAL . . . . . 1.117 HG11 ' CD2' ' A' ' 152' ' ' LEU . 29.3 m -143.99 -179.38 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.195 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.452 ' O ' ' HB2' ' A' ' 150' ' ' GLU . 0.5 OUTLIER -137.49 160.54 38.85 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.068 -179.853 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' PHE . . . . . 0.421 ' O ' ' CB ' ' A' ' 149' ' ' ASP . 1.2 t80 -44.52 121.88 2.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.843 179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' ASP . . . . . 0.421 ' CB ' ' O ' ' A' ' 148' ' ' PHE . 4.9 t0 78.24 34.92 0.27 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.74 -179.846 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' GLU . . . . . 0.452 ' HB2' ' O ' ' A' ' 147' ' ' GLU . 3.9 tp10 -107.36 74.15 0.4 Allowed Pre-proline 0 C--N 1.327 -0.411 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.94 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' PRO . . . . . 0.765 ' O ' HG23 ' A' ' 140' ' ' VAL . 61.6 Cg_exo -34.7 119.65 0.14 Allowed 'Trans proline' 0 N--CA 1.457 -0.619 0 C-N-CA 122.79 2.327 . . . . 0.0 111.915 179.577 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' LEU . . . . . 1.117 ' CD2' HG11 ' A' ' 146' ' ' VAL . 0.0 OUTLIER -116.06 -70.69 0.78 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.746 -179.163 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' VAL . . . . . 0.914 HG13 ' CG2' ' A' ' 83' ' ' VAL . 1.4 p -93.06 109.95 22.44 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.252 0 CA-C-O 121.152 0.501 . . . . 0.0 111.836 -179.13 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' VAL . . . . . 1.015 HG13 HD12 ' A' ' 82' ' ' ILE . 4.1 t -92.3 132.79 35.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.474 -0.784 . . . . 0.0 110.638 179.261 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.75 HG23 ' N ' ' A' ' 134' ' ' THR . 39.5 mt -132.73 140.0 48.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.441 -0.345 . . . . 0.0 111.229 -179.938 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.512 ' HB2' ' CD ' ' A' ' 136' ' ' LYS . 31.7 tt0 . . . . . 0 C--O 1.249 1.041 0 CA-C-O 118.22 -0.895 . . . . 0.0 110.943 179.943 . . . . . . . . 1 1 . 1 stop_ save_